Serotonin B
receptor O
2A O
( O
HTR2A O
) O
gene O
polymorphism O
predicts O
treatment O
response O
to O
venlafaxine B
XR I
in O
generalized O
anxiety O
disorder O
. O

We O
tested O
the O
hypothesis O
that O
the O
genetic O
polymorphism O
rs7997012 O
in O
the O
HTR2A O
gene O
predicts O
treatment O
outcome O
in O
GAD O
patients O
treated O
with O
venlafaxine B
XR I
. O

Treatment O
response O
was O
assessed O
in O
156 O
patients O
that O
participated O
in O
a O
6 O
- O
month O
open O
- O
label O
clinical O
trial O
of O
venlafaxine B
XR I
for O
GAD O
. O

The O
data O
indicates O
that O
fetal O
exposure O
to O
dioxins B
and O
furans B
( O
PCDD B
/ O
Fs O
) O
, O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
p B
, I
p I
' I
- I
DDE I
, O
and O
methylmercury B
depends O
on O
the O
mother O
' O
s O
parity O
, O
and O
age O
. O

Activities O
of O
the O
antioxidant O
enzymes O
of O
erythrocytes O
such O
as O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
S B
- O
transferase O
and O
glutathione B
peroxidase O
increased O
significantly O
in O
a O
dose O
- O
dependent O
manner O
with O
significant O
elevation O
in O
hydrogen B
peroxide I
and O
malondialdehyde B
levels O
, O
whereas O
glutathione B
level O
was O
not O
significantly O
decreased O
in O
BLCO O
- O
treated O
animals O
. O

Diclavatol B
and O
tetronic B
acids I
from O
Penicillium O
griseoroseum O
. O

In O
our O
continuous O
studies O
on O
the O
chemistry O
of O
the O
endophytic O
fungus O
Penicillium O
griseoroseum O
, O
an O
endophyte O
isolated O
from O
fruits O
of O
Coffea O
arabica O
, O
we O
isolated O
clavatol B
, O
a O
dimethylated B
tetraketide I
, O
and O
its O
dimer O
which O
appears O
to O
be O
a O
novel O
natural O
compound O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

Two O
other O
tetronic B
acids I
congeners O
were O
identified O
through O
HPLC O
/ O
MS O
/ O
MS O
studies O
, O
based O
on O
fragmentation O
pattern O
of O
ions O
produced O
from O
ionised O
tetronic B
acids I
, O
and O
UV O
light O
absorptions O
. O

Two O
other O
tetronic B
acids I
congeners O
were O
identified O
through O
HPLC O
/ O
MS O
/ O
MS O
studies O
, O
based O
on O
fragmentation O
pattern O
of O
ions O
produced O
from O
ionised O
tetronic B
acids I
, O
and O
UV O
light O
absorptions O
. O

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

Exposure O
of O
rats O
to O
arsenic B
caused O
also O
a O
significant O
increase O
in O
liver O
, O
kidney O
and O
testicular O
thiobarbituric B
acid I
reactive O
substances O
compared O
to O
control O
. O

Determination O
of O
aflatoxin B
M1 I
in O
milk O
by O
high O
- O
performance O
liquid O
chromatography O
in O
Mashhad O
( O
north O
east O
of O
Iran O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
aflatoxin B
M1 I
( O
AFM1 B
) O
contamination O
in O
milk O
samples O
in O
Mashhad O
in O
Iran O
. O

Among O
the O
tested O
preparations O
, O
formulations O
with O
20 O
% O
risperidone B
, O
3 O
: O
2 O
ERL B
100 I
and O
ERS B
100 I
as O
polymers O
, O
mixture O
of O
olive O
oil O
and O
jojoba O
oil O
as O
enhancer O
, O
exhibited O
greatest O
cumulative O
amount O
of O
drug O
permeated O
( O
1 O
. O
87 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
cm O
( O
2 O
) O
) O
in O
72 O
h O
, O
so O
batch O
ROJ O
was O
concluded O
as O
optimized O
formulation O
and O
assessed O
for O
pharmacokinetic O
, O
pharmacodynamic O
and O
skin O
irritation O
potential O
. O

Among O
the O
tested O
preparations O
, O
formulations O
with O
20 O
% O
risperidone B
, O
3 O
: O
2 O
ERL B
100 I
and O
ERS B
100 I
as O
polymers O
, O
mixture O
of O
olive O
oil O
and O
jojoba O
oil O
as O
enhancer O
, O
exhibited O
greatest O
cumulative O
amount O
of O
drug O
permeated O
( O
1 O
. O
87 O
+ O
/ O
- O
0 O
. O
09 O
mg O
/ O
cm O
( O
2 O
) O
) O
in O
72 O
h O
, O
so O
batch O
ROJ O
was O
concluded O
as O
optimized O
formulation O
and O
assessed O
for O
pharmacokinetic O
, O
pharmacodynamic O
and O
skin O
irritation O
potential O
. O

Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

Oxygenated O
monoterpenes B
were O
the O
main O
compounds O
with O
51 O
. O
6 O
% O
followed O
by O
sesquiterpene B
hydrocarbons I
( O
13 O
. O
3 O
% O
) O
, O
monoterpene B
hydrocarbons I
( O
9 O
. O
9 O
% O
) O
and O
other O
compounds O
( O
8 O
. O
3 O
% O
) O
. O

Oxygenated O
monoterpenes B
were O
the O
main O
compounds O
with O
51 O
. O
6 O
% O
followed O
by O
sesquiterpene B
hydrocarbons I
( O
13 O
. O
3 O
% O
) O
, O
monoterpene B
hydrocarbons I
( O
9 O
. O
9 O
% O
) O
and O
other O
compounds O
( O
8 O
. O
3 O
% O
) O
. O

This O
coincided O
with O
significantly O
elevated O
oxidative O
damage O
evidenced O
by O
a O
marked O
reduction O
in O
glutathione B
redox O
status O
( O
ratio O
of O
reduced B
GSH I
/ O
oxidized B
GSSG I
) O
and O
an O
increase O
in O
lipid O
peroxidation O
( O
TBARS O
levels O
) O
. O

This O
coincided O
with O
significantly O
elevated O
oxidative O
damage O
evidenced O
by O
a O
marked O
reduction O
in O
glutathione B
redox O
status O
( O
ratio O
of O
reduced B
GSH I
/ O
oxidized B
GSSG I
) O
and O
an O
increase O
in O
lipid O
peroxidation O
( O
TBARS O
levels O
) O
. O

When O
cultures O
of O
Serratia O
marcescens O
, O
an O
enterobacteria O
isolated O
from O
the O
microflora O
associated O
with O
banana O
plantations O
incubated O
at O
27 O
degrees O
C O
in O
a O
yeast O
- O
calcium B
carbonate I
- O
dextrose B
solid O
medium O
( O
10 O
g O
of O
yeast O
extract O
, O
20 O
g O
dextrose B
, O
15 O
g O
bacteriological O
agar O
, O
20 O
g O
calcium B
carbonate I
and O
1000 O
mL O
distilled O
water O
) O
were O
extracted O
with O
chloroform B
and O
purified O
by O
column O
chromatography O
, O
we O
obtained O
a O
new O
colourless O
bacterial O
metabolite O
which O
according O
to O
spectroscopic O
data O
proved O
to O
be O
serratin B
. O

When O
cultures O
of O
Serratia O
marcescens O
, O
an O
enterobacteria O
isolated O
from O
the O
microflora O
associated O
with O
banana O
plantations O
incubated O
at O
27 O
degrees O
C O
in O
a O
yeast O
- O
calcium B
carbonate I
- O
dextrose B
solid O
medium O
( O
10 O
g O
of O
yeast O
extract O
, O
20 O
g O
dextrose B
, O
15 O
g O
bacteriological O
agar O
, O
20 O
g O
calcium B
carbonate I
and O
1000 O
mL O
distilled O
water O
) O
were O
extracted O
with O
chloroform B
and O
purified O
by O
column O
chromatography O
, O
we O
obtained O
a O
new O
colourless O
bacterial O
metabolite O
which O
according O
to O
spectroscopic O
data O
proved O
to O
be O
serratin B
. O

Pharmacokinetic O
and O
pharmacodynamic O
evaluation O
of O
floating O
microspheres O
of O
metformin B
hydrochloride I
. O

Metformin B
hydrochloride I
( O
MH O
) O
, O
a O
biguanide B
antidiabetic O
, O
is O
the O
drug O
of O
choice O
in O
obese O
patients O
. O

Firstly O
, O
sustained O
release O
ketoprofen B
fine O
granules O
were O
developed O
by O
spray O
drying O
the O
aqueous O
dispersions O
composed O
of O
Eudragit B
RS I
- I
30D I
, O
Starch O
1500 O
and O
PEG B
6000 I
. O

Exogenous O
stimulation O
of O
PKA O
activity O
, O
achieved O
by O
forskolin B
treatment O
, O
protected O
K O
- O
ras O
- O
transformed O
cells O
from O
apoptosis O
induced O
by O
glucose B
deprivation O
, O
enhanced O
complex O
I O
activity O
, O
intracellular O
adenosine B
triphosphate I
( O
ATP B
) O
levels O
, O
mitochondrial O
fusion O
and O
decreased O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
levels O
. O

A O
new O
chromone B
, O
5 B
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
hydroxymethyl I
) I
- I
6 I
, I
8 I
- I
dimethyl I
- I
chromen I
- I
4 I
- I
one I
, O
named O
melachromone B
, O
together O
with O
12 O
known O
compounds O
, O
including O
chromones B
, O
anthraquinone B
, O
flavonoids B
, O
flavonoid B
glycosides I
, O
benzene B
derivatives O
, O
ellagic B
acids I
and O
terpenes B
, O
were O
isolated O
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

A O
new O
chromone B
, O
5 B
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
hydroxymethyl I
) I
- I
6 I
, I
8 I
- I
dimethyl I
- I
chromen I
- I
4 I
- I
one I
, O
named O
melachromone B
, O
together O
with O
12 O
known O
compounds O
, O
including O
chromones B
, O
anthraquinone B
, O
flavonoids B
, O
flavonoid B
glycosides I
, O
benzene B
derivatives O
, O
ellagic B
acids I
and O
terpenes B
, O
were O
isolated O
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

Two O
new O
triterpenoid B
saponins I
from O
the O
husks O
of O
Xanthoceras O
sorbifolia O
. O

Two O
new O
oleanane B
triterpenoid B
saponins I
, O
xanthohuskisides B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
husks O
of O
Xanthoceras O
sorbifolia O
. O

Sinensetin B
is O
a O
rare O
polymethoxylated B
flavone I
found O
in O
certain O
citrus O
fruits O
. O

New O
immunosuppressive O
cyclomyrsinol B
diterpenes I
from O
Euphorbia O
kopetdaghi O
Prokh O
. O

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha B
- I
pinene I
, O
germacrene B
D I
, O
delta B
- I
3 I
- I
carene I
and O
gamma B
- I
cadinene I
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

Ascorbic B
acid I
( O
100 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
was O
used O
as O
a O
standard O
drug O
. O

The O
MKA O
improved O
the O
level O
of O
protective O
antioxidants O
such O
as O
glutathione B
peroxidase O
( O
GPx O
) O
, O
reduced B
glutathione I
( O
GSH B
) O
, O
glutathione B
reductase O
( O
GRD O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
in O
brain O
homogenate O
at O
higher O
doses O
( O
20 O
and O
40 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
. O

Moreover O
, O
a O
dose O
dependent O
decline O
was O
noted O
in O
lipid O
peroxidation O
( O
LPO O
) O
and O
the O
nitric B
oxide I
assay O
( O
NO O
) O
at O
all O
doses O
of O
MKA O
( O
10 O
, O
20 O
and O
40 O
mg O
/ O
kg O
, O
p O
. O
o O
. O
) O
. O

In O
addition O
, O
a O
significant O
elevation O
of O
serum O
albumin O
( O
ALBU O
) O
, O
alkaline O
phosphatase O
( O
ALP O
) O
, O
alanine B
transaminase O
( O
ALT O
) O
, O
aspartate B
transaminase O
( O
AST O
) O
and O
total O
protein O
as O
well O
as O
a O
decline O
in O
creatinine B
, O
total O
cholesterol B
, O
urea B
nitrogen I
and O
glucose B
levels O
with O
MKA O
also O
ameliorated O
the O
hepatic O
and O
renal O
functions O
in O
normal O
ageing O
process O
. O

It O
also O
significantly O
reduced O
HFD O
- O
induced O
increases O
in O
serum O
lipids O
, O
including O
cholesterol B
, O
triglyceride B
, O
and O
thiobarbituric B
acid I
- O
reactive O
substance O
( O
TBARS O
) O
. O

In O
hyperlipidemia O
induced O
by O
Triton B
WR1339 I
, O
400 O
and O
800 O
mg O
/ O
kg O
AEBO O
reduced O
triglycerides B
( O
TG O
) O
serum O
levels O
at O
24 O
h O
and O
48 O
h O
. O

A O
new O
abietane B
diterpenoid I
from O
Salvia O
xanthocheila O
Boiss O
. O

From O
the O
chloroform B
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane B
diterpenoid I
, O
xantoquinone B
( O
5 B
alpha I
, I
6 I
alpha I
- I
dimethoxy I
- I
7 I
, I
11 I
, I
14 I
- I
trioxoabieta I
- I
8 I
, I
12 I
- I
diene I
) O
and O
one O
known O
oleanene B
triterpenoid I
namely O
1 B
beta I
, I
3 I
beta I
- I
dihydroxy I
- I
12 I
- I
oleanene I
were O
isolated O
. O

From O
the O
chloroform B
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane B
diterpenoid I
, O
xantoquinone B
( O
5 B
alpha I
, I
6 I
alpha I
- I
dimethoxy I
- I
7 I
, I
11 I
, I
14 I
- I
trioxoabieta I
- I
8 I
, I
12 I
- I
diene I
) O
and O
one O
known O
oleanene B
triterpenoid I
namely O
1 B
beta I
, I
3 I
beta I
- I
dihydroxy I
- I
12 I
- I
oleanene I
were O
isolated O
. O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

phytoconstituents O
alpha B
- I
amyrin I
acetate I
, O
beta B
- I
amyrin I
- I
beta I
- I
D I
- I
glucopyranoside I
and O
betulinic B
acid I
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Morus O
alba O
L O
. O

Herein O
we O
add O
physiological O
and O
functional O
support O
to O
this O
hypothesis O
using O
Lu B
AF21934 I
, O
a O
novel O
selective O
and O
brain O
- O
penetrant O
mGlu4 O
receptor O
positive O
allosteric O
modulator O
( O
PAM O
) O
tool O
compound O
. O

By O
in O
vitro O
electrophysiological O
recordings O
we O
demonstrate O
that O
Lu B
AF21934 I
inhibits O
corticostriatal O
synaptic O
transmission O
and O
enhances O
the O
effect O
of O
the O
orthosteric O
mGlu4 O
receptor O
- O
preferred O
agonist O
LSP1 B
- I
2111 I
. O

In O
na O
i O
ve O
rats O
, O
Lu B
AF21934 I
dose O
- O
dependently O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
alleviated O
haloperidol B
- O
induced O
catalepsy O
. O

In O
hemiparkinsonian O
rats O
( O
unilateral O
6 B
- I
hydroxydopamine I
lesion O
of O
the O
substantia O
nigra O
pars O
compacta O
) O
, O
Lu B
AF21934 I
alone O
did O
not O
affect O
akinesia O
at O
the O
doses O
tested O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
. O

However O
, O
when O
Lu B
AF21934 I
was O
combined O
with O
sub O
- O
threshold O
doses O
of O
l B
- I
DOPA I
( O
1 O
and O
5 O
mg O
/ O
kg O
) O
, O
it O
acted O
synergistically O
in O
alleviating O
akinesia O
in O
a O
dose O
- O
dependent O
manner O
and O
, O
notably O
, O
also O
reduced O
the O
incidence O
of O
LID O
but O
not O
its O
severity O
. O

Interestingly O
, O
these O
effects O
occurred O
at O
Lu B
AF21934 I
brain O
free O
concentrations O
that O
showed O
functional O
activity O
in O
in O
vitro O
screens O
( O
calcium B
flux O
and O
electrophysiology O
assays O
) O
. O

A O
new O
pentacyclic B
triterpenoid I
and O
three O
new O
derivatives O
based O
on O
the O
taraxer B
- I
14 I
- I
ene I
skeleton O
with O
a O
C O
- O
28 O
attached O
a O
carboxylic B
acid I
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
, O
together O
with O
six O
known O
compounds O
. O

A O
new O
pentacyclic B
triterpenoid I
and O
three O
new O
derivatives O
based O
on O
the O
taraxer B
- I
14 I
- I
ene I
skeleton O
with O
a O
C O
- O
28 O
attached O
a O
carboxylic B
acid I
group O
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Hypodaphnis O
zenkeri O
, O
together O
with O
six O
known O
compounds O
. O

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p B
- I
bromobenzyl I

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p B
- I
bromobenzyl I

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p B
- I
bromobenzyl I

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p B
- I
bromobenzyl I

acetylmaprounate I
. O
Journal O
Natural O
Products O
, O
52 O
, O
212 O
) O
, O
3 B
alpha I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
isoaleuritolic B
acid I
( O
6 O
) O
, O
3 B
alpha I
- I
acetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
acetate I
or O
aleuritolic B
acid I
acetate I
( O
7 O
) O
( O
Chaudhuri O
, O
S O
. O
K O
. O
, O
Fullas O
, O
F O
. O
, O
Brown O
, O
D O
. O
M O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
, O
Cai O
, O
L O
. O
, O
. O
. O
. O

A O
new O
acylated B
flavonoid I
, O
3 B
- I
O I
- I
rhamnocitrin I
- I
6 I
- I
O I
- I
benzoyl I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
1 O
) O
, O
together O
with O
five O
known O
flavonoids B
, O
rhamnocitrin B
( O
2 O
) O
, O
pratensein B
( O
3 O
) O
, O
( B
3R I
) I
- I
7 I
, I
3 I
' I
- I
dihydroxy I
- I
2 I
' I
, I
4 I
' I
- I
dimethoxyisoflavan I
( O
4 O
) O
, O
( B
3R I
) I
- I
7 I
, I
2 I
' I
- I
dihydroxy I
- I
3 I
' I
, I
4 I
' I
- I

Phagocytotic O
assay O
by O
fluorescein B
isothiocyanate I
- O
dextran O
internalization O
showed O
that O
PSG O
- O
1 O
stimulated O
the O
phagocytosis O
of O
macrophages O
. O

G O
. O
atrum O
polysaccharide O
increased O
the O
production O
of O
NO B
, O
and O
the O
level O
of O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
in O
a O
dose O
- O
response O
manner O
. O

Prevention O
of O
hydrogen B
peroxide I
- O
induced O
red O
blood O
cells O
lysis O
by O
Ilex O
paraguariensis O
aqueous O
extract O
: O
participation O
of O
phenolic B
and O
xanthine B
compounds O
. O

The O
aim O
of O
this O
work O
was O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
I O
. O
paraguariensis O
( O
green O
leaves O
) O
on O
the O
hemolysis O
of O
red O
blood O
cells O
induced O
by O
hydrogen B
peroxide I
and O
to O
correlate O
this O
activity O
with O
the O
enzymatic O
activity O
related O
to O
hydrogen B
peroxide I
metabolism O
. O

The O
aim O
of O
this O
work O
was O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
I O
. O
paraguariensis O
( O
green O
leaves O
) O
on O
the O
hemolysis O
of O
red O
blood O
cells O
induced O
by O
hydrogen B
peroxide I
and O
to O
correlate O
this O
activity O
with O
the O
enzymatic O
activity O
related O
to O
hydrogen B
peroxide I
metabolism O
. O

The O
antioxidant O
activity O
of O
chlorogenic B
acid I
and O
caffeine B
was O
also O
analysed O
to O
evaluate O
their O
contribution O
to O
the O
activity O
of O
the O
crude O
extract O
. O

Model O
drug O
rhodamine B
B I
was O
encapsulated O
in O
the O
range O
of O
50 O
micro O
g O
to O
450 O
micro O
g O
per O
microneedle O
array O
. O

The O
fabricated O
microneedles O
containing O
rhodamine B
B I
increased O
the O
permeability O
by O
four O
times O
than O
the O
control O
. O

Various O
polymers O
were O
evaluated O
as O
stabilizing O
agents O
among O
which O
polyvinylpyrrolidone B
17PF O
and O
amino B
methacrylate I
copolymer O
exhibited O
a O
significant O
inhibitory O
effect O
on O
fenofibrate B
recrystallization O
in O
the O
hot O
- O
melt O
extrudates O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoid B
orthoesters I
, O
chukvelutilide B
G I
( O
1 O
) O
and O
chukrasine B
F I
( O
2 O
) O
, O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoid B
orthoesters I
, O
chukvelutilide B
G I
( O
1 O
) O
and O
chukrasine B
F I
( O
2 O
) O
, O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoid B
orthoesters I
, O
chukvelutilide B
G I
( O
1 O
) O
and O
chukrasine B
F I
( O
2 O
) O
, O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

Preparation O
and O
cyclodextrin O
assisted O
dissolution O
rate O
enhancement O
of O
itraconazolium B
dinitrate I
salt O
. O

To O
improve O
its O
solubility O
and O
dissolution O
profile O
, O
itraconazolium B
dinitrate I
salt O
( O
ITRDNT B
) O
was O
prepared O
and O
characterized O
using O
various O
spectral O
and O
thermal O
techniques O
. O

" O
Vitamin B
E I
" O
fortified O
parenteral O
lipid O
emulsions O
: O
Plackett O
- O
Burman O
screening O
of O
primary O
process O
and O
composition O
parameters O
. O

The O
objective O
of O
this O
study O
was O
to O
screen O
the O
effect O
of O
eight O
formulations O
and O
process O
parameters O
on O
the O
physical O
attributes O
and O
stability O
of O
" O
Vitamin B
E I
" O
- O
rich O
parenteral O
lipid O
emulsions O
. O

This O
design O
was O
employed O
to O
construct O
polynomial O
equations O
that O
identified O
the O
magnitude O
and O
direction O
of O
the O
linear O
effect O
of O
homogenization O
pressure O
, O
number O
of O
homogenization O
cycles O
, O
primary O
and O
secondary O
emulsifiers O
, O
pre O
- O
homogenization O
temperature O
, O
oil O
loading O
, O
and O
ratio O
of O
vitamin B
E I
to O
medium O
- O
chain O
triglycerides B
( O
MCT O
) O
in O
the O
oil O
phase O
on O
particle O
size O
, O
polydispersity O
index O
, O
short O
- O
term O
stability O
, O
and O
outlet O
temperature O
of O
manufactured O
emulsions O
. O

The O
viscosity O
of O
vitamin B
E I
was O
reduced O
from O
3700 O
( O
100 O
% O
) O
to O
64 O
mPa O
. O
s O
( O
30 O
% O
) O
by O
MCT O
addition O
. O

Recently O
, O
a O
downregulation O
in O
the O
expression O
of O
GABAergic O
genes O
( O
i O
. O
e O
. O
, O
glutamic B
acid I
decarboxylase O
67 O
and O
reelin O
) O
associated O
with O
DNA O
methyltransferase O
( O
DNMT O
) O
overexpression O
in O
GABAergic O
neurons O
has O
been O
regarded O
as O
a O
characteristic O
phenotypic O
component O
of O
the O
neuropathology O
of O
psychotic O
disorders O
( O
Guidotti O
et O
al O
. O
, O
2011 O
) O
. O

Behaviorally O
, O
adult O
PRS O
mice O
showed O
hyperactivity O
and O
deficits O
in O
social O
interaction O
, O
prepulse O
inhibition O
, O
and O
fear O
conditioning O
that O
were O
corrected O
by O
administration O
of O
valproic B
acid I
( O
a O
histone O
deacetylase O
inhibitor O
) O
or O
clozapine B
( O
an O
atypical O
antipsychotic O
with O
DNA O
- O
demethylation O
activity O
) O
. O

A O
new O
method O
for O
preparing O
pentacyclic B
triterpene I
rich O
Centella O
asiatica O
extracts O
. O

This O
study O
evaluated O
microwave O
- O
assisted O
extraction O
( O
MAE O
) O
for O
four O
pentacyclic B
triterpenes I
as O
well O
as O
developed O
a O
method O
for O
preparing O
a O
pentacyclic B
triterpenene I
rich O
extract O
from O
Centella O
asiatica O
. O

This O
study O
evaluated O
microwave O
- O
assisted O
extraction O
( O
MAE O
) O
for O
four O
pentacyclic B
triterpenes I
as O
well O
as O
developed O
a O
method O
for O
preparing O
a O
pentacyclic B
triterpenene I
rich O
extract O
from O
Centella O
asiatica O
. O

MAE O
was O
capable O
of O
increasing O
the O
yield O
of O
the O
pentacyclic B
triterpenes I
up O
to O
twice O
that O
produced O
by O
the O
heat O
reflux O
method O
, O
and O
it O
was O
also O
much O
less O
time O
consuming O
. O

Here O
, O
we O
provide O
a O
simple O
method O
for O
the O
preparation O
of O
the O
pentacyclic B
triterpene I
rich O
C O
. O
asiatica O
extracts O
, O
which O
contained O
not O
less O
than O
65 O
% O
w O
/ O
w O
total O
pentacyclic B
triterpenes I
. O

Here O
, O
we O
provide O
a O
simple O
method O
for O
the O
preparation O
of O
the O
pentacyclic B
triterpene I
rich O
C O
. O
asiatica O
extracts O
, O
which O
contained O
not O
less O
than O
65 O
% O
w O
/ O
w O
total O
pentacyclic B
triterpenes I
. O

By O
synthesizing O
and O
testing O
a O
series O
of O
alanine B
point O
- O
mutated O
cyclic O
peptides O
, O
we O
identified O
which O
amino B
acid I
was O
important O
for O
the O
inhibition O
of O
the O
phospholamban O
function O
. O

p B
- I
Coumaric I
acid I
, O
a O
hydroxy B
derivative O
of O
cinnamic B
acid I
, O
has O
been O
known O
to O
possess O
antioxidant O
and O
anticancer O
activities O
. O

Fatty B
acid I
composition O
of O
selected O
macrophytes O
. O

The O
content O
of O
total O
lipids O
and O
the O
fatty B
acid I
( O
FA O
) O
profile O
were O
determined O
for O
eight O
macroalgae O
( O
Cystoseira O
abies O
- O
marina O
, O
Fucus O
spiralis O
, O
Chaetomorpha O
pachynema O
, O
Codium O
elisabethae O
, O
Porphyra O
sp O
. O
, O
Osmundea O
pinnatifida O
, O
Pterocladiella O
capillacea O
and O
Sphaeroccoccus O
coronopifolius O
) O
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic B
( O
C16 B
: I
0 I
) O
and O
myristic B
( O
C14 B
: I
0 I
) O
, O
while O
oleic B
( O
C18 B
: I
1 I
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated B
acid I
. O

All O
seaweeds O
contained O
linoleic B
FA I
( O
C18 B
: I
2 I
n O
- O
6 O
) O
. O

Intake O
of O
SCH B
also O
greatly O
increased O
the O
antioxidant O
capacity O
and O
decreased O
the O
values O
of O
thiobarbituric B
acid I
reactive O
substances O
, O
total O
free O
radicals O
, O
and O
superoxide B
anion O
radicals O
in O
the O
plasma O
. O

Single O
non O
- O
ionic O
surfactant O
based O
self O
- O
nanoemulsifying O
drug O
delivery O
system O
( O
SNEDDS O
) O
was O
formulated O
and O
characterised O
for O
poor O
water O
soluble O
drug O
, O
Atorvastatin B
calcium I
. O

Capmul O
MCM O
oil O
showing O
highest O
solubility O
for O
Atorvastatin B
calcium I
was O
selected O
as O
oil O
phase O
. O

Self O
- O
nanoemulsifying O
capacity O
of O
Cremophor O
RH O
40 O
, O
Cremophor O
EL O
, O
Tween B
20 I
, O
Tween B
60 I
, O
Tween B
80 I
and O
Labrasol O
were O
tested O
for O
the O
selected O
oil O
. O

Self O
- O
nanoemulsifying O
capacity O
of O
Cremophor O
RH O
40 O
, O
Cremophor O
EL O
, O
Tween B
20 I
, O
Tween B
60 I
, O
Tween B
80 I
and O
Labrasol O
were O
tested O
for O
the O
selected O
oil O
. O

Self O
- O
nanoemulsifying O
capacity O
of O
Cremophor O
RH O
40 O
, O
Cremophor O
EL O
, O
Tween B
20 I
, O
Tween B
60 I
, O
Tween B
80 I
and O
Labrasol O
were O
tested O
for O
the O
selected O
oil O
. O

Capmul O
MCM O
was O
found O
to O
be O
better O
nanoemulsified O
in O
decreasing O
order O
of O
Cremophor O
RH O
40 O
> O
Cremophor O
EL O
> O
Tween B
20 I
> O
Tween B
60 I
> O
Tween B
80 I
. O

Capmul O
MCM O
was O
found O
to O
be O
better O
nanoemulsified O
in O
decreasing O
order O
of O
Cremophor O
RH O
40 O
> O
Cremophor O
EL O
> O
Tween B
20 I
> O
Tween B
60 I
> O
Tween B
80 I
. O

Capmul O
MCM O
was O
found O
to O
be O
better O
nanoemulsified O
in O
decreasing O
order O
of O
Cremophor O
RH O
40 O
> O
Cremophor O
EL O
> O
Tween B
20 I
> O
Tween B
60 I
> O
Tween B
80 I
. O

SNEDDS O
formulated O
with O
Tween B
20 I
surfactant O
showed O
enhanced O
dissolution O
with O
t85 O
% O
and O
DE O
values O
at O
10 O
min O
and O
78 O
. O
70 O
, O
respectively O
. O

Tween B
20 I
based O
SNEDDS O
enhanced O
permeation O
of O
the O
drug O
as O
compared O
with O
pure O
drug O
across O
cell O
lines O
. O

It O
can O
be O
concluded O
that O
SNEDDS O
can O
be O
formulated O
by O
using O
single O
non O
- O
ionic O
surfactant O
system O
for O
enhance O
dissolution O
and O
absorption O
of O
poorly O
soluble O
drug O
, O
Atorvastatin B
calcium I
. O

Two O
new O
alkaloid B
galactosides I
from O
the O
kernel O
of O
Prinsepia O
uniflora O
. O

Two O
new O
alkaloid B
galactosides I
have O
been O
isolated O
from O
the O
kernel O
of O
Prinsepia O
uniflora O
. O

Solid O
lipid O
nanoparticles O
and O
nanosuspension O
of O
adefovir B
dipivoxil I
for O
bioavailability O
improvement O
: O
formulation O
, O
characterization O
, O
pharmacokinetic O
and O
biodistribution O
studies O
. O

The O
present O
study O
was O
aimed O
at O
developing O
colloidal O
formulations O
like O
solid O
lipid O
nanoparticles O
( O
SLN O
) O
and O
nanosuspension O
( O
NS O
) O
for O
improving O
bioavailability O
of O
adefovir B
dipivoxil I
( O
AD O
) O
, O
a O
nucleoside B
reverse O
transcriptase O
inhibitor O
which O
displays O
poor O
oral O
bioavailability O
. O

Leaves O
of O
Olea O
europaea O
, O
cultivar O
Nocellara O
del O
Belice O
, O
were O
examined O
with O
respect O
to O
the O
medium O
- O
polar O
fraction O
, O
obtained O
by O
an O
ethyl B
acetate I
extraction O
of O
the O
whole O
extract O
. O

Composition O
of O
microemulsion O
( O
ME O
) O
systems O
consisting O
of O
butyl B
lactate I
, O
Brij B
( O
( O
R O
) O
) O
97 O
, O
Transcutol B
( O
( O
R O
) O
) O
and O
water O
was O
optimized O
using O
augmented O
simplex O
lattice O
mixture O
design O
. O

The O
independent O
variables O
selected O
were O
the O
percentages O
of O
butyl B
lactate I
, O
surfactant O
mixture O
and O
water O
. O

Betula O
aetnensis O
showed O
also O
an O
interesting O
reducing O
power O
with O
TEAC O
values O
of O
9 O
. O
7 O
and O
a O
good O
inhibition O
of O
linoleic B
acid I
oxidation O
with O
an O
IC50 O
value O
of O
22 O
. O
0 O
micro O
g O
mL O
( O
- O
1 O
) O
after O
30 O
min O
of O
incubation O
. O

Feroniellides B
C I
- I
E I
, O
new O
apotirucallane B
triterpenoids I
from O
the O
stem O
bark O
of O
Feroniella O
lucida O
. O

Bioassay O
- O
directed O
isolation O
of O
Feroniella O
lucida O
stem O
bark O
yielded O
three O
new O
apotirucallane B
triterpenoids I
named O
feroniellides B
C I
- I
E I
. O

Garcinielliptone B
FC I
( O
GFC B
) O
, O
a O
natural O
prenylated B
benzophenone I
, O
was O
extracted O
from O
Platonia O
insignis O
Mart O
. O

Garcinielliptone B
FC I
( O
GFC B
) O
, O
a O
natural O
prenylated B
benzophenone I
, O
was O
extracted O
from O
Platonia O
insignis O
Mart O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

The O
results O
showed O
that O
the O
extract O
inhibited O
the O
contraction O
induced O
by O
a O
submaximal O
dose O
of O
acetylcholine B
( O
2 O
. O
04 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
, O
oxytocin B
( O
1 O
. O
54 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
and O
prostaglandin B
E2 I
( O
PGE2 B
) O
( O
6 O
. O
00 O
x O
10 O
( O
- O
4 O
) O
mg O
mL O
( O
- O
1 O
) O
) O
. O

A O
new O
caryolane B
sesquiterpene I
from O
Heteropappus O
altaicus O
( O
Willd O
. O
) O
Novopokr O
. O

A O
new O
caryolane B
sesquiterpene I
, O
1 B
beta I
- I
methoxycaryol I
- I
9 I
- I
one I
( O
1 O
) O
, O
along O
with O
eight O
known O
compounds O
( O
2 O
- O
9 O
) O
, O
was O
isolated O
from O
the O
whole O
plant O
of O
Heteropappus O
altaicus O
. O

Isolation O
and O
structure O
determination O
of O
new O
siderophore O
tsukubachelin B
B I
from O
Streptomyces O
sp O
. O

The O
new O
siderophore O
tsukubachelin B
B I
( O
1 O
) O
was O
isolated O
from O
the O
iron B
- O
deficient O
culture O
medium O
of O
the O
newly O
isolated O
strain O
Streptomyces O
sp O
. O

The O
chemical O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
was O
established O
via O
interpretation O
of O
2D O
nuclear O
magnetic O
resonance O
and O
electrospray O
ionization O
- O
mass O
spectroscopic O
data O
. O

The O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
comprises O
6 O
mol O
of O
amino B
acids I
, O
including O
2 O
mol O
of O
serine B
and O
1 O
mol O
each O
of O
ornithine B
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxy I
- I
N I
- I
delta I
- I
formylornithine I
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxyornithine I
, O
and O
cyclic B
N I
- I
hydroxyornithine I
. O

The O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
comprises O
6 O
mol O
of O
amino B
acids I
, O
including O
2 O
mol O
of O
serine B
and O
1 O
mol O
each O
of O
ornithine B
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxy I
- I
N I
- I
delta I
- I
formylornithine I
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxyornithine I
, O
and O
cyclic B
N I
- I
hydroxyornithine I
. O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

The O
acute O
treatment O
with O
LSL B
61122 I
( O
10 O
mg O
/ O
kg O
) O
reduced O
the O
content O
of O
mitochondrial O
( O
pro O
- O
apoptotic O
) O
Bax O
( O
- O
33 O
% O
) O
and O
cytochrome O
c O
( O
- O
31 O
% O
) O
, O
which O
was O
prevented O
by O
idazoxan B
, O
an O
I O
( O
2 O
) O
- O
receptor O
antagonist O
. O

Similar O
chronic O
treatments O
with O
LSL B
60101 I
( O
the O
imidazole B
analogue O
of O
2 B
- I
BFI I
) O
and O
idazoxan B
( O
a O
mixed O
I O
( O
2 O
) O
/ O
alpha O
( O
2 O
) O
- O
ligand O
) O
did O
not O
induce O
significant O
alterations O
of O
pro O
- O
or O
anti O
- O
apoptotic O
proteins O
. O

Rescue O
of O
both O
impaired O
extinction O
acquisition O
and O
deficient O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
prior O
extinction O
training O
administration O
of O
valproic B
acid I
( O
a O
GABAergic O
enhancer O
and O
HDAC O
inhibitor O
) O
or O
AMN082 B
[ O
metabotropic O
glutamate B
receptor O
7 O
( O
mGlu7 O
) O
agonist O
] O
, O
while O
MS B
- I
275 I
or O
PEPA B
( O
AMPA B
receptor O
potentiator O
) O
failed O
to O
affect O
extinction O
acquisition O
in O
S1 O
mice O
. O

Alleviation O
of O
high O
salt O
toxicity O
- O
induced O
oxidative O
damage O
by O
salicylic B
acid I
pretreatment O
in O
two O
wheat O
cultivars O
. O

Role O
of O
exogenous O
salicylic B
acid I
( O
SA O
) O
in O
the O
antioxidative O
response O
to O
salt O
toxicity O
of O
two O
wheat O
( O
Triticum O
aestivum O
) O
cultivars O
( O
Gerek O
- O
79 O
and O
Bezostaya O
) O
was O
investigated O
. O

In O
silico O
electron O
transfer O
to O
the O
precursor O
dications O
, O
( O
GtK B
+ O
2H B
) O
( O
2 O
+ O
) O
, O
( O
AtK B
+ O
2H B
) O
( O
2 O
+ O
) O
, O
and O
( O
AtR B
+ O
2H B
) O
( O
2 O
+ O
) O
, O
formed O
zwitterionic O
intermediates O
containing O
thioenol B
anion I
- I
radical I
and O
ammonium B
cation I
groups O
that O
were O
local O
energy O
minima O
on O
the O
potential O
energy O
surface O
of O
the O
ground O
electronic O
state O
. O

Effects O
of O
collisional O
and O
vibrational O
velocity O
on O
proton O
and O
deuteron B
transfer O
in O
the O
reaction O
of O
HOD B
+ I
with O
CO B
. O

IMI O
subsequently O
undergoes O
the O
cyclization O
process O
through O
a O
secondary B
ammonia I
removal O
via O
similar O
manner O
. O

Two O
new O
cassane B
- O
type O
diterpenes B
, O
Caesalpinolide B
F I
( O
1 O
) O
and O
Caesalpinolide B
G I
( O
2 O
) O
were O
isolated O
from O
Caesalpinia O
minax O
Hance O
. O

Two O
new O
cassane B
- O
type O
diterpenes B
, O
Caesalpinolide B
F I
( O
1 O
) O
and O
Caesalpinolide B
G I
( O
2 O
) O
were O
isolated O
from O
Caesalpinia O
minax O
Hance O
. O

Disposition O
of O
diiosononyl B
phthalate I
and O
its O
effects O
on O
sexual O
development O
of O
the O
male O
fetus O
following O
repeated O
dosing O
in O
pregnant O
rats O
. O

Pregnant O
Sprague O
- O
Dawley O
rats O
received O
50 O
, O
250 O
, O
and O
500 O
mg O
/ O
kg O
/ O
day O
diisononyl B
phthalate I
( O
DiNP B
) O
from O
GD O
12 O
to O
19 O
via O
corn O
oil O
gavage O
to O
study O
the O
dose O
response O
for O
effects O
on O
fetal O
male O
rat O
sexual O
development O
as O
well O
as O
metabolite O
disposition O
in O
the O
dam O
and O
fetus O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

Chrysin B
, O
apigenin B
, O
and O
luteolin B
dose O
- O
dependently O
up O
- O
regulated O
the O
protein O
expression O
of O
heme B
oxygenase O
1 O
( O
HO O
- O
1 O
) O
and O
glutamate B
cysteine B
ligase O
( O
GCL O
) O
catalytic O
( O
GCLC O
) O
and O
modifier O
subunit O
( O
GCLM O
) O
and O
increased O
the O
intracellular O
glutathione B
( O
GSH B
) O
content O
and O
the O
ratio O
of O
GSH B
to O
oxidized B
GSH I
. O

Cellular O
reactive O
oxygen B
species O
production O
induced O
by O
tBHP B
was O
attenuated O
by O
pretreatment O
with O
chrysin B
, O
apigenin B
, O
and O
luteolin B
( O
P O
< O
. O
05 O
) O
, O
and O
this O
protection O
was O
reversed O
by O
the O
GCL O
inhibitor O
l B
- I
buthionine I
- I
S I
- I
sulfoximine I
and O
the O
HO O
- O
1 O
inhibitor O
zinc B
protoporphyrin I
. O

Effect O
of O
chalcones B
on O
lipid O
peroxidation O
, O
heme B
oxygenase O
1 O
( O
HO O
- O
1 O
) O
, O
cyclooxygenase O
( O
COX O
) O
, O
interleukin O
5 O
( O
IL O
- O
5 O
) O
, O
nitric B
oxide I
( O
NO B
) O
and O
expression O
of O
cell O
adhesion O
molecules O
( O
CAM O
) O
is O
summarized O
stepwise O
. O

TZDs B
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic B
acid I
uptake O
. O

The O
chemicals O
used O
for O
the O
synthesis O
of O
various O
shaped O
ZnO B
are O
Zn B
salt O
, O
sodium B
hydroxide I
and O
ammonia B
solution I
without O
other O
structure O
directing O
agent O
or O
surfactant O
needed O
. O

The O
chemicals O
used O
for O
the O
synthesis O
of O
various O
shaped O
ZnO B
are O
Zn B
salt O
, O
sodium B
hydroxide I
and O
ammonia B
solution I
without O
other O
structure O
directing O
agent O
or O
surfactant O
needed O
. O

Vitamin B
D I
binding O
protein O
is O
a O
key O
determinant O
of O
25 B
- I
hydroxyvitamin I
D I
levels O
in O
infants O
and O
toddlers O
. O

Only O
limited O
information O
regarding O
determinants O
of O
these O
measures O
is O
available O
for O
infants O
and O
children O
, O
particularly O
in O
minority O
groups O
at O
greatest O
risk O
for O
vitamin B
D I
deficiency O
. O

We O
identified O
demographic O
determinants O
of O
circulating O
25 B
- I
OHD I
in O
a O
large O
cohort O
of O
minority O
children O
, O
and O
now O
extend O
our O
studies O
to O
examine O
potential O
roles O
of O
vitamin B
D I
binding O
protein O
( O
DBP O
) O
as O
a O
determinant O
of O
25 B
- I
OHD I
levels O
. O

An O
application O
to O
propylene B
oxide I
. O

In O
this O
article O
we O
report O
calculations O
of O
the O
activation O
free O
energy O
for O
a O
chemical O
reaction O
between O
propylene B
oxide I
and O
DNA O
, O
in O
particular O
with O
the O
guanine B
at O
the O
N7 O
position O
. O

The O
influence O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
eicosapentaenoic B
acid I
( O
EPA B
) O
intake O
on O
LPO O
level O
was O
investigated O
. O

The O
influence O
of O
docosahexaenoic B
acid I
( O
DHA B
) O
and O
eicosapentaenoic B
acid I
( O
EPA B
) O
intake O
on O
LPO O
level O
was O
investigated O
. O

Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP B
phenols I
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates B
. O

Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance O
- O
associated O
proteins O
( O
ABCCs O
) O
are O
involved O
in O
the O
transport O
of O
BPDE B
glutathione I
conjugates O
. O

Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE B
glutathione I
conjugates O
. O

Structural O
differences O
between O
insect O
and O
mammalian O
AChE O
are O
also O
evident O
in O
their O
genomics O
, O
amino B
acid I
sequences O
and O
active O
site O
conformations O
. O

A O
green O
and O
simple O
approach O
to O
assembling O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
via O
three O
- O
component O
reaction O
of O
kojic B
acid I
, O
malononitrile B
, O
and O
aromatic B
aldehydes I
in O
aqueous O
media O
under O
ultrasound O
irradiation O
is O
described O
. O

A O
green O
and O
simple O
approach O
to O
assembling O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
via O
three O
- O
component O
reaction O
of O
kojic B
acid I
, O
malononitrile B
, O
and O
aromatic B
aldehydes I
in O
aqueous O
media O
under O
ultrasound O
irradiation O
is O
described O
. O

In O
comparison O
to O
conventional O
methods O
, O
experimental O
simplicity O
, O
good O
functional O
group O
tolerance O
, O
excellent O
yields O
, O
short O
routine O
, O
and O
selectivity O
without O
the O
need O
for O
a O
transition B
metal I
or O
base O
catalyst O
are O
prominent O
features O
of O
this O
green O
procedure O
. O

These O
animal O
models O
are O
based O
on O
chemical O
interventions O
( O
e O
. O
g O
. O
pentylenetetrazol B
, O
kainic B
acid I
, O
pilocarpine B
) O
, O
electrical O
stimulations O
( O
e O
. O
g O
. O
kindling O
, O
electroshock O
) O
, O
and O
genetic O
/ O
selective O
breeding O
paradigms O
( O
e O
. O
g O
. O
genetically O
epilepsy O
- O
prone O
rats O
( O
GEPRs O
) O
, O
genetic O
absence O
epilepsy O
rat O
from O
Strasbourg O
( O
GAERS O
) O
, O
WAG O
/ O
Rij O
rats O
, O
swim O
lo O
- O
active O
rats O
( O
SwLo O
) O
) O
. O

The O
results O
indicated O
that O
exposure O
of O
RBE4 O
cells O
to O
AgNPs O
lead O
to O
significant O
reduction O
in O
dye O
uptake O
as O
measured O
with O
the O
Neutral B
red I
( O
NR O
) O
assay O
. O

Involvement O
of O
interleukin O
- O
6 O
- O
regulated O
nitric B
oxide I
synthase O
in O
hemorrhagic O
cystitis O
and O
impaired O
bladder O
contractions O
in O
young O
rats O
induced O
by O
acrolein B
, O
a O
urinary O
metabolite O
of O
cyclophosphamide B
. O

Inducible O
nitric B
oxide I
( O
NO B
) O
synthase O
( O
iNOS O
) O
protein O
expressions O
were O
markedly O
induced O
in O
bladders O
24 O
h O
after O
acrolein B
treatment O
. O

Modulation O
of O
the O
nitric B
oxide I
producing O
system O
( O
demonstrated O
via O
the O
NADPH B
- O
diaphorase O
histochemical O
reaction O
) O
by O
oestradiol B
has O
been O
established O
in O
several O
structures O
of O
the O
rat O
brain O
. O

Separate O
groups O
of O
mice O
underwent O
3 O
consecutive O
days O
of O
the O
same O
exposure O
sequence O
for O
3h O
each O
consisting O
of O
the O
following O
: O
( O
1 O
) O
6h O
of O
filtered O
air O
( O
FAFA O
) O
, O
( O
2 O
) O
O B
( I
3 I
) I
then O
FA O
( O
O B
( I
3 I
) I
FA O
) O
, O
( O
3 O
) O
FA O
then O
carbon B
black I
( O
FACB O
) O
, O
or O
( O
4 O
) O
O B
( I
3 I
) I
then O
CB O
. O

The O
growth O
of O
sphere O
- O
like O
trimanganese B
tetraoxide I
( O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
) O
nanoparticles O
on O
silk O
fiber O
was O
achieved O
by O
sequential O
dipping O
in O
an O
alternating O
bath O
of O
potassium B
hydroxide I
and O
manganese B
( I
II I
) I
nitrate I
under O
ultrasound O
irradiation O
. O

The O
growth O
of O
sphere O
- O
like O
trimanganese B
tetraoxide I
( O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
) O
nanoparticles O
on O
silk O
fiber O
was O
achieved O
by O
sequential O
dipping O
in O
an O
alternating O
bath O
of O
potassium B
hydroxide I
and O
manganese B
( I
II I
) I
nitrate I
under O
ultrasound O
irradiation O
. O

Since O
PARP O
- O
1 O
is O
supposed O
to O
be O
part O
of O
a O
multimeric O
repressor O
of O
sodium B
iodide I
symporter O
( O
NIS O
) O
expression O
, O
in O
this O
study O
the O
effect O
of O
the O
PARP O
inhibitor O
PJ34 B
on O
several O
properties O
of O
thyroid O
cancer O
cell O
lines O
was O
investigated O
. O

While O
the O
human O
studies O
, O
which O
modulated O
the O
dietary O
or O
serum O
phosphate B
showed O
in O
rather O
controversial O
results O
, O
manipulation O
of O
the O
active O
vitamin B
D I
definitely O
affected O
FGF O
- O
23 O
in O
animals O
. O

This O
study O
was O
conducted O
to O
elucidate O
the O
relationship O
between O
active O
vitamin B
D I
directly O
stimulated O
by O
ultraviolet O
B O
( O
UVB O
) O
exposure O
and O
FGF O
- O
23 O
level O
in O
human O
. O

Withaferin B
A I
- O
stimulated O
Ca2 B
+ I
entry O
, O
ceramide B
formation O
and O
suicidal O
death O
of O
erythrocytes O
. O

Withaferin B
A I
- O
stimulated O
Ca2 B
+ I
entry O
, O
ceramide B
formation O
and O
suicidal O
death O
of O
erythrocytes O
. O

Withaferin B
A I
, O
a O
triterpenoid B
component O
from O
Withania O
somnifera O
, O
counteracts O
malignancy O
, O
an O
effect O
attributed O
to O
stimulation O
of O
apoptosis O
. O

Withaferin B
A I
is O
partially O
effective O
through O
induction O
of O
oxidative O
stress O
, O
altered O
gene O
expression O
and O
mitochondrial O
depolarization O
. O

The O
present O
study O
explored O
, O
whether O
withaferin B
A I
triggers O
eryptosis O
. O

A O
48 O
h O
exposure O
to O
withaferin B
A I
significantly O
decreased O
forward O
scatter O
( O
at O
> O
= O
10 O
mu O
M O
withaferin B
concentration O
) O
and O
increased O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
( O
> O
= O
5 O
mu O
M O
) O
, O
ROS O
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
ceramide B
- O
formation O
( O
> O
= O
10 O
mu O
M O
) O
as O
well O
as O
annexin O
- O
V O
- O
binding O
( O
> O
= O
5 O
mu O
M O
) O
. O

Withaferin B
A I
treatment O
was O
followed O
by O
slight O
but O
significant O
increase O
of O
hemolysis O
. O

Extracellular O
Ca B
( I
2 I
+ I
) I
removal O
, O
amiloride B
, O
and O
the O
antioxidant O
N B
- I
acetyl I
- I
l I
- I
cysteine I
significantly O
blunted O
withaferin B
A I
- O
triggered O
annexin O
- O
V O
- O
binding O
. O

The O
present O
observations O
reveal O
that O
withaferin B
A I
triggers O
suicidal O
erythrocyte O
death O
despite O
the O
absence O
of O
gene O
expression O
and O
key O
elements O
of O
apoptosis O
such O
as O
mitochondria O
. O

Aryl B
methylcarbamates I
: O
Potency O
and O
selectivity O
towards O
wild O
- O
type O
and O
carbamate B
- O
insensitive O
( O
G119S O
) O
Anopheles O
gambiae O
acetylcholinesterase O
, O
and O
toxicity O
to O
G3 O
strain O
An O
. O
gambiae O
. O

Valproic B
acid I
but O
not O
D B
- I
cycloserine I
facilitates O
sleep O
- O
dependent O
offline O
learning O
of O
extinction O
and O
habituation O
of O
conditioned O
fear O
in O
humans O
. O

The O
effectiveness O
of O
D B
- I
cycloserine I
( O
DCS B
) O
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
glutamate I
receptor O
partial O
agonist O
, O
and O
valproic B
acid I
( O
VPA B
) O
, O
a O
histone O
deacetylase O
inhibitor O
, O
in O
facilitating O
the O
extinction O
of O
fear O
- O
conditioned O
memory O
has O
been O
explored O
in O
humans O
and O
animals O
. O

Neurotoxic O
potential O
of O
iron B
oxide I
nanoparticles O
in O
the O
rat O
brain O
striatum O
and O
hippocampus O
. O

It O
has O
recently O
been O
reported O
that O
iron B
oxide I
nanoparticles O
( O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
, O
30 O
nm O
) O
have O
the O
ability O
to O
translocate O
directly O
from O
the O
olfactory O
nerve O
to O
the O
brain O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone B
A I
( O
Epo B
A I
) O
and O
epothilone B
B I
( O
Epo B
B I
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel B
( O
PTX B
) O
, O
a O
classic O
taxane B
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone B
A I
( O
Epo B
A I
) O
and O
epothilone B
B I
( O
Epo B
B I
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel B
( O
PTX B
) O
, O
a O
classic O
taxane B
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone B
A I
( O
Epo B
A I
) O
and O
epothilone B
B I
( O
Epo B
B I
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel B
( O
PTX B
) O
, O
a O
classic O
taxane B
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
effects O
of O
epothilone B
A I
( O
Epo B
A I
) O
and O
epothilone B
B I
( O
Epo B
B I
) O
on O
ovarian O
cancer O
cell O
line O
SKOV O
- O
3 O
with O
those O
of O
paclitaxel B
( O
PTX B
) O
, O
a O
classic O
taxane B
. O

Apoptotic O
and O
necrotic O
cell O
levels O
were O
measured O
by O
double O
staining O
with O
Hoechst B
33258 I
and O
propidium B
iodide I
( O
PI O
) O
as O
well O
as O
Annexin O
V O
staining O
. O

Apoptotic O
and O
necrotic O
cell O
levels O
were O
measured O
by O
double O
staining O
with O
Hoechst B
33258 I
and O
propidium B
iodide I
( O
PI O
) O
as O
well O
as O
Annexin O
V O
staining O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

The O
results O
obtained O
demonstrated O
that O
the O
antiproliferative O
capacity O
of O
Epo B
A I
and O
Epo B
B I
in O
SKOV O
- O
3 O
cell O
line O
( O
measured O
as O
IC O
( O
50 O
) O
after O
72 O
h O
continuous O
treatment O
) O
was O
six O
and O
five O
times O
greater O
than O
that O
of O
PTX B
' O
s O
respectively O
. O

The O
results O
obtained O
demonstrated O
that O
the O
antiproliferative O
capacity O
of O
Epo B
A I
and O
Epo B
B I
in O
SKOV O
- O
3 O
cell O
line O
( O
measured O
as O
IC O
( O
50 O
) O
after O
72 O
h O
continuous O
treatment O
) O
was O
six O
and O
five O
times O
greater O
than O
that O
of O
PTX B
' O
s O
respectively O
. O

The O
optimum O
formulation O
of O
SMEDDS O
was O
a O
system O
consisting O
of O
ethyl B
oleate I
, O
tween B
80 I
, O
and O
propylene B
glycol I
with O
a O
mean O
droplet O
size O
of O
39 O
. O
42 O
nm O
. O

The O
optimum O
formulation O
of O
SMEDDS O
was O
a O
system O
consisting O
of O
ethyl B
oleate I
, O
tween B
80 I
, O
and O
propylene B
glycol I
with O
a O
mean O
droplet O
size O
of O
39 O
. O
42 O
nm O
. O

The O
optimum O
formulation O
of O
SMEDDS O
was O
a O
system O
consisting O
of O
ethyl B
oleate I
, O
tween B
80 I
, O
and O
propylene B
glycol I
with O
a O
mean O
droplet O
size O
of O
39 O
. O
42 O
nm O
. O

With O
regard O
to O
alkylating O
damage O
repair O
H O
. O
perforatum O
, O
H O
. O
androsaemum O
and O
chlorogenic B
acid I
increased O
repair O
of O
alkylating O
DNA O
damage O
by O
base O
excision O
repair O
pathway O
. O

Ten O
microlitres O
aliquots O
of O
peripheral O
venous O
human O
blood O
were O
incubated O
with O
tarragon O
extract O
, O
saline O
, O
or O
the O
mutagen O
sodium B
dichromate I
. O

Cell O
suspensions O
dispersed O
in O
low O
- O
melting O
agarose O
were O
electrophoresed O
in O
ethidium B
bromide I
. O

Gallic B
acid I
and O
p B
- I
cumaric I
acid I
were O
identified O
for O
Ayval O
i O
k O
and O
Domat O
at O
each O
period O
of O
ripening O
, O
respectively O
. O

In O
addition O
, O
gallic B
acid I
, O
p B
- I
cumaric I
acid I
, O
sinapinic B
and I
apigenin I
acids I
were O
detected O
in O
Gemlik O
olive O
fruit O
. O

Hydroxytyrosol B
, O
rutin B
, O
oleoropein B
, O
luteolin B
, O
tyrosol B
, O
vanilic B
acid I
and O
gallic B
acid I
in O
Ayval O
i O
k O
olive O
fruit O
in O
all O
ripening O
periods O
were O
determined O
. O

Hydroxytyrosol B
, O
rutin B
, O
oleoropein B
, O
luteolin B
, O
tyrosol B
, O
vanilic B
acid I
and O
gallic B
acid I
in O
Ayval O
i O
k O
olive O
fruit O
in O
all O
ripening O
periods O
were O
determined O
. O

Vanillic B
acid I
contents O
of O
oils O
ranged O
between O
0 O
. O
08 O
to O
2 O
. O
38mg O
/ O
kg O
. O

The O
total O
solids O
, O
a O
( O
w O
) O
value O
, O
total O
phenolics B
, O
vitamin B
C I
, O
antioxidant O
activity O
, O
anthocyanin B
content O
, O
total O
colour O
change O
and O
firmness O
were O
used O
as O
quality O
indicators O
of O
dried O
sour O
cherry O
. O

Under O
these O
optimal O
conditions O
, O
the O
predicted O
amount O
of O
total O
phenolics B
was O
744mg O
CAE O
/ O
100 O
dw O
, O
vitamin B
C I
1 O
. O
44mg O
/ O
100g O
per O
dry O
weight O
( O
g O
dw O
) O
, O
anthocyanin B
content O
125mg O
/ O
100g O
dw O
, O
IC O
( O
50 O
) O
3 O
. O
23mg O
/ O
ml O
, O
total O
solids O
70 O
. O
72 O
% O
, O
a O
( O
w O
) O
value O
0 O
. O
646 O
, O
total O
colour O
change O
52 O
. O
61 O
and O
firmness O
3395 O
. O
4g O
. O

Occurrence O
of O
ochratoxin B
A I
in O
cocoa O
by O
- O
products O
and O
determination O
of O
its O
reduction O
during O
chocolate O
manufacture O
. O

This O
work O
reports O
an O
investigation O
carried O
out O
to O
assess O
the O
natural O
occurrence O
of O
ochratoxin B
A I
in O
168 O
samples O
from O
different O
fractions O
obtained O
during O
the O
technological O
processing O
of O
cocoa O
( O
shell O
, O
nibs O
, O
liquor O
, O
butter O
, O
cake O
and O
cocoa O
powder O
) O
and O
the O
reduction O
of O
ochratoxin B
A I
during O
chocolate O
manufacture O
. O

This O
work O
reports O
an O
investigation O
carried O
out O
to O
assess O
the O
natural O
occurrence O
of O
ochratoxin B
A I
in O
168 O
samples O
from O
different O
fractions O
obtained O
during O
the O
technological O
processing O
of O
cocoa O
( O
shell O
, O
nibs O
, O
liquor O
, O
butter O
, O
cake O
and O
cocoa O
powder O
) O
and O
the O
reduction O
of O
ochratoxin B
A I
during O
chocolate O
manufacture O
. O

Ochratoxin B
A I
analyses O
were O
performed O
with O
immunoaffinity O
columns O
and O
detection O
by O
high O
performance O
liquid O
chromatography O
. O

Concerning O
the O
natural O
ochratoxin B
A I
contamination O
in O
cocoa O
by O
- O
products O
, O
the O
highest O
levels O
of O
ochratoxin B
A I
were O
found O
in O
the O
shell O
, O
cocoa O
powder O
and O
cocoa O
cake O
. O

Concerning O
the O
natural O
ochratoxin B
A I
contamination O
in O
cocoa O
by O
- O
products O
, O
the O
highest O
levels O
of O
ochratoxin B
A I
were O
found O
in O
the O
shell O
, O
cocoa O
powder O
and O
cocoa O
cake O
. O

The O
cocoa O
butter O
was O
the O
least O
contaminated O
, O
showing O
that O
ochratoxin B
A I
seems O
to O
remain O
in O
the O
defatted O
cocoa O
solids O
. O

Under O
the O
technological O
conditions O
applied O
during O
the O
manufacture O
of O
chocolate O
in O
this O
study O
and O
the O
level O
of O
contamination O
present O
in O
the O
cocoa O
beans O
, O
this O
experiment O
demonstrated O
that O
93 O
. O
6 O
% O
of O
ochratoxin B
A I
present O
in O
the O
beans O
was O
reduced O
during O
the O
chocolate O
producing O
. O

The O
bitter O
amino B
acids I
were O
significantly O
decreased O
and O
the O
umami O
acids O
were O
markedly O
increased O
in O
MSPC O
. O

Among O
three O
different O
solvent O
fractions O
of O
GRPE O
and O
GOPE O
, O
ethyl B
acetate I
( O
EA O
) O
fractions O
had O
the O
greatest O
effect O
on O
sleep O
duration O
at O
250mg O
/ O
kg O
. O

Metabolite O
accumulation O
levels O
along O
the O
time O
course O
suggest O
that O
flavanones B
, O
flavones B
, O
polymethoxylated B
flavones I
and O
scoparone B
are O
induced O
in O
citrus O
fruit O
in O
response O
to O
P O
. O
digitatum O
infection O
, O
although O
with O
different O
trends O
depending O
on O
the O
tissue O
. O

The O
oral O
( O
po O
) O
bioavailability O
of O
gemifloxacin B
mesylate I
in O
rats O
and O
its O
possible O
association O
with O
efflux O
transporters O
was O
investigated O
. O

3 O
. O
Main O
circulating O
metabolites O
were O
abiraterone B
sulfate I
and O
N B
- I
oxide I
abiraterone I
sulfate I
. O

Specifically O
, O
expression O
of O
the O
67 O
- O
kD O
isoform O
of O
the O
GABA B
synthesis O
enzyme O
glutamic B
acid I
decarboxylase O
( O
GAD67 O
) O
is O
reduced O
in O
parvalbumin O
- O
containing O
fast O
- O
spiking O
GABA B
interneurons O
. O

Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium B
arsenite I
. O

In O
this O
study O
, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro O
- O
2a O
cells O
expressing O
SCAT3 O
, O
a O
caspase O
- O
3 O
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins O
; O
enhanced O
cyan O
fluorescence O
protein O
( O
ECFP O
) O
and O
Venus O
, O
to O
determine O
whether O
sodium B
arsenite I
( O
NaAsO B
( I
2 I
) I
; O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
mu O
M O
) O
affects O
both O
neurite O
outgrowth O
and O
/ O
or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O

Peroxisome O
proliferator O
- O
activated O
receptor O
- O
beta O
/ O
delta O
( O
PPAR O
delta O
) O
is O
a O
ubiquitously O
expressed O
, O
ligand O
- O
activated O
transcriptional O
factor O
that O
performs O
diverse O
critical O
functions O
in O
normal O
cells O
( O
e O
. O
g O
. O
, O
fatty B
acid I
metabolism O
, O
obesity O
, O
apoptosis O
, O
and O
inflammation O
) O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

ibuprofen B
, O
8 B
- I
methoxypsoralen I
, O
retinoic B
acid I
) O
; O
and O
negative O
compounds O
( O
lactic B
acid I
, O
SDS B
and O
p B
- I
phenilendiamine I
) O
was O
investigated O
. O

ibuprofen B
, O
8 B
- I
methoxypsoralen I
, O
retinoic B
acid I
) O
; O
and O
negative O
compounds O
( O
lactic B
acid I
, O
SDS B
and O
p B
- I
phenilendiamine I
) O
was O
investigated O
. O

Differing O
effects O
of O
PTH O
1 O
- O
34 O
, O
PTH O
1 O
- O
84 O
, O
and O
zoledronic B
acid I
on O
bone O
microarchitecture O
and O
estimated O
strength O
in O
postmenopausal O
women O
with O
osteoporosis O
: O
an O
18 O
- O
month O
open O
- O
labeled O
observational O
study O
using O
HR O
- O
pQCT O
. O

A O
group O
of O
postmenopausal O
osteoporotic O
women O
receiving O
zoledronic B
acid I
( O
5 O
mg O
infusion O
once O
yearly O
, O
n O
= O
33 O
) O
was O
also O
included O
. O

Zoledronic B
acid I
did O
not O
impact O
cortical O
porosity O
at O
either O
site O
but O
increased O
cortical O
thickness O
( O
3 O
. O
0 O
+ O
/ O
- O
3 O
. O
5 O
% O
, O
p O
< O
0 O
. O
01 O
) O
, O
total O
( O
2 O
. O
7 O
+ O
/ O
- O
2 O
. O
5 O
% O
, O
p O
< O
0 O
. O
001 O
) O
and O
cortical O
density O
( O
1 O
. O
5 O
+ O
/ O
- O
2 O
. O
0 O
% O
, O
p O
< O
0 O
. O
01 O
) O
in O
tibia O
as O
well O
as O
trabecular O
volume O
fraction O
in O
radius O
( O
2 O
. O
5 O
+ O
/ O
- O
5 O
. O
1 O
% O
, O
p O
< O
0 O
. O
05 O
) O
and O
tibia O
( O
2 O
. O
2 O

FE O
estimated O
bone O
strength O
was O
preserved O
, O
but O
not O
increased O
, O
with O
PTH O
1 O
- O
34 O
and O
zoledronic B
acid I
at O
both O
sites O
, O
whereas O
it O
decreased O
with O
PTH O
1 O
- O
84 O
in O
radius O
( O
- O
2 O
. O
8 O
+ O
/ O
- O
5 O
. O
8 O
% O
, O
p O
< O
0 O
. O
05 O
) O
and O
tibia O
( O
- O
3 O
. O
9 O
+ O
/ O
- O
4 O
. O
8 O
% O
, O
p O
< O
0 O
. O
001 O
) O
. O

Conclusively O
, O
divergent O
treatment O
- O
specific O
effects O
in O
cortical O
and O
trabecular O
bone O
were O
observed O
with O
anabolic O
and O
zoledronic B
acid I
therapy O
. O

Adipocyte O
fatty B
acid I
binding O
protein O
: O
a O
novel O
adipokine O
involved O
in O
the O
pathogenesis O
of O
metabolic O
and O
vascular O
disease O
? O

Adipocyte O
fatty B
acid I
binding O
protein O
( O
AFABP O
, O
also O
known O
as O
aP2 O
and O
FABP4 O
) O
has O
recently O
been O
introduced O
as O
a O
novel O
fat O
- O
derived O
circulating O
protein O
. O

Magnesium B
sulfate I
treatment O
against O
sarin B
poisoning O
: O
dissociation O
between O
overt O
convulsions O
and O
recorded O
cortical O
seizure O
activity O
. O

Magnesium B
sulfate I
( O
MGS B
) O
is O
used O
to O
suppress O
eclamptic O
seizures O
in O
pregnant O
women O
with O
hypertension O
and O
was O
shown O
to O
block O
kainate B
- O
induced O
convulsions O
. O

Magnesium B
sulfate I
was O
evaluated O
herein O
as O
an O
anticonvulsant O
against O
sarin O
poisoning O
and O
its O
efficacy O
was O
compared O
with O
the O
potent O
anticonvulsants O
midazolam B
( O
MDZ B
) O
and O
caramiphen B
( O
CRM B
) O
. O

The O
new O
Al B
/ O
Pd B
Janus O
microspheres O
- O
prepared O
by O
depositing O
a O
Pd B
layer O
on O
one O
side O
of O
Al B
microparticles O
- O
are O
propelled O
efficiently O
by O
the O
thrust O
of O
hydrogen B
bubbles O
generated O
from O
different O
reactions O
of O
Al B
in O
strong O
acidic O
and O
alkaline O
environments O
, O
and O
by O
an O
oxygen B
bubble O
thrust O
produced O
at O
their O
partial O
Pd B
coating O
in O
hydrogen B
peroxide I
media O
. O

Suppressive O
effect O
of O
accumulated O
aluminum B
trichloride I
on O
the O
hepatic O
microsomal O
cytochrome O
P450 O
enzyme O
system O
in O
rats O
. O

Thus O
, O
the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
aluminum B
trichloride I
( O
AlCl B
( I
3 I
) I
) O
on O
CYPS O
in O
rats O
. O

Owing O
to O
their O
unique O
physical O
and O
chemical O
properties O
, O
graphene B
and O
its O
derivatives O
such O
as O
graphene B
oxide I
( O
GO O
) O
, O
reduced B
graphene I
oxide I
( O
RGO B
) O
and O
GO O
- O
nanocomposites O
have O
attracted O
tremendous O
interest O
in O
many O
different O
fields O
including O
biomedicine O
in O
recent O
years O
. O

Based O
on O
mild O
local O
irritation O
after O
topical O
application O
of O
1 O
. O
0 O
% O
sodium B
metaphosphate I
[ O
( B
NaPO I
( I
3 I
) I
) I
6 I
* I
H2O I
] O
to O
intact O
skin O
of O
sensitive O
volunteers O
, O
a O
do O
not O
use O
concentration O
of O
8 O
, O
000 O
mg O
PO4 B
/ O
L O
can O
be O
assigned O
. O

Using O
wet O
- O
milling O
with O
organic O
milling O
beads O
, O
a O
stable O
nanosuspension O
with O
particle O
size O
in O
the O
range O
of O
200nm O
and O
an O
ITRA B
concentration O
of O
20 O
% O
( O
v O
/ O
w O
) O
could O
be O
obtained O
, O
using O
polysorbate B
80 I
at O
a O
concentration O
of O
14 O
% O
relative O
to O
ITRA B
. O

Adenosine B
levels O
and O
receptor O
- O
mediated O
effects O
of O
adenosine B
are O
regulated O
by O
intracellular O
ATP B
consumption O
, O
cellular O
release O
of O
ATP B
, O
metabolism O
of O
extracellular O
ATP B
( O
and O
other O
adenine B
nucleotides I
) O
, O
adenosine B
influx O
, O
adenosine B
efflux O
and O
adenosine B
metabolism O
. O

The O
third O
plasma O
radiometabolite O
was O
suggested O
to O
be O
a O
carboxylic B
acid I
compound O
that O
accounted O
for O
15 O
% O
of O
the O
rat O
brain O
radioactivity O
. O

Polymorphisms O
in O
the O
vitamin B
D I
receptor O
gene O
and O
risk O
of O
autoimmune O
thyroid O
diseases O
: O
a O
meta O
- O
analysis O
. O

Polymorphisms O
of O
vitamin B
D I
receptor O
( O
VDR O
) O
were O
implicated O
in O
AITDs O
risk O
. O

Here O
, O
we O
report O
the O
role O
each O
constituent O
amino B
acid I
plays O
within O
core O
peptide O
using O
an O
alanine B
scan O
and O
the O
amino B
acid I
effect O
on O
function O
using O
a O
biological O
antigen O
presentation O
assay O
. O

Here O
, O
we O
report O
the O
role O
each O
constituent O
amino B
acid I
plays O
within O
core O
peptide O
using O
an O
alanine B
scan O
and O
the O
amino B
acid I
effect O
on O
function O
using O
a O
biological O
antigen O
presentation O
assay O
. O

Removal O
of O
any O
single O
hydrophobic O
amino B
acid I
between O
the O
two O
charged O
amino B
acids I
in O
core O
peptide O
( O
R O
, O
K O
) O
resulted O
in O
lower O
binding O
. O

Removal O
of O
any O
single O
hydrophobic O
amino B
acid I
between O
the O
two O
charged O
amino B
acids I
in O
core O
peptide O
( O
R O
, O
K O
) O
resulted O
in O
lower O
binding O
. O

Here O
, O
we O
show O
that O
a O
kinase O
- O
inducible O
bimolecular O
switch O
comprising O
a O
kinase O
- O
specific O
substrate O
and O
a O
phosphoamino B
acid I
binding O
domain O
can O
be O
used O
for O
acute O
regulation O
of O
cellular O
events O
. O

An O
anticancer O
drug O
, O
doxorubicin B
hydrochloride I
( O
Dox B
) O
, O
has O
been O
loaded O
into O
MSNs O
and O
HA O
- O
MSNs O
as O
drug O
delivery O
vehicles O
. O

The O
evaluated O
parameters O
were O
passage O
of O
DON B
and O
tylosin B
through O
the O
epithelial O
monolayer O
, O
the O
integrity O
of O
the O
monolayer O
by O
measurements O
of O
the O
trans O
- O
epithelial O
electrical O
resistance O
and O
the O
viability O
of O
the O
monolayer O
using O
the O
neutral B
red I
assay O
. O

Sub O
- O
lethal O
effects O
of O
titanium B
dioxide I
nanoparticles O
on O
the O
physiology O
and O
reproduction O
of O
zebrafish O
. O

There O
are O
limited O
data O
on O
the O
sub O
- O
lethal O
physiological O
effects O
of O
titanium B
dioxide I
nanoparticles O
( O
TiO B
( I
2 I
) I
NPs O
) O
in O
adult O
fishes O
, O
and O
the O
consequences O
of O
TiO B
( I
2 I
) I
NP O
exposure O
on O
reproductive O
success O
are O
also O
unclear O
. O

Ultrasound O
- O
promoted O
coating O
of O
silk O
yarn O
with O
different O
morphology O
of O
magnesium B
hydroxide I
nanostructures O
. O

The O
growth O
of O
magnesium B
hydroxide I
nanostructures O
on O
silk O
yarn O
was O
achieved O
by O
sequential O
dipping O
steps O
in O
alternating O
bath O
of O
magnesium B
nitrate I
and O
potassium B
hydroxide I
under O
ultrasound O
irradiation O
. O

The O
growth O
of O
magnesium B
hydroxide I
nanostructures O
on O
silk O
yarn O
was O
achieved O
by O
sequential O
dipping O
steps O
in O
alternating O
bath O
of O
magnesium B
nitrate I
and O
potassium B
hydroxide I
under O
ultrasound O
irradiation O
. O

The O
growth O
of O
magnesium B
hydroxide I
nanostructures O
on O
silk O
yarn O
was O
achieved O
by O
sequential O
dipping O
steps O
in O
alternating O
bath O
of O
magnesium B
nitrate I
and O
potassium B
hydroxide I
under O
ultrasound O
irradiation O
. O

Furthermore O
, O
antibodies O
to O
DNA O
show O
localized O
binding O
to O
these O
microstructures O
, O
which O
also O
react O
positively O
with O
DNA O
intercalating O
stains O
propidium B
iodide I
( O
PI O
) O
and O
4 B
' I
, I
6 I
' I
- I
diamidino I
- I
2 I
- I
phenylindole I
dihydrochloride I
( O
DAPI B
) O
. O

Upregulated O
interleukin O
( O
IL O
) O
- O
1 O
beta O
maturation O
, O
IL O
- O
18 O
secretion O
, O
and O
caspase O
- O
1 O
cleavage O
were O
observed O
in O
MDMs O
from O
type O
2 O
diabetic O
patients O
after O
stimulation O
with O
various O
danger O
molecules O
( O
ATP B
, O
high O
- O
mobility O
group O
protein O
B1 O
, O
free O
fatty B
acids I
, O
islet O
amyloid O
polypeptide O
, O
and O
monosodium B
uric I
acid I
crystals O
) O
. O

Cholesterol B
ester I
droplets O
and O
steroidogenesis O
. O

Cholesteryl B
ester I
( O
CE O
) O
- O
rich O
LDs O
normally O
accumulate O
in O
steroidogenic O
cells O
and O
their O
mobilization O
is O
the O
preferred O
initial O
source O
of O
cholesterol B
for O
steroidogenesis O
. O

Enhanced O
charge O
carrier O
mobility O
in O
two O
- O
dimensional O
high O
dielectric O
molybdenum B
oxide I
. O

Combination O
lopinavir B
and O
ritonavir B
alter O
exogenous O
and O
endogenous O
bile B
acid I
disposition O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
. O

Inhibition O
of O
the O
bile B
salt I
export O
pump O
( O
BSEP O
) O
can O
cause O
intracellular O
accumulation O
of O
bile B
acids I
and O
is O
a O
risk O
factor O
for O
drug O
- O
induced O
liver O
injury O
in O
humans O
. O

Inhibition O
of O
the O
bile B
salt I
export O
pump O
( O
BSEP O
) O
can O
cause O
intracellular O
accumulation O
of O
bile B
acids I
and O
is O
a O
risk O
factor O
for O
drug O
- O
induced O
liver O
injury O
in O
humans O
. O

However O
, O
the O
consequences O
of O
LPV B
and O
RTV B
, O
alone O
and O
combined O
( O
LPV B
/ O
r O
) O
, O
on O
hepatocyte O
viability O
, O
bile B
acid I
transport O
, O
and O
endogenous O
bile B
acid I
disposition O
in O
rat O
hepatocytes O
have O
not O
been O
examined O
. O

However O
, O
the O
consequences O
of O
LPV B
and O
RTV B
, O
alone O
and O
combined O
( O
LPV B
/ O
r O
) O
, O
on O
hepatocyte O
viability O
, O
bile B
acid I
transport O
, O
and O
endogenous O
bile B
acid I
disposition O
in O
rat O
hepatocytes O
have O
not O
been O
examined O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

Quantification O
of O
endogenous O
bile B
acids I
in O
SCRH O
may O
reveal O
important O
adaptive O
responses O
associated O
with O
exposure O
to O
known O
BSEP O
inhibitors O
. O

Following O
CdCl B
2 I
treatment O
, O
ICAM2 O
was O
found O
to O
be O
upregulated O
during O
restructuring O
of O
the O
seminiferous O
epithelium O
, O
with O
round O
spermatids O
becoming O
increasingly O
immunoreactive O
for O
ICAM2 O
by O
6 O
- O
16 O
h O
. O

Interestingly O
, O
there O
was O
a O
loss O
in O
the O
binding O
of O
ICAM2 O
to O
actin O
during O
CdCl B
2 I
- O
induced O
germ O
cell O
loss O
, O
suggesting O
that O
a O
loss O
of O
ICAM2 O
- O
actin O
interactions O
might O
have O
facilitated O
junction O
restructuring O
. O

Two O
new O
dimeric O
anthraquinone B
derivatives O
, O
bulgareone B
A I
( O
1 O
) O
and O
bulgareone B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
fruit O
bodies O
of O
Bulgaria O
inquinans O
. O

Two O
new O
dimeric O
anthraquinone B
derivatives O
, O
bulgareone B
A I
( O
1 O
) O
and O
bulgareone B
B I
( O
2 O
) O
, O
were O
isolated O
from O
the O
fruit O
bodies O
of O
Bulgaria O
inquinans O
. O

Sex O
differences O
in O
effects O
of O
low O
level O
domoic B
acid I
exposure O
. O

Consumption O
of O
seafood O
containing O
the O
phytoplankton O
- O
derived O
toxin O
domoic B
acid I
( O
DOM B
) O
causes O
neurotoxicity O
in O
humans O
and O
in O
animals O
. O

DOM B
exposure O
also O
significantly O
increased O
stereotypic O
behaviours O
and O
decreased O
phosphorylated B
cAMP I
response O
element O
- O
binding O
protein O
immunoreactivity O
( O
pCREB O
- O
IR O
) O
. O

Citrus O
peel O
polymethoxylated B
flavones I
extract O
modulates O
liver O
and O
heart O
function O
parameters O
in O
diet O
induced O
hypercholesterolemic O
rats O
. O

The O
primary O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
Ortanique O
peel O
polymethoxylated B
flavones I
extract O
( O
PMF B
( O
ort O
) O
) O
on O
organ O
function O
parameters O
in O
the O
serum O
of O
hypercholesterolemic O
and O
normal O
rats O
. O

Biology O
and O
therapeutic O
potential O
of O
hydrogen B
sulfide I
and O
hydrogen B
sulfide I
- O
releasing O
chimeras O
. O

Biology O
and O
therapeutic O
potential O
of O
hydrogen B
sulfide I
and O
hydrogen B
sulfide I
- O
releasing O
chimeras O
. O

Hydrogen B
sulfide I
, O
H2S B
, O
is O
a O
colorless O
gas O
with O
a O
strong O
odor O
that O
until O
recently O
was O
only O
considered O
to O
be O
a O
toxic O
environmental O
pollutant O
with O
little O
or O
no O
physiological O
significance O
. O

However O
, O
the O
past O
few O
years O
have O
demonstrated O
its O
role O
in O
many O
biological O
systems O
and O
it O
is O
becoming O
increasingly O
clear O
that O
H2S B
is O
likely O
to O
join O
nitric B
oxide I
( O
NO B
) O
and O
carbon B
monoxide I
( O
CO B
) O
as O
a O
major O
player O
in O
mammalian O
biology O
. O

However O
, O
the O
past O
few O
years O
have O
demonstrated O
its O
role O
in O
many O
biological O
systems O
and O
it O
is O
becoming O
increasingly O
clear O
that O
H2S B
is O
likely O
to O
join O
nitric B
oxide I
( O
NO B
) O
and O
carbon B
monoxide I
( O
CO B
) O
as O
a O
major O
player O
in O
mammalian O
biology O
. O

H9C2 O
rat O
cardiac O
myoblasts O
were O
pre O
- O
treated O
with O
bafilomycin B
A1 I
( O
autophagy O
inhibitor O
, O
10 O
nM O
) O
or O
rapamycin B
( O
autophagy O
inducer O
, O
50 O
mu O
M O
) O
followed O
by O
DXR B
treatment O
( O
3 O
mu O
M O
) O
. O

Arsenic B
reduced O
the O
formation O
of O
lipid O
droplets O
and O
the O
expression O
of O
adipogenesis O
- O
related O
proteins O
, O
such O
as O
CCAAT O
enhancer O
binding O
protein O
- O
( O
C O
/ O
EBPs O
) O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
gamma O
( O
PPAR O
- O
gamma O
) O
, O
and O
adipocyte O
fatty B
acid I
- O
binding O
protein O
aP2 O
( O
aP2 O
) O
. O

Ethyl B
acetate I
: O
X O
- O
ray O
, O
solvent O
and O
computed O
structures O
. O

Ethyl B
acetate I
( O
ethyl B
ethanoate I
) O
was O
crystallized O
in O
situ O
and O
the O
crystal O
structure O
was O
determined O
. O

Ethyl B
acetate I
( O
ethyl B
ethanoate I
) O
was O
crystallized O
in O
situ O
and O
the O
crystal O
structure O
was O
determined O
. O

The O
geometric O
details O
of O
ethyl B
acetate I
as O
a O
solvate O
are O
analyzed O
statistically O
using O
the O
Cambridge O
Structural O
Database O
, O
uncovering O
a O
high O
degree O
of O
hidden O
disorder O
. O

The O
drug O
efflux O
activity O
was O
determined O
using O
two O
dyes O
, O
Rhodamine6G B
( O
R6G B
) O
and O
fluorescent O
Hoechst B
33342 I
. O

In O
the O
present O
study O
, O
we O
explored O
the O
effect O
of O
nicotine B
treatment O
using O
different O
routes O
of O
administration O
in O
the O
dextran O
sodium B
sulfate I
( O
DSS O
) O
colitis O
mouse O
model O
. O

TCDD B
acts O
through O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
which O
interacts O
with O
the O
androgen B
receptor O
( O
AR O
) O
. O

Phillyrin B
strongly O
inhibited O
high O
glucose B
- O
induced O
fatty B
acid I
synthase O
( O
FAS O
) O
expression O
by O
modulating O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1c O
( O
SREBP O
- O
1c O
) O
activation O
. O

Moreover O
, O
use O
of O
the O
pharmacological O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
compound B
C I
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP O
- O
1c O
expression O
in O
phillyrin B
- O
treated O
cells O
. O

The O
whole O
fruit O
also O
contained O
higher O
levels O
of O
terpene B
alcohols I
. O

Salicylic B
acid I
- O
induced O
elicitation O
of O
folates O
in O
coriander O
( O
Coriandrum O
sativum O
L O
. O
) O
improves O
bioaccessibility O
and O
reduces O
pro O
- O
oxidant O
status O
. O

Foliage O
of O
Coriandrum O
sativum O
is O
a O
rich O
source O
of O
natural O
folates O
amenable O
for O
enhancement O
through O
salicylic B
acid I
- O
mediated O
elicitation O
, O
thereby O
holding O
a O
great O
promise O
for O
natural O
- O
mode O
alleviation O
of O
this O
vitamin B
( I
B I
( I
9 I
) I
) I
deficiency O
. O

In O
the O
present O
study O
we O
report O
salicylic B
acid I
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates B
- O
5 B
- I
methyltetrahydrofola I
, O
5 B
- I
formyltetrahydrofola I
and O
10 B
- I
formyltetrahydrofola I
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

Short O
- O
term O
comparative O
study O
of O
the O
influence O
of O
fried O
edible O
oils O
intake O
on O
the O
metabolism O
of O
essential O
fatty B
acids I
in O
obese O
individuals O
. O

The O
effect O
of O
breakfast O
intake O
of O
fried O
oils O
containing O
natural O
antioxidants O
or O
a O
synthetic O
autooxidation O
inhibitor O
on O
the O
metabolism O
of O
essential O
fatty B
acids I
focused O
on O
obese O
individuals O
. O

The O
effect O
was O
a O
significant O
increase O
in O
the O
concentration O
of O
hydroxyoctadecadieno B
acid I
( O
HODE B
) O
metabolites O
, O
indicative O
markers O
of O
the O
intake O
of O
fried O
oils O
. O

Twenty O
- O
three O
compounds O
, O
including O
various O
phenolic B
glycosides I
, O
a O
new O
dimeric O
phenylpropanoid B
glucoside I
, O
saponins B
, O
and O
fatty B
acids I
were O
identified O
online O
, O
or O
after O
targeted O
isolation O
. O

Twenty O
- O
three O
compounds O
, O
including O
various O
phenolic B
glycosides I
, O
a O
new O
dimeric O
phenylpropanoid B
glucoside I
, O
saponins B
, O
and O
fatty B
acids I
were O
identified O
online O
, O
or O
after O
targeted O
isolation O
. O

Twenty O
- O
three O
compounds O
, O
including O
various O
phenolic B
glycosides I
, O
a O
new O
dimeric O
phenylpropanoid B
glucoside I
, O
saponins B
, O
and O
fatty B
acids I
were O
identified O
online O
, O
or O
after O
targeted O
isolation O
. O

In O
addition O
, O
substances O
relevant O
for O
nutrition O
, O
such O
as O
beta B
- I
carotene I
, O
fatty B
acids I
, O
ascorbic B
acid I
and O
minerals O
were O
quantified O
in O
leaves O
and O
flowers O
. O

In O
addition O
, O
substances O
relevant O
for O
nutrition O
, O
such O
as O
beta B
- I
carotene I
, O
fatty B
acids I
, O
ascorbic B
acid I
and O
minerals O
were O
quantified O
in O
leaves O
and O
flowers O
. O

Gangliosides O
and O
sialic B
acid I
effects O
upon O
newborn O
pathogenic O
bacteria O
adhesion O
: O
an O
in O
vitro O
study O
. O

The O
effect O
of O
the O
main O
gangliosides O
( O
GM O
( O
1 O
) O
, O
GM O
( O
3 O
) O
, O
GD O
( O
3 O
) O
) O
and O
free O
sialic B
acid I
( O
Neu5Ac B
) O
upon O
the O
adhesion O
of O
pathogenic O
bacteria O
implicated O
in O
infant O
diarrhoea O
is O
assessed O
in O
vitro O
using O
the O
Caco O
- O
2 O
cell O
line O
. O

Remarkable O
quantities O
of O
corosolic B
acid I
were O
found O
in O
dried O
extracts O
from O
aerial O
parts O
of O
Lagerstroemia O
speciosa O
and O
Ortosiphon O
stamineus O
( O
14233 O
and O
1132 O
mg O
/ O
kg O
, O
respectively O
) O
, O
while O
oleanolic B
acid I
was O
abundant O
in O
O O
. O
stamineus O
and O
Crataegus O
monogyna O
flowers O
( O
2774 O
and O
2339 O
mg O
/ O
kg O
) O
; O
ursolic B
was O
identified O
in O
O O
. O
stamineus O
, O
C O
. O
monogyna O
, O
L O
. O
speciosa O
and O
Arctostaphylos O
uva O
- O
ursi O
leaves O
( O
7773 O
, O
4165 O

Remarkable O
quantities O
of O
corosolic B
acid I
were O
found O
in O
dried O
extracts O
from O
aerial O
parts O
of O
Lagerstroemia O
speciosa O
and O
Ortosiphon O
stamineus O
( O
14233 O
and O
1132 O
mg O
/ O
kg O
, O
respectively O
) O
, O
while O
oleanolic B
acid I
was O
abundant O
in O
O O
. O
stamineus O
and O
Crataegus O
monogyna O
flowers O
( O
2774 O
and O
2339 O
mg O
/ O
kg O
) O
; O
ursolic B
was O
identified O
in O
O O
. O
stamineus O
, O
C O
. O
monogyna O
, O
L O
. O
speciosa O
and O
Arctostaphylos O
uva O
- O
ursi O
leaves O
( O
7773 O
, O
4165 O

Only O
L O
. O
speciosa O
was O
rich O
in O
maslinic B
acid I
( O
4958 O
mg O
/ O
kg O
) O
, O
while O
minor O
amounts O
of O
betulinic B
acid I
( O
257 O
and O
80 O
mg O
/ O
kg O
) O
were O
detected O
in O
L O
. O
speciosa O
and O
C O
. O
monogyna O
extracts O
. O

Only O
L O
. O
speciosa O
was O
rich O
in O
maslinic B
acid I
( O
4958 O
mg O
/ O
kg O
) O
, O
while O
minor O
amounts O
of O
betulinic B
acid I
( O
257 O
and O
80 O
mg O
/ O
kg O
) O
were O
detected O
in O
L O
. O
speciosa O
and O
C O
. O
monogyna O
extracts O
. O

Lower O
quantities O
of O
triterpenic B
acids I
were O
identified O
in O
dried O
extracts O
of O
Harpagophyton O
procumbens O
root O
, O
propolis O
, O
Punica O
granatum O
root O
, O
Styrax O
benzoin O
, O
Vaccinium O
myrtillus O
fruits O
and O
Vitis O
vinifera O
seeds O
. O

Decoctions O
and O
fluid O
extracts O
lacked O
or O
contained O
very O
low O
amounts O
of O
triterpenic B
acids I
. O

The O
presence O
of O
egg O
yolk O
slightly O
increased O
the O
susceptibility O
to O
hydrolysis O
of O
egg O
white O
proteins O
and O
abrogated O
bile B
salt I
- O
induced O
precipitation O
of O
LYS O
in O
the O
duodenal O
medium O
. O

Changes O
in O
the O
oil O
were O
assessed O
by O
the O
free O
fatty B
acid I
( O
FFA O
) O
content O
, O
p B
- I
anisidine I
value O
( O
AnV O
) O
, O
colour O
, O
viscosity O
, O
fatty B
acid I
profile O
and O
concentration O
of O
tocols O
. O

Changes O
in O
the O
oil O
were O
assessed O
by O
the O
free O
fatty B
acid I
( O
FFA O
) O
content O
, O
p B
- I
anisidine I
value O
( O
AnV O
) O
, O
colour O
, O
viscosity O
, O
fatty B
acid I
profile O
and O
concentration O
of O
tocols O
. O

Identification O
of O
flavonoids B
and O
flavonoid B
rhamnosides I
from O
Rhododendron O
mucronulatum O
for O
. O
albiflorum O
and O
their O
inhibitory O
activities O
against O
aldose B
reductase O
. O

Of O
these O
, O
the O
ethyl B
acetate I
( O
EtOAc B
) O
fraction O
exhibited O
AR O
inhibitory O
activity O
( O
IC O
( O
50 O
) O
0 O
. O
15 O
mu O
g O
/ O
mL O
) O
. O

Encapsulation O
of O
food O
grade O
antioxidant O
in O
natural O
biopolymer O
by O
electrospinning O
technique O
: O
a O
physicochemical O
study O
based O
on O
zein O
- O
gallic B
acid I
system O
. O

Gallic B
acid I
was O
successfully O
incorporated O
into O
zein O
ultra O
- O
fine O
fibres O
at O
different O
loading O
amount O
( O
5 O
% O
, O
10 O
% O
and O
20 O
% O
) O
in O
order O
to O
develop O
an O
encapsulating O
technology O
for O
functional O
ingredient O
delivery O
using O
electrospinning O
. O

The O
physical O
and O
thermal O
properties O
of O
encapsulated O
gallic B
acid I
were O
determined O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
and O
differential O
scanning O
calorimetry O
( O
DSC O
) O
; O
and O
the O
interaction O
between O
gallic B
acid I
and O
zein O
was O
attested O
by O
attenuated O
total O
reflection O
- O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
. O

The O
physical O
and O
thermal O
properties O
of O
encapsulated O
gallic B
acid I
were O
determined O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
and O
differential O
scanning O
calorimetry O
( O
DSC O
) O
; O
and O
the O
interaction O
between O
gallic B
acid I
and O
zein O
was O
attested O
by O
attenuated O
total O
reflection O
- O
Fourier O
transform O
infrared O
( O
ATR O
- O
FTIR O
) O
. O

Thermogravimetric O
analysis O
( O
TGA O
) O
demonstrated O
a O
different O
thermal O
stability O
of O
the O
fabricated O
complex O
before O
and O
after O
the O
gallic B
acid I
incorporation O
. O

Lastly O
, O
the O
1 B
, I
1 I
' I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
assay O
showed O
that O
the O
gallic B
acid I
had O
retained O
its O
antioxidant O
activity O
after O
incorporation O
in O
zein O
electrospun O
fibres O
. O

Therefore O
, O
in O
this O
study O
, O
the O
effects O
of O
rosemary O
on O
the O
activation O
of O
nuclear O
factor O
kappa O
beta O
( O
NF O
- O
kB O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
, O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
and O
the O
production O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
and O
cytokine O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O

Therefore O
, O
in O
this O
study O
, O
the O
effects O
of O
rosemary O
on O
the O
activation O
of O
nuclear O
factor O
kappa O
beta O
( O
NF O
- O
kB O
) O
and O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
, O
the O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
and O
the O
production O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E I
( I
2 I
) I
( O
PGE B
( I
2 I
) I
) O
, O
and O
cytokine O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O

CSEE O
enhanced O
the O
phosphorylation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
primary O
downstream O
targeting O
enzyme O
, O
acetyl B
- I
CoA I
carboxylase O
, O
up O
- O
regulated O
gene O
expression O
of O
carnitine B
palmitoyl B
transferase O
1 O
, O
and O
down O
- O
regulated O
sterol O
regulatory O
element O
- O
binding O
protein O
1 O
and O
fatty B
acid I
synthase O
protein O
levels O
in O
epididymal O
WAT O
of O
HFD O
- O
fed O
rats O
. O

Although O
methionine B
dependency O
is O
a O
phenotypic O
characteristic O
of O
tumor O
cells O
, O
the O
role O
of O
sulfur B
amino B
acid I
metabolism O
in O
chemotherapy O
resistance O
remains O
to O
be O
elucidated O
. O

This O
study O
compared O
metabolite O
profiles O
of O
sulfur B
amino B
acid I
metabolism O
from O
methionine B
to O
taurine B
or O
glutathione B
( O
GSH B
) O
between O
normal O
MCF O
- O
7 O
and O
TAM B
- O
resistant O
MCF O
- O
7 O
( O
TAMR O
- O
MCF O
- O
7 O
) O
cells O
. O

The O
addition O
of O
propargylglycine B
, O
a O
specific O
cystathionine B
gamma O
- O
lyase O
inhibitor O
, O
and O
buthionine B
sulfoximine I
, O
a O
specific O
gamma B
- I
glutamylcysteine I
ligase O
inhibitor O
, O
to O
TAMR O
- O
MCF O
- O
7 O
cells O
, O
but O
not O
to O
MCF O
- O
7 O
cells O
, O
resulted O
in O
cytotoxicity O
after O
sulfur B
amino B
acid I
deprivation O
. O

The O
addition O
of O
propargylglycine B
, O
a O
specific O
cystathionine B
gamma O
- O
lyase O
inhibitor O
, O
and O
buthionine B
sulfoximine I
, O
a O
specific O
gamma B
- I
glutamylcysteine I
ligase O
inhibitor O
, O
to O
TAMR O
- O
MCF O
- O
7 O
cells O
, O
but O
not O
to O
MCF O
- O
7 O
cells O
, O
resulted O
in O
cytotoxicity O
after O
sulfur B
amino B
acid I
deprivation O
. O

These O
results O
suggest O
that O
cell O
viability O
of O
TAMR O
- O
MCF O
- O
7 O
cells O
is O
affected O
by O
inhibition O
of O
sulfur B
amino B
acid I
metabolism O
, O
particularly O
cysteine B
synthesis O
from O
homocysteine B
and O
GSH B
synthesis O
from O
cysteine B
. O

Absolute O
quantitation O
of O
stevioside B
and O
rebaudioside B
A I
in O
commercial O
standards O
by O
quantitative O
NMR O
. O

The O
extract O
prepared O
from O
the O
leaves O
of O
Stevia O
rebaudiana O
BERTONI O
( O
Asteraceae O
) O
contains O
sweet O
steviol B
glycosides I
, O
mainly O
stevioside B
and O
rebaudioside B
A I
. O

The O
extract O
prepared O
from O
the O
leaves O
of O
Stevia O
rebaudiana O
BERTONI O
( O
Asteraceae O
) O
contains O
sweet O
steviol B
glycosides I
, O
mainly O
stevioside B
and O
rebaudioside B
A I
. O

They O
contain O
various O
types O
of O
steviol B
glycosides I
, O
and O
their O
main O
components O
are O
stevioside B
and O
rebaudioside B
A I
. O

They O
contain O
various O
types O
of O
steviol B
glycosides I
, O
and O
their O
main O
components O
are O
stevioside B
and O
rebaudioside B
A I
. O

The O
content O
of O
each O
steviol B
glycoside I
is O
quantified O
by O
comparing O
the O
ratios O
of O
the O
molecular O
weights O
and O
the O
chromatographic O
peak O
areas O
of O
the O
samples O
to O
those O
of O
stevioside B
or O
rebaudioside B
A I
standards O
of O
the O
Food O
and O
Agriculture O
Organization O
of O
the O
United O
Nations O
( O
FAO O
) O
/ O
World O
Health O
Organization O
( O
WHO O
) O
Joint O
Expert O
Committee O
on O
Food O
Additives O
( O
JECFA O
) O
and O
other O
specifications O
. O

The O
content O
of O
each O
steviol B
glycoside I
is O
quantified O
by O
comparing O
the O
ratios O
of O
the O
molecular O
weights O
and O
the O
chromatographic O
peak O
areas O
of O
the O
samples O
to O
those O
of O
stevioside B
or O
rebaudioside B
A I
standards O
of O
the O
Food O
and O
Agriculture O
Organization O
of O
the O
United O
Nations O
( O
FAO O
) O
/ O
World O
Health O
Organization O
( O
WHO O
) O
Joint O
Expert O
Committee O
on O
Food O
Additives O
( O
JECFA O
) O
and O
other O
specifications O
. O

However O
, O
various O
commercial O
standard O
reagents O
of O
stevioside B
and O
rebaudioside B
A I
are O
available O
. O

Therefore O
, O
the O
measured O
values O
of O
stevioside B
and O
rebaudioside B
A I
contained O
in O
a O
sample O
vary O
according O
to O
the O
standard O
used O
for O
the O
quantification O
. O

In O
this O
study O
, O
we O
utilized O
an O
accurate O
method O
, O
quantitative O
NMR O
( O
qNMR O
) O
, O
for O
determining O
the O
contents O
of O
stevioside B
and O
rebaudioside B
A I
in O
standards O
, O
with O
traceability O
to O
the O
International O
System O
of O
Units O
( O
SI O
units O
) O
. O

Structures O
of O
the O
isolated O
compounds O
were O
elucidated O
as O
sclareol B
, O
beta B
- I
sitosterol I
, O
salvigenin B
, O
oleanolic B
acid I
and O
ursolic B
acid I
. O

Structures O
of O
the O
isolated O
compounds O
were O
elucidated O
as O
sclareol B
, O
beta B
- I
sitosterol I
, O
salvigenin B
, O
oleanolic B
acid I
and O
ursolic B
acid I
. O

This O
device O
can O
reduce O
the O
possibility O
of O
reaction O
between O
bioactive O
compounds O
and O
sulfur B
/ O
sulfurous B
acid I
, O
as O
well O
as O
control O
the O
limitation O
of O
SO B
( I
2 I
) I
residues O
. O

Nine O
new O
steroidal B
glycosides I
from O
the O
roots O
of O
Cynanchum O
stauntonii O
. O

Nine O
new O
steroidal B
glycosides I
, O
named O
as O
stauntosides B
C I
- I
K I
( O
2 O
, O
5 O
, O
7 O
- O
10 O
, O
13 O
, O
14 O
, O
and O
16 O
) O
, O
along O
with O
seven O
known O
compounds O
( O
1 O
, O
3 O
, O
4 O
, O
6 O
, O
11 O
, O
12 O
, O
and O
15 O
) O
were O
isolated O
from O
the O
95 O
% O
ethanol B
extract O
of O
the O
roots O
of O
Cynanchum O
stauntonii O
. O

Results O
using O
annexin O
V O
/ O
propidium B
iodide I
- O
stained O
cells O
showed O
that O
both O
apoptosis O
and O
necrosis O
were O
involved O
in O
cell O
death O
due O
to O
SM O
; O
FasR O
siRNA O
decreased O
both O
apoptotic O
and O
necrotic O
cell O
populations O
. O

By O
genetic O
perturbations O
and O
metabolic O
rescue O
, O
we O
provide O
evidence O
to O
illustrate O
that O
fat O
body O
dSir2 O
mediates O
its O
effects O
on O
the O
muscles O
via O
free O
fatty B
acids I
( O
FFA O
) O
and O
dILPs O
( O
from O
the O
insulin O
- O
producing O
cells O
[ O
IPCs O
] O
) O
. O

Cadmium B
( O
Cd B
) O
affects O
the O
expression O
of O
estrogen B
receptor O
( O
ER O
) O
and O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
associated O
genes O
in O
rat O
uterus O
and O
elicits O
estrogen B
- O
like O
activity O
in O
vitro O
. O

We O
investigated O
the O
effects O
of O
Cd B
and O
17 B
- I
alpha I
- I
ethinylestradiol I
( O
EE B
2 I
) O
on O
AhR O
- O
associated O
gene O
expression O
after O
oral O
exposure O
of O
ovariectomized O
female O
Wistar O
rats O
, O
and O
metallothionein O
( O
Mt1a O
) O
expression O
as O
a O
typical O
metal O
- O
response O
marker O
. O

Mt1a O
in O
the O
small O
intestine O
was O
strongly O
induced O
by O
co O
- O
treatment O
with O
CdCl B
2 I
at O
2 O
mg O
/ O
kg O
b O
. O
wt O
( O
Cd B
2 O
) O
and O
0 O
. O
1 O
mg O
/ O
kg O
b O
. O
wt O
EE2 B
than O
by O
the O
single O
compound O
( O
3 O
- O
day O
gavage O
) O
. O

Interestingly O
, O
the O
EE B
2 I
- O
induced O
down O
- O
regulation O
of O
Cyp1a1 O
, O
Gsta2 O
, O
and O
Nqo1 O
mRNA O
was O
antagonized O
by O
Cd B
2 O
in O
vivo O
and O
in O
colon O
cancer O
cell O
lines O
( O
HT O
- O
29 O
and O
CaCo O
- O
2 O
, O
treated O
5 O
days O
with O
Cd B
1 O
micro O
M O
and O
/ O
or O
E O
2 O
0 O
. O
01 O
micro O
M O
) O
with O
low O
or O
no O
ER O
- O
beta O
expression O
. O

Dose O
dependency O
was O
studied O
after O
Cd B
exposure O
with O
drinking O
water O
( O
5 O
and O
50 O
ppm O
CdCl B
2 I
equivalent O
to O
0 O
. O
4 O
and O
4 O
mg O
/ O
kg O
b O
. O
wt O
; O
Cd B
0 O
. O
4 O
, O
Cd B
4 O
) O
for O
28 O
days O
and O
EE B
2 I
as O
reference O
. O

Dose O
dependency O
was O
studied O
after O
Cd B
exposure O
with O
drinking O
water O
( O
5 O
and O
50 O
ppm O
CdCl B
2 I
equivalent O
to O
0 O
. O
4 O
and O
4 O
mg O
/ O
kg O
b O
. O
wt O
; O
Cd B
0 O
. O
4 O
, O
Cd B
4 O
) O
for O
28 O
days O
and O
EE B
2 I
as O
reference O
. O

Intestinal O
Mt1a O
expression O
was O
dose O
dependently O
induced O
, O
while O
AhR O
target O
genes O
were O
down O
- O
regulated O
by O
Cd B
0 O
. O
4 O
similar O
to O
EE B
2 I
and O
more O
pronounced O
than O
by O
Cd B
4 O
. O

High O
- O
dose O
sodium B
selenite I
toxicity O
cannot O
be O
prevented O
by O
the O
co O
- O
administration O
of O
pharmacological O
levels O
of O
epigallocatechin B
- I
3 I
- I
gallate I
which O
in O
turn O
aggravates O
the O
toxicity O
. O

A O
proof O
- O
in O
- O
principle O
experiment O
was O
conducted O
to O
determine O
if O
EGCG B
would O
ameliorate O
sodium B
selenite I
- O
induced O
growth O
suppression O
. O

Hoechst B
33258 I
staining O
and O
Western O
blot O
analysis O
of O
apoptosis O
- O
related O
proteins O
showed O
that O
WK O
induced O
SGC O
- O
7901 O
cell O
death O
was O
not O
through O
apoptosis O
. O

The O
neonatal O
maternal O
separation O
( O
NMS O
) O
on O
Sprague O
- O
Dawley O
pups O
was O
employed O
to O
evaluate O
the O
therapeutic O
effect O
of O
KT O
by O
virtue O
of O
various O
parameters O
including O
visceral O
hyperalgesia O
, O
serum O
nitric B
oxide I
( O
NO B
) O
level O
, O
and O
tissue O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
level O
. O

Consequently O
, O
a O
chromatographic O
condition O
, O
which O
was O
carried O
at O
30 O
degrees O
C O
with O
a O
flow O
rate O
of O
0 O
. O
5 O
ml O
/ O
min O
on O
AQUA O
3 O
mu O
C18 O
column O
with O
mobile O
phase O
of O
acetonitrile B
and O
water O
- O
phosphoric B
acid I
( O
100 O
: O
0 O
. O
1 O
, O
v O
/ O
v O
) O
, O
was O
established O
to O
give O
a O
common O
fingerprint O
chromatography O
under O
254 O
nm O
with O
a O
similarity O
index O
of O
0 O
. O
963 O
within O
ten O
batches O
of O
KT O
samples O
. O

The O
plasma O
level O
of O
nitric B
oxide I
was O
increased O
after O
PLA O
( O
2 O
) O
fraction O
injection O
but O
not O
with O
MP O
fraction O
injection O
. O

The O
nucleotide B
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino B
acid I
residues O
- O
104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O

Deletion O
analysis O
revealed O
that O
the O
C B
- O
terminal O
21 O
- O
amino B
acid I
sequence O
of O
Rev1 O
is O
uniquely O
required O
for O
its O
interaction O
with O
Rad5 O
and O
is O
essential O
for O
its O
non O
- O
catalytic O
function O
. O

Inhibition O
of O
vitellogenin O
gene O
induction O
by O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
is O
mediated O
by O
aryl B
hydrocarbon I
receptor O
2 O
( O
AHR2 O
) O
in O
zebrafish O
( O
Danio O
rerio O
) O
. O

To O
better O
understand O
chemical O
effects O
on O
vitellogenin O
gene O
regulation O
, O
we O
tested O
the O
hypothesis O
that O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
2 O
( O
AHR2 O
) O
by O
dioxin B
inhibits O
the O
estrogen B
receptor O
pathway O
regulation O
of O
3 O
vitellogenin O
genes O
( O
vtg1 O
- O
3 O
) O
in O
vivo O
, O
using O
zebrafish O
( O
Danio O
rerio O
) O
as O
a O
model O
teleost O
. O

Effects O
of O
octylphenol B
and O
bisphenol B
A I
on O
the O
expression O
of O
calcium B
transport O
genes O
in O
the O
mouse O
duodenum O
and O
kidney O
during O
pregnancy O
. O

Octylphenol B
( O
OP O
) O
is O
the O
degradative O
product O
of O
alkylphenol B
ethoxylates I
that O
are O
widely O
used O
to O
produce O
rubber O
, O
pesticides O
, O
and O
paints O
. O

Bisphenol B
A I
( O
BPA B
) O
is O
an O
organic O
compound O
with O
two O
functional O
phenol B
groups O
, O
and O
used O
for O
manufacturing O
polycarbonate B
plastic O
and O
epoxy B
resins O
, O
as O
well O
as O
other O
applications O
. O

Calbindin O
refers O
to O
several O
Ca B
- O
binding O
proteins O
originally O
described O
as O
vitamin B
D I
- O
dependent O
Ca B
- O
binding O
factors O
in O
the O
intestine O
, O
and O
kidney O
of O
birds O
and O
mammals O
. O

The O
functional O
analysis O
of O
differentially O
transcribed O
genes O
suggests O
that O
IBU B
can O
interfere O
with O
various O
signalling O
pathways O
in O
clams O
, O
such O
as O
arachidonic B
acid I
metabolism O
, O
apoptosis O
, O
peroxisomal O
proliferator O
- O
activated O
receptors O
, O
and O
nuclear O
factor O
- O
kappa O
B O
. O

In O
vitro O
exposure O
of O
precision O
- O
cut O
lung O
slices O
to O
2 B
- I
( I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
) I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
( O
NSC B
710305 I
, O
Phortress B
) O
increases O
inflammatory O
cytokine O
content O
and O
tissue O
damage O
. O

The O
anticancer O
drug O
( O
2 B
- I
[ I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
] I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
) O
( O
NSC B
710305 I
, O
Phortress B
) O
is O
a O
metabolically O
activated O
prodrug O
that O
causes O
DNA O
adduct O
formation O
and O
subsequent O
toxicity O
. O

An O
ex O
vivo O
precision O
- O
cut O
lung O
slice O
( O
PCLS O
) O
model O
was O
used O
to O
search O
for O
concentration O
dependent O
effects O
of O
NSC B
710305 I
( O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
micro O
M O
) O
on O
cytokine O
content O
, O
protein O
content O
, O
and O
immuno O
/ O
histological O
endpoints O
. O

Preparation O
and O
culture O
of O
PCLS O
caused O
an O
initial O
spike O
in O
proinflammatory O
cytokine O
expression O
and O
therefore O
treatment O
with O
NSC B
710305 I
was O
delayed O
until O
48 O
h O
after O
initiating O
the O
slice O
cultures O
to O
avoid O
confounding O
the O
response O
to O
slicing O
with O
any O
drug O
response O
. O

PCLSs O
were O
evaluated O
after O
24 O
, O
48 O
, O
and O
72 O
h O
exposures O
to O
NSC B
710305 I
. O

NSC B
710305 I
caused O
a O
concentration O
- O
dependent O
cytokine O
response O
, O
and O
only O
the O
toxicity O
caused O
by O
a O
72 O
- O
h O
exposure O
to O
25 O
micro O
M O
reversed O
during O
the O
24 O
- O
h O
recovery O
period O
. O

In O
conclusion O
, O
the O
concentration O
- O
and O
time O
- O
dependent O
inflammatory O
response O
of O
PCLS O
to O
NSC B
710305 I
preceded O
relevant O
tissue O
damage O
by O
a O
few O
days O
. O

The O
no O
- O
observable O
adverse O
effect O
level O
( O
NOAEL O
) O
for O
24 O
, O
48 O
, O
and O
72 O
h O
exposures O
was O
established O
as O
10 O
micro O
M O
NSC B
710305 I
. O

This O
study O
was O
designed O
to O
evaluate O
the O
potential O
effects O
of O
puerarin B
( O
PR O
) O
, O
an O
effective O
isoflavonoid B
compound O
purified O
from O
Pueraria O
lobata O
, O
in O
treating O
hepatic O
fibrosis O
( O
HF O
) O
rats O
induced O
by O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
, O
2 O
mL O
kg O
( O
- O
1 O
) O
d O
( O
- O
1 O
) O
) O
. O

Moreover O
, O
it O
also O
was O
attributed O
to O
decreased O
mRNA O
level O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
using O
RT O
- O
PCR O
analysis O
. O

Hepatoprotective O
effects O
of O
Gentiana O
asclepiadea O
L O
. O
extracts O
against O
carbon B
tetrachloride I
induced O
liver O
injury O
in O
rats O
. O

This O
study O
is O
an O
attempt O
to O
evaluate O
the O
hepatoprotective O
activity O
of O
Gentiana O
asclepiadea O
L O
. O
against O
carbon B
tetrachloride I
- O
induced O
liver O
injury O
in O
rats O
. O

Treatment O
with O
the O
extracts O
resulted O
in O
a O
significant O
increase O
in O
the O
levels O
of O
catalase O
, O
superoxide B
dismutase O
and O
reduced B
glutathione I
, O
accompanied O
with O
a O
marked O
reduction O
in O
the O
levels O
of O
malondialdehyde B
, O
as O
compared O
to O
CCl B
( I
4 I
) I
treated O
group O
. O

PBMCs O
, O
isolated O
from O
blood O
samples O
of O
four O
male O
and O
four O
female O
healthy O
individuals O
, O
were O
exposed O
in O
vitro O
for O
18h O
to O
either O
a O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB126 B
, O
1 O
mu O
M O
) O
, O
a O
non O
- O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB153 B
, O
10 O
mu O
M O
) O
, O
a O
brominated O
flame O
retardant O
( O
BDE47 B
, O
10 O
mu O
M O
) O
, O
a O
perfluorinated B
alkyl I
acid I
( O
PFOA B
, O
10 O
mu O
M O
) O
or O

PBMCs O
, O
isolated O
from O
blood O
samples O
of O
four O
male O
and O
four O
female O
healthy O
individuals O
, O
were O
exposed O
in O
vitro O
for O
18h O
to O
either O
a O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB126 B
, O
1 O
mu O
M O
) O
, O
a O
non O
- O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB153 B
, O
10 O
mu O
M O
) O
, O
a O
brominated O
flame O
retardant O
( O
BDE47 B
, O
10 O
mu O
M O
) O
, O
a O
perfluorinated B
alkyl I
acid I
( O
PFOA B
, O
10 O
mu O
M O
) O
or O

The O
mechanism O
of O
carvacrol B
- O
evoked O
[ O
Ca2 B
+ I
] O
i O
rises O
and O
non O
- O
Ca2 B
+ I
- O
triggered O
cell O
death O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

The O
mechanism O
of O
carvacrol B
- O
evoked O
[ O
Ca2 B
+ I
] O
i O
rises O
and O
non O
- O
Ca2 B
+ I
- O
triggered O
cell O
death O
in O
OC2 O
human O
oral O
cancer O
cells O
. O

The O
aromatase O
inhibitor O
CGS B
16949A I
abolished O
this O
stimulatory O
activity O
and O
reduced O
estradiol B
levels O
in O
the O
control O
and O
treatment O
groups O
. O

Cholestatic O
effect O
of O
epigallocatechin B
gallate I
in O
rats O
is O
mediated O
via O
decreased O
expression O
of O
Mrp2 O
. O

Epigallocatechin B
gallate I
( O
EGCG B
) O
has O
been O
shown O
to O
be O
protective O
in O
various O
experimental O
models O
of O
liver O
injury O
, O
although O
opposite O
effects O
have O
also O
been O
reported O
. O

Since O
its O
effect O
on O
biliary O
physiology O
has O
not O
been O
thoroughly O
investigated O
, O
the O
present O
study O
evaluated O
effect O
of O
EGCG B
on O
bile O
flow O
and O
bile B
acid I
homeostasis O
in O
rats O
. O

Hepatic O
paracellular O
permeability O
and O
biliary O
bile B
acid I
excretion O
were O
not O
altered O
by O
EGCG B
administration O
, O
but O
biliary O
glutathione B
excretion O
was O
reduced O
by O
70 O
% O
. O

EGCG B
administration O
also O
doubled O
plasma O
bile B
acid I
levels O
compared O
to O
controls O
. O

While O
protein O
levels O
of O
the O
main O
hepatic O
bile B
acid I
transporters O
were O
unchanged O
, O
the O
rate O
- O
limiting O
enzyme O
in O
the O
bile B
acid I
synthesis O
, O
Cyp7a1 O
, O
was O
significantly O
increased O
by O
EGCG B
. O

While O
protein O
levels O
of O
the O
main O
hepatic O
bile B
acid I
transporters O
were O
unchanged O
, O
the O
rate O
- O
limiting O
enzyme O
in O
the O
bile B
acid I
synthesis O
, O
Cyp7a1 O
, O
was O
significantly O
increased O
by O
EGCG B
. O

Enhanced O
bile B
acid I
synthesis O
in O
these O
animals O
was O
also O
confirmed O
by O
a O
2 O
- O
fold O
increase O
in O
plasma O
marker O
7 B
alpha I
- I
hydroxy I
- I
4 I
- I
cholesten I
- I
3 I
- I
one I
. O

In O
contrast O
, O
EGCG B
markedly O
downregulated O
major O
bile B
acid I
transporters O
( O
Asbt O
and O
Ost O
alpha O
) O
and O
regulatory O
molecules O
( O
Shp O
and O
Fgf15 O
) O
in O
the O
ileum O
. O

This O
study O
shows O
ability O
of O
EGCG B
to O
raise O
plasma O
bile B
acid I
concentrations O
, O
mainly O
through O
Cyp7a1 O
upregulation O
, O
and O
to O
decrease O
bile O
production O
through O
reduction O
in O
Mrp2 O
- O
mediated O
bile B
acid I
- O
independent O
bile O
flow O
. O

This O
study O
shows O
ability O
of O
EGCG B
to O
raise O
plasma O
bile B
acid I
concentrations O
, O
mainly O
through O
Cyp7a1 O
upregulation O
, O
and O
to O
decrease O
bile O
production O
through O
reduction O
in O
Mrp2 O
- O
mediated O
bile B
acid I
- O
independent O
bile O
flow O
. O

Microbial O
metabolism O
of O
dietary O
carbohydrates B
results O
mainly O
in O
the O
formation O
of O
short O
chain O
fatty B
acids I
and O
gases O
. O

Certain O
bacterial O
species O
in O
the O
colon O
survive O
by O
cross O
- O
feeding O
, O
using O
either O
the O
breakdown O
products O
of O
complex O
carbohydrate B
degradation O
or O
fermentation O
products O
such O
as O
lactic B
acid I
for O
growth O
. O

Effects O
- O
based O
marine O
ecological O
risk O
assessment O
at O
a O
polychlorinated B
biphenyl I
- O
contaminated O
site O
in O
Saglek O
, O
Labrador O
, O
Canada O
. O

Although O
the O
presence O
and O
distribution O
of O
polychlorinated B
biphenyls I
( O
PCBs B
) O
in O
Arctic O
marine O
environments O
has O
been O
well O
documented O
, O
the O
implications O
for O
the O
health O
of O
biota O
are O
poorly O
understood O
. O

The O
inhibitory O
activities O
against O
BCRP O
and O
P O
- O
gp O
were O
assayed O
using O
a O
Hoechst B
33342 I
assay O
for O
BCRP O
and O
a O
calcein O
AM O
assay O
for O
P O
- O
gp O
. O

An O
increase O
in O
Cyp26a1 O
mRNA O
( O
10 O
- O
fold O
) O
and O
retinoic B
acid I
receptor O
( O
Rar O
) O
beta O
mRNA O
( O
2 O
. O
8 O
- O
fold O
) O
was O
also O
observed O
during O
pregnancy O
. O

The O
increase O
in O
Cyp26a1 O
and O
Rar O
beta O
mRNA O
during O
pregnancy O
indicates O
increased O
retinoic B
acid I
signaling O
in O
the O
liver O
during O
pregnancy O
. O

A O
putative O
retinoic B
acid I
response O
element O
was O
identified O
within O
the O
Cyp2d40 O
promoter O
and O
the O
mRNA O
of O
Cyp2d40 O
correlated O
( O
P O
< O
0 O
. O
05 O
) O
with O
Cyp26a1 O
and O
Rar O
beta O
. O

Our O
findings O
also O
suggest O
that O
retinoic B
acid I
signaling O
in O
the O
liver O
is O
increased O
during O
pregnancy O
, O
which O
may O
have O
broader O
implications O
to O
energy O
homeostasis O
in O
the O
liver O
during O
pregnancy O
. O

Susceptibility O
to O
fatty B
acid I
- O
induced O
beta O
- O
cell O
dysfunction O
is O
enhanced O
in O
prediabetic O
diabetes O
- O
prone O
biobreeding O
rats O
: O
a O
potential O
link O
between O
beta O
- O
cell O
lipotoxicity O
and O
islet O
inflammation O
. O

To O
determine O
this O
, O
we O
examined O
the O
effects O
of O
prolonged O
free O
fatty B
acids I
elevation O
on O
beta O
- O
cell O
secretory O
function O
in O
the O
prediabetic O
diabetes O
- O
prone O
BioBreeding O
( O
dp O
- O
BB O
) O
rat O
, O
its O
diabetes O
- O
resistant O
BioBreeding O
( O
dr O
- O
BB O
) O
control O
, O
and O
normal O
Wistar O
- O
Furth O
( O
WF O
) O
rats O
. O

Rats O
received O
a O
48 O
- O
h O
iv O
infusion O
of O
saline O
or O
Intralipid O
plus O
heparin O
( O
IH O
) O
( O
to O
elevate O
free O
fatty B
acid I
levels O
~ O
2 O
- O
fold O
) O
followed O
by O
hyperglycemic O
clamp O
or O
islet O
secretion O
studies O
ex O
vivo O
. O

A O
number O
of O
integral O
membrane O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
share O
common O
structural O
features O
( O
including O
palmytoilated B
aminoacid I
residues O
and O
consensus O
sequences O
specific O
for O
interaction O
with O
cholesterol B
) O
that O
allow O
them O
to O
interact O
with O
lipid O
rafts O
, O
membrane O
cholesterol B
- O
rich O
microdomains O
able O
to O
regulate O
GPCR O
signalling O
and O
functions O
. O

Lipid O
analysis O
demonstrated O
that O
eight O
of O
the O
nine O
classes O
of O
ceramides B
were O
increased O
by O
TCDD B
, O
altering O
the O
ratio O
of O
ceramides B
to O
free O
fatty B
acids I
. O

Mitochondrial O
glutathione B
( O
GSH B
) O
reductase O
activity O
and O
the O
GSH B
/ O
glutathione B
disulfide I
ratio O
were O
decreased O
by O
TCDD B
, O
ultimately O
leading O
to O
mitochondrial O
dysfunction O
, O
characterized O
by O
decreased O
inner O
mitochondrial O
membrane O
potential O
and O
ATP B
production O
, O
and O
increased O
production O
of O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
hydrogen B
peroxide I
. O

Mitochondrial O
glutathione B
( O
GSH B
) O
reductase O
activity O
and O
the O
GSH B
/ O
glutathione B
disulfide I
ratio O
were O
decreased O
by O
TCDD B
, O
ultimately O
leading O
to O
mitochondrial O
dysfunction O
, O
characterized O
by O
decreased O
inner O
mitochondrial O
membrane O
potential O
and O
ATP B
production O
, O
and O
increased O
production O
of O
the O
reactive O
oxygen B
species O
( O
ROS O
) O
, O
hydrogen B
peroxide I
. O

Aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
antagonists O
blocked O
the O
response O
of O
many O
transcripts O
to O
TCDD B
, O
and O
the O
endpoints O
of O
decreased O
ATP B
production O
and O
differentiation O
, O
suggesting O
regulation O
by O
the O
AHR O
. O

Various O
risk O
factors O
have O
been O
suggested O
for O
the O
development O
of O
HBS O
, O
including O
older O
age O
, O
weight O
/ O
volume O
of O
the O
resected O
parathyroid O
glands O
, O
radiological O
evidence O
of O
bone O
disease O
and O
vitamin B
D I
deficiency O
. O

Treatment O
is O
aimed O
at O
replenishing O
the O
severe O
calcium B
deficit O
by O
using O
high O
doses O
of O
calcium B
supplemented O
by O
high O
doses O
of O
active O
metabolites O
of O
vitamin B
D I
. O

Hot O
isotropic O
mixture O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
was O
spontaneously O
self O
nano O
- O
emulsify O
in O
hot O
water O
and O
SLNs O
were O
formed O
with O
subsequent O
rapid O
cooling O
. O

Hot O
isotropic O
mixture O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
was O
spontaneously O
self O
nano O
- O
emulsify O
in O
hot O
water O
and O
SLNs O
were O
formed O
with O
subsequent O
rapid O
cooling O
. O

Self O
nano O
- O
emulsification O
ability O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
mixture O
was O
assessed O
by O
ternary O
phase O
diagram O
study O
. O

Self O
nano O
- O
emulsification O
ability O
of O
stearic B
acid I
, O
poloxamer B
and O
polyethylene B
glycol I
mixture O
was O
assessed O
by O
ternary O
phase O
diagram O
study O
. O

Results O
indicate O
that O
SLNs O
of O
higher O
fatty B
acids I
can O
be O
successfully O
prepared O
by O
hot O
SNE O
technique O
. O

Amino B
acid I
derivatives O
as O
transdermal O
permeation O
enhancers O
. O

In O
this O
study O
, O
we O
investigated O
enhancers O
with O
amino B
acids I
( O
proline B
, O
sarcosine B
, O
alanine B
, O
beta B
- I
alanine I
, O
and O
glycine B
) O
attached O
to O
hydrophobic O
chain O
( O
s O
) O
via O
a O
biodegradable O
ester B
link O
. O

The O
proline B
derivative O
l B
- I
Pro2 I
reached O
enhancement O
ratios O
of O
up O
to O
40 O
at O
1 O
% O
concentration O
, O
which O
is O
higher O
than O
that O
of O
the O
well O
- O
established O
and O
standard O
enhancers O
Azone B
, O
DDAIP B
, O
DDAK B
, O
and O
Transkarbam B
12 I
. O

l B
- I
Pro2 I
acted O
synergistically O
with O
propylene B
glycol I
. O

The O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
is O
composed O
of O
nicotinamide B
adenine I
dinucleotide I
( I
phosphate I
) I
( O
NAD B
( I
P I
) I
( I
+ I
) I
) O
- O
dependent O
enzymes O
that O
catalyze O
the O
oxidation O
of O
aldehydes B
to O
their O
corresponding O
carboxylic B
acids I
. O

The O
levels O
of O
hepatotoxicity O
markers O
- O
alanine B
aminotransaminase O
( O
ALT O
) O
, O
aspartate B
aminotransaminase O
( O
AST O
) O
and O
total O
bilirubin B
, O
histological O
changes O
, O
oxidative O
stress O
indices O
, O
phase O
I O
and O
phase O
II O
xenobiotic O
metabolizing O
enzymes O
- O
cytochrome O
P450 O
( O
CYP O
) O
and O
glutathione B
S B
- O
transferase O
( O
GST O
) O
and O
pro O
- O
inflammatory O
molecules O
- O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 B
- I
propanol I
or O
D B
- I
limonene I
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine B
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium B
bromate I
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D B
- I
limonene I
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

HDN O
- O
induced O
renal O
biomarker O
changes O
in O
male O
rats O
were O
potentially O
compound O
specific O
: O
( O
1 O
) O
2 B
- I
propanol I
induced O
mild O
HDN O
without O
increased O
renal O
biomarkers O
, O
( O
2 O
) O
potassium B
bromate I
induced O
moderate O
HDN O
with O
increased O
clusterin O
, O
and O
( O
3 O
) O
D B
- I
limonene I
induced O
marked O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
. O

Administration O
of O
potassium B
bromate I
did O
not O
result O
in O
oxidative O
stress O
- O
induced O
kidney O
injury O
, O
based O
on O
histopathology O
and O
renal O
biomarkers O
creatinine O
and O
BUN O
. O

Here O
we O
have O
characterized O
the O
second O
human O
STAT5b O
amino B
acid I
substitution O
mutation O
in O
an O
individual O
with O
similar O
pathophysiological O
features O
. O

New O
horizons O
for O
diagnostics O
and O
therapeutic O
applications O
of O
graphene B
and O
graphene B
oxide I
. O

Interestingly O
, O
fructose B
- O
fed O
rats O
treated O
with O
ChREBP O
ASO O
had O
increased O
plasma O
uric B
acid I
, O
alanine B
transaminase O
, O
and O
aspartate B
aminotransferase O
concentrations O
. O

To O
investigate O
the O
combined O
toxic O
effects O
of O
pesticide O
cocktails O
previously O
identified O
in O
the O
French O
diet O
, O
we O
first O
studied O
the O
cytotoxicity O
induced O
by O
seven O
cocktails O
composed O
of O
two O
to O
six O
pesticides O
on O
human O
hepatic O
( O
HepG2 O
) O
and O
colon O
( O
Caco O
- O
2 O
) O
cell O
lines O
using O
the O
MTT B
and O
neutral B
red I
uptake O
assays O
. O

SS O
phages O
are O
genetically O
enginnered O
by O
replacing O
2 O
N B
- O
terminal O
amino B
acids I
of O
the O
p8 O
coat O
protein O
of O
the O
fd O
phage O
. O

Using O
a O
newly O
developed O
strategy O
whose O
key O
step O
is O
the O
regioselective O
propargylation O
of O
hydroxyxanthone B
substrates O
, O
99 O
structurally O
diverse O
Garcinia O
natural O
- O
product O
- O
like O
xanthones B
based O
on O
gambogic B
acid I
were O
designed O
and O
synthesized O
and O
their O
in O
vitro O
antitumor O
activity O
was O
evaluated O
. O

The O
antitumor O
activity O
of O
compound O
112 O
, O
administered O
po O
, O
showed O
more O
potent O
in O
vivo O
oral O
antitumor O
activity O
than O
gambogic B
acid I
. O

Plasma O
concentrations O
of O
darexaban B
glucuronide I
( O
M1 O
) O
, O
the O
pharmacological O
activity O
of O
which O
is O
equipotent O
to O
darexaban B
in O
vitro O
, O
also O
peaked O
at O
approximately O
0 O
. O
75 O
h O
. O

3 B
- I
Methylcholanthrene I
( O
MC O
) O
is O
a O
readily O
metabolized O
aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
agonist O
. O

Spo0A O
links O
de O
novo O
fatty B
acid I
synthesis O
to O
sporulation O
and O
biofilm O
development O
in O
Bacillus O
subtilis O
. O

Exogenous O
fatty B
acid I
supplementation O
to O
accDA O
( O
0A O
) O
cells O
overcomes O
their O
inability O
to O
synthesize O
lipids O
during O
development O
and O
restores O
sporulation O
and O
biofilm O
proficiencies O
. O

We O
found O
that O
a O
gene O
designated O
mimG O
, O
which O
lies O
downstream O
of O
mimABCD O
, O
exhibits O
similarity O
in O
the O
amino B
acid I
sequence O
of O
its O
product O
with O
the O
products O
of O
genes O
encoding O
the O
chaperonin O
GroEL O
. O

The O
as O
- O
prepared O
CuO B
samples O
can O
be O
directly O
used O
as O
integrated O
electrodes O
for O
lithium B
- O
ion O
batteries O
and O
pseudo O
- O
supercapacitors O
without O
the O
addition O
of O
other O
ancillary O
materials O
such O
as O
carbon B
black I
or O
a O
binder O
to O
enhance O
electrode O
conductivity O
and O
cycling O
stability O
. O

A O
parallel O
comparison O
of O
these O
compounds O
in O
a O
cell O
- O
based O
assay O
system O
showed O
meayamycin B
B I
as O
the O
most O
potent O
splicing O
inhibitor O
among O
these O
small O
molecules O
. O

Though O
not O
belonging O
to O
the O
same O
protein O
family O
, O
the O
Per O
- O
Sim O
- O
ARNT O
domain O
receptor O
aryl B
hydrocarbon I
receptor O
functionally O
overlaps O
with O
the O
three O
nuclear O
receptors O
in O
many O
aspects O
and O
is O
therefore O
included O
in O
this O
review O
. O

Histopathological O
effects O
of O
waterborne O
copper B
nanoparticles O
and O
copper B
sulphate I
on O
the O
organs O
of O
rainbow O
trout O
( O
Oncorhynchus O
mykiss O
) O
. O

Five O
anthraquinones B
were O
tested O
to O
determine O
their O
inhibitory O
activities O
on O
NO B
production O
and O
the O
protein O
and O
mRNA O
expression O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
. O

( I
2 I
) I
( O
a O
) O
+ O
CO B
( O
g O
) O
- O
- O
> O
CO B
( I
2 I
) I
( O
g O
) O
+ O
O B
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO B
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO B
oxidation O
follows O
the O
order O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co B

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

Seizure O
control O
by O
ketogenic O
diet O
- O
associated O
medium O
chain O
fatty B
acids I
. O

This O
diet O
increases O
the O
plasma O
levels O
of O
medium O
straight O
chain O
fatty B
acids I
. O

A O
role O
for O
these O
and O
related O
fatty B
acids I
in O
seizure O
control O
has O
not O
been O
established O
. O

We O
compared O
the O
potency O
of O
an O
established O
epilepsy O
treatment O
, O
Valproate B
( O
VPA B
) O
, O
with O
a O
range O
of O
MCT O
diet O
- O
associated O
fatty B
acids I
( O
and O
related O
branched O
compounds O
) O
, O
using O
in O
vitro O
seizure O
and O
in O
vivo O
epilepsy O
models O
, O
and O
assessed O
side O
effect O
potential O
in O
vitro O
for O
one O
aspect O
of O
teratogenicity O
, O
for O
liver O
toxicology O
and O
in O
vivo O
for O
sedation O
, O
and O
for O
a O
neuroprotective O
effect O
. O

We O
identify O
specific O
medium O
chain O
fatty B
acids I
( O
both O
prescribed O
in O
the O
MCT O
diet O
, O
and O
related O
compounds O
branched O
on O
the O
fourth O
carbon O
) O
that O
provide O
significantly O
enhanced O
in O
vitro O
seizure O
control O
compared O
to O
VPA B
. O

Our O
data O
therefore O
implicates O
medium O
chain O
fatty B
acids I
in O
the O
mechanism O
of O
the O
MCT O
ketogenic O
diet O
, O
and O
highlights O
a O
related O
new O
family O
of O
compounds O
that O
are O
more O
potent O
than O
VPA B
in O
seizure O
control O
with O
a O
reduced O
potential O
for O
side O
effects O
. O

Vitamin B
D I
receptor O
signaling O
mechanisms O
: O
integrated O
actions O
of O
a O
well O
- O
defined O
transcription O
factor O
. O

The O
main O
physiological O
actions O
of O
the O
biologically O
most O
active O
metabolite O
of O
vitamin B
D I
, O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
) O
, O
are O
calcium B
and O
phosphorus B
uptake O
and O
transport O
and O
thereby O
controlling O
bone O
formation O
. O

All O
genomic O
actions O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
are O
mediated O
by O
the O
transcription O
factor O
vitamin B
D I
receptor O
( O
VDR O
) O
that O
has O
been O
the O
subject O
of O
intense O
study O
since O
the O
1980 O
' O
s O
. O

Thus O
, O
vitamin B
D I
signaling O
primarily O
implies O
the O
molecular O
actions O
of O
the O
VDR O
. O

By O
comparing O
the O
actions O
of O
the O
VDR O
, O
a O
relatively O
well O
- O
understood O
and O
characterized O
protein O
, O
with O
those O
of O
other O
transcription O
factors O
, O
we O
aim O
to O
build O
a O
realistic O
positioning O
of O
vitamin B
D I
signaling O
in O
the O
context O
of O
other O
intracellular O
signaling O
systems O
. O

Garlic O
- O
derived O
diallyl B
disulfide I
modulates O
peroxisome O
proliferator O
activated O
receptor O
gamma O
co O
- O
activator O
1 O
alpha O
in O
neuroblastoma O
cells O
. O

In O
the O
present O
report O
we O
show O
that O
, O
in O
SH O
- O
SY5Y O
neuroblastoma O
cells O
, O
garlic O
- O
derived O
diallyl B
disulfide I
( O
DADS O
) O
is O
able O
to O
increase O
PGC1 O
alpha O
expression O
in O
a O
ROS O
- O
dependent O
manner O
and O
to O
induce O
mitochondrial O
biogenesis O
at O
early O
stage O
of O
treatment O
that O
precede O
cell O
cycle O
arrest O
and O
apoptosis O
outcome O
. O

The O
highly O
hydrophobic O
drug O
docetaxel B
( O
DTXL B
) O
was O
physically O
entrapped O
within O
the O
PBS B
/ O
PBDL B
copolyester O
core O
and O
the O
hydrophilic O
drug O
doxorubicin B
hydrochloride I
( O
DOX B
. I
HCl I
) O
was O
chemically O
conjugated O
to O
the O
reactive O
PHPMA B
copolymer O
shell O
via O
hydrazone B
bonding O
that O
allowed O
its O
pH O
- O
sensitive O
release O
. O

Serum O
levels O
of O
insulin O
, O
nitric B
oxide I
, O
and O
iron B
were O
measured O
. O

The O
MFe O
diet O
resulted O
in O
decreased O
obesity O
index O
, O
insulin O
level O
, O
and O
nitric B
oxide I
serum O
concentration O
in O
the O
rats O
, O
when O
compared O
with O
both O
the O
M O
and O
C O
diets O
. O

The O
decrease O
in O
insulin O
and O
nitric B
oxide I
in O
rats O
fed O
the O
diet O
high O
in O
iron B
, O
fat O
, O
fructose B
, O
and O
salt O
was O
associated O
with O
disorders O
of O
zinc B
, O
copper B
, O
and O
calcium B
status O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
relative O
mass O
of O
the O
gonads O
. O

Retraction O
note O
to O
: O
The O
effect O
of O
lead B
acetate I
toxicity O
on O
experimental O
male O
albino O
rat O
. O

Generally O
, O
nutrients O
stimulated O
, O
and O
atrazine B
reduced O
chlorophyll B
a I
( O
Chl B
a I
) O
in O
chambers O
. O

Generally O
, O
nutrients O
stimulated O
, O
and O
atrazine B
reduced O
chlorophyll B
a I
( O
Chl B
a I
) O
in O
chambers O
. O

Total O
nitrogen B
( O
TN O
) O
was O
inversely O
related O
to O
Chl B
a I
, O
and O
total O
phosphorus B
was O
inversely O
related O
to O
respiration O
( O
R O
) O
rates O
. O

Valproic B
acid I
( O
VPA B
) O
and O
methylmercury B
( O
MeHg B
) O
were O
used O
as O
positive O
control O
compounds O
to O
address O
the O
following O
fundamental O
questions O
: O
( O
1 O
) O
Does O
transcriptome O
analysis O
allow O
discrimination O
of O
the O
two O
compounds O
? O

The O
currently O
available O
hydrocortisone B
or O
cortisone B
acetate I
preparations O
do O
not O
allow O
an O
accurate O
reproduction O
of O
the O
physiological O
secretion O
pattern O
of O
cortisol B
. O

Methyl B
mercury I
( O
MeHg B
) O
is O
one O
of O
the O
most O
hazardous O
contaminants O
in O
the O
environment O
, O
adversely O
affecting O
the O
health O
of O
wildlife O
and O
humans O
. O

This O
system O
is O
used O
to O
investigate O
the O
lateral O
diffusion O
of O
40 O
nm O
gold O
spheres O
tethered O
to O
biotinylated O
lipids O
through O
antibody O
- O
functionalized O
ligands O
( O
single O
- O
stranded O
DNA O
or O
polyethylene B
glycol I
) O
. O

Its O
polar O
extracts O
consist O
of O
phenolic B
acids I
, O
tannins B
and O
flavonoids B
. O

Control O
of O
hypercholesterolemia O
and O
atherosclerosis O
using O
the O
cholesterol B
recognition O
/ O
interaction O
amino B
acid I
sequence O
of O
the O
translocator O
protein O
TSPO O
. O

A O
domain O
in O
the O
carboxy B
- O
terminus O
of O
TSPO O
was O
identified O
and O
characterized O
as O
the O
cholesterol B
recognition O
/ O
interaction O
amino B
acid I
consensus O
( O
CRAC O
) O
. O

Disrupted O
cytoskeletal O
homeostasis O
, O
astrogliosis O
and O
apoptotic O
cell O
death O
in O
the O
cerebellum O
of O
preweaning O
rats O
injected O
with O
diphenyl B
ditelluride I
. O

In O
the O
present O
report O
15 O
day O
- O
old O
rats O
were O
injected O
with O
0 O
. O
3 O
mu O
mol O
of O
diphenyl B
ditelluride I
( B
PhTe I
) I
( I
2 I
) I
/ O
kg O
body O
weight O
and O
parameters O
of O
neurodegeneration O
were O
analyzed O
in O
slices O
from O
cerebellum O
3 O
and O
6 O
days O
afterwards O
. O

Six O
days O
after O
( B
PhTe I
) I
( I
2 I
) I
injection O
we O
found O
persistent O
astrogliosis O
, O
increased O
propidium B
iodide I
( O
PI O
) O
positive O
cells O
in O
NeuN O
positive O
population O
evidenced O
by O
flow O
cytometry O
and O
reduced O
immunofluorescence O
for O
NeuN O
, O
suggesting O
that O
the O
in O
vivo O
exposure O
to O
( B
PhTe I
) I
( I
2 I
) I
progressed O
to O
neuronal O
death O
. O

Recent O
studies O
proposed O
a O
functional O
coupling O
between O
17 B
beta I
- I
hydroxysteroid I
dehydrogenase O
3 O
( O
17 O
beta O
- O
HSD3 O
) O
- O
dependent O
testosterone O
formation O
and O
11 B
beta I
- I
hydroxysteroid I
dehydrogenase O
1 O
( O
11 O
beta O
- O
HSD1 O
) O
- O
mediated O
interconversion O
of O
glucocorticoids O
through O
competition O
for O
the O
luminal O
pyridine B
nucleotide I
pool O
. O

One O
pot O
synthesis O
and O
biological O
activity O
evaluation O
of O
novel O
Schiff B
bases I
derived O
from O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
. O

Considering O
the O
structural O
features O
of O
a O
group O
of O
known O
potent O
inhibitors O
of O
human O
platelet O
aggregation O
containing O
hydrazone B
structural O
backbone O
, O
a O
series O
of O
novel O
hydrazone B
derivatives O
of O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
were O
synthesized O
using O
a O
one O
- O
pot O
process O
and O
tested O
for O
their O
inhibitory O
activity O
against O
platelet O
aggregation O
induced O
by O
arachidonic B
acid I
and O
ADP B
. O

Evaluation O
of O
romidepsin B
for O
clinical O
activity O
and O
radioactive B
iodine I
reuptake O
in O
radioactive B
iodine I
- O
refractory O
thyroid O
carcinoma O
. O

Evaluation O
of O
romidepsin B
for O
clinical O
activity O
and O
radioactive B
iodine I
reuptake O
in O
radioactive B
iodine I
- O
refractory O
thyroid O
carcinoma O
. O

Background O
: O
Historically O
, O
systemic O
therapy O
for O
radioactive B
iodine I
( O
RAI B
) O
- O
refractory O
thyroid O
cancer O
has O
been O
understudied O
. O

In O
thyroid O
cancer O
cell O
lines O
, O
romidepsin O
increases O
expression O
of O
both O
thyroglobulin O
and O
the O
sodium B
iodide I
symporter O
messenger O
RNAs O
, O
suggesting O
the O
possibility O
of O
improved O
iodine B
concentrating O
ability O
of O
RAI B
- O
resistant O
tumors O
. O

Also O
, O
the O
presence O
of O
structural O
defects O
in O
the O
system O
will O
stiffen O
the O
system O
upon O
low O
strain O
, O
but O
reduces O
the O
elastic O
limit O
from O
more O
than O
20 O
% O
strain O
for O
pristine B
graphene I
to O
less O
than O
10 O
% O
strain O
when O
defects O
are O
present O
. O

Mechanism O
of O
the O
antiproliferative O
activity O
of O
some O
naphthalene B
diimide I
G O
- O
quadruplex O
ligands O
. O

We O
report O
here O
on O
investigations O
into O
the O
mechanism O
of O
action O
of O
tetra O
- O
substituted O
naphthalene B
diimide I
ligands O
on O
the O
basis O
of O
cell O
biologic O
data O
together O
with O
a O
National O
Cancer O
Institute O
COMPARE O
study O
. O

In O
the O
mangiferin B
molecule O
, O
four O
aromatic B
hydroxyl I
groups O
determine O
its O
strong O
antiradical O
and O
antioxidant O
properties O
. O

It O
catalyzes O
the O
hydration O
of O
carbon B
dioxide I
( O
CO B
( I
2 I
) I
) O
to O
bicarbonate B
( O
HCO B
( I
3 I
) I
- I
) O
and O
the O
corresponding O
dehydration O
of O
HCO B
( I
3 I
) I
- I
in O
acidic O
medium O
with O
regeneration O
of O
CO B
( I
2 I
) I
. O

Also O
, O
CA O
isoforms O
are O
found O
in O
a O
variety O
of O
tissues O
where O
they O
participate O
in O
several O
important O
biological O
processes O
such O
as O
acid O
- O
base O
balance O
, O
respiration O
, O
carbon B
dioxide I
and O
ion O
transport O
, O
bone O
resorption O
, O
ureagenesis O
, O
gluconeogenesis O
, O
lipogenesis O
and O
electrolyte O
secretion O
. O

A O
family O
of O
cheap O
and O
easily O
accessible O
beta B
- I
amino I
alcohols I
, O
obtained O
in O
one O
step O
from O
naturally O
occurring O
amino B
acids I
, O
was O
shown O
to O
successfully O
catalyze O
the O
asymmetric O
aldol B
reaction O
between O
a O
series O
of O
ketones B
and O
aromatic B
aldehydes I
. O

A O
family O
of O
cheap O
and O
easily O
accessible O
beta B
- I
amino I
alcohols I
, O
obtained O
in O
one O
step O
from O
naturally O
occurring O
amino B
acids I
, O
was O
shown O
to O
successfully O
catalyze O
the O
asymmetric O
aldol B
reaction O
between O
a O
series O
of O
ketones B
and O
aromatic B
aldehydes I
. O

The O
heat O
treatment O
and O
the O
gelation O
are O
strong O
determinants O
of O
the O
kinetics O
of O
milk O
proteins O
digestion O
and O
of O
the O
peripheral O
availability O
of O
amino B
acids I
. O

This O
study O
aimed O
to O
determine O
the O
kinetics O
of O
milk O
protein O
digestion O
and O
amino B
acid I
absorption O
after O
ingestion O
of O
four O
dairy O
matrices O
by O
six O
minipigs O
: O
unheated O
or O
heated O
skim O
milk O
and O
corresponding O
rennet O
gels O
. O

Gelation O
of O
milk O
slowed O
down O
the O
outflow O
of O
the O
meal O
from O
the O
stomach O
and O
the O
subsequent O
absorption O
of O
amino B
acids I
, O
and O
decreased O
their O
bioavailability O
in O
peripheral O
blood O
. O

The O
in O
vivo O
antioxidant O
and O
antifibrotic O
properties O
of O
green O
tea O
( O
Camellia O
sinensis O
, O
Theaceae O
) O
were O
investigated O
with O
a O
study O
of O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
) O
- O
induced O
oxidative O
stress O
and O
hepatic O
fibrosis O
in O
male O
ICR O
mice O
. O

Oral O
administration O
of O
green O
tea O
extract O
at O
doses O
of O
125 O
, O
625 O
and O
1250 O
mg O
/ O
kg O
for O
8 O
weeks O
significantly O
reduced O
( O
p O
< O
0 O
. O
05 O
) O
the O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substances O
( O
TBARS O
) O
and O
protein O
carbonyls B
in O
the O
liver O
by O
at O
least O
28 O
% O
compared O
with O
that O
was O
induced O
by O
CCl B
( I
4 I
) I
( O
1 O
mL O
/ O
kg O
) O
in O
mice O
. O

A O
new O
QSAR O
model O
, O
for O
angiotensin B
I I
- O
converting O
enzyme O
inhibitory O
oligopeptides O
. O

A O
new O
quantitative O
structure O
activity O
relationship O
( O
QSAR O
) O
model O
is O
established O
for O
oligopeptides O
that O
inhibit O
angiotensin B
I I
- O
converting O
enzyme O
( O
ACE O
) O
. O

However O
, O
in O
the O
C O
- O
4 O
position O
, O
the O
model O
indicates O
a O
clear O
preference O
for O
bulky O
hydrophobic O
amino B
acids I
and O
for O
sulphur B
- O
containing O
amino B
acids I
. O

However O
, O
in O
the O
C O
- O
4 O
position O
, O
the O
model O
indicates O
a O
clear O
preference O
for O
bulky O
hydrophobic O
amino B
acids I
and O
for O
sulphur B
- O
containing O
amino B
acids I
. O

The O
results O
showed O
that O
the O
molecular O
weight O
of O
CPP O
was O
900 O
kDa O
, O
and O
it O
contained O
64 O
. O
8 O
% O
total O
sugar O
, O
23 O
. O
5 O
% O
uronic B
acid I
, O
9 O
. O
26 O
% O
protein O
, O
and O
six O
kinds O
of O
monosaccharides B
, O
including O
glucose B
, O
rhamnose B
, O
arabinose B
, O
xylose B
, O
mannose B
and O
galactose B
, O
with O
molar O
percentages O
of O
32 O
. O
7 O
% O
, O
9 O
. O
33 O
% O
, O
30 O
. O
6 O
% O
, O
3 O
. O
48 O
% O
, O
10 O
. O
4 O
% O
, O
and O
13 O
. O
5 O
% O
, O
respectively O
. O

We O
also O
analysed O
the O
post O
- O
mortem O
baseline O
levels O
of O
monoamines B
and O
amino B
acids I
in O
different O
brain O
regions O
. O

These O
findings O
suggest O
that O
CPF B
induced O
a O
long O
- O
term O
compulsivity O
that O
was O
apparent O
in O
the O
5 O
- O
CSRT O
task O
and O
associated O
with O
changes O
in O
monoaminergic O
and O
amino B
acid I
brain O
systems O
of O
inhibitory O
control O
function O
. O

Although O
the O
tumor O
- O
promoting O
effects O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
coplanar O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
and O
related O
compounds O
in O
liver O
tissue O
are O
primarily O
attributed O
to O
the O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
the O
underlying O
molecular O
mechanisms O
are O
still O
unclear O
. O

Although O
the O
tumor O
- O
promoting O
effects O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
coplanar O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
and O
related O
compounds O
in O
liver O
tissue O
are O
primarily O
attributed O
to O
the O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
the O
underlying O
molecular O
mechanisms O
are O
still O
unclear O
. O

To O
better O
understand O
AhR O
- O
driven O
pathways O
, O
we O
analyzed O
the O
transcriptional O
program O
in O
response O
to O
coplanar O
PCB B
126 I
in O
contact O
- O
inhibited O
rat O
liver O
progenitor O
WB O
- O
F344 O
cells O
using O
high O
- O
density O
microarrays O
. O

Proximate O
composition O
, O
fatty B
acid I
profile O
, O
cholesterol B
, O
alpha B
- I
tocoferol I
content O
and O
essential O
( O
K B
, O
Na B
, O
Cl B
, O
S B
, O
Mg B
, O
Ca B
, O
Zn B
, O
Cu B
, O
Fe B
, O
Mn B
, O
and O
Se B
) O
and O
contaminant O
element O
( O
Hg B
/ O
MeHg B
, O
Cd B
, O
Pb B
, O
and O
As B
) O
levels O
in O
silver B
scabbardfish O
( O
Lepidopus O
caudatus O
) O
, O
hake O
( O
Merluccius O
merluccius O
) O
, O
and O
ray O
( O
Raja O
spp O
. O
) O
were O
investigated O
. O

Polyunsaturated B
fatty I
acids I
( O
PUFA B
) O
were O
the O
dominant O
group O
of O
the O
fatty B
acids I
, O
being O
80 O
% O
of O
the O
n O
- O
3 O
family O
. O

The O
toxins O
were O
extracted O
with O
acetonitrile B
/ O
water O
( O
90 O
: O
10 O
, O
v O
/ O
v O
) O
containing O
0 O
. O
1 O
% O
formic B
acid I
and O
cleaned O
by O
HLB O
and O
GCB B
sorbents O
. O

Stearoyl B
- I
PEG I
- I
polySDM I
was O
synthesised O
using O
a O
multi O
- O
step O
procedure O
that O
includes O
pH O
- O
sensitive O
sulfadimethoxine B
methacrylate I
polymerisation O
by O
AGET O
- O
ATRP O
at O
the O
amino B
terminal O
side O
of O
stearoyl B
- I
PEG I
- I
NH2 I
. O

Chemical O
analysis O
showed O
that O
the O
stearoyl B
- I
PEG I
- I
polySDM I
co O
- O
polymer O
contained O
a O
mean O
of O
seven O
methacryloyl B
sulfadimethoxines I
per O
molecule O
. O

Activity O
within O
the O
social O
behavior O
neural O
network O
is O
modulated O
by O
the O
neuropeptide O
arginine B
vasotocin I
( O
AVT B
) O
and O
its O
mammalian O
homologue O
arginine B
vasopressin I
( O
AVP B
) O
. O

Activity O
within O
the O
social O
behavior O
neural O
network O
is O
modulated O
by O
the O
neuropeptide O
arginine B
vasotocin I
( O
AVT B
) O
and O
its O
mammalian O
homologue O
arginine B
vasopressin I
( O
AVP B
) O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

Vitamin B
B1 I
was O
antimutagenic O
against O
alkylatings O
MNNG B
( O
P O
< O
0 O
. O
05 O
) O
or O
ENNG B
( O
P O
< O
0 O
. O
001 O
) O
. O

Vitamin B
B12 I
( O
4 O
mg O
/ O
kg O
) O
reduced O
urinary O
mutagens O
of O
NOR B
or O
NLX B
( O
P O
< O
0 O
. O
02 O
) O
. O

Vitamins B
B I
inhibited O
DNA O
mutations O
induced O
by O
ROS O
generated O
by O
NLX B
or O
NOR B
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Vitamin B
B1is I
antimutagenic O
against O
mutations O
induced O
by O
the O
alkylating O
MNNG B
or O
ENNG B
. O

Based O
on O
the O
observations O
, O
employment O
of O
vitamins B
B I
in O
vivo O
can O
be O
a O
promising O
alternative O
to O
reduce O
genotoxic O
risk O
exposure O
to O
ROS O
. O

Cardioprotective O
effect O
of O
salvianolic B
acid I
B I
against O
arsenic B
trioxide I
- O
induced O
injury O
in O
cardiac O
H9c2 O
cells O
via O
the O
PI3K O
/ O
Akt O
signal O
pathway O
. O

The O
clinical O
use O
of O
arsenic B
trioxide I
( O
ATO B
) O
, O
a O
potent O
anti O
- O
neoplastic O
agent O
, O
is O
often O
limited O
because O
of O
its O
severe O
cardiotoxicity O
. O

One O
of O
the O
most O
abundant O
ingredients O
of O
S O
. O
miltiorrhiza O
is O
salvianolic B
acid I
B I
( O
Sal B
B I
) O
. O

The O
present O
study O
was O
designed O
to O
evaluate O
whether O
Sal B
B I
protects O
against O
ATO B
- O
induced O
cardiac O
cell O
injury O
in O
vitro O
. O

With O
MTT B
cell O
viability O
assay O
, O
LDH O
release O
, O
ROS O
generation O
, O
caspase O
- O
3 O
activity O
assay O
and O
Hoechst B
33342 I
/ O
PI O
staining O
, O
we O
found O
that O
Sal B
B I
pretreatment O
provided O
significantly O
protection O
against O
ATO B
- O
induced O
cell O
death O
. O

With O
MTT B
cell O
viability O
assay O
, O
LDH O
release O
, O
ROS O
generation O
, O
caspase O
- O
3 O
activity O
assay O
and O
Hoechst B
33342 I
/ O
PI O
staining O
, O
we O
found O
that O
Sal B
B I
pretreatment O
provided O
significantly O
protection O
against O
ATO B
- O
induced O
cell O
death O
. O

Conversely O
, O
blocking O
Akt O
activation O
with O
the O
PI3K O
inhibitor O
LY294002 B
effectively O
suppressed O
the O
protective O
effect O
of O
Sal B
B I
against O
ATO B
- O
induced O
cell O
apoptosis O
. O

In O
addition O
, O
the O
PI3K O
inhibitor O
partially O
blocked O
the O
effects O
of O
Sal B
B I
on O
the O
upregulation O
of O
Bcl O
- O
2 O
and O
Bcl O
- O
xl O
protein O
expression O
, O
and O
downregulation O
of O
Bax O
protein O
expression O
. O

Collectively O
, O
the O
results O
showed O
that O
Sal B
B I
decreased O
the O
apoptosis O
and O
necrosis O
of O
H9c2 O
cardiomyocytes O
caused O
by O
ATO B
treatment O
, O
and O
PI3K O
played O
a O
crucial O
role O
in O
enhancing O
cell O
survival O
during O
this O
process O
. O

These O
observations O
indicate O
that O
Sal B
B I
has O
the O
potential O
to O
exert O
cardioprotective O
effects O
against O
ATO B
toxicity O
. O

An O
increase O
of O
endogenous O
jasmonic B
acid I
concentration O
was O
observed O
only O
in O
K O
. O
obovata O
, O
both O
at O
Day O
1 O
and O
at O
Day O
49 O
, O
which O
suggests O
that O
this O
hormone O
plays O
an O
important O
role O
in O
metal O
tolerance O
under O
short O
- O
term O
and O
long O
- O
term O
metal O
treatment O
. O

A O
rechargeable O
room O
- O
temperature O
sodium B
superoxide I
( O
NaO2 B
) O
battery O
. O

Crystalline O
sodium B
superoxide I
( O
NaO B
( I
2 I
) I
) O
forms O
in O
a O
one O
- O
electron O
transfer O
step O
as O
a O
solid O
discharge O
product O
. O

Two O
series O
of O
chalcone B
based O
sulfone B
and O
bisulfone B
derivatives O
were O
synthesized O
using O
chalcone B
, O
thiophenol B
and O
sodium B
metal O
at O
room O
temperature O
, O
followed O
by O
oxidation O
of O
chalcone B
sulfides I
with O
m B
- I
CPBA I
at O
0 O
degrees O
C O
in O
a O
novel O
method O
. O

This O
enhanced O
activity O
of O
5 O
compared O
to O
4 O
could O
be O
due O
to O
the O
effective O
location O
of O
hydroxyl B
group O
of O
allylic B
alcohol I
moiety O
of O
5 O
in O
the O
3D O
structure O
. O

The O
electron O
withdrawing O
substituents O
at O
position O
4 O
of O
phenyl B
ring O
of O
5 O
enhances O
the O
activity O
possibly O
due O
to O
an O
increase O
in O
the O
strength O
of O
hydrogen B
bonding O
property O
of O
hydroxyl B
group O
of O
allylic B
alcohol I
moiety O
. O

Because O
the O
receptor O
for O
TCDD B
is O
the O
aryl B
hydrocarbon I
receptor O
ligand O
- O
activated O
transcriptional O
regulator O
, O
we O
examined O
the O
effects O
of O
TCDD B
exposure O
on O
gene O
expression O
in O
the O
ventricle O
using O
DNA O
microarrays O
. O

The O
calmodulin O
regulator O
protein O
, O
PEP O
- O
19 O
, O
sensitizes O
ATP B
- O
induced O
Ca2 B
+ I
release O
. O

The O
Fraction O
of O
Exhaled O
Nitric B
Oxide I
( O
FeNO O
) O
was O
calculated O
, O
dynamic O
flow O
volumes O
were O
assessed O
through O
spirometry O
; O
while O
airway O
impedance O
( O
Z O
) O
, O
resistance O
( O
R O
) O
, O
and O
reactance O
( O
X O
) O
was O
assessed O
through O
impulse O
oscillometry O
before O
and O
after O
exposure O
. O

Effects O
of O
the O
lipid O
environment O
, O
cholesterol B
and O
bile B
acids I
on O
the O
function O
of O
the O
purified O
and O
reconstituted O
human O
ABCG2 O
protein O
. O

By O
using O
the O
purified O
and O
reconstituted O
protein O
we O
demonstrate O
that O
cholesterol B
is O
an O
essential O
activator O
, O
whereas O
bile B
acids I
are O
important O
modulators O
of O
ABCG2 O
activity O
. O

Bile B
acids I
strongly O
decrease O
the O
basal O
ABCG2 O
- O
ATPase O
activity O
both O
in O
the O
wild O
- O
type O
ABCG2 O
and O
in O
the O
mutant O
variant O
. O

These O
data O
reinforce O
the O
results O
for O
the O
modulatory O
effects O
of O
cholesterol B
and O
bile B
acids I
of O
ABCG2 O
investigated O
in O
a O
complex O
cell O
membrane O
environment O
. O

Three O
PEMs O
are O
considered O
: O
Nafion B
, O
sulfonated B
polystyrene I
( O
sPS B
) O
that O
forms O
the O
hydrophilic O
subphase O
of O
segregated O
sPS B
- O
polyolefin B
block O
copolymers O
, O
and O
random O
sPS B
- O
polyethylene B
copolymer O
. O

We O
found O
that O
sarin B
concentrates O
at O
the O
interface O
between O
the O
hydrophilic O
and O
hydrophobic O
subphases O
of O
hydrated B
Nafion I
acting O
as O
a O
surfactant O
. O

In O
hydrated B
sPS I
, O
where O
the O
scale O
of O
water O
- O
polymer O
segregation O
is O
much O
smaller O
( O
1 O
- O
2 O
nm O
) O
, O
sarin B
also O
interacts O
favorably O
with O
hydrophobic O
and O
hydrophilic O
components O
. O

The O
behavior O
of O
sarin B
is O
similar O
to O
that O
of O
its O
common O
simulant O
, O
dimethyl B
methylphosphonate I
. O

Belatacept O
combined O
with O
corticosteroids B
and O
a O
mycophenolic B
acid I
is O
indicated O
for O
prophylaxis O
of O
graft O
rejection O
in O
adults O
receiving O
renal O
transplant O
. O

A O
systematic O
study O
of O
the O
degradation O
of O
dimethyl B
phthalate I
using O
a O
high O
- O
frequency O
ultrasonic O
process O
. O

A O
comprehensive O
study O
of O
the O
sonochemical O
degradation O
of O
dimethyl B
phthalate I
( O
DMP B
) O
was O
carried O
out O
using O
high O
- O
frequency O
ultrasonic O
processes O
. O

The O
effects O
of O
various O
operating O
parameters O
were O
investigated O
, O
including O
ultrasonic O
frequency O
, O
power O
density O
, O
initial O
DMP B
concentration O
, O
solution O
pH O
and O
the O
presence O
of O
hydrogen B
peroxide I
. O

The O
addition O
of O
hydrogen B
peroxide I
can O
increase O
the O
radical O
generation O
to O
some O
extent O
. O

Comparison O
of O
hydroxyl B
radical O
formation O
in O
aqueous O
solutions O
at O
different O
ultrasound O
frequencies O
and O
powers O
using O
the O
salicylic B
acid I
dosimeter O
. O

Ultrasonic O
frequencies O
of O
20kHz O
, O
382kHz O
, O
584kHz O
, O
862kHz O
( O
and O
998kHz O
) O
have O
been O
compared O
with O
regard O
to O
energy O
output O
and O
hydroxyl B
radical O
formation O
utilising O
the O
salicylic B
acid I
dosimeter O
. O

Using O
the O
salicylic B
acid I
dosimeter O
and O
inputting O
virtually O
the O
same O
Wattages O
it O
is O
established O
that O
862kHz O
is O
around O
10 O
% O
more O
efficient O
at O
generating O
hydroxyl B
radicals O
than O
the O
382kHz O
but O
both O
of O
these O
are O
far O
more O
effective O
than O
the O
other O
frequencies O
. O

Also O
, O
it O
is O
found O
that O
as O
temperature O
increases O
to O
42 O
degrees O
C O
then O
the O
total O
dihydroxybenzoic B
acid I
( O
Total O
DHBA B
) O
produced O
is O
virtually O
identical O
for O
382kHz O
and O
862kHz O
, O
though O
582kHz O
is O
substantially O
lower O
, O
when O
the O
power O
levels O
are O
set O
at O
approximately O
9W O
for O
all O
systems O
. O

Triterpene B
saponins I
from O
Clethra O
barbinervis O
and O
their O
hyaluronidase O
inhibitory O
activities O
. O

From O
the O
active O
fractions O
, O
seven O
new O
triterpene B
saponins I
( O
1 O
- O
4 O
, O
6 O
- O
8 O
) O
and O
a O
new O
lignan B
glycoside I
( O
14 O
) O
were O
isolated O
together O
with O
14 O
known O
compounds O
( O
5 O
, O
9 O
- O
13 O
, O
15 O
- O
22 O
) O
. O

From O
the O
active O
fractions O
, O
seven O
new O
triterpene B
saponins I
( O
1 O
- O
4 O
, O
6 O
- O
8 O
) O
and O
a O
new O
lignan B
glycoside I
( O
14 O
) O
were O
isolated O
together O
with O
14 O
known O
compounds O
( O
5 O
, O
9 O
- O
13 O
, O
15 O
- O
22 O
) O
. O

A O
simple O
, O
colorimetric O
, O
sensitive O
, O
cost O
- O
effective O
and O
high O
- O
throughput O
system O
based O
on O
a O
positively O
charged O
graphene B
oxide I
- O
enzyme O
complex O
was O
developed O
for O
bacterial O
detection O
and O
drug O
screening O
. O

Total O
synthesis O
of O
the O
polyhydroxy B
caprolactam I
amide I
natural O
product O
, O
bengamide B
E I
, O
is O
accomplished O
starting O
from O
tartaric B
acid I
. O

Total O
synthesis O
of O
the O
polyhydroxy B
caprolactam I
amide I
natural O
product O
, O
bengamide B
E I
, O
is O
accomplished O
starting O
from O
tartaric B
acid I
. O

Key O
reactions O
in O
the O
synthesis O
include O
desymmetrization O
of O
the O
bis B
( I
dimethylamide I
) I
unit O
of O
tartaric B
acid I
, O
Zn B
( I
BH I
( I
4 I
) I
) I
( I
2 I
) I
- O
mediated O
anti O
- O
selective O
reduction O
, O
and O
a O
Horner O
- O
Wadsworth O
- O
Emmons O
olefination O
. O

The O
chemical O
breath O
of O
modulators O
includes O
natural O
products O
such O
as O
fusicoccin B
A I
and O
derivatives O
but O
also O
compounds O
identified O
via O
high O
- O
throughput O
and O
in O
silico O
screening O
, O
which O
has O
yielded O
a O
toolbox O
of O
useful O
inhibitors O
and O
stabilizers O
for O
this O
interesting O
class O
of O
adapter O
proteins O
. O

In O
the O
last O
two O
decades O
, O
there O
have O
been O
numerous O
empirical O
approaches O
to O
improve O
the O
biotechnological O
production O
of O
taxanes B
, O
leading O
to O
the O
conclusion O
that O
treatment O
of O
Taxus O
sp O
. O
cells O
with O
methyl B
jasmonate I
or O
other O
elicitors O
is O
the O
most O
effective O
strategy O
. O

The O
pentacyclic B
triterpenoids I
in O
herbal O
medicines O
and O
their O
pharmacological O
activities O
in O
diabetes O
and O
diabetic O
complications O
. O

Pentacyclic B
triterpenoids I
including O
the O
oleanane B
, O
ursane B
and O
lupane B
groups O
are O
widely O
distributed O
in O
many O
medicinal O
plants O
, O
such O
as O
Glycyrrhiza O
species O
, O
Gymnema O
species O
, O
Centella O
asiatica O
, O
Camellia O
sinensis O
, O
Crataegus O
species O
and O
Olea O
europaea O
, O
which O
are O
commonly O
used O
in O
traditional O
medicine O
for O
the O
treatment O
of O
diabetes O
and O
diabetic O
complications O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin B
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin B
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin B
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin B
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

A O
large O
number O
of O
bioactive O
pentacyclic B
triterpenoids I
, O
such O
as O
oleanolic B
acid I
, O
glycyrrhizin B
, O
glycyrrhetinic B
acid I
, O
ursolic B
acid I
, O
betulin B
, O
betulinic B
acid I
and O
lupeol B
have O
shown O
multiple O
biological O
activities O
with O
apparent O
effects O
on O
glucose B
absorption O
, O
glucose B
uptake O
, O
insulin O
secretion O
, O
diabetic O
vascular O
dysfunction O
, O
retinopathy O
and O
nephropathy O
. O

The O
versatility O
of O
the O
pentacyclic B
triterpenes I
provides O
a O
promising O
approach O
for O
diabetes O
management O
. O

In O
contrast O
, O
cinnamtannin B
B1 I
and O
crocin B
exhibit O
antiapoptotic O
effects O
. O

Synthesis O
and O
HIV O
- O
1 O
inhibitory O
activities O
of O
dicaffeoyl B
and I
digalloyl I
esters I
of O
quinic B
acid I
derivatives O
. O

Twenty O
analogues O
of O
the O
anti O
- O
HIV O
- O
1 O
integrase O
( O
IN O
) O
inhibitors O
dicaffeoylquinic B
acids I
( O
DCQAs B
) O
were O
prepared O
. O

SCO5461 O
was O
further O
found O
to O
ADP B
- O
ribosylate O
deoxyguanosine B
, O
GMP B
, O
dGMP B
, O
GTP B
, O
dGTP B
, O
and O
cyclic B
GMP I
with O
k O
( O
cat O
) O
values O
of O
150 O
- O
370 O
s O
( O
- O
1 O
) O
. O

This O
is O
the O
first O
report O
of O
the O
ADP B
- O
ribosylation O
of O
guanosine B
and O
guanine B
mononucleotides I
among O
the O
family O
members O
of O
various O
ADP B
- O
ribosylating O
enzymes O
. O

Vitamin B
K I
antagonists O
( O
VKAs O
) O
were O
, O
until O
recently O
, O
the O
only O
option O
for O
chronic O
anticoagulation O
in O
patients O
with O
atrial O
fibrillation O
. O

All O
three O
colloidal O
O O
- O
MWNTs O
exhibit O
strong O
adsorption O
affinities O
to O
the O
three O
test O
compounds O
( O
with O
K O
( O
OC O
) O
values O
orders O
of O
magnitude O
greater O
than O
those O
of O
natural O
organic O
matter O
) O
, O
likely O
resulting O
from O
strong O
nonhydrophobic O
interactions O
such O
as O
pi O
- O
pi O
electron O
donor O
- O
acceptor O
interactions O
and O
Lewis B
acid I
- O
base O
interactions O
. O

Previous O
studies O
have O
shown O
inexplicable O
declines O
in O
breeding O
waterbirds O
within O
western O
New O
York O
/ O
New O
Jersey O
Harbor O
between O
1996 O
and O
2002 O
and O
elevated O
polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and O
polychlorinated B
biphenyls I
( O
PCBs B
) O
in O
double O
- O
crested O
cormorant O
( O
Phalacrocorax O
auritus O
) O
eggs O
. O

Functionalized O
alkynyl B
polyvinyl I
alcohol I
magnetic O
microspheres O
( O
PVA B
MMs O
) O
were O
developed O
for O
the O
specific O
enrichment O
of O
sialic B
acid I
- O
rich O
glycoproteins O
by O
click O
chemistry O
. O

The O
functionalized O
alkynyl B
PVA I
MMs O
showed O
a O
high O
specificity O
and O
strong O
binding O
capability O
for O
glycoproteins O
through O
a O
[ O
3 O
+ O
2 O
] O
cycloaddition O
reaction O
. O

The O
results O
indicated O
that O
the O
functionalized O
alkynyl B
PVA I
MMs O
could O
be O
applied O
to O
the O
enrichment O
of O
cell O
glycoproteins O
, O
and O
the O
merits O
of O
the O
MMs O
suggested O
an O
attractive O
and O
potential O
way O
to O
facilitate O
glycoprotein O
research O
. O

Metachromins B
are O
a O
series O
of O
sesquiterpenoid B
quinones I
isolated O
from O
Okinawan O
marine O
sponges O
. O

Inhibitory O
effects O
of O
metachromins B
L I
- I
Q I
( O
1 O
- O
6 O
) O
, O
sesquiterpenoid B
quinones I
with O
an O
amino B
acid I
residue O
, O
and O
their O
related O
analogs O
( O
7 O
- O
18 O
) O
prepared O
from O
metachromins B
A O
( O
19 O
) O
and O
C O
( O
20 O
) O
against O
receptor O
tyrosine B
kinases O
EGFR O
and O
HER2 O
were O
investigated O
. O

Inhibitory O
effects O
of O
metachromins B
L I
- I
Q I
( O
1 O
- O
6 O
) O
, O
sesquiterpenoid B
quinones I
with O
an O
amino B
acid I
residue O
, O
and O
their O
related O
analogs O
( O
7 O
- O
18 O
) O
prepared O
from O
metachromins B
A O
( O
19 O
) O
and O
C O
( O
20 O
) O
against O
receptor O
tyrosine B
kinases O
EGFR O
and O
HER2 O
were O
investigated O
. O

Esters B
of O
phthalic B
acid I
are O
chemical O
agents O
used O
to O
improve O
the O
plasticity O
of O
industrial O
polymers O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di B
- I
( I
2 I
- I
ethy I
hexyl I
) I
phthalate I
( O
DEHP B
) O
, O
diethyl B
phthalate I
( O
DEP B
) O
, O
dibutyl B
phthalate I
( O
DBP B
) O
and O
benzyl B
butyl I
phthalate I
( O
BBP B
) O
in O
developing O
fish O
embryos O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di B
- I
( I
2 I
- I
ethy I
hexyl I
) I
phthalate I
( O
DEHP B
) O
, O
diethyl B
phthalate I
( O
DEP B
) O
, O
dibutyl B
phthalate I
( O
DBP B
) O
and O
benzyl B
butyl I
phthalate I
( O
BBP B
) O
in O
developing O
fish O
embryos O
. O

All O
phthalates B
exhibited O
weak O
potency O
as O
agonists O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
. O

In O
the O
case O
of O
capreomycin B
oleate I
, O
both O
instruments O
, O
mini O
and O
nano O
spray O
- O
dryer O
, O
were O
suitable O
to O
maintain O
a O
high O
ion O
- O
paired O
content O
, O
while O
for O
capreomycin B
linoleate I
and I
linolenate I
, O
mini O
spray O
- O
dryer O
was O
the O
most O
appropriate O
instrument O
. O

Capreomycin B
oleate I
and I
linoleate I
showed O
the O
same O
efficacy O
of O
capreomycin B
sulfate I
against O
M O
. O
tuberculosis O
, O
while O
capreomycin B
linolenate I
showed O
a O
reduced O
efficacy O
, O
even O
though O
strain O
growth O
was O
inhibited O
at O
10 O
( O
- O
4 O
) O
mycobacterial O
inoculum O
. O

Capreomycin B
oleate I
and I
linoleate I
showed O
the O
same O
efficacy O
of O
capreomycin B
sulfate I
against O
M O
. O
tuberculosis O
, O
while O
capreomycin B
linolenate I
showed O
a O
reduced O
efficacy O
, O
even O
though O
strain O
growth O
was O
inhibited O
at O
10 O
( O
- O
4 O
) O
mycobacterial O
inoculum O
. O

In O
vivo O
acute O
toxicity O
studies O
evidenced O
the O
lowest O
toxic O
potential O
for O
capreomycin B
oleate I
when O
compared O
to O
the O
single O
components O
or O
the O
other O
two O
salts O
. O

Overall O
, O
capreomycin B
oleate I
seems O
to O
possess O
the O
most O
promising O
characteristics O
to O
be O
used O
as O
supergenerics O
in O
pulmonary O
tuberculosis O
treatment O
. O

The O
most O
active O
was O
also O
physodic B
acid I
. O

Lecithin O
in O
mixed O
micelles O
attenuates O
the O
cytotoxicity O
of O
bile B
salts I
in O
Caco O
- O
2 O
cells O
. O

This O
study O
was O
designed O
to O
investigate O
the O
cytotoxicity O
of O
bile B
salt I
- O
lecithin O
mixed O
micelles O
on O
the O
Caco O
- O
2 O
cell O
model O
. O

The O
mixed O
micelles O
with O
lower O
than O
0 O
. O
2mM O
sodium B
deoxycholate I
( O
SDC B
) O
had O
no O
significant O
effects O
on O
cell O
viability O
and O
proliferation O
. O

These O
results O
demonstrate O
that O
relatively O
higher O
concentrations O
of O
mixed O
micelles O
are O
toxic O
to O
Caco O
- O
2 O
cells O
, O
while O
phospholipids O
can O
attenuate O
the O
toxicity O
of O
the O
bile B
salts I
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l B
- I
polylactide I
, O
d B
- I
polylactide I
, O
chitosan O
, O
polyglycolic B
acid I
, O
polyethylene B
glycol I
and O
cellulose O
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l B
- I
polylactide I
, O
d B
- I
polylactide I
, O
chitosan O
, O
polyglycolic B
acid I
, O
polyethylene B
glycol I
and O
cellulose O
. O

Cyclosporine B
A I
has O
been O
chosen O
as O
a O
model O
drug O
substance O
. O

Because O
GK O
contains O
polyacetylenes B
and O
because O
other O
polyacetylenes B
have O
been O
found O
to O
exhibit O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
, O
we O
hypothesized O
that O
the O
polyacetylene B
gymnasterkoreayne B
B I
( O
GKB B
) O
, O
known O
to O
increase O
hepatic O
detoxification O
enzymes O
, O
may O
also O
exert O
anti O
- O
inflammatory O
and O
anti O
- O
cancer O
activities O
. O

2 B
- I
Phenoxy I
- I
nicotinamides I
are O
potent O
agonists O
at O
the O
bile B
acid I
receptor O
GPBAR1 O
( O
TGR5 O
) O
. O

When O
THP B
exposed O
NF O
- O
L O
was O
subjected O
to O
amino B
acid I
analysis O
, O
glutamate B
, O
proline B
and O
lysine B
residues O
were O
found O
to O
be O
particularly O
sensitive O
. O

All O
the O
11 O
, O
4 O
' O
' O
- O
disubstituted O
analogs O
exhibited O
excellent O
activity O
( O
0 O
. O
03 O
- O
0 O
. O
12 O
mu O
g O
/ O
ml O
) O
against O
erythromycin B
- O
susceptible O
Streptococcus O
pneumoniae O
, O
and O
significantly O
improved O
activity O
against O
three O
phenotypes O
of O
erythromycin B
- O
resistant O
S O
. O
pneumoniae O
compared O
with O
erythromycin B
A I
, O
clarithromycin B
or O
azithromycin B
. O

An O
important O
effector O
of O
the O
ISR O
is O
activating O
transcription O
factor O
4 O
( O
ATF4 O
) O
, O
a O
transcription O
factor O
that O
regulates O
genes O
involved O
in O
redox O
homeostasis O
and O
amino B
acid I
metabolism O
and O
transport O
. O

The O
bovine O
adenosine B
triphosphate I
- O
binding O
cassette O
transporter O
G2 O
( O
ABCG2 O
/ O
breast O
cancer O
resistance O
protein O
) O
polymorphism O
Tyr581Ser O
( O
Y581S O
) O
has O
recently O
been O
shown O
to O
increase O
in O
vitro O
transepithelial O
transport O
of O
antibiotics O
. O

These O
insights O
should O
stimulate O
surface O
conductance O
studies O
at O
SG O
monolayers O
with O
sulfonic B
acid I
groups O
, O
and O
they O
bolster O
efforts O
in O
designing O
proton O
conducting O
polymers O
conducive O
to O
fuel O
cell O
operation O
above O
~ O
100 O
degrees O
C O
. O

In O
contrast O
, O
mutation O
c O
. O
1244T O
> O
C O
results O
in O
an O
amino B
acid I
substitution O
( O
Ile415Thr O
) O
, O
which O
abolishes O
signal O
transduction O
due O
to O
structural O
changes O
. O

New O
amide B
alkaloids I
from O
Piper O
longum O
. O

Functionalization O
of O
monodisperse O
iron B
oxide I
NPs O
and O
their O
properties O
as O
magnetically O
recoverable O
catalysts O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine B
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine B
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

We O
determined O
that O
both O
LLA B
and O
LEA B
stabilize O
magnetic O
iron B
oxide I
NPs O
, O
allowing O
the O
formation O
of O
pi O
- O
complexes O
with O
bis B
( I
acetonitrile I
) I
dichloropalladium I
( I
II I
) I
in O
the O
NP O
shells O
. O

The O
interaction O
of O
PPCA B
- O
based O
particles O
with O
Pd B
acetate I
also O
leads O
to O
aggregation O
because O
of O
interparticle O
interactions O
, O
but O
the O
aggregates O
that O
are O
formed O
are O
much O
smaller O
. O

The O
sulfonylurea B
herbicides O
exert O
their O
activity O
by O
inhibiting O
plant O
acetohydroxyacid O
synthase O
( O
AHAS O
) O
, O
the O
first O
enzyme O
in O
the O
branched O
- O
chain O
amino B
acid I
biosynthesis O
pathway O
. O

The O
inhibition O
of O
soluble O
epoxide B
hydrolase O
leads O
to O
elevated O
levels O
of O
epoxyeicosatrienoic B
acids I
( O
EETs B
) O
, O
and O
thus O
inhibitors O
of O
sEH O
represent O
one O
of O
a O
novel O
approach O
to O
the O
development O
of O
vasodilatory O
and O
anti O
- O
inflammatory O
drugs O
. O

The O
alkaloids O
induced O
apoptosis O
in O
MDR O
cells O
which O
was O
accompanied O
by O
an O
activation O
of O
caspase O
- O
3 O
, O
- O
8 O
, O
- O
6 O
/ O
9 O
, O
and O
phosphatidyl B
serine I
( O
PS O
) O
exposure O
. O

Phase O
1 O
and O
phase O
2 O
drug O
metabolism O
and O
bile B
acid I
production O
of O
HepaRG O
cells O
in O
a O
bioartificial O
liver O
in O
absence O
of O
dimethyl B
sulfoxide I
. O

Phase O
1 O
and O
phase O
2 O
drug O
metabolism O
and O
bile B
acid I
production O
of O
HepaRG O
cells O
in O
a O
bioartificial O
liver O
in O
absence O
of O
dimethyl B
sulfoxide I
. O

The O
HepaRG O
- O
AMC O
- O
BAL O
secreted O
bile B
acids I
at O
43 O
% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile B
salts I
. O

The O
HepaRG O
- O
AMC O
- O
BAL O
secreted O
bile B
acids I
at O
43 O
% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile B
salts I
. O

The O
time O
scale O
tau O
( O
c O
) O
and O
the O
activation O
energy O
of O
PF B
( I
6 I
) I
( I
- I
) I
rotation O
in O
this O
RTIL O
are O
found O
to O
be O
comparable O
with O
those O
observed O
in O
ordinary O
alkali O
and O
ammonium B
salts I
despite O
the O
large O
counterion O
size O
and O
low O
melting O
point O
of O
the O
former O
. O

Valproic B
acid I
- O
induced O
gene O
expression O
changes O
were O
most O
comparable O
out O
of O
the O
six O
developmental O
toxicants O
between O
the O
ESTn O
and O
ESTc O
. O

In O
this O
work O
, O
novel O
B B
- O
doped O
nanoplatelets O
( O
borane B
- O
reduced O
graphene B
oxide I
, O
B B
- O
rG O
- O
O B
) O
were O
produced O
on O
a O
large O
scale O
via O
the O
reduction O
of O
graphene B
oxide I
by O
a O
borane B
- O
tetrahydrofuran B
adduct O
under O
reflux O
, O
and O
their O
use O
for O
supercapacitor O
electrodes O
was O
studied O
. O

In O
this O
work O
, O
novel O
B B
- O
doped O
nanoplatelets O
( O
borane B
- O
reduced O
graphene B
oxide I
, O
B B
- O
rG O
- O
O B
) O
were O
produced O
on O
a O
large O
scale O
via O
the O
reduction O
of O
graphene B
oxide I
by O
a O
borane B
- O
tetrahydrofuran B
adduct O
under O
reflux O
, O
and O
their O
use O
for O
supercapacitor O
electrodes O
was O
studied O
. O

The O
brush O
- O
adsorbed O
biomolecules O
were O
recovered O
by O
treating O
the O
nanobrush O
with O
ammonium B
hydroxide I
, O
which O
effectively O
collapsed O
the O
brush O
, O
thereby O
releasing O
the O
trapped O
compounds O
for O
MALDI O
MS O
analysis O
. O

Substituent O
effects O
of O
a O
series O
of O
N1 O
protio O
and O
methyl B
naphthyridinone I
HIV O
- O
1 O
integrase O
strand O
- O
transfer O
inhibitors O
has O
been O
explored O
. O

A O
thirteen O
week O
feeding O
study O
was O
conducted O
by O
feeding O
young O
adult O
male O
and O
female O
Sprague O
Dawley O
[ O
Crl O
: O
CD O
( O
R O
) O
( O
SD O
) O
] O
rats O
diets O
containing O
grain O
from O
genetically O
modified O
( O
GM O
) O
DP O
- O
O O
O O
4114 O
- O
3 O
maize O
that O
was O
either O
untreated O
( O
4114 O
) O
or O
treated O
in O
the O
field O
with O
glufosinate B
ammonium I
( O
4114GLU O
) O
. O

Hydrogen B
peroxide I
induced O
samples O
were O
used O
as O
positive O
control O
. O

Influence O
of O
developmental O
lead O
exposure O
on O
expression O
of O
DNA O
methyltransferases O
and O
methyl B
cytosine I
- O
binding O
proteins O
in O
hippocampus O
. O

Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl B
cytosine I
- O
binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb B
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O

Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb B
acetate I
( O
0 O
, O
150 O
, O
375 O
, O
750 O
ppm O
) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
( O
perinatal O
exposure O
group O
) O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

The O
formulation O
approaches O
used O
were O
as O
follows O
: O
( O
a O
) O
an O
inclusion O
complex O
with O
hydroxypropyl B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
, O
( O
b O
) O
a O
solid O
dispersion O
with O
Soluplus B
( O
R O
) O
, O
a O
new O
highly O
water O
soluble O
polyvinyl B
caprolactam I
- O
polyvinyl B
acetate I
- O
polyethylene B
glycol I
graft O
copolymer O
and O
( O
c O
) O
a O
ternary O
inclusion O
complex O
with O
both O
HP B
- I
beta I
- I
CD I
and O
Soluplus B
( O
R O
) O
. O

Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino B
acid I
sequences O
. O

A O
comparative O
VCD O
study O
of O
methyl B
mandelate I
in O
methanol B
, O
dimethyl B
sulfoxide I
, O
and O
chloroform B
: O
explicit O
and O
implicit O
solvation O
models O
. O

A O
comparative O
VCD O
study O
of O
methyl B
mandelate I
in O
methanol B
, O
dimethyl B
sulfoxide I
, O
and O
chloroform B
: O
explicit O
and O
implicit O
solvation O
models O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl B
mandelate I
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol B
( O
MeOH B
- I
d I
( I
4 I
) I
) O
, O
dimethyl B
sulfoxide I
( O
DMSO B
- I
d I
( I
6 I
) I
) O
, O
and O
chloroform B
( O
CDCl B
( I
3 I
) I
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl B
mandelate I
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol B
( O
MeOH B
- I
d I
( I
4 I
) I
) O
, O
dimethyl B
sulfoxide I
( O
DMSO B
- I
d I
( I
6 I
) I
) O
, O
and O
chloroform B
( O
CDCl B
( I
3 I
) I
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

Initial O
geometry O
searches O
have O
been O
carried O
out O
at O
the O
B3LYP O
/ O
6 O
- O
31G O
( O
d O
) O
level O
for O
the O
methyl B
mandelate I
monomer O
and O
its O
explicit O
1 O
: O
1 O
and O
1 O
: O
2 O
solute O
- O
solvent O
hydrogen B
- O
bonded O
complexes O
. O

ORD O
spectra O
of O
methyl B
mandelate I
in O
the O
aforementioned O
solvents O
at O
different O
concentrations O
under O
5 O
excitation O
wavelengths O
have O
also O
been O
measured O
. O

Enhancement O
of O
the O
water O
solubility O
of O
flavone B
glycosides I
by O
disruption O
of O
molecular O
planarity O
of O
the O
aglycone O
moiety O
. O

We O
applied O
this O
strategy O
to O
some O
natural O
flavone B
glycosides I
, O
especially O
diosmin B
, O
a O
highly O
insoluble O
citroflavonoid B
prescribed O
as O
an O
oral O
phlebotropic O
drug O
. O

Interplay O
between O
structure O
and O
relaxations O
in O
perfluorosulfonic B
acid I
proton O
conducting O
membranes O
. O

The O
spectral O
changes O
evident O
in O
the O
vibrational O
spectra O
of O
the O
3M O
membranes O
can O
be O
associated O
with O
two O
major O
phenomena O
: O
( O
1 O
) O
dissociation O
of O
the O
proton O
from O
the O
sulfonic B
acid I
groups O
even O
in O
the O
presence O
of O
small O
amounts O
of O
water O
; O
and O
( O
2 O
) O
changes O
in O
the O
conformation O
or O
the O
degree O
of O
crystallinity O
of O
the O
poly B
( I
tetrafluoroethylene I
) I
hydrophobic O
domains O
both O
as O
a O
function O
of O
EW O
and O
membrane O
water O
content O
. O

Receptor O
function O
is O
also O
influenced O
by O
amino B
acid I
substitutions O
in O
the O
protein O
sequence O
. O

Dabrafenib O
is O
a O
BRAF O
( O
gene O
encoding O
serine B
/ O
threonine B
- O
protein O
kinase O
B O
- O
Raf O
) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine B
600 O
to O
glutamic B
acid I
substitution O
( O
BRAF O
( O
V600E O
) O
) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O

Pretreatment O
of O
porcine O
skin O
was O
performed O
with O
ethanol B
( O
control O
vehicle O
) O
, O
decenoic B
acid I
, O
oleic B
acid I
, O
R B
- I
( I
+ I
) I
- I
limonene I
, O
and O
laurocapram B
( O
Azone B
( O
R O
) O
) O
( O
5 O
% O
in O
ethanol B
, O
w O
/ O
w O
, O
respectively O
) O
. O

Pretreatment O
of O
porcine O
skin O
was O
performed O
with O
ethanol B
( O
control O
vehicle O
) O
, O
decenoic B
acid I
, O
oleic B
acid I
, O
R B
- I
( I
+ I
) I
- I
limonene I
, O
and O
laurocapram B
( O
Azone B
( O
R O
) O
) O
( O
5 O
% O
in O
ethanol B
, O
w O
/ O
w O
, O
respectively O
) O
. O

Pretreatment O
of O
skin O
with O
oleic B
acid I
or O
laurocapram B
led O
to O
statistically O
significant O
differences O
in O
the O
transdermal O
flux O
of O
esculetin B
with O
respect O
to O
controls O
. O

Design O
and O
exploration O
of O
novel O
boronic B
acid I
inhibitors O
reveals O
important O
interactions O
with O
a O
clavulanic B
acid I
- O
resistant O
sulfhydryl B
- O
variable O
( O
SHV O
) O
beta O
- O
lactamase O
. O

Design O
and O
exploration O
of O
novel O
boronic B
acid I
inhibitors O
reveals O
important O
interactions O
with O
a O
clavulanic B
acid I
- O
resistant O
sulfhydryl B
- O
variable O
( O
SHV O
) O
beta O
- O
lactamase O
. O

A O
panel O
of O
boronic B
acid I
inhibitors O
was O
designed O
and O
tested O
against O
SHV O
- O
1 O
and O
SHV O
K234R O
. O

Vasorelaxing O
effects O
and O
inhibition O
of O
nitric B
oxide I
in O
macrophages O
by O
new O
iron B
- O
containing O
carbon B
monoxide I
- O
releasing O
molecules O
( O
CO O
- O
RMs O
) O
. O

Vasorelaxing O
effects O
and O
inhibition O
of O
nitric B
oxide I
in O
macrophages O
by O
new O
iron B
- O
containing O
carbon B
monoxide I
- O
releasing O
molecules O
( O
CO O
- O
RMs O
) O
. O

Carbon B
monoxide I
- O
releasing O
molecules O
( O
CO B
- O
RMs O
) O
are O
a O
class O
of O
organometallo B
carbonyl I
complexes O
capable O
of O
delivering O
controlled O
quantities O
of O
CO B
gas O
to O
cells O
and O
tissues O
thus O
exerting O
a O
broad O
spectrum O
of O
pharmacological O
effects O
. O

Carbon B
monoxide I
- O
releasing O
molecules O
( O
CO B
- O
RMs O
) O
are O
a O
class O
of O
organometallo B
carbonyl I
complexes O
capable O
of O
delivering O
controlled O
quantities O
of O
CO B
gas O
to O
cells O
and O
tissues O
thus O
exerting O
a O
broad O
spectrum O
of O
pharmacological O
effects O
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

More O
specifically O
, O
iron B
carbonyls I
soluble O
in O
DMSO B
released O
CO B
with O
a O
fast O
kinetic O
and O
displayed O
a O
marked O
cytotoxic O
effect O
in O
smooth O
muscle O
cells O
and O
RAW O
247 O
. O
6 O
macrophages O
despite O
exerting O
a O
rapid O
and O
pronounced O
vasorelaxation O
ex O
vivo O
. O

These O
data O
suggest O
that O
iron B
carbonyls I
can O
be O
used O
as O
scaffolds O
for O
the O
design O
and O
synthesis O
of O
pharmacologically O
active O
CO B
- O
RMs O
and O
indicate O
that O
increasing O
water O
solubility O
and O
controlling O
the O
rate O
of O
CO B
release O
are O
important O
parameters O
for O
limiting O
their O
potential O
toxic O
effects O
. O

For O
instance O
, O
crystals O
grown O
at O
the O
interface O
of O
a O
0 O
. O
01 O
% O
diglycerol B
monolaurate I
( O
C B
( I
12 I
) I
G I
( I
2 I
) I
) O
nonionic O
surfactant O
in O
butanol B
with O
benzene B
lead O
to O
the O
formation O
of O
flower O
- O
shaped O
microcrystals O
of O
average O
sizes O
in O
the O
range O
of O
10 O
- O
35 O
mu O
m O
. O

Flower O
- O
shaped O
C B
( I
60 I
) I
microcrystals O
are O
also O
observed O
with O
anionic O
surfactants O
cetyltrimethylammoni B
bromide I
( O
CTAB B
) O
and O
cetyltrimethylammoni B
chloride I
( O
CTAC B
) O
. O

Flower O
- O
shaped O
C B
( I
60 I
) I
microcrystals O
are O
also O
observed O
with O
anionic O
surfactants O
cetyltrimethylammoni B
bromide I
( O
CTAB B
) O
and O
cetyltrimethylammoni B
chloride I
( O
CTAC B
) O
. O

The O
first O
example O
of O
Ir B
- O
catalyzed O
asymmetric O
substitution O
reaction O
with O
vinyl B
trifluoroborates I
is O
described O
. O

The O
direct O
reaction O
between O
branched O
, O
racemic O
allylic B
alcohols I
and O
potassium B
alkenyltrifluorobora I
proceeded O
with O
high O
site O
selectivity O
and O
excellent O
enantioselectivity O
( O
up O
to O
99 O
% O
) O
mediated O
by O
an O
Ir B
- I
( I
P I
, I
olefin I
) I
complex O
. O

The O
direct O
reaction O
between O
branched O
, O
racemic O
allylic B
alcohols I
and O
potassium B
alkenyltrifluorobora I
proceeded O
with O
high O
site O
selectivity O
and O
excellent O
enantioselectivity O
( O
up O
to O
99 O
% O
) O
mediated O
by O
an O
Ir B
- I
( I
P I
, I
olefin I
) I
complex O
. O

Gene O
expression O
analysis O
showed O
that O
25HC3S B
significantly O
suppressed O
the O
SREBP O
- O
1c O
signaling O
pathway O
that O
was O
associated O
with O
the O
suppression O
of O
the O
key O
enzymes O
involved O
in O
lipogenesis O
: O
fatty B
acid I
synthase O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
and O
glycerol B
- I
3 I
- I
phosphate I
acyltransferase O
. O

The O
surface O
of O
graphene B
oxide I
is O
first O
sensitized O
by O
Sn B
( I
2 I
+ I
) I
ions O
, O
and O
subsequently O
, O
Pd B
or O
Pt B
nanoparticles O
are O
deposited O
on O
the O
surface O
of O
graphene B
oxide I
. O

The O
surface O
of O
graphene B
oxide I
is O
first O
sensitized O
by O
Sn B
( I
2 I
+ I
) I
ions O
, O
and O
subsequently O
, O
Pd B
or O
Pt B
nanoparticles O
are O
deposited O
on O
the O
surface O
of O
graphene B
oxide I
. O

Finally O
, O
graphene B
oxide I
was O
reduced O
to O
graphene B
by O
further O
adding O
NaBH B
( I
4 I
) I
. O

The O
C B
- I
H I
bonds O
of O
precise O
location O
of O
inert O
polymer O
surfaces O
were O
readily O
transferred O
to O
bromoalkyl B
initiator O
, O
followed O
by O
ATRP O
of O
2 B
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
( O
DMAEMA B
) O
and O
glycidyl B
methacrylate I
( O
GMA B
) O
, O
respectively O
, O
to O
produce O
the O
resultant O
patterned O
BOPP O
- O
g O
- O
P B
( I
DMAEMA I
) I
and O
BOPP O
- O
g O
- O
P B
( I
GMA I
) I
films O
. O

OlfGST O
omega O
contained O
an O
open O
reading O
frame O
of O
720bp O
and O
encoded O
a O
protein O
of O
239 O
amino B
acids I
. O

OlfGST O
pi O
and O
OlfGST O
rho O
contained O
open O
reading O
frames O
of O
627 O
and O
681nt O
, O
respectively O
, O
and O
encoded O
proteins O
of O
208 O
and O
226 O
amino B
acids I
. O

The O
olfactory O
GSTs O
conjugated O
prototypical O
GST O
substrates O
, O
but O
only O
OlfGST O
rho O
catalyzed O
the O
demethylation O
of O
the O
pesticide O
methyl B
parathion I
. O

Salsolinol B
( O
SAL B
) O
, O
a O
catechol B
isoquinoline I
has O
invited O
considerable O
attention O
due O
to O
its O
structural O
similarity O
with O
dopaminergic O
neurotoxin O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
. O

The O
classic O
Neutral B
Red I
Uptake O
( O
NRU O
) O
assay O
proved O
to O
be O
robust O
and O
reliable O
to O
be O
applied O
as O
viability O
assay O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

The O
results O
from O
a O
subchronic O
feeding O
study O
conducted O
in O
Sprague O
- O
Dawley O
rats O
fed O
with O
diets O
containing O
grain O
from O
4114 O
( O
OECD O
unique O
identifier O
: O
DP O
- O
O O
O O
4114 O
- O
3 O
) O
maize O
that O
was O
untreated O
( O
4114 O
) O
or O
sprayed O
in O
field O
with O
glufosinate B
ammonium I
( O
4114GLU O
) O
in O
a O
design O
similar O
to O
previous O
studies O
are O
reported O
. O

The O
test O
material O
, O
4114 O
maize O
, O
is O
a O
hybrid O
maize O
produced O
by O
transformation O
with O
a O
DNA O
construct O
encoding O
4 O
different O
transgenic O
proteins O
for O
resistance O
to O
lepidopteran O
pests O
, O
coleopteran O
pests O
, O
and O
tolerance O
to O
the O
herbicidal O
active O
ingredient O
glufosinate B
ammonium I
. O

Monotropein B
was O
found O
to O
inhibit O
the O
expressions O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
cyclooxygenase O
- O
2 O
( O
COX O
- O
2 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
alpha O
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
mRNA O
in O
LPS O
- O
induced O
RAW O
264 O
. O
7 O
macrophages O
. O

Four O
proteins O
, O
namely O
albumin O
, O
hemopexin O
, O
transferrin O
and O
vitamin B
D I
binding O
protein O
were O
increased O
in O
the O
urine O
in O
temporal O
association O
with O
the O
appearance O
of O
chronic O
predisposition O
. O

A O
novel O
series O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
onewere I
synthesized O
starting O
from O
2 B
- I
aminobenzothiazole I
and O
1 B
- I
aryl I
- I
3 I
, I
3 I
- I
bis I
- I
( I
methylsulfanyl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
onesin I
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B
hydride I
in O
THF B
. O

Especially O
, O
dysfunction O
of O
excitatory O
amino B
acid I
transporter O
type O
3 O
( O
EAAT3 O
) O
can O
lead O
to O
seizures O
. O

The O
electroreduction O
of O
benzoic B
acid I
: O
voltammetric O
observation O
of O
adsorbed O
hydrogen B
at O
a O
platinum B
microelectrode O
in O
room O
temperature O
ionic O
liquids O
. O

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag B
( I

Furthermore O
, O
the O
adsorbed O
H B
atoms O
, O
formed O
from O
the O
reduction O
of O
benzoic B
acid I
, O
could O
be O
used O
to O
achieve O
the O
rapid O
hydrogenolysis O
of O
the O
organic O
compound O
( O
bis B
( I
benzyloxycarbonyl I
) I
- I
l I
- I
lysine I
) O
on O
the O
timescale O
of O
the O
voltammetric O
technique O
under O
moderate O
conditions O
( O
25 O
degrees O
C O
) O
. O

The O
yeast O
eukaryotic O
translation O
initiation O
factor O
2B O
translation O
initiation O
complex O
interacts O
with O
the O
fatty B
acid I
synthesis O
enzyme O
YBR159W O
and O
endoplasmic O
reticulum O
membranes O
. O

Using O
affinity O
purifications O
coupled O
with O
mass O
spectrometry O
and O
yeast O
two O
- O
hybrid O
assays O
, O
we O
show O
the O
Saccharomyces O
cerevisiae O
translation O
initiation O
factor O
complex O
eukaryotic O
translation O
initiation O
factor O
2B O
( O
eIF2B O
) O
and O
the O
very O
- O
long O
- O
chain O
fatty B
acid I
( O
VLCFA O
) O
synthesis O
keto O
- O
reductase O
enzyme O
YBR159W O
physically O
interact O
. O

A O
ybr159w O
Delta O
null O
strain O
has O
a O
slow O
- O
growth O
phenotype O
and O
a O
reduced O
translation O
rate O
but O
a O
normal O
GCN4 O
response O
to O
amino B
acid I
starvation O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino B
acids I
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino B
acids I
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

This O
decrease O
was O
, O
therefore O
, O
correlated O
with O
starch O
concentration O
, O
and O
the O
composition O
and O
stability O
of O
the O
potassium B
triiodide I
solution O
were O
optimised O
. O

Milk O
samples O
were O
purchased O
from O
local O
grocery O
stores O
( O
Columbus O
, O
OH O
, O
USA O
) O
and O
spiked O
at O
different O
concentrations O
of O
whey O
, O
hydrogen B
peroxide I
, O
synthetic O
urine O
, O
urea B
and O
synthetic O
milk O
. O

Partial O
Least O
Squares O
Regression O
( O
PLSR O
) O
showed O
standard O
error O
of O
prediction O
( O
SEP O
) O
~ O
2 O
. O
33 O
, O
0 O
. O
06 O
, O
0 O
. O
41 O
, O
0 O
. O
30 O
and O
0 O
. O
014 O
g O
/ O
L O
for O
estimation O
of O
levels O
of O
adulteration O
with O
whey O
, O
synthetic O
milk O
, O
synthetic O
urine O
, O
urea B
and O
hydrogen B
peroxide I
, O
respectively O
. O

The O
acridine B
orange I
analysis O
and O
annexin O
V O
- O
FITC B
/ O
PI O
double O
- O
staining O
results O
confirmed O
that O
myricetin B
and O
myricitrin B
were O
effective O
in O
inducing O
PC O
- O
3 O
cell O
apoptosis O
. O

The O
pesticides O
were O
extracted O
from O
the O
sample O
by O
cyclohexane B
- O
ethyl B
acetate I
mixture O
( O
1 O
: O
1 O
v O
/ O
v O
) O
and O
cleaned O
up O
by O
florosil B
column O
. O

White O
bread O
contained O
the O
lowest O
amounts O
of O
free O
umami O
amino B
acids I
and O
umami O
5 O
' O
- O
nucleotides B
and O
showed O
the O
lowest O
EUC O
value O
. O

Hepatoprotective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
on O
carbon B
tetrachloride I
- O
induced O
liver O
injury O
in O
rats O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
2 B
, I
3 I
- I
dehydrosilybin I
( O
DHS B
) O
against O
carbon B
tetrachloride I
( O
CCl B
( I
4 I
) I
) O
- O
induced O
liver O
injury O
in O
rats O
. O

Furthermore O
, O
we O
found O
that O
DHS B
significantly O
inhibited O
the O
production O
of O
serum O
nitric B
oxide I
as O
well O
as O
the O
levels O
of O
serum O
IL O
- O
6 O
, O
IFN O
- O
gamma O
, O
and O
TNF O
- O
alpha O
in O
CCl B
( I
4 I
) I
- O
treated O
rats O
. O

Simultaneous O
detection O
of O
flavonoids B
and O
phenolic B
acids I
in O
Herba O
Lysimachiae O
and O
Herba O
Desmodii O
Styracifolii O
using O
liquid O
chromatography O
tandem O
mass O
spectrometry O
. O

A O
sensitive O
liquid O
chromatography O
and O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
and O
validated O
for O
the O
simultaneous O
analysis O
of O
15 O
flavonoids B
and O
3 O
phenolic B
acids I
in O
Herba O
Lysimachiae O
and O
Herba O
Desmodii O
Styracifolii O
. O

Separation O
was O
performed O
using O
a O
Diamonsil O
C O
( O
18 O
) O
column O
, O
which O
was O
eluted O
with O
methanol B
( O
A O
) O
and O
0 O
. O
1 O
/ O
1000 O
acetic B
acid I
( O
B O
) O
. O

LC O
- O
ESI O
- O
MS O
studies O
corroborated O
the O
identities O
of O
four O
glucosides O
and O
seven O
aglycones O
, O
among O
them O
vanillin B
( O
5 O
. O
7 O
/ O
100 O
g O
) O
, O
4 B
- I
hydroxybenzyl I
alcohol I
( O
3 O
. O
6 O
/ O
100 O
g O
) O
, O
and O
anisyl B
alcohol I
( O
7 O
. O
1 O
/ O
100 O
g O
) O
were O
found O
in O
high O
concentrations O
. O

The O
fruits O
were O
rich O
in O
vitamin B
C I
( O
15 O
. O
0 O
+ O
/ O
- O
0 O
. O
0 O
- O
43 O
. O
8 O
+ O
/ O
- O
0 O
. O
02 O
mg O
100 O
g O
( O
- O
1 O
) O
) O
and O
the O
energy O
values O
ranged O
between O
1516 O
. O
0 O
+ O
/ O
- O
1 O
. O
73 O
and O
1575 O
. O
0 O
+ O
/ O
- O
2 O
. O
3 O
kJ O
100 O
g O
( O
- O
1 O
) O
. O

The O
masau O
fruit O
is O
therefore O
a O
good O
potential O
source O
of O
carbohydrates B
, O
proteins O
and O
micronutrients O
, O
such O
as O
calcium B
, O
potassium B
, O
sodium B
, O
phosphorous B
, O
copper B
, O
iron B
, O
Vitamin B
C I
and O
zinc B
. O

Development O
of O
sample O
preparation O
method O
for O
isoliquiritigenin B
, O
liquiritin B
, O
and O
glycyrrhizic B
acid I
analysis O
in O
licorice O
by O
ionic O
liquids O
- O
ultrasound O
based O
extraction O
and O
high O
- O
performance O
liquid O
chromatography O
detection O
. O

An O
ionic O
liquid O
- O
based O
ultrasonic O
- O
assisted O
extraction O
( O
ILUAE O
) O
method O
had O
been O
used O
for O
the O
effective O
extraction O
of O
isoliquiritigenin B
( O
IQ O
) O
, O
liquiritin B
( O
LQ O
) O
and O
glycyrrhizic B
acid I
( O
GA O
) O
from O
licorice O
. O

UPLC O
and O
HPLC O
of O
caffeoyl B
esters I
in O
wild O
and O
cultivated O
Arctium O
lappa O
L O
. O

Analytical O
methods O
including O
ultra O
- O
performance O
liquid O
chromatography O
( O
UPLC O
) O
and O
high O
- O
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
photodiode O
array O
( O
PDA O
) O
detector O
were O
developed O
for O
the O
analysis O
of O
caffeoylquinic B
acid I
derivatives O
in O
seeds O
, O
leaves O
and O
roots O
of O
Arctium O
lappa O
L O
. O

Separation O
was O
performed O
on O
C O
( O
18 O
) O
column O
utilising O
5 O
% O
( O
v O
/ O
v O
) O
acetic B
acid I
in O
water O
and O
acetonitrile B
at O
330 O
nm O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic B
acid I
( O
5 B
- I
CQA I
) O
and O
1 B
, I
5 I
- I
dicaffeoylquinic I
acid I
( O
1 B
, I
5 I
- I
DCQA I
) O
as O
main O
compounds O
in O
samples O
. O

The O
chromatographic O
and O
spectral O
data O
revealed O
the O
presence O
of O
several O
simple O
phenolic B
acids I
, O
derivatives O
of O
both O
caffeic B
and I
benzoic I
acids I
, O
and O
flavonoids B
in O
the O
produced O
extracts O
. O

59 O
. O
7 O
mg O
of O
78 O
. O
0 O
% O
gallic B
acid I
could O
be O
separated O
simultaneously O
. O

Binding O
of O
vitamin B
A I
with O
milk O
alpha O
- O
and O
beta O
- O
caseins O
. O

The O
binding O
sites O
of O
retinol B
and O
retinoic B
acid I
with O
milk O
alpha O
- O
and O
beta O
- O
caseins O
were O
determined O
, O
using O
constant O
protein O
concentration O
and O
various O
retinoid O
contents O
. O

FTIR O
, O
UV O
- O
visible O
and O
fluorescence O
spectroscopic O
methods O
as O
well O
as O
molecular O
modelling O
were O
used O
to O
analyse O
retinol B
and O
retinoic B
acid I
binding O
sites O
, O
the O
binding O
constant O
and O
the O
effect O
of O
retinoid B
complexation O
on O
the O
stability O
and O
conformation O
of O
caseins O
. O

Structural O
analysis O
showed O
that O
retinoids B
bind O
caseins O
via O
both O
hydrophilic O
and O
hydrophobic O
contacts O
with O
overall O
binding O
constants O
of O
K O
( O
retinol B
- O
) O
( O
alpha O
) O
( O
- O
caseins O
) O
= O
1 O
. O
21 O
( O
+ O
/ O
- O
0 O
. O
4 O
) O
x O
10 O
( O
5 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinol B
- O
) O
( O
beta O
) O
( O
- O
caseins O
) O
= O
1 O
. O
11 O
( O
+ O
/ O
- O
0 O
. O
5 O
) O
x O
10 O
( O
5 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinoic B
acid I
- O
) O
( O
alpha O
) O
( O
- O
caseins O
) O
= O
6 O
. O
2 O
( O
+ O

/ O
- O
0 O
. O
6 O
) O
x O
10 O
( O
4 O
) O
M O
( O
- O
1 O
) O
and O
K O
( O
retinoic B
acid I
- O
) O
( O
beta O
) O
( O
- O
caseins O
) O
= O
6 O
. O
3 O
( O
+ O
/ O
- O
0 O
. O
6 O
) O
x O
10 O
( O
4 O
) O
M O
( O
- O
1 O
) O
. O

The O
number O
of O
bound O
retinol B
molecules O
per O
protein O
( O
n O
) O
was O
1 O
. O
5 O
( O
+ O
/ O
- O
0 O
. O
1 O
) O
for O
alpha O
- O
casein O
and O
1 O
. O
0 O
( O
+ O
/ O
- O
0 O
. O
1 O
) O
for O
beta O
- O
casein O
, O
while O
1 O
molecule O
of O
retinoic B
acid I
was O
bound O
in O
the O
alpha O
- O
and O
beta O
- O
casein O
complexes O
. O

Molecular O
modelling O
showed O
different O
binding O
sites O
for O
retinol B
and O
retinoic B
acid I
on O
alpha O
- O
and O
beta O
- O
caseins O
with O
more O
stable O
complexes O
formed O
with O
alpha O
- O
casein O
. O

Highly O
selective O
separation O
of O
arsenite B
species O
[ O
As B
( I
III I
) I
] O
was O
achieved O
by O
chelation O
with O
sodium B
diethyldithiocarbama I
( O
DDTC B
) O
followed O
by O
dispersion O
with O
40 O
mg O
of O
1 B
- I
octyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
8 I
) I
mim I
] I
[ I
PF I
( I
6 I
) I
] I
) O
IL O
. O

Burdock O
fructooligosaccharid O
induces O
fungal O
resistance O
in O
postharvest O
Kyoho O
grapes O
by O
activating O
the O
salicylic B
acid I
- O
dependent O
pathway O
and O
inhibiting O
browning O
. O

These O
results O
indicated O
that O
the O
salicylic B
acid I
- O
dependent O
signalling O
pathway O
was O
induced O
. O

Anticancer O
activities O
were O
evaluated O
on O
three O
different O
cell O
lines O
( O
renal O
adenocarcinoma O
( O
TK O
- O
10 O
) O
, O
breast O
adenocarcinoma O
( O
MCF O
- O
7 O
) O
and O
melanoma O
( O
UACC O
- O
62 O
) O
) O
by O
sulphorhodamine B
B I
method O
. O

This O
work O
studies O
the O
influence O
of O
some O
process O
variables O
( O
percentage O
of O
sugar B
, O
pectin O
and O
citric B
acid I
, O
and O
time O
of O
thermal O
treatment O
) O
on O
the O
volatile O
profile O
of O
these O
spreads O
with O
different O
formulations O
. O

The O
ripeness O
of O
the O
raw O
strawberries O
influences O
the O
concentrations O
of O
some O
of O
the O
compounds O
in O
the O
spreads O
, O
such O
as O
isobutyl B
acetate I
, O
butyl B
butyrate I
, O
3 B
- I
hexen I
- I
1 I
- I
yl I
acetate I
or O
propan B
- I
2 I
- I
ol I
. O

The O
ripeness O
of O
the O
raw O
strawberries O
influences O
the O
concentrations O
of O
some O
of O
the O
compounds O
in O
the O
spreads O
, O
such O
as O
isobutyl B
acetate I
, O
butyl B
butyrate I
, O
3 B
- I
hexen I
- I
1 I
- I
yl I
acetate I
or O
propan B
- I
2 I
- I
ol I
. O

In O
general O
, O
the O
spreads O
formulated O
with O
sucrose B
- O
isomaltulose B
that O
contained O
higher O
levels O
of O
pectin O
and O
citric B
acid I
gave O
better O
results O
in O
the O
preservation O
of O
the O
original O
aromatic O
compounds O
in O
raw O
strawberries O
. O

Aliphatic B
aldehydes I
such O
as O
hexanal B
, O
( B
E I
) I
- I
2 I
- I
octenal I
, O
and O
nonanal B
were O
produced O
as O
off O
- O
odours O
during O
storage O
. O

Although O
the O
overall O
quality O
of O
roasted O
almonds O
produced O
with O
SIRHA O
and O
HA O
heating O
was O
similar O
during O
the O
first O
three O
months O
of O
storage O
, O
their O
peroxide B
value O
and O
concentration O
of O
aliphatic B
aldehydes I
differed O
significantly O
for O
different O
roasting O
methods O
and O
increased O
significantly O
in O
all O
roasted O
samples O
during O
storage O
. O

Synthesis O
of O
new O
triazole B
acetamides I
with O
inotropic O
effects O
. O

A O
series O
of O
new O
triazole B
acetamides I
5a O
- O
w O
were O
synthesized O
and O
evaluated O
for O
their O
positive O
inotropic O
activity O
of O
left O
atrium O
stroke O
volume O
on O
isolated O
rabbit O
- O
heart O
preparations O
. O

Among O
them O
triazole B
acetamide I
5a O
was O
identified O
as O
the O
most O
potent O
with O
20 O
. O
29 O
+ O
/ O
- O
0 O
. O
18 O
% O
increased O
stroke O
volume O
( O
milrinone B
: O
2 O
. O
46 O
+ O
/ O
- O
0 O
. O
07 O
% O
) O
at O
a O
concentration O
of O
3 O
x O
10 O
( O
- O
5 O
) O
M O
. O

Screening O
of O
synthesized O
and O
isolated O
marine O
natural O
products O
for O
in O
vitro O
activity O
against O
four O
parasitic O
protozoa O
has O
identified O
the O
ascidian O
metabolite O
1 B
, I
14 I
- I
sperminedihomovanill I
( O
orthidine B
F I
, O
1 O
) O
as O
being O
a O
non O
- O
toxic O
, O
moderate O
growth O
inhibitor O
of O
Plasmodium O
falciparum O
( O
IC O
( O
50 O
) O
0 O
. O
89 O
mu O
M O
) O
. O

Here O
we O
did O
not O
only O
observe O
the O
expected O
increase O
of O
Fgf23 O
expression O
in O
the O
latter O
ones O
, O
but O
also O
a O
differential O
expression O
of O
genes O
that O
are O
either O
induced O
by O
or O
involved O
in O
retinoic B
acid I
signaling O
, O
which O
led O
us O
to O
analyze O
whether O
dietary O
retinol B
deprivation O
would O
influence O
the O
phenotype O
of O
Hyp O
mice O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
complexes O
of O
biologically O
important O
orotic B
acid I
: O
synthesis O
, O
spectroscopic O
studies O
, O
in O
vitro O
anti O
- O
cancer O
, O
DNA O
fragmentation O
, O
enzyme O
assays O
and O
in O
vivo O
anti O
- O
inflammatory O
activities O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Furthermore O
, O
in O
human O
urine O
conversion O
of O
the O
ultimate O
, O
inactive O
mercapturic B
acid I
conjugate O
back O
into O
its O
corresponding O
bioactive O
form O
is O
increased O
at O
alkaline O
as O
compared O
to O
neutral O
pH O
. O

HTS O
of O
2560 O
small O
molecules O
to O
search O
for O
inhibitory O
compounds O
yielded O
several O
hits O
, O
including O
suramin B
, O
doxorubicin B
and O
ellagic B
acid I
. O

Both O
suramin B
and O
doxorubicin B
are O
potent O
( O
low O
- O
micro O
M O
) O
DNA O
- O
and O
nucleotide B
triphosphate I
- O
competitive O
priming O
inhibitors O
that O
interact O
with O
more O
than O
one O
site O
on O
Mtb O
DnaG O
. O

Neu2000 B
exerted O
scavenging O
activity O
against O
superoxide B
, O
nitric B
oxide I
, O
and O
hydroxyl B
radicals O
, O
and O
efficiently O
scavenged O
peroxynitrite B
. O

In O
the O
mitochondrial O
studies O
, O
Neu2000 B
markedly O
inhibited O
ROS O
/ O
RNS O
and O
hydrogen B
peroxide I
levels O
following O
antimycin B
treatment O
. O

Interestingly O
, O
two O
different O
PTP O
inhibitors O
( O
namely O
, O
cyclosporin B
A I
and O
nortriptyline B
) O
prevented O
both O
ethanol B
- O
induced O
neuronal O
death O
in O
vivo O
and O
ethanol B
- O
induced O
behavioral O
modifications O
. O

Differential O
Effects O
of O
Crambescins O
and O
Crambescidin B
816 I
in O
Voltage O
- O
Gated O
Sodium B
, O
Potassium B
and O
Calcium B
Channels O
in O
Neurons O
. O

Crambescins B
and O
crambescidins B
are O
two O
families O
of O
guanidine B
alkaloids I
from O
the O
marine O
sponge O
Crambe O
crambe O
. O

Although O
very O
little O
information O
about O
their O
biological O
effect O
has O
been O
reported O
, O
it O
is O
known O
that O
crambescidin B
816 I
( O
Cramb816 B
) O
blocks O
calcium B
channels O
in O
a O
neuroblastoma O
X O
glioma O
cell O
line O
. O

Taking O
this O
into O
account O
, O
and O
the O
fact O
that O
ion O
channels O
are O
frequent O
targets O
for O
natural O
toxins O
, O
we O
examined O
the O
effect O
of O
Cramb816 B
and O
three O
compounds O
from O
the O
crambescin B
family O
, O
norcrambescin B
A2 I
( O
NcrambA2 B
) O
, O
crambescin B
A2 I
( O
CrambA2 B
) O
, O
and O
crambescin B
C1 I
( O
CrambC1 B
) O
, O
in O
the O
main O
voltage O
- O
dependent O
ion O
channels O
in O
neurons O
: O
sodium B
, O
potassium B
, O
and O
calcium B
channels O
. O

Taking O
this O
into O
account O
, O
and O
the O
fact O
that O
ion O
channels O
are O
frequent O
targets O
for O
natural O
toxins O
, O
we O
examined O
the O
effect O
of O
Cramb816 B
and O
three O
compounds O
from O
the O
crambescin B
family O
, O
norcrambescin B
A2 I
( O
NcrambA2 B
) O
, O
crambescin B
A2 I
( O
CrambA2 B
) O
, O
and O
crambescin B
C1 I
( O
CrambC1 B
) O
, O
in O
the O
main O
voltage O
- O
dependent O
ion O
channels O
in O
neurons O
: O
sodium B
, O
potassium B
, O
and O
calcium B
channels O
. O

Taking O
this O
into O
account O
, O
and O
the O
fact O
that O
ion O
channels O
are O
frequent O
targets O
for O
natural O
toxins O
, O
we O
examined O
the O
effect O
of O
Cramb816 B
and O
three O
compounds O
from O
the O
crambescin B
family O
, O
norcrambescin B
A2 I
( O
NcrambA2 B
) O
, O
crambescin B
A2 I
( O
CrambA2 B
) O
, O
and O
crambescin B
C1 I
( O
CrambC1 B
) O
, O
in O
the O
main O
voltage O
- O
dependent O
ion O
channels O
in O
neurons O
: O
sodium B
, O
potassium B
, O
and O
calcium B
channels O
. O

Electrophysiological O
recordings O
of O
voltage O
gated O
sodium B
, O
potassium B
, O
and O
calcium B
currents O
, O
in O
the O
presence O
of O
these O
guanidine B
alkaloids I
, O
were O
performed O
in O
cortical O
neurons O
from O
embryonic O
mice O
. O

These O
two O
families O
of O
guanidine B
alkaloids I
clearly O
showed O
a O
structure O
- O
activity O
relationship O
with O
the O
crambescins B
acting O
on O
voltage O
- O
gated O
potassium B
channels O
, O
while O
Cramb816 B
blocks O
the O
voltage O
- O
gated O
calcium B
channel O
Cav1 O
with O
higher O
potency O
than O
nifedipine B
. O

Licochalcone B
A I
( O
I O
) O
, O
isolated O
from O
the O
roots O
of O
Chinese O
licorice O
, O
is O
the O
most O
promising O
antimalarial O
compound O
reported O
so O
far O
. O

We O
hypothesized O
that O
conformational O
resemblance O
of O
semirigid O
scaffolds O
expressing O
amino B
acid I
side O
- O
chains O
to O
PPI O
- O
interface O
regions O
could O
guide O
this O
process O
. O

Bioavailability O
of O
stabilised O
ferrous B
gluconate I
with O
glycine B
in O
fresh O
cheese O
matrix O
: O
a O
novel O
iron B
compound O
for O
food O
fortification O
. O

This O
study O
aims O
to O
investigate O
the O
bioavailability O
of O
ferrous B
gluconate I
stabilised O
with O
glycine B
( O
FGSG O
) O
in O
a O
fresh O
cheese O
fortified O
with O
zinc B
. O

The O
iron B
bioavailability O
of O
fresh O
cheese O
fortified O
with O
either O
FGSG O
and O
with O
or O
without O
zinc B
and O
FGSG O
in O
aqueous O
solution O
and O
a O
water O
solution O
of O
ferrous B
ascorbate I
( O
reference O
dose O
) O
was O
studied O
using O
double O
radio B
iron I
( O
( B
55 I
) I
Fe I
and O
( B
59 I
) I
Fe I
) O
erythrocyte O
incorporation O
in O
15 O
male O
subjects O
. O

The O
iron B
bioavailability O
of O
fresh O
cheese O
fortified O
with O
either O
FGSG O
and O
with O
or O
without O
zinc B
and O
FGSG O
in O
aqueous O
solution O
and O
a O
water O
solution O
of O
ferrous B
ascorbate I
( O
reference O
dose O
) O
was O
studied O
using O
double O
radio B
iron I
( O
( B
55 I
) I
Fe I
and O
( B
59 I
) I
Fe I
) O
erythrocyte O
incorporation O
in O
15 O
male O
subjects O
. O

The O
results O
of O
the O
present O
study O
show O
that O
the O
novel O
iron B
compound O
ferrous B
gluconate I
stabilised O
with O
glycine B
in O
a O
fresh O
cheese O
matrix O
is O
a O
good O
source O
of O
iron B
and O
can O
be O
used O
in O
iron B
fortification O
programmes O
. O

Quantum O
chemical O
calculations O
at O
the O
B3LYP O
/ O
LACV3P O
/ O
6 O
- O
311G O
* O
* O
level O
yield O
the O
optimized O
geometries O
and O
IR O
spectra O
for O
the O
conceivable O
isomers O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
, O
whereby O
the O
cisplatin B
residue O
is O
attached O
to O
the O
N7 O
, O
N3 O
, O
or O
carbonyl B
oxygen I
atom O
, O
( O
O6 B
) O
, O

We O
tested O
our O
structural O
predictions O
by O
mutational O
analysis O
of O
base O
excision O
and O
found O
a O
single O
amino B
acid I
responsible O
at O
least O
in O
part O
for O
Mag2 O
' O
s O
lack O
of O
activity O
. O

New O
targets O
for O
the O
antitumor O
activity O
of O
gambogic B
acid I
in O
hematologic O
malignancies O
. O

Gambogic B
acid I
( O
GA O
) O
is O
the O
main O
active O
ingredient O
of O
gamboge O
, O
a O
brownish O
to O
orange O
dry O
resin O
secreted O
from O
Garcinia O
hanburyi O
, O
a O
plant O
that O
is O
widely O
distributed O
in O
nature O
. O

Trichothecenes B
are O
sesquiterpenoid B
mycotoxins I
commonly O
found O
as O
contaminants O
in O
cereal O
grains O
and O
are O
a O
major O
health O
and O
food O
safety O
concern O
due O
to O
their O
toxicity O
to O
humans O
and O
farm O
animals O
. O

In O
vitro O
cytotoxicity O
and O
genotoxicity O
studies O
of O
titanium B
dioxide I
( O
TiO2 B
) O
nanoparticles O
in O
Chinese O
hamster O
lung O
fibroblast O
cells O
. O

The O
unique O
physical O
and O
chemical O
characteristics O
of O
titanium B
dioxide I
( O
TiO2 B
) O
nanoparticles O
result O
in O
different O
chemical O
and O
biological O
activities O
compared O
to O
their O
larger O
micron O
- O
sized O
counterparts O
, O
and O
can O
subsequently O
play O
an O
important O
role O
in O
influencing O
toxicity O
. O

The O
CSN O
/ O
IRF5 O
interaction O
occurred O
on O
the O
carboxyl B
and O
amino B
termini O
of O
IRF5 O
; O
a O
single O
internal O
deletion O
from O
amino B
acids I
455 O
to O
466 O
( O
Delta O
455 O
- O
466 O
) O
was O
found O
to O
significantly O
reduce O
IRF5 O
protein O
stability O
. O

Most O
of O
the O
quinazolinone B
alkaloids I
belong O
to O
this O
class O
of O
molecules O
. O

We O
synthesized O
copolymers O
composed O
of O
methyl B
methacrylate I
and O
2 B
- I
aminoethyl I
methacrylate I
with O
different O
protecting O
groups O
or O
ion O
- O
complexes O
on O
their O
amino B
groups O
, O
then O
dip O
- O
coated O
the O
copolymers O
onto O
a O
poly B
( I
methyl I
methacrylate I
) I
( O
PMMA B
) O
substrate O
. O

Kinetics O
of O
the O
reaction O
of O
crystal B
violet I
with O
hydroxide B
ion O
in O
the O
critical O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
. O

The O
kinetics O
of O
alkaline O
fading O
of O
crystal B
violet I
( O
CV O
) O
has O
been O
studied O
by O
UV O
spectrophotometry O
and O
microcalorimetry O
in O
the O
critical O
binary O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
at O
the O
initial O
reaction O
stage O
and O
various O
temperatures O
. O

Biomarkers O
of O
toluene B
exposure O
in O
rats O
: O
mercapturic B
acids I
versus O
traditional O
indicators O
( O
urinary O
hippuric B
acid I
and O
o B
- I
cresol I
and O
blood O
toluene B
) O
. O

Biomarkers O
of O
toluene B
exposure O
in O
rats O
: O
mercapturic B
acids I
versus O
traditional O
indicators O
( O
urinary O
hippuric B
acid I
and O
o B
- I
cresol I
and O
blood O
toluene B
) O
. O

The O
aims O
of O
this O
study O
were O
( O
1 O
) O
to O
provide O
data O
on O
MAs B
excretion O
in O
rat O
urine O
following O
TOL B
exposure O
by O
inhalation O
, O
( O
2 O
) O
to O
compare O
them O
to O
data O
from O
traditional O
TOL B
biomarkers O
, O
i O
. O
e O
. O
TOL B
in O
blood O
( O
Tol B
- O
B O
) O
, O
and O
urinary O
hippuric B
acid I
( O
HA O
) O
and O
o B
- I
cresol I
( O
oCre B
) O
and O
( O
3 O
) O
to O
establish O
a O
relationship O
between O
these O
different O
indicators O
and O
the O
airborne O
TOL B
concentration O
( O
Tol B
- O
A O
) O
. O

Mammalian O
pharmacological O
and O
toxicological O
information O
were O
used O
to O
guide O
the O
experimental O
design O
and O
the O
selection O
of O
relevant O
endpoints O
, O
according O
to O
the O
so O
- O
called O
" O
read O
- O
across O
approach O
" O
, O
suggesting O
that O
dutasteride B
may O
affect O
male O
fertility O
and O
steroid B
hormone I
dynamics O
. O

Aliquots O
of O
the O
sediment O
extracts O
were O
analyzed O
for O
4 B
- I
nonylphenols I
and O
natural O
steroidal B
estrogens I
as O
possible O
candidates O
with O
an O
estrogenic O
potential O
. O

Tritiated B
amitriptyline I
was O
added O
to O
laboratory O
microcosms O
containing O
soils O
, O
and O
the O
metabolism O
of O
the O
extractable O
( B
3 I
) I
H I
was O
monitored O
during O
incubation O
at O
30 O
degrees O
C O
. O

Tetracyclic B
BePI I
derivatives O
are O
characterized O
by O
a O
particular O
curved O
shape O
, O
and O
the O
presence O
of O
an O
oxo B
group O
on O
the O
pyridine B
ring O
was O
found O
to O
be O
required O
for O
aurora O
kinase O
B O
inhibition O
. O

New O
cyclomyrsinol B
diterpenes I
from O
Euphorbia O
aellenii O
with O
their O
immunomodulatory O
effects O
. O

Thyroid B
hormone I
replacement O
therapy O
attenuates O
the O
decline O
of O
renal O
function O
in O
chronic O
kidney O
disease O
patients O
with O
subclinical O
hypothyroidism O
. O

Even O
though O
previous O
studies O
have O
demonstrated O
that O
thyroid B
hormone I
replacement O
therapy O
( O
THRT O
) O
improved O
cardiac O
function O
and O
dyslipidemia O
in O
patients O
with O
subclinical O
hypothyroidism O
, O
it O
remains O
unclear O
as O
to O
whether O
THRT O
can O
improve O
renal O
function O
in O
CKD O
patients O
with O
SH O
. O

Furthermore O
, O
we O
were O
able O
to O
show O
that O
thioether B
bond O
formation O
is O
specific O
toward O
hydrophobic O
amino B
acids I
at O
the O
acceptor O
site O
. O

The O
most O
important O
amino B
acids I
involved O
in O
the O
interactions O
were O
identified O
. O

However O
, O
the O
glycosylated B
flavonoids I
showed O
relatively O
weaker O
inhibition O
which O
may O
be O
attributed O
to O
their O
hindered O
binding O
into O
the O
active O
site O
of O
AO O
by O
bulky O
sugar B
groups O
. O

THP O
- O
1 O
cells O
were O
pre O
- O
loaded O
with O
a O
ROS O
sensitive O
fluorescent O
dye O
, O
5 B
- I
( I
and I
6 I
- I
) I
- I
chloromethyl I
- I
2 I
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
, O
acetyl B
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
for O
15min O
, O
then O
incubated O
with O
test O
chemicals O
for O
30min O
. O

From O
cloning O
studies O
CBPTI O
- O
1 O
was O
found O
to O
consist O
of O
66 O
amino B
acid I
residues O
, O
while O
CBPTI O
- O
2 O
and O
CBPTI O
- O
3 O
precursors O
consist O
of O
60 O
amino B
acid I
residues O
, O
including O
6 O
cysteine B
residues O
. O

From O
cloning O
studies O
CBPTI O
- O
1 O
was O
found O
to O
consist O
of O
66 O
amino B
acid I
residues O
, O
while O
CBPTI O
- O
2 O
and O
CBPTI O
- O
3 O
precursors O
consist O
of O
60 O
amino B
acid I
residues O
, O
including O
6 O
cysteine B
residues O
. O

Previous O
phytochemical O
studies O
have O
shown O
that O
the O
plants O
of O
the O
Albizia O
genus O
( O
Fabaceae O
) O
contain O
bioactive O
saponins B
, O
lignans B
, O
spermine B
alkaloids I
, O
flavonoids B
, O
glycosides B
phenols I
and O
pyridoxine B
derivatives O
. O

Previous O
phytochemical O
studies O
have O
shown O
that O
the O
plants O
of O
the O
Albizia O
genus O
( O
Fabaceae O
) O
contain O
bioactive O
saponins B
, O
lignans B
, O
spermine B
alkaloids I
, O
flavonoids B
, O
glycosides B
phenols I
and O
pyridoxine B
derivatives O
. O

Diets O
deficient O
in O
iodine B
were O
prepared O
by O
adding O
975 O
, O
200 O
, O
125 O
, O
25 O
, O
or O
0 O
micro O
g O
/ O
kg O
potassium B
iodate I
to O
the O
base O
casein O
diet O
to O
produce O
five O
nominal O
iodine B
levels O
ranging O
from O
ample O
( O
Diet O
1 O
: O
1000 O
mu O
g O
iodine B
/ O
kg O
chow O
, O
D1 O
) O
to O
deficient O
( O
Diet O
5 O
: O
25 O
micro O
g O
iodine B
/ O
kg O
chow O
, O
D5 O
) O
. O

Sunitinib B
, O
a O
tyrosine B
kinase O
inhibitor O
, O
induces O
cytochrome O
P450 O
1A1 O
gene O
in O
human O
breast O
cancer O
MCF7 O
cells O
through O
ligand O
- O
independent O
aryl B
hydrocarbon I
receptor O
activation O
. O

The O
increase O
in O
CYP1A1 O
mRNA O
by O
SUN B
was O
completely O
blocked O
by O
the O
transcriptional O
inhibitor O
, O
actinomycin B
D I
; O
implying O
that O
SUN B
increased O
de O
novo O
RNA O
synthesis O
. O

Furthermore O
, O
the O
ability O
of O
SUN B
to O
increase O
luciferase O
reporter O
gene O
expression O
suggests O
an O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
- O
dependent O
transcriptional O
control O
and O
excludes O
the O
possibility O
of O
any O
posttranscriptional O
mechanisms O
. O

The O
combined O
results O
reveal O
the O
strong O
preference O
of O
UGT1A10 O
for O
the O
3 B
- I
OH I
of O
physiologic O
estrogens B
and O
the O
equivalently O
strong O
preference O
of O
UGT2B7 O
and O
UGT2B17 O
for O
the O
hydroxyls B
on O
ring O
D O
of O
such O
steroid B
hormones I
. O

Induced O
expression O
of O
cytochrome O
P450 O
1A O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
determined O
at O
mRNA O
, O
protein O
, O
and O
enzyme O
activity O
levels O
in O
rats O
exposed O
to O
the O
carcinogenic O
azo B
dye O
1 B
- I
phenylazo I
- I
2 I
- I
naphthol I
( O
Sudan B
I I
) O
. O

Sudan B
I I
( O
1 B
- I
phenylazo I
- I
2 I
- I
hydroxynaphthol I
) O
is O
a O
suspected O
human O
carcinogen O
causing O
tumors O
in O
the O
livers O
and O
urinary O
bladders O
of O
rats O
, O
mice O
, O
and O
rabbits O
. O

Here O
, O
we O
investigated O
for O
the O
first O
time O
the O
influence O
of O
Sudan B
I I
exposure O
on O
the O
expression O
of O
several O
biotransformation O
enzymes O
in O
the O
livers O
, O
kidneys O
, O
and O
lungs O
of O
rats O
concomitantly O
at O
the O
mRNA O
and O
protein O
levels O
and O
assayed O
their O
enzymatic O
activities O
. O

We O
also O
studied O
its O
effect O
on O
the O
formation O
of O
Sudan B
I I
- O
derived O
DNA O
adducts O
in O
vitro O
. O

Sudan B
I I
increased O
the O
total O
amounts O
of O
cytochrome O
P450 O
( O
P450 O
) O
in O
all O
organs O
tested O
. O

Western O
blots O
using O
antibodies O
raised O
against O
various O
P450s O
, O
NADPH B
: O
P450 O
reductase O
, O
and O
NAD B
( I
P I
) I
H I
: O
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
showed O
that O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
was O
induced O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
of O
rats O
treated O
with O
Sudan B
I I
. O

Furthermore O
, O
9 O
. O
9 O
- O
, O
5 O
. O
9 O
- O
, O
and O
2 O
. O
8 O
- O
fold O
increases O
in O
the O
formation O
of O
Sudan B
I I
oxidative O
metabolites O
catalyzed O
by O
microsomes O
isolated O
from O
the O
liver O
, O
kidney O
, O
and O
lung O
, O
respectively O
, O
of O
rats O
treated O
with O
Sudan B
I I
were O
found O
. O

Furthermore O
, O
9 O
. O
9 O
- O
, O
5 O
. O
9 O
- O
, O
and O
2 O
. O
8 O
- O
fold O
increases O
in O
the O
formation O
of O
Sudan B
I I
oxidative O
metabolites O
catalyzed O
by O
microsomes O
isolated O
from O
the O
liver O
, O
kidney O
, O
and O
lung O
, O
respectively O
, O
of O
rats O
treated O
with O
Sudan B
I I
were O
found O
. O

The O
relative O
amounts O
of O
P450 O
1A O
and O
NQO1 O
mRNA O
, O
measured O
by O
real O
- O
time O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
, O
demonstrated O
that O
Sudan B
I I
induced O
the O
expression O
of O
P450 O
1A1 O
and O
NQO1 O
mRNA O
in O
the O
liver O
, O
kidney O
, O
and O
lung O
, O
and O
of O
P450 O
1A2 O
mRNA O
in O
kidney O
and O
lung O
. O

Finally O
, O
microsomes O
isolated O
from O
livers O
, O
kidneys O
, O
and O
lungs O
of O
Sudan B
I I
exposed O
rats O
more O
effectively O
catalyzed O
the O
formation O
of O
Sudan B
I I
- O
DNA O
adducts O
than O
microsomes O
from O
organs O
of O
control O
rats O
. O

Finally O
, O
microsomes O
isolated O
from O
livers O
, O
kidneys O
, O
and O
lungs O
of O
Sudan B
I I
exposed O
rats O
more O
effectively O
catalyzed O
the O
formation O
of O
Sudan B
I I
- O
DNA O
adducts O
than O
microsomes O
from O
organs O
of O
control O
rats O
. O

Because O
P450 O
1A1 O
is O
playing O
a O
major O
role O
in O
the O
bioactivation O
of O
Sudan B
I I
in O
rat O
and O
human O
systems O
, O
its O
induction O
by O
Sudan B
I I
may O
have O
a O
profound O
effect O
on O
cancer O
risk O
by O
this O
azo B
dye O
. O

Because O
P450 O
1A1 O
is O
playing O
a O
major O
role O
in O
the O
bioactivation O
of O
Sudan B
I I
in O
rat O
and O
human O
systems O
, O
its O
induction O
by O
Sudan B
I I
may O
have O
a O
profound O
effect O
on O
cancer O
risk O
by O
this O
azo B
dye O
. O

Herein O
, O
absorption O
spectrometric O
, O
Thioflavin B
T I
fluorescence O
, O
and O
circular O
dichroism O
spectroscopic O
and O
transmission O
electron O
microscopic O
measurements O
revealed O
that O
the O
iron B
center O
is O
not O
required O
for O
the O
inhibition O
of O
A O
beta O
aggregation O
but O
do O
influence O
the O
binding O
affinity O
of O
heme B
toward O
A O
beta O
and O
the O
dismantlement O
rate O
and O
degree O
of O
the O
A O
beta O
aggregates O
. O

Inhibition O
of O
HIV O
- O
1 O
replication O
by O
a O
tricyclic B
coumarin I
GUT B
- I
70 I
in O
acutely O
and O
chronically O
infected O
cells O
. O

Aryl B
hydrocarbon I
receptor O
activation O
attenuates O
Per1 O
gene O
induction O
and O
influences O
circadian O
clock O
resetting O
. O

Our O
previous O
studies O
indicate O
that O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
agonist O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
attenuates O
light O
- O
induced O
phase O
resetting O
in O
early O
night O
. O

There O
were O
synthesized O
new O
types O
of O
ribbon O
type O
steroidal O
dimers O
derived O
from O
three O
types O
of O
steroidal O
skeletons O
( O
cholic B
acid I
, O
etienic B
acid I
, O
estrone B
) O
using O
Cu B
( I
I I
) I
catalyzed O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
. O

There O
were O
synthesized O
new O
types O
of O
ribbon O
type O
steroidal O
dimers O
derived O
from O
three O
types O
of O
steroidal O
skeletons O
( O
cholic B
acid I
, O
etienic B
acid I
, O
estrone B
) O
using O
Cu B
( I
I I
) I
catalyzed O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
. O

In O
particular O
, O
introducing O
unnatural O
amino B
acids I
( O
UAAs O
) O
has O
enabled O
modifications O
that O
are O
not O
found O
in O
natural O
proteins O
. O

Minimal O
expression O
changes O
were O
associated O
with O
retinoic B
acid I
receptor O
or O
vitamin B
D I
receptor O
heterodimers O
by O
any O
of O
the O
agonists O
. O

Minimal O
expression O
changes O
were O
associated O
with O
retinoic B
acid I
receptor O
or O
vitamin B
D I
receptor O
heterodimers O
by O
any O
of O
the O
agonists O
. O

UAB30 B
unexpectedly O
and O
uniquely O
activated O
genes O
associated O
with O
the O
aryl B
hydrocarbon I
hydroxylase O
( O
Ah O
) O
receptor O
( O
Cyp1a1 O
, O
Cyp1a2 O
, O
Cyp1b1 O
, O
and O
Nqo1 O
) O
. O

The O
authors O
evaluated O
effects O
of O
feeding O
ranch O
mink O
( O
Mustela O
vison O
) O
diets O
containing O
polychlorinated B
biphenyl I
( O
PCB B
) O
- O
contaminated O
fish O
from O
the O
upper O
Hudson O
River O
( O
New O
York O
, O
USA O
) O
on O
adult O
and O
offspring O
organ O
mass O
and O
pathology O
. O

The O
activities O
of O
superoxide B
dismutase O
, O
catalase O
, O
glutathione B
peroxidase O
, O
glutathione B
reductase O
and O
the O
levels O
of O
reduced B
glutathione I
, O
vitamins B
C I
and I
E I
in O
the O
liver O
and O
kidney O
of O
the O
animals O
decreased O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
. O

Three O
new O
ent B
- I
eudesmane I
sesquiterpenoids I
, O
arundinols B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
one O
isochroman B
- I
1 I
- I
one I
, O
arundinone B
A I
( O
4 O
) O
, O
and O
a O
polyoxygenated B
benzofuran I
- I
3 I
( I
2H I
) I
- I
one I
dimer O
, O
arundinone B
B I
( O
5 O
) O
, O
were O
isolated O
from O
the O
extract O
of O
a O
plant O
endophytic O
fungus O
, O
Microsphaeropsis O
arundinis O
. O

Three O
new O
ent B
- I
eudesmane I
sesquiterpenoids I
, O
arundinols B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
one O
isochroman B
- I
1 I
- I
one I
, O
arundinone B
A I
( O
4 O
) O
, O
and O
a O
polyoxygenated B
benzofuran I
- I
3 I
( I
2H I
) I
- I
one I
dimer O
, O
arundinone B
B I
( O
5 O
) O
, O
were O
isolated O
from O
the O
extract O
of O
a O
plant O
endophytic O
fungus O
, O
Microsphaeropsis O
arundinis O
. O

The O
absolute O
configuration O
of O
1 O
was O
assigned O
by O
X O
- O
ray O
crystallography O
using O
Cu B
K O
alpha O
radiation O
, O
whereas O
those O
of O
the O
C O
- O
11 O
tertiary B
alcohols I
in O
2 O
and O
3 O
were O
deduced O
via O
the O
circular O
dichroism O
data O
of O
the O
in O
situ O
formed O
[ B
Rh I
( I
2 I
) I
( I
OCOCF I
( I
3 I
) I
) I
( I
4 I
) I
] I
complexes O
. O

Arundinone B
B I
( O
5 O
) O
represents O
the O
first O
dimeric O
benzofuran B
- I
3 I
( I
2H I
) I
- I
one I
, O
showing O
cytotoxicity O
against O
T24 O
and O
A549 O
cells O
. O

We O
investigated O
the O
influence O
of O
maternal O
airway O
exposure O
to O
nanoparticulate O
titanium B
dioxide I
( O
TiO2 B
, O
UV O
- O
Titan O
) O
and O
carbon B
black I
( O
CB O
, O
Printex90 B
) O
, O
on O
male O
reproductive O
function O
in O
the O
two O
following O
generations O
. O

We O
investigated O
the O
influence O
of O
maternal O
airway O
exposure O
to O
nanoparticulate O
titanium B
dioxide I
( O
TiO2 B
, O
UV O
- O
Titan O
) O
and O
carbon B
black I
( O
CB O
, O
Printex90 B
) O
, O
on O
male O
reproductive O
function O
in O
the O
two O
following O
generations O
. O

The O
nuclear O
receptor O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
alpha O
is O
known O
primarily O
as O
a O
regulator O
of O
fatty B
acid I
metabolism O
, O
energy O
balance O
, O
and O
inflammation O
, O
but O
evidence O
suggests O
a O
wider O
role O
in O
regulating O
the O
biotransformation O
of O
drugs O
and O
other O
lipophilic O
chemicals O
. O

The O
purpose O
of O
this O
work O
was O
to O
improve O
the O
efficacy O
of O
triamcinolone B
acetonide I
( O
TA O
) O
in O
the O
treatment O
of O
endotoxin O
- O
induced O
uveitis O
( O
EIU O
) O
using O
a O
polymeric O
nanoparticulate O
drug O
delivery O
system O
. O

Results O
indicated O
statistically O
significant O
differences O
between O
the O
effect O
of O
nanoparticles O
in O
the O
treatment O
of O
EIU O
compared O
to O
microparticles O
of O
TA O
and O
prednisolone B
acetate I
( O
PA O
) O
. O

A O
novel O
approach O
, O
called O
isothermal O
isotope O
exchange O
( O
IIE O
) O
, O
was O
applied O
to O
varying O
A O
- O
and O
B O
- O
site O
lanthanum B
manganites I
, O
ferrites B
, O
and O
cobaltites B
in O
the O
perovskite B
crystal O
structure O
in O
order O
to O
extract O
accurate O
surface O
exchange O
coefficients O
( O
k O
* O
) O
. O

Endocrine O
disrupting O
effects O
of O
ochratoxin B
A I
at O
the O
level O
of O
nuclear O
receptor O
activation O
and O
steroidogenesis O
. O

Ochratoxin B
A I
( O
OTA B
) O
is O
a O
mycotoxin O
and O
extrolite O
of O
fungi O
which O
has O
been O
reported O
in O
a O
range O
of O
foods O
. O

Following O
repetitive O
administration O
( O
2 O
. O
5 O
mg O
/ O
kg O
/ O
day O
during O
10 O
days O
) O
, O
we O
observed O
a O
13 O
- O
fold O
increase O
in O
the O
effective O
dose O
- O
50 O
% O
( O
ED O
5 O
0 O
) O
of O
morphine B
- O
induced O
analgesia O
in O
comparison O
to O
a O
2 O
- O
or O
4 O
- O
fold O
increase O
in O
the O
ED O
5 O
0 O
of O
its O
related O
increase O
in O
inspiratory O
time O
determined O
in O
air O
and O
4 O
% O
CO B
2 I
, O
respectively O
. O

FTIR O
spectra O
revealed O
that O
the O
addition O
of O
manganese B
oxide I
contributes O
the O
transformation O
of O
TeO B
( I
4 I
) I
trigonal O
bipyramids O
with O
bridging O
oxygen B
( O
BO O
) O
to O
TeO B
( I
3 I
) I
trigonal O
pyramids O
with O
non O
- O
bridging O
oxygen B
( O
NBO O
) O
. O

Contractions O
were O
produced O
by O
electrical O
field O
stimulation O
of O
perivascular O
nerves O
( O
EFS O
) O
, O
norepinephrine B
( O
NE O
) O
, O
adenosine B
5 I
' I
- I
triphosphate I
( O
ATP B
) O
, O
high O
K B
( I
+ I
) I
solution O
and O
by O
calcium B
chloride I
( O
CaCl B
( I
2 I
) I
) O
in O
Ca B
( I
2 I
+ I
) I
- O
free O
and O
high O
K B
( I
+ I
) I
, O
Ca B
( I
2 I
+ I
) I
- O
free O
solution O
. O

Resveratrol B
more O
potently O
inhibited O
CaCl B
( I
2 I
) I
than O
potassium B
chloride I
contractions O
of O
RPV O
. O

The O
antinociceptive O
effect O
of O
milnacipran B
in O
the O
monosodium B
iodoacetate I
model O
of O
osteoarthritis O
pain O
and O
its O
relation O
to O
changes O
in O
descending O
inhibition O
. O

These O
studies O
used O
monoamine B
receptor O
agents O
combined O
with O
behavioral O
studies O
and O
single O
- O
unit O
dorsal O
horn O
recordings O
to O
examine O
whether O
descending O
noradrenergic O
and O
serotonergic O
inhibitions O
are O
altered O
in O
the O
monosodium B
iodoacetate I
model O
of O
OA O
pain O
, O
and O
whether O
increasing O
these O
inhibitions O
with O
the O
serotonin B
/ O
noradrenaline B
reuptake O
inhibitor O
milnacipran B
can O
attenuate O
the O
attendant O
hypersensitivity O
. O

Essential O
oils O
of O
Thymus O
leucospermus O
Hartvig O
, O
a O
Greek O
endemic O
rich O
in O
phenolic B
monoterpenes I
. O

The O
oils O
were O
particularly O
rich O
in O
phenolic B
monoterpenes I
: O
they O
had O
a O
high O
thymol B
( O
64 O
. O
7 O
- O
92 O
. O
0 O
% O
) O
or O
carvacrol B
( O
93 O
. O
4 O
% O
) O
content O
, O
whereas O
in O
one O
of O
the O
oils O
considerable O
amount O
of O
both O
compounds O
was O
found O
( O
thymol B
61 O
. O
6 O
% O
and O
carvacrol B
26 O
. O
4 O
% O
) O
. O

The O
method O
consists O
of O
antisolvent O
co O
- O
precipitation O
from O
an O
aqueous O
solution O
containing O
both O
an O
amino B
acid I
core O
material O
( O
e O
. O
g O
. O
D B
, I
L I
- I
valine I
) O
, O
and O
either O
bovine O
serum O
albumin O
( O
BSA O
) O
or O
lysozyme O
( O
Lys O
) O
as O
model O
proteins O
. O

The O
use O
of O
a O
polysorbate B
or O
sorbitan B
ester I
derivatives O
as O
stabilizers O
proved O
to O
be O
necessary O
to O
yield O
submicron O
particles O
. O

Synthesis O
, O
characterization O
and O
targeting O
potential O
of O
zidovudine B
loaded O
sialic B
acid I
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
dendrimers O
. O

The O
present O
investigation O
was O
aimed O
at O
exploring O
dual O
targeting O
of O
anti O
- O
HIV O
drug O
, O
zidovudine B
( O
ZDV B
) O
via O
sialic B
acid I
conjugated O
- O
mannosylated B
poly I
( I
propyleneimine I
) I
( O
PPI B
) O
dendritic O
nano O
- O
constructs O
. O

Fourth O
generation O
PPI B
dendrimers O
, O
sialic B
acid I
conjugated O
PPI B
dendrimers O
( O
SPPI O
) O
, O
mannose B
conjugated O
PPI B
dendrimers O
( O
MPPI O
) O
and O
dual O
ligand O
system O
i O
. O
e O
. O
sialic B
acid I
conjugated O
- O
mannosylated B
PPI I
dendrimers O
( O
SMPPI O
) O
were O
synthesized O
and O
characterized O
by O
FT O
- O
IR O
and O
( B
1 I
) I
H I
NMR O
spectroscopies O
and O
were O
further O
confirmed O
by O
size O
exclusion O
chromatography O
and O
differential O
scanning O
calorimetry O
. O

Fourth O
generation O
PPI B
dendrimers O
, O
sialic B
acid I
conjugated O
PPI B
dendrimers O
( O
SPPI O
) O
, O
mannose B
conjugated O
PPI B
dendrimers O
( O
MPPI O
) O
and O
dual O
ligand O
system O
i O
. O
e O
. O
sialic B
acid I
conjugated O
- O
mannosylated B
PPI I
dendrimers O
( O
SMPPI O
) O
were O
synthesized O
and O
characterized O
by O
FT O
- O
IR O
and O
( B
1 I
) I
H I
NMR O
spectroscopies O
and O
were O
further O
confirmed O
by O
size O
exclusion O
chromatography O
and O
differential O
scanning O
calorimetry O
. O

Fourth O
generation O
PPI B
dendrimers O
, O
sialic B
acid I
conjugated O
PPI B
dendrimers O
( O
SPPI O
) O
, O
mannose B
conjugated O
PPI B
dendrimers O
( O
MPPI O
) O
and O
dual O
ligand O
system O
i O
. O
e O
. O
sialic B
acid I
conjugated O
- O
mannosylated B
PPI I
dendrimers O
( O
SMPPI O
) O
were O
synthesized O
and O
characterized O
by O
FT O
- O
IR O
and O
( B
1 I
) I
H I
NMR O
spectroscopies O
and O
were O
further O
confirmed O
by O
size O
exclusion O
chromatography O
and O
differential O
scanning O
calorimetry O
. O

Our O
work O
aimed O
to O
explore O
the O
transport O
mechanism O
of O
the O
antiretroviral O
lamivudine B
( O
deoxycytidine B
nucleoside I
analogue O
) O
, O
using O
a O
three O
- O
part O
strategy O
: O
in O
vitro O
, O
an O
ex O
vivo O
and O
an O
in O
situ O
method O
, O
represented O
by O
PAMPA O
, O
rat O
jejunum O
patches O
and O
rat O
Single O
Pass O
Intestinal O
Perfusion O
( O
SPIP O
) O
, O
respectively O
. O

Polyethylenimine B
combined O
with O
liposomes O
and O
with O
decreased O
numbers O
of O
primary B
amine I
residues O
strongly O
enhanced O
therapeutic O
antiviral O
efficiency O
against O
herpes O
simplex O
virus O
type O
2 O
in O
a O
mouse O
model O
. O

In O
this O
study O
, O
to O
develop O
therapeutic O
anti O
- O
HSV O
- O
2 O
agents O
, O
the O
most O
potent O
PEI B
combined O
with O
~ O
200 O
nm O
- O
sized O
liposomes O
with O
or O
without O
oleic B
acid I
( O
liposomes O
/ O
PEI B
) O
was O
selected O
in O
vitro O
and O
further O
evaluated O
using O
in O
vivo O
studies O
. O

The O
mechanism O
of O
action O
in O
vivo O
was O
elucidated O
using O
PEIs B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
, O
resulting O
from O
ethylene B
carbonate I
treatment O
, O
and O
polyallylamine B
, O
a O
linear O
polyamine B
consisting O
of O
primary B
amines I
. O

The O
mechanism O
of O
action O
in O
vivo O
was O
elucidated O
using O
PEIs B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
, O
resulting O
from O
ethylene B
carbonate I
treatment O
, O
and O
polyallylamine B
, O
a O
linear O
polyamine B
consisting O
of O
primary B
amines I
. O

The O
mechanism O
of O
action O
in O
vivo O
was O
elucidated O
using O
PEIs B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
, O
resulting O
from O
ethylene B
carbonate I
treatment O
, O
and O
polyallylamine B
, O
a O
linear O
polyamine B
consisting O
of O
primary B
amines I
. O

Liposome O
/ O
PEI B
and O
PEI B
with O
decreased O
numbers O
of O
primary B
amine I
residues O
at O
a O
dose O
of O
0 O
. O
2 O
mg O
PEI B
/ O
mouse O
exhibited O
more O
potent O
therapeutic O
antiviral O
activity O
than O
acyclovir B
and O
PEI B
alone O
without O
acute O
lesion O
appearance O
or O
toxicity O
pre O
- O
or O
postinfection O
, O
but O
polyallylamine B
was O
moderately O
effective O
only O
preinfection O
. O

This O
finding O
suggests O
that O
PEI B
combined O
with O
liposomes O
and O
with O
slightly O
decreased O
numbers O
of O
primary B
amines I
may O
be O
an O
effective O
vaginally O
administrated O
antiviral O
drug O
, O
and O
secondary B
and I
tertiary I
amine I
residues O
of O
PEI B
may O
contribute O
to O
the O
inhibitory O
efficiency O
against O
viral O
infection O
. O

Locally O
administered O
prostaglandin B
E2 I
prevents O
aeroallergen O
- O
induced O
airway O
sensitization O
in O
mice O
through O
immunomodulatory O
mechanisms O
. O

Prostaglandin B
E2 I
attenuates O
airway O
pathology O
in O
asthmatic O
patients O
and O
exerts O
a O
protective O
effect O
in O
antigen O
- O
sensitized O
mice O
when O
administered O
systemically O
. O

The O
intrinsic O
clearance O
for O
R B
- I
and I
S I
- I
EDDP I
formation O
from O
racemic B
methadone I
was O
diminished O
approximately O
6 O
- O
fold O
and O
3 O
- O
fold O
for O
R B
- I
and I
S I
- I
methadone I
, O
respectively O
. O

The O
nuclear O
receptors O
constitutive O
androstane B
receptor O
( O
CAR O
) O
, O
pregnane B
X O
receptor O
( O
PXR O
) O
and O
vitamin B
D I
receptor O
( O
VDR O
) O
control O
a O
large O
array O
of O
genes O
that O
code O
for O
important O
proteins O
in O
humans O
including O
metabolic O
enzymes O
and O
transporters O
. O

Subacute O
oral O
toxicity O
of O
combinations O
of O
selected O
synthetic O
pyrethroids B
, O
piperonyl B
butoxide I
, O
and O
tetramethrin B
in O
rats O
. O

Different O
combinations O
of O
insecticides O
were O
administered O
daily O
to O
the O
experimental O
groups O
( O
group O
1 O
: O
cypermethrin B
+ O
piperonyl B
butoxide I
( O
PBO B
) O
; O
group O
2 O
: O
alphacypermethrin B
+ O
PBO B
; O
group O
3 O
: O
deltamethrin B
+ O
PBO B
; O
group O
4 O
: O
cypermethrin B
+ O
PBO B
+ O
tetramethrin B
; O
group O
5 O
: O
alphacypermethrin B
+ O
PBO B
+ O
tetramethrin B
; O
and O
group O
6 O
: O
deltamethrin B
+ O
PBO B
+ O
tetramethrin O
) O
for O
28 O
days O
. O

Phenyl B
, O
propyl B
, O
and O
amyl B
moieties O
were O
used O
as O
linkers O
between O
SAK O
and O
polyethylene B
glycol I
( O
PEG B
) O
, O
respectively O
. O

Optical O
probing O
of O
the O
electronic O
interaction O
between O
graphene B
and O
hexagonal O
boron B
nitride I
. O

In O
this O
report O
, O
we O
demonstrate O
that O
Raman O
spectroscopy O
can O
be O
utilized O
to O
detect O
a O
few O
percent O
decrease O
in O
the O
Fermi O
velocity O
( O
v O
( O
F O
) O
) O
of O
graphene B
caused O
by O
the O
vdW O
interaction O
with O
underlying O
hexagonal O
boron B
nitride I
( O
hBN O
) O
. O

The O
analysis O
reveals O
that O
spectral O
features O
of O
graphene B
on O
hBN O
are O
mainly O
affected O
by O
change O
in O
v O
( O
F O
) O
and O
mechanical O
strain O
but O
not O
by O
charge O
doping O
, O
unlike O
graphene B
supported O
on O
SiO B
2 I
substrates O
. O

Eight O
new O
compounds O
, O
including O
two O
cyclopenta B
[ I
b I
] I
benzopyran I
derivatives O
( O
1 O
, O
2 O
) O
, O
two O
cyclopenta B
[ I
b I
] I
benzofuran I
derivatives O
( O
3 O
, O
4 O
) O
, O
three O
cycloartane B
triterpenoids I
( O
5 O
- O
7 O
) O
, O
and O
an O
apocarotenoid O
( O
8 O
) O
, O
together O
with O
16 O
known O
compounds O
, O
were O
isolated O
from O
the O
chloroform B
- O
soluble O
partitions O
of O
separate O
methanol B
extracts O
of O
a O
combination O
of O
the O
fruits O
, O
leaves O
, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O

The O
Mosher O
ester O
method O
was O
employed O
to O
determine O
the O
absolute O
configurations O
of O
5 O
- O
7 O
, O
and O
the O
absolute O
configuration O
of O
the O
9 O
, O
10 O
- O
diol B
unit O
of O
compound O
8 O
was O
established O
by O
a O
dimolybdenum B
tetraacetate I
[ O
Mo2 B
( I
AcO I
) I
4 I
] O
induced O
circular O
dichroism O
procedure O
. O

In O
addition O
, O
the O
new O
compound O
perviridicin B
B I
( O
2 O
) O
, O
three O
known O
rocaglate B
derivatives O
( O
9 O
, O
11 O
, O
12 O
) O
, O
and O
a O
known O
sesquiterpene B
, O
2 B
- I
oxaisodauc I
- I
5 I
- I
en I
- I
12 I
- I
al I
( O
17 O
) O
, O
showed O
significant O
NF O
- O
kappa O
B O
( O
p65 O
) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

A O
powerful O
aluminum B
catalyst O
for O
the O
synthesis O
of O
highly O
functional O
organic B
carbonates I
. O

An O
aluminum B
complex O
based O
on O
an O
amino B
triphenolate I
ligand O
scaffold O
shows O
unprecedented O
high O
activity O
( O
initial O
TOFs O
up O
to O
36 O
, O
000 O
h O
( O
- O
1 O
) O
) O
, O
broad O
substrate O
scope O
, O
and O
functional O
group O
tolerance O
in O
the O
formation O
of O
highly O
functional O
organic B
carbonates I
prepared O
from O
epoxides B
and O
CO B
( I
2 I
) I
. O

An O
aluminum B
complex O
based O
on O
an O
amino B
triphenolate I
ligand O
scaffold O
shows O
unprecedented O
high O
activity O
( O
initial O
TOFs O
up O
to O
36 O
, O
000 O
h O
( O
- O
1 O
) O
) O
, O
broad O
substrate O
scope O
, O
and O
functional O
group O
tolerance O
in O
the O
formation O
of O
highly O
functional O
organic B
carbonates I
prepared O
from O
epoxides B
and O
CO B
( I
2 I
) I
. O

We O
used O
a O
sensitive O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
and O
LC O
/ O
MS O
/ O
MS O
method O
to O
show O
that O
L B
- I
tyrosine I
( O
Tyr B
) O
, O
an O
amino B
acid I
with O
a O
highly O
reactive O
hydroxyl B
group O
, O
readily O
reacts O
with O
cigarette O
smoke O
extract O
( O
CSE O
) O
at O
body O
temperature O
( O
37 O
degrees O
C O
) O
to O
form O
various O
Tyr B
derivatives O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

The O
presence O
of O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
in O
CSE O
was O
confirmed O
by O
gas O
chromatography O
- O
mass O
spectrometry O
( O
GC O
/ O
MS O
) O
. O

Schisphenlignans B
A I
- I
E I
: O
five O
new O
dibenzocyclooctadien B
lignans I
from O
Schisandra O
sphenanthera O
. O

Five O
new O
dibenzocyclooctadien B
lignans I
, O
schisphenlignans B
A I
- I
E I
( O
1 O
- O
5 O
) O
, O
together O
with O
eight O
known O
ones O
, O
were O
isolated O
from O
the O
stems O
of O
Schisandra O
sphenanthera O
. O

Enhancing O
catalytic O
selectivity O
of O
supported O
metal O
nanoparticles O
with O
capping O
ligands O
is O
demonstrated O
using O
an O
Au B
/ O
SiO B
( I
2 I
) I
catalyst O
in O
liquid O
phase O
aerobic O
oxidation O
of O
benzyl B
alcohol I
. O

FTIR O
spectroscopy O
shows O
that O
dissolving O
a O
carboxylic B
acid I
anhydride I
in O
IL O
- O
F O
leads O
to O
the O
formation O
of O
acyl B
fluoride I
. O

Surface O
transformations O
of O
Bioglass B
45S5 I
during O
scaffold O
synthesis O
for O
bone O
tissue O
engineering O
. O

In O
physiological O
fluid O
, O
a O
layer O
of O
hydroxycarbonate B
apatite I
, O
similar O
to O
bone O
mineral O
, O
develops O
on O
the O
surface O
of O
Bioglass B
45S5 I
. O

In O
physiological O
fluid O
, O
a O
layer O
of O
hydroxycarbonate B
apatite I
, O
similar O
to O
bone O
mineral O
, O
develops O
on O
the O
surface O
of O
Bioglass B
45S5 I
. O

Canine O
metabolite O
disposition O
was O
generally O
similar O
, O
with O
the O
notable O
exception O
of O
dog O
- O
unique O
LY2090314 B
glucuronide I
. O

Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK O
- O
2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane B
, O
tert B
- I
butylhydroquinone I
, O
cinnamic B
aldehyde I
, O
and O
hydrogen B
peroxide I
) O
showed O
that O
the O
aldo O
- O
keto O
reductase O
( O
AKR O
) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O

Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK O
- O
2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane B
, O
tert B
- I
butylhydroquinone I
, O
cinnamic B
aldehyde I
, O
and O
hydrogen B
peroxide I
) O
showed O
that O
the O
aldo O
- O
keto O
reductase O
( O
AKR O
) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O

Effects O
of O
tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
and O
triphenyl B
phosphate I
on O
receptor O
- O
associated O
mRNA O
expression O
in O
zebrafish O
embryos O
/ O
larvae O
. O

Tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
( O
TDCPP B
) O
and O
triphenyl B
phosphate I
( O
TPP B
) O
are O
frequently O
detected O
in O
biota O
, O
including O
fish O
. O

Real O
- O
time O
PCR O
revealed O
alterations O
in O
expression O
of O
mRNAs O
involved O
in O
aryl B
hydrocarbon I
receptors O
( O
AhRs O
) O
- O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
- O
, O
estrogenic O
receptors O
( O
ERs O
) O
- O
, O
thyroid B
hormone I
receptor O
alpha O
( O
TR O
alpha O
) O
- O
, O
glucocorticoid O
receptor O
( O
GR O
) O
- O
, O
and O
mineralocorticoid O
receptor O
( O
MR O
) O
- O
centered O
gene O
networks O
. O

Real O
- O
time O
PCR O
revealed O
alterations O
in O
expression O
of O
mRNAs O
involved O
in O
aryl B
hydrocarbon I
receptors O
( O
AhRs O
) O
- O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
( O
PPAR O
alpha O
) O
- O
, O
estrogenic O
receptors O
( O
ERs O
) O
- O
, O
thyroid B
hormone I
receptor O
alpha O
( O
TR O
alpha O
) O
- O
, O
glucocorticoid O
receptor O
( O
GR O
) O
- O
, O
and O
mineralocorticoid O
receptor O
( O
MR O
) O
- O
centered O
gene O
networks O
. O

Fatty B
acids I
are O
the O
fundamental O
structural O
components O
of O
membrane O
lipids O
, O
and O
the O
degree O
of O
saturation O
of O
the O
long O
hydrocarbon B
chains O
in O
microalgae O
contributes O
to O
regulation O
of O
growth O
, O
biomass O
production O
and O
reproduction O
of O
aquatic O
consumers O
. O

This O
research O
aimed O
at O
evaluating O
the O
effects O
of O
cadmium B
( O
2 O
x O
10 O
( O
- O
8 O
) O
; O
10 O
( O
- O
7 O
) O
mol O
L O
( O
- O
1 O
) O
Cd B
) O
on O
lipid O
class O
and O
fatty B
acid I
composition O
of O
the O
microalga O
Chlorella O
vulgaris O
under O
varying O
phosphate B
( O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
concentrations O
( O
6 O
. O
0 O
x O
10 O
( O
- O
7 O
) O
to O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
) O
. O

Fatty B
acid I
composition O
revealed O
that O
the O
degree O
of O
saturation O
increased O
with O
increasing O
Cd B
stress O
and O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
. O

Decreasing O
PO B
( I
4 I
) I
( I
3 I
- I
) I
and O
increasing O
Cd B
concentrations O
resulted O
in O
higher O
saturated B
fatty I
acid I
( O
SAFA B
) O
and O
monounsaturated B
FA I
( O
MUFA B
) O
concentrations O
. O

Total O
polyunsaturated B
FA I
( O
PUFA B
) O
and O
omega B
3 I
PUFA I
, O
and O
PUFA B
: O
SAFA B
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
cells O
than O
in O
either O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
or O
Cd B
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

The O
hepatoprotection O
of O
caffeic B
acid I
and O
rosmarinic B
acid I
, O
major O
compounds O
of O
Perilla O
frutescens O
, O
against O
t B
- I
BHP I
- O
induced O
oxidative O
liver O
damage O
. O

The O
hepatoprotection O
of O
caffeic B
acid I
and O
rosmarinic B
acid I
, O
major O
compounds O
of O
Perilla O
frutescens O
, O
against O
t B
- I
BHP I
- O
induced O
oxidative O
liver O
damage O
. O

In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
effects O
of O
caffeic B
acid I
( O
CA O
) O
, O
rosmarinic B
acid I
( O
RA O
) O
, O
and O
their O
combination O
. O

In O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
effects O
of O
caffeic B
acid I
( O
CA O
) O
, O
rosmarinic B
acid I
( O
RA O
) O
, O
and O
their O
combination O
. O

CA O
remarkably O
reduced O
the O
oxidative O
damage O
than O
rosmarinic B
acid I
in O
an O
in O
vitro O
study O
. O

Oral O
intubation O
with O
CA O
or O
RA O
alone O
for O
five O
days O
was O
conducted O
prior O
to O
treatment O
with O
a O
single O
dose O
of O
tert B
- I
butyl I
hydroperoxide I
( O
0 O
. O
5mmol O
/ O
kg O
b O
. O
w O
. O
, O
i O
. O
p O
. O
) O
, O
which O
led O
to O
a O
significant O
reduction O
of O
indicators O
of O
hepatic O
toxicity O
, O
such O
as O
aspartate B
aminotransferase O
, O
alanine B
aminotransferase O
, O
oxidized B
glutathione I
, O
lipid O
peroxidation O
and O
enzyme O
activities O
related O
to O
antioxidant O
such O
as O
catalase O
, O
glutathione B
peroxidase O
and O
superoxide B

Interestingly O
, O
compared O
to O
treatment O
with O
CA O
or O
RA O
alone O
, O
a O
combination O
of O
both O
compounds O
more O
increased O
the O
endogenous O
antioxidant O
enzymes O
and O
glutathione B
( O
GSH O
) O
and O
decreased O
lipid O
peroxidation O
in O
livers O
. O

MC3T3 O
- O
E1 O
was O
cultured O
as O
mature O
osteoblasts O
and O
treated O
with O
sodium B
metasilicate I
( O
0 O
, O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
as O
a O
source O
of O
Si B
. O

After O
7 O
days O
of O
treatment O
, O
5 O
and O
10 O
mu O
M O
of O
sodium B
metasilicate I
significantly O
increased O
intracellular O
alkaline O
phosphatase O
activity O
( O
p O
< O
0 O
. O
05 O
) O
when O
compared O
to O
the O
control O
. O

Additionally O
, O
all O
doses O
of O
sodium B
metasilicate I
( O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
increased O
mineralized O
nodule O
formation O
at O
14 O
days O
of O
differentiation O
as O
evidenced O
by O
increased O
Alizarin B
Red I
S I
staining O
. O

In O
the O
analysis O
of O
gene O
expression O
, O
50 O
mu O
M O
of O
sodium B
metasilicate I
upregulated O
type O
I O
collagen O
( O
COL O
- O
I O
) O
compared O
to O
the O
control O
group O
. O

However O
, O
the O
increase O
of O
COL O
- O
I O
gene O
expression O
as O
a O
result O
of O
treatment O
with O
1 O
, O
10 O
, O
25 O
, O
and O
100 O
mu O
M O
of O
sodium B
metasilicate I
did O
not O
reach O
statistical O
significance O
. O

mRNA O
expression O
of O
insulin O
- O
like O
growth O
factor O
- O
I O
and O
receptor O
activator O
of O
NF O
- O
kappa O
B O
ligand O
was O
not O
significantly O
changed O
at O
any O
dose O
of O
sodium B
metasilicate I
( O
0 O
, O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
. O

FMO3 O
expression O
is O
induced O
by O
dietary O
bile B
acids I
by O
a O
mechanism O
that O
involves O
the O
farnesoid O
X O
receptor O
( O
FXR O
) O
, O
a O
bile B
acid I
- O
activated O
nuclear O
receptor O
. O

FMO3 O
expression O
is O
induced O
by O
dietary O
bile B
acids I
by O
a O
mechanism O
that O
involves O
the O
farnesoid O
X O
receptor O
( O
FXR O
) O
, O
a O
bile B
acid I
- O
activated O
nuclear O
receptor O
. O

Investigation O
of O
a O
limited O
number O
of O
prodrug O
esters O
led O
to O
the O
discovery O
of O
the O
ethyl B
ester I
prodrug O
42 O
, O
which O
demonstrated O
good O
intestinal O
fluid O
stability O
and O
good O
permeability O
. O

Ethyl B
ester I
prodrug O
42 O
advanced O
to O
human O
clinical O
trials O
based O
on O
the O
excellent O
intestinal O
fluid O
stability O
, O
good O
permeability O
and O
superior O
efficacy O
in O
non O
- O
human O
primates O
. O

Aphagrandinoids B
A I
- I
D I
, O
cycloartane B
triterpenoids I
with O
antibacterial O
activities O
from O
Aphanamixis O
grandifolia O
. O

Three O
new O
cycloartane B
triterpenoids I
, O
aphagrandinoids B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
natural O
product O
, O
aphagrandinoid B
D I
( O
4 O
) O
, O
together O
with O
a O
known O
compound O
, O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Aphanamixis O
grandifolia O
. O

Three O
new O
cycloartane B
triterpenoids I
, O
aphagrandinoids B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
natural O
product O
, O
aphagrandinoid B
D I
( O
4 O
) O
, O
together O
with O
a O
known O
compound O
, O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Aphanamixis O
grandifolia O
. O

Aphagrandinoid B
A I
( O
1 O
) O
, O
a O
29 B
- I
nor I
- I
cycloart I
triterpenoid I
, O
features O
with O
a O
sprio O
ring O
system O
at O
the O
side O
chain O
, O
while O
aphagrandinoid B
C I
( O
3 O
) O
is O
a O
pentnortriterpenoid B
. O

Aphagrandinoid B
A I
( O
1 O
) O
, O
a O
29 B
- I
nor I
- I
cycloart I
triterpenoid I
, O
features O
with O
a O
sprio O
ring O
system O
at O
the O
side O
chain O
, O
while O
aphagrandinoid B
C I
( O
3 O
) O
is O
a O
pentnortriterpenoid B
. O

Mouse O
model O
for O
brain O
injury O
showed O
reactive O
astrocytes O
with O
increased O
glial O
fibrillary O
acidic O
protein O
, O
and O
formation O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
. O

The O
former O
comprised O
exhaled O
nitric B
oxide I
( O
NOE O
) O
and O
' O
enhanced O
pause O
' O
( O
Penh O
) O
both O
measured O
in O
spontaneous O
breathing O
conscious O
rats O
. O

A O
divergent O
synthesis O
was O
used O
, O
with O
all O
compounds O
being O
elaborated O
from O
a O
single O
chiral O
aldehyde B
derived O
from O
ethyl B
lactate I
. O

Bacitracin B
and O
sodium B
taurocholate I
were O
incorporated O
in O
the O
formulations O
as O
proteolytic O
enzyme O
inhibitor O
and O
absorption O
enhancer O
, O
respectively O
. O

2 B
- I
Amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
is O
one O
of O
the O
most O
abundant O
heterocyclic B
amines I
( O
HCAs B
) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O

alpha B
- I
Santonin I
derived O
new O
series O
of O
1 B
, I
2 I
, I
3 I
- I
triazoles I
synthesized O
through O
Azide B
- I
Alkyne I
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl B
azide I
and O
a O
propargylated B
alpha I
- I
desmotrosantonin I
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

Inositol B
triphosphate I
( O
InsP3 O
) O
receptor O
antagonist O
2 B
- I
APB I
( O
10 O
( O
- O
4 O
) O
M O
) O
significantly O
reduced O
, O
and O
high O
concentration O
of O
caffeine B
( O
20mM O
) O
almost O
totally O
suppressed O
the O
contractions O
. O

Complex O
II O
of O
the O
mitochondrial O
respiratory O
chain O
is O
the O
key O
mediator O
of O
divalent B
manganese I
- O
induced O
hydrogen B
peroxide I
production O
in O
microglia O
. O

Complex O
II O
of O
the O
mitochondrial O
respiratory O
chain O
is O
the O
key O
mediator O
of O
divalent B
manganese I
- O
induced O
hydrogen B
peroxide I
production O
in O
microglia O
. O

We O
have O
recently O
reported O
that O
divalent B
Mn I
( O
Mn B
( I
2 I
+ I
) I
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen B
peroxide I
( O
H2O2 B
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn B
( I
2 I
+ I
) I
- O
induced O
dopaminergic O
neurotoxicity O
. O

We O
have O
recently O
reported O
that O
divalent B
Mn I
( O
Mn B
( I
2 I
+ I
) I
) O
stimulates O
brain O
microglia O
to O
produce O
and O
release O
hydrogen B
peroxide I
( O
H2O2 B
) O
, O
and O
microglial O
- O
free O
radical O
generation O
facilitates O
Mn B
( I
2 I
+ I
) I
- O
induced O
dopaminergic O
neurotoxicity O
. O

The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic B
acid I
( O
AA O
) O
, O
linoleic B
acid I
( O
LA O
) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O

The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic B
acid I
( O
AA O
) O
, O
linoleic B
acid I
( O
LA O
) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O

Finally O
, O
it O
has O
also O
been O
shown O
that O
SFE O
is O
very O
selective O
towards O
some O
specific O
components O
such O
as O
manoyl B
oxide I
, O
trans B
- I
totarol I
and O
alpha B
- I
acoradiene I
. O

While O
the O
metabolism O
of O
extracellular O
ATP B
and O
cyclic B
AMP I
are O
well O
recognized O
sources O
, O
evidences O
regarding O
the O
role O
of O
the O
equilibrative O
nucleoside B
transporters O
in O
controlling O
adenosine B
availability O
and O
promoting O
diabetic O
glomerulopathy O
have O
recently O
acquired O
a O
pivotal O
role O
. O

Solphenazines B
A I
- I
F I
, O
glycosylated B
phenazines I
from O
Streptomyces O
sp O
. O
strain O
DL O
- O
93 O
. O

The O
structure O
- O
activity O
relationship O
studies O
of O
a O
novel O
series O
of O
carboxylic B
acid I
derivatives O
of O
pyridine B
- I
carboxamides I
as O
DGAT O
- O
1 O
inhibitors O
is O
described O
. O

Butein B
protects O
human O
dental O
pulp O
cells O
from O
hydrogen B
peroxide I
- O
induced O
oxidative O
toxicity O
via O
Nrf2 O
pathway O
- O
dependent O
heme O
oxygenase O
- O
1 O
expressions O
. O

Here O
, O
we O
found O
that O
butein B
possesses O
cytoprotective O
effects O
on O
hydrogen B
peroxide I
( O
H2O2 B
) O
- O
induced O
dental O
cell O
death O
. O

EMIQ O
increased O
liver O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substance O
and O
8 B
- I
hydroxydeoxyguanosin I
, O
and O
TUNEL O
( O
+ O
) O
apoptotic O
cells O
, O
death O
receptor O
5 O
( O
DR5 O
) O
( O
+ O
) O
cells O
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
+ O
) O
cells O
within O
GST O
- O
P O
( O
+ O
) O
foci O
. O

The O
first O
17 O
amino B
acids I
( O
N17 O
) O
of O
Htt O
play O
a O
key O
role O
in O
regulating O
its O
toxicity O
and O
aggregation O
. O

We O
have O
defined O
amino B
acids I
within O
N17 O
that O
constitute O
the O
nuclear O
export O
sequence O
( O
NES O
) O
. O

Nuclear O
export O
of O
Htt O
is O
sensitive O
to O
leptomycin B
B I
and O
is O
reduced O
by O
knockdown O
of O
exportin O
1 O
. O

According O
to O
quantum O
mechanics O
/ O
molecular O
mechanics O
( O
QM O
/ O
MM O
) O
calculations O
on O
the O
full O
solvated O
protein O
, O
the O
enzyme O
- O
catalyzed O
glutathione B
addition O
reaction O
involves O
two O
major O
chemical O
steps O
that O
both O
proceed O
in O
the O
sextet O
state O
: O
proton O
transfer O
from O
the O
GSH B
thiol I
group O
to O
the O
Tyr39 B
anion O
and O
nucleophilic O
attack O
by O
the O
GSH B
thiolate I
leading O
to O
epoxide B
ring O
- O
opening O
. O

According O
to O
quantum O
mechanics O
/ O
molecular O
mechanics O
( O
QM O
/ O
MM O
) O
calculations O
on O
the O
full O
solvated O
protein O
, O
the O
enzyme O
- O
catalyzed O
glutathione B
addition O
reaction O
involves O
two O
major O
chemical O
steps O
that O
both O
proceed O
in O
the O
sextet O
state O
: O
proton O
transfer O
from O
the O
GSH B
thiol I
group O
to O
the O
Tyr39 B
anion O
and O
nucleophilic O
attack O
by O
the O
GSH B
thiolate I
leading O
to O
epoxide B
ring O
- O
opening O
. O

The O
second O
step O
is O
rate O
- O
limiting O
and O
is O
facilitated O
by O
the O
presence O
of O
the O
high O
- O
spin O
Mn B
( I
2 I
+ I
) I
ion O
that O
functions O
as O
a O
Lewis B
acid I
and O
stabilizes O
the O
leaving O
oxyanion O
through O
direct O
coordination O
. O

Cardioprotective O
potential O
of O
N B
, I
alpha I
- I
L I
- I
rhamnopyranosyl I
vincosamide I
, O
an O
indole B
alkaloid I
, O
isolated O
from O
the O
leaves O
of O
Moringa O
oleifera O
in O
isoproterenol B
induced O
cardiotoxic O
rats O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

There O
has O
been O
much O
recent O
interest O
in O
lysophosphatidic B
acid I
( O
LPA B
) O
signaling O
through O
one O
of O
its O
receptors O
, O
LPA1 O
, O
in O
fibrotic O
diseases O
, O
but O
the O
mechanisms O
by O
which O
LPA B
- O
LPA1 O
signaling O
promotes O
pathological O
fibrosis O
remain O
to O
be O
fully O
elucidated O
. O

Well O
structured O
: O
As O
a O
new O
triose B
phosphate I
isomerase O
( O
TIM O
) O
barrel O
- O
fold O
prenyl O
transferase O
, O
PcrB O
catalyzes O
the O
production O
of O
heptaprenylglyceryl B
phosphate I
from O
heptaprenyl B
diphosphate I
and O
glycerol B
- I
1 I
- I
phosphate I
. O

Well O
structured O
: O
As O
a O
new O
triose B
phosphate I
isomerase O
( O
TIM O
) O
barrel O
- O
fold O
prenyl O
transferase O
, O
PcrB O
catalyzes O
the O
production O
of O
heptaprenylglyceryl B
phosphate I
from O
heptaprenyl B
diphosphate I
and O
glycerol B
- I
1 I
- I
phosphate I
. O

Well O
structured O
: O
As O
a O
new O
triose B
phosphate I
isomerase O
( O
TIM O
) O
barrel O
- O
fold O
prenyl O
transferase O
, O
PcrB O
catalyzes O
the O
production O
of O
heptaprenylglyceryl B
phosphate I
from O
heptaprenyl B
diphosphate I
and O
glycerol B
- I
1 I
- I
phosphate I
. O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate B
, O
sum O
perfluoroalkyl B
sulfonates I
, O
perfluorooctane B
sulfonate I
, O
perfluorooctanoic B
acid I
, O
and O
perfluorodecanoic B
acid I
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate B
, O
sum O
perfluoroalkyl B
sulfonates I
, O
perfluorooctane B
sulfonate I
, O
perfluorooctanoic B
acid I
, O
and O
perfluorodecanoic B
acid I
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate B
, O
sum O
perfluoroalkyl B
sulfonates I
, O
perfluorooctane B
sulfonate I
, O
perfluorooctanoic B
acid I
, O
and O
perfluorodecanoic B
acid I
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

The O
authors O
investigated O
the O
relationship O
between O
PFCs O
( O
including O
sum O
perfluorocarboxylate B
, O
sum O
perfluoroalkyl B
sulfonates I
, O
perfluorooctane B
sulfonate I
, O
perfluorooctanoic B
acid I
, O
and O
perfluorodecanoic B
acid I
) O
and O
the O
clinocopathologic O
and O
immune O
parameters O
in O
a O
highly O
exposed O
population O
( O
n O
= O
79 O
) O
of O
Atlantic O
bottlenose O
dolphins O
( O
mean O
sum O
PFCs O
= O
1970 O
ng O
/ O
ml O
; O
range O
574 O
- O
8670 O
ng O
/ O
ml O
) O
sampled O
from O
2003 O
to O
2005 O
near O
Charleston O
, O
South O
Carolina O

While O
conducting O
toxicity O
tests O
with O
nano O
titanium B
dioxide I
, O
the O
authors O
found O
that O
test O
suspensions O
were O
being O
contaminated O
with O
aluminum B
and O
titanium B
from O
tip O
erosion O
during O
direct O
sonication O
. O

Bioisosterism O
of O
alpha B
- I
amino I
acids I
is O
often O
accomplished O
by O
replacing O
the O
alpha B
- I
carboxylate I
with O
one O
of O
the O
many O
known O
carboxylic B
acid I
bioisosteres O
. O

The O
reported O
bioisosteres O
share O
the O
following O
essential O
structural O
features O
for O
mimicking O
alpha B
- I
amino I
acids I
: O
an O
aromatic O
ring O
system O
joined O
to O
a O
lactam O
ring O
system O
with O
an O
acidic O
feature O
next O
to O
the O
lactam B
carbonyl I
, O
where O
this O
acidic O
feature O
together O
with O
the O
lactam B
carbonyl I
can O
mimic O
the O
alpha O
- O
carboxylate O
, O
and O
the O
lactam O
nitrogen O
together O
with O
the O
aromatic O
ring O
system O
can O
mimic O
the O
alpha B
- I
ammonium I
. O

The O
reported O
bioisosteres O
share O
the O
following O
essential O
structural O
features O
for O
mimicking O
alpha B
- I
amino I
acids I
: O
an O
aromatic O
ring O
system O
joined O
to O
a O
lactam O
ring O
system O
with O
an O
acidic O
feature O
next O
to O
the O
lactam B
carbonyl I
, O
where O
this O
acidic O
feature O
together O
with O
the O
lactam B
carbonyl I
can O
mimic O
the O
alpha O
- O
carboxylate O
, O
and O
the O
lactam O
nitrogen O
together O
with O
the O
aromatic O
ring O
system O
can O
mimic O
the O
alpha B
- I
ammonium I
. O

The O
majority O
of O
these O
heterocycles O
can O
be O
prepared O
from O
three O
common O
corresponding O
starting O
materials O
: O
the O
corresponding O
anilines B
, O
isatins B
or O
anthranilic B
esters I
. O

We O
tested O
whether O
antiresorptive O
therapies O
result O
in O
higher O
fasting O
glucose B
, O
increased O
weight O
, O
or O
greater O
diabetes O
incidence O
in O
post O
- O
hoc O
analyses O
of O
three O
randomized O
, O
placebo O
- O
controlled O
trials O
in O
postmenopausal O
women O
: O
Fracture O
Intervention O
Trial O
( O
FIT O
) O
( O
N O
= O
6151 O
) O
of O
alendronate B
( O
4 O
years O
) O
, O
Health O
Outcomes O
and O
Reduced O
Incidence O
with O
Zoledronic B
Acid I
Once O
Yearly O
Pivotal O
Fracture O
Trial O
( O
HORIZON O
- O
PFT O
) O
( O
N O
= O
7113 O
) O
of O
zoledronic B
acid I
( O

We O
tested O
whether O
antiresorptive O
therapies O
result O
in O
higher O
fasting O
glucose B
, O
increased O
weight O
, O
or O
greater O
diabetes O
incidence O
in O
post O
- O
hoc O
analyses O
of O
three O
randomized O
, O
placebo O
- O
controlled O
trials O
in O
postmenopausal O
women O
: O
Fracture O
Intervention O
Trial O
( O
FIT O
) O
( O
N O
= O
6151 O
) O
of O
alendronate B
( O
4 O
years O
) O
, O
Health O
Outcomes O
and O
Reduced O
Incidence O
with O
Zoledronic B
Acid I
Once O
Yearly O
Pivotal O
Fracture O
Trial O
( O
HORIZON O
- O
PFT O
) O
( O
N O
= O
7113 O
) O
of O
zoledronic B
acid I
( O

Treatment O
of O
the O
silicon B
base O
and O
carbon B
nanotubes O
with O
hydrofluoric B
acid I
and O
a O
strong O
oxidizer O
( O
thionyl B
chloride I
) O
leads O
to O
a O
significant O
improvement O
in O
performance O
. O

Treatment O
of O
the O
silicon B
base O
and O
carbon B
nanotubes O
with O
hydrofluoric B
acid I
and O
a O
strong O
oxidizer O
( O
thionyl B
chloride I
) O
leads O
to O
a O
significant O
improvement O
in O
performance O
. O

The O
regulation O
of O
Runx2 O
by O
FGF2 O
and O
connexin43 O
requires O
the O
inositol B
polyphosphate I
/ O
protein O
kinase O
C O
delta O
cascade O
. O

In O
this O
study O
, O
we O
examined O
the O
contribution O
of O
the O
phospholipase O
C O
gamma O
1 O
/ O
inositol B
polyphosphate I
/ O
PKC O
delta O
cascade O
to O
the O
Cx43 O
- O
dependent O
transcriptional O
response O
of O
MC3T3 O
osteoblasts O
to O
FGF2 O
. O

Knockdown O
of O
expression O
and O
/ O
or O
inhibition O
of O
function O
of O
phospholipase O
C O
gamma O
1 O
, O
inositol B
polyphosphate I
multikinase O
, O
which O
generates O
InsP O
( O
4 O
) O
and O
InsP O
( O
5 O
) O
, O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
, O
which O
generates O
inositol B
pyrophosphates I
, O
prevented O
the O
ability O
of O
Cx43 O
to O
potentiate O
FGF2 O
- O
induced O
signaling O
through O
Runx2 O
. O

Knockdown O
of O
expression O
and O
/ O
or O
inhibition O
of O
function O
of O
phospholipase O
C O
gamma O
1 O
, O
inositol B
polyphosphate I
multikinase O
, O
which O
generates O
InsP O
( O
4 O
) O
and O
InsP O
( O
5 O
) O
, O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
, O
which O
generates O
inositol B
pyrophosphates I
, O
prevented O
the O
ability O
of O
Cx43 O
to O
potentiate O
FGF2 O
- O
induced O
signaling O
through O
Runx2 O
. O

Knockdown O
of O
expression O
and O
/ O
or O
inhibition O
of O
function O
of O
phospholipase O
C O
gamma O
1 O
, O
inositol B
polyphosphate I
multikinase O
, O
which O
generates O
InsP O
( O
4 O
) O
and O
InsP O
( O
5 O
) O
, O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
, O
which O
generates O
inositol B
pyrophosphates I
, O
prevented O
the O
ability O
of O
Cx43 O
to O
potentiate O
FGF2 O
- O
induced O
signaling O
through O
Runx2 O
. O

Conversely O
, O
overexpression O
of O
phospholipase O
C O
gamma O
1 O
and O
inositol B
hexakisphosphate I
kinase O
1 O
/ O
2 O
enhanced O
FGF2 O
activation O
of O
Runx2 O
and O
the O
effect O
of O
Cx43 O
overexpression O
on O
this O
response O
. O

These O
data O
reveal O
that O
FGF2 O
- O
signaling O
involves O
the O
inositol B
polyphosphate I
cascade O
, O
including O
IP6K O
, O
and O
demonstrate O
that O
IP6K O
regulates O
Runx2 O
and O
osteoblast O
gene O
expression O
. O

Additionally O
, O
these O
data O
implicate O
the O
water O
- O
soluble O
inositol B
polyphosphates I
as O
mediators O
of O
the O
Cx43 O
- O
dependent O
amplification O
of O
the O
osteoblast O
response O
to O
FGF2 O
, O
and O
suggest O
that O
these O
low O
molecular O
weight O
second O
messengers O
may O
be O
biologically O
relevant O
mediators O
of O
osteoblast O
function O
that O
are O
communicated O
by O
Cx43 O
- O
gap O
junctions O
. O

Repression O
of O
farnesyltransferase O
( O
FNTA O
) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin B
A I
caused O
elevation O
of O
ApoA O
- O
I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA O
- O
I O
and O
cholesterol B
ester I
transfer O
protein O
transgenes O
. O

Repression O
of O
farnesyltransferase O
( O
FNTA O
) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin B
A I
caused O
elevation O
of O
ApoA O
- O
I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA O
- O
I O
and O
cholesterol B
ester I
transfer O
protein O
transgenes O
. O

incubated O
with O
phenobarbital B
- O
treated O
rat O
liver O
microsomes O
. O

Controlled O
assembly O
and O
release O
of O
retinoic B
acid I
based O
on O
the O
layer O
- O
by O
- O
layer O
method O
. O

Direct O
condensation O
of O
3 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
methylhomophthalic I
acid I
( O
1 O
) O
with O
cinnamoyl B
chloride I
at O
elevated O
temperature O
under O
inert O
conditions O
afforded O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styrylisocoumarin I
( O
2 O
) O
. O

Hydrolysis O
of O
isocoumarin B
to O
keto B
acid I
( O
3 O
) O
followed O
by O
reduction O
and O
cyclodehydration O
of O
hydroxy B
acid I
analog O
( O
4 O
) O
afforded O
( B
+ I
/ I
- I
) I
- I
6 I
, I
8 I
- I
dimethoxy I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
( O
5 O
) O
. O

Hydrolysis O
of O
isocoumarin B
to O
keto B
acid I
( O
3 O
) O
followed O
by O
reduction O
and O
cyclodehydration O
of O
hydroxy B
acid I
analog O
( O
4 O
) O
afforded O
( B
+ I
/ I
- I
) I
- I
6 I
, I
8 I
- I
dimethoxy I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
( O
5 O
) O
. O

Demethylation O
of O
the O
latter O
using O
anhydrous O
aluminum B
chloride I
/ O
ethane B
thiol I
furnished O
the O
title O
isocoumarin B
( O
6 O
) O
. O

Demethylation O
of O
the O
latter O
using O
anhydrous O
aluminum B
chloride I
/ O
ethane B
thiol I
furnished O
the O
title O
isocoumarin B
( O
6 O
) O
. O

Fasciospyrinadine B
, O
a O
novel O
sesquiterpene B
pyridine B
alkaloid I
from O
a O
Guangxi O
sponge O
Fasciospongia O
sp O
. O

Fasciospyrinadine B
( O
1 O
) O
, O
a O
novel O
sesquiterpene B
pyridine B
alkaloid I
with O
a O
previously O
unreported O
skeleton O
featuring O
a O
monocyclicfarnesane B
moiety O
attached O
to O
a O
3 B
- I
methylenepyridine I
residue O
, O
was O
isolated O
from O
the O
sponge O
Fasciospongia O
sp O
. O
from O
Weizhou O
Island O
, O
Guangxi O
Autonomous O
Region O
. O

The O
resolution O
of O
aglinin B
A I
epimers O
and O
their O
NMR O
assignments O
. O

Aglinin B
A I
( O
1 O
) O
is O
a O
mixture O
of O
C O
( O
24 O
) O
- O
epimeric O
20S B
, I
24 I
- I
epoxy I
- I
24 I
, I
25 I
- I
dihydroxy I
- I
3 I
, I
4 I
- I
secodammar I
- I
4 I
( I
28 I
) I
- I
en I
- I
3 I
- I
oic I
acid I
and O
present O
in O
plants O
of O
the O
family O
Meliaceae O
. O

This O
protozoan O
parasite O
relies O
on O
inosine B
5 I
' I
- I
monophosphate I
dehydrogenase O
( O
IMPDH O
) O
for O
the O
production O
of O
guanine B
nucleotides I
. O

Activation O
of O
AMP B
- O
activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
beta O
Mediate O
Ursolic B
Acid I
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells O
. O

Despite O
the O
antitumour O
effect O
of O
ursolic B
acid I
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O

Ursolic B
acid I
significantly O
exerted O
cytotoxicity O
, O
increased O
the O
sub O
- O
G1 O
population O
and O
the O
number O
of O
ethidium B
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase O
( O
TdT O
) O
mediated O
dUTP B
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O

Interestingly O
, O
ursolic B
acid I
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3 O
beta O
at O
inactive O
form O
serine B
9 O
, O
whereas O
ursolic B
acid I
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O

Interestingly O
, O
ursolic B
acid I
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3 O
beta O
at O
inactive O
form O
serine B
9 O
, O
whereas O
ursolic B
acid I
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O

Conversely O
, O
AMPK O
inhibitor O
compound B
C I
or O
GSK3 O
beta O
inhibitor O
SB216763 B
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic B
acid I
in O
HepG2 O
cells O
. O

Conversely O
, O
AMPK O
inhibitor O
compound B
C I
or O
GSK3 O
beta O
inhibitor O
SB216763 B
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic B
acid I
in O
HepG2 O
cells O
. O

Furthermore O
, O
proteosomal O
inhibitor O
MG132 B
suppressed O
AMPK O
activation O
, O
GSK3 O
beta O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG O
- O
1 O
induced O
by O
ursolic B
acid I
in O
HepG2 O
cells O
. O

Overall O
, O
our O
findings O
suggest O
that O
ursolic B
acid I
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3 O
beta O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O

RbgA O
, O
unlike O
many O
members O
of O
the O
Ras O
superfamily O
of O
GTPases O
, O
lacks O
a O
defined O
catalytic O
residue O
for O
carrying O
out O
guanosine B
triphosphate I
( O
GTP B
) O
hydrolysis O
. O

With O
carboxylic B
acid I
functionalized O
DWCNT O
TFTs O
, O
we O
obtained O
excellent O
gate O
modulation O
( O
on O
/ O
off O
ratio O
as O
high O
as O
4000 O
) O
with O
relatively O
high O
ON O
currents O
at O
a O
CNT O
areal O
density O
as O
low O
as O
35 O
ng O
/ O
cm O
( O
2 O
) O
. O

The O
proportions O
of O
SIS B
copolymer O
, O
tackifying O
resin O
and O
plasticizer O
were O
selected O
as O
the O
independent O
variables O
while O
tack O
force O
, O
peel O
strength O
of O
the O
patch O
and O
skin O
penetrability O
of O
methyl B
salicylate I
were O
selected O
as O
the O
dependent O
variables O
. O

The O
macrocyclic B
tetrapeptide I
natural O
product O
CJ B
- I
15 I
, I
208 I
( O
cyclo B
[ I
Phe I
- I
d I
- I
Pro I
- I
Phe I
- I
Trp I
] I
) O
exhibited O
both O
dose O
- O
dependent O
antinociception O
and O
kappa O
opioid O
receptor O
( O
KOR O
) O
antagonist O
activity O
after O
oral O
administration O
. O

Semi O
- O
Synthetic O
Mithramycin B
SA I
Derivatives O
with O
Improved O
AntiCancer O
Activity O
. O

Mithramycin B
SA I
is O
a O
previously O
discovered O
analogue O
produced O
by O
the O
M7W1 O
mutant O
strain O
alongside O
the O
improved O
mithramycin B
analogues O
mithramycin B
SK I
and O
mithramycin B
SDK I
. O

Mithramycin B
SA I
is O
a O
previously O
discovered O
analogue O
produced O
by O
the O
M7W1 O
mutant O
strain O
alongside O
the O
improved O
mithramycin B
analogues O
mithramycin B
SK I
and O
mithramycin B
SDK I
. O

Mithramycin B
SA I
is O
a O
previously O
discovered O
analogue O
produced O
by O
the O
M7W1 O
mutant O
strain O
alongside O
the O
improved O
mithramycin B
analogues O
mithramycin B
SK I
and O
mithramycin B
SDK I
. O

Mithramycin B
SA I
shows O
decreased O
anti O
- O
cancer O
activity O
compared O
to O
mithramycin B
and O
has O
a O
shorter O
, O
two O
carbon B
aglycon O
side O
chain O
that O
is O
terminated O
in O
a O
carboxylic B
acid I
. O

Mithramycin B
SA I
shows O
decreased O
anti O
- O
cancer O
activity O
compared O
to O
mithramycin B
and O
has O
a O
shorter O
, O
two O
carbon B
aglycon O
side O
chain O
that O
is O
terminated O
in O
a O
carboxylic B
acid I
. O

It O
was O
therefore O
decided O
to O
further O
functionalize O
this O
side O
chain O
through O
reactions O
with O
the O
terminal O
carboxylic B
acid I
in O
an O
effort O
to O
enhance O
the O
interaction O
with O
the O
DNA O
phosphate B
backbone O
and O
improve O
the O
anti O
- O
cancer O
activity O
. O

This O
side O
chain O
was O
modified O
with O
a O
variety O
of O
molecules O
increasing O
the O
anti O
- O
cancer O
activity O
to O
a O
comparable O
level O
to O
mithramycin B
SK I
. O

This O
work O
shows O
the O
ability O
to O
transform O
the O
previously O
useless O
mithramycin B
SA I
into O
a O
valuable O
molecule O
and O
opens O
the O
door O
to O
further O
functionalization O
and O
semi O
- O
synthetic O
modification O
for O
the O
development O
of O
molecules O
with O
increased O
specificity O
and O
/ O
or O
drug O
formulation O
. O

Gene O
expression O
analysis O
revealed O
that O
ORX O
mice O
fed O
HFD O
showed O
significantly O
decreased O
expression O
of O
microsomal O
triglyceride B
transfer O
protein O
, O
lipin O
- O
1 O
, O
peroxisome O
proliferator O
- O
activated O
receptor O
( O
PPAR O
) O
- O
alpha O
and O
PPAR O
- O
gamma O
coactivator O
1 O
- O
alpha O
, O
and O
significantly O
increased O
sterol B
regulatory O
element O
- O
binding O
protein O
- O
1 O
, O
diacylglycerol B
acyltransferase O
- O
2 O
and O
fatty B
acid I
synthase O
. O

Mitochondrial O
electron O
transport O
is O
inhibited O
by O
disappearance O
of O
metallothionein O
in O
human O
bronchial O
epithelial O
cells O
following O
exposure O
to O
silver B
nitrate I
. O

In O
a O
separate O
experiment O
, O
we O
found O
that O
hydrogen B
peroxide I
( O
H2O2 B
) O
at O
concentrations O
as O
low O
as O
0 O
. O
001 O
% O
( O
equivalent O
to O
the O
concentration O
of O
H2O2 B
in O
Ag B
- O
exposed O
cells O
) O
removed O
Ag B
from O
MT O
. O

Nitric B
oxide I
generated O
by O
the O
compound O
RuBPY B
promotes O
the O
vascular O
smooth O
cell O
membrane O
hyperpolarization O
. O

The O
cis B
- I
[ I
Ru I
( I
bpy I
) I
( I
2 I
) I
( I
py I
) I
NO I
( I
2 I
) I
] I
( I
PF I
( I
6 I
) I
) I
specie O
( O
RuBPY B
) O
has O
been O
used O
as O
nitric B
oxide I
( O
NO B
) O
delivery O
agent O
. O

This O
study O
aimed O
to O
evaluate O
the O
NO B
specie O
generated O
by O
RuBPY B
as O
compared O
to O
NO B
released O
from O
sodium B
nitroprusside I
( O
SNP B
) O
and O
to O
study O
the O
cellular O
mechanisms O
specially O
focusing O
the O
activation O
of O
soluble O
guanylyl B
- O
cyclase O
( O
sGC O
) O
, O
K B
( I
+ I
) I
channels O
and O
the O
cell O
membrane O
hyperpolarization O
, O
which O
are O
the O
main O
targets O
for O
NO B
- O
inducing O
vascular O
relaxation O
. O

RuBPY B
released O
only O
radicalar B
NO I
( O
0 O
) O
and O
SNP B
released O
both O
NO B
( I
- I
) I
and O
NO B
( O
0 O
) O
. O

Cryptotanshinone B
and O
dihydrotanshinone B
I I
exhibit O
strong O
inhibition O
towards O
human O
liver O
microsome O
( O
HLM O
) O
- O
catalyzed O
propofol B
glucuronidation O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
inhibitory O
situation O
of O
cryptotanshinone B
and O
dihydrotanshinone B
I I
towards O
UGT O
enzyme O
- O
catalyzed O
propofol B
glucuronidation O
. O

In O
vitro O
the O
human O
liver O
microsome O
( O
HLM O
) O
incubation O
system O
was O
used O
, O
and O
the O
results O
showed O
that O
cryptotanshinone B
and O
dihydrotanshinone B
I I
exhibited O
dose O
- O
dependent O
inhibition O
towards O
HLM O
- O
catalyzed O
propofol B
glucuronidation O
. O

Dixon O
plot O
and O
Lineweaver O
- O
Burk O
plot O
showed O
that O
the O
inhibition O
type O
was O
best O
fit O
to O
competitive O
inhibition O
type O
for O
both O
cryptotanshinone B
and O
dihydrotanshinone B
I I
. O

The O
second O
plot O
using O
the O
slopes O
from O
the O
Lineweaver O
- O
Burk O
plot O
versus O
the O
concentrations O
of O
cryptotanshinone B
or O
dihydrotanshinone B
I I
was O
employed O
to O
calculate O
the O
inhibition O
parameters O
( O
Ki O
) O
to O
be O
0 O
. O
4 O
and O
1 O
. O
7 O
mu O
M O
, O
respectively O
. O

Using O
the O
reported O
maximum O
plasma O
concentration O
( O
Cmax O
) O
, O
the O
altered O
in O
vivo O
exposure O
of O
propofol B
increased O
by O
10 O
% O
and O
8 O
. O
2 O
% O
for O
the O
co O
- O
administration O
of O
dihydrotanshinone B
I I
and O
cryptotanshinone B
, O
respectively O
. O

All O
these O
results O
indicated O
the O
possible O
danshen O
- O
propofol B
interaction O
due O
to O
the O
inhibition O
of O
dihydrotanshinone B
I I
and O
cryptotanshinone B
towards O
the O
glucuronidation O
reaction O
of O
propofol B
. O

A O
facile O
electrodeposition O
technique O
was O
utilized O
to O
deposit O
single O
- O
walled O
carbon B
nanotubes O
( O
SWNTs O
) O
with O
cadmium B
telluride I
( O
CdTe B
) O
with O
well O
- O
controlled O
size O
, O
density O
, O
surface O
morphology O
, O
and O
composition O
. O

Each O
was O
up O
- O
regulated O
at O
a O
different O
time O
following O
stimulation O
of O
the O
pepper O
leaves O
by O
Phytophthora O
capcisi O
and O
abiotic O
stresses O
including O
salicylic B
acid I
, O
methyl B
jasmonate I
, O
abscisic B
acid I
, O
wounding O
and O
cold O
treatment O
. O

Each O
was O
up O
- O
regulated O
at O
a O
different O
time O
following O
stimulation O
of O
the O
pepper O
leaves O
by O
Phytophthora O
capcisi O
and O
abiotic O
stresses O
including O
salicylic B
acid I
, O
methyl B
jasmonate I
, O
abscisic B
acid I
, O
wounding O
and O
cold O
treatment O
. O

Each O
was O
up O
- O
regulated O
at O
a O
different O
time O
following O
stimulation O
of O
the O
pepper O
leaves O
by O
Phytophthora O
capcisi O
and O
abiotic O
stresses O
including O
salicylic B
acid I
, O
methyl B
jasmonate I
, O
abscisic B
acid I
, O
wounding O
and O
cold O
treatment O
. O

Separation O
was O
by O
a O
reversed O
- O
phase O
Chiralcel O
OD O
- O
RH O
column O
, O
under O
isocratic O
conditions O
using O
a O
mixture O
of O
acetonitrile B
- O
2 O
mM O
ammonium B
acetate I
in O
water O
( O
60 O
/ O
40 O
, O
v O
/ O
v O
) O
as O
the O
mobile O
phase O
at O
a O
flow O
rate O
of O
0 O
. O
4 O
mL O
/ O
min O
. O

A O
new O
aliphatic O
enone O
, O
( B
17Z I
, I
20Z I
) I
- I
hexacosa I
- I
17 I
, I
20 I
- I
dien I
- I
9 I
- I
one I
( O
3 O
) O
, O
and O
one O
new O
bisindole B
alkaloid I
, O
gangenoid B
( O
6 O
) O
, O
together O
with O
seven O
known O
compounds O
were O
isolated O
from O
the O
roots O
and O
aerial O
parts O
of O
Desmodium O
gangeticum O
( O
family O
: O
Leguminosae O
) O
. O

Osteoblasts O
survive O
the O
arsenic B
trioxide I
treatment O
by O
activation O
of O
ATM O
- O
mediated O
pathway O
. O

Arsenic B
trioxide I
( O
ATO B
) O
is O
widely O
used O
in O
tumor O
treatment O
, O
but O
excessive O
arsenic B
exposure O
can O
have O
adverse O
effects O
. O

The O
use O
of O
reverse O
micellar O
medium O
not O
only O
enhanced O
the O
conversion O
rate O
, O
but O
also O
showed O
selectivity O
towards O
mono O
- O
coupled O
product O
in O
aryl B
chloride I
- O
aniline B
coupling O
reactions O
. O

Thyroid B
hormone I
levels O
within O
reference O
range O
are O
associated O
with O
heart O
rate O
, O
cardiac O
structure O
and O
function O
in O
middle O
- O
aged O
men O
and O
women O
. O

We O
investigated O
whether O
between O
- O
subject O
variation O
in O
thyroid B
hormone I
levels O
within O
the O
euthyroid O
range O
is O
also O
associated O
with O
heart O
rate O
and O
echocardiographic O
heart O
function O
and O
structure O
. O

Conclusion O
We O
have O
demonstrated O
a O
strong O
positive O
association O
between O
thyroid B
hormone I
levels O
within O
the O
euthyroid O
range O
and O
heart O
rate O
, O
and O
more O
subtle O
effects O
on O
cardiac O
function O
and O
structure O
. O

More O
specifically O
, O
we O
suggest O
smaller O
LV O
cavity O
size O
( O
with O
increased O
relative O
wall O
thickness O
) O
, O
an O
enhanced O
atrial O
and O
ventricular O
contraction O
and O
LV O
relaxation O
with O
higher O
circulating O
thyroid B
hormones I
. O

These O
results O
illustrate O
that O
variation O
of O
thyroid B
hormone I
levels O
even O
within O
the O
reference O
range O
exerts O
effects O
on O
the O
heart O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic B
compounds O
( O
furan B
, O
2 B
- I
furfural I
, O
furfuryl B
alcohol I
, O
2 B
- I
pentylfuran I
, O
5 B
- I
hydroxymethylfurfura I
) O
in O
breaded O
fish O
products O
. O

This O
allows O
direct O
comparison O
with O
similar O
effects O
found O
for O
other O
environmental O
contaminants O
like O
polychlorinated B
biphenyls I
and O
brominated O
flame O
- O
retardants O
. O

The O
increase O
in O
ROS O
formation O
and O
cell O
death O
was O
assayed O
using O
the O
fluorescent O
probe O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
( O
DCFH B
- I
DA I
) O
and O
the O
trypan B
blue I
exclusion O
assay O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctane B
sulfonylamide I
( O
PFOSA B
) O
and O
the O
fluorotelomer B
alcohol I
1H B
, I
1H I
, I
2H I
, I
2H I
- I
perfluorodecanol I
( O
FTOH B
8 I
: I
2 I
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctane B
sulfonylamide I
( O
PFOSA B
) O
and O
the O
fluorotelomer B
alcohol I
1H B
, I
1H I
, I
2H I
, I
2H I
- I
perfluorodecanol I
( O
FTOH B
8 I
: I
2 I
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctane B
sulfonylamide I
( O
PFOSA B
) O
and O
the O
fluorotelomer B
alcohol I
1H B
, I
1H I
, I
2H I
, I
2H I
- I
perfluorodecanol I
( O
FTOH B
8 I
: I
2 I
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

PFOS B
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
and O
PFOSA B
induced O
a O
concentration O
dependent O
increase O
in O
ROS O
formation O
with O
EC O
( O
50 O
) O
- O
values O
of O
27 O
+ O
/ O
- O
9 O
. O
0 O
, O
25 O
+ O
/ O
- O
11 O
and O
57 O
+ O
/ O
- O
19 O
mu O
M O
respectively O
. O

Carboxy B
- O
terminal O
deletion O
of O
32 O
amino B
acids I
in O
the O
beta O
- O
alpha O
MTL O
construct O
resulted O
in O
loss O
of O
agonist O
activity O
. O

Geranylgeranylaceton B
( O
GGA B
) O
is O
an O
acyclic B
polyisoprenoid I
that O
induces O
expression O
of O
heat O
shock O
protein O
( O
HSP O
) O
70 O
, O
a O
soluble O
intracellular O
chaperone O
protein O
expressed O
in O
various O
tissues O
, O
protecting O
cells O
against O
stress O
conditions O
. O

The O
role O
of O
silver B
and O
vanadium B
release O
in O
the O
toxicity O
of O
silver B
vanadate I
nanowires O
toward O
Daphnia O
similis O
. O

Recently O
, O
a O
new O
type O
of O
silver B
vanadate I
nanowire O
decorated O
with O
silver B
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
with O
promising O
antimicrobial O
activity O
against O
different O
pathogenic O
bacteria O
was O
described O
. O

Silver B
vanadate I
nanowires O
decorated O
with O
silver B
nanoparticles O
( O
SVSN O
- O
LQES1 O
) O
are O
acutely O
toxic O
to O
D O
. O
similis O
. O

They O
were O
also O
characterized O
by O
the O
absence O
of O
myrtenyl B
acetate I
. O

Groups O
I O
( O
78 O
% O
of O
the O
samples O
) O
and O
II O
were O
differentiated O
on O
the O
basis O
of O
the O
contents O
of O
alpha B
- I
pinene I
, O
linalool B
, O
and O
linalyl B
acetate I
. O

Effect O
of O
doping O
on O
the O
magnetostructural O
ordered O
phase O
of O
iron B
arsenides I
: O
a O
comparative O
study O
of O
the O
resistivity O
anisotropy O
in O
doped O
BaFe2As2 B
with O
doping O
into O
three O
different O
sites O
. O

Efficient O
two O
- O
electron O
reduction O
of O
dioxygen B
to O
hydrogen B
peroxide I
with O
one O
- O
electron O
reductants O
with O
a O
small O
overpotential O
catalyzed O
by O
a O
cobalt B
chlorin I
complex O
. O

Efficient O
two O
- O
electron O
reduction O
of O
dioxygen B
to O
hydrogen B
peroxide I
with O
one O
- O
electron O
reductants O
with O
a O
small O
overpotential O
catalyzed O
by O
a O
cobalt B
chlorin I
complex O
. O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile B
( O
PhCN B
) O
at O
298 O
K O
. O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile B
( O
PhCN B
) O
at O
298 O
K O
. O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile B
( O
PhCN B
) O
at O
298 O
K O
. O

The O
catalytic O
reactivity O
of O
Co B
( I
II I
) I
( I
Ch I
) I
was O
much O
higher O
than O
that O
of O
a O
cobalt B
porphyrin I
complex O
( O
Co B
( I
II I
) I
( I
OEP I
) I
, O
OEP B
( I
2 I
- I
) I
= O
octaethylporphyrin B
dianion O
) O
, O
which O
is O
a O
typical O
porphyrinoid O
complex O
. O

A O
divergent O
approach O
to O
the O
synthesis O
of O
the O
yohimbinoid B
alkaloids I
venenatine B
and O
alstovenine B
. O

The O
yohimbinoid B
alkaloids I
continue O
to O
receive O
considerable O
attention O
from O
the O
synthetic O
community O
because O
of O
their O
interesting O
chemical O
structures O
and O
varied O
biological O
activity O
. O

Some O
beta B
- I
lactam I
antibiotics O
interact O
with O
Oat3 O
, O
and O
penicillin B
G I
exhibits O
a O
strong O
dependence O
on O
Oat3 O
for O
renal O
elimination O
. O

Several O
hydroxylated B
PBDEs I
( O
OH B
- I
PBDEs I
) O
were O
detected O
in O
serum O
samples O
from O
the O
two O
fish O
species O
, O
but O
no O
methoxylated O
PBDEs B
were O
found O
. O

Three O
groups O
of O
catalysts O
clearly O
show O
affinities O
toward O
: O
( O
1 O
) O
hydrogen B
formation O
[ O
on O
early O
transition B
metals I
( O
Ti B
, O
V B
, O
Cr B
, O
Mn B
, O
Zr B
, O
Nb B
, O
Mo B
, O
Hf B
, O
Ta B
, O
We B
, O
and O
Re B
) O
and O
platinum B
group O
metals O
( O
Ru B
, O
Rh B
, O
Ir B
, O
and O
Pt B
) O
] O
, O
( O
2 O
) O
sorbitol B
formation O
[ O
on O
late O
transition B
metals I
( O
Fe B
, O
Co B
, O
Ni B
, O
Cu B
, O
Pd B
, O
Au B
, O
and O
Ag B
) O
and O
Al B
( O
sp O
metal O
) O
] O
, O
and O
( O
3 O
) O
sorbitol B
and O
2 B
- I

Three O
groups O
of O
catalysts O
clearly O
show O
affinities O
toward O
: O
( O
1 O
) O
hydrogen B
formation O
[ O
on O
early O
transition B
metals I
( O
Ti B
, O
V B
, O
Cr B
, O
Mn B
, O
Zr B
, O
Nb B
, O
Mo B
, O
Hf B
, O
Ta B
, O
We B
, O
and O
Re B
) O
and O
platinum B
group O
metals O
( O
Ru B
, O
Rh B
, O
Ir B
, O
and O
Pt B
) O
] O
, O
( O
2 O
) O
sorbitol B
formation O
[ O
on O
late O
transition B
metals I
( O
Fe B
, O
Co B
, O
Ni B
, O
Cu B
, O
Pd B
, O
Au B
, O
and O
Ag B
) O
and O
Al B
( O
sp O
metal O
) O
] O
, O
and O
( O
3 O
) O
sorbitol B
and O
2 B
- I

Controlled O
synthesis O
of O
amino B
acid I
- O
based O
pH O
- O
responsive O
chiral O
polymers O
and O
self O
- O
assembly O
of O
their O
block O
copolymers O
. O

The O
synthesis O
and O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
of O
amino B
acid I
- O
based O
chiral O
monomers O
, O
namely O
Boc B
- I
L I
- I
leucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEMA I
, O
1a O
) O
, O
Boc B
- I
L I
- I
leucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Leu I
- I
HEA I
, O
1b O
) O
, O
Boc B
- I
L I
- I
isoleucine I
methacryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I

Deprotection O
of O
Boc B
groups O
in O
the O
homopolymers O
and O
block O
copolymers O
under O
acidic O
conditions O
produced O
cationic O
, O
pH O
- O
responsive O
polymers O
with O
primary B
amine I
moieties O
at O
the O
side O
chains O
. O

DFT O
calculations O
show O
that O
mercaptopropionic B
acid I
( O
MPA B
) O
and O
cysteine B
( O
Cys B
) O
exhibit O
characteristic O
binding O
configurations O
on O
TiO B
( I
2 I
) I
surfaces O
. O

While O
no O
nonsynonymous O
substitutions O
were O
found O
in O
either O
alpha O
globin O
gene O
, O
three O
amino B
acid I
substitutions O
were O
observed O
in O
the O
beta O
( O
A O
) O
globin O
. O

This O
stepwise O
colonization O
pattern O
accompanied O
by O
polarized O
beta O
( O
A O
) O
globin O
amino B
acid I
replacements O
suggest O
that O
ruddy O
ducks O
first O
acclimatized O
or O
adapted O
to O
the O
Andean O
highlands O
and O
then O
again O
to O
the O
lowlands O
. O

Biotransformation O
and O
pharmacokinetics O
of O
inositol B
hexanicotinate I
in O
rats O
. O

Inositol B
hexanicotinate I
( O
IHN B
) O
is O
an O
ester O
of O
the O
anti O
- O
hyperlipidemic O
drug O
nicotinic B
acid I
( O
NA O
) O
. O

Inositol B
hexanicotinate I
( O
IHN B
) O
is O
an O
ester O
of O
the O
anti O
- O
hyperlipidemic O
drug O
nicotinic B
acid I
( O
NA O
) O
. O

The O
percentage O
of O
patients O
with O
detectable O
bisphenol B
A I
( O
BPA B
) O
concentrations O
was O
significantly O
higher O
in O
the O
infertile O
patients O
compared O
with O
fertile O
subjects O
. O

No O
significant O
difference O
was O
found O
between O
the O
groups O
with O
regard O
to O
perfluorooctane B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
, O
mono B
- I
ethylhexyl I
phthalate I
( O
MEHP B
) O
and O
di B
- I
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
concentrations O
. O

No O
significant O
difference O
was O
found O
between O
the O
groups O
with O
regard O
to O
perfluorooctane B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
, O
mono B
- I
ethylhexyl I
phthalate I
( O
MEHP B
) O
and O
di B
- I
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
concentrations O
. O

The O
mean O
expression O
of O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
and O
peroxisome O
proliferator O
- O
activated O
receptor O
gamma O
( O
PPAR O
gamma O
) O
did O
not O
show O
significant O
differences O
between O
two O
groups O
. O

Quercetin B
ameliorate O
insulin O
resistance O
and O
up O
- O
regulates O
cellular O
antioxidants O
during O
oleic B
acid I
induced O
hepatic O
steatosis O
in O
HepG2 O
cells O
. O

Addition O
of O
2 O
. O
0mM O
oleic B
acid I
( O
OA O
) O
into O
the O
culture O
media O
induced O
fatty O
liver O
condition O
in O
HepG2 O
cells O
by O
24h O
. O

Hence O
, O
quercetin B
effectively O
reversed O
NAFLD O
symptoms O
by O
decreased O
triacyl B
glycerol I
accumulation O
, O
insulin O
resistance O
, O
inflammatory O
cytokine O
secretion O
and O
increased O
cellular O
antioxidants O
in O
OA O
induced O
hepatic O
steatosis O
in O
HepG2 O
cells O
. O

The O
male O
mammary O
gland O
: O
a O
target O
for O
the O
xenoestrogen O
bisphenol B
A I
. O

We O
also O
examined O
the O
effects O
of O
bisphenol B
A I
( O
BPA B
) O
, O
an O
estrogen B
mimic O
that O
alters O
development O
of O
the O
female O
mouse O
mammary O
gland O
. O

In O
the O
vasculature O
, O
insulin O
signaling O
plays O
a O
critical O
role O
in O
normal O
vascular O
function O
via O
endothelial O
cell O
nitric B
oxide I
production O
and O
modulation O
of O
Ca B
( I
2 I
+ I
) I
handling O
and O
sensitivity O
in O
vascular O
smooth O
muscle O
cells O
. O

Photocatalytic O
properties O
of O
graphdiyne B
and O
graphene B
modified O
TiO B
2 I
: O
from O
theory O
to O
experiment O
. O

The O
chemical O
structure O
and O
electronic O
properties O
of O
two O
- O
dimensional O
( O
2D O
) O
carbon B
- O
supported O
TiO B
2 I
, O
TiO B
2 I
- I
graphdiyne I
, O
and O
TiO B
2 I
- I
graphene I
composites O
have O
been O
studied O
by O
first O
- O
principles O
density O
functional O
theory O
. O

Calculation O
results O
show O
that O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composites O
possess O
superior O
charge O
separation O
and O
oxidation O
properties O
, O
having O
the O
longest O
lifetimes O
of O
photoexcited O
carriers O
among O
all O
of O
the O
2D O
composites O
containing O
TiO B
2 I
of O
different O
facets O
. O

Calculation O
results O
show O
that O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composites O
possess O
superior O
charge O
separation O
and O
oxidation O
properties O
, O
having O
the O
longest O
lifetimes O
of O
photoexcited O
carriers O
among O
all O
of O
the O
2D O
composites O
containing O
TiO B
2 I
of O
different O
facets O
. O

Our O
experimental O
results O
further O
proved O
that O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composites O
could O
be O
a O
promising O
photocatalyst O
. O

For O
photocatalytic O
degradation O
of O
methylene B
blue I
, O
the O
rate O
constant O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO B
2 I
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphene B
composite O
. O

For O
photocatalytic O
degradation O
of O
methylene B
blue I
, O
the O
rate O
constant O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO B
2 I
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphene B
composite O
. O

For O
photocatalytic O
degradation O
of O
methylene B
blue I
, O
the O
rate O
constant O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO B
2 I
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphene B
composite O
. O

For O
photocatalytic O
degradation O
of O
methylene B
blue I
, O
the O
rate O
constant O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphdiyne B
composite O
is O
1 O
. O
63 O
+ O
/ O
- O
0 O
. O
15 O
times O
that O
of O
the O
pure O
TiO B
2 I
( O
001 O
) O
and O
1 O
. O
27 O
+ O
/ O
- O
0 O
. O
12 O
times O
that O
of O
the O
TiO B
2 I
( O
001 O
) O
- O
graphene B
composite O
. O

In O
vivo O
microdialysis O
for O
the O
evaluation O
of O
transfersomes O
as O
a O
novel O
transdermal O
delivery O
vehicle O
for O
cinnamic B
acid I
. O

Abstract O
In O
this O
study O
, O
cinnamic B
acid I
- O
loaded O
transfersomes O
were O
prepared O
and O
dermal O
microdialysis O
sampling O
was O
used O
in O
Sprague O
- O
Dawley O
rats O
to O
compare O
the O
amount O
of O
drug O
released O
into O
the O
skin O
using O
transfersomes O
as O
transdermal O
carriers O
with O
that O
released O
on O
using O
conventional O
liposomes O
. O

The O
formulation O
of O
cinnamic B
acid I
- O
loaded O
transfersomes O
was O
optimized O
by O
a O
uniform O
design O
through O
in O
vitro O
transdermal O
permeation O
studies O
. O

The O
fluxes O
of O
cinnamic B
acid I
from O
transfersomes O
were O
all O
higher O
than O
those O
from O
conventional O
liposomes O
, O
and O
the O
flux O
from O
the O
optimal O
transfersome O
formulation O
was O
3 O
. O
01 O
- O
fold O
higher O
than O
that O
from O
the O
conventional O
liposomes O
( O
p O
< O
0 O
. O
05 O
) O
. O

After O
the O
administration O
of O
drug O
- O
containing O
transfersomes O
and O
liposomes O
on O
abdominal O
skin O
regions O
of O
rats O
for O
a O
period O
of O
10 O
h O
, O
the O
C O
( O
max O
) O
of O
cinnamic B
acid I
from O
the O
compared O
liposomes O
was O
3 O
. O
21 O
+ O
/ O
- O
0 O
. O
25 O
mu O
g O
/ O
mL O
and O
that O
from O
the O
transfersomes O
was O
merely O
0 O
. O
59 O
+ O
/ O
- O
0 O
. O
02 O
mu O
g O
/ O
mL O
. O

The O
results O
suggest O
that O
transfersomes O
can O
be O
used O
as O
carriers O
to O
enhance O
the O
transdermal O
delivery O
of O
cinnamic B
acid I
, O
and O
that O
these O
vehicles O
may O
penetrate O
the O
skin O
in O
the O
complete O
form O
, O
given O
their O
significant O
deformability O
. O

To O
realize O
the O
therapeutic O
potential O
of O
these O
cyclodepsipeptides O
, O
we O
probed O
the O
cellular O
effects O
of O
a O
novel O
and O
representative O
family O
member O
, O
symplostatin B
5 I
( O
1 O
) O
, O
which O
attenuated O
the O
downstream O
cellular O
effects O
of O
elastase O
in O
an O
epithelial O
lung O
airway O
model O
system O
, O
alleviating O
clinical O
hallmarks O
of O
chronic O
pulmonary O
diseases O
such O
as O
cell O
death O
, O
cell O
detachment O
, O
and O
inflammation O
. O

Cytotoxic O
constituents O
of O
ethyl B
acetate I
fraction O
from O
Dianthus O
superbus O
. O

The O
ethyl B
acetate I
fraction O
( O
EE O
- O
DS O
) O
from O
Dianthus O
superbus O
was O
found O
to O
possess O
the O
cytotoxic O
activity O
against O
cancer O
cells O
in O
previous O
study O
. O

The O
present O
study O
was O
undertaken O
in O
order O
to O
investigate O
the O
antioxidant O
and O
antiapoptotic O
activities O
of O
the O
lavender O
essential O
oils O
from O
Lavandula O
angustifolia O
ssp O
. O
angustifolia O
Mill O
. O
and O
Lavandula O
hybrida O
Rev O
. O
using O
superoxide B
dismutase O
( O
SOD O
) O
, O
glutathione B
peroxidase O
( O
GPX O
) O
and O
catalase O
( O
CAT O
) O
specific O
activities O
, O
total O
content O
of O
reduced B
glutathione I
( O
GSH B
) O
, O
malondialdehyde B
( O
MDA B
) O
level O
( O
lipid O
peroxidation O
) O
and O
DNA O
fragmentation O

The O
target O
compounds O
were O
screened O
for O
their O
in O
vivo O
anticonvulsant O
activity O
following O
maximal O
electroshock O
( O
MES O
) O
and O
subcutaneous O
pentylene B
tetrazole I
( O
scPTZ O
) O
methods O
at O
a O
small O
test O
dose O
of O
10 O
mg O
/ O
kg O
. O

The O
copolymer O
unimers O
inhibited O
P O
- O
gp O
ATPase O
activity O
in O
a O
similar O
way O
as O
Pluronic B
P85 I
, O
favoring O
DOXO B
accumulation O
in O
the O
resistant O
cell O
line O
, O
but O
not O
in O
the O
sensitive O
cell O
line O
. O

All B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
is O
the O
active O
form O
of O
vitamin B
A I
, O
known O
to O
activate O
retinoid O
receptors O
, O
especially O
the O
heterodimer O
retinoid O
X O
receptor O
( O
RXR O
) O
: O
retinoic B
acid I
receptor O
( O
RAR O
) O
that O
otherwise O
may O
play O
a O
role O
in O
regulation O
of O
some O
drug O
transporters O
. O

All B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
is O
the O
active O
form O
of O
vitamin B
A I
, O
known O
to O
activate O
retinoid O
receptors O
, O
especially O
the O
heterodimer O
retinoid O
X O
receptor O
( O
RXR O
) O
: O
retinoic B
acid I
receptor O
( O
RAR O
) O
that O
otherwise O
may O
play O
a O
role O
in O
regulation O
of O
some O
drug O
transporters O
. O

Labdane B
diterpenoids I
and O
lignans B
from O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane B
diterpenoids I
, O
calomacrins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl B
butyrolactone I
- O
type O
lignan B
, O
calomacrol B
A I
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane B
diterpenoids I
and O
six O
known O
lignans B
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane B
diterpenoids I
, O
calomacrins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl B
butyrolactone I
- O
type O
lignan B
, O
calomacrol B
A I
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane B
diterpenoids I
and O
six O
known O
lignans B
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane B
diterpenoids I
, O
calomacrins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl B
butyrolactone I
- O
type O
lignan B
, O
calomacrol B
A I
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane B
diterpenoids I
and O
six O
known O
lignans B
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

Three O
new O
labdane B
diterpenoids I
, O
calomacrins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
a O
new O
diaryl B
butyrolactone I
- O
type O
lignan B
, O
calomacrol B
A I
( O
8 O
) O
, O
as O
well O
as O
four O
known O
labdane B
diterpenoids I
and O
six O
known O
lignans B
, O
were O
isolated O
from O
the O
twigs O
and O
leaves O
of O
Calocedrus O
macrolepis O
. O

The O
addition O
of O
either O
tamoxifen B
, O
VX B
- I
710 I
, O
verapamil B
, O
or O
cyclosporin B
A I
, O
antagonists O
of O
P O
- O
gp O
, O
enhanced O
C6 B
- I
ceramide I
cytotoxicity O
in O
all O
cell O
lines O
. O

Involvement O
of O
Src O
and O
the O
actin O
cytoskeleton O
in O
the O
antitumorigenic O
action O
of O
adenosine B
dialdehyde I
. O

Treatment O
with O
adenosine B
dialdehyde I
( O
AdOx B
) O
, O
an O
inhibitor O
of O
transmethylation O
- O
suppressive O
adenosylhomocysteine B
( O
SAH B
) O
hydrolase O
( O
SAHH O
) O
, O
enhanced O
the O
level O
of O
SAH B
and O
effectively O
blocked O
the O
proliferation O
, O
migration O
, O
and O
invasion O
of O
cancer O
cells O
; O
the O
treatment O
also O
induced O
the O
differentiation O
of O
C6 O
glioma O
cells O
and O
suppressed O
the O
neovascular O
genesis O
of O
eggs O
in O
a O
dose O
- O
dependent O
manner O
. O

Synthesis O
of O
derivatives O
of O
methyl B
rosmarinate I
and O
their O
inhibitory O
activities O
against O
matrix O
metalloproteinase O
- O
1 O
( O
MMP O
- O
1 O
) O
. O

A O
series O
of O
MMP O
- O
1 O
inhibitors O
have O
been O
identified O
based O
upon O
a O
methyl B
rosmarinate I
scaffold O
using O
structure O
- O
based O
drug O
design O
methods O
. O

A O
series O
of O
novel O
benzoxepins B
6 O
was O
designed O
and O
prepared O
as O
rigid O
- O
isoCA B
- I
4 I
analogs O
according O
to O
a O
convergent O
strategy O
using O
the O
coupling O
of O
N B
- I
tosylhydrazones I
with O
aryl B
iodides I
under O
palladium B
catalysis O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

Novel O
agmatine B
dipeptide I
inhibitors O
against O
the O
West O
Nile O
virus O
NS2B O
/ O
NS3 O
protease O
: O
A O
P3 O
and O
N O
- O
cap O
optimization O
study O
. O

This O
communication O
describes O
the O
synthesis O
and O
inhibitory O
activities O
of O
thirty O
- O
seven O
novel O
C B
- O
terminal O
agmatine B
dipeptides I
used O
as O
screening O
compounds O
to O
study O
the O
structure O
- O
activity O
relationship O
between O
active O
- O
site O
peptidomimetics O
and O
the O
West O
Nile O
virus O
( O
WNV O
) O
NS2B O
/ O
NS3 O
serine B
protease O
. O

Our O
efforts O
lead O
to O
the O
discovery O
of O
a O
novel O
agmatine B
dipeptide I
inhibitor O
( O
compound O
33 O
, O
IC50 O
2 O
. O
6 O
+ O
/ O
- O
0 O
. O
3 O
mu O
M O
) O
with O
improved O
inhibitory O
activity O
in O
comparison O
to O
the O
most O
potent O
inhibitor O
described O
in O
our O
recent O
report O
[ O
IC50 O
4 O
. O
7 O
+ O
/ O
- O
1 O
. O
2 O
mu O
M O
; O
Lim O
et O
al O
. O
, O
Eur O
. O
J O
. O
Med O
. O
Chem O
. O
46 O
( O
2011 O
) O
3130 O
- O
3134 O
] O
. O

Here O
we O
describe O
polymersomes O
able O
to O
encapsulate O
up O
to O
6 O
% O
( O
w O
/ O
w O
) O
of O
doxorubicin B
( O
DOX B
) O
together O
with O
30 O
% O
( O
w O
/ O
w O
) O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
USPIO O
; O
gamma B
- I
Fe I
( I
2 I
) I
O I
( I
3 I
) I
) O
. O

Liposomes O
were O
prepared O
by O
hydration O
and O
extrusion O
method O
and O
fasudil B
was O
loaded O
by O
ammonium B
sulfate I
- O
induced O
transmembrane O
electrochemical O
gradient O
. O

Commercially O
- O
available O
5 O
- O
HT2C O
agonists O
( O
CP B
809101 I
, O
Ro B
60 I
- I
0175 I
, O
WAY B
161503 I
, O
mCPP B
, O
and O
1 B
- I
methylpsilocin I
) O
, O
novel O
4 B
- I
phenyl I
- I
2 I
- I
N I
, I
N I
- I
dimethyl I
- I
aminotetralin I
( O
PAT B
) O
- O
type O
5 O
- O
HT2C O
agonists O
( O
with O
5 O
- O
HT2A O
/ O
2B O
antagonist O
activity O
) O
, O
and O
antagonists O
selective O
for O
5 O
- O
HT2A O
( O
M100907 B
) O
, O
5 O
- O
HT2C O
( O
SB B
- I

Commercially O
- O
available O
5 O
- O
HT2C O
agonists O
( O
CP B
809101 I
, O
Ro B
60 I
- I
0175 I
, O
WAY B
161503 I
, O
mCPP B
, O
and O
1 B
- I
methylpsilocin I
) O
, O
novel O
4 B
- I
phenyl I
- I
2 I
- I
N I
, I
N I
- I
dimethyl I
- I
aminotetralin I
( O
PAT B
) O
- O
type O
5 O
- O
HT2C O
agonists O
( O
with O
5 O
- O
HT2A O
/ O
2B O
antagonist O
activity O
) O
, O
and O
antagonists O
selective O
for O
5 O
- O
HT2A O
( O
M100907 B
) O
, O
5 O
- O
HT2C O
( O
SB B
- I

After O
the O
brain O
samples O
were O
incinerated O
with O
nitric B
acid I
and O
perchloric B
acid I
, O
the O
element O
contents O
were O
determined O
by O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectrometry O
. O

After O
the O
brain O
samples O
were O
incinerated O
with O
nitric B
acid I
and O
perchloric B
acid I
, O
the O
element O
contents O
were O
determined O
by O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectrometry O
. O

These O
agents O
include O
newer O
incretin O
- O
based O
therapies O
and O
PPAR O
agonists O
, O
as O
well O
as O
new O
therapeutic O
classes O
such O
as O
sodium B
- O
coupled O
glucose B
cotransporter O
2 O
inhibitors O
, O
free O
fatty B
acid I
receptor O
agonists O
, O
11 B
- I
beta I
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
inhibitors O
, O
glucokinase O
activators O
, O
and O
several O
others O
that O
may O
enter O
clinical O
use O
over O
the O
next O
decade O
. O

Iron B
bisterpyridine I
complexes O
are O
incorporated O
into O
a O
polymer O
network O
based O
on O
methacrylates B
, O
resulting O
in O
self O
- O
healing O
properties O
of O
these O
materials O
. O

Moderate O
binding O
affinities O
were O
observed O
, O
ranging O
from O
K O
( O
d O
) O
= O
32 O
. O
3 O
mu O
M O
for O
lead O
phenylbenzamide B
NSC B
104999 I
( O
1 O
) O
to O
K O
( O
d O
) O
= O
1 O
. O
1 O
mu O
M O
for O
a O
structurally O
related O
compound O
, O
NSC B
57148 I
( O
2 O
) O
. O

Moderate O
binding O
affinities O
were O
observed O
, O
ranging O
from O
K O
( O
d O
) O
= O
32 O
. O
3 O
mu O
M O
for O
lead O
phenylbenzamide B
NSC B
104999 I
( O
1 O
) O
to O
K O
( O
d O
) O
= O
1 O
. O
1 O
mu O
M O
for O
a O
structurally O
related O
compound O
, O
NSC B
57148 I
( O
2 O
) O
. O

Deconvolution O
of O
the O
affinity O
data O
into O
its O
components O
revealed O
differences O
in O
lead O
binding O
, O
from O
being O
entropy O
based O
( O
lead O
1 O
) O
to O
enthalpically O
driven O
( O
NSC B
100874 I
( O
3 O
) O
, O
NSC B
55158 I
( O
4 O
) O
, O
and O
compound O
2 O
) O
. O

Deconvolution O
of O
the O
affinity O
data O
into O
its O
components O
revealed O
differences O
in O
lead O
binding O
, O
from O
being O
entropy O
based O
( O
lead O
1 O
) O
to O
enthalpically O
driven O
( O
NSC B
100874 I
( O
3 O
) O
, O
NSC B
55158 I
( O
4 O
) O
, O
and O
compound O
2 O
) O
. O

Phosphodiesterases O
( O
PDEs O
) O
degrade O
cyclic B
nucleotides I
, O
signalling O
molecules O
that O
play O
important O
roles O
in O
synaptic O
plasticity O
and O
memory O
. O

Roles O
for O
PDE2 O
, O
4 O
, O
5 O
and O
9 O
in O
synaptic O
plasticity O
have O
so O
far O
been O
demonstrated O
and O
we O
review O
these O
studies O
here O
in O
the O
context O
of O
cyclic B
nucleotide I
signalling O
more O
generally O
. O

The O
role O
of O
other O
PDE O
families O
in O
synaptic O
plasticity O
has O
not O
yet O
been O
investigated O
, O
and O
this O
area O
promises O
to O
advance O
our O
understanding O
of O
cyclic B
nucleotide I
signalling O
in O
synaptic O
plasticity O
in O
the O
future O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

We O
have O
previously O
reported O
that O
pyrroloquinoline B
quinone I
( O
PQQ B
) O
prevents O
the O
amyloid O
formation O
of O
alpha O
- O
synuclein O
, O
amyloid O
beta O
( O
1 O
- O
42 O
) O
( O
A O
beta O
( O
1 O
- O
42 O
) O
) O
, O
and O
mouse O
prion O
protein O
. O

In O
addition O
, O
the O
alpha O
- O
synuclein O
partial O
peptide O
modified O
with O
other O
small O
- O
molecule O
inhibitors O
, O
Baicalein B
and O
epigallocatechin B
gallate I
( O
EGCG B
) O
, O
prevented O
alpha O
- O
synuclein O
fibril O
formation O
. O

The O
colloidal O
particles O
consist O
of O
a O
solid O
polystyrene B
core O
and O
a O
cross O
- O
linked O
poly B
- I
N I
- I
( I
isopropylacrylamide I
) I
shell O
with O
embedded O
crystalline O
titanium B
dioxide I
( O
TiO B
( I
2 I
) I
) O
nanoparticles O
( O
d O
= O
6 O
+ O
/ O
- O
3 O
nm O
) O
. O

To O
explore O
the O
acceptor O
regioselectivity O
of O
OleD O
- O
catalyzed O
glucosylation O
, O
the O
products O
of O
OleD O
- O
catalyzed O
reactions O
with O
six O
structurally O
diverse O
acceptors O
flavones B
- O
( O
daidzein B
) O
, O
isoflavones B
( O
flavopiridol B
) O
, O
stilbenes B
( O
resveratrol B
) O
, O
indole B
alkaloids I
( O
10 B
- I
hydroxycamptothecin I
) O
, O
and O
steroids B
( O
2 B
- I
methoxyestradiol I
) O
- O
were O
determined O
. O

Epitaxial O
silicon B
dots O
self O
- O
assembled O
on O
aluminum B
nitride I
/ O
Si B
( I
111 I
) I
. O

In O
transmission O
electron O
microscopy O
, O
optimized O
thioflavin B
T I
and O
cell O
survival O
assays O
, O
CP B
- I
2 I
inhibits O
the O
formation O
of O
A O
beta O
aggregates O
, O
entirely O
disassembles O
preformed O
aggregated O
and O
fibrillar O
A O
beta O
, O
and O
protects O
rat O
pheochromocytoma O
PC12 O
cells O
from O
A O
beta O
toxicity O
, O
without O
inducing O
any O
toxicity O
by O
itself O
. O

X O
- O
ray O
absorption O
spectroscopy O
and O
energy O
storage O
of O
Ni B
- O
doped O
cobalt B
nitride I
, O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
, O
prepared O
by O
a O
simple O
synthesis O
route O
. O

Metal B
nitride I
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
are O
prepared O
by O
nitridation O
using O
NiCo B
( I
2 I
) I
O I
( I
4 I
) I
as O
a O
precursor O
material O
by O
heating O
at O
335 O
degrees O
C O
for O
2 O
h O
in O
flowing O
NH B
( I
3 I
) I
+ O
N B
( I
2 I
) I
gas O
and O
characterized O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
field O
emission O
- O
scanning O
electron O
microscopy O
( O
FE O
- O
SEM O
) O
, O
high O
resolution O
- O
transmission O
electron O
microscopy O
( O
HR O
- O
TEM O
) O
, O
along O
with O
selective O
area O
electron O
diffraction O
( O
SAED O
) O
and O
X O

Data O
is O
presented O
for O
ethylammonium B
nitrate I
( O
EAN B
) O
and O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoro I
- I
methylsulfonyl I
) I
imide I
( O
EMIm B
TFSI I
) O
. O

Data O
is O
presented O
for O
ethylammonium B
nitrate I
( O
EAN B
) O
and O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoro I
- I
methylsulfonyl I
) I
imide I
( O
EMIm B
TFSI I
) O
. O

Whereas O
EAN B
is O
a O
protic O
IL O
that O
forms O
a O
nanostructured O
sponge O
phase O
in O
the O
bulk O
, O
EMIm B
TFSI I
is O
aprotic O
and O
has O
weak O
( O
or O
absent O
) O
bulk O
association O
structure O
. O

These O
include O
trials O
of O
administering O
dichloroacetate B
( O
an O
activator O
of O
pyruvate B
dehydrogenase O
complex O
) O
, O
arginine B
or O
citrulline B
( O
precursors O
of O
nitric B
oxide I
) O
, O
coenzyme B
Q10 I
( O
CoQ10 B
; O
part O
of O
the O
electron O
transport O
chain O
and O
an O
antioxidant O
) O
, O
idebenone B
( O
a O
synthetic O
analogue O
of O
CoQ10 B
) O
, O
EPI B
- I
743 I
( O
a O
novel O
oral O
potent O
2 O
- O
electron O
redox O
cycling O
agent O
) O
, O
creatine B
( O
a O
precursor O
of O
phosphocreatine B
) O
, O
combined O
administration O
( O
of O

These O
include O
trials O
of O
administering O
dichloroacetate B
( O
an O
activator O
of O
pyruvate B
dehydrogenase O
complex O
) O
, O
arginine B
or O
citrulline B
( O
precursors O
of O
nitric B
oxide I
) O
, O
coenzyme B
Q10 I
( O
CoQ10 B
; O
part O
of O
the O
electron O
transport O
chain O
and O
an O
antioxidant O
) O
, O
idebenone B
( O
a O
synthetic O
analogue O
of O
CoQ10 B
) O
, O
EPI B
- I
743 I
( O
a O
novel O
oral O
potent O
2 O
- O
electron O
redox O
cycling O
agent O
) O
, O
creatine B
( O
a O
precursor O
of O
phosphocreatine B
) O
, O
combined O
administration O
( O
of O

Subjects O
received O
intravenous O
plus O
oral O
( O
deuterium B
- O
labeled O
) O
racemic B
methadone I
before O
and O
after O
ticlopidine B
. O

Carboxylic B
acid I
( O
bio O
) O
isosteres O
in O
drug O
design O
. O

The O
carboxylic B
acid I
functional O
group O
can O
be O
an O
important O
constituent O
of O
a O
pharmacophore O
, O
however O
, O
the O
presence O
of O
this O
moiety O
can O
also O
be O
responsible O
for O
significant O
drawbacks O
, O
including O
metabolic O
instability O
, O
toxicity O
, O
as O
well O
as O
limited O
passive O
diffusion O
across O
biological O
membranes O
. O

To O
avoid O
some O
of O
these O
shortcomings O
while O
retaining O
the O
desired O
attributes O
of O
the O
carboxylic B
acid I
moiety O
, O
medicinal O
chemists O
often O
investigate O
the O
use O
of O
carboxylic B
acid I
( O
bio O
) O
isosteres O
. O

To O
avoid O
some O
of O
these O
shortcomings O
while O
retaining O
the O
desired O
attributes O
of O
the O
carboxylic B
acid I
moiety O
, O
medicinal O
chemists O
often O
investigate O
the O
use O
of O
carboxylic B
acid I
( O
bio O
) O
isosteres O
. O

Several O
carboxylic B
acid I
isosteres O
have O
been O
reported O
, O
however O
, O
the O
outcome O
of O
any O
isosteric O
replacement O
cannot O
be O
readily O
predicted O
as O
this O
strategy O
is O
generally O
found O
to O
be O
dependent O
upon O
the O
particular O
context O
( O
i O
. O
e O
. O
, O
the O
characteristic O
properties O
of O
the O
drug O
and O
the O
drug O
- O
target O
) O
. O

In O
this O
context O
, O
the O
discovery O
and O
development O
of O
novel O
carboxylic B
acid I
surrogates O
that O
could O
complement O
the O
existing O
palette O
of O
isosteres O
remains O
an O
important O
area O
of O
research O
. O

The O
goal O
of O
this O
Minireview O
is O
to O
provide O
an O
overview O
of O
the O
most O
commonly O
employed O
carboxylic B
acid I
( O
bio O
) O
isosteres O
and O
to O
present O
representative O
examples O
demonstrating O
the O
use O
and O
utility O
of O
each O
isostere O
in O
drug O
design O
. O

Graphene B
Oxide I
- O
Based O
Fluorescent O
Biosensor O
for O
Protein O
Detection O
via O
Terminal O
Protection O
of O
Small O
- O
Molecule O
- O
Linked O
DNA O
. O

A O
fluorescence O
method O
for O
protein O
detection O
is O
developed O
based O
on O
terminal O
protection O
of O
small O
- O
molecule O
- O
linked O
DNA O
by O
target O
protein O
and O
a O
graphene B
oxide I
- O
assisted O
DNA O
assay O
strategy O
. O

Using O
the O
mTOR O
inhibitor O
PP242 B
, I
we O
found O
that O
TGF O
beta O
- O
induced O
both O
early O
and O
sustained O
activation O
of O
TORC1 O
and O
TORC2 O
was O
necessary O
for O
deptor O
suppression O
. O

Tuning O
the O
magnetic O
properties O
of O
metal B
oxide I
nanocrystal O
heterostructures O
by O
cation O
exchange O
. O

The O
recent O
discovery O
of O
superconductivity O
in O
iron B
selenide I
has O
attracted O
considerable O
attention O
due O
to O
the O
simplicity O
of O
composition O
, O
unconventional O
nature O
of O
superconductivity O
, O
and O
ease O
of O
synthesis O
. O

The O
precursors O
were O
chosen O
to O
be O
elemental O
Se B
and O
iron B
acetylacetonate I
[ O
Fe B
( I
III I
) I
( I
C I
5 I
H I
8 I
O I
2 I
) I
3 I
] O
. O

The O
presence O
of O
carbon B
nanofibers O
as O
a O
shell O
around O
the O
FeSe B
protected O
the O
FeSe B
nanowires O
from O
both O
atmospheric O
O B
2 I
and O
moisture O
attack O
, O
as O
was O
evident O
from O
the O
very O
long O
ambient O
condition O
shelf O
life O
of O
these O
nanocables O
, O
and O
also O
makes O
them O
more O
stable O
under O
e O
- O
beam O
irradiation O
. O

A O
fully O
bio O
- O
based O
homopolyester O
( O
PManxS O
) O
has O
been O
synthesized O
by O
polycondensation O
in O
the O
melt O
from O
dimethyl B
succinate I
and O
Manx O
. O

In O
addition O
, O
random O
copolyesters O
( O
PBxManxyS O
) O
covering O
a O
broad O
range O
of O
compositions O
have O
been O
obtained O
using O
mixtures O
of O
Manx O
and O
1 B
, I
4 I
- I
butanediol I
in O
the O
reaction O
with O
dimethyl B
succinate I
. O

Investigation O
of O
the O
toxicokinetics O
of O
petroleum B
hydrocarbon I
distillates O
with O
the O
earthworm O
Eisenia O
andrei O
. O

The O
Canada O
- O
wide O
standards O
for O
petroleum B
hydrocarbons I
in O
soils O
regulate O
petroleum B
hydrocarbons I
based O
on O
four O
distillate O
ranges O
: O
F1 O
( O
C6 O
- O
C10 O
) O
, O
F2 O
( O
> O
C10 O
- O
C16 O
) O
, O
F3 O
( O
> O
C16 O
- O
C34 O
) O
, O
and O
F4 O
( O
> O
C34 O
) O
. O

The O
Canada O
- O
wide O
standards O
for O
petroleum B
hydrocarbons I
in O
soils O
regulate O
petroleum B
hydrocarbons I
based O
on O
four O
distillate O
ranges O
: O
F1 O
( O
C6 O
- O
C10 O
) O
, O
F2 O
( O
> O
C10 O
- O
C16 O
) O
, O
F3 O
( O
> O
C16 O
- O
C34 O
) O
, O
and O
F4 O
( O
> O
C34 O
) O
. O

Biota O
- O
soil O
accumulation O
factors O
were O
> O
1 O
for O
total O
F2 O
aliphatics O
and O
aromatics O
and O
F3a O
aromatics O
as O
well O
as O
for O
several O
individual O
polyaromatic B
hydrocarbons I
for O
each O
distillate O
. O

Heracleifolinosides B
A I
- I
F I
, O
new O
triterpene B
glycosides I
from O
Cimicifuga O
heracleifolia O
, O
and O
their O
inhibitory O
activities O
against O
hypoxia O
and O
reoxygenation O
. O

Heracleifolinoside B
B I
( O
2 O
) O
is O
effectively O
resistant O
to O
hypoxia O
and O
reoxygenation O
- O
induced O
human O
umbilical O
vein O
endothelial O
cell O
injury O
, O
with O
cell O
viabilities O
of O
61 O
. O
95 O
+ O
/ O
- O
2 O
. O
04 O
% O
, O
77 O
. O
04 O
+ O
/ O
- O
4 O
. O
44 O
% O
, O
and O
83 O
. O
65 O
+ O
/ O
- O
3 O
. O
29 O
% O
at O
concentrations O
of O
1 O
, O
10 O
, O
and O
100 O
micro O
M O
, O
respectively O
. O

Crystallization O
of O
glycine B
in O
the O
cylindrical O
nanopores O
of O
anodic O
aluminum B
oxide I
( O
AAO B
) O
revealed O
the O
formation O
of O
metastable O
beta B
- I
glycine I
in O
pores O
having O
diameters O
less O
than O
200 O
nm O
. O

When O
the O
beta B
- I
glycine I
nanocrystals O
were O
formed O
in O
the O
AAO B
cylinders O
in O
the O
presence O
of O
small O
amounts O
of O
racemic O
hydrophobic O
amino B
acid I
auxiliaries O
, O
which O
are O
known O
to O
bind O
selectively O
to O
the O
( O
010 O
) O
and O
( O
010 O
) O
faces O
on O
the O
fast O
- O
growing O
end O
of O
beta B
- I
glycine I
enantiomorphs O
, O
the O
beta O
- O
- O
> O
alpha O
phase O
transition O
at O
90 O
% O
RH O
was O
suppressed O
. O

In O
contrast O
, O
beta B
- I
glycine I
nanocrystals O
grown O
in O
the O
presence O
of O
an O
enantiopure O
amino B
acid I
auxiliary O
, O
which O
binds O
to O
the O
fast O
- O
growing O
end O
of O
only O
one O
of O
the O
enantiomorphs O
, O
thus O
suppressing O
its O
formation O
and O
leaving O
the O
other O
enantiomorph O
unperturbed O
, O
transformed O
into O
the O
alpha O
polymorph O
under O
the O
same O
conditions O
. O

This O
observation O
confirms O
that O
binding O
of O
an O
amino B
acid I
to O
the O
{ O
010 O
} O
faces O
is O
stereoselective O
and O
that O
access O
of O
water O
to O
these O
faces O
is O
essential O
for O
the O
transition O
to O
the O
alpha O
polymorph O
. O

The O
contrasting O
activity O
of O
iodido B
versus O
chlorido B
ruthenium I
and O
osmium B
arene I
azo I
- I
and I
imino I
- I
pyridine I
anticancer O
complexes O
: O
control O
of O
cell O
selectivity O
, O
cross O
- O
resistance O
, O
p53 O
dependence O
, O
and O
apoptosis O
pathway O
. O

A O
hydrothermal O
reaction O
of O
HNbO B
3 I
and O
LiOH B
. I
H I
2 I
O I
in O
PEG200 B
and O
water O
at O
~ O
180 O
degrees O
C O
yields O
~ O
15 O
- O
40 O
nm O
Li B
3 I
NbO I
4 I
particles O
. O

The O
new O
structure O
was O
characterized O
by O
single O
- O
crystal O
X O
- O
ray O
diffraction O
to O
have O
a O
condensed O
network O
consisting O
of O
NbO B
7 I
polyhedra O
and O
chains O
of O
elongated O
CuO B
4 I
tetrahedra O
. O

The O
new O
structure O
was O
characterized O
by O
single O
- O
crystal O
X O
- O
ray O
diffraction O
to O
have O
a O
condensed O
network O
consisting O
of O
NbO B
7 I
polyhedra O
and O
chains O
of O
elongated O
CuO B
4 I
tetrahedra O
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA B
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA B
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

Formulation O
, O
in O
vitro O
evaluation O
and O
study O
of O
variables O
on O
tri O
- O
layered O
gastro O
- O
retentive O
delivery O
system O
of O
diltiazem B
HCl I
. O

Abstract O
Context O
: O
Tri O
- O
layered O
floating O
tablets O
using O
only O
one O
grade O
of O
polyethylene B
oxide I
( O
PEO B
) O
would O
enable O
easy O
manufacturing O
, O
reproducibility O
and O
controlled O
release O
for O
highly O
soluble O
drugs O
. O

Objective O
: O
To O
evaluate O
the O
potential O
of O
PEO B
as O
a O
sole O
polymer O
for O
the O
controlled O
release O
and O
to O
study O
the O
effect O
of O
formulation O
variables O
on O
release O
and O
gastric O
retention O
of O
highly O
soluble O
Diltiazem B
hydrochloride I
( O
DTZ B
) O
. O

Methods O
: O
Tablets O
were O
compressed O
with O
middle O
layer O
consisting O
of O
drug O
and O
polymer O
while O
outer O
layers O
consisted O
of O
polymer O
with O
sodium B
bicarbonate I
. O

Design O
of O
formulation O
to O
obtain O
12 O
h O
, O
zero O
- O
order O
release O
and O
rapid O
floatation O
was O
done O
by O
varying O
the O
grades O
, O
quantity O
of O
PEO B
and O
sodium B
bicarbonate I
. O

With O
an O
increase O
in O
the O
amount O
of O
sodium B
bicarbonate I
, O
faster O
buoyancy O
was O
achieved O
due O
to O
the O
increased O
CO B
( I
2 I
) I
gas O
formation O
. O

Conclusion O
: O
Zero O
- O
order O
, O
controlled O
release O
profile O
with O
the O
desired O
buoyancy O
can O
be O
achieved O
by O
using O
optimum O
formula O
quantities O
of O
sodium B
bicarbonate I
and O
polymer O
. O

Liver O
, O
plasma O
and O
erythrocyte O
levels O
of O
thiamine B
and O
its O
phosphate B
esters I
in O
rats O
with O
acute O
ethanol B
intoxication O
: O
a O
comparison O
of O
thiamine B
and O
benfotiamine B
administration O
. O

Thiamine B
and O
benfotiamine B
are O
vitamin B
B1 I
and O
pro B
- I
vitamin I
B1 I
substances O
, O
respectively O
. O

Vitamin B
B1 I
plays O
an O
essential O
role O
in O
energy O
metabolism O
, O
and O
its O
deficiency O
leads O
to O
neurologic O
and O
cardiovascular O
pathologies O
, O
as O
seen O
in O
alcoholics B
. O

This O
study O
presents O
new O
data O
about O
the O
effects O
of O
thiamine B
hydrochloride I
or O
benfotiamine B
treatment O
given O
to O
rats O
with O
acute O
alcohol B
intoxication O
, O
on O
the O
distribution O
of O
thiamine B
and O
its O
phosphate B
esters I
in O
liver O
, O
plasma O
and O
erythrocytes O
. O

This O
study O
presents O
new O
data O
about O
the O
effects O
of O
thiamine B
hydrochloride I
or O
benfotiamine B
treatment O
given O
to O
rats O
with O
acute O
alcohol B
intoxication O
, O
on O
the O
distribution O
of O
thiamine B
and O
its O
phosphate B
esters I
in O
liver O
, O
plasma O
and O
erythrocytes O
. O

The O
liver O
endogenous O
antioxidant O
enzymes O
( O
copper B
/ O
zinc B
and O
manganese B
superoxide I
dismutase O
) O
expressions O
were O
significantly O
increased O
in O
the O
rats O
receiving O
the O
highest O
dose O
of O
SODB O
( O
160USOD O
/ O
day O
) O
whatever O
the O
coating O
. O

The O
OLETF O
rats O
were O
divided O
into O
the O
following O
four O
groups O
according O
to O
diet O
for O
2months O
: O
NAFLD O
( O
chew O
) O
, O
KRG O
( O
chew O
+ O
KRG O
[ O
200mg O
/ O
kg O
/ O
day O
] O
) O
, O
urushiol B
( O
chew O
+ O
urushiol B
[ O
0 O
. O
5mg O
/ O
kg O
/ O
day O
] O
) O
, O
and O
ursodeoxycholic B
acid I
( O
UDCA B
) O
( O
chew O
+ O
UDCA B
[ O
15mg O
/ O
kg O
/ O
day O
] O
) O
groups O
. O

The O
apoptosis O
was O
verified O
by O
staining O
with O
Annexin O
V O
- O
FITC B
and O
propidium B
iodide I
. O

APE1 O
/ O
Ref O
- O
1 O
prevents O
oxidative O
inactivation O
of O
ERK O
for O
G1 O
- O
to O
- O
S O
progression O
following O
lead B
acetate I
exposure O
. O

Previously O
, O
we O
have O
showed O
that O
lead B
acetate I
( O
Pb B
) O
elicits O
EGFR O
activation O
to O
initiate O
the O
SFK O
/ O
PKC O
alpha O
/ O
Ras O
/ O
Raf O
- O
1 O
/ O
MKK1 O
/ O
2 O
/ O
ERK O
signaling O
cascade O
functioning O
against O
genotoxicity O
. O

The O
decay O
mechanism O
was O
found O
to O
involve O
the O
loss O
of O
Ag B
( I
+ I
) I
ions O
and O
silver B
glutathionates I
. O

Emulsion O
- O
templated O
self O
- O
assembly O
of O
iron B
oxide I
nanoparticles O
into O
microparticles O
using O
oil O
- O
in O
- O
water O
emulsions O
was O
carried O
out O
using O
a O
modified O
Couette O
shear O
mixer O
with O
separate O
inlet O
ports O
for O
the O
oil O
and O
aqueous O
phases O
, O
enabling O
high O
throughput O
microparticle O
synthesis O
. O

Superparamagnetic O
microparticles O
with O
dimpled O
and O
crumpled O
morphologies O
were O
found O
to O
have O
higher O
specific O
binding O
capacities O
compared O
to O
spherical O
microparticles O
, O
while O
maintaining O
high O
magnetic O
field O
velocities O
due O
to O
their O
high O
iron B
oxide I
content O
. O

Here O
, O
we O
have O
perturbed O
vibrational O
motions O
in O
pentaerythritol B
tetranitrate I
reductase O
( O
PETNR O
) O
by O
isotopic O
substitution O
where O
all O
non O
- O
exchangeable O
atoms O
were O
replaced O
with O
the O
corresponding O
heavy O
isotope O
( O
( B
13 I
) I
C I
, O
( B
15 I
) I
N I
, O
and O
( B
2 I
) I
H I
) O
. O

A O
recent O
ion O
mobility O
- O
mass O
spectrometry O
( O
IM O
- O
MS O
) O
study O
of O
the O
nonapeptide O
bradykinin B
( O
BK O
, O
amino B
acid I
sequence O
Arg B
( O
1 O
) O
- O
Pro B
( O
2 O
) O
- O
Pro B
( O
3 O
) O
- O
Gly B
( O
4 O
) O
- O
Phe B
( O
5 O
) O
- O
Ser B
( O
6 O
) O
- O
Pro B
( O
7 O
) O
- O
Phe B
( O
8 O
) O
- O
Arg B
( O
9 O
) O
) O
found O
evidence O
for O
10 O
populations O
of O
conformations O
that O
depend O
upon O
the O
solution O
composition O
[ O
J O
. O
Am O
. O
Chem O
. O
Soc O
. O
2011 O
, O
133 O
, O
13810 O
] O
. O

Guided O
by O
the O
acetylcholinesterase O
inhibiting O
activity O
, O
the O
bisindole B
alkaloid I
3 B
' I
- I
R I
/ I
S I
- I
hydroxyvoacamine I
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata O
, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory O
. O

Understanding O
these O
long O
- O
range O
amino B
acid I
networks O
in O
alpha O
TS O
thus O
gives O
insight O
into O
the O
coordination O
of O
the O
two O
active O
sites O
within O
TS O
. O

Projection O
analysis O
of O
the O
chemical O
shift O
changes O
by O
site O
- O
specific O
amino B
acid I
substitutions O
and O
ligand O
titrations O
indicates O
that O
alpha O
TS O
has O
three O
important O
conformational O
states O
: O
ligand O
- O
free O
, O
glyceraldehyde B
- I
3 I
- I
phosphate I
- O
bound O
( O
like O
) O
, O
and O
the O
active O
states O
. O

The O
amino B
acid I
networks O
within O
these O
conformations O
are O
different O
, O
as O
suggested O
by O
chemical O
shift O
correlation O
analysis O
. O

The O
newly O
synthesized O
compounds O
were O
evaluated O
for O
their O
anti O
- O
inflammatory O
and O
analgesic O
activity O
using O
diclofenac B
Na I
as O
a O
reference O
standard O
. O

Elimination O
and O
utilization O
of O
oxidized O
guanine B
nucleotides I
in O
the O
synthesis O
of O
RNA O
and O
its O
precursors O
. O

During O
the O
de O
novo O
synthesis O
of O
guanine B
nucleotides I
, O
GMP B
is O
formed O
first O
, O
and O
it O
is O
converted O
to O
GDP B
by O
guanylate B
kinase O
. O

PURPOSE O
: O
The O
impact O
of O
prophylactic O
supplementation O
of O
N B
- I
acetyl I
- I
cysteine I
( O
NAC B
) O
and O
epigallocatechin B
gallate I
( O
EGCG B
) O
on O
intramuscular O
expression O
of O
proteolytic O
genes O
after O
unaccustomed O
eccentric O
muscle O
contractions O
was O
investigated O
. O

This O
study O
evaluates O
the O
developmental O
toxicity O
of O
two O
high O
molecular O
weight O
dialkyl B
phthalate I
esters I
, O
diundecyl B
phthalate I
( O
DUDP B
) O
and O
ditridecyl B
phthalate I
( O
DTDP B
) O
. O

This O
study O
evaluates O
the O
developmental O
toxicity O
of O
two O
high O
molecular O
weight O
dialkyl B
phthalate I
esters I
, O
diundecyl B
phthalate I
( O
DUDP B
) O
and O
ditridecyl B
phthalate I
( O
DTDP B
) O
. O

Here O
, O
we O
report O
that O
GPI O
- O
APs O
that O
have O
not O
undergone O
fatty B
acid I
remodeling O
exhibit O
reduced O
immunoreactivities O
in O
Western O
blotting O
, O
similar O
to O
delipidated O
proteins O
, O
compared O
with O
normal O
remodeled O
GPI O
- O
APs O
. O

Thus O
, O
this O
study O
clarifies O
the O
significance O
of O
GPI O
fatty B
acid I
remodeling O
in O
oligomerization O
of O
GPI O
- O
APs O
and O
provides O
useful O
information O
for O
technical O
studies O
of O
these O
cell O
components O
. O

As O
a O
first O
step O
, O
we O
describe O
molecular O
modeling O
to O
guide O
focused O
chemical O
syntheses O
of O
conjugates O
having O
nucleoside B
( O
d4T B
) O
and O
nonnucleoside O
( O
TIBO B
) O
moieties O
tethered O
by O
a O
flexible O
polyethylene B
glycol I
( O
PEG B
) O
linker O
. O

The O
pharmacological O
inhibitor O
, O
Bafilomycin B
A1 I
, O
rescued O
the O
cell O
death O
while O
suppressing O
autophagy O
. O

A O
Serum O
- O
Resistant O
Low O
- O
Generation O
Polyamidoamine B
with O
PEI B
423 I
Outer O
Layer O
for O
Gene O
Delivery O
Vector O
. O

A O
new O
derivative O
of O
polyamidoamine B
and O
polyethylenimine B
, O
G2 O
. O
5 O
- O
PEI B
423 I
or O
G1 O
. O
5 O
- O
PEI B
423 I
, O
is O
prepared O
by O
an O
amidation O
reaction O
of O
PAMAM B
G2 O
. O
5 O
or O
PAMAM B
G1 O
. O
5 O
using O
PEI B
423 I
. O

A O
new O
derivative O
of O
polyamidoamine B
and O
polyethylenimine B
, O
G2 O
. O
5 O
- O
PEI B
423 I
or O
G1 O
. O
5 O
- O
PEI B
423 I
, O
is O
prepared O
by O
an O
amidation O
reaction O
of O
PAMAM B
G2 O
. O
5 O
or O
PAMAM B
G1 O
. O
5 O
using O
PEI B
423 I
. O

A O
new O
derivative O
of O
polyamidoamine B
and O
polyethylenimine B
, O
G2 O
. O
5 O
- O
PEI B
423 I
or O
G1 O
. O
5 O
- O
PEI B
423 I
, O
is O
prepared O
by O
an O
amidation O
reaction O
of O
PAMAM B
G2 O
. O
5 O
or O
PAMAM B
G1 O
. O
5 O
using O
PEI B
423 I
. O

The O
G2 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
much O
higher O
transfection O
efficiencies O
than O
PAMAM B
G5 O
and O
Lipo O
- O
2k O
, O
and O
the O
G1 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
higher O
transfection O
efficiencies O
than O
PAMAM B
G4 O
and O
PEI B
- O
25k O
. O

The O
G2 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
much O
higher O
transfection O
efficiencies O
than O
PAMAM B
G5 O
and O
Lipo O
- O
2k O
, O
and O
the O
G1 O
. O
5 O
- O
PEI B
423 I
complexes O
display O
higher O
transfection O
efficiencies O
than O
PAMAM B
G4 O
and O
PEI B
- O
25k O
. O

The O
G2 O
. O
5 O
- O
PEI B
423 I
has O
a O
great O
potential O
to O
be O
used O
as O
a O
serum O
- O
resistant O
gene O
vector O
. O

In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel B
and O
clarithromycin B
, O
known O
CYP2B6 O
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic B
sibutramine I
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O

Coincubation O
of O
a O
P O
- O
gp O
inhibitor O
( O
ketoconazole B
or O
cyclosporin B
A I
) O
and O
a O
BCRP O
inhibitor O
( O
Ko134 B
) O
provided O
more O
complete O
inhibition O
of O
apixaban O
efflux O
in O
Caco O
- O
2 O
cells O
than O
separate O
inhibition O
by O
individual O
inhibitors O
. O

Polyethylene B
glycol I
was O
also O
grafted O
at O
the O
nanoparticle O
surface O
to O
enhance O
the O
nanoparticle O
residence O
time O
in O
the O
bloodstream O
. O

This O
intervention O
was O
assisted O
by O
the O
use O
of O
plasmapheresis O
to O
obtain O
rapid O
normalization O
of O
serum O
thyroid B
hormone I
levels O
. O

Acitretin B
induced O
Ca B
( I
2 I
+ I
) I
- O
mediated O
mitochondrial O
permeability O
transition O
( O
MPT O
) O
and O
decreased O
the O
adenine B
nucleotide I
translocase O
( O
ANT O
) O
content O
. O

As O
the O
selenocysteine B
( O
SeCys B
) O
amino B
acid I
, O
selenium B
is O
integrated O
in O
several O
Se B
- O
containing O
proteins O
( O
selenoproteins O
) O
, O
many O
of O
which O
are O
fundamental O
for O
cell O
homeostasis O
. O

An O
inorganic O
( O
sodium B
selenite I
, O
Na2SeO3 B
) O
and O
organic O
( O
selenocysteine B
, O
Cys B
- I
Se I
- I
Se I
- I
Cys I
) O
selenocompound O
have O
been O
used O
as O
Se B
sources O
. O

Previously O
, O
we O
reported O
the O
synthesis O
of O
amphiphilic O
polyvinyl B
alcohol I
and O
dextrin O
- O
based O
nanogel O
conjugates O
with O
the O
phosphorylated B
5 I
- I
FU I
nucleoside I
Floxuridine B
and O
demonstrated O
their O
enhanced O
activity O
against O
regular O
and O
drug O
- O
resistant O
cancers O
( O
T O
. O
H O
. O
Senanayake O
, O
G O
. O
Warren O
, O
S O
. O
V O
. O
Vinogradov O
, O
Novel O
anticancer O
polymeric O
conjugates O
of O
activated O
nucleoside B
analogs O
, O
Bioconjug O
. O
Chem O
. O
22 O
( O
2011 O
) O
1983 O
- O
1993 O
) O
. O

Integrated O
analysis O
of O
transcriptomics O
and O
metabonomics O
profiles O
in O
aflatoxin B
B1 I
- O
induced O
hepatotoxicity O
in O
rat O
. O

The O
aim O
of O
this O
work O
was O
to O
identify O
mechanisms O
and O
potential O
biomarkers O
for O
predicting O
the O
development O
and O
progression O
of O
aflatoxin B
B1 I
( O
AFB1 B
) O
- O
induced O
acute O
hepatotoxicity O
. O

In O
this O
article O
, O
we O
show O
that O
in O
combination O
with O
a O
recent O
reparametrization O
, O
the O
approximate O
DFT O
method O
, O
DFTB O
, O
is O
able O
to O
describe O
the O
effects O
of O
hydrogen B
bonding O
on O
the O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
stretch O
vibration O
in O
carboxylic B
acids I
reliably O
and O
agrees O
well O
with O
full O
DFT O
results O
. O

We O
apply O
DFTB O
in O
a O
QM O
/ O
MM O
framework O
to O
perform O
vibrational O
analysis O
of O
buried O
aspartic B
acids I
in O
bacteriorhodopsin O
and O
channelrhodopsin O
- O
2 O
. O

Preparation O
and O
evaluation O
of O
sustained O
- O
release O
doxazosin B
mesylate I
pellets O
. O

Doxazosin B
mesylate I
( O
DXM B
) O
sustained O
release O
pellets O
were O
prepared O
by O
an O
extrusion O
- O
spheronization O
and O
fluid O
- O
bed O
coating O
technique O
. O

Polymethacrylate B
derivatives O
( O
Eudragit B
( O
R O
) O
RS O
PO O
and O
RL O
PO O
) O
were O
used O
for O
coating O
agents O
, O
and O
polyethylene B
glycol I
6000 I
( O
PEG B
6000 I
) O
, O
triethyl B
citrate I
( O
TEC B
) O
and O
castor O
oil O
were O
as O
plasticizers O
. O

Polymethacrylate B
derivatives O
( O
Eudragit B
( O
R O
) O
RS O
PO O
and O
RL O
PO O
) O
were O
used O
for O
coating O
agents O
, O
and O
polyethylene B
glycol I
6000 I
( O
PEG B
6000 I
) O
, O
triethyl B
citrate I
( O
TEC B
) O
and O
castor O
oil O
were O
as O
plasticizers O
. O

PEG B
6000 I
was O
an O
appropriate O
plasticizer O
for O
DXM B
pellets O
, O
and O
increasing O
the O
content O
of O
PEG B
6000 I
, O
was O
also O
slightly O
decreasing O
the O
dissolution O
rate O
. O

PEG B
6000 I
was O
an O
appropriate O
plasticizer O
for O
DXM B
pellets O
, O
and O
increasing O
the O
content O
of O
PEG B
6000 I
, O
was O
also O
slightly O
decreasing O
the O
dissolution O
rate O
. O

Nocapyrone B
H I
( O
1 O
) O
reduced O
the O
pro O
- O
inflammatory O
factor O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
. O

Nocapyrone B
H I
( O
1 O
) O
reduced O
the O
pro O
- O
inflammatory O
factor O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
. O

Nocapyrone B
H I
( O
1 O
) O
reduced O
the O
pro O
- O
inflammatory O
factor O
such O
as O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
. O

Moreover O
, O
nocapyrone B
H I
showed O
5 O
. O
82 O
% O
stronger O
inhibitory O
effect O
on O
NO B
production O
than O
chrysin O
at O
a O
concentration O
of O
10 O
micro O
m O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
BV O
- O
2 O
microglial O
cells O
. O

Among O
all O
the O
metal B
oxides I
, O
tin B
dioxide I
( O
SnO B
( I
2 I
) I
) O
is O
regarded O
as O
a O
promising O
candidate O
to O
serve O
as O
the O
anode O
material O
for O
LIBs O
due O
to O
its O
high O
theoretical O
capacity O
. O

Among O
all O
the O
metal B
oxides I
, O
tin B
dioxide I
( O
SnO B
( I
2 I
) I
) O
is O
regarded O
as O
a O
promising O
candidate O
to O
serve O
as O
the O
anode O
material O
for O
LIBs O
due O
to O
its O
high O
theoretical O
capacity O
. O

By O
focusing O
on O
SnO B
( I
2 I
) I
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal B
oxides I
, O
such O
as O
titanium B
dioxide I
or O
iron B
oxides I
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal B
- I
oxide I
based O
negative O
electrodes O
for O
LIBs O
. O

By O
focusing O
on O
SnO B
( I
2 I
) I
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal B
oxides I
, O
such O
as O
titanium B
dioxide I
or O
iron B
oxides I
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal B
- I
oxide I
based O
negative O
electrodes O
for O
LIBs O
. O

By O
focusing O
on O
SnO B
( I
2 I
) I
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal B
oxides I
, O
such O
as O
titanium B
dioxide I
or O
iron B
oxides I
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal B
- I
oxide I
based O
negative O
electrodes O
for O
LIBs O
. O

Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl B
glucuronides I
. O

Carboxylesterases O
hydrolyze O
esters B
, O
amides B
, O
and O
thioesters B
to O
produce O
carboxylic B
acids I
and O
resulting O
alcohols B
, O
amines B
, O
and O
thiols B
, O
respectively O
. O

Uridine B
5 I
' I
- I
diphosphate I
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B
acids I
to O
acyl B
glucuronides I
, O
but O
it O
is O
currently O
unknown O
if O
acyl B
glucuronides I
, O
being O
esters B
, O
also O
interact O
with O
carboxylesterases O
. O

Uridine B
5 I
' I
- I
diphosphate I
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B
acids I
to O
acyl B
glucuronides I
, O
but O
it O
is O
currently O
unknown O
if O
acyl B
glucuronides I
, O
being O
esters B
, O
also O
interact O
with O
carboxylesterases O
. O

Uridine B
5 I
' I
- I
diphosphate I
- O
glucuronosyltransfer O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B
acids I
to O
acyl B
glucuronides I
, O
but O
it O
is O
currently O
unknown O
if O
acyl B
glucuronides I
, O
being O
esters B
, O
also O
interact O
with O
carboxylesterases O
. O

Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl B
glucuronides I
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
( O
hCES1 O
) O
and O
2 O
( O
hCES2 O
) O
. O

Methods O
: O
The O
stability O
of O
six O
acyl B
glucuronides I
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
( O
100 O
mM O
potassium B
phosphate I
, O
pH O
7 O
. O
4 O
, O
37 O
degrees O
C O
) O
were O
investigated O
. O

Methods O
: O
The O
stability O
of O
six O
acyl B
glucuronides I
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
( O
100 O
mM O
potassium B
phosphate I
, O
pH O
7 O
. O
4 O
, O
37 O
degrees O
C O
) O
were O
investigated O
. O

Reversible O
inhibition O
of O
4 B
- I
nitrophenyl I
acetate I
hydrolysis O
by O
the O
acyl B
glucuronides I
was O
also O
studied O
. O

Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl B
glucuronides I
studied O
. O

Conclusion O
: O
Drug O
- O
drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl B
glucuronides I
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

The O
hexane B
fraction O
from O
leaves O
( O
HL O
) O
and O
ethyl B
acetate I
( O
EAR O
) O
, O
chloroform B
( O
CR O
) O
and O
hydromethanolic O
( O
HMR O
) O
fractions O
from O
roots O
were O
the O
most O
active O
fractions O
against O
K O
- O
562 O
with O
GI O
( O
50 O
) O
values O
being O
lower O
than O
1 O
mu O
g O
mL O
( O
- O
1 O
) O
. O

We O
describe O
a O
controllable O
method O
to O
fabricate O
hexagonally O
close O
- O
packed O
Langmuir O
- O
Blodgett O
( O
LB O
) O
monolayers O
with O
stearic B
acid I
( O
SA O
) O
as O
co O
- O
surfactant O
and O
methanol B
as O
co O
- O
solvent O
. O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

The O
amphiphilic O
diblock O
copolymer O
poly B
( I
epsilon I
- I
caprolactone I
) I
- I
b I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PCL B
- I
b I
- I
PEO I
) O
was O
first O
conjugated O
with O
the O
cyclic B
( I
Arginine I
- I
Glycine I
- I
Aspartic I
acid I
- I
d I
- I
Phenylalanine I
- I
Lysine I
) I
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein B
isothiocyannate I
( O
FITC B
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

New O
casbane B
diterpenoids I
from O
a O
South O
China O
Sea O
soft O
coral O
, O
Sinularia O
sp O
. O

Six O
new O
casbane B
diterpenoids I
, O
named O
as O
sinularcasbanes B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
along O
with O
six O
known O
analogues O
7 O
- O
12 O
, O
were O
isolated O
from O
a O
South O
China O
Sea O
soft O
coral O
, O
Sinularia O
sp O
. O

All O
compounds O
were O
evaluated O
for O
their O
cytotoxicity O
against O
selected O
cancer O
cell O
lines O
and O
the O
inhibition O
of O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
nitric B
oxide I
( O
NO B
) O
production O
in O
mouse O
peritoneal O
macrophages O
. O

A O
series O
of O
iron B
oxide I
nanoparticles O
with O
varying O
stabilizing O
ligand O
brush O
lengths O
were O
synthesized O
. O

Using O
a O
glucocorticoid O
response O
element O
( O
GRE O
) O
luciferase O
reporter O
transfected O
into O
human O
airway O
epithelial O
cells O
[ O
both O
bronchial O
epithelium O
+ O
adenovirus O
12 O
- O
SV40 O
hybrid O
( O
BEAS O
- O
2B O
) O
cells O
and O
primary O
cultures O
] O
, O
roflumilast B
enhanced O
fluticasone B
propionate I
- O
induced O
GRE O
- O
dependent O
transcription O
. O

Here O
we O
examine O
how O
changes O
in O
bulk O
solvent O
( O
water O
, O
methanol B
, O
or O
DMF B
) O
or O
applied O
pressure O
( O
up O
to O
150 O
MPa O
) O
affect O
the O
rotational O
dynamics O
of O
encapsulated O
benzyl B
phosphonium I
guests O
, O
as O
a O
way O
to O
probe O
changes O
in O
host O
cavity O
size O
or O
flexibility O
. O

The O
aromatic B
sulfonamides I
were O
weak O
inhibitors O
( O
K O
( O
I O
) O
values O
of O
192 O
nM O
to O
84 O
mu O
M O
) O
, O
whereas O
some O
heterocyclic O
compounds O
inhibited O
the O
enzyme O
with O
K O
( O
I O
) O
values O
in O
the O
range O
61 O
. O
6 O
- O
93 O
. O
6 O
nM O
. O

Toxicological O
, O
toxicokinetic O
and O
gastroprotective O
evaluation O
of O
the O
benzaldehyde B
semicarbazone I
. O

Benzaldehyde B
semicarbazone I
( O
BS O
) O
has O
presented O
positive O
results O
in O
several O
pharmacological O
models O
, O
including O
anticonvulsivant O
and O
anti O
- O
inflammatory O
models O
. O

Synthesis O
of O
Li B
- O
Mn B
- O
O B
mesocrystals O
with O
controlled O
crystal O
phases O
through O
topotactic O
transformation O
of O
MnCO B
3 I
. O

Stable O
aqueous O
dispersions O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
were O
synthesized O
in O
one O
step O
in O
the O
presence O
of O
a O
zwitterionic B
siloxane I
as O
the O
stabilizing O
/ O
capping O
/ O
solubilizing O
ligand O
. O

Stable O
aqueous O
dispersions O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
were O
synthesized O
in O
one O
step O
in O
the O
presence O
of O
a O
zwitterionic B
siloxane I
as O
the O
stabilizing O
/ O
capping O
/ O
solubilizing O
ligand O
. O

The O
hydrodynamic O
diameter O
of O
the O
particles O
was O
tuned O
by O
controlling O
the O
concentration O
of O
zwitterion B
siloxane I
, O
which O
ultimately O
yielded O
monodisperse O
nanoparticles O
small O
enough O
for O
renal O
filtration O
( O
< O
6 O
nm O
diameter O
) O
. O

Tetracyclic B
diterpenoids I
with O
isomerized O
isospongian B
skeleton O
and O
labdane B
diterpenoids I
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Tetracyclic B
diterpenoids I
with O
isomerized O
isospongian B
skeleton O
and O
labdane B
diterpenoids I
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Four O
novel O
diterpenoids B
, O
including O
three O
tetracyclic B
diterpenes I
with O
isomerized O
isospongian B
skeletons O
, O
kravanhins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
kravanhin B
D I
( O
4 O
) O
, O
and O
three O
new O
labdane B
diterpenes I
( O
5 O
- O
7 O
) O
were O
isolated O
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Four O
novel O
diterpenoids B
, O
including O
three O
tetracyclic B
diterpenes I
with O
isomerized O
isospongian B
skeletons O
, O
kravanhins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
kravanhin B
D I
( O
4 O
) O
, O
and O
three O
new O
labdane B
diterpenes I
( O
5 O
- O
7 O
) O
were O
isolated O
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Four O
novel O
diterpenoids B
, O
including O
three O
tetracyclic B
diterpenes I
with O
isomerized O
isospongian B
skeletons O
, O
kravanhins B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
and O
kravanhin B
D I
( O
4 O
) O
, O
and O
three O
new O
labdane B
diterpenes I
( O
5 O
- O
7 O
) O
were O
isolated O
from O
the O
fruits O
of O
Amomum O
kravanh O
. O

Compounds O
1 O
- O
4 O
had O
unprecedented O
isospongian B
diterpene I
skeletons O
with O
a O
trans O
- O
anti O
- O
cis O
fused O
tricyclic O
ring O
system O
. O

Compound O
2 O
showed O
inhibitory O
activity O
on O
nitric B
oxide I
production O
in O
lipopolysaccharide O
- O
induced O
RAW264 O
. O
7 O
macrophages O
with O
an O
IC O
( O
50 O
) O
value O
of O
36 O
. O
2 O
mu O
M O
. O

A O
new O
type O
of O
anthracene B
organogelator O
based O
on O
uracil B
was O
obtained O
using O
organic O
aromatic O
solvents O
, O
cyclohexane B
, O
DMSO B
, O
ethanol B
, O
and O
ethyl B
acetate I
. O

Growth O
of O
highly O
fluorescent O
polyethylene B
glycol I
- O
and O
zwitterion O
- O
functionalized O
gold O
nanoclusters O
. O

We O
have O
prepared O
and O
characterized O
a O
new O
set O
of O
highly O
fluorescent O
gold O
nanoclusters O
( O
AuNCs O
) O
using O
one O
- O
step O
aqueous O
reduction O
of O
a O
gold O
precursor O
in O
the O
presence O
of O
bidentate O
ligands O
made O
of O
lipoic B
acid I
anchoring O
groups O
, O
appended O
with O
either O
a O
poly B
( I
ethylene I
glycol I
) I
short O
chain O
or O
a O
zwitterion O
group O
. O

The O
growth O
strategy O
further O
permitted O
the O
controlled O
, O
in O
situ O
functionalization O
of O
the O
NCs O
with O
reactive O
groups O
( O
e O
. O
g O
. O
, O
carboxylic B
acid I
or O
amine B
) O
, O
making O
these O
nanoclusters O
compatible O
with O
common O
and O
simple O
- O
to O
- O
implement O
coupling O
strategies O
, O
such O
as O
carbodiimide B
chemistry O
. O

Gut O
microbiota O
regulates O
bile B
acid I
metabolism O
by O
reducing O
the O
levels O
of O
tauro B
- I
beta I
- I
muricholic I
acid I
, O
a O
naturally O
occurring O
FXR O
antagonist O
. O

Bile B
acids I
are O
synthesized O
from O
cholesterol B
in O
the O
liver O
and O
further O
metabolized O
by O
the O
gut O
microbiota O
into O
secondary O
bile B
acids I
. O

Bile B
acids I
are O
synthesized O
from O
cholesterol B
in O
the O
liver O
and O
further O
metabolized O
by O
the O
gut O
microbiota O
into O
secondary O
bile B
acids I
. O

Bile B
acid I
synthesis O
is O
under O
negative O
feedback O
control O
through O
activation O
of O
the O
nuclear O
receptor O
farnesoid O
X O
receptor O
( O
FXR O
) O
in O
the O
ileum O
and O
liver O
. O

Here O
we O
profiled O
the O
bile B
acid I
composition O
throughout O
the O
enterohepatic O
system O
in O
germ O
- O
free O
( O
GF O
) O
and O
conventionally O
raised O
( O
CONV O
- O
R O
) O
mice O
. O

We O
confirmed O
a O
dramatic O
reduction O
in O
muricholic B
acid I
, O
but O
not O
cholic B
acid I
, O
levels O
in O
CONV O
- O
R O
mice O
. O

We O
confirmed O
a O
dramatic O
reduction O
in O
muricholic B
acid I
, O
but O
not O
cholic B
acid I
, O
levels O
in O
CONV O
- O
R O
mice O
. O

These O
studies O
suggest O
that O
the O
gut O
microbiota O
not O
only O
regulates O
secondary O
bile B
acid I
metabolism O
but O
also O
inhibits O
bile B
acid I
synthesis O
in O
the O
liver O
by O
alleviating O
FXR O
inhibition O
in O
the O
ileum O
. O

These O
studies O
suggest O
that O
the O
gut O
microbiota O
not O
only O
regulates O
secondary O
bile B
acid I
metabolism O
but O
also O
inhibits O
bile B
acid I
synthesis O
in O
the O
liver O
by O
alleviating O
FXR O
inhibition O
in O
the O
ileum O
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

In O
the O
work O
presented O
here O
, O
primary O
hepatocytes O
were O
isolated O
from O
specific O
pathogen O
- O
free O
male O
SD O
rats O
and O
incubated O
with O
200 O
mu O
mol O
/ O
L O
oleic B
acid I
for O
24h O
to O
induce O
steatotic O
model O
, O
then O
treated O
with O
sophocarpine B
for O
72 O
h O
. O

Prolactin O
regulates O
transcription O
of O
the O
ion O
uptake O
Na B
+ I
/ O
Cl B
- I
cotransporter O
( O
ncc O
) O
gene O
in O
zebrafish O
gill O
. O

Prolactin O
regulates O
transcription O
of O
the O
ion O
uptake O
Na B
+ I
/ O
Cl B
- I
cotransporter O
( O
ncc O
) O
gene O
in O
zebrafish O
gill O
. O

Here O
we O
designed O
a O
fusion O
protein O
named O
APP O
- O
IP O
- O
TIMP O
- O
2 O
, O
in O
which O
the O
ten O
amino B
acid I
residue O
sequence O
of O
APP O
- O
derived O
MMP O
- O
2 O
selective O
inhibitory O
peptide O
( O
APP O
- O
IP O
) O
is O
added O
to O
the O
N B
terminus O
of O
TIMP O
- O
2 O
. O

All O
the O
compounds O
are O
more O
active O
and O
less O
toxic O
than O
meglumine B
antimoniate I
( O
Glucantime B
) O
. O

Alcohol B
modulates O
expression O
of O
DNA O
methyltranferases O
and O
methyl B
CpG I
- O
/ O
CpG B
domain O
- O
binding O
proteins O
in O
murine O
embryonic O
fibroblasts O
. O

The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol B
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
( O
DNMTs O
) O
and O
various O
methyl B
CpG I
- O
binding O
proteins O
. O

In O
addition O
, O
ethanol B
induced O
degradation O
of O
DNA O
methyltransferases O
( O
DNMT O
- O
1 O
, O
DNMT O
- O
3a O
, O
and O
DNMT O
- O
3b O
) O
, O
as O
well O
as O
the O
methyl B
CpG I
- O
binding O
proteins O
( O
MeCP O
- O
2 O
, O
MBD O
- O
2 O
and O
MBD O
- O
3 O
) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O

Mouse O
hepatocytes O
cultured O
either O
in O
monolayer O
or O
sandwich O
configurations O
were O
finally O
shown O
to O
exhibit O
up O
- O
regulation O
of O
referent O
transporters O
in O
response O
to O
exposure O
to O
prototypical O
activators O
of O
the O
drug O
sensing O
receptors O
pregnane B
X O
receptor O
, O
aryl B
hydrocarbon I
receptor O
or O
constitutive O
androstane B
receptor O
. O

BZA B
/ O
TNF O
- O
alpha O
- O
mediated O
IL O
- O
6 O
induction O
in O
MCF O
- O
7 O
cells O
was O
counteracted O
by O
silencing O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
known O
to O
mediates O
most O
of O
PAH B
effects O
. O

Quercetin B
prevents O
protein O
nitration O
and O
glycolytic O
block O
of O
proliferation O
in O
hydrogen B
peroxide I
insulted O
cultured O
neuronal O
precursor O
cells O
( O
NPCs O
) O
: O
Implications O
on O
CNS O
regeneration O
. O

Here O
, O
we O
report O
that O
Golgi O
fragmentation O
induced O
by O
brefeldin B
A I
( O
BFA B
) O
or O
coatomer O
protein O
( O
beta O
- O
COP O
) O
knockdown O
( O
KD O
) O
in O
Panc1 O
- O
bC2GnT O
- O
M O
( O
c O
- O
Myc O
) O
cells O
is O
accompanied O
by O
the O
increased O
association O
of O
NMIIA O
with O
C2GnT O
- O
M O
and O
its O
degradation O
by O
proteasomes O
. O

Hematite B
photoanodes O
were O
coated O
with O
an O
ultrathin O
cobalt B
oxide I
layer O
by O
atomic O
layer O
deposition O
( O
ALD O
) O
. O

Adsorption O
of O
an O
in O
- O
house O
synthesized O
organic O
- O
inorganic O
Al B
( I
OH I
) I
3 I
- I
PAM I
( O
Al B
- I
PAM I
) O
as O
an O
example O
of O
cationic O
hybrid O
PAM B
and O
a O
commercially O
available O
partially O
hydrolyzed O
polyacrylamide B
( O
MF1011 B
) O
as O
an O
example O
of O
anionic B
PAM I
was O
studied O
. O

In O
contrast O
, O
anionic B
MF1011 I
adsorbed O
strongly O
on O
aluminum B
- I
hydroxy I
basal O
planes O
, O
while O
its O
adsorption O
on O
tetrahedral O
silica B
basal O
planes O
was O
weak O
and O
reversible O
. O

Strong O
effects O
of O
cluster O
size O
and O
air O
exposure O
on O
oxygen B
reduction O
and O
carbon B
oxidation O
electrocatalysis O
by O
size O
- O
selected O
Pt B
( I
n I
) I
( O
n O
< O
= O
11 O
) O
on O
glassy B
carbon I
electrodes O
. O

Model O
Pt B
( I
n I
) I
/ O
glassy B
carbon I
electrodes O
( O
Pt B
( I
n I
) I
/ O
GCE O
) O
were O
prepared O
by O
deposition O
of O
mass O
- O
selected O
Pt B
( I
n I
) I
( I
+ I
) I
( O
n O
< O
= O
11 O
) O
on O
GCE O
substrates O
in O
ultrahigh O
vacuum O
. O

On O
8 O
visits O
, O
healthy O
women O
( O
n O
= O
8 O
) O
received O
intravaginal O
taggant O
( O
2 B
- I
butyl I
acetate I
, O
2 B
- I
pentyl I
acetate I
, O
isopropyl B
butyrate I
, O
or O
2 B
- I
pentyl I
butyrate I
; O
30 O
mg O
) O
formulated O
in O
hydroxyethylcellulos O
or O
tenofovir B
placebo O
gel O
. O

After O
vaginal O
administration O
, O
2 B
- I
butyl I
acetate I
, O
2 B
- I
pentyl I
acetate I
, O
and O
metabolites O
were O
observed O
in O
breath O
, O
whereas O
isopropyl B
butyrate I
, O
2 B
- I
pentyl I
butyrate I
, O
and O
metabolites O
were O
not O
. O

The O
Lignan B
( B
- I
) I
- I
Cubebin I
Inhibits O
Vascular O
Contraction O
and O
Induces O
Relaxation O
Via O
Nitric B
Oxide I
Activation O
in O
Isolated O
Rat O
Aorta O
. O

Endothelium O
- O
dependent O
relaxation O
was O
evoked O
by O
acetylcholine B
and O
( B
- I
) I
- I
cubebin I
in O
intact O
aortic O
rings O
, O
while O
endothelium O
- O
independent O
vasorelaxation O
was O
elicited O
by O
sodium B
nitroprusside I
and O
( B
- I
) I
- I
cubebin I
in O
denuded O
rings O
. O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N B
omega I
- I
nitro I
- I
L I
- I
arginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
( O
a O
non O
- O
specific O
nitric B
oxide I
synthase O
inhibitor O
) O
, O
indomethacin B
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
( O
a O
guanylyl O
cyclase O

[ B
6 I
] I
- I
Shogaol I
Attenuates O
Neuronal O
Apoptosis O
in O
Hydrogen B
Peroxide I
- O
Treated O
Astrocytes O
Through O
the O
Up O
- O
Regulation O
of O
Neurotrophic O
Factors O
. O

Here O
, O
we O
show O
that O
the O
anti O
- O
apoptotic O
activity O
of O
[ B
6 I
] I
- I
shogaol I
in O
astrocytes O
following O
exposure O
to O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
involves O
a O
marked O
up O
- O
regulation O
of O
neurotrophic O
factors O
such O
as O
nerve O
growth O
factor O
, O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
, O
and O
brain O
- O
derived O
neurotrophic O
factor O
. O

In O
vivo O
Antimalarial O
Activity O
of O
a O
Labdane B
Diterpenoid I
from O
the O
Leaves O
of O
Otostegia O
integrifolia O
Benth O
. O

Activity O
- O
guided O
fractionation O
of O
this O
extract O
which O
showed O
potent O
antiplasmodial O
activity O
resulted O
in O
the O
isolation O
of O
a O
labdane B
diterpenoid I
identified O
as O
otostegindiol B
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

Vitamin B
B12 I
and O
homocysteine B
status O
during O
pregnancy O
in O
the O
metformin B
in O
gestational O
diabetes O
trial O
: O
responses O
to O
maternal O
metformin B
compared O
with O
insulin O
treatment O
( O
+ O
) O

AIM O
: O
The O
aim O
of O
the O
study O
is O
to O
compare O
the O
effects O
of O
metformin B
and O
insulin O
treatment O
for O
gestational O
diabetes O
mellitus O
( O
GDM O
) O
on O
vitamin B
B12 I
and O
homocysteine B
( O
Hcy B
) O
status O
. O

Fasting O
serum O
total O
vitamin B
B12 I
( O
TB12 O
) O
, O
holotranscobalamin O
( O
HoloTC O
) O
, O
a O
marker O
of O
functional O
B12 O
status O
and O
plasma O
Hcy B
concentrations O
were O
measured O
at O
20 O
- O
34 O
weeks O
( O
at O
randomization O
) O
and O
36 O
weeks O
gestation O
, O
then O
at O
6 O
- O
8 O
weeks O
postpartum O
. O

CONCLUSIONS O
: O
Total O
, O
but O
not O
bioavailable O
, O
vitamin B
B12 I
stores O
were O
depleted O
during O
pregnancy O
to O
a O
greater O
extent O
in O
metformin B
- O
treated O
than O
in O
insulin O
- O
treated O
women O
with O
GDM O
, O
but O
neither O
analyte O
differed O
between O
groups O
at O
any O
stage O
. O

New O
insight O
into O
artifactual O
phenomena O
during O
in O
vitro O
toxicity O
assessment O
of O
engineered O
nanoparticles O
: O
study O
of O
TNF O
- O
alpha O
adsorption O
on O
alumina B
oxide I
nanoparticle O
. O

The O
animal O
' O
s O
liver O
was O
assessed O
using O
biomarkers O
as O
activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
glutathione B
S O
- O
transferase O
( O
GST O
) O
, O
and O
glutathione B
peroxidase O
( O
GPx O
) O
, O
and O
concentrations O
of O
reduced B
glutathione I
( O
GSH B
) O
and O
lipoperoxidation O
( O
LPO O
) O
and O
protein O
carbonylation O
( O
PCO O
) O
. O

Elemental O
composition O
of O
dog O
foods O
using O
nitric B
acid I
and O
simulated O
gastric O
digestions O
. O

Eighteen O
dry O
dog O
foods O
obtained O
commercially O
in O
the O
United O
States O
were O
digested O
using O
microwave O
assisted O
nitric B
acid I
digestion O
and O
a O
simulated O
gastric O
digestion O
. O

Data O
, O
expressed O
as O
dry O
matter O
concentrations O
, O
were O
compared O
to O
published O
nitric B
acid I
digestion O
results O
. O

Nitric B
acid I
data O
obtained O
in O
the O
present O
study O
were O
not O
statistically O
different O
from O
published O
data O
, O
with O
the O
exception O
of O
Mo B
, O
Sn B
, O
Sb B
, O
Tl B
and O
Th B
. O

Evaluation O
against O
Reference O
Doses O
( O
RfDs O
) O
showed O
concentrations O
for O
many O
elements O
obtained O
by O
nitric B
acid I
digestion O
to O
be O
above O
RfD O
levels O
. O

Pyrogallol B
- O
related O
chemicals O
and O
tannins B
are O
present O
in O
dietary O
sources O
and O
individually O
produced O
strong O
activity O
: O
pyrogallol B
( O
30 O
x O
) O
, O
3 B
- I
methoxycatechol I
( O
25 O
x O
) O
, O
gallic B
acid I
( O
21 O
x O
) O
, O
and O
1 B
, I
2 I
, I
4 I
- I
benzenetriol I
( O
21 O
x O
) O
. O

Various O
substituted O
indazole B
and O
benzoxazolone B
amino B
acids I
were O
investigated O
as O
d B
- I
tyrosine I
surrogates O
in O
highly O
potent O
CGRP O
receptor O
antagonists O
. O

Formulations O
contained O
either O
microcrystalline O
cellulose O
( O
MCC O
) O
or O
dicalcium B
phosphate I
( O
DCP B
) O
as O
diluent O
, O
hydroxypropyl O
methylcellulose O
( O
HPMC O
) O
, O
lactose B
, O
and O
water O
. O

Extrudates O
were O
characterized O
for O
their O
tensile O
strength O
, O
Young O
' O
s O
modulus O
of O
elasticity O
, O
water O
absorption O
, O
gel O
forming O
capacity O
, O
and O
release O
of O
two O
model O
drugs O
, O
coumarin B
( O
COU B
) O
and O
propranolol B
hydrochloride I
( O
PRO B
) O
. O

Amongst O
the O
polymers O
tested O
in O
this O
study O
, O
EUDRAGIT B
E I
PO I
was O
found O
to O
have O
the O
greatest O
inhibitory O
effect O
on O
crystallization O
, O
whilst O
PVP B
K30 I
was O
found O
to O
have O
the O
least O
protective O
effect O
; O
presumably O
because O
of O
its O
hygroscopic O
nature O
. O

In O
this O
study O
, O
using O
recombinant O
human O
insulin O
( O
insulin O
) O
as O
a O
model O
, O
we O
investigated O
the O
ability O
of O
several O
excipients O
, O
in O
particular O
triethylenetetramine B
( O
TETA B
) O
, O
reduced B
glutathione I
( O
GSH B
) O
and O
ethylenediamine B
tetraacetic I
acid I
( O
EDTA B
) O
, O
for O
their O
ability O
to O
prevent O
protein O
oxidation O
, O
aggregation O
, O
and O
fragmentation O
. O

Insulin O
( O
1mg O
/ O
ml O
) O
was O
oxidized O
with O
40 O
mu O
M O
Cu B
( I
2 I
+ I
) I
and O
4mM O
ascorbic B
acid I
in O
absence O
or O
presence O
of O
excipients O
. O

Antofine B
, O
a O
phenanthroindolizidi B
alkaloid I
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family O
, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O

The O
applied O
depolymerization O
conditions O
, O
which O
take O
advantage O
of O
the O
use O
of O
formic B
acid I
as O
a O
hydrogen B
- O
donating O
solvent O
, O
did O
not O
generate O
any O
biochar O
in O
the O
systems O
. O

Finding O
microRNA O
targets O
in O
the O
coding O
region O
is O
difficult O
due O
to O
the O
overwhelming O
signal O
encoding O
the O
amino B
acid I
sequence O
. O

Here O
, O
we O
introduce O
an O
algorithm O
( O
called O
PACCMIT O
- O
CDS O
) O
that O
finds O
potential O
microRNA O
targets O
within O
coding O
sequences O
by O
searching O
for O
conserved O
motifs O
that O
are O
complementary O
to O
the O
microRNA O
seed O
region O
and O
also O
overrepresented O
in O
comparison O
with O
a O
background O
model O
preserving O
both O
codon O
usage O
and O
amino B
acid I
sequence O
. O

Evaluation O
of O
oxidant O
- O
antioxidant O
status O
in O
oral O
toxicity O
of O
fish O
oil O
methyl B
esters I
and O
diesel O
fuel O
in O
male O
rats O
. O

At O
the O
end O
of O
the O
study O
, O
malondialdehyde B
( O
MDA B
) O
and O
reduced B
glutathione I
( O
GSH B
) O
levels O
were O
measured O
in O
the O
whole O
blood O
; O
catalase O
( O
CAT O
) O
activity O
level O
was O
measured O
in O
erythrocytes O
; O
and O
nitrite B
( O
NO B
( I
2 I
) I
) O
and O
nitrate B
( O
NO B
( I
3 I
) I
) O
levels O
were O
measured O
in O
the O
serum O
. O

In O
brine O
shrimp O
toxicology O
assays O
, O
profound O
cytotoxicity O
was O
displayed O
by O
ethyl B
acetate I
( O
LD O
( O
50 O
) O
8 O
. O
3 O
mu O
g O
/ O
ml O
) O
and O
chloroform B
( O
LD O
( O
50 O
) O
8 O
. O
8 O
mu O
g O
/ O
ml O
) O
fractions O
, O
followed O
by O
relatively O
weak O
crude O
methanolic O
extract O
of O
H O
. O
strigosum O
( O
LD O
( O
50 O
) O
909 O
mu O
g O
/ O
ml O
) O
and O
n B
- I
hexane I
fraction O
( O
LD O
( O
50 O
) O
1000 O
mu O
g O
/ O
ml O
) O
. O

In O
case O
of O
phytotoxicity O
activity O
against O
Lemna O
acquinoctialis O
, O
highest O
phytotoxic O
effect O
was O
showed O
by O
ethyl B
acetate I
fraction O
( O
LD O
( O
50 O
) O
91 O
. O
0 O
mu O
g O
/ O
ml O
) O
, O
while O
chloroform B
fraction O
, O
plant O
crude O
extract O
and O
n B
- I
hexane I
, O
respectively O
, O
caused O
50 O
% O
, O
30 O
. O
76 O
+ O
/ O
- O
1 O
. O
1 O
% O
and O
30 O
. O
7 O
+ O
/ O
- O
1 O
. O
1 O
% O
inhibitory O
action O
at O
maximum O
concentration O
used O
, O
that O
is O
, O
1000 O
mu O
g O
/ O
ml O
. O

The O
ethyl B
acetate I
and O
chloroform B
fractions O
were O
more O
potent O
for O
the O
evaluated O
toxicity O
effects O
, O
thus O
recommended O
for O
isolation O
and O
identification O
of O
the O
active O
compounds O
. O

In O
order O
to O
determine O
a O
time O
course O
of O
Pb B
elimination O
after O
oral O
exposure O
to O
two O
different O
forms O
of O
this O
heavy O
metal O
( O
lead B
acetate I
vs O
. O
phyto O
- O
bound O
Pb B
) O
, O
a O
feeding O
study O
was O
carried O
out O
in O
experimental O
rats O
using O
the O
Pb B
phyto O
- O
hyperaccumulator O
Pistia O
stratiotes O
as O
a O
model O
diet O
. O

Considerable O
differences O
were O
revealed O
concerning O
total O
excretion O
levels O
; O
lead B
acetate I
was O
excreted O
in O
amount O
greater O
extent O
than O
those O
of O
phytobound O
Pb B
. O

Results O
of O
our O
study O
suggest O
that O
Pb B
forms O
occurring O
in O
the O
P O
. O
stratiotes O
tissues O
are O
absorbed O
through O
the O
gastrointestinal O
tract O
to O
a O
greater O
extent O
than O
Pb B
from O
lead B
acetate I
. O

To O
assess O
the O
PBDE B
concentration O
trend O
, O
and O
determine O
the O
concentrations O
of O
the O
emerging O
flame O
retardants O
Dechlorane B
Plus I
( O
DP O
) O
and O
bis B
( I
2 I
- I
ethylhexyl I
) I
- I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
tetrabromophthalate I
( O
TBPH B
) O
, O
the O
authors O
measured O
the O
concentrations O
of O
8 O
PBDE B
congeners O
, O
2 O
DP O
isomers O
, O
and O
TBPH B
in O
10 O
composite O
samples O
, O
which O
were O
pooled O
from O
the O
serum O
collected O
from O
305 O
Laizhou O
Bay O
residents O
in O
October O
2011 O
. O

Accordingly O
, O
the O
synthesis O
and O
identification O
of O
novel O
chromone B
carboxamide I
derivatives O
with O
electron O
- O
donating O
and O
electron O
- O
withdrawing O
substituents O
in O
different O
positions O
of O
the O
exocyclic O
ring O
are O
reported O
in O
this O
work O
. O

We O
examined O
a O
number O
of O
anti O
- O
resorptive O
treatments O
to O
either O
block O
osteoclast O
activity O
, O
including O
the O
potent O
bisphosphonates B
zoledronic B
acid I
( O
ZA O
) O
and O
clodronate B
( O
CLOD B
) O
, O
which O
work O
via O
differing O
mechanisms O
, O
or O
antagonize O
osteoclastogenesis O
with O
recombinant O
OPG O
( O
HuOPG O
- O
Fc O
) O
, O
comparing O
these O
directly O
to O
an O
inhibitor O
of O
matrix O
metalloproteinase O
( O
MMP O
) O
activity O
( O
MMI270 O
) O
. O

The O
therapeutic O
potential O
of O
allosteric O
ligands O
for O
free O
fatty B
acid I
sensitive O
GPCRs O
. O

The O
present O
review O
will O
consider O
the O
advantages O
and O
challenges O
associated O
with O
allosteric O
GPCR O
ligands O
, O
and O
examine O
how O
the O
particular O
properties O
of O
these O
ligands O
may O
be O
exploited O
to O
uncover O
the O
therapeutic O
potential O
for O
free O
fatty B
acid I
sensitive O
GPCRs O
. O

DNA O
polymerases O
replicate O
DNA O
by O
catalyzing O
the O
template O
- O
directed O
polymerization O
of O
deoxynucleoside B
triphosphate I
( O
dNTP B
) O
substrates O
onto O
the O
3 O
' O
end O
of O
a O
growing O
DNA O
primer O
strand O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
indazole B
arylsulfonamides I
as O
allosteric O
CC O
- O
chemokine O
receptor O
4 O
( O
CCR4 O
) O
antagonists O
. O

A O
series O
of O
indazole B
arylsulfonamides I
were O
synthesized O
and O
examined O
as O
human O
CCR4 O
antagonists O
. O

Aryl B
sulfonamide I
antagonists O
bind O
to O
CCR4 O
at O
an O
intracellular O
allosteric O
site O
denoted O
site O
II O
. O

X O
- O
ray O
diffraction O
studies O
on O
two O
indazole B
sulfonamide I
fragments O
suggested O
the O
presence O
of O
an O
important O
intramolecular O
interaction O
in O
the O
active O
conformation O
. O

Acute O
arsenic B
treatment O
alters O
cytochrome O
P450 O
expression O
and O
arachidonic B
acid I
metabolism O
in O
lung O
, O
liver O
and O
kidney O
of O
C57Bl O
/ O
6 O
mice O
. O

Therefore O
, O
in O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
acute O
As B
( I
III I
) I
treatment O
on O
pulmonary O
, O
hepatic O
and O
renal O
cytochrome O
( O
CYP O
) O
P450 O
- O
mediated O
arachidonic B
acid I
metabolism O
. O

3 O
. O
Furthermore O
, O
As B
( I
III I
) I
increased O
the O
formation O
of O
epoxyeicosatrienoic B
acids I
( O
EETs B
) O
in O
the O
kidney O
without O
affecting O
their O
levels O
in O
the O
lung O
or O
liver O
. O

In O
addition O
, O
acute O
As B
( I
III I
) I
treatment O
increased O
dihydroxyeicosatrien B
acid I
( O
DHETs B
) O
formation O
in O
the O
lung O
, O
while O
it O
did O
not O
affect O
liver O
DHETs B
formation O
and O
decreased O
kidney O
DHETs B
formation O
. O

In O
conclusion O
, O
this O
is O
the O
first O
demonstration O
that O
As B
( I
III I
) I
alters O
arachidonic B
acid I
metabolism O
in O
a O
tissue O
specific O
manner O
. O

The O
benzo B
- I
b I
- I
acronycine I
derivative O
S23906 B
- I
1 I
alkylates O
guanine B
nucleobases I
in O
the O
minor O
groove O
of O
the O
DNA O
helix O
and O
presents O
an O
original O
ability O
to O
locally O
open O
the O
double O
helix O
of O
DNA O
, O
which O
appears O
to O
be O
associated O
with O
its O
cytotoxic O
activity O
. O

Injectable O
superparamagnets O
: O
highly O
elastic O
and O
degradable O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
superparamagnetic O
iron B
oxide I
nanoparticle O
( O
SPION O
) O
composite O
hydrogels O
. O

Membrane O
fusion O
protein O
of O
hefABC O
efflux O
system O
, O
50 O
S O
ribosomal O
protein O
L33 O
, O
Hydrogenase O
expression O
protein O
/ O
formation O
of O
HypD O
, O
Cag O
pathogenecity O
island O
protein O
X O
, O
Apolipoprotein O
N B
acyl I
transferase O
, O
DNA O
methyalse O
, O
Histone O
like O
binding O
protein O
, O
Peptidoglycan O
- O
associated O
lipoprotein O
OprL O
were O
found O
to O
be O
critical O
drug O
targets O
to O
H O
. O
pylori O
. O

A O
new O
butenolide B
isoaspulvinone B
E I
( O
1 O
) O
, O
together O
with O
two O
known O
butenolides B
aspulvinone B
E I
( O
2 O
) O
and O
pulvic B
acid I
( O
3 O
) O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
, O
Aspergillus O
terreus O
Gwq O
- O
48 O
. O

A O
new O
butenolide B
isoaspulvinone B
E I
( O
1 O
) O
, O
together O
with O
two O
known O
butenolides B
aspulvinone B
E I
( O
2 O
) O
and O
pulvic B
acid I
( O
3 O
) O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
, O
Aspergillus O
terreus O
Gwq O
- O
48 O
. O

A O
new O
butenolide B
isoaspulvinone B
E I
( O
1 O
) O
, O
together O
with O
two O
known O
butenolides B
aspulvinone B
E I
( O
2 O
) O
and O
pulvic B
acid I
( O
3 O
) O
were O
isolated O
from O
the O
marine O
- O
derived O
fungus O
, O
Aspergillus O
terreus O
Gwq O
- O
48 O
. O

Seven O
new O
cyclotriphosphazene B
amphiphiles O
were O
prepared O
from O
combinations O
of O
hydrophilic O
MPEGs B
with O
different O
molecular O
weights O
of O
350 O
, O
550 O
, O
750 O
and O
1000 O
and O
four O
different O
fatty B
acids I
of O
different O
hydrophobicity O
including O
lauric B
, I
myristic I
, I
palmitic I
and I
stearic I
acids I
. O

These O
steric O
amphiphiles O
bearing O
fatty B
acids I
as O
a O
hydrophobic O
group O
were O
found O
to O
form O
more O
stable O
micelles O
with O
very O
low O
critical O
micelle O
concentrations O
( O
CMC O
) O
( O
2 O
. O
95 O
- O
7 O
. O
80mg O
/ O
L O
) O
compared O
with O
oligopeptide O
analogues O
, O
and O
their O
highly O
hydrophobic O
core O
environment O
is O
unique O
and O
potentially O
useful O
for O
various O
biomedical O
applications O
. O

Electrochemical O
determination O
of O
Sudan B
I I
in O
food O
samples O
at O
graphene B
modified O
glassy O
carbon B
electrode O
based O
on O
the O
enhancement O
effect O
of O
sodium B
dodecyl I
sulphonate I
. O

This O
paper O
describes O
a O
novel O
electrochemical O
method O
for O
the O
determination O
of O
Sudan B
I I
in O
food O
samples O
based O
on O
the O
electrochemical O
catalytic O
activity O
of O
graphene B
modified O
glassy O
carbon B
electrode O
( O
GMGCE O
) O
and O
the O
enhancement O
effect O
of O
an O
anionic O
surfactant O
: O
sodium B
dodecyl I
sulphonate I
( O
SDS B
) O
. O

Using O
pH O
6 O
. O
0 O
phosphate B
buffer O
solution O
( O
PBS O
) O
as O
supporting O
electrolyte O
and O
in O
the O
presence O
of O
1 O
. O
5 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
SDS B
, O
Sudan B
I I
yielded O
a O
well O
- O
defined O
and O
sensitive O
oxidation O
peak O
at O
a O
GMGCE O
. O

The O
oxidation O
peak O
current O
of O
Sudan B
I I
remarkably O
increased O
in O
the O
presence O
of O
SDS B
. O

The O
experimental O
parameters O
, O
such O
as O
supporting O
electrolyte O
, O
concentration O
of O
SDS B
, O
and O
accumulation O
time O
, O
were O
optimised O
for O
Sudan B
I I
determination O
. O

The O
oxidation O
peak O
current O
showed O
a O
linear O
relationship O
with O
the O
concentrations O
of O
Sudan B
I I
in O
the O
range O
of O
7 O
. O
50 O
x O
10 O
( O
- O
8 O
) O
- O
7 O
. O
50 O
x O
10 O
( O
- O
6 O
) O
mol O
L O
( O
- O
1 O
) O
, O
with O
the O
detection O
limit O
of O
4 O
. O
0 O
x O
10 O
( O
- O
8 O
) O
mol O
L O
( O
- O
1 O
) O
. O

This O
new O
voltammetric O
method O
was O
successfully O
used O
to O
determine O
Sudan B
I I
in O
food O
products O
such O
as O
ketchup O
and O
chili O
sauce O
with O
satisfactory O
results O
. O

Significantly O
( O
p O
< O
0 O
. O
05 O
) O
increased O
levels O
of O
polyphenol B
metabolites O
, O
hippuric B
acid I
and O
4 B
- I
hydroxyhippuric I
acid I
, O
and O
decreased O
creatinine B
and O
dimethylamine B
levels O
were O
the O
major O
explanations O
for O
the O
grouping O
of O
the O
postprandial O
samples O
after O
the O
different O
meals O
. O

Simultaneous O
determination O
of O
Mn2 B
+ I
and O
Fe3 B
+ I
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
complexes O
in O
some O
foods O
, O
vegetable O
and O
water O
samples O
by O
artificial O
neural O
networks O
. O

Simultaneous O
determination O
of O
Mn2 B
+ I
and O
Fe3 B
+ I
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
complexes O
in O
some O
foods O
, O
vegetable O
and O
water O
samples O
by O
artificial O
neural O
networks O
. O

Relative O
percentages O
of O
lipid O
classes O
and O
fatty B
acids I
/ O
acyls B
composition O
of O
the O
commercial O
feeds O
and O
fish O
dorsal O
muscles O
were O
assessed O
by O
means O
of O
an O
interdisciplinary O
analytical O
approach O
. O

While O
defined O
effects O
of O
feed O
composition O
on O
fatty B
acid I
profiles O
of O
fillets O
were O
ascertained O
, O
the O
relative O
increase O
of O
fatty B
acyls I
in O
triglycerides B
and O
phospholipids O
were O
also O
estimated O
enabling O
detailed O
evaluation O
of O
TAG O
: O
PL O
ratio O
in O
adult O
offshore O
- O
farmed O
gilthead O
sea O
bream O
. O

While O
defined O
effects O
of O
feed O
composition O
on O
fatty B
acid I
profiles O
of O
fillets O
were O
ascertained O
, O
the O
relative O
increase O
of O
fatty B
acyls I
in O
triglycerides B
and O
phospholipids O
were O
also O
estimated O
enabling O
detailed O
evaluation O
of O
TAG O
: O
PL O
ratio O
in O
adult O
offshore O
- O
farmed O
gilthead O
sea O
bream O
. O

Ascorbic B
acid I
and O
chlorogenic B
acid I
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin B
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

Ascorbic B
acid I
and O
chlorogenic B
acid I
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin B
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

All O
cooking O
treatments O
reduced O
ascorbic B
and I
chlorogenic B
acid I
contents O
, O
total O
glycoalkaloids B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
with O
the O
exception O
of O
total O
anthocyanins B
. O

All O
cooking O
treatments O
reduced O
ascorbic B
and I
chlorogenic B
acid I
contents O
, O
total O
glycoalkaloids B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
with O
the O
exception O
of O
total O
anthocyanins B
. O

Moreover O
, O
due O
to O
higher O
initial O
levels O
, O
red O
- O
and O
purple O
- O
fleshed O
cultivars O
retained O
higher O
amounts O
of O
antioxidants O
( O
ascorbic B
acid I
, O
chlorogenic B
acid I
and O
total O
anthocyanin B
) O
after O
boiling O
and O
may O
be O
healthier O
as O
compared O
with O
white O
or O
yellow O
cultivars O
. O

Moreover O
, O
due O
to O
higher O
initial O
levels O
, O
red O
- O
and O
purple O
- O
fleshed O
cultivars O
retained O
higher O
amounts O
of O
antioxidants O
( O
ascorbic B
acid I
, O
chlorogenic B
acid I
and O
total O
anthocyanin B
) O
after O
boiling O
and O
may O
be O
healthier O
as O
compared O
with O
white O
or O
yellow O
cultivars O
. O

Antioxidant O
activity O
of O
phytosteryl B
phenolates I
in O
different O
model O
systems O
. O

As O
part O
of O
a O
comprehensive O
study O
of O
the O
physiochemical O
and O
biological O
properties O
of O
phytosteryl B
phenolates I
, O
successfully O
synthesized O
chemoenzymatically O
in O
our O
lab O
, O
their O
antioxidant O
activity O
was O
evaluated O
using O
three O
different O
in O
vitro O
model O
systems O
, O
namely O
bulk O
oil O
model O
system O
, O
beta B
- I
carotene I
- O
linoleate B
model O
system O
and O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
oxidation O
assay O
. O

In O
the O
bulk O
oil O
system O
, O
phytosteryl B
phenolates I
showed O
similar O
or O
lower O
antioxidant O
activity O
compared O
with O
those O
of O
phenolic B
acids I
. O

In O
the O
bulk O
oil O
system O
, O
phytosteryl B
phenolates I
showed O
similar O
or O
lower O
antioxidant O
activity O
compared O
with O
those O
of O
phenolic B
acids I
. O

However O
, O
in O
beta B
- I
carotene I
- O
linoleate B
assay O
, O
an O
emulsion O
model O
system O
, O
phytosteryl B
phenolates I
showed O
enhanced O
antioxidant O
activity O
except O
phytosteryl B
ferulates I
. O

However O
, O
in O
beta B
- I
carotene I
- O
linoleate B
assay O
, O
an O
emulsion O
model O
system O
, O
phytosteryl B
phenolates I
showed O
enhanced O
antioxidant O
activity O
except O
phytosteryl B
ferulates I
. O

Moderate O
inhibitory O
effect O
of O
LDL O
- O
C O
oxidation O
by O
phytosteryl B
phenolates I
was O
observed O
. O

These O
findings O
demonstrate O
that O
use O
of O
multidimensional O
antioxidant O
activity O
determinations O
with O
differing O
reaction O
mechanisms O
is O
necessary O
to O
provide O
an O
overall O
understanding O
of O
the O
mechanisms O
of O
antioxidant O
action O
of O
phytosteryl B
phenolates I
. O

The O
method O
is O
based O
on O
the O
catalytic O
effect O
of O
silver B
nanoparticle O
( O
AgNPs O
) O
on O
the O
oxidation O
reaction O
of O
tartrazine B
by O
potassium B
iodate I
in O
the O
acetate B
buffer O
medium O
. O

Root O
tubers O
of O
Lactuca O
tuberosa O
as O
a O
source O
of O
antioxidant O
phenolic B
compounds O
and O
new O
furofuran B
lignans I
. O

From O
the O
root O
tubers O
of O
Lactuca O
tuberosa O
, O
a O
wild O
edible O
plant O
species O
, O
nine O
phenolic B
compounds O
were O
isolated O
, O
including O
two O
new O
furofuran B
lignan I
glucosides I
, O
named O
lactuberin B
A I
and O
lactuberin B
B I
. O

From O
the O
root O
tubers O
of O
Lactuca O
tuberosa O
, O
a O
wild O
edible O
plant O
species O
, O
nine O
phenolic B
compounds O
were O
isolated O
, O
including O
two O
new O
furofuran B
lignan I
glucosides I
, O
named O
lactuberin B
A I
and O
lactuberin B
B I
. O

This O
is O
the O
first O
time O
that O
compounds O
belonging O
to O
the O
epi O
series O
of O
2 B
, I
6 I
- I
diaryl I
- I
3 I
, I
7 I
- I
dioxabicyclo I
[ I
3 I
. I
3 I
. I
0 I
] I
octane I
type O
furofuran B
lignans I
have O
been O
found O
in O
Lactuca O
species O
. O

The O
total O
phenolic O
content O
of O
the O
root O
tuber O
extract O
was O
evaluated O
and O
its O
major O
phenolic B
constituents O
, O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
3 B
, I
5 I
dicaffeoylquinic I
acid I
, O
known O
to O
possess O
antioxidant O
activity O
, O
were O
quantified O
. O

The O
total O
phenolic O
content O
of O
the O
root O
tuber O
extract O
was O
evaluated O
and O
its O
major O
phenolic B
constituents O
, O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
3 B
, I
5 I
dicaffeoylquinic I
acid I
, O
known O
to O
possess O
antioxidant O
activity O
, O
were O
quantified O
. O

HPLC O
analysis O
also O
showed O
similar O
profiles O
of O
monosaccharide O
composition O
for O
APP O
and O
AFP O
with O
arabinose B
, O
galactose B
and O
galacturonic B
acid I
being O
main O
component O
monosaccharides O
. O

The O
kinetics O
of O
degradation O
of O
chlorogenic B
acid I
( O
CG O
) O
, O
( B
- I
) I
epicatechin I
( O
EPI B
) O
, O
L B
- I
ascorbic I
acid I
( O
AA O
) O
and O
polyphenoloxidase O
( O
PPO O
) O
activity O
from O
Marie O
- O
M O
e O
nard O
apple O
in O
pH O
3 O
. O
8 O
solutions O
at O
20 O
and O
50 O
degrees O
C O
were O
investigated O
to O
provide O
information O
on O
the O
impact O
of O
the O
presence O
of O
CG O
, O
EPI B
and O
/ O
or O
AA O
on O
PPO O
thermostability O
. O

Quantitative O
data O
from O
UHPLC O
and O
qualitative O
studies O
using O
HPLC O
- O
DAD O
- O
MS O
showed O
that O
in O
addition O
to O
commonly O
found O
phenolic B
acids I
, O
flavonoids B
and O
anthocyanins B
, O
R O
. O
hirta O
fruit O
contained O
a O
novel O
group O
of O
unique O
anthocyanins B
with O
aglycones O
( O
anthocyanidins B
) O
at O
449 O
, O
419 O
and O
433 O
Da O
. O

The O
chromogenic O
array O
used O
eight O
sensing O
materials O
( O
based O
on O
aluminium B
oxide I
and O
silica B
gel I
) O
containing O
pH O
indicators O
, O
Lewis B
acids I
and O
an O
oxidation O
- O
reduction O
indicator O
. O

The O
chromogenic O
array O
used O
eight O
sensing O
materials O
( O
based O
on O
aluminium B
oxide I
and O
silica B
gel I
) O
containing O
pH O
indicators O
, O
Lewis B
acids I
and O
an O
oxidation O
- O
reduction O
indicator O
. O

The O
chromogenic O
array O
used O
eight O
sensing O
materials O
( O
based O
on O
aluminium B
oxide I
and O
silica B
gel I
) O
containing O
pH O
indicators O
, O
Lewis B
acids I
and O
an O
oxidation O
- O
reduction O
indicator O
. O

Using O
HPLC O
- O
ESI O
- O
HR O
- O
MS O
, O
19 O
phenolic B
compounds O
( O
PCs O
) O
were O
tentatively O
characterised O
and O
included O
stilbenes B
and O
ellagitannins O
as O
major O
components O
, O
followed O
by O
anthocyanins B
, O
flavonols B
, O
and O
gallic B
acid I
. O

The O
hypocholesterolemic O
and O
antioxidant O
activities O
of O
various O
extracts O
( O
water O
, O
methanol B
, O
ethyl B
acetate I
, O
hexane B
, O
dichloro B
- I
methane I
) O
of O
fenugreek O
seeds O
were O
investigated O
in O
cholesterol B
- O
fed O
rats O
. O

Only O
the O
ethyl B
acetate I
extract O
reduced O
total O
cholesterol B
, O
triglycerides B
, O
and O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
and O
increased O
high O
- O
density O
lipoprotein O
cholesterol B
( O
HDL O
- O
C O
) O
compared O
with O
those O
of O
rats O
fed O
a O
cholesterol B
- O
rich O
diet O
( O
HCD O
) O
. O

Furthermore O
, O
the O
content O
of O
thiobarbituric B
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
catalase O
and O
superoxide B
dismutase O
( O
SOD O
) O
in O
liver O
, O
heart O
and O
kidney O
decreased O
significantly O
after O
oral O
administration O
of O
the O
ethyl B
acetate I
extract O
, O
compared O
with O
those O
of O
HCD O
- O
fed O
rats O
. O

Furthermore O
, O
the O
content O
of O
thiobarbituric B
acid I
- O
reactive O
substances O
( O
TBARS O
) O
, O
and O
catalase O
and O
superoxide B
dismutase O
( O
SOD O
) O
in O
liver O
, O
heart O
and O
kidney O
decreased O
significantly O
after O
oral O
administration O
of O
the O
ethyl B
acetate I
extract O
, O
compared O
with O
those O
of O
HCD O
- O
fed O
rats O
. O

The O
phenolic B
and O
flavono B
i I
d I
contents O
were O
highest O
in O
the O
methanol B
and O
the O
ethyl B
acetate I
extracts O
. O

These O
results O
showed O
that O
the O
ethyl B
acetate I
extract O
of O
the O
fenugreek O
seeds O
had O
a O
significant O
hypocholesterolemic O
effect O
and O
antioxidant O
activity O
in O
cholesterol B
- O
fed O
rats O
, O
whether O
this O
is O
partly O
due O
to O
the O
presence O
of O
flavono B
i I
ds I
in O
the O
extract O
needs O
further O
study O
. O

We O
searched O
for O
inhibitors O
of O
HDC O
from O
the O
ethyl B
acetate I
extract O
of O
the O
petal O
of O
Filipendula O
ulmaria O
, O
also O
called O
meadowsweet O
. O

Rugosin B
D I
, O
rugosin B
A I
, O
rugosin B
A I
methyl I
ester I
( O
a O
novel O
compound O
) O
, O
and O
tellimagrandin B
II I
were O
the O
main O
components O
; O
these O
4 O
ellagitannins O
exhibited O
a O
non O
- O
competitive O
type O
of O
inhibition O
, O
with O
K O
( O
i O
) O
values O
of O
approximately O
0 O
. O
35 O
- O
1 O
mu O
M O
. O

Rugosin B
D I
, O
rugosin B
A I
, O
rugosin B
A I
methyl I
ester I
( O
a O
novel O
compound O
) O
, O
and O
tellimagrandin B
II I
were O
the O
main O
components O
; O
these O
4 O
ellagitannins O
exhibited O
a O
non O
- O
competitive O
type O
of O
inhibition O
, O
with O
K O
( O
i O
) O
values O
of O
approximately O
0 O
. O
35 O
- O
1 O
mu O
M O
. O

Rugosin B
D I
, O
rugosin B
A I
, O
rugosin B
A I
methyl I
ester I
( O
a O
novel O
compound O
) O
, O
and O
tellimagrandin B
II I
were O
the O
main O
components O
; O
these O
4 O
ellagitannins O
exhibited O
a O
non O
- O
competitive O
type O
of O
inhibition O
, O
with O
K O
( O
i O
) O
values O
of O
approximately O
0 O
. O
35 O
- O
1 O
mu O
M O
. O

Total O
phenolics B
, O
radical O
scavenging O
activity O
( O
RSA O
) O
on O
DPPH B
, O
ascorbic B
acid I
content O
and O
chelating O
activity O
on O
Fe B
( I
2 I
+ I
) I
of O
Pleurotus O
citrinopileatus O
, O
Pleurotus O
djamor O
, O
Pleurotus O
eryngii O
, O
Pleurotus O
flabellatus O
, O
Pleurotus O
florida O
, O
Pleurotus O
ostreatus O
, O
Pleurotus O
sajor O
- O
caju O
and O
Hypsizygus O
ulmarius O
have O
been O
evaluated O
. O

The O
assayed O
mushrooms O
contained O
3 O
. O
94 O
- O
21 O
. O
67 O
mg O
TAE O
of O
phenolics B
, O
13 O
. O
63 O
- O
69 O
. O
67 O
% O
DPPH B
scavenging O
activity O
, O
3 O
. O
76 O
- O
6 O
. O
76 O
mg O
ascorbic B
acid I
and O
60 O
. O
25 O
- O
82 O
. O
7 O
% O
chelating O
activity O
. O

Principal O
Component O
Analysis O
( O
PCA O
) O
revealed O
that O
significantly O
higher O
total O
phenolics B
, O
RSA O
on O
DPPH B
and O
growth O
/ O
day O
was O
present O
in O
P O
. O
eryngii O
whereas O
P O
. O
citrinopileatus O
showed O
higher O
ascorbic B
acid I
and O
chelating O
activity O
. O

Procyanidin B
B3 I
spontaneously O
binds O
lysozyme O
, O
inducing O
the O
multilevel O
structural O
changes O
in O
lysozyme O
and O
the O
formation O
of O
insoluble O
complexes O
. O

Total O
amino B
acid I
profiles O
of O
heat O
- O
processed O
fresh O
Elaeis O
guineensis O
and O
Raphia O
hookeri O
wines O
. O

Total O
amino B
acid I
( O
AA O
) O
profiles O
of O
heat O
- O
processed O
fresh O
Elaeis O
guineensis O
and O
Raphia O
hookeri O
wines O
were O
studied O
. O

Iron B
( I
III I
) I
was O
reduced O
to O
iron B
( I
II I
) I
by O
ascorbic B
acid I
and O
preconcentrated O
on O
a O
mini O
- O
column O
packed O
with O
polyurethane B
foam O
( O
PUF O
) O
functionalized O
with O
N B
, I
N I
- I
bis I
( I
salicylidene I
) I
- I
1 I
, I
3 I
- I
propanediamine I
( O
SPDA B
) O
. O

The O
retained O
Fe B
( I
II I
) I
was O
eluted O
with O
hydrochloric B
acid I
and O
subsequently O
reacted O
to O
2 B
, I
4 I
, I
6 I
- I
tri I
( I
2 I
' I
- I
pyridyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
TPTZ B
) O
then O
measured O
at O
593 O
nm O
. O

Among O
them O
, O
apigenin B
- I
glucuronide I
, O
lucenin B
- I
2 I
and O
lithospermic B
acid I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
wines O
, O
there O
was O
an O
observed O
increase O
in O
yeast O
- O
derived O
metabolites O
, O
including O
volatile O
esters B
, O
dimethyl B
sulfide I
, O
glycerol B
and O
mannoproteins O
with O
harvest O
date O
. O

Wine O
volatiles O
which O
were O
significantly O
influenced O
by O
harvest O
date O
were O
isobutyl B
methoxypyrazine I
, O
C O
( O
6 O
) O
alcohols B
and O
hexyl B
acetate I
, O
all O
of O
which O
decreased O
as O
ripening O
progressed O
. O

Wine O
volatiles O
which O
were O
significantly O
influenced O
by O
harvest O
date O
were O
isobutyl B
methoxypyrazine I
, O
C O
( O
6 O
) O
alcohols B
and O
hexyl B
acetate I
, O
all O
of O
which O
decreased O
as O
ripening O
progressed O
. O

D B
/ O
H B
exchange O
in O
C B
- I
H I
bonds O
of O
fatty B
acids I
: O
implication O
for O
geographical O
discrimination O
of O
food O
materials O
. O

To O
further O
evaluate O
the O
reliability O
of O
hydrogen B
isotopes O
of O
organic O
molecules O
, O
we O
examined O
the O
isotope O
exchangeability O
in O
fatty B
acids I
within O
phospholipid O
bilayers O
exposed O
to O
D B
( I
2 I
) I
O I
for O
12h O
. O

The O
results O
indicate O
that O
the O
isotope O
ratio O
is O
clearly O
increased O
during O
all O
examines O
( O
e O
. O
g O
. O
, O
93 O
- O
328 O
/ O
1000 O
in O
50 O
% O
D B
( I
2 I
) I
O I
) O
, O
in O
which O
its O
magnitude O
depends O
on O
type O
of O
fatty B
acids I
and O
state O
of O
bilayers O
. O

Thermal O
degradation O
of O
broccoli O
glucoraphanin B
was O
investigated O
in O
addition O
to O
the O
effects O
of O
thermal O
processing O
on O
the O
formation O
of O
sulforaphane B
and O
sulforaphane B
nitrile I
. O

To O
this O
end O
, O
unheated O
and O
heated O
sesame O
seeds O
, O
sesame O
products O
, O
rye O
grains O
, O
rye O
flour O
, O
rye O
bread O
and O
flax O
seeds O
were O
extracted O
by O
sonication O
with O
ethanol B
/ O
water O
( O
70 O
: O
30 O
, O
v O
: O
v O
) O
or O
sodium B
methoxide I
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

Effect O
of O
ferrous B
sulfate I
fortification O
in O
germinated O
brown O
rice O
on O
seed O
iron B
concentration O
and O
bioavailability O
. O

Iron B
fortification O
during O
germination O
process O
with O
0 O
. O
05 O
- O
2 O
g O
/ O
L O
ferrous B
sulfate I
increased O
the O
iron B
concentration O
in O
germinated O
brown O
rice O
from O
1 O
. O
1 O
to O
15 O
. O
6 O
times O
than O
those O
in O
raw O
brown O
rice O
. O

Apoptosis O
of O
human O
breast O
cancer O
cells O
induced O
by O
microencapsulated O
betulinic B
acid I
from O
sour O
jujube O
fruits O
through O
the O
mitochondria O
transduction O
pathway O
. O

Betulinic B
acid I
( O
BA O
) O
, O
a O
natural O
pentacyclic B
triterpenoid I
, O
was O
isolated O
from O
sour O
jujube O
fruits O
for O
the O
first O
time O
. O

Betulinic B
acid I
( O
BA O
) O
, O
a O
natural O
pentacyclic B
triterpenoid I
, O
was O
isolated O
from O
sour O
jujube O
fruits O
for O
the O
first O
time O
. O

High O
serum O
vitamin B
D I
levels O
reduce O
the O
risk O
for O
nonalcoholic O
fatty O
liver O
disease O
in O
healthy O
men O
independent O
of O
metabolic O
syndrome O
. O

Recent O
studies O
suggest O
an O
association O
of O
vitamin B
D I
with O
obesity O
, O
diabetes O
and O
cardiovascular O
diseases O
. O

We O
analyzed O
the O
association O
of O
serum O
vitamin B
D I
level O
assessed O
by O
25 B
- I
hydroxyvitamin I
D I
( I
3 I
) I
{ O
25 B
( I
OH I
) I
D I
( I
3 I
) I
} O
with O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
in O
apparently O
healthy O
men O
. O

Thus O
, O
pH O
- O
sensitive O
polyvinylpyrrolidone B
- O
poly B
( I
acrylic I
acid I
) I
( O
PVP B
/ O
PAAc B
) O
nanogels O
prepared O
by O
gamma O
radiation O
- O
induced O
polymerization O
of O
acrylic B
acid I
( O
AAc B
) O
in O
an O
aqueous O
solution O
of O
polyvinylpyrrolidone B
( O
PVP B
) O
as O
a O
template O
polymer O
were O
used O
to O
encapsulate O
pilocarpine B
. O

Three O
pyrazolyl B
- I
diamine I
- O
containing O
chelators O
were O
conjugated O
to O
beta B
AlaNleCycMSHhex I
, O
with O
the O
resulting O
peptide O
conjugates O
displaying O
subnanomolar O
MC1R O
binding O
affinity O
. O

Reduction O
of O
dimethylarsinic B
acid I
to O
the O
highly O
toxic O
dimethylarsinous B
acid I
by O
rats O
and O
rat O
liver O
cytosol O
. O

Reduction O
of O
dimethylarsinic B
acid I
to O
the O
highly O
toxic O
dimethylarsinous B
acid I
by O
rats O
and O
rat O
liver O
cytosol O
. O

Dimethylarsinic B
acid I
( O
DMAs B
( I
V I
) I
) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic B
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous B
acid I
( O
DMAs B
( I
III I
) I
) O
, O
is O
highly O
toxic O
. O

Dimethylarsinic B
acid I
( O
DMAs B
( I
V I
) I
) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic B
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous B
acid I
( O
DMAs B
( I
III I
) I
) O
, O
is O
highly O
toxic O
. O

With O
a O
high O
throughput O
, O
HFs O
and O
necklace O
- O
like O
HFs O
of O
graphene B
oxide I
have O
been O
well O
- O
controlled O
produced O
with O
the O
ease O
of O
functionalization O
and O
conversion O
to O
graphene B
HFs O
via O
simply O
thermal O
or O
chemical O
reduction O
. O

Cyclosporine B
A I
, O
an O
immunosuppressant O
produced O
by O
a O
microbe O
, O
was O
derivatized O
to O
possess O
5 B
- I
sulfonyl I
tetrazole I
and O
a O
tag O
group O
, O
which O
enabled O
chemical O
tagging O
of O
cyclophilin O
A O
, O
the O
cellular O
receptor O
of O
cyclosporine B
A I
. O

Cyclosporine B
A I
, O
an O
immunosuppressant O
produced O
by O
a O
microbe O
, O
was O
derivatized O
to O
possess O
5 B
- I
sulfonyl I
tetrazole I
and O
a O
tag O
group O
, O
which O
enabled O
chemical O
tagging O
of O
cyclophilin O
A O
, O
the O
cellular O
receptor O
of O
cyclosporine B
A I
. O

Cyclosporine B
A I
derivative O
possessing O
5 B
- I
sulfinyl I
tetrazole I
could O
not O
tag O
cyclophilin O
A O
. O

Inorganic O
anions O
such O
as O
cyanate B
, O
cyanide B
, O
hydrogen B
sulfide I
, O
hydrogen B
sulfite I
, O
and O
trithiocarbonate B
were O
effective O
VchCA O
inhibitors O
with O
inhibition O
constants O
in O
the O
range O
of O
33 O
- O
88 O
mu O
M O
. O

Inorganic O
anions O
such O
as O
cyanate B
, O
cyanide B
, O
hydrogen B
sulfide I
, O
hydrogen B
sulfite I
, O
and O
trithiocarbonate B
were O
effective O
VchCA O
inhibitors O
with O
inhibition O
constants O
in O
the O
range O
of O
33 O
- O
88 O
mu O
M O
. O

Other O
effective O
inhibitors O
were O
diethyldithiocarbama B
, O
sulfamide B
, O
sulfamate B
, O
phenylboronic B
acid I
and O
phenylarsonic B
acid I
, O
with O
KIs O
of O
7 O
- O
43 O
mu O
M O
. O

Other O
effective O
inhibitors O
were O
diethyldithiocarbama B
, O
sulfamide B
, O
sulfamate B
, O
phenylboronic B
acid I
and O
phenylarsonic B
acid I
, O
with O
KIs O
of O
7 O
- O
43 O
mu O
M O
. O

Synthesis O
of O
tetrazole O
analogues O
of O
phosphonohydroxamic B
acids I
: O
an O
attempt O
to O
improve O
the O
inhibitory O
activity O
against O
the O
DXR O
. O

Stability O
of O
black O
cohosh O
triterpene B
glycosides I
and O
polyphenols B
: O
Potential O
clinical O
relevance O
. O

Analytical O
results O
showed O
that O
the O
major O
constituents O
, O
both O
triterpene B
glycosides I
and O
polyphenols B
, O
were O
stable O
over O
the O
3 O
- O
year O
period O
of O
testing O
. O

Efficient O
synthesis O
of O
anacardic B
acid I
analogues O
and O
their O
antibacterial O
activities O
. O

Anacardic B
acid I
derivatives O
exhibit O
a O
broad O
range O
of O
biological O
activities O
. O

In O
this O
report O
, O
an O
efficient O
method O
for O
the O
synthesis O
of O
anacardic B
acid I
derivatives O
was O
explored O
, O
and O
a O
small O
set O
of O
salicylic B
acid I
variants O
synthesised O
retaining O
a O
constant O
hydrophobic O
element O
( O
a O
naphthyl B
tail O
) O
. O

In O
this O
report O
, O
an O
efficient O
method O
for O
the O
synthesis O
of O
anacardic B
acid I
derivatives O
was O
explored O
, O
and O
a O
small O
set O
of O
salicylic B
acid I
variants O
synthesised O
retaining O
a O
constant O
hydrophobic O
element O
( O
a O
naphthyl B
tail O
) O
. O

The O
failure O
of O
ortho O
- O
metalation O
using O
unprotected O
carboxylic B
acid I
group O
compelled O
us O
to O
use O
directed O
ortho O
- O
metalation O
in O
which O
a O
tertiary B
amide I
was O
used O
as O
a O
strong O
ortho O
- O
directing O
group O
. O

The O
failure O
of O
ortho O
- O
metalation O
using O
unprotected O
carboxylic B
acid I
group O
compelled O
us O
to O
use O
directed O
ortho O
- O
metalation O
in O
which O
a O
tertiary B
amide I
was O
used O
as O
a O
strong O
ortho O
- O
directing O
group O
. O

In O
the O
initial O
route O
, O
tertiary B
amide I
cleavage O
during O
final O
step O
was O
challenging O
, O
but O
cleaving O
the O
tertiary B
amide I
before O
Wittig O
reaction O
was O
beneficial O
. O

In O
the O
initial O
route O
, O
tertiary B
amide I
cleavage O
during O
final O
step O
was O
challenging O
, O
but O
cleaving O
the O
tertiary B
amide I
before O
Wittig O
reaction O
was O
beneficial O
. O

The O
Wittig O
reaction O
with O
protected O
carboxylic B
group O
( O
methyl B
ester I
) O
resulted O
in O
side O
- O
products O
whereas O
using O
sodium B
salt O
resulted O
in O
higher O
yields O
. O

Improvement O
of O
the O
inhibitory O
activity O
and O
chemical O
stability O
of O
this O
series O
of O
compounds O
was O
respectively O
achieved O
by O
the O
introduction O
of O
bulky O
groups O
at O
the O
4 O
- O
position O
and O
1 O
- O
position O
of O
the O
piperidinyl B
glycine I
, O
leading O
to O
a O
series O
of O
potent O
and O
stable O
DPP O
- O
IV O
inhibitors O
. O

The O
crystal O
structure O
of O
HSA O
complexed O
with O
fatty B
acid I
and O
acetyldiflunisal B
revealed O
that O
acetyldiflunisal B
binds O
to O
the O
IIA O
subdomain O
and O
that O
upon O
binding O
, O
it O
acetylates O
lysine B
199 O
. O

DCVC B
and O
TCVC B
have O
previously O
been O
demonstrated O
to O
be O
mutagenic O
by O
the O
Ames O
Salmonella O
mutagenicity O
assay O
, O
and O
reduction O
in O
mutagenicity O
was O
observed O
upon O
treatment O
with O
the O
beta O
- O
lyase O
inhibitor O
aminooxyacetic B
acid I
( O
AOAA B
) O
. O

The O
synthesis O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
was O
achieved O
by O
intramolecular O
Friedel O
- O
Crafts O
reaction O
of O
the O
acid B
chloride I
3 B
- I
methyl I
- I
1 I
, I
6 I
- I
diphenyl I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazine I
- I
5 I
- I
carboxylic I
acid I
chloride I
( O
4 O
) O
using O
AlCl3 B
in O
boiling O
CS2 B
. O

The O
extent O
to O
which O
different O
forms O
of O
nanoparticles O
of O
titanium B
dioxide I
( O
nano O
- O
TiO2 B
) O
aggregated O
with O
microalgae O
, O
decreased O
food O
levels O
and O
hence O
impaired O
growth O
, O
reproduction O
and O
fitness O
of O
Daphnia O
magna O
individuals O
were O
studied O
. O

Previous O
laboratory O
based O
studies O
have O
shown O
that O
oil O
sands O
process O
- O
affected O
waters O
( O
OSPWs O
) O
containing O
high O
concentrations O
of O
naphthenic B
acids I
( O
> O
25 O
mg O
/ O
l O
) O
have O
adverse O
effects O
on O
the O
reproductive O
physiology O
of O
fish O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
reproductive O
development O
and O
health O
of O
a O
wild O
population O
of O
fathead O
minnows O
( O
Pimephales O
promelas O
) O
inhabiting O
an O
OSPW O
pond O
that O
has O
moderate O
concentrations O
of O
naphthenic B
acids I
( O
~ O
10 O
mg O
/ O
l O
) O
. O

The O
present O
study O
addresses O
the O
bioaccumulation O
behavior O
of O
cadmium B
selenide I
quantum O
dots O
by O
Eisenia O
andrei O
earthworms O
in O
a O
terrestrial O
environment O
. O

Results O
were O
compared O
with O
those O
from O
earthworms O
exposed O
to O
cadmium B
nitrate I
and O
selenious B
acid I
, O
as O
positive O
controls O
, O
and O
those O
exposed O
in O
untreated O
soil O
( O
negative O
control O
) O
. O

Results O
were O
compared O
with O
those O
from O
earthworms O
exposed O
to O
cadmium B
nitrate I
and O
selenious B
acid I
, O
as O
positive O
controls O
, O
and O
those O
exposed O
in O
untreated O
soil O
( O
negative O
control O
) O
. O

In O
contrast O
to O
pristine O
zinc B
phthalocyanine I
( O
1 O
) O
, O
zinc B
phthalocyanine I
based O
oPPV B
- O
oligomers O
( O
2 O
- O
4 O
) O
of O
different O
chain O
lengths O
interact O
tightly O
and O
reversibly O
with O
graphite B
, O
affording O
stable O
and O
finely O
dispersed O
suspensions O
of O
mono O
- O
to O
few O
- O
layer O
graphene B
- O
nanographene O
( O
NG O
) O
- O
that O
are O
photoactive O
. O

In O
contrast O
to O
pristine O
zinc B
phthalocyanine I
( O
1 O
) O
, O
zinc B
phthalocyanine I
based O
oPPV B
- O
oligomers O
( O
2 O
- O
4 O
) O
of O
different O
chain O
lengths O
interact O
tightly O
and O
reversibly O
with O
graphite B
, O
affording O
stable O
and O
finely O
dispersed O
suspensions O
of O
mono O
- O
to O
few O
- O
layer O
graphene B
- O
nanographene O
( O
NG O
) O
- O
that O
are O
photoactive O
. O

In O
NG O
/ O
2 O
, O
NG O
/ O
3 O
, O
and O
NG O
/ O
4 O
hybrids O
, O
strong O
electronic O
coupling O
between O
the O
individual O
components O
gives O
rise O
to O
charge O
transfer O
from O
the O
photoexcited O
zinc B
phthalocyanines I
to O
NG O
to O
form O
hundreds O
of O
picoseconds O
lived O
charge O
transfer O
states O
. O

Seventeen O
steviol B
derivatives O
, O
i O
. O
e O
. O
, O
2 O
- O
18 O
, O
and O
19 O
isosteviol B
derivatives O
, O
i O
. O
e O
. O
, O
19 O
- O
37 O
, O
were O
prepared O
from O
a O
diterpenoid B
glycoside I
, O
stevioside B
( O
1 O
) O
. O

The O
root O
essential O
oil O
was O
distinguished O
by O
its O
high O
content O
in O
acetylenes B
( O
matricaria B
ester I
, O
4 O
; O
74 O
. O
3 O
% O
) O
, O
while O
those O
from O
flower O
heads O
and O
leaves O
were O
dominated O
by O
oxygenated O
sesquiterpenes B
( O
61 O
. O
1 O
and O
50 O
. O
3 O
% O
, O
resp O
. O
) O
. O

The O
oils O
of O
C O
. O
sumatrensis O
from O
Tunisia O
belonged O
to O
a O
matricaria B
ester I
/ O
caryophyllene B
oxide I
chemotype O
. O

The O
oils O
of O
C O
. O
sumatrensis O
from O
Tunisia O
belonged O
to O
a O
matricaria B
ester I
/ O
caryophyllene B
oxide I
chemotype O
. O

Optical O
response O
of O
individual O
Au B
- I
Ag I
@ O
SiO B
2 I
heterodimers O
. O

Beyond O
H B
( I
2 I
) I
S I
and O
NO B
Interplay O
: O
Hydrogen B
Sulfide I
and O
Nitroprusside B
React O
Directly O
to O
Give O
Nitroxyl B
( O
HNO B
) O
. O

Hydrogen B
sulfide I
( O
H B
( I
2 I
) I
S I
) O
has O
been O
increasingly O
recognized O
as O
an O
important O
signaling O
molecule O
that O
regulates O
both O
blood O
pressure O
and O
neuronal O
activity O
. O

Attention O
has O
been O
drawn O
to O
its O
interactions O
with O
another O
gasotransmitter O
, O
nitric B
oxide I
( O
NO B
) O
. O

Here O
, O
we O
provide O
evidence O
that O
the O
physiological O
effects O
observed O
upon O
the O
application O
of O
sodium B
nitroprusside I
( O
SNP B
) O
and O
H B
( I
2 I
) I
S I
can O
be O
ascribed O
to O
the O
generation O
of O
nitroxyl B
( O
HNO B
) O
, O
which O
is O
a O
direct O
product O
of O
the O
reaction O
between O
SNP B
and O
H B
( I
2 I
) I
S I
, O
not O
a O
consequence O
of O
released O
NO B
subsequently O
reacting O
with O
H B
( I
2 I
) I
S I
. O

PT O
cells O
from O
NPX O
rats O
that O
were O
first O
preincubated O
with O
GSH B
were O
protected O
from O
cytotoxicity O
due O
to O
the O
mitochondrial O
inhibitor O
antimycin B
A I
by O
overexpression O
of O
either O
of O
the O
two O
mitochondrial O
GSH B
transporters O
. O

Screening O
of O
transition O
and O
post O
- O
transition O
metals O
to O
incorporate O
into O
copper B
oxide I
and O
copper B
bismuth I
oxide I
for O
photoelectrochemical O
hydrogen B
evolution O
. O

Of O
the O
22 O
metals O
tested O
, O
10 O
show O
a O
M O
- O
Cu B
oxide I
with O
higher O
photoactivity O
than O
CuO B
and O
10 O
show O
a O
Bi B
- O
M O
- O
Cu B
oxide B
with O
higher O
photoactivity O
than O
CuBi2O4 B
. O

SCOT O
catalyzes O
the O
first O
, O
rate O
- O
limiting O
step O
of O
ketone B
body O
utilization O
in O
peripheral O
tissues O
, O
by O
transferring O
a O
CoA B
moiety O
from O
succinyl B
- I
CoA I
to O
form O
acetoacetyl B
- I
CoA I
, O
for O
entry O
into O
the O
tricarboxylic B
acid I
cycle O
for O
energy O
production O
. O

Three O
new O
lanostanoid B
triterpenes I
from O
the O
fruiting O
bodies O
of O
Ganoderma O
tropicum O
. O

Three O
new O
lanostanoid B
triterpenes I
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
methyl I
ester I
( O
2 O
) O
, O
and O
3 B
beta I
, I
15 I
beta I
- I
dihydroxy I
- I
7 I
, I
11 I
, I
23 I
- I
trioxo I

Reversal O
effect O
of O
rosmarinic B
acid I
on O
multidrug O
resistance O
in O
SGC7901 O
/ O
Adr B
cell O
. O

In O
this O
study O
, O
the O
aim O
was O
to O
explore O
the O
reversal O
effect O
and O
its O
potential O
mechanism O
of O
rosmarinic B
acid I
( O
RA O
) O
on O
SGC7901 O
/ O
Adr O
cells O
. O

Two O
new O
piperidine B
alkaloids I
from O
Streptomyces O
sp O
. O

Two O
new O
piperidine B
alkaloids I
, O
streptazones B
E O
( O
1 O
) O
and O
F O
( O
2 O
) O
, O
were O
isolated O
from O
Streptomyces O
sp O
. O

Berberine B
is O
an O
isoquinoline B
alkaloid I
that O
has O
drawn O
extensive O
attention O
since O
it O
possesses O
various O
biological O
activities O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

We O
have O
investigated O
the O
adsorption O
and O
organization O
at O
the O
air O
/ O
water O
interface O
of O
catanionic O
molecules O
released O
from O
a O
dispersion O
of O
solid O
- O
like O
catanionic O
vesicles O
composed O
of O
myristic B
acid I
and O
cetyl B
trimethylammonium I
chloride I
at O
the O
2 O
: O
1 O
ratio O
. O

Two O
new O
coumarin B
glycosides I
from O
Chimonanthus O
nitens O
. O

Two O
new O
coumarin B
glycosides I
, O
namely O
nitensosides B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
six O
known O
compounds O
, O
scopolin B
( O
3 O
) O
, O
5 B
, I
6 I
, I
7 I
- I
trimethoxycoumarin I
( O
4 O
) O
, O
d B
- I
calycanthine I
( O
5 O
) O
, O
calycanthoside B
( O
6 O
) O
, O
xeroboside B
( O
7 O
) O
, O
and O
scopoletin B
( O
8 O
) O
, O
were O
isolated O
from O
Chimonanthus O
nitens O
. O

Electronic O
Spectroscopy O
and O
Electronic O
Structure O
of O
Copper B
Acetylide I
, O
CuCCH B
. O

Chromatographic O
separation O
of O
the O
ethyl B
acetate I
soluble O
part O
of O
the O
methanolic O
extract O
from O
Seriphidium O
stenocephalum O
yielded O
three O
new O
compounds O
: O
stenocepflavone B
( O
1 O
) O
, O
stenocepflavan B
( O
2 O
) O
, O
and O
stenocephol B
( O
3 O
) O
, O
together O
with O
cirsimaritin B
( O
4 O
) O
, O
5 B
, I
7 I
, I
5 I
' I
- I
trihydroxy I
- I
3 I
' I
, I
4 I
' I
, I
6 I
- I
trimethoxyflavone I
( O
5 O
) O
, O
5 B
, I
6 I
, I
7 I
, I
5 I
' I
- I
tetrahydroxy I

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

Compound O
1 O
was O
characterized O
as O
an O
unusual O
cyanogenic B
glycoside I
, O
while O
compound O
8 O
was O
isolated O
for O
the O
first O
time O
from O
a O
natural O
source O
. O

This O
is O
the O
first O
report O
of O
a O
cyanogenic B
glycoside I
from O
mistletoes O
. O

The O
neuroprotector O
kynurenic B
acid I
increases O
neuronal O
cell O
survival O
through O
neprilysin O
induction O
. O

Kynurenic B
acid I
( O
KYNA B
) O
, O
one O
of O
the O
main O
product O
of O
the O
kynurenine B
pathway O
originating O
from O
tryptophan B
, O
is O
considered O
to O
be O
neuroprotective O
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly B
{ I
N I
' I
- I
[ I
N I
- I
( I
2 I
- I
aminoethyl I
) I
- I
2 I
- I
aminoethyl I
] I
aspartamide I
} I
P B
[ I
Asp I
( I
DET I
) I
] I
and O
block O
copolymer O
: O
polyethylene B
glycol I
( B
PEG I
) I
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

Tissue O
thiobarbituric B
acid I
reactive O
substance O
( O
TBARS O
) O
and O
nitric B
oxide I
( O
NO B
) O
levels O
were O
highest O
in O
the O
DOX B
group O
. O

Tissue O
thiobarbituric B
acid I
reactive O
substance O
( O
TBARS O
) O
and O
nitric B
oxide I
( O
NO B
) O
levels O
were O
highest O
in O
the O
DOX B
group O
. O

Moreover O
, O
the O
energy O
barrier O
for O
the O
piperazine B
carboxylate I
was O
significantly O
lower O
than O
that O
for O
the O
cyclohexyl B
carbamate I
derived O
from O
URB597 B
. O

Moreover O
, O
the O
energy O
barrier O
for O
the O
piperazine B
carboxylate I
was O
significantly O
lower O
than O
that O
for O
the O
cyclohexyl B
carbamate I
derived O
from O
URB597 B
. O

Vapor O
- O
solid O
growth O
of O
high O
optical O
quality O
MoS B
2 I
monolayers O
with O
near O
- O
unity O
valley O
polarization O
. O

Evaluation O
of O
difluoromethyl B
ketones I
as O
agonists O
of O
the O
gamma B
- I
aminobutyric I
acid I
type O
B O
( O
GABAB O
) O
receptor O
. O

The O
design O
, O
synthesis O
, O
biological O
evaluation O
, O
and O
in O
vivo O
studies O
of O
difluoromethyl B
ketones I
as O
GABAB O
agonists O
that O
are O
not O
structurally O
analogous O
to O
known O
GABAB O
agonists O
, O
such O
as O
baclofen B
or O
3 B
- I
aminopropyl I
phosphinic I
acid I
, O
are O
presented O
. O

The O
difluoromethyl B
ketones I
were O
assembled O
in O
three O
synthetic O
steps O
using O
a O
trifluoroacetate B
- O
release O
aldol O
reaction O
. O

Following O
evaluation O
at O
clinically O
relevant O
GABA B
receptors O
, O
we O
have O
identified O
a O
difluoromethyl B
ketone I
that O
is O
a O
potent O
GABAB O
agonist O
, O
obtained O
its O
X O
- O
ray O
structure O
, O
and O
presented O
preliminary O
in O
vivo O
data O
in O
alcohol B
- O
preferring O
mice O
. O

Structure O
- O
activity O
investigations O
determined O
that O
replacing O
the O
fluorines B
of O
the O
difluoromethyl B
ketone I
with O
hydrogens B
resulted O
in O
an O
inactive O
analogue O
. O

Resolution O
of O
the O
individual O
enantiomers O
of O
the O
difluoromethyl B
ketone I
provided O
a O
compound O
with O
full O
biological O
activity O
at O
concentrations O
less O
than O
an O
order O
of O
magnitude O
greater O
than O
the O
pharmaceutical O
, O
baclofen B
. O

Cardiac O
hypertrophy O
, O
structural O
remodeling O
, O
and O
expression O
of O
the O
genes O
associated O
with O
fatty B
acid I
metabolism O
were O
examined O
in O
rats O
treated O
with O
triiodothyronine B
( O
T3 O
) O
alone O
( O
8 O
mu O
g O
/ O
100 O
g O
body O
weight O
( O
BW O
) O
, O
i O
. O
p O
. O
) O
for O
15 O
days O
or O
along O
with O
a O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
agonist O
bezafibrate B
( O
Bzf B
; O
30 O
mu O
g O
/ O
100 O
g O
BW O
, O
oral O
) O
and O
were O
found O
to O
improve O
in O
the O
Bzf B
co O
- O
treated O
condition O
. O

A O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
phenylmethanesulfony B
fluoride I
reversed O
the O
inhibitory O
effect O
of O
( B
- I
) I
- I
cannabidiol I
on O
anandamide B
- O
induced O
contractions O
. O

The O
objective O
of O
this O
study O
was O
to O
investigate O
protective O
effects O
of O
calcium B
channel O
blockers O
( O
CCBs O
) O
verapamil B
and O
nimodipine B
on O
nephrotoxicity O
induced O
by O
Pb B
acetate I
in O
mice O
. O

Pb B
acetate I
was O
injected O
intraperitoneally O
( O
i O
. O
p O
. O
) O
at O
40 O
mg O
/ O
kg O
body O
weight O
/ O
day O
for O
10 O
days O
to O
establish O
the O
Pb B
toxicity O
model O
. O

In O
addition O
, O
verapamil B
and O
nimodipine B
administration O
decreased O
malondialdehyde B
content O
and O
increased O
activities O
of O
super B
oxide I
dismutase O
activity O
and O
glutathione B
peroxidase O
in O
the O
kidney O
homogenate O
. O

Therefore O
, O
to O
reveal O
the O
existence O
of O
more O
permanent O
alterations O
of O
DNA O
structure O
after O
genotoxic O
stress O
, O
the O
RTG O
- O
2 O
rainbow O
trout O
cell O
line O
was O
exposed O
for O
3days O
to O
benzo B
[ I
a I
] I
pyrene I
( O
B B
[ I
a I
] I
P I
, O
0 O
. O
1 O
- O
10 O
mu O
M O
) O
and O
ethyl B
methanesulfonate I
( O
EMS B
, O
0 O
. O
1 O
- O
1mM O
) O
followed O
by O
3days O
of O
recovery O
period O
. O

Four O
extracts O
were O
spiked O
with O
different O
doses O
of O
the O
sensitizers O
citral B
, O
cinnamic B
aldehyde I
and O
isoeugenol B
. O

The O
pro O
- O
apoptotic O
BCL O
- O
2 O
family O
member O
BOK O
is O
widely O
expressed O
and O
resembles O
the O
multi O
- O
BH O
domain O
proteins O
BAX O
and O
BAK O
based O
on O
its O
amino B
acid I
sequence O
. O

A O
role O
for O
BOK O
on O
the O
Golgi O
apparatus O
and O
the O
ER O
is O
supported O
by O
an O
abnormal O
response O
of O
Bok O
- O
deficient O
cells O
to O
the O
Golgi O
/ O
ER O
stressor O
brefeldin B
A I
. O

Cyclic O
stretch O
induces O
inducible O
nitric B
oxide I
synthase O
and O
soluble O
guanylate B
cyclase O
in O
pulmonary O
artery O
smooth O
muscle O
cells O
. O

Nitric B
oxide I
is O
a O
potent O
regulator O
of O
soluble O
guanylate B
cyclase O
( O
sGC O
) O
, O
which O
drives O
cGMP B
production O
, O
causing O
vasorelaxation O
. O

Pulmonary O
artery O
smooth O
muscle O
cells O
( O
PASMCs O
) O
express O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
, O
and O
while O
iNOS O
expression O
increases O
during O
late O
gestation O
, O
little O
is O
known O
about O
how O
cyclic O
stretch O
impacts O
this O
pathway O
. O

The O
difficulties O
associated O
with O
the O
decision O
whether O
testicular O
toxicity O
is O
primary O
or O
secondary O
to O
hypoxia O
are O
exemplified O
by O
the O
results O
of O
inhalation O
studies O
with O
nickel B
subsulphide I
and O
gallium B
arsenide I
( O
GaAs B
) O
. O

The O
difficulties O
associated O
with O
the O
decision O
whether O
testicular O
toxicity O
is O
primary O
or O
secondary O
to O
hypoxia O
are O
exemplified O
by O
the O
results O
of O
inhalation O
studies O
with O
nickel B
subsulphide I
and O
gallium B
arsenide I
( O
GaAs B
) O
. O

This O
may O
first O
be O
explained O
by O
different O
effects O
on O
the O
blood O
: O
nickel B
subsulphide I
inhalation O
leads O
to O
a O
compensatory O
erythropoiesis O
that O
may O
mitigate O
pulmonary O
lack O
of O
oxygen B
uptake O
. O

Furthermore O
, O
the O
predominant O
pulmonary O
effect O
caused O
by O
GaAs B
( O
but O
not O
by O
nickel B
subsulphide I
) O
is O
alveolar O
proteinosis O
. O

Exogenous O
sodium B
nitroprusside I
alleviates O
arsenic B
- O
induced O
oxidative O
stress O
in O
wheat O
( O
Triticum O
aestivum O
L O
. O
) O
seedlings O
by O
enhancing O
antioxidant O
defense O
and O
glyoxalase O
system O
. O

The O
present O
study O
investigates O
the O
possible O
regulatory O
role O
of O
exogenous O
nitric B
oxide I
( O
NO B
) O
in O
mitigating O
oxidative O
stress O
in O
wheat O
seedlings O
exposed O
to O
arsenic B
( O
As B
) O
. O

Seedlings O
were O
treated O
with O
NO B
donor O
( O
0 O
. O
25 O
mM O
sodium B
nitroprusside I
, O
SNP B
) O
and O
As B
( O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
Na2HAsO4 B
. I
7H2O I
) O
separately O
and O
/ O
or O
in O
combination O
and O
grown O
for O
72 O
h O
. O

The O
amount O
of O
reduced O
glutathione B
( O
GSH B
) O
and O
glutathione B
disulfide I
( O
GSSG B
) O
significantly O
increased O
with O
an O
increase O
in O
the O
level O
of O
As B
( O
both O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
) O
, O
while O
the O
GSH B
/ O
GSSG B
ratio O
decreased O
at O
higher O
concentration O
( O
0 O
. O
5 O
mM O
) O
. O

Recent O
studies O
demonstrate O
that O
Ca2 B
+ I
signal O
is O
essential O
for O
fibroblast O
proliferation O
, O
differentiation O
, O
and O
ECM O
- O
protein O
production O
. O

This O
review O
focuses O
on O
the O
recent O
advances O
in O
understanding O
molecular O
mechanisms O
of O
Ca2 B
+ I
signaling O
in O
cardiac O
fibrogenesis O
, O
and O
potential O
role O
of O
Ca2 B
+ I
- O
permeable O
channels O
, O
in O
particular O
, O
the O
transient O
potential O
( O
TRP O
) O
channels O
in O
fibrotic O
heart O
disease O
. O

This O
review O
focuses O
on O
the O
recent O
advances O
in O
understanding O
molecular O
mechanisms O
of O
Ca2 B
+ I
signaling O
in O
cardiac O
fibrogenesis O
, O
and O
potential O
role O
of O
Ca2 B
+ I
- O
permeable O
channels O
, O
in O
particular O
, O
the O
transient O
potential O
( O
TRP O
) O
channels O
in O
fibrotic O
heart O
disease O
. O

Thus O
, O
the O
Ca2 B
+ I
- O
permeable O
TRP O
channels O
may O
serve O
as O
potential O
novel O
targets O
for O
developing O
anti O
- O
fibrotic O
drugs O
. O

Multiple O
TRP O
subtypes O
are O
expressed O
in O
vascular O
smooth O
muscle O
cells O
and O
endothelial O
cells O
, O
where O
they O
form O
diverse O
non O
- O
selective O
cation O
channels O
permeable O
to O
Ca2 B
+ I
. O

These O
channels O
mediate O
Ca2 B
+ I
entry O
following O
receptor O
stimulation O
, O
Ca2 B
+ I
store O
depletion O
and O
mechanical O
stimulation O
of O
vascular O
myocytes O
and O
endothelial O
cells O
. O

These O
channels O
mediate O
Ca2 B
+ I
entry O
following O
receptor O
stimulation O
, O
Ca2 B
+ I
store O
depletion O
and O
mechanical O
stimulation O
of O
vascular O
myocytes O
and O
endothelial O
cells O
. O

Phase O
discrimination O
through O
oxidant O
selection O
in O
low O
- O
temperature O
atomic O
layer O
deposition O
of O
crystalline O
iron B
oxides I
. O

Control O
over O
the O
oxidation O
state O
and O
crystalline O
phase O
of O
thin O
- O
film O
iron B
oxides I
was O
achieved O
by O
low O
- O
temperature O
atomic O
layer O
deposition O
( O
ALD O
) O
, O
utilizing O
a O
novel O
iron B
precursor O
, O
bis B
( I
2 I
, I
4 I
- I
methylpentadienyl I
) I
iron I
. O

We O
utilized O
this O
process O
to O
prepare O
conformal O
iron B
oxide I
thin O
films O
on O
a O
porous O
framework O
, O
for O
which O
alpha B
- I
Fe2O3 I
is O
active O
for O
photocatalytic O
water O
splitting O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic B
acid I
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

Farnesylthiosalisyli B
acid I
( O
FTS B
) O
is O
a O
potent O
non O
- O
toxic O
anticancer O
drug O
that O
targets O
oncogenic O
and O
pathologically O
activated O
Ras O
. O

In O
- O
depth O
analysis O
of O
operando O
X O
- O
ray O
pair O
distribution O
function O
( O
PDF O
) O
data O
is O
combined O
with O
Li B
NMR O
spectroscopy O
to O
gain O
comprehensive O
insights O
into O
the O
electrochemical O
reaction O
mechanism O
of O
high O
- O
performance O
iron B
oxyfluoride I
electrodes O
. O

Herein O
we O
discuss O
a O
novel O
class O
of O
bioactive O
lipid O
mediators O
, O
which O
are O
enzymatically O
biosynthesized O
in O
vivo O
from O
omega B
- I
3 I
eicosapentaenoic I
acid I
( O
EPA B
) O
and O
docosahexaenoic B
acid I
( O
DHA B
) O
, O
termed O
resolvins B
. O

A O
library O
of O
novel O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
diaryl I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitriles I
have O
been O
synthesized O
regioselectively O
in O
good O
yields O
through O
the O
one O
- O
pot O
domino O
reactions O
of O
5 B
- I
aryldihydro I
- I
3 I
( I
2H I
) I
- I
thiophenones I
, O
malononitrile B
and O
aromatic B
aldehydes I
in O
the O
presence O
of O
morpholine B
. O

Synthesis O
and O
cytotoxicity O
evaluation O
of O
oleanolic B
acid I
derivatives O
. O

Twelve O
derivatives O
of O
oleanolic B
acid I
( O
1 O
) O
have O
been O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activities O
against O
the O
growth O
of O
prostate O
PC3 O
, O
breast O
MCF O
- O
7 O
, O
lung O
A549 O
, O
and O
gastric O
BGC O
- O
823 O
cancer O
cells O
by O
MTT B
assays O
. O

SAR O
analysis O
indicates O
that O
H B
- O
donor O
substitution O
at O
C O
- O
3 O
position O
of O
oleanolic B
acid I
may O
be O
advantageous O
for O
improvement O
of O
cytotoxicity O
against O
PC3 O
, O
A549 O
and O
MCF O
- O
7 O
cell O
lines O
. O

Coenzyme B
Q10 I
protects O
Pc12 O
cells O
from O
cisplatin B
- O
induced O
DNA O
damage O
and O
neurotoxicity O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
neuroprotective O
effect O
of O
a O
water O
- O
soluble O
formulation O
of O
coenzyme B
Q10 I
( O
WS O
- O
CoQ10 B
) O
in O
PC12 O
cells O
exposed O
to O
cisplatin B
, O
a O
chemotherapeutic O
agent O
with O
a O
dose O
- O
limiting O
factor O
due O
to O
neurotoxicity O
. O

Rapid O
and O
Sensitive O
Determination O
of O
Timosaponin B
AIII I
in O
Rat O
Plasma O
by O
LC O
- O
MS O
/ O
MS O
and O
Its O
Pharmacokinetic O
Application O
. O

A O
rapid O
sensitive O
and O
selective O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
for O
determination O
of O
timosaponin B
AIII I
( O
TA B
- I
III I
) O
in O
rat O
plasma O
, O
using O
ginsenoside B
Re I
as O
an O
internal O
standard O
( O
IS O
) O
. O

A O
rapid O
sensitive O
and O
selective O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
for O
determination O
of O
timosaponin B
AIII I
( O
TA B
- I
III I
) O
in O
rat O
plasma O
, O
using O
ginsenoside B
Re I
as O
an O
internal O
standard O
( O
IS O
) O
. O

Osteopontin O
( O
OPN O
) O
, O
an O
extracellular O
matrix O
protein O
, O
has O
a O
functional O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
domain O
for O
binding O
to O
integrin O
. O

Asperolide B
A I
, O
a O
marine O
- O
derived O
tetranorditerpenoid B
, O
induces O
G2 O
/ O
M O
arrest O
in O
human O
NCI O
- O
H460 O
lung O
carcinoma O
cells O
, O
is O
mediated O
by O
p53 O
- O
p21 O
stabilization O
and O
modulated O
by O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
. O

Here O
we O
first O
demonstrate O
that O
asperolide B
A I
, O
a O
very O
recently O
reported O
marine O
- O
derived O
tetranorditerpenoid B
, O
leads O
to O
the O
inhibition O
of O
NCI O
- O
H460 O
lung O
carcinoma O
cell O
proliferation O
by O
G2 O
/ O
M O
arrest O
with O
the O
activation O
of O
the O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
and O
p53 O
- O
dependent O
p21 O
pathway O
. O

Treatment O
with O
35 O
mu O
M O
asperolide B
A I
( O
2 O
x O
IC O
( O
50 O
) O
) O
resulted O
in O
a O
significant O
increase O
in O
the O
proportion O
of O
G2 O
/ O
M O
phase O
cells O
, O
about O
a O
2 O
. O
9 O
- O
fold O
increase O
during O
48 O
h O
. O

Moreover O
, O
asperolide B
A I
significantly O
activated O
MAP O
kinases O
( O
ERK1 O
/ O
2 O
, O
JNK O
and O
p38 O
MAP O
kinase O
) O
by O
phosphorylation O
, O
and O
only O
the O
inhibition O
of O
ERK O
activation O
by O
PD98059 B
reversed O
downregulation O
of O
G2 O
/ O
M O
regulatory O
proteins O
CDC2 O
, O
and O
suppressed O
upregulation O
of O
p21 O
and O
p O
- O
p53 O
levels O
. O

Transfection O
of O
cells O
with O
dominant O
- O
negative O
Ras O
( O
RasN17 O
) O
mutant O
genes O
up O
- O
regulated O
asperolide B
A I
- O
induced O
the O
decrease O
of O
cyclin O
B1 O
and O
CDC2 O
, O
suppressed O
Raf O
, O
ERK O
activity O
and O
p53 O
- O
p21 O
expression O
, O
and O
at O
last O
, O
abolished O
G2 O
/ O
M O
arrest O
. O

This O
study O
indicates O
that O
asperolide B
A I
- O
induced O
G2 O
/ O
M O
arrest O
in O
human O
NCI O
- O
H460 O
lung O
carcinoma O
cells O
relys O
on O
the O
participation O
of O
the O
Ras O
/ O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
in O
p53 O
- O
p21 O
stabilization O
. O

An O
in O
vivo O
study O
with O
asperolide B
A I
illustrated O
a O
marked O
inhibition O
of O
tumor O
growth O
, O
and O
little O
toxcity O
compared O
to O
Cisplatin B
therapy O
. O

Overall O
, O
these O
findings O
provide O
potential O
effectiveness O
and O
a O
theoretical O
basis O
for O
the O
therapeutic O
use O
of O
asperolide B
A I
in O
the O
treatment O
of O
malignancies O
. O

The O
lipid B
A I
moiety O
of O
Escherichia O
coli O
lipopolysaccharide O
is O
a O
hexaacylated B
disaccharide I
of O
glucosamine B
phosphorylated O
at O
the O
1 O
- O
and O
4 O
' O
- O
positions O
. O

The O
lipid B
A I
moiety O
of O
Escherichia O
coli O
lipopolysaccharide O
is O
a O
hexaacylated B
disaccharide I
of O
glucosamine B
phosphorylated O
at O
the O
1 O
- O
and O
4 O
' O
- O
positions O
. O

The O
toxicity O
of O
lipid B
A I
depends O
on O
its O
structure O
. O

In O
this O
study O
, O
two O
E O
. O
coli O
mutants O
, O
HW001 O
and O
HW002 O
, O
were O
constructed O
by O
deleting O
or O
integrating O
key O
genes O
related O
to O
lipid B
A I
biosynthesis O
in O
the O
chromosome O
of O
E O
. O
coli O
W3110 O
. O

The O
structures O
of O
lipid B
A I
made O
in O
HW001 O
and O
HW002 O
were O
confirmed O
by O
thin O
layer O
chromatography O
and O
electrospray O
ionization O
mass O
spectrometry O
. O

This O
study O
provides O
a O
feasible O
way O
to O
produce O
interesting O
lipid B
A I
species O
in O
E O
. O
coli O
. O

It O
was O
considered O
different O
patterns O
of O
amino B
acid I
substitution O
related O
to O
the O
lipocalins O
' O
motif O
2 O
, O
which O
was O
recently O
shown O
to O
modulate O
cell O
survival O
. O

Changes O
in O
morphometry O
and O
association O
between O
whole O
- O
body O
fatty B
acids I
and O
steroid B
hormone O
profiles O
in O
relation O
to O
bioaccumulation O
patterns O
in O
salmon O
larvae O
exposed O
to O
perfluorooctane B
sulfonic I
or I
perfluorooctane I
carboxylic I
acids I
. O

Tissue O
bioaccumulations O
were O
determined O
by O
HPLC O
/ O
MS O
/ O
MS O
, O
steroid B
hormones O
, O
fatty B
acids I
( O
FAs B
) O
and O
lipids O
were O
determined O
by O
GC O
- O
MS O
, O
while O
mRNA O
expression O
levels O
of O
genes O
were O
determined O
by O
qPCR O
in O
whole O
body O
homogenate O
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic B
MUFA I
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs B
alpha B
- I
linolenic I
acid I
[ O
ALA B
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic B
acid I
[ O
EPA B
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA B
: O
arachidonic B
acid I
[ O
ARA B
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic B
acid I
( O
DPA B
) O
by O
PFOA B
and O
PFOS B
were O
observed O
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic B
MUFA I
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs B
alpha B
- I
linolenic I
acid I
[ O
ALA B
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic B
acid I
[ O
EPA B
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA B
: O
arachidonic B
acid I
[ O
ARA B
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic B
acid I
( O
DPA B
) O
by O
PFOA B
and O
PFOS B
were O
observed O
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic B
MUFA I
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs B
alpha B
- I
linolenic I
acid I
[ O
ALA B
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic B
acid I
[ O
EPA B
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA B
: O
arachidonic B
acid I
[ O
ARA B
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic B
acid I
( O
DPA B
) O
by O
PFOA B
and O
PFOS B
were O
observed O
. O

Particularly O
, O
an O
increase O
in O
- O
pentadecenoic B
MUFA I
( O
15 O
: O
1 O
) O
, O
two O
n O
- O
3 O
PUFAs B
alpha B
- I
linolenic I
acid I
[ O
ALA B
: O
18 O
: O
3 O
n3 O
] O
and O
eicosapentaenoic B
acid I
[ O
EPA B
: O
20 O
: O
5 O
n O
- O
3 O
] O
and O
n O
- O
6 O
PUFA B
: O
arachidonic B
acid I
[ O
ARA B
: O
20 O
: O
4 O
n6 O
] O
, O
docosapentaenoic B
acid I
( O
DPA B
) O
by O
PFOA B
and O
PFOS B
were O
observed O
. O

Ferredoxin O
1 O
( O
FDX1 O
; O
adrenodoxin O
) O
is O
an O
iron B
- O
sulfur B
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid B
hormone I
synthesis O
in O
mammalian O
tissues O
. O

These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP B
signaling O
, O
and O
participates O
in O
steroid B
hormone I
production O
in O
ovarian O
granulosa O
cells O
. O

Pharmacogenomics O
of O
acetylsalicylic B
acid I
and O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
: O
clinical O
implications O
. O

The O
emerging O
role O
of O
hepatic O
transporters O
in O
regulating O
the O
movement O
of O
endogenous O
and O
exogenous O
chemicals O
( O
e O
. O
g O
. O
, O
bile B
acids I
and O
drugs O
) O
across O
cellular O
and O
tissue O
membranes O
is O
critical O
in O
determining O
the O
pathophysiology O
of O
liver O
disease O
as O
well O
as O
drug O
toxicity O
and O
efficacy O
. O

Liquid O
acetaminophen B
preparations O
contain O
propylene B
glycol I
, O
a O
common O
excipient O
that O
has O
been O
shown O
to O
reduce O
hepatocellular O
injury O
in O
vitro O
and O
in O
rodents O
. O

Propylene B
glycol I
, O
an O
established O
CYP2E1 O
competitive O
antagonist O
, O
was O
detected O
in O
the O
liquid O
formulation O
but O
not O
solid O
formulation O
arm O
. O

Readily O
accessible O
fluorescent O
probes O
for O
sensitive O
biological O
imaging O
of O
hydrogen B
peroxide I
. O

Hydrogen B
peroxide I
is O
a O
major O
component O
of O
oxygen B
metabolism O
in O
biological O
systems O
that O
, O
when O
present O
in O
high O
concentrations O
, O
can O
lead O
to O
oxidative O
stress O
in O
cells O
. O

Herein O
, O
we O
detail O
the O
development O
of O
robust O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
sensitive O
fluorescent O
probes O
using O
a O
boronic B
ester I
trigger O
appended O
to O
the O
fluorophore O
through O
a O
benzyl B
ether I
linkage O
. O

Herein O
, O
we O
detail O
the O
development O
of O
robust O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
sensitive O
fluorescent O
probes O
using O
a O
boronic B
ester I
trigger O
appended O
to O
the O
fluorophore O
through O
a O
benzyl B
ether I
linkage O
. O

Mifepristone B
( O
RU B
486 I
) O
, O
a O
first O
- O
in O
- O
class O
glucocorticoid O
receptor O
antagonist O
, O
was O
approved O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
in O
2012 O
for O
use O
in O
Cushing O
' O
s O
syndrome O
to O
control O
hyperglycemia O
in O
patients O
who O
are O
not O
surgical O
candidates O
or O
have O
not O
achieved O
remission O
from O
surgery O
. O

Gallic B
acid I
, O
a O
water O
- O
soluble O
ingredient O
in O
Pu O
- O
erh O
tea O
, O
stimulated O
Akt O
phosphorylation O
, O
but O
not O
AMPK O
phosphorylation O
. O

This O
protein O
, O
named O
MlatA1 O
, O
possesses O
61 O
amino B
acids I
with O
8 O
conserved O
cysteine B
residues O
, O
sharing O
30 O
- O
91 O
% O
sequence O
identity O
with O
other O
fully O
sequenced O
Micrurus O
toxins O
. O

Modified O
nanoprecipitation O
method O
was O
used O
for O
improved O
incorporation O
of O
hydrophilic O
drug O
( O
irinotecan B
hydrochloride I
) O
into O
the O
PLGA B
/ O
PEO B
- I
PPO I
- I
PEO I
blended O
and O
blended O
/ O
adsorbed O
nanoparticles O
. O

Ghrelin O
inhibits O
sodium B
metabisulfite I
induced O
oxidative O
stress O
and O
apoptosis O
in O
rat O
gastric O
mucosa O
. O

Forty O
male O
albino O
Wistar O
rats O
were O
randomized O
into O
control O
( O
C O
) O
, O
sodium B
metabisulfite I
( O
Na2S2O5 B
) O
treated O
( O
S O
) O
, O
ghrelin O
treated O
( O
G O
) O
and O
, O
Na2S2O5 B
+ O
ghrelin O
treated O
( O
SG O
) O
groups O
. O

Sodium B
metabisulfite I
( O
100mg O
/ O
kg O
/ O
day O
) O
was O
given O
by O
gastric O
gavage O
and O
, O
ghrelin O
( O
20 O
mu O
g O
/ O
kg O
/ O
day O
) O
was O
given O
intraperitoneally O
for O
5weeks O
. O

Vitamin B
A I
and O
retinoid B
signaling O
: O
genomic O
and O
non O
- O
genomic O
effects O
. O

Vitamin B
A I
or O
retinol B
is O
arguably O
the O
most O
multifunctional O
vitamin B
in O
the O
human O
body O
as O
it O
is O
essential O
from O
embryogenesis O
to O
adulthood O
. O

The O
pleiotropic O
effects O
of O
vitamin B
A I
are O
exerted O
mainly O
by O
one O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
which O
regulates O
the O
expression O
of O
a O
battery O
of O
target O
genes O
through O
several O
families O
of O
nuclear O
receptors O
( O
RARs O
, O
RXRs O
and O
PPAR O
beta O
/ O
delta O
) O
, O
polymorphic O
retinoic B
acid I
( O
RA O
) O
response O
elements O
and O
multiple O
coregulators O
. O

The O
pleiotropic O
effects O
of O
vitamin B
A I
are O
exerted O
mainly O
by O
one O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( O
atRA B
) O
, O
which O
regulates O
the O
expression O
of O
a O
battery O
of O
target O
genes O
through O
several O
families O
of O
nuclear O
receptors O
( O
RARs O
, O
RXRs O
and O
PPAR O
beta O
/ O
delta O
) O
, O
polymorphic O
retinoic B
acid I
( O
RA O
) O
response O
elements O
and O
multiple O
coregulators O
. O

However O
, O
vitamin B
A I
itself O
proved O
recently O
to O
be O
active O
and O
RARs O
to O
be O
present O
in O
the O
cytosol O
to O
regulate O
translation O
and O
cell O
plasticity O
. O

All O
these O
new O
concepts O
expand O
the O
scope O
of O
the O
biologic O
functions O
of O
vitamin B
A I
and O
RA O
. O

Phase O
stability O
and O
elastic O
properties O
of O
chromium B
borides I
with O
various O
stoichiometries O
. O

By O
first O
- O
principles O
calculations O
, O
we O
establish O
the O
phase O
stability O
of O
chromium B
borides I
with O
various O
stoichiometries O
. O

The O
synthetic O
polymer O
- O
based O
sorbent O
Diaion B
HP20SS I
( O
cross O
- O
linked O
polystyrene B
matrix O
) O
is O
used O
as O
an O
alternative O
to O
prepare O
purified O
natural O
product O
libraries O
. O

To O
evaluate O
the O
impact O
of O
chromatographic O
media O
on O
the O
isolation O
of O
biologically O
active O
, O
yet O
chromatographically O
unstable O
natural O
products O
, O
Diaion B
HP20SS I
was O
evaluated O
side O
- O
by O
- O
side O
with O
normal O
- O
phase O
sorbents O
for O
irreversible O
binding O
of O
extract O
constituents O
and O
their O
effects O
on O
bioactivity O
. O

A O
new O
pentacyclic B
phenol I
and O
other O
constituents O
from O
the O
root O
bark O
of O
Bauhinia O
racemosa O
Lamk O
. O

Racemosolone B
( O
1 O
) O
was O
characterised O
as O
a O
pentacyclic B
phenolic I
compound O
possessing O
an O
unusual O
skeleton O
with O
a O
cycloheptane B
ring O
and O
a O
rare O
furopyran B
moiety O
. O

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol B
and O
1 B
, I
7 I
, I
8 I
, I
12b I
- I
tetrahydro I
- I
2 I
, I
2 I
, I
4 I
- I
trimethyl I
- I
2H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
[ I
1 I
] I

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol B
and O
1 B
, I
7 I
, I
8 I
, I
12b I
- I
tetrahydro I
- I
2 I
, I
2 I
, I
4 I
- I
trimethyl I
- I
2H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
[ I
1 I
] I

Palytoxin B
( O
PLTX B
) O
is O
the O
reference O
compound O
for O
a O
group O
of O
potent O
marine O
biotoxins O
, O
for O
which O
the O
molecular O
target O
is O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

Palytoxin B
( O
PLTX B
) O
is O
the O
reference O
compound O
for O
a O
group O
of O
potent O
marine O
biotoxins O
, O
for O
which O
the O
molecular O
target O
is O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

However O
, O
in O
an O
effort O
to O
explain O
incomplete O
inhibition O
of O
PLTX B
cytotoxicity O
, O
some O
studies O
suggest O
the O
possibility O
of O
two O
different O
binding O
sites O
on O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

However O
, O
in O
an O
effort O
to O
explain O
incomplete O
inhibition O
of O
PLTX B
cytotoxicity O
, O
some O
studies O
suggest O
the O
possibility O
of O
two O
different O
binding O
sites O
on O
Na B
+ I
/ O
K B
+ I
- O
ATPase O
. O

This O
work O
is O
performed O
on O
the O
benchmark O
rare O
gas O
- O
hydrogen B
halide I
interaction O
( O
HCl B
- O
He B
) O
system O
. O

It O
interacts O
with O
cellular O
membrane O
of O
P O
. O
mirabilis O
and O
makes O
it O
highly O
permeable O
, O
forming O
nonspecific O
pores O
on O
plasma O
membrane O
, O
which O
in O
turn O
directs O
the O
release O
of O
260 O
nm O
absorbing O
materials O
and O
uptake O
of O
more O
crystal B
violet I
from O
the O
medium O
into O
the O
cells O
. O

The O
human O
cytosolic O
sulfotransferase O
hSULT2A1 O
catalyzes O
the O
sulfation O
of O
a O
broad O
range O
of O
xenobiotics O
, O
as O
well O
as O
endogenous O
hydroxysteroids B
and O
bile B
acids I
. O

Three O
thiol B
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1 O
: O
glutathione B
disulfide I
, O
5 B
, I
5 I
' I
- I
dithiobis I
( I
2 I
- I
nitrobenzoic I
acid I
) I
, O
and O
1 B
, I
1 I
' I
- I
azobis I
( I
N I
, I
N I
- I
dimethylformamide I
) O
( O
diamide B
) O
. O

Ypc1p O
can O
catalyze O
the O
reverse O
reaction O
, O
i O
. O
e O
. O
the O
condensation O
of O
free O
fatty B
acids I
with O
phytosphingosine B
or O
dihydrosphingosine B
and O
overexpression O
of O
YPC1 O
or O
YDC1 O
can O
provide O
enough O
ceramide B
synthesis O
as O
to O
rescue O
the O
viability O
of O
cells O
lacking O
the O
normal O
acyl B
- I
CoA I
- O
dependent O
ceramide O
synthases O
. O

The O
data O
allow O
inferring O
that O
all O
amino B
acids I
of O
Ypc1p O
that O
are O
conserved O
in O
the O
pfam O
PF05875 O
ceramidase O
motif O
and O
the O
CREST O
superfamily O
are O
located O
in O
or O
near O
the O
ER O
lumen O
. O

Rapid O
method O
for O
the O
separation O
and O
recovery O
of O
endocrine O
- O
disrupting O
compound O
bisphenol B
AP I
from O
wastewater O
. O

The O
removal O
of O
bisphenol B
AP I
( O
BPAP B
) O
by O
a O
multiwalled O
carbon B
nanotube O
( O
MWCNT O
) O
was O
investigated O
. O

The O
MWCNT O
has O
higher O
stability O
within O
8 O
removal O
- O
regeneration O
recycles O
, O
and O
up O
to O
95 O
% O
of O
recovery O
could O
be O
obtained O
by O
eluting O
the O
adsorbed O
BPAP B
on O
MWCNT O
adsorbent O
using O
ethanol B
/ O
sodium B
hydrate I
solution O
. O

Direct O
observation O
of O
a O
bent O
carbonyl B
ligand O
in O
a O
19 O
- O
electron O
transition B
metal I
complex O
. O

The O
minocycline B
hydrochloride I
( O
MH O
) O
, O
at O
higher O
doses O
, O
is O
useful O
in O
the O
treatment O
of O
neurodegenerative O
disorders O
and O
owing O
to O
its O
antioxidant O
potential O
, O
it O
may O
have O
nootropic O
effects O
. O

MH O
loaded O
nanoparticles O
( O
MHNP O
) O
were O
coated O
with O
tween B
80 I
( O
cMHNP O
) O
to O
improve O
its O
brain O
uptake O
followed O
by O
their O
optimization O
employing O
two O
factor O
- O
three O
level O
( O
3 O
( O
2 O
) O
) O
central O
composite O
design O
( O
CCD O
) O
in O
order O
to O
minimize O
particle O
size O
and O
maximize O
drug O
entrapment O
efficiency O
( O
DEE O
) O
and O
validated O
. O

The O
pharmacodynamic O
study O
was O
carried O
out O
using O
elevated O
plus O
maze O
( O
EPM O
) O
and O
Morris O
water O
maze O
( O
MWM O
) O
behavioral O
models O
for O
nootropic O
activity O
in O
swiss O
albino O
mice O
; O
and O
biochemical O
estimations O
( O
acetylcholine B
esterase O
, O
reduced B
glutathione I
, O
malondialdehyde B
and O
brain O
nitrite B
level O
) O
. O

Although O
cMHNP O
did O
not O
produce O
significant O
change O
in O
brain O
acetylcholinesterase O
, O
but O
, O
significantly O
increased O
reduced B
glutathione I
, O
malondialdehyde B
and O
reduced O
brain O
nitrite B
level O
as O
compared O
to O
saline O
, O
MH O
solution O
and O
MHNP O
treated O
groups O
. O

Increasing O
the O
proportion O
of O
magnesium B
stearate I
extended O
disintegration O
time O
. O

Three O
new O
orcinol B
( O
3 B
- I
hydroxy I
- I
5 I
- I
methylphenol I
) O
- O
conjugated O
hydrolysable O
tannins B
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin B
A I
( O
1 O
) O
, O
cleyeratannin B
B I
( O
2 O
) O
and O
cleyeratannin B
C I
( O
3 O
) O
. O

Three O
new O
orcinol B
( O
3 B
- I
hydroxy I
- I
5 I
- I
methylphenol I
) O
- O
conjugated O
hydrolysable O
tannins B
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin B
A I
( O
1 O
) O
, O
cleyeratannin B
B I
( O
2 O
) O
and O
cleyeratannin B
C I
( O
3 O
) O
. O

Three O
new O
orcinol B
( O
3 B
- I
hydroxy I
- I
5 I
- I
methylphenol I
) O
- O
conjugated O
hydrolysable O
tannins B
, O
together O
with O
two O
known O
compounds O
were O
isolated O
from O
the O
leaves O
of O
Cleyera O
japonica O
( O
CJ O
) O
, O
and O
have O
been O
tentatively O
named O
cleyeratannin B
A I
( O
1 O
) O
, O
cleyeratannin B
B I
( O
2 O
) O
and O
cleyeratannin B
C I
( O
3 O
) O
. O

To O
evaluate O
their O
anti O
- O
oxidative O
activities O
, O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
/ O
free O
radical O
scavenging O
activity O
and O
nitroblue B
tetrazolium I
( O
NBT B
) O
/ O
superoxide B
anion O
scavenging O
activity O
were O
determined O
. O

Ceramide B
phosphoethanolamine I
biosynthesis O
in O
Drosophila O
is O
mediated O
by O
a O
unique O
ethanolamine B
phosphotransferase O
in O
the O
Golgi O
lumen O
. O

Drosophila O
lacks O
SM O
and O
instead O
synthesizes O
the O
SM O
analogue O
ceramide B
phosphoethanolamine I
( O
CPE B
) O
as O
the O
principal O
membrane O
sphingolipid B
. O

Bacteriopheophytin B
a I
in O
the O
active O
branch O
of O
the O
reaction O
center O
of O
rhodobacter O
sphaeroides O
is O
not O
disturbed O
by O
the O
protein O
matrix O
as O
shown O
by O
13C B
photo O
- O
CIDNP O
MAS O
NMR O
. O

The O
electronic O
structure O
of O
bacteriopheophytin B
a I
( O
BPhe B
a I
) O
, O
the O
primary O
electron O
acceptor O
( O
Phi O
A O
) O
in O
photosynthetic O
reaction O
centers O
( O
RCs O
) O
of O
the O
purple O
bacterium O
Rhodobacter O
sphaeroides O
, O
is O
investigated O
by O
photochemically O
induced O
dynamic O
nuclear O
polarization O
( O
photo O
- O
CIDNP O
) O
magic O
- O
angle O
spinning O
( O
MAS O
) O
NMR O
spectroscopy O
at O
atomic O
resolution O
. O

The O
electronic O
structure O
of O
bacteriopheophytin B
a I
( O
BPhe B
a I
) O
, O
the O
primary O
electron O
acceptor O
( O
Phi O
A O
) O
in O
photosynthetic O
reaction O
centers O
( O
RCs O
) O
of O
the O
purple O
bacterium O
Rhodobacter O
sphaeroides O
, O
is O
investigated O
by O
photochemically O
induced O
dynamic O
nuclear O
polarization O
( O
photo O
- O
CIDNP O
) O
magic O
- O
angle O
spinning O
( O
MAS O
) O
NMR O
spectroscopy O
at O
atomic O
resolution O
. O

By O
comparison O
of O
these O
chemical O
shifts O
to O
those O
obtained O
from O
monomeric O
BPhe B
a I
in O
solution O
, O
it O
is O
demonstrated O
that O
Phi O
A O
in O
the O
active O
branch O
appears O
to O
be O
electronically O
close O
to O
free O
bacteriopheophytin B
. O

beta O
- O
Sheet O
Nanocrystalline O
Domains O
Formed O
from O
Phosphorylated B
Serine I
- O
Rich O
Motifs O
in O
Caddisfly O
Larval O
Silk O
: O
A O
Solid O
State O
NMR O
and O
XRD O
Study O
. O

Caddisfly O
larval O
silk O
is O
a O
fibroin O
protein O
based O
biopolymer O
containing O
mostly O
repetitive O
amino B
acid I
motifs O
. O

NMR O
and O
X O
- O
ray O
results O
provide O
strong O
supporting O
evidence O
for O
a O
structural O
model O
in O
which O
phosphorylated B
serine I
repeats O
( O
pSX O
) O
4 O
complex O
with O
divalent O
cations O
Ca B
( I
2 I
+ I
) I
and O
Mg B
( I
2 I
+ I
) I
to O
form O
rigid O
nanocrystalline O
beta O
- O
sheet O
structures O
in O
caddisfly O
silk O
. O

( B
13 I
) I
C I
NMR O
data O
suggests O
that O
both O
phosphorylated B
serine I
and O
neighboring O
valine B
residues O
exist O
in O
a O
beta O
- O
sheet O
conformation O
while O
glycine B
and O
leucine B
residues O
common O
in O
GGX O
repeats O
likely O
reside O
in O
random O
coil O
conformations O
. O

Jacaric B
acid I
and O
its O
octadecatrienoic B
acid I
geoisomers O
induce O
apoptosis O
selectively O
in O
cancerous O
human O
prostate O
cells O
: O
a O
mechanistic O
and O
3 O
- O
D O
structure O
- O
activity O
study O
. O

Jacaric B
acid I
and O
its O
octadecatrienoic B
acid I
geoisomers O
induce O
apoptosis O
selectively O
in O
cancerous O
human O
prostate O
cells O
: O
a O
mechanistic O
and O
3 O
- O
D O
structure O
- O
activity O
study O
. O

Plant O
- O
derived O
non O
- O
essential O
fatty B
acids I
are O
important O
dietary O
nutrients O
, O
and O
some O
are O
purported O
to O
have O
chemopreventive O
properties O
against O
various O
cancers O
, O
including O
that O
of O
the O
prostate O
. O

These O
fatty B
acids I
included O
jacaric B
and I
punicic I
acid I
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha B
- I
and I
beta I
- I
calendic I
and I
catalpic I
acid I
) O
and O
two O
mono B
- I
unsaturated I
C I
- I
18 I
fatty I
acids I
( O
trans B
- I
and I
cis I
- I
vaccenic I
acid I
) O
. O

Jacaric B
acid I
and O
four O
of O
its O
octadecatrienoic O
geoisomers O
selectively O
induced O
apoptosis O
in O
hormone O
- O
dependent O
( O
LNCaP O
) O
and O
- O
independent O
( O
PC O
- O
3 O
) O
human O
prostate O
cancer O
cells O
, O
whilst O
not O
affecting O
the O
viability O
of O
normal O
human O
prostate O
epithelial O
cells O
( O
RWPE O
- O
1 O
) O
. O

Jacaric B
acid I
induced O
concentration O
- O
and O
time O
- O
depedent O
LNCaP O
cell O
death O
through O
activation O
of O
intrinsic O
and O
extrinsic O
apoptotic O
pathways O
resulting O
in O
cleavage O
of O
PARP O
- O
1 O
, O
modulation O
of O
pro O
- O
and O
antiapoptotic O
Bcl O
- O
2 O
family O
of O
proteins O
and O
increased O
cleavage O
of O
caspase O
- O
3 O
, O
- O
8 O
and O
- O
9 O
. O

Jacaric B
acid I
induced O
apoptosis O
in O
PC O
- O
3 O
cells O
by O
activation O
of O
the O
intrinsic O
pathway O
only O
. O

The O
spatial O
conformation O
cis O
, O
trans O
, O
cis O
of O
jacaric B
and I
punicic I
acid I
was O
shown O
to O
play O
a O
key O
role O
in O
the O
increased O
potency O
and O
efficacy O
of O
these O
two O
fatty B
acids I
in O
comparison O
to O
the O
five O
other O
C B
- I
18 I
fatty I
acids I
tested O
. O

Three O
- O
dimensional O
conformational O
analysis O
using O
the O
PubChem O
Database O
( O
http O
: O
/ O
/ O
pubchem O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
) O
showed O
that O
the O
cytotoxic O
potency O
of O
the O
C B
- I
18 I
fatty I
acids I
was O
related O
to O
their O
degree O
of O
conformational O
similarity O
to O
our O
cytotoxic O
reference O
compound O
, O
punicic B
acid I
, O
based O
on O
optimized O
shape O
( O
ST O
) O
and O
feature O
( O
CT O
) O
similarity O
scores O
, O
with O
jacaric B
acid I
being O
most O
' O
biosimilar O
' O
( O
ST O
( O
ST O
- O
opt O
) O
= O
0 O
. O
81 O
; O
CT O
( O
CT O
- O
opt O
) O
= O

Three O
- O
dimensional O
conformational O
analysis O
using O
the O
PubChem O
Database O
( O
http O
: O
/ O
/ O
pubchem O
. O
ncbi O
. O
nlm O
. O
nih O
. O
gov O
) O
showed O
that O
the O
cytotoxic O
potency O
of O
the O
C B
- I
18 I
fatty I
acids I
was O
related O
to O
their O
degree O
of O
conformational O
similarity O
to O
our O
cytotoxic O
reference O
compound O
, O
punicic B
acid I
, O
based O
on O
optimized O
shape O
( O
ST O
) O
and O
feature O
( O
CT O
) O
similarity O
scores O
, O
with O
jacaric B
acid I
being O
most O
' O
biosimilar O
' O
( O
ST O
( O
ST O
- O
opt O
) O
= O
0 O
. O
81 O
; O
CT O
( O
CT O
- O
opt O
) O
= O

This O
3 O
- O
D O
analysis O
of O
structural O
similarity O
enabled O
us O
to O
rank O
geoisomeric O
fatty B
acids I
according O
to O
cytotoxic O
potency O
, O
whereas O
a O
2 O
- O
D O
positional O
assessment O
of O
cis O
/ O
trans O
structure O
did O
not O
. O

Our O
findings O
provide O
mechanistic O
evidence O
that O
nutrition O
- O
derived O
non O
- O
essential O
fatty B
acids I
have O
chemopreventive O
biological O
activities O
and O
Exhibit O
3 O
- O
D O
structure O
- O
activity O
relationships O
that O
could O
be O
exploited O
to O
develop O
new O
strategies O
for O
the O
prevention O
or O
treatment O
of O
prostate O
cancer O
regardless O
of O
hormone O
dependency O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

N B
- I
Alkyldeoxynojirimyci I
derivatives O
with O
novel O
terminal O
tertiary B
amide I
substitution O
for O
treatment O
of O
bovine O
viral O
diarrhea O
virus O
( O
BVDV O
) O
, O
Dengue O
, O
and O
Tacaribe O
virus O
infections O
. O

A O
novel O
NADNJ B
containing O
a O
terminal O
tertiary B
carboxamide I
moiety O
was O
discovered O
that O
was O
a O
potent O
inhibitor O
against O
BVDV O
. O

In O
particular O
, O
substituents O
with O
a O
tertiary B
amine I
linked O
via O
a O
two O
carbon B
chain O
show O
improved O
inhibitory O
potency O
for O
both O
enzyme O
isoforms O
. O

This O
potency O
improvement O
can O
be O
rationalized O
by O
X O
- O
ray O
crystallography O
, O
which O
shows O
a O
water O
- O
mediated O
contact O
between O
the O
basic O
nitrogen B
and O
the O
carboxylic B
acid I
side O
chain O
of O
Asp200 B
, O
which O
is O
situated O
at O
the O
mouth O
of O
the O
active O
site O
pocket O
of O
arginase O
II O
( O
Asp181 B
in O
arginase O
I O
) O
. O

Photofrin B
( O
R O
) O
( O
porfimer B
sodium I
) O
is O
a O
photosensitive O
reagent O
used O
for O
photodynamic O
therapy O
( O
PDT O
) O
of O
tumors O
and O
dysplasias O
. O

Examination O
of O
the O
effect O
of O
increasing O
the O
number O
of O
intra O
- O
disulfide B
amino I
functional O
groups O
on O
the O
performance O
of O
small O
molecule O
cyclic O
polyamine B
disulfide I
vectors O
. O

Examination O
of O
the O
effect O
of O
increasing O
the O
number O
of O
intra O
- O
disulfide B
amino I
functional O
groups O
on O
the O
performance O
of O
small O
molecule O
cyclic O
polyamine B
disulfide I
vectors O
. O

Herein O
we O
report O
on O
the O
significantly O
more O
challenging O
syntheses O
of O
cyclic B
disulfides I
with O
longer O
polyamine O
motifs O
. O

Toxins O
of O
Escherichia O
coli O
( O
STEC O
) O
causing O
Uremic O
Hemolytic O
Syndrome O
( O
UHS O
) O
generate O
oxidative O
stress O
in O
human O
blood O
with O
more O
production O
of O
nitric B
oxide I
( O
NO B
) O
than O
reactive O
oxygen B
species O
( O
ROS O
) O
. O

A O
cell O
- O
penetrating O
peptide O
suppresses O
the O
hypoxia O
inducible O
factor O
- O
1 O
function O
by O
binding O
to O
the O
helix O
- O
loop O
- O
helix O
domain O
of O
the O
aryl B
hydrocarbon I
receptor O
nuclear O
translocator O
. O

The O
heterodimeric O
hypoxia O
inducible O
factor O
- O
1 O
( O
HIF O
- O
1 O
) O
complex O
is O
composed O
of O
the O
hypoxia O
inducible O
factor O
- O
1 O
alpha O
( O
HIF O
- O
1 O
alpha O
) O
and O
the O
aryl B
hydrocarbon I
receptor O
nuclear O
translocator O
( O
ARNT O
) O
. O

At O
2 O
mu O
M O
concentration O
, O
6His B
- O
TAT O
- O
Ainp1 O
is O
not O
cytotoxic O
in O
HeLa O
cells O
but O
suppresses O
the O
cobalt B
chloride I
- O
activated O
, O
hypoxia O
responsive O
enhancer O
- O
driven O
luciferase O
expression O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
addition O
, O
it O
decreases O
the O
cobalt B
chloride I
- O
dependent O
induction O
of O
the O
HIF O
- O
1 O
target O
genes O
at O
both O
the O
message O
( O
vascular O
endothelial O
growth O
factor O
and O
aldolase O
C O
) O
and O
protein O
( O
carbonic O
anhydrase O
IX O
and O
glucose B
transporter O
1 O
) O
levels O
. O

Synthesis O
and O
biochemical O
activities O
of O
antiproliferative O
amino B
acid I
and O
phosphate B
derivatives O
of O
microtubule O
- O
disrupting O
beta B
- I
lactam I
combretastatins I
. O

Synthesis O
, O
evaluation O
and O
absolute O
configuration O
assignment O
of O
novel O
dihydropyrimidin B
- I
2 I
- I
ones I
as O
picomolar O
sodium B
iodide I
symporter O
inhibitors O
. O

Twelve O
compounds O
were O
tested O
for O
the O
inhibition O
of O
sodium B
iodide I
symporter O
( O
NIS O
) O
in O
a O
cell O
- O
based O
assay O
. O

the O
presence O
of O
sodium B
alkoxide I
in O
the O
corresponding O
alcohol B
. O

All O
the O
synthesized O
compounds O
showed O
significant O
vasodilation O
properties O
using O
isolated O
thoracic O
aortic O
rings O
of O
rats O
pre O
- O
contracted O
with O
norepinephrine B
hydrochloride I
standard O
technique O
. O

Compounds O
4d O
, O
4p O
, O
4l O
, O
and O
4f O
exhibited O
remarkable O
activity O
compared O
with O
prazosin B
hydrochloride I
, O
which O
was O
used O
as O
a O
reference O
standard O
in O
the O
present O
study O
. O

Molecular O
modeling O
studies O
concluded O
that O
recognition O
with O
key O
amino B
acid I
Arg38 B
and O
Lys31 B
are O
essential O
for O
binding O
and O
biological O
activities O
. O

Cyclic B
AMP I
signaling O
has O
a O
key O
role O
in O
retinoid B
treatment O
efficacy O
: O
it O
enhances O
ATRA B
- O
induced O
maturation O
in O
ATRA B
- O
sensitive O
APL O
cells O
( O
including O
NB4 O
cells O
) O
and O
restores O
it O
in O
some O
ATRA B
- O
resistant O
cells O
( O
including O
NB4 O
- O
LR1 O
cells O
) O
. O

Furthermore O
, O
the O
malondialdehyde B
level O
, O
superoxide B
dismutase O
, O
glutathione B
and O
glutathione B
peroxidase O
activities O
against O
aflatoxin B
B1 I
were O
determined O
for O
understanding O
the O
ways O
in O
which O
the O
lichens O
showed O
their O
genotoxic O
properties O
. O

One O
new O
flavonol B
, O
chlorflavonin B
A I
( O
1 O
) O
, O
four O
new O
diterpenoids B
, O
aspergiloids B
E I
- I
H I
( O
3 O
, O
5 O
- O
7 O
) O
, O
together O
with O
eight O
known O
compounds O
( O
2 O
, O
4 O
, O
8 O
- O
13 O
) O
were O
isolated O
from O
solid O
fermentation O
of O
Aspergillus O
sp O
. O

Thioflavin B
T I
and O
its O
photoirradiative O
derivatives O
: O
exploring O
their O
spectroscopic O
properties O
in O
the O
absence O
and O
presence O
of O
amyloid O
fibrils O
. O

In O
anti O
- O
inflammatory O
assays O
, O
usneoidone B
Z I
( O
11 O
) O
and O
its O
corresponding O
6E O
isomer O
( O
12 O
) O
showed O
significant O
activity O
as O
inhibitors O
of O
the O
production O
of O
the O
proinflammatory O
cytokine O
TNF O
- O
alpha O
in O
LPS O
- O
stimulated O
THP O
- O
1 O
human O
macrophages O
. O

Zinc B
oxide I
nanoparticle O
induced O
autophagic O
cell O
death O
and O
mitochondrial O
damage O
via O
reactive O
oxygen B
species O
generation O
. O

Zinc B
oxide I
nanoparticles O
( O
ZnO B
- O
np O
) O
are O
used O
in O
an O
increasing O
number O
of O
industrial O
products O
such O
as O
paint O
, O
coating O
and O
cosmetics O
, O
and O
in O
other O
biological O
applications O
. O

In O
vitro O
and O
in O
vivo O
evaluation O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
coated O
by O
bisphosphonates B
: O
The O
effects O
of O
electrical O
charge O
and O
molecule O
length O
. O

Physicochemical O
coating O
properties O
are O
often O
considered O
to O
be O
determining O
factors O
for O
in O
vivo O
characteristics O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
, O
used O
as O
contrast O
agent O
in O
Magnetic O
Resonance O
Imaging O
( O
MRI O
) O
. O

To O
investigate O
the O
electrical O
charge O
( O
modified O
by O
zero O
, O
one O
or O
two O
ammonium B
groups O
) O
and O
the O
molecule O
length O
( O
3 O
, O
5 O
or O
7 O
methylene B
chains O
) O
effects O
of O
bisphosphonate B
- O
type O
coatings O
, O
we O
assessed O
the O
complement O
activation O
, O
in O
vivo O
plasma O
and O
tissue O
relaxation O
time O
alterations O
of O
intravenously O
injected O
small O
iron B
oxide I
nanoparticles O
( O
< O
25nm O
) O
on O
male O
healthy O
Wistar O
rats O
. O

Polyethylene B
oxide I
( O
PEO B
) O
is O
used O
as O
a O
carrier O
polymer O
in O
a O
chemically O
cross O
- O
linking O
poly B
( I
ethylene I
glycol I
) I
- O
high O
molecular O
weight O
heparin O
( O
PEG B
- O
HMWH O
) O
hydrogel O
. O

Rhodamine B
B I
( O
Rh B
B I
) O
and O
fluorescein B
isothiocyanate I
( O
FITC B
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly B
lactic I
- I
co I
- I
glycolic I
acid I
( O
PLGA B
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Rhodamine B
B I
( O
Rh B
B I
) O
and O
fluorescein B
isothiocyanate I
( O
FITC B
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly B
lactic I
- I
co I
- I
glycolic I
acid I
( O
PLGA B
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Rhodamine B
B I
( O
Rh B
B I
) O
and O
fluorescein B
isothiocyanate I
( O
FITC B
) O
as O
model O
hydrophilic O
and O
hydrophobic O
small O
/ O
medium O
- O
size O
molecules O
, O
respectively O
, O
were O
encapsulated O
in O
poly B
lactic I
- I
co I
- I
glycolic I
acid I
( O
PLGA B
) O
nanoparticles O
( O
NPs O
) O
and O
delivered O
through O
full O
thickness O
porcine O
skin O
pretreated O
with O
MN O
array O
. O

Correlation O
between O
aflatoxin B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
aflatoxin B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
Ogun O
State O
, O
Nigeria O
. O

Correlation O
between O
aflatoxin B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
aflatoxin B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
Ogun O
State O
, O
Nigeria O
. O

Aflatoxin B
M1 I
( O
AF B
M1 I
) O
, O
a O
hydroxylated O
metabolite O
of O
AF B
B1 I
, O
is O
an O
important O
toxin O
that O
can O
contaminate O
the O
milk O
of O
lactating O
mothers O
. O

Aflatoxin B
M1 I
( O
AF B
M1 I
) O
, O
a O
hydroxylated O
metabolite O
of O
AF B
B1 I
, O
is O
an O
important O
toxin O
that O
can O
contaminate O
the O
milk O
of O
lactating O
mothers O
. O

Aflatoxin B
M1 I
( O
AF B
M1 I
) O
, O
a O
hydroxylated O
metabolite O
of O
AF B
B1 I
, O
is O
an O
important O
toxin O
that O
can O
contaminate O
the O
milk O
of O
lactating O
mothers O
. O

A O
correlation O
study O
was O
conducted O
to O
determine O
the O
relationship O
between O
AF B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
AF B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
the O
three O
Senatorial O
districts O
of O
Ogun O
State O
, O
Nigeria O
. O

A O
correlation O
study O
was O
conducted O
to O
determine O
the O
relationship O
between O
AF B
M1 I
content O
of O
breast O
milk O
, O
dietary O
exposure O
to O
AF B
B1 I
and O
socioeconomic O
status O
of O
lactating O
mothers O
in O
the O
three O
Senatorial O
districts O
of O
Ogun O
State O
, O
Nigeria O
. O

The O
level O
of O
contamination O
of O
the O
foods O
by O
AF B
B1 I
was O
low O
( O
0 O
. O
16 O
- O
0 O
. O
33 O
mu O
g O
/ O
kg O
) O
and O
differed O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
across O
the O
state O
but O
did O
not O
exceed O
the O
EU O
limit O
of O
2 O
mu O
g O
/ O
kg O
. O

The O
occurrence O
level O
of O
AF B
B1 I
was O
however O
high O
( O
93 O
. O
75 O
- O
94 O
. O
45 O
% O
) O
and O
was O
more O
pronounced O
in O
Ogun O
East O
Senatorial O
district O
( O
94 O
. O
45 O
% O
) O
. O

Eighty O
- O
two O
percent O
of O
the O
breast O
milk O
was O
contaminated O
with O
AF B
M1 I
( O
3 O
. O
49 O
- O
35ng O
/ O
l O
) O
and O
16 O
% O
exceeded O
the O
EU O
limit O
of O
25ng O
/ O
l O
while O
a O
100 O
% O
occurrence O
risk O
was O
recorded O
in O
Ogun O
Central O
Senatorial O
district O
. O

The O
socioeconomic O
status O
of O
the O
mothers O
also O
significantly O
influenced O
their O
dietary O
exposure O
and O
exposure O
risk O
of O
the O
sucklings O
to O
AF B
M1 I
. O

Cell O
cycle O
arrest O
, O
extracellular O
matrix O
changes O
and O
intrinsic O
apoptosis O
in O
human O
melanoma O
cells O
are O
induced O
by O
Boron B
Neutron O
Capture O
Therapy O
. O

A O
series O
of O
PACA B
- O
hydrogel O
hybrid O
systems O
with O
increasing O
PACA B
side O
chain O
hydrophobicity O
was O
prepared O
using O
physically O
crosslinked O
alginate O
films O
and O
hydrophilic O
diclofenac B
sodium I
as O
model O
hydrogel O
/ O
drug O
system O
. O

Anticancer O
drugs O
directed O
against O
the O
microtubule O
, O
including O
taxanes B
and O
vinca B
alkaloids I
, O
have O
been O
the O
backbone O
of O
many O
chemotherapy O
regimes O
for O
decades O
. O

Uncinataflavone B
, O
a O
new O
flavonoid B
with O
a O
methyl B
benzoate I
substituent O
from O
Selaginella O
uncinata O
. O

A O
new O
flavanol B
, O
named O
songarin B
A I
( O
1 O
) O
, O
was O
isolated O
from O
Cynomorium O
songaricum O
Rupr O
. O

Design O
, O
synthesis O
and O
antithrombotic O
evaluation O
of O
novel O
dabigatran B
prodrugs O
containing O
methyl B
ferulate I
. O

A O
novel O
series O
of O
prodrugs O
containing O
dabigatran B
and O
methyl B
( I
E I
) I
- I
3 I
- I
( I
4 I
- I
hydroxy I
- I
2 I
- I
methoxyphenyl I
) I
propenoate I
( O
methyl B
ferulate I
) O
were O
synthesized O
. O

In O
addition O
, O
in O
vivo O
experiment O
shows O
that O
one O
of O
the O
target O
compounds O
, O
X O
- O
2 O
( O
ED50 O
= O
3 O
. O
7 O
+ O
/ O
- O
1 O
. O
0 O
mu O
mol O
/ O
kg O
) O
possesses O
a O
more O
potent O
activity O
for O
inhibiting O
venous O
thrombosis O
than O
that O
of O
dabigatran B
etexilate I
( O
ED50 O
= O
7 O
. O
8 O
+ O
/ O
- O
1 O
. O
5 O
mu O
mol O
/ O
kg O
) O
. O

A O
series O
of O
3 B
- I
S I
- I
beta I
- I
d I
- I
glucosides I
- I
4 I
- I
arylideneamino I
- I
5 I
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazoles I
were O
rationally O
designed O
and O
synthesized O
according O
to O
the O
principle O
of O
superposition O
of O
bioactive O
substructures O
by O
the O
combination O
of O
1 B
, I
2 I
, I
4 I
- I
triazole I
, O
Schiff B
base I
and O
glucosides B
. O

Membranar O
effects O
exerted O
in O
vitro O
by O
polyphenols B
- O
quercetin B
, O
epigallocatechin B
gallate I
and O
curcumin B
- O
on O
HUVEC O
and O
Jurkat O
cells O
, O
relevant O
for O
diabetes O
mellitus O
. O

In O
the O
present O
study O
we O
assessed O
the O
effects O
exerted O
in O
vitro O
by O
quercetin B
, O
epigallocatechin B
gallate I
and O
curcumin B
on O
membrane O
fluidity O
and O
transmembrane O
potential O
of O
human O
umbilical O
vein O
endothelial O
cells O
and O
Jurkat O
T O
lymphoblasts O
, O
in O
experimental O
conditions O
mimicking O
diabetes O
mellitus O
, O
i O
. O
e O
. O
high O
glucose B
conditions O
or O
increased O
concentration O
of O
advanced O
glycation O
end O
products O
. O

Inhibition O
of O
Akt O
using O
PI3K O
inhibitor O
LY B
294002 I
could O
abrogate O
miR O
- O
21 O
induced O
cell O
survival O
. O

Since O
1985 O
, O
when O
Heyliger O
et O
al O
. O
, O
first O
demonstrated O
a O
serendipitous O
discovery O
that O
oral O
administration O
of O
0 O
. O
8 O
mg O
/ O
ml O
of O
sodium B
orthovanadate I
in O
drinking O
water O
to O
streptozotocin B
- O
induced O
diabetic O
rats O
resulted O
in O
normoglycemia O
, O
numerous O
extensive O
studies O
have O
been O
pursued O
on O
the O
anti O
- O
diabetic O
and O
insulinomimetic O
actions O
of O
vanadium B
. O

3 B
- I
Hydroxyazetidine I
carboxylic I
acids I
: O
non O
- O
proteinogenic O
amino B
acids I
for O
medicinal O
chemists O
. O

The O
long O
- O
term O
stability O
of O
3 B
- I
hydroxyazetidine I
amides I
is O
established O
at O
acidic O
and O
neutral O
pH O
and O
implies O
their O
value O
as O
non O
- O
proteinogenic O
amino B
acid I
components O
of O
peptides O
, O
providing O
medicinal O
chemists O
with O
a O
new O
class O
of O
peptide O
isosteres O
. O

The O
pinacolyl B
group O
of O
soman B
is O
retained O
, O
suggesting O
that O
pinacolyl B
methylphosphonate I
bound O
to O
tyrosine B
could O
generate O
specific O
antibodies O
. O

The O
soman B
- O
labeled O
tyrosines B
in O
these O
proteins O
are O
surrounded O
by O
different O
amino B
acid I
sequences O
, O
suggesting O
that O
the O
polyclonal O
recognizes O
soman B
- O
tyrosine B
independent O
of O
the O
amino B
acid I
sequence O
. O

The O
soman B
- O
labeled O
tyrosines B
in O
these O
proteins O
are O
surrounded O
by O
different O
amino B
acid I
sequences O
, O
suggesting O
that O
the O
polyclonal O
recognizes O
soman B
- O
tyrosine B
independent O
of O
the O
amino B
acid I
sequence O
. O

Crystalline O
growth O
of O
rubrene B
film O
enhanced O
by O
vertical O
ordering O
in O
cadmium B
arachidate I
multilayer O
substrate O
. O

Here O
, O
we O
report O
on O
the O
vapor O
- O
deposited O
growth O
of O
rubrene B
films O
on O
the O
substrates O
made O
of O
cadmium B
arachidate I
( O
CdA B
) O
multilayers O
deposited O
onto O
SiO2 B
/ O
Si B
( O
100 O
) O
via O
the O
Langmuir O
- O
Blodgett O
technique O
. O

A O
newly O
synthesized O
sinapic B
Acid I
derivative O
inhibits O
endothelial O
activation O
in O
vitro O
and O
in O
vivo O
. O

Sinapic B
acid I
( O
SA O
) O
, O
a O
phenylpropanoid B
compound O
, O
is O
found O
in O
natural O
herbs O
and O
high O
- O
bran O
cereals O
and O
has O
moderate O
antioxidant O
activity O
. O

Measurement O
of O
Transport O
Activities O
of O
3 B
beta I
- I
Hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
Acids I
in O
Bile B
Salt I
Export O
Pump O
and O
Multidrug O
Resistance O
- O
Associated O
Proteins O
Using O
LC O
- O
MS O
/ O
MS O
. O

Calibration O
curves O
for O
the O
bile B
acids I
were O
linear O
over O
the O
range O
of O
10 O
to O
2000 O
pmol O
/ O
mL O
, O
and O
the O
detection O
limit O
was O
less O
than O
1 O
pmol O
/ O
mL O
for O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
using O
selected O
reaction O
monitoring O
analysis O
. O

The O
analytical O
method O
was O
applied O
to O
measurements O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
human O
multidrug O
resistance O
- O
associated O
protein O
2 O
- O
, O
3 O
- O
, O
and O
human O
bile B
salt I
export O
pump O
- O
expressing O
Sf9 O
cells O
for O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
along O
with O
common O
bile B
acids I
such O
as O
glycocholic B
acid I
and O
taurolithocholic B
acid I
3 I
- I
sulfate I
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
along O
with O
common O
bile B
acids I
such O
as O
glycocholic B
acid I
and O
taurolithocholic B
acid I
3 I
- I
sulfate I
. O

A O
new O
anti O
- O
inflammatory O
triterpene B
saponin I
isolated O
from O
Anabasis O
setifera O
. O

Energies O
and O
Spin O
States O
of O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
Clusters O
. O

Energies O
and O
Spin O
States O
of O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
Clusters O
. O

Energies O
and O
Spin O
States O
of O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
Clusters O
. O

The O
structures O
and O
energies O
of O
the O
electronic O
ground O
states O
of O
the O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
neutral O
and O
anionic O
clusters O
have O
been O
computed O
systematically O
with O
nine O
computational O
methods O
in O
combination O
with O
seven O
basis O
sets O
. O

The O
structures O
and O
energies O
of O
the O
electronic O
ground O
states O
of O
the O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
neutral O
and O
anionic O
clusters O
have O
been O
computed O
systematically O
with O
nine O
computational O
methods O
in O
combination O
with O
seven O
basis O
sets O
. O

The O
structures O
and O
energies O
of O
the O
electronic O
ground O
states O
of O
the O
FeS B
( O
0 O
/ O
- O
) O
, O
FeS2 B
( O
0 O
/ O
- O
) O
, O
Fe2 B
S2 I
( O
0 O
/ O
- O
) O
, O
Fe3 B
S4 I
( O
0 O
/ O
- O
) O
, O
and O
Fe4 B
S4 I
( O
0 O
/ O
- O
) O
neutral O
and O
anionic O
clusters O
have O
been O
computed O
systematically O
with O
nine O
computational O
methods O
in O
combination O
with O
seven O
basis O
sets O
. O

Detailed O
comparisons O
between O
the O
available O
experimental O
and O
computed O
AEA O
data O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
identified O
the O
electronic O
ground O
state O
of O
( O
5 O
) O
Delta O
for O
FeS B
, O
( O
4 O
) O
Delta O
for O
FeS B
( I
- I
) I
, O
( O
5 O
) O
B2 O
for O
FeS2 B
, O
( O
6 O
) O
A1 O
for O
FeS2 B
( I
- I
) I
, O
( O
1 O
) O
A1 O
for O
Fe2 B
S2 I
, O
( O
8 O
) O
A O
' O
for O
Fe2 B
S2 I
( I
- I
) I
, O
( O
5 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
, O
( O
6 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
( I
- I
) I
, O
( O

Detailed O
comparisons O
between O
the O
available O
experimental O
and O
computed O
AEA O
data O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
identified O
the O
electronic O
ground O
state O
of O
( O
5 O
) O
Delta O
for O
FeS B
, O
( O
4 O
) O
Delta O
for O
FeS B
( I
- I
) I
, O
( O
5 O
) O
B2 O
for O
FeS2 B
, O
( O
6 O
) O
A1 O
for O
FeS2 B
( I
- I
) I
, O
( O
1 O
) O
A1 O
for O
Fe2 B
S2 I
, O
( O
8 O
) O
A O
' O
for O
Fe2 B
S2 I
( I
- I
) I
, O
( O
5 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
, O
( O
6 O
) O
A O
' O
' O
for O
Fe3 B
S4 I
( I
- I
) I
, O
( O

1 O
) O
A1 O
for O
Fe4 B
S4 I
, O
and O
( O
1 O
) O
A2 O
for O
Fe4 B
S4 I
( I
- I
) I
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

In O
addition O
, O
Fe2 B
S2 I
, O
Fe3 B
S4 I
, O
Fe3 B
S4 I
( I
- I
) I
, O
Fe4 B
S4 I
, O
and O
Fe4 B
S4 I
( I
- I
) I
are O
antiferromagnetic O
at O
the O
B3LYP O
/ O
6 O
- O
311 O
+ O
G O
* O
level O
. O

In O
the O
second O
part O
of O
the O
study O
, O
the O
various O
x O
, O
y O
- O
ionenes O
( O
x O
, O
y O
are O
numbers O
of O
methylene B
groups O
between O
the O
adjacent O
charges O
) O
with O
fluoride B
, O
bromide B
, O
and O
iodide B
counterions O
are O
mixed O
with O
aqueous O
sodium B
sulfate I
solution O
. O

We O
show O
that O
the O
salts O
when O
ordered O
by O
heat O
effects O
produced O
by O
mixing O
of O
NaF B
and O
NaBr B
with O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
or I
6 I
, I
12 I
- I
ionene I
fluorides I
and I
bromides I
follow O
the O
opposite O
ordering O
than O
in O
the O
case O
when O
the O
same O
alkali B
halide I
salts O
are O
mixed O
with O
more O
hydrophobic O
12 B
, I
12 I
- I
ionene I
salts O
. O

Biodistribution O
of O
different O
sized O
nanoparticles O
assessed O
by O
positron O
emission O
tomography O
: O
a O
general O
strategy O
for O
direct O
activation O
of O
metal B
oxide I
particles O
. O

We O
present O
a O
simple O
and O
straightforward O
method O
for O
the O
direct O
proton O
beam O
activation O
of O
synthetic O
or O
commercially O
available O
aluminum B
oxide I
NPs O
( O
Al2O3 B
NPs O
) O
via O
the O
( B
16 I
) I
O I
( O
p O
, O
alpha O
) O
( B
13 I
) I
N I
nuclear O
reaction O
in O
order O
to O
assess O
their O
biological O
fate O
using O
positron O
emission O
tomography O
( O
PET O
) O
. O

The O
incorporation O
of O
radioactive O
( B
13 I
) I
N I
atoms O
in O
the O
Al2O3 B
NPs O
allowed O
the O
study O
of O
the O
biodistribution O
of O
the O
metal B
oxide I
NPs O
in O
rats O
after O
intravenous O
administration O
via O
PET O
. O

This O
simple O
and O
robust O
activation O
strategy O
can O
be O
applied O
to O
any O
synthetic O
or O
commercially O
available O
metal B
oxide I
particle O
. O

Discovery O
of O
the O
Antibiotic O
Phosacetamycin B
via O
a O
New O
Mass O
Spectrometry O
- O
Based O
Method O
for O
Phosphonic B
Acid I
Detection O
. O

The O
cytotoxicity O
assay O
was O
carried O
out O
in O
macrophages O
J774G O
. O
8 O
by O
sulforhodamine B
B I
colorimetric O
assay O
. O

Prilling O
of O
fatty B
acids I
as O
a O
continuous O
process O
for O
the O
development O
of O
controlled O
release O
multiparticulate O
dosage O
forms O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty B
acids I
, O
stearic B
acid I
, O
and O
behenic B
acid I
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol B
tartrate I
( O
MPT B
) O
, O
a O
highly O
water O
soluble O
drug O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty B
acids I
, O
stearic B
acid I
, O
and O
behenic B
acid I
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol B
tartrate I
( O
MPT B
) O
, O
a O
highly O
water O
soluble O
drug O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty B
acids I
, O
stearic B
acid I
, O
and O
behenic B
acid I
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol B
tartrate I
( O
MPT B
) O
, O
a O
highly O
water O
soluble O
drug O
. O

In O
this O
study O
, O
prilling O
was O
evaluated O
as O
a O
technique O
for O
the O
development O
of O
multiparticulate O
dosage O
forms O
using O
the O
fatty B
acids I
, O
stearic B
acid I
, O
and O
behenic B
acid I
as O
potential O
matrix O
formers O
to O
control O
the O
release O
of O
metoprolol B
tartrate I
( O
MPT B
) O
, O
a O
highly O
water O
soluble O
drug O
. O

The O
in O
vitro O
drug O
release O
was O
dependent O
on O
the O
drug O
load O
, O
type O
of O
fatty B
acid I
, O
and O
pH O
of O
the O
dissolution O
medium O
. O

Higher O
drug O
loads O
resulted O
in O
faster O
release O
with O
behenic B
acid I
releasing O
drug O
over O
longer O
periods O
relative O
to O
stearic B
acid I
. O

Higher O
drug O
loads O
resulted O
in O
faster O
release O
with O
behenic B
acid I
releasing O
drug O
over O
longer O
periods O
relative O
to O
stearic B
acid I
. O

Due O
to O
ionization O
of O
the O
fatty B
acid I
at O
pH O
7 O
. O
4 O
, O
drug O
release O
was O
susceptible O
to O
the O
ionic O
strength O
at O
this O
pH O
value O
. O

Solid O
state O
characterization O
indicated O
that O
the O
crystalline O
state O
of O
the O
fatty B
acids I
was O
not O
affected O
by O
thermal O
processing O
via O
prilling O
, O
while O
the O
crystallinity O
of O
MPT B
was O
decreased O
. O

Drug O
release O
from O
behenic B
acid I
matrices O
was O
increased O
during O
storage O
at O
40 O
degrees O
C O
; O
however O
, O
no O
polymorphism O
of O
behenic B
acid I
was O
detected O
. O

Drug O
release O
from O
behenic B
acid I
matrices O
was O
increased O
during O
storage O
at O
40 O
degrees O
C O
; O
however O
, O
no O
polymorphism O
of O
behenic B
acid I
was O
detected O
. O

The O
bioavailability O
of O
MPT B
, O
after O
oral O
administration O
to O
dogs O
as O
prills O
containing O
30 O
% O
and O
40 O
% O
MPT B
using O
behenic B
acid I
as O
matrix O
former O
, O
was O
not O
significantly O
different O
from O
a O
commercial O
sustained O
release O
reference O
formulation O
, O
although O
the O
40 O
% O
MPT B
prills O
showed O
a O
burst O
release O
. O

Synthesis O
of O
the O
target O
compounds O
was O
readily O
accomplished O
in O
good O
yields O
through O
a O
cyclisation O
reaction O
between O
indole B
- I
3 I
- I
carboxylic I
acid I
hydrazide I
and O
carbon B
disulfide I
under O
basic O
conditions O
, O
followed O
by O
S B
- O
benzylation O
. O

More O
generally O
, O
we O
show O
that O
stability O
and O
electrohydrodynamics O
of O
viruses O
differ O
according O
to O
purification O
by O
( O
i O
) O
dialysis O
, O
( O
ii O
) O
isopycnic O
centrifugation O
in O
the O
cesium B
chloride I
gradient O
, O
and O
( O
iii O
) O
precipitation O
using O
polyethylene B
glycol I
( O
PEG B
) O
. O

More O
generally O
, O
we O
show O
that O
stability O
and O
electrohydrodynamics O
of O
viruses O
differ O
according O
to O
purification O
by O
( O
i O
) O
dialysis O
, O
( O
ii O
) O
isopycnic O
centrifugation O
in O
the O
cesium B
chloride I
gradient O
, O
and O
( O
iii O
) O
precipitation O
using O
polyethylene B
glycol I
( O
PEG B
) O
. O

Practical O
synthesis O
of O
a O
chromene B
analog O
for O
use O
as O
a O
retinoic B
acid I
receptor O
alpha O
antagonist O
lead O
compound O
. O

Retinoic B
acid I
receptor O
alpha O
( O
RAR O
alpha O
) O
selective O
compounds O
may O
guide O
the O
design O
of O
drugs O
that O
can O
be O
used O
in O
conjunction O
with O
hormonal O
adjuvant O
therapy O
in O
the O
treatment O
of O
breast O
cancer O
. O

Incorporation O
of O
a O
defined O
number O
( O
ten O
) O
of O
quaternary B
ammonium I
cationic O
charges O
per O
C60 B
in O
1 O
was O
aimed O
to O
enhance O
its O
ability O
to O
target O
pathogenic O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacterial O
cells O
. O

We O
used O
the O
well O
- O
characterized O
malonato B
[ I
60 I
] I
fullerene I
diester I
monoadduct O
C60 B
[ I
> I
M I
( I
t I
- I
Bu I
) I
2 I
] I
as O
the O
starting O
fullerene B
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
via O
transesterification O
reaction O
under O
trifluoroacetic B
acid I
catalyzed O
conditions O
. O

Arsenic B
speciation O
analysis O
showed O
that O
the O
less O
- O
toxic O
arsenobetaine B
( O
AsB B
) O
constituted O
80 O
. O
6 O
- O
98 O
. O
8 O
% O
of O
all O
As O
compounds O
, O
and O
dimethylarsinic B
acid I
( O
DMA B
) O
constituted O
0 O
. O
47 O
- O
3 O
. O
44 O
% O
. O

Monomethylarsonic B
acid I
( O
MMA B
) O
and O
As B
( I
V I
) I
were O
only O
detected O
in O
the O
whelk O
Drupa O
fiscella O
and O
the O
crab O
Heteropilumnus O
ciliatus O
, O
respectively O
. O

Adult O
male O
rats O
were O
pre O
- O
exposed O
to O
two O
different O
doses O
of O
nicotine B
( O
0 O
. O
75 O
and O
3 O
mg O
/ O
kg O
, O
intraperitoneally O
) O
for O
7 O
days O
followed O
by O
30 O
days O
of O
arsenic B
exposure O
( O
50 O
ppm O
sodium B
arsenite I
in O
drinking O
water O
) O
. O

The O
fruits O
are O
an O
excellent O
source O
of O
health O
- O
related O
compounds O
, O
such O
as O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
carotenoids O
( O
provitamin O
A O
) O
, O
tocopherols B
( O
vitamin B
E I
) O
, O
flavonoids B
, O
and O
capsaicinoids B
. O

The O
fruits O
are O
an O
excellent O
source O
of O
health O
- O
related O
compounds O
, O
such O
as O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
carotenoids O
( O
provitamin O
A O
) O
, O
tocopherols B
( O
vitamin B
E I
) O
, O
flavonoids B
, O
and O
capsaicinoids B
. O

The O
fruits O
are O
an O
excellent O
source O
of O
health O
- O
related O
compounds O
, O
such O
as O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
carotenoids O
( O
provitamin O
A O
) O
, O
tocopherols B
( O
vitamin B
E I
) O
, O
flavonoids B
, O
and O
capsaicinoids B
. O

A O
study O
of O
parabens B
and O
bisphenol B
A I
in O
surface O
water O
and O
fish O
brain O
tissue O
from O
the O
Greater O
Pittsburgh O
Area O
. O

Paraben B
detection O
in O
surface O
waters O
was O
as O
follows O
: O
methyl B
paraben I
ranged O
between O
2 O
. O
2 O
to O
17 O
. O
3 O
ppt O
; O
ethyl B
paraben I
was O
not O
detectable O
; O
propyl B
paraben I
was O
detected O
at O
9 O
. O
2 O
and O
12 O
. O
0 O
ppt O
; O
butyl B
paraben I
was O
detected O
at O
0 O
. O
2 O
ppt O
. O

Paraben B
detection O
in O
surface O
waters O
was O
as O
follows O
: O
methyl B
paraben I
ranged O
between O
2 O
. O
2 O
to O
17 O
. O
3 O
ppt O
; O
ethyl B
paraben I
was O
not O
detectable O
; O
propyl B
paraben I
was O
detected O
at O
9 O
. O
2 O
and O
12 O
. O
0 O
ppt O
; O
butyl B
paraben I
was O
detected O
at O
0 O
. O
2 O
ppt O
. O

Paraben B
detection O
in O
surface O
waters O
was O
as O
follows O
: O
methyl B
paraben I
ranged O
between O
2 O
. O
2 O
to O
17 O
. O
3 O
ppt O
; O
ethyl B
paraben I
was O
not O
detectable O
; O
propyl B
paraben I
was O
detected O
at O
9 O
. O
2 O
and O
12 O
. O
0 O
ppt O
; O
butyl B
paraben I
was O
detected O
at O
0 O
. O
2 O
ppt O
. O

Paraben B
detection O
in O
surface O
waters O
was O
as O
follows O
: O
methyl B
paraben I
ranged O
between O
2 O
. O
2 O
to O
17 O
. O
3 O
ppt O
; O
ethyl B
paraben I
was O
not O
detectable O
; O
propyl B
paraben I
was O
detected O
at O
9 O
. O
2 O
and O
12 O
. O
0 O
ppt O
; O
butyl B
paraben I
was O
detected O
at O
0 O
. O
2 O
ppt O
. O

Hydrogen B
sulfide I
( O
H2S B
) O
is O
a O
toxic O
gaseous O
substance O
, O
and O
accidental O
exposure O
to O
high O
concentrations O
of O
H2S B
has O
been O
reported O
to O
be O
lethal O
to O
humans O
. O

Cells O
were O
exposed O
to O
a O
H2S B
donor O
, O
sodium B
hydroxysulfide I
( O
NaHS B
) O
, O
at O
pH O
6 O
. O
0 O
, O
7 O
. O
0 O
, O
or O
8 O
. O
0 O
for O
1 O
h O
at O
37 O
degrees O
C O
in O
a O
sealed O
conical O
tube O
to O
avoid O
the O
loss O
of O
dissolved O
H2S B
gas O
. O

High O
- O
density O
lipoprotein O
( O
HDL O
) O
remodeling O
within O
the O
plasma O
compartment O
and O
the O
association O
between O
lecithin O
- O
cholesterol B
acyltransferase O
( O
LCAT O
) O
and O
cholesterol B
ester I
transfer O
protein O
( O
CETP O
) O
activity O
, O
and O
lipid O
, O
lipoprotein O
concentrations O
and O
composition O
were O
investigated O
. O

Chronic O
use O
of O
glyceryl B
trinitrate I
is O
limited O
by O
serious O
side O
effects O
, O
inter O
alia O
tolerance O
and O
endothelial O
dysfunction O
of O
coronary O
and O
resistance O
arteries O
. O

The O
natural O
flavonoid O
quercetin B
has O
been O
shown O
to O
counteract O
the O
development O
of O
glyceryl B
trinitrate I
tolerance O
in O
vitro O
. O

Two O
mitochondriotropic O
, O
4 B
- I
O I
- I
triphenylphosphonium I
derivatives O
of O
quercetin B
( O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
) O
were O
compared O
to O
quercetin B
for O
protection O
against O
glyceryl B
trinitrate I
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Both O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl B
trinitrate I
and O
acetylcholine B
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl B
trinitrate I
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin B
. O

Both O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl B
trinitrate I
and O
acetylcholine B
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl B
trinitrate I
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin B
. O

Since O
Q B
- I
3BTPI I
antagonized O
in O
vitro O
nitrate B
tolerance O
and O
endothelial O
dysfunction O
of O
vessels O
, O
this O
encourages O
assessing O
whether O
this O
effect O
is O
displayed O
also O
in O
vivo O
during O
long O
- O
term O
glyceryl B
trinitrate I
treatment O
. O

Cytotoxic O
pentacyclic B
triterpenoids I
from O
Prinsepia O
utilis O
. O

Phytochemical O
investigation O
of O
the O
aerial O
parts O
of O
Prinsepia O
utilis O
Royle O
resulted O
in O
the O
isolation O
and O
identification O
of O
ten O
pentacyclic B
triterpenoids I
, O
including O
two O
new O
triterpenoids B
, O
2 B
alpha I
- I
O I
- I
trans I
- I
p I
- I
coumaroyl I
- I
3 I
beta I
, I
19 I
alpha I
- I
dihydroxy I
- I
urs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
and O
2 B
alpha I
- I
O I
- I
cis I
- I
p I
- I
coumaroyl I
- I
3 I
beta I
, I
19 I
alpha I
- I
dihydroxy I
- I
urs I
- I
12 I
- I
en I
- I
28 I
- I

iPSPs O
are O
cofactor O
- O
dependent O
phosphoglycerate B
mutase O
( O
dPGM O
) O
- O
like O
phosphatases O
that O
have O
significant O
amino B
acid I
sequence O
similarity O
to O
dPGMs O
but O
lack O
phosphoglycerate B
mutase O
activity O
. O

Very O
interesting O
is O
the O
compound O
bearing O
a O
meta B
- I
fluorophenyl I
substituent O
on O
the O
carbonyl B
carbon I
of O
the O
amide B
group O
, O
which O
shows O
significantly O
high O
A1 O
/ O
A2A O
- O
A3 O
selectivity O
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl B
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

BNDPP B
) O
, O
in O
mixed O
micelles O
with O
cetylpyridinium B
bromide I
( O
CPB B
) O
. O

Acid O
dissociation O
constants O
( O
pKa O
) O
were O
determined O
, O
the O
effect O
of O
functional O
surfactant O
alkyl B
chain O
length O
and O
pH O
on O
the O
observed O
rate O
constant O
( O
kobs O
) O
for O
phosphate B
ester I
cleavage O
has O
been O
discussed O
, O
and O
the O
effect O
of O
substrate O
on O
the O
supernucleophiliciti O
of O
the O
studied O
oximes B
was O
monitored O
. O

A O
short O
and O
efficient O
total O
synthesis O
of O
naturally O
occurring O
carbazole B
clauraila B
A I
( O
1 O
) O
is O
described O
. O

Free O
fatty B
acid I
binding O
protein O
- O
4 O
and O
retinol B
binding O
protein O
- O
4 O
in O
polycystic O
ovary O
syndrome O
: O
response O
to O
simvastatin B
and O
metformin B
therapies O
. O

Abstract O
Free O
fatty B
acid I
binding O
protein O
- O
4 O
( O
FABP4 O
) O
and O
retinol B
binding O
protein O
- O
4 O
( O
RBP4 O
) O
contribute O
to O
metabolic O
syndrome O
. O

Temperature O
- O
Dependent O
Conformations O
of O
a O
Membrane O
Supported O
Zinc B
Porphyrin I
Tweezer O
by O
2D O
Fluorescence O
Spectroscopy O
. O

We O
studied O
the O
equilibrium O
conformations O
of O
a O
zinc B
porphyrin I
tweezer O
composed O
of O
two O
carboxylphenyl B
- O
functionalized O
zinc B
tetraphenyl I
porphyrin I
subunits O
connected O
by O
a O
1 B
, I
4 I
- I
butyndiol I
spacer O
, O
which O
was O
suspended O
inside O
the O
amphiphilic O
regions O
of O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DSPC B
) O
liposomes O
. O

By O
combining O
phase O
- O
modulation O
two O
- O
dimensional O
fluorescence O
spectroscopy O
( O
2D O
FS O
) O
with O
linear O
absorbance O
and O
fluorimetry O
, O
we O
determined O
that O
the O
zinc B
porphyrin I
tweezer O
adopts O
a O
mixture O
of O
folded O
and O
extended O
conformations O
in O
the O
membrane O
. O

Efficient O
MRI O
labeling O
of O
endothelial O
progenitor O
cells O
: O
Design O
of O
thiolated O
surface O
stabilized O
superparamagnetic O
iron B
oxide I
nanoparticles O
. O

The O
aim O
of O
this O
study O
was O
to O
design O
thiolated O
surface O
stabilized O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
TSS O
- O
SPIONs O
) O
for O
efficient O
internalization O
with O
high O
MRI O
sensitivity O
. O

TSS O
- O
SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan O
- O
thioglycolic B
acid I
( O
chitosan O
- O
TGA B
) O
hydrogel O
and O
iron B
ions O
( O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
) O
. O

TSS O
- O
SPIONs O
demonstrated O
an O
iron B
oxide I
core O
diameter O
( O
crystallite O
size O
by O
XRD O
) O
of O
3 O
. O
1 O
+ O
/ O
- O
0 O
. O
02nm O
, O
a O
hydrodynamic O
diameter O
of O
94 O
+ O
/ O
- O
20nm O
, O
a O
zeta O
potential O
of O
+ O
21 O
+ O
/ O
- O
5mV O
, O
and O
an O
iron B
content O
of O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
9mg O
/ O
mL O
. O

Alternatively O
, O
when O
TMS B
diazomethane I
is O
used O
as O
the O
dipole O
, O
the O
resulting O
2 B
- I
pyrazoline I
obtained O
after O
desilylation O
may O
be O
reduced O
with O
NaCNBH3 B
to O
provide O
the O
trans B
azakainate I
analog O
exclusively O
. O

Alternatively O
, O
when O
TMS B
diazomethane I
is O
used O
as O
the O
dipole O
, O
the O
resulting O
2 B
- I
pyrazoline I
obtained O
after O
desilylation O
may O
be O
reduced O
with O
NaCNBH3 B
to O
provide O
the O
trans B
azakainate I
analog O
exclusively O
. O

New O
Azalomycin B
F I
Analogs O
from O
Mangrove O
Streptomyces O
sp O
. O

Seven O
new O
azalomycin B
F I
analogs O
( O
1 O
- O
7 O
) O
were O
isolated O
from O
the O
broth O
of O
mangrove O
Streptomyces O
sp O
. O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

However O
, O
initial O
[ B
( I
14 I
) I
C I
] I
sorafenib I
hepatocyte O
uptake O
was O
reduced O
by O
46 O
and O
30 O
% O
compared O
to O
control O
values O
in O
the O
presence O
of O
the O
organic O
anion O
transporting O
polypeptide O
( O
OATP O
) O
inhibitor O
rifamycin B
SV I
, O
and O
the O
organic O
cation O
transporter O
( O
OCT O
) O
inhibitor O
decynium B
22 I
, O
respectively O
. O

However O
, O
initial O
[ B
( I
14 I
) I
C I
] I
sorafenib I
hepatocyte O
uptake O
was O
reduced O
by O
46 O
and O
30 O
% O
compared O
to O
control O
values O
in O
the O
presence O
of O
the O
organic O
anion O
transporting O
polypeptide O
( O
OATP O
) O
inhibitor O
rifamycin B
SV I
, O
and O
the O
organic O
cation O
transporter O
( O
OCT O
) O
inhibitor O
decynium B
22 I
, O
respectively O
. O

Effects O
of O
treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
and O
a O
heme O
oxygenase O
1 O
inducer O
in O
the O
antinociceptive O
effects O
of O
morphine B
in O
different O
models O
of O
acute O
and O
chronic O
pain O
in O
mice O
. O

RATIONALE O
: O
Treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
( O
tricarbonyldichloror B
( I
II I
) I
dimer O
, O
CORM B
- I
2 I
) O
or O
a O
classical O
heme O
oxygenase O
1 O
inducer O
( O
cobalt B
protoporphyrin I
IX I
, O
CoPP B
) O
has O
potent O
anti O
- O
inflammatory O
effects O
, O
but O
the O
role O
played O
by O
these O
treatments O
in O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
was O
not O
evaluated O
. O

OBJECTIVES O
: O
In O
wild O
type O
( O
WT O
) O
, O
neuronal O
( O
NOS1 O
- O
KO O
) O
, O
or O
inducible O
( O
NOS2 O
- O
KO O
) O
nitric B
oxide I
synthases O
knockout O
mice O
, O
we O
evaluated O
the O
effects O
of O
CORM B
- I
2 I
and O
CoPP B
treatments O
in O
the O
antinociceptive O
actions O
of O
morphine B
and O
their O
interaction O
with O
nitric B
oxide I
during O
acute O
, O
visceral O
, O
and O
chronic O
inflammatory O
or O
neuropathic O
pain O
. O

OBJECTIVES O
: O
In O
wild O
type O
( O
WT O
) O
, O
neuronal O
( O
NOS1 O
- O
KO O
) O
, O
or O
inducible O
( O
NOS2 O
- O
KO O
) O
nitric B
oxide I
synthases O
knockout O
mice O
, O
we O
evaluated O
the O
effects O
of O
CORM B
- I
2 I
and O
CoPP B
treatments O
in O
the O
antinociceptive O
actions O
of O
morphine B
and O
their O
interaction O
with O
nitric B
oxide I
during O
acute O
, O
visceral O
, O
and O
chronic O
inflammatory O
or O
neuropathic O
pain O
. O

METHODS O
: O
Acute O
and O
visceral O
pain O
was O
assessed O
through O
formalin B
and O
acid B
acetic I
writhing O
tests O
. O

RESULTS O
: O
While O
nitric B
oxide I
, O
synthetized O
by O
NOS1 O
and O
/ O
or O
NOS2 O
, O
increased O
the O
local O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
, O
it O
decreased O
the O
inhibitory O
effects O
of O
morphine B
after O
visceral O
pain O
. O

CONCLUSIONS O
: O
CORM B
- I
2 I
and O
CoPP B
treatments O
improved O
the O
local O
antinociceptive O
effects O
of O
morphine B
during O
chronic O
inflammatory O
and O
neuropathic O
pain O
by O
interaction O
with O
nitric B
oxide I
synthetized O
by O
NOS1 O
and O
NOS2 O
isoforms O
. O

Paclitaxel B
is O
an O
inhibitor O
and O
its O
boron B
dipyrromethene I
derivative O
is O
a O
fluorescent O
recognition O
agent O
for O
botulinum O
neurotoxin O
subtype O
a O
. O

The O
absolute O
configuration O
of O
embellicine B
A I
( O
1 O
) O
was O
determined O
by O
TDDFT O
ECD O
calculations O
of O
solution O
conformers O
, O
whereas O
that O
of O
embellicine B
B I
( O
2 O
) O
was O
deduced O
based O
on O
ROESY O
correlations O
and O
on O
biogenetic O
considerations O
in O
comparison O
to O
1 O
. O

The O
absolute O
configuration O
of O
embellicine B
A I
( O
1 O
) O
was O
determined O
by O
TDDFT O
ECD O
calculations O
of O
solution O
conformers O
, O
whereas O
that O
of O
embellicine B
B I
( O
2 O
) O
was O
deduced O
based O
on O
ROESY O
correlations O
and O
on O
biogenetic O
considerations O
in O
comparison O
to O
1 O
. O

Embellicine B
B I
( O
2 O
) O
was O
the O
most O
active O
compound O
encountered O
in O
this O
study O
and O
acts O
at O
nanomolar O
concentrations O
without O
affecting O
tumor O
microenvironment O
. O

Stage O
40 O
- O
47 O
tadpoles O
were O
also O
incubated O
1 O
h O
with O
microtubule O
stabilizing O
agents O
, O
epothilone B
D I
or O
discodermolide B
, O
followed O
by O
dosing O
with O
1 B
- I
aminoanthracene I
. O

Epothilone B
D I
similarly O
mitigated O
the O
effects O
of O
a O
clinical O
neurosteroid O
general O
anesthetic O
, O
allopregnanolone B
, O
believed O
to O
occupy O
the O
colchicine B
site O
in O
tubulin O
. O

Three O
chemical O
modifications O
increased O
the O
glass O
transition O
temperature O
of O
the O
polymer O
: O
( O
a O
) O
substitution O
of O
n B
- I
butyl I
by O
t B
- I
butyl I
groups O
, O
( O
b O
) O
reduction O
of O
the O
dimethylaminoethyl B
methacrylate I
( O
DMAEMA B
) O
content O
, O
and O
( O
c O
) O
incorporation O
of O
a O
bulky O
isobornyl B
repeating O
unit O
. O

Cadmium B
telluride I
quantum O
dots O
cause O
oxidative O
stress O
leading O
to O
extrinsic O
and O
intrinsic O
apoptosis O
in O
hepatocellular O
carcinoma O
HepG2 O
cells O
. O

The O
mechanisms O
of O
toxicity O
related O
to O
human O
hepatocellular O
carcinoma O
HepG2 O
cell O
exposures O
to O
cadmium B
telluride I
quantum O
dots O
( O
CdTe B
- O
QDs O
) O
were O
investigated O
. O

Altered O
antioxidant O
levels O
were O
demonstrated O
by O
depletion O
of O
reduced B
glutathione I
( O
GSH B
) O
, O
a O
decreased O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
( O
GSH B
/ O
GSSG B
) O
and O
an O
increased O
NF O
- O
E2 O
- O
related O
Factor O
2 O
( O
Nrf2 O
) O
activation O
. O

Altered O
antioxidant O
levels O
were O
demonstrated O
by O
depletion O
of O
reduced B
glutathione I
( O
GSH B
) O
, O
a O
decreased O
ratio O
of O
reduced O
glutathione B
to O
oxidized B
glutathione I
( O
GSH B
/ O
GSSG B
) O
and O
an O
increased O
NF O
- O
E2 O
- O
related O
Factor O
2 O
( O
Nrf2 O
) O
activation O
. O

Multienzyme O
branched O
- O
chain O
alpha B
- I
ketoacid I
dehydrogenase O
complex O
( O
BCKDH O
) O
catalyzes O
the O
regulatory O
step O
of O
oxidative O
catabolism O
of O
indispensable O
branched O
- O
chain O
amino B
acids I
( O
BCAA O
) O
. O

The O
reactive O
uptake O
coefficients O
( O
gamma O
) O
of O
OH B
by O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol B
serving O
as O
surrogate O
compounds O
for O
biomass O
burning O
aerosol O
have O
been O
determined O
employing O
a O
chemical O
ionisation O
mass O
spectrometer O
coupled O
to O
a O
rotating O
- O
wall O
flow O
- O
tube O
reactor O
over O
a O
wide O
range O
of O
[ O
OH B
] O
~ O
10 O
( O
7 O
) O
- O
10 O
( O
11 O
) O
molecule O
cm O
( O
- O
3 O
) O
. O

Amongst O
the O
common O
volatile O
organic O
compounds O
( O
VOCs O
) O
identified O
between O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol B
were O
methanol B
, O
acetaldehyde B
, O
formic B
acid I
, O
and O
acetic B
acid I
. O

Amongst O
the O
common O
volatile O
organic O
compounds O
( O
VOCs O
) O
identified O
between O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol B
were O
methanol B
, O
acetaldehyde B
, O
formic B
acid I
, O
and O
acetic B
acid I
. O

Amongst O
the O
common O
volatile O
organic O
compounds O
( O
VOCs O
) O
identified O
between O
levoglucosan B
, O
abietic B
acid I
, O
and O
nitroguaiacol B
were O
methanol B
, O
acetaldehyde B
, O
formic B
acid I
, O
and O
acetic B
acid I
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic B
acid I
from O
levoglucosan B
, O
glycolic B
acid I
from O
abietic B
acid I
, O
and O
methanol B
and O
nitric B
acid I
from O
nitroguaiacol B
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic B
acid I
from O
levoglucosan B
, O
glycolic B
acid I
from O
abietic B
acid I
, O
and O
methanol B
and O
nitric B
acid I
from O
nitroguaiacol B
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic B
acid I
from O
levoglucosan B
, O
glycolic B
acid I
from O
abietic B
acid I
, O
and O
methanol B
and O
nitric B
acid I
from O
nitroguaiacol B
. O

VOCs O
having O
the O
greatest O
enhancement O
over O
background O
were O
glucic B
acid I
from O
levoglucosan B
, O
glycolic B
acid I
from O
abietic B
acid I
, O
and O
methanol B
and O
nitric B
acid I
from O
nitroguaiacol B
. O

Reaction O
mechanisms O
leading O
to O
the O
formation O
of O
glucic B
acid I
, O
glycolic B
acid I
, O
methanol B
, O
and O
nitric B
acid I
are O
proposed O
. O

Reaction O
mechanisms O
leading O
to O
the O
formation O
of O
glucic B
acid I
, O
glycolic B
acid I
, O
methanol B
, O
and O
nitric B
acid I
are O
proposed O
. O

Reaction O
mechanisms O
leading O
to O
the O
formation O
of O
glucic B
acid I
, O
glycolic B
acid I
, O
methanol B
, O
and O
nitric B
acid I
are O
proposed O
. O

An O
efficient O
evaporation O
- O
induced O
coating O
method O
combining O
microwave O
- O
assisted O
hydrothermal O
transformation O
and O
annealing O
is O
developed O
to O
fabricate O
an O
ideal O
electrode O
material O
from O
composites O
with O
a O
layer O
of O
hydrous B
RuO2 I
on O
mesoporous O
silica B
nanoparticles O
( O
MSNs O
) O
, O
for O
a O
high O
- O
performance O
supercapacitor O
. O

n O
- O
Doping O
of O
solution O
- O
processible O
organic O
semiconductors O
: O
highly O
conductive O
fullerenes B
are O
demonstrated O
through O
solution O
- O
processed O
fulleropyrrolidinium B
iodide I
( O
FPI B
) O
and O
FPI B
- O
doped O
PCBM B
to O
reach O
a O
high O
conductivity O
( O
3 O
. O
2 O
S O
/ O
m O
) O
. O

Influence O
of O
the O
Green O
Tea O
Leaf O
Extract O
on O
Neurotoxicity O
of O
Aluminium B
Chloride I
in O
Rats O
. O

Because O
green O
tea O
( O
Camellia O
sinensis O
L O
. O
) O
reportedly O
has O
health O
- O
promoting O
effects O
in O
the O
central O
nervous O
system O
, O
we O
evaluated O
the O
effects O
of O
green O
tea O
leaf O
extract O
( O
GTLE O
) O
on O
aluminium B
chloride I
( O
AlCl3 B
) O
neurotoxicity O
in O
rats O
. O

Though O
no O
significant O
difference O
was O
observed O
in O
the O
activities O
of O
these O
conjugates O
, O
cholic B
acid I
- O
containing O
dimeric O
conjugates O
generally O
exhibit O
higher O
activities O
than O
the O
corresponding O
deoxycholic B
acid I
- O
derived O
analogs O
. O

Though O
no O
significant O
difference O
was O
observed O
in O
the O
activities O
of O
these O
conjugates O
, O
cholic B
acid I
- O
containing O
dimeric O
conjugates O
generally O
exhibit O
higher O
activities O
than O
the O
corresponding O
deoxycholic B
acid I
- O
derived O
analogs O
. O

This O
is O
in O
contrast O
to O
the O
finding O
that O
a O
monomeric O
deoxycholic B
acid I
- O
spermine B
conjugate O
was O
more O
active O
than O
the O
corresponding O
cholic B
acid I
- O
derived O
analog O
. O

This O
is O
in O
contrast O
to O
the O
finding O
that O
a O
monomeric O
deoxycholic B
acid I
- O
spermine B
conjugate O
was O
more O
active O
than O
the O
corresponding O
cholic B
acid I
- O
derived O
analog O
. O

In O
this O
study O
, O
we O
modified O
the O
amino B
groups O
of O
the O
polymer O
with O
succinyl B
anhydride I
( O
PU B
- I
Su I
) O
or O
acetyl B
anhydride I
( O
PU B
- I
Ac I
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

In O
this O
study O
, O
we O
modified O
the O
amino B
groups O
of O
the O
polymer O
with O
succinyl B
anhydride I
( O
PU B
- I
Su I
) O
or O
acetyl B
anhydride I
( O
PU B
- I
Ac I
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

Extraction O
of O
the O
volatile O
oil O
from O
Carum O
carvi O
of O
Tunisia O
and O
Lithuania O
by O
supercritical O
carbon B
dioxide I
: O
chemical O
composition O
and O
antiulcerogenic O
activity O
. O

Structural O
Rearrangement O
in O
the O
Formation O
of O
Jet O
- O
Cooled O
Complexes O
of O
Chiral O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
Tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
with O
Methyl B
Lactate I
: O
Chirality O
Effect O
in O
Conformer O
Selection O
. O

The O
jet O
- O
cooled O
complexes O
between O
the O
two O
enantiomers O
of O
methyl B
lactate I
( O
ML O
) O
and O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
( O
THIQM B
) O
are O
studied O
by O
double O
resonance O
spectroscopy O
combined O
with O
ab O
initio O
calculations O
. O

Here O
we O
use O
vibrational O
sum O
frequency O
spectroscopy O
( O
SF O
) O
to O
study O
the O
origin O
of O
the O
opposite O
Delta O
V O
signs O
of O
Langmuir O
films O
of O
CH3 B
( I
CH2 I
) I
20COCH2CH3 I
( O
ethyl B
ether I
, O
EE O
) O
and O
CH3 B
( I
CH2 I
) I
20COCH2CF3 I
( O
fluorinated B
ethyl I
ether I
, O
FEE B
) O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl B
ferulate I
, O
p B
- I
coumarate I
and O
caffeate B
esters I
, O
the O
separation O
of O
cis O
- O
from O
trans B
- I
ferulate I
isomers O
, O
the O
splitting O
of O
steroid B
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl B
ferulate I
, O
p B
- I
coumarate I
and O
caffeate B
esters I
, O
the O
separation O
of O
cis O
- O
from O
trans B
- I
ferulate I
isomers O
, O
the O
splitting O
of O
steroid B
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

The O
samples O
were O
characterised O
by O
high O
content O
of O
marine O
wax O
esters B
( O
55 O
- O
67 O
mol O
% O
of O
lipid O
classes O
) O
, O
of O
docosahexaenoic B
( O
22 O
: O
6 O
n O
- O
3 O
, O
25 O
w O
% O
) O
and O
oleic B
( O
18 O
: O
1 O
n O
- O
9 O
, O
19 O
w O
% O
) O
fatty B
acids I
. O

Free O
fatty B
acids I
, O
index O
of O
lipid O
hydrolysis O
, O
represented O
32 O
- O
39 O
mol O
% O
over O
total O
fatty B
acids I
. O

Free O
fatty B
acids I
, O
index O
of O
lipid O
hydrolysis O
, O
represented O
32 O
- O
39 O
mol O
% O
over O
total O
fatty B
acids I
. O

The O
microflora O
comprised O
staphylococci O
, O
enterococci O
( O
2 O
. O
2 O
log O
( O
10 O
) O
CFU O
/ O
g O
) O
and O
lactic B
acid I
bacteria O
( O
3 O
log O
( O
10 O
) O
CFU O
/ O
g O
) O
. O

Theaflavins B
, O
dimeric B
catechins I
, O
inhibit O
peptide O
transport O
across O
Caco O
- O
2 O
cell O
monolayers O
via O
down O
- O
regulation O
of O
AMP B
- O
activated O
protein O
kinase O
- O
mediated O
peptide O
transporter O
PEPT1 O
. O

In O
TF B
3 I
' I
- I
O I
- I
gallate I
- O
pretreated O
cells O
, O
Western O
blot O
analysis O
revealed O
attenuated O
expression O
of O
PEPT1 O
transporter O
and O
Gly B
- I
Sar I
transport O
was O
completely O
ameliorated O
by O
10 O
mu O
M O
Compound B
C I
, O
an O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
. O

Monitoring O
the O
effect O
of O
high O
pressure O
and O
transglutaminase O
treatment O
of O
milk O
on O
the O
evolution O
of O
flavour O
compounds O
during O
lactic B
acid I
fermentation O
using O
PTR O
- O
ToF O
- O
MS O
. O

The O
presence O
of O
several O
tentatively O
identified O
volatile O
flavour O
compounds O
( O
VOCs O
) O
, O
both O
during O
the O
enzymatic O
treatment O
and O
the O
lactic B
acid I
fermentation O
of O
the O
milk O
base O
, O
were O
monitored O
using O
a O
proton O
transfer O
reaction O
time O
- O
of O
- O
flight O
mass O
spectrometer O
( O
PTR O
- O
ToF O
- O
MS O
) O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
interactions O
between O
ABCG2 O
and O
56 O
naturally O
- O
occurring O
phytochemicals O
including O
phenolic B
acids I
, O
flavonoids B
, O
triterpenes B
and O
other O
common O
dietary O
phytochemicals O
, O
as O
well O
as O
two O
non O
plant O
- O
based O
compounds O
( O
hippuric B
acid I
and O
propyl B
gallate I
) O
using O
cell O
- O
and O
membrane O
- O
based O
transport O
inhibition O
assays O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
interactions O
between O
ABCG2 O
and O
56 O
naturally O
- O
occurring O
phytochemicals O
including O
phenolic B
acids I
, O
flavonoids B
, O
triterpenes B
and O
other O
common O
dietary O
phytochemicals O
, O
as O
well O
as O
two O
non O
plant O
- O
based O
compounds O
( O
hippuric B
acid I
and O
propyl B
gallate I
) O
using O
cell O
- O
and O
membrane O
- O
based O
transport O
inhibition O
assays O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
interactions O
between O
ABCG2 O
and O
56 O
naturally O
- O
occurring O
phytochemicals O
including O
phenolic B
acids I
, O
flavonoids B
, O
triterpenes B
and O
other O
common O
dietary O
phytochemicals O
, O
as O
well O
as O
two O
non O
plant O
- O
based O
compounds O
( O
hippuric B
acid I
and O
propyl B
gallate I
) O
using O
cell O
- O
and O
membrane O
- O
based O
transport O
inhibition O
assays O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin B
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin B
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin B
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin B
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Of O
the O
non O
- O
flavonoid B
phytochemicals O
tested O
, O
berberine B
, O
celastrol B
, O
ellagic B
acid I
, O
limonin B
, O
oleanolic B
acid I
, O
propyl B
gallate I
, O
sinapic B
acid I
and O
ursolic B
acid I
demonstrated O
significant O
inhibition O
of O
ABCG2 O
- O
mediated O
transport O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon B
- O
carbon B
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde B
, O
formic B
acid I
, O
glycolaldehyde B
, O
glyoxal B
, O
acetic B
acid I
, O
glycolic B
acid I
, O
glyceraldehyde B
, O
2 B
- I
hydroxypropanedialde I
and O
lactic O
acid O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon B
- O
carbon B
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde B
, O
formic B
acid I
, O
glycolaldehyde B
, O
glyoxal B
, O
acetic B
acid I
, O
glycolic B
acid I
, O
glyceraldehyde B
, O
2 B
- I
hydroxypropanedialde I
and O
lactic O
acid O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon B
- O
carbon B
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde B
, O
formic B
acid I
, O
glycolaldehyde B
, O
glyoxal B
, O
acetic B
acid I
, O
glycolic B
acid I
, O
glyceraldehyde B
, O
2 B
- I
hydroxypropanedialde I
and O
lactic O
acid O
. O

Potato O
protein O
isolate O
( O
PPI O
) O
was O
phosphorylated O
with O
sodium B
trimetaphosphate I
( O
STMP B
) O
at O
ambient O
temperature O
and O
various O
reaction O
pH O
( O
5 O
. O
2 O
, O
6 O
. O
2 O
, O
8 O
. O
0 O
and O
10 O
. O
5 O
) O
to O
improve O
the O
functional O
properties O
without O
impairing O
the O
nutritional O
availability O
. O

Changes O
in O
chemical O
composition O
( O
total O
and O
coagulable O
protein O
content O
, O
ash O
and O
minerals O
content O
and O
amino B
acid I
composition O
) O
, O
functional O
properties O
( O
protein O
solubility O
index O
, O
emulsifying O
activity O
and O
foaming O
capacity O
, O
water O
and O
oil O
absorption O
capacity O
) O
and O
phosphorus B
were O
determined O
. O

The O
PP O
- O
PPI O
at O
pH O
5 O
. O
2 O
was O
characterised O
by O
the O
highest O
content O
of O
all O
amino B
acids I
, O
whereas O
, O
PP O
- O
PPI O
under O
alkaline O
conditions O
( O
pH O
10 O
. O
5 O
) O
caused O
decrease O
in O
these O
compounds O
. O

The O
volatile O
oil O
was O
fractioned O
by O
silica B
gel I
column O
chromatography O
. O

Effect O
of O
dietary O
carnosic B
acid I
on O
the O
fatty B
acid I
profile O
and O
flavour O
stability O
of O
meat O
from O
fattening O
lambs O
. O

Effect O
of O
dietary O
carnosic B
acid I
on O
the O
fatty B
acid I
profile O
and O
flavour O
stability O
of O
meat O
from O
fattening O
lambs O
. O

Thirty O
- O
two O
lambs O
were O
fed O
with O
barley O
straw O
supplemented O
by O
a O
concentrate O
alone O
, O
or O
a O
concentrate O
enriched O
with O
either O
vitamin B
E I
( O
VITE006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
or O
carnosic B
acid I
( O
CARN006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
; O
or O
CARN012 B
: O
1 O
. O
2 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
. O

Thirty O
- O
two O
lambs O
were O
fed O
with O
barley O
straw O
supplemented O
by O
a O
concentrate O
alone O
, O
or O
a O
concentrate O
enriched O
with O
either O
vitamin B
E I
( O
VITE006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
or O
carnosic B
acid I
( O
CARN006 B
: O
0 O
. O
6 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
; O
or O
CARN012 B
: O
1 O
. O
2 O
g O
kg O
( O
- O
1 O
) O
feed O
concentrate O
) O
. O

In O
order O
to O
elucidate O
the O
influence O
of O
the O
dietary O
supplementation O
of O
carnosic O
compared O
with O
a O
reference O
diet O
antioxidant O
( O
vitamin B
E I
) O
, O
the O
animals O
were O
slaughtered O
and O
the O
longissimus O
thoracis O
were O
lyophilised O
to O
determine O
the O
FAs B
profile O
and O
the O
phenolic B
compounds O
. O

Dietary O
carnosic B
acid I
did O
not O
modify O
the O
FAs B
profile O
, O
but O
had O
a O
clear O
effect O
on O
the O
production O
of O
volatile O
compounds O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

These O
results O
have O
implications O
for O
the O
food O
industry O
, O
since O
dietary O
carnosic B
acid I
seems O
to O
extend O
the O
shelf O
life O
of O
lamb O
meat O
. O

Innovative O
microwave O
- O
assisted O
hydrolysis O
of O
ellagitannins O
and O
quantification O
as O
ellagic B
acid I
equivalents O
. O

The O
health O
- O
promoting O
effects O
of O
ellagic B
acid I
and O
its O
intestinal O
degradation O
products O
are O
well O
- O
known O
. O

In O
plants O
, O
ellagic B
acid I
mainly O
appears O
in O
the O
form O
of O
its O
precursors O
, O
the O
so O
- O
called O
ellagitannins O
. O

Therefore O
, O
determination O
of O
total O
ellagic B
acid I
content O
has O
been O
accomplished O
by O
cleaving O
ellagitannins O
with O
high O
temperatures O
and O
strong O
acids O
. O

In O
further O
anti O
- O
inflammatory O
research O
, O
thienopyridine B
derivative O
1a O
showed O
potent O
inhibition O
of O
nitric B
oxide I
( O
NO B
) O
production O
. O

A O
case O
study O
on O
radiolabeled B
fenofibrate I
. O

In O
the O
current O
study O
, O
four O
different O
nanosuspension O
formulations O
containing O
iodinated B
fenofibrate I
were O
prepared O
, O
physicochemically O
characterized O
and O
investigated O
concerning O
their O
in O
- O
vitro O
release O
kinetics O
from O
osmotic O
pumps O
. O

The O
resulting O
diblock O
polymers O
consisted O
of O
one O
block O
with O
triethylene B
glycol I
brushes O
and O
another O
block O
with O
carboxylic B
acid I
groups O
to O
bind O
doxorubicin B
and O
Fe3O4 B
MNs O
. O

The O
resulting O
diblock O
polymers O
consisted O
of O
one O
block O
with O
triethylene B
glycol I
brushes O
and O
another O
block O
with O
carboxylic B
acid I
groups O
to O
bind O
doxorubicin B
and O
Fe3O4 B
MNs O
. O

The O
aim O
of O
the O
current O
investigations O
was O
to O
compare O
cytotoxicity O
of O
ticlopidine B
, O
clopidogrel B
, O
clopidogrel B
carboxylate I
and O
prasugrel B
for O
human O
neutrophil O
granulocytes O
with O
the O
toxicity O
for O
lymphocytes O
and O
to O
investigate O
underlying O
mechanisms O
. O

For O
granulocytes O
, O
clopidogrel B
, O
ticlopidine B
, O
clopidogrel B
carboxylate I
and O
prasugrel B
were O
concentration O
- O
dependently O
toxic O
starting O
at O
10 O
mu O
M O
. O

Granulocytes O
metabolized O
ticlopidine B
, O
clopidogrel B
, O
clopidogrel B
carboxylate I
and O
prasugrel B
, O
and O
metabolization O
was O
inhibited O
by O
rutin B
, O
but O
not O
by O
ketoconazole B
. O

In O
conclusion O
, O
ticlopidine B
, O
clopidogrel B
, O
clopidogrel B
carboxylate I
and O
prasugrel B
are O
toxic O
for O
both O
granulocytes O
and O
lymphocytes O
. O

Female O
C57BL O
/ O
6 O
mice O
were O
exposed O
to O
dextran O
sodium B
sulphate I
( O
DSS O
) O
and O
treated O
by O
intrarectal O
administration O
with O
either O
CD O
. O
siRNA O
TNF O
- O
alpha O
or O
a O
control O
solution O
. O

Here O
, O
we O
report O
the O
first O
crystal O
structure O
of O
KIF4 O
complexed O
with O
the O
non O
- O
hydrolyzable O
ATP B
analog O
, O
AMPPNP B
( O
adenylyl B
imidodiphosphate I
) O
, O
at O
1 O
. O
7 O
A O
resolution O
. O

The O
lowest O
levels O
of O
peroxide B
value O
( O
PV O
) O
, O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARs O
) O
, O
cholesterol B
oxidation O
products O
( O
COPs O
) O
and O
the O
highest O
level O
of O
polyunsaturated B
fatty I
acids I
( O
PUFAs B
) O
content O
, O
especially O
PUFA B
n I
- I
3 I
, O
were O
found O
in O
the O
untreated O
sardines O
( O
time O
zero O
) O
. O

The O
high O
purity O
, O
molecular O
weight O
and O
correct O
compositions O
of O
each O
new O
polypeptide O
have O
been O
confirmed O
via O
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
, O
sodium B
dodecyl I
sulfate I
polyacrylamide I
gel I
electrophoresis O
( O
SDS B
- O
PAGE O
) O
, O
matrix O
- O
assisted O
laser O
desorption O
/ O
ionization O
mass O
spectrometry O
( O
MALDI O
- O
MS O
) O
, O
and O
amino B
acid I
analysis O
. O

Recently O
, O
alpha B
- I
ketoglutarate I
( O
alpha B
KG I
) O
, O
the O
carbon B
substrate O
for O
ammonia B
assimilation O
, O
has O
been O
observed O
to O
inhibit O
Escherichia O
coli O
enzyme O
I O
( O
EI O
) O
, O
the O
first O
component O
of O
the O
bacterial O
phosphotransferase O
system O
( O
PTS O
) O
, O
thereby O
providing O
a O
direct O
biochemical O
link O
between O
central O
carbon B
and O
nitrogen B
metabolism O
. O

Here O
we O
investigate O
the O
EI O
- O
alpha B
KG I
interaction O
by O
NMR O
and O
enzymatic O
assays O
. O

We O
show O
that O
alpha B
KG I
binds O
with O
a O
KD O
of O
~ O
2 O
. O
2 O
mM O
at O
the O
active O
site O
of O
EI O
, O
acting O
as O
a O
competitive O
inhibitor O
. O

We O
expect O
that O
the O
EI O
- O
alpha B
KG I
structure O
presented O
here O
will O
provide O
a O
starting O
point O
for O
structure O
- O
based O
design O
of O
EI O
mutants O
resistant O
to O
alpha B
KG I
. O

We O
expect O
that O
the O
EI O
- O
alpha B
KG I
structure O
presented O
here O
will O
provide O
a O
starting O
point O
for O
structure O
- O
based O
design O
of O
EI O
mutants O
resistant O
to O
alpha B
KG I
. O

Then O
, O
the O
chemical O
profile O
was O
determined O
using O
a O
C18 O
reversed O
column O
chromatography O
in O
a O
gradient O
solvent O
system O
with O
10 O
- O
40 O
% O
acetonitrile B
in O
0 O
. O
1 O
% O
formic B
acid I
, O
for O
60 O
min O
. O

A O
comparison O
of O
the O
constituents O
in O
the O
nine O
commercial O
products O
of O
Dang O
- O
shen O
showed O
that O
compounds O
codonopyrrolidum B
A I
, I
B I
and O
codonoside B
A I
only O
exist O
in O
C O
. O
tangshen O
, O
but O
not O
in O
C O
. O
pilosula O
var O
. O
modesta O
and O
C O
. O
pilosula O
. O

A O
predominate O
compound O
, O
codonopyrrolidum B
A I
, O
can O
be O
used O
to O
distinguish O
the O
herbs O
, O
C O
. O
tangshen O
from O
C O
. O
pilosula O
var O
. O
modesta O
and O
C O
. O
pilosula O
. O

In O
contrast O
, O
silicon B
nitride I
wears O
through O
removal O
of O
the O
cluster O
of O
atoms O
and O
plastic O
deformation O
. O

Cellulose O
nanowhiskers O
( O
CNWs O
, O
the O
crystalline O
portion O
of O
cellulose O
) O
, O
microcrystalline O
cellulose O
Avicel O
PH101 O
( O
partially O
crystalline O
cellulose O
) O
, O
and O
phosphoric B
acid I
swollen O
cellulose O
( O
PASC O
, O
amorphous O
cellulose O
) O
were O
used O
as O
representative O
models O
for O
cellulose O
to O
better O
understand O
the O
binding O
interactions O
between O
the O
CBMs O
and O
different O
regions O
of O
native O
cellulose O
. O

Isoprostanes B
are O
stable O
products O
of O
arachidonic B
acid I
peroxidation O
and O
are O
regarded O
as O
the O
most O
reliable O
markers O
of O
oxidative O
stress O
in O
vivo O
. O

Lysophosphatidic B
acid I
impairs O
glucose B
homeostasis O
and O
inhibits O
insulin O
secretion O
in O
high O
- O
fat O
diet O
obese O
mice O
. O

AIMS O
/ O
HYPOTHESIS O
: O
Lysophosphatidic B
acid I
( O
LPA B
) O
is O
a O
lipid O
mediator O
produced O
by O
adipocytes O
that O
acts O
via O
specific O
G O
- O
protein O
- O
coupled O
receptors O
; O
its O
synthesis O
is O
modulated O
in O
obesity O
. O

Molecular O
Basis O
for O
Sialic B
Acid I
- O
dependent O
Receptor O
Recognition O
by O
the O
Plasmodium O
falciparum O
Invasion O
Protein O
Erythrocyte O
- O
binding O
Antigen O
- O
140 O
/ O
BAEBL O
. O

Plasmodium O
falciparum O
erythrocyte O
invasion O
is O
dependent O
on O
high O
affinity O
recognition O
of O
sialic B
acid I
on O
cell O
surface O
receptors O
. O

The O
erythrocyte O
binding O
- O
like O
( O
EBL O
) O
family O
of O
invasion O
ligands O
mediates O
recognition O
of O
sialic B
acid I
on O
erythrocyte O
glycoproteins O
. O

Erythrocyte O
- O
binding O
antigen O
- O
140 O
( O
PfEBA O
- O
140 O
/ O
BAEBL O
) O
is O
a O
critical O
EBL O
ligand O
that O
binds O
sialic B
acid I
on O
its O
receptor O
glycophorin O
C O
. O

We O
present O
here O
the O
crystal O
structure O
of O
the O
two O
- O
domain O
receptor O
- O
binding O
region O
of O
PfEBA O
- O
140 O
in O
complex O
with O
a O
glycan O
containing O
sialic B
acid I
. O

Specific O
molecular O
interactions O
that O
enable O
receptor O
engagement O
are O
identified O
and O
reveal O
that O
the O
glycan O
binding O
mode O
is O
distinct O
from O
that O
of O
apicomplexan O
and O
viral O
cell O
surface O
recognition O
ligands O
as O
well O
as O
host O
immune O
factors O
that O
bind O
sialic B
acid I
. O

The O
studies O
described O
here O
provide O
the O
first O
full O
description O
of O
sialic B
acid I
- O
dependent O
molecular O
interactions O
at O
the O
P O
. O
falciparum O
erythrocyte O
invasion O
interface O
and O
define O
a O
framework O
for O
development O
of O
PfEBA O
- O
140 O
- O
based O
therapeutics O
, O
vaccines O
, O
and O
diagnostics O
assessing O
vaccine O
efficacy O
and O
natural O
immunity O
to O
infection O
. O

24 O
% O
of O
the O
PDLLA B
core O
into O
lactic B
acid I
within O
5 O
d O
, O
as O
opposed O
to O
only O
ca O
. O

Therapeutic O
Nanocarriers O
with O
Hydrogen B
Peroxide I
- O
Triggered O
Drug O
Release O
for O
Cancer O
Treatment O
. O

Metabolism O
of O
Beclomethasone B
Dipropionate I
by O
Cytochrome O
P450 O
3A O
Enzymes O
. O

Inhaled O
glucocorticoids O
, O
such O
as O
beclomethasone B
dipropionate I
( O
BDP B
) O
, O
are O
the O
mainstay O
treatment O
of O
asthma O
. O

The O
Tumor O
Suppressor O
Kruppel O
- O
Like O
Factor O
6 O
is O
a O
Novel O
Aryl B
Hydrocarbon I
Receptor O
DNA O
Binding O
Partner O
. O

The O
Aryl B
Hydrocarbon I
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
halogenated B
aromatic I
hydrocarbons I
, O
most O
notably O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

ROS O
activity O
was O
measured O
by O
the O
nitroblue B
tetrazolium I
reduction O
assay O
and O
visualized O
by O
fluorescent O
microscopy O
. O

Acetohydroxyacid O
synthases O
( O
AHASs O
) O
, O
which O
catalyze O
the O
first O
step O
in O
the O
biosynthesis O
of O
branched O
- O
chain O
amino B
acids I
, O
are O
composed O
of O
a O
catalytic O
subunit O
( O
CSU O
) O
and O
a O
regulatory O
subunit O
( O
RSU O
) O
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

Colocalization O
of O
the O
Ganglioside B
GM1 I
and O
Cholesterol B
Detected O
by O
Secondary O
Ion O
Mass O
Spectrometry O
. O

We O
report O
here O
the O
use O
of O
secondary O
ion O
mass O
spectrometry O
( O
SIMS O
) O
to O
image O
the O
cholesterol B
- O
dependent O
cohesive O
phase O
separation O
of O
the O
ganglioside B
GM1 I
into O
nano O
- O
and O
microscale O
assemblies O
in O
a O
canonical O
lipid O
raft O
composition O
of O
lipids O
. O

This O
assembly O
of O
domains O
was O
interrogated O
in O
a O
model O
membrane O
system O
composed O
of O
palmitoyl B
sphingomyelin I
( O
PSM B
) O
, O
cholesterol B
, O
and O
an O
unsaturated O
lipid O
( O
dioleoylphosphatidyl B
, O
DOPC B
) O
. O

The O
structure O
of O
1 O
was O
determined O
via O
mass O
spectrometry O
and O
1D O
and O
2D O
NMR O
spectroscopy O
, O
while O
its O
absolute O
configuration O
was O
determined O
via O
X O
- O
ray O
crystallographic O
analysis O
performed O
on O
its O
methyl B
ester I
derivative O
2 O
. O

Treatment O
of O
ovariectomized O
rats O
with O
estradiol B
benzoate I
or O
3 B
beta I
- I
diol I
for O
4 O
days O
increased O
OT O
mRNA O
selectively O
in O
the O
midcaudal O
, O
but O
not O
rostral O
PVN O
compared O
with O
vehicle O
- O
treated O
controls O
. O

In O
vitro O
study O
demonstrated O
that O
the O
addition O
of O
0 O
. O
5 O
mM O
Fe B
( I
2 I
+ I
) I
and O
0 O
. O
1 O
mM O
ascorbate B
caused O
increase O
in O
the O
production O
of O
MDA B
level O
in O
placental O
tissue O
with O
PE O
than O
normal O
placentas O
, O
and O
vitamin B
E I
( O
100 O
micro O
M O
) O
caused O
lower O
inhibition O
of O
in O
vitro O
lipid O
peroxidation O
in O
placental O
tissue O
with O
PE O
when O
compared O
with O
normal O
tissue O
. O

Oxidative O
DNA O
damage O
is O
involved O
in O
ochratoxin B
A I
- O
induced O
G2 O
arrest O
through O
ataxia O
telangiectasia O
- O
mutated O
( O
ATM O
) O
pathways O
in O
human O
gastric O
epithelium O
GES O
- O
1 O
cells O
in O
vitro O
. O

Ochratoxin B
A I
( O
OTA B
) O
, O
one O
of O
the O
most O
abundant O
mycotoxin O
food O
contaminants O
, O
is O
classified O
as O
" O
possibly O
carcinogenic O
to O
humans O
. O
" O
Our O
previous O
study O
showed O
that O
OTA B
could O
induce O
a O
G2 O
arrest O
in O
immortalized O
human O
gastric O
epithelium O
cells O
( O
GES O
- O
1 O
) O
. O

Primary O
mitochondrial O
disorders O
are O
clinically O
and O
genetically O
heterogeneous O
, O
caused O
by O
an O
alteration O
( O
s O
) O
in O
either O
mitochondrial O
DNA O
or O
nuclear O
DNA O
, O
and O
affect O
the O
respiratory O
chain O
' O
s O
ability O
to O
undergo O
oxidative O
phosphorylation O
, O
leading O
to O
decreased O
production O
of O
adenosine B
triphosphophate I
and O
subsequent O
energy O
failure O
. O

Conclusions O
: O
Our O
data O
demonstrate O
that O
hepatic O
LRP1 O
expression O
and O
function O
decrease O
in O
hypothyroidism O
and O
are O
regulated O
by O
thyroid B
hormone I
. O

The O
solvent O
quality O
of O
an O
aqueous O
mixture O
of O
two O
good O
solvents O
, O
urea B
and O
guanidinium B
chloride I
( O
GdmCl B
) O
, O
for O
a O
hydrophobic O
polymer O
was O
investigated O
using O
atomistic O
molecular O
dynamics O
simulations O
. O

Intestinal O
and O
hepatic O
first O
- O
pass O
extraction O
of O
the O
11 O
beta O
- O
HSD1 O
inhibitor O
AMG B
221 I
in O
rats O
with O
chronic O
vascular O
catheters O
. O

A O
catheterized O
rat O
model O
was O
used O
to O
define O
the O
intestinal O
and O
hepatic O
components O
of O
oral O
bioavailability O
for O
an O
11 O
beta O
- O
HSD1 O
inhibitor O
, O
AMG B
221 I
. O

Intestinal O
and O
hepatic O
extraction O
ratios O
of O
AMG B
221 I
obtained O
using O
a O
five O
- O
catheter O
rat O
model O
were O
0 O
. O
56 O
and O
0 O
. O
32 O
, O
respectively O
. O

Mass O
balance O
data O
and O
in O
vivo O
metabolite O
characterization O
obtained O
after O
administration O
of O
[ B
( I
14 I
) I
C I
] I
AMG I
221 I
to O
rat O
showed O
that O
AMG B
221 I
was O
completely O
absorbed O
from O
the O
gut O
lumen O
following O
an O
oral O
dose O
, O
primarily O
excreted O
in O
urine O
and O
was O
almost O
completely O
metabolized O
prior O
to O
excretion O
. O

Hepatic O
bioavailability O
( O
FH O
) O
, O
measured O
in O
two O
animals O
at O
various O
time O
points O
after O
oral O
dose O
administration O
was O
somewhat O
variable O
but O
generally O
characterized O
by O
an O
initial O
reduction O
during O
the O
absorption O
phase O
followed O
by O
an O
increase O
during O
the O
elimination O
phase O
, O
consistent O
with O
hepatic O
distribution O
of O
AMG B
221 I
. O

A O
novel O
series O
of O
compounds O
were O
synthesized O
by O
cyclic O
condensation O
reaction O
of O
substituted O
isothiocyanate B
( O
2a O
- O
c O
) O
with O
2 B
- I
thiophenecarboxylic I
acid I
hydrazide I
( O
1 O
) O
in O
the O
presence O
of O
ethyl B
alcohol I
, O
to O
obtain O
intermediate O
thiosemicarbazides B
( O
3a O
- O
c O
) O
, O
which O
were O
further O
treated O
with O
sodium B
hydroxide I
in O
the O
presence O
of O
ethanol B
to O
obtain O
triazole B
derivatives O
( O
4a O
- O
c O
) O
. O

A O
novel O
series O
of O
compounds O
were O
synthesized O
by O
cyclic O
condensation O
reaction O
of O
substituted O
isothiocyanate B
( O
2a O
- O
c O
) O
with O
2 B
- I
thiophenecarboxylic I
acid I
hydrazide I
( O
1 O
) O
in O
the O
presence O
of O
ethyl B
alcohol I
, O
to O
obtain O
intermediate O
thiosemicarbazides B
( O
3a O
- O
c O
) O
, O
which O
were O
further O
treated O
with O
sodium B
hydroxide I
in O
the O
presence O
of O
ethanol B
to O
obtain O
triazole B
derivatives O
( O
4a O
- O
c O
) O
. O

The O
latter O
were O
refluxed O
with O
substituted O
secondary B
amines I
and O
formaldehyde B
for O
6 O
- O
10 O
h O
to O
afford O
Mannich B
bases I
( O
5a O
- O
k O
) O
. O

The O
latter O
were O
refluxed O
with O
substituted O
secondary B
amines I
and O
formaldehyde B
for O
6 O
- O
10 O
h O
to O
afford O
Mannich B
bases I
( O
5a O
- O
k O
) O
. O

Embryonic O
fibroblasts O
derived O
from O
the O
ser994 B
mutant O
mice O
were O
not O
sensitive O
to O
killing O
by O
a O
range O
of O
DNA O
damaging O
agents O
, O
but O
they O
were O
sensitive O
to O
the O
induction O
of O
sister O
chromatid O
exchanges O
induced O
by O
ultraviolet O
light O
or O
mitomycin B
C I
. O

Neuraminidases O
( O
sialidases O
) O
catalyze O
the O
removal O
of O
sialic B
acid I
residues O
from O
sialylated O
glycoconjugates O
. O

Insulin O
binding O
to O
its O
receptor O
rapidly O
induces O
interaction O
of O
the O
receptor O
with O
Neu1 O
, O
which O
hydrolyzes O
sialic B
acid I
residues O
in O
the O
glycan O
chains O
of O
the O
receptor O
and O
, O
consequently O
, O
induces O
its O
activation O
. O

Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic B
Acid I
. O

One O
exception O
is O
tranexamic B
acid I
( O
TXA B
) O
, O
which O
, O
as O
a O
lysine B
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O

Screening O
of O
a O
small O
in O
- O
house O
library O
of O
1863 O
compounds O
identified O
29 O
compounds O
that O
protected O
Jurkat O
cells O
from O
hydrogen B
peroxide I
- O
induced O
cytotoxicity O
. O

Four O
cytoprotective O
dibenzoylmethane B
( O
DBM B
) O
derivatives O
were O
investigated O
in O
more O
detail O
as O
they O
did O
not O
scavenge O
hydrogen B
peroxide I
nor O
did O
they O
inhibit O
PARylation O
. O

Hydrogen B
peroxide I
activated O
extracellular O
signal O
regulated O
kinase O
( O
ERK1 O
/ O
2 O
) O
and O
p38 O
MAP O
kinases O
but O
not O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
. O

We O
found O
that O
AVM B
induced O
upregulation O
of O
P O
- O
gp O
protein O
expression O
, O
increased O
P O
- O
gp O
ATPase O
activity O
and O
enhanced O
cellular O
efflux O
of O
the O
P O
- O
gp O
substrate O
rhodamine B
123 I
from O
cells O
. O

These O
results O
are O
supported O
by O
our O
observations O
that O
verapamil B
, O
a O
Ca B
( I
2 I
+ I
) I
channel O
blocker O
, O
and O
niflumic B
acid I
, O
a O
chloride B
channel O
antagonist O
, O
significantly O
attenuated O
AVM B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
elevation O
, O
thereby O
reducing O
P O
- O
gp O
expression O
. O

Inhibition O
of O
P O
- O
gp O
with O
anti O
- O
P O
- O
gp O
antibody O
or O
cyclosporine B
A I
( O
a O
P O
- O
gp O
inhibitor O
) O
reduced O
the O
AVM B
- O
induced O
elevation O
of O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
, O
implying O
that O
P O
- O
gp O
and O
[ O
Ca B
( I
2 I
+ I
) I
] O
i O
regulate O
each O
other O
. O

Methyl B
mercury I
, O
held O
in O
the O
school O
laboratory O
for O
experimental O
purpose O
, O
may O
be O
a O
source O
of O
poisoning O
. O

High O
electrochemical O
cycling O
stability O
, O
chloride B
( O
Cl B
( I
- I
) I
) O
tolerance O
and O
good O
selectivity O
are O
also O
obtained O
for O
the O
Pt B
NP O
@ O
PPy B
NF O
structure O
, O
as O
the O
electrode O
showed O
no O
obvious O
response O
to O
the O
common O
interfering O
agents O
, O
such O
as O
ascorbic B
acid I
( O
AA O
) O
, O
uric B
acid I
( O
UA O
) O
, O
and O
4 B
- I
acetamidophenol I
( O
AP O
) O
. O

High O
electrochemical O
cycling O
stability O
, O
chloride B
( O
Cl B
( I
- I
) I
) O
tolerance O
and O
good O
selectivity O
are O
also O
obtained O
for O
the O
Pt B
NP O
@ O
PPy B
NF O
structure O
, O
as O
the O
electrode O
showed O
no O
obvious O
response O
to O
the O
common O
interfering O
agents O
, O
such O
as O
ascorbic B
acid I
( O
AA O
) O
, O
uric B
acid I
( O
UA O
) O
, O
and O
4 B
- I
acetamidophenol I
( O
AP O
) O
. O

Free O
fatty B
acids I
induce O
Lhb O
mRNA O
but O
suppress O
Fshb O
mRNA O
in O
pituitary O
L O
beta O
T2 O
gonadotropes O
and O
diet O
- O
induced O
obesity O
reduces O
FSH O
levels O
in O
male O
mice O
and O
disrupts O
the O
proestrus O
LH O
/ O
FSH O
surge O
in O
female O
mice O
. O

We O
hypothesized O
that O
elevated O
free O
fatty B
acids I
( O
FFAs O
) O
might O
directly O
modulate O
pituitary O
gonadotropin O
production O
. O

Polyurethane B
elastomers O
coating O
were O
synthesised O
by O
using O
typical O
diisocyanates B
, O
polyether B
and O
polyester B
polyols I
and O
HO B
- O
tertiary B
amines I
or O
diols B
as O
a O
chain O
extenders O
. O

Polyurethane B
elastomers O
coating O
were O
synthesised O
by O
using O
typical O
diisocyanates B
, O
polyether B
and O
polyester B
polyols I
and O
HO B
- O
tertiary B
amines I
or O
diols B
as O
a O
chain O
extenders O
. O

It O
has O
been O
found O
that O
use O
of O
2 B
, I
2 I
, I
3 I
, I
3 I
- I
tetrafluoro I
- I
1 I
, I
4 I
- I
butanediol I
as O
a O
fluorinated O
extender O
of O
prepolymer O
chains O
is O
essential O
to O
obtain O
coatings O
with O
increased O
hydrophobicity O
, O
applied O
among O
others O
as O
biomaterials O
- O
next O
to O
diphenylmethane B
diisocyanate I
and O
polyoxyethylene B
glycol I
. O

It O
has O
been O
found O
that O
use O
of O
2 B
, I
2 I
, I
3 I
, I
3 I
- I
tetrafluoro I
- I
1 I
, I
4 I
- I
butanediol I
as O
a O
fluorinated O
extender O
of O
prepolymer O
chains O
is O
essential O
to O
obtain O
coatings O
with O
increased O
hydrophobicity O
, O
applied O
among O
others O
as O
biomaterials O
- O
next O
to O
diphenylmethane B
diisocyanate I
and O
polyoxyethylene B
glycol I
. O

To O
vary O
degradability O
, O
a O
co O
- O
monomer O
, O
acrylic B
acid I
( O
AA O
) O
or O
2 B
- I
hydroxypropyl I
methacrylamide I
( O
HPMA B
) O
, O
was O
introduced O
, O
coupled O
with O
altering O
the O
concentration O
of O
the O
cross O
- O
linker O
and O
of O
the O
bioceramic O
. O

Nicotinic B
Acid I
and O
Nicotinamide B
: O
A O
Review O
of O
Their O
Use O
for O
Hyperphosphatemia O
in O
Dialysis O
Patients O
. O

New O
evidence O
suggests O
that O
nicotinic B
acid I
and O
its O
metabolites O
may O
effectively O
decrease O
phosphorus B
absorption O
in O
the O
gastrointestinal O
tract O
, O
thereby O
reducing O
serum O
phosphorus B
concentrations O
. O

We O
searched O
PubMed O
using O
the O
search O
terms O
niacin B
, O
nicotinic B
acid I
, O
niacinamide B
, O
nicotinamide B
and O
hyperphosphatemia O
. O

Among O
the O
seven O
studies O
that O
met O
our O
exclusion O
criteria O
, O
three O
used O
nicotinic B
acid I
as O
the O
therapeutic O
intervention O
and O
four O
used O
nicotinamide B
. O

Both O
nicotinic B
acid I
and O
nicotinamide B
were O
effective O
in O
significantly O
reducing O
serum O
phosphorus B
concentrations O
in O
patients O
with O
ESRD O
on O
either O
hemodialysis O
or O
peritoneal O
dialysis O
. O

Multiple O
Phytoestrogens O
Inhibit O
Cell O
Growth O
and O
Confer O
Cytoprotection O
By O
Inducing O
Manganese B
Superoxide I
Dismutase O
Expression O
. O

Here O
, O
we O
show O
that O
one O
mechanism O
by O
which O
a O
number O
of O
phytoestrogens O
achieve O
their O
growth O
inhibitory O
and O
cytoprotective O
effects O
is O
via O
induction O
of O
the O
mitochondrial O
manganese B
superoxide I
dismutase O
( O
MnSOD O
) O
. O

Five O
of O
these O
, O
resveratrol B
, O
coumestrol B
, O
kaempferol B
, O
genistein B
and O
daidzein B
, O
significantly O
increased O
MnSOD O
expression O
, O
slowed O
proliferative O
growth O
and O
enhanced O
stress O
resistance O
( O
hydrogen B
peroxide I
LD50 O
) O
. O

Thiolactone B
Sulfoxides I
as O
New O
Reactive O
Metabolites O
Acting O
as O
Bis O
- O
Electrophiles O
: O
Implication O
in O
Clopidogrel B
and O
Prasugrel B
Bioactivation O
. O

The O
second O
step O
is O
a O
cytochrome O
P450 O
( O
P450 O
) O
- O
dependent O
oxidation O
of O
this O
thiolactone B
resulting O
in O
the O
formation O
of O
a O
sulfenic B
acid I
that O
is O
eventually O
reduced O
into O
the O
corresponding O
active O
thiol B
. O

It O
has O
been O
postulated O
that O
the O
sulfenic B
acid I
metabolite O
resulted O
from O
a O
nucleophilic O
attack O
of O
water O
on O
a O
highly O
reactive O
thiolactone B
sulfoxide I
derived O
from O
P450 O
- O
dependent O
oxidation O
of O
the O
thiolactone B
primary O
metabolite O
. O

It O
has O
been O
postulated O
that O
the O
sulfenic B
acid I
metabolite O
resulted O
from O
a O
nucleophilic O
attack O
of O
water O
on O
a O
highly O
reactive O
thiolactone B
sulfoxide I
derived O
from O
P450 O
- O
dependent O
oxidation O
of O
the O
thiolactone B
primary O
metabolite O
. O

The O
data O
described O
in O
the O
present O
article O
are O
in O
complete O
agreement O
with O
this O
proposition O
as O
they O
show O
that O
it O
was O
possible O
to O
trap O
these O
thiolactone B
sulfoxides I
by O
a O
series O
of O
nucleophiles O
such O
as O
amines B
, O
thiols B
, O
or O
cyclopentane B
- I
1 I
, I
3 I
- I
dione I
( O
CPDH B
) O
, O
an O
equivalent O
of O
dimedone B
that O
is O
used O
as O
a O
sulfenic B
acid I
trapping O
agent O
. O

The O
data O
described O
in O
the O
present O
article O
are O
in O
complete O
agreement O
with O
this O
proposition O
as O
they O
show O
that O
it O
was O
possible O
to O
trap O
these O
thiolactone B
sulfoxides I
by O
a O
series O
of O
nucleophiles O
such O
as O
amines B
, O
thiols B
, O
or O
cyclopentane B
- I
1 I
, I
3 I
- I
dione I
( O
CPDH B
) O
, O
an O
equivalent O
of O
dimedone B
that O
is O
used O
as O
a O
sulfenic B
acid I
trapping O
agent O
. O

All O
metabolites O
derived O
from O
an O
attack O
of O
H2O B
or O
an O
amine B
at O
the O
CO B
carbon B
of O
the O
intermediate O
thiolactone B
sulfoxide I
existed O
as O
a O
mixture O
of O
two O
diastereomers O
having O
a O
cis O
configuration O
of O
the O
double O
bond O
, O
whereas O
those O
formed O
in O
the O
presence O
of O
thiols B
appeared O
as O
a O
mixture O
of O
four O
diastereomers O
with O
a O
cis O
or O
trans O
configuration O
of O
the O
double O
bond O
. O

The O
results O
described O
in O
this O
article O
showed O
that O
thiolactone B
sulfoxides I
are O
formed O
as O
reactive O
metabolites O
during O
the O
metabolism O
of O
clopidogrel B
and O
prasugrel B
and O
are O
able O
to O
react O
as O
bis O
- O
electrophiles O
with O
a O
variety O
of O
nucleophiles O
. O

Arylpiperazines B
as O
fatty B
acid I
transport O
protein O
1 O
( O
FATP1 O
) O
inhibitors O
with O
improved O
potency O
and O
pharmacokinetic O
properties O
. O

Molecular O
design O
, O
synthesis O
and O
biological O
evaluation O
of O
cyclic B
imides I
bearing O
benzenesulfonamide B
fragment O
as O
potential O
COX O
- O
2 O
inhibitors O
. O

A O
group O
of O
cyclic B
imides I
( O
1 O
- O
10 O
) O
was O
designed O
for O
evaluation O
as O
a O
selective O
COX O
- O
2 O
inhibitors O
and O
investigated O
in O
vivo O
for O
their O
anti O
- O
inflammatory O
activity O
. O

Protection O
of O
glycyrrhizic B
acid I
against O
AGEs O
- O
induced O
endothelial O
dysfunction O
through O
inhibiting O
RAGE O
/ O
NF O
- O
kappa O
B O
pathway O
activation O
in O
human O
umbilical O
vein O
endothelial O
cells O
. O

Glycyrrhizic B
acid I
( O
GA O
, O
also O
known O
as O
Glycyrrhizin B
) O
, O
a O
triterpenoid B
saponin I
glycoside I
, O
is O
considered O
to O
be O
a O
bioactive O
component O
in O
Licorice O
and O
is O
beneficial O
to O
diabetic O
vascular O
complications O
. O

Circulating O
Vitamin B
D I
Metabolites O
and O
Subclinical O
Atherosclerosis O
in O
Type O
1 O
Diabetes O
. O

Existing O
evidence O
suggests O
that O
impaired O
vitamin B
D I
metabolism O
may O
contribute O
to O
the O
development O
of O
atherosclerosis O
. O

We O
tested O
associations O
of O
circulating O
vitamin B
D I
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
, O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
, O
and O
24 B
, I
25 I
- I
dihydroxyvitamin I
D I
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

We O
hypothesized O
that O
lower O
concentrations O
of O
each O
vitamin B
D I
metabolite O
would O
be O
associated O
with O
increased O
risk O
of O
CAC O
and O
greater O
carotid O
IMT O
. O
RESULTSAt O
the O
time O
metabolites O
were O
measured O
, O
mean O
age O
was O
32 O
. O
4 O
years O
and O
mean O
duration O
of O
diabetes O
was O
7 O
. O
5 O
years O
. O

The O
prevalence O
and O
severity O
of O
CAC O
tended O
to O
be O
lower O
- O
not O
higher O
- O
with O
lower O
concentrations O
of O
each O
vitamin B
D I
metabolite O
. O

No O
vitamin B
D I
metabolite O
was O
associated O
with O
either O
common O
or O
internal O
mean O
IMT O
. O
CONCLUSIONSWe O
did O
not O
find O
evidence O
linking O
impaired O
vitamin B
D I
metabolism O
with O
increased O
subclinical O
atherosclerosis O
in O
type O
1 O
diabetes O
. O

No O
vitamin B
D I
metabolite O
was O
associated O
with O
either O
common O
or O
internal O
mean O
IMT O
. O
CONCLUSIONSWe O
did O
not O
find O
evidence O
linking O
impaired O
vitamin B
D I
metabolism O
with O
increased O
subclinical O
atherosclerosis O
in O
type O
1 O
diabetes O
. O

Silicone O
sheets O
are O
first O
plasma O
treated O
and O
then O
functionalized O
by O
grafting O
sequentially O
under O
stretching O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
chains O
and O
biotin B
or O
arginine B
- O
glycine B
- O
aspartic B
acid I
( O
RGD O
) O
peptides O
. O

Nickel B
( I
II I
) I
Dithiocarbamate I
Complexes O
Containing O
Sulforhodamine B
B I
as O
Fluorescent O
Probes O
for O
Selective O
Detection O
of O
Nitrogen B
Dioxide I
. O

Nickel B
( I
II I
) I
Dithiocarbamate I
Complexes O
Containing O
Sulforhodamine B
B I
as O
Fluorescent O
Probes O
for O
Selective O
Detection O
of O
Nitrogen B
Dioxide I
. O

We O
synthesized O
complexes O
of O
Ni B
( I
II I
) I
with O
dithiocarbamate B
ligands O
derived O
from O
the O
ortho O
and O
para O
isomers O
of O
sulforhodamine B
B I
fluorophores O
and O
demonstrated O
they O
are O
highly O
selective O
in O
reactions O
with O
nitrogen B
dioxide I
( O
NO2 B
) O
. O

We O
synthesized O
complexes O
of O
Ni B
( I
II I
) I
with O
dithiocarbamate B
ligands O
derived O
from O
the O
ortho O
and O
para O
isomers O
of O
sulforhodamine B
B I
fluorophores O
and O
demonstrated O
they O
are O
highly O
selective O
in O
reactions O
with O
nitrogen B
dioxide I
( O
NO2 B
) O
. O

We O
applied O
this O
probe O
for O
visual O
detection O
of O
1 O
ppm O
NO2 B
in O
the O
gas O
phase O
and O
fluorescence O
imaging O
of O
NO2 B
in O
macrophage O
cells O
treated O
with O
a O
nitrogen B
dioxide I
donor O
. O

In O
Vivo O
Degradation O
and O
Elimination O
of O
Injectable O
Ricinoleic B
Acid I
- O
Based O
Poly B
( I
ester I
- I
anhydride I
) I
. O

( B
1 I
) I
H I
NMR O
spectral O
analysis O
was O
used O
to O
determine O
the O
structures O
and O
content O
of O
ricinoleic B
acid I
containing O
oligomeric O
chains O
present O
in O
the O
degraded O
polymer O
. O

The O
polymer O
degrades O
into O
ester O
oligomers O
of O
2 O
- O
4 O
ricinoleic B
acid I
units O
which O
further O
degrade O
to O
ricinoleic B
acid I
, O
a O
natural O
fatty B
acid I
. O

The O
polymer O
degrades O
into O
ester O
oligomers O
of O
2 O
- O
4 O
ricinoleic B
acid I
units O
which O
further O
degrade O
to O
ricinoleic B
acid I
, O
a O
natural O
fatty B
acid I
. O

The O
polymer O
degrades O
into O
ester O
oligomers O
of O
2 O
- O
4 O
ricinoleic B
acid I
units O
which O
further O
degrade O
to O
ricinoleic B
acid I
, O
a O
natural O
fatty B
acid I
. O

To O
evaluate O
the O
protective O
effects O
of O
alpha B
- I
lipoic I
acid I
on O
the O
kidneys O
of O
Goto O
- O
Kakisaki O
( O
GK O
) O
diabetic O
rats O
, O
ten O
GK O
diabetic O
rats O
were O
randomly O
divided O
into O
a O
diabetic O
control O
group O
and O
a O
lipoic B
acid I
- O
treated O
diabetic O
group O
with O
alpha B
- I
lipoic I
acid I
35 O
mg O
. O
Kg O
- O
1 O
intraperitoneal O
injections O
. O

Malonaldehyde B
( O
MDA B
) O
, O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
vitamin B
E I
, O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
levels O
in O
renal O
homogenate O
, O
and O
urine O
protein O
excretion O
were O
measured O
. O

Malonaldehyde B
( O
MDA B
) O
, O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
vitamin B
E I
, O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
levels O
in O
renal O
homogenate O
, O
and O
urine O
protein O
excretion O
were O
measured O
. O

Malonaldehyde B
( O
MDA B
) O
, O
ascorbic B
acid I
( O
vitamin B
C I
) O
, O
vitamin B
E I
, O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
levels O
in O
renal O
homogenate O
, O
and O
urine O
protein O
excretion O
were O
measured O
. O

There O
were O
significant O
increases O
in O
urine O
protein O
excretion O
, O
MDA B
levels O
and O
the O
expression O
of O
mRNA O
of O
NF O
- O
kappa O
B O
, O
p22phox O
and O
p47phox O
, O
and O
significant O
decreases O
in O
GSH B
, O
SOD O
, O
vitamin B
C I
and O
vitamin B
E I
levels O
in O
the O
diabetic O
control O
group O
compared O
with O
the O
normal O
control O
group O
. O

There O
were O
significant O
increases O
in O
urine O
protein O
excretion O
, O
MDA B
levels O
and O
the O
expression O
of O
mRNA O
of O
NF O
- O
kappa O
B O
, O
p22phox O
and O
p47phox O
, O
and O
significant O
decreases O
in O
GSH B
, O
SOD O
, O
vitamin B
C I
and O
vitamin B
E I
levels O
in O
the O
diabetic O
control O
group O
compared O
with O
the O
normal O
control O
group O
. O

We O
report O
results O
of O
noncellular O
tests O
, O
revealing O
the O
occurrence O
of O
photocatalytic O
interactions O
between O
titanium B
dioxide I
( O
TiO2 B
, O
titania B
) O
nanoparticles O
and O
the O
MTT B
[ O
3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
- I
bromide I
] O
cytotoxicity O
indicator O
. O

Classical O
MTT B
assays O
have O
been O
performed O
to O
evaluate O
the O
production O
of O
formazan B
in O
DMEM O
- O
F12 O
and O
RPMI O
- O
1640 O
cell O
culture O
media O
( O
containing O
10 O
% O
fetal O
bovine O
serum O
- O
FBS O
) O
treated O
with O
Degussa O
- O
P25 B
TiO2 I
nanoparticles O
, O
in O
the O
absence O
of O
cells O
. O

The O
absorption O
spectra O
of O
these O
materials O
are O
red O
- O
shifted O
by O
115 O
nm O
to O
the O
visible O
region O
of O
the O
solar O
spectrum O
compared O
with O
P25 B
TiO2 I
. O

A O
pyrrolidinium B
nitrate I
protic O
ionic O
liquid O
- O
based O
electrolyte O
for O
very O
low O
- O
temperature O
electrical O
double O
- O
layer O
capacitors O
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium B
nitrate I
( O
[ B
Pyrr I
] I
[ I
NO3 I
] I
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma B
butyrolactone I
( O
gamma B
- I
BL I
) O
as O
an O
electrolyte O
for O
carbon B
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium B
nitrate I
( O
[ B
Pyrr I
] I
[ I
NO3 I
] I
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma B
butyrolactone I
( O
gamma B
- I
BL I
) O
as O
an O
electrolyte O
for O
carbon B
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

At O
the O
same O
time O
, O
exceptional O
residual O
conductivity O
was O
measured O
for O
this O
composition O
at O
- O
40 O
degrees O
C O
( O
9 O
mS O
cm O
( O
- O
1 O
) O
) O
, O
thanks O
to O
the O
superionic O
character O
of O
pyrrolidinium B
nitrate I
PIL O
. O

METHODS O
: O
C57BL O
/ O
6 O
diabetic O
mice O
were O
transplanted O
with O
syngeneic O
islets O
in O
the O
liver O
and O
simultaneously O
abdominally O
implanted O
with O
a O
mini O
- O
osmotic O
pump O
delivering O
BrdU O
alone O
or O
together O
with O
an O
immunosuppressant O
( O
tacrolimus B
, O
sirolimus B
, O
everolimus B
or O
mycophenolate B
mofetil I
[ O
MMF B
] O
) O
. O

Baseline O
cortisol B
( O
Cor0 O
) O
, O
DHEA B
- O
S O
( O
DHEA B
- O
S0 O
) O
, O
cortisol B
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol B
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol B
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol B
( O
Cor60 O
) O
, O
and O
DHEA B
- O
S O
( O
DHEA B
- O
S60 O
) O
, O
delta B
cortisol I
( O
Delta B
Cor I
) O
, O
delta B
DHEA I
- O
S O
( O
Delta B
DHEA I
- O
S O
) O
responses O

Baseline O
cortisol B
( O
Cor0 O
) O
, O
DHEA B
- O
S O
( O
DHEA B
- O
S0 O
) O
, O
cortisol B
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol B
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol B
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol B
( O
Cor60 O
) O
, O
and O
DHEA B
- O
S O
( O
DHEA B
- O
S60 O
) O
, O
delta B
cortisol I
( O
Delta B
Cor I
) O
, O
delta B
DHEA I
- O
S O
( O
Delta B
DHEA I
- O
S O
) O
responses O

Baseline O
cortisol B
( O
Cor0 O
) O
, O
DHEA B
- O
S O
( O
DHEA B
- O
S0 O
) O
, O
cortisol B
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol B
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol B
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol B
( O
Cor60 O
) O
, O
and O
DHEA B
- O
S O
( O
DHEA B
- O
S60 O
) O
, O
delta B
cortisol I
( O
Delta B
Cor I
) O
, O
delta B
DHEA I
- O
S O
( O
Delta B
DHEA I
- O
S O
) O
responses O

Baseline O
cortisol B
( O
Cor0 O
) O
, O
DHEA B
- O
S O
( O
DHEA B
- O
S0 O
) O
, O
cortisol B
binding O
globulin O
( O
CBG O
) O
, O
ACTH O
, O
calculated O
free O
cortisol B
( O
by O
Coolen O
' O
s O
equation O
= O
CFC O
) O
, O
free O
cortisol B
index O
( O
FCI O
) O
, O
60 O
- O
min O
cortisol B
( O
Cor60 O
) O
, O
and O
DHEA B
- O
S O
( O
DHEA B
- O
S60 O
) O
, O
delta B
cortisol I
( O
Delta B
Cor I
) O
, O
delta B
DHEA I
- O
S O
( O
Delta B
DHEA I
- O
S O
) O
responses O

Cor60 O
, O
Delta B
Cor I
, O
and O
Delta B
DHEA I
- O
S O
were O
lower O
in O
hyperthyroidism O
. O

Cor60 O
, O
Delta B
Cor I
, O
and O
Delta B
DHEA I
- O
S O
were O
lower O
in O
hyperthyroidism O
. O

ACTH O
- O
stimulated O
peak O
cortisol B
, O
delta B
cortisol I
, O
and O
delta B
DHEA I
- O
S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O

ACTH O
- O
stimulated O
peak O
cortisol B
, O
delta B
cortisol I
, O
and O
delta B
DHEA I
- O
S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O

Although O
the O
amino B
acid I
sequence O
of O
LaeA O
contains O
the O
motifs O
characteristic O
of O
seven O
- O
beta O
- O
strand O
methyltransferases O
, O
a O
methyl B
- O
accepting O
substrate O
of O
LaeA O
has O
not O
been O
identified O
. O

Amino B
acid I
hydrolysis O
of O
radioactively O
- O
labeled O
LaeA O
followed O
by O
cation O
exchange O
and O
reverse O
phase O
chromatography O
identified O
methionine B
as O
the O
modified O
residue O
. O

We O
performed O
chemical O
modifications O
of O
ifenprodil B
at O
the O
benzylic B
position O
and O
on O
the O
phenol B
ring O
by O
introducing O
secondary B
amine I
or I
amide I
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary B
amide I
functions O
as O
spacers O
. O

Synthesis O
and O
biological O
evaluation O
of O
tricyclic B
guanidine I
analogues O
of O
batzelladine B
K I
for O
antimalarial O
, O
antileishmanial O
, O
antibacterial O
, O
antifungal O
, O
and O
anti O
- O
HIV O
activities O
. O

Synthesis O
and O
biological O
evaluation O
of O
tricyclic B
guanidine I
analogues O
of O
batzelladine B
K I
for O
antimalarial O
, O
antileishmanial O
, O
antibacterial O
, O
antifungal O
, O
and O
anti O
- O
HIV O
activities O
. O

Fifty O
analogues O
of O
batzelladine B
K I
were O
synthesized O
and O
evaluated O
for O
in O
vitro O
antimalarial O
( O
Plasmodium O
falciparum O
) O
, O
antileishmanial O
( O
Leishmania O
donovani O
) O
, O
antimicrobial O
( O
panel O
of O
bacteria O
and O
fungi O
) O
, O
antiviral O
( O
HIV O
- O
1 O
) O
activities O
. O

Our O
study O
demonstrated O
that O
the O
tricyclic B
guanidine I
compounds O
provide O
new O
structural O
class O
for O
broad O
spectrum O
activity O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
pyripyropene B
A I
derivatives O
as O
potent O
and O
selective O
acyl B
- I
CoA I
: O
cholesterol B
acyltransferase O
2 O
( O
ACAT2 O
) O
inhibitors O
: O
Part O
2 O
. O

A O
comparative O
study O
of O
the O
lipid O
status O
( O
i O
. O
e O
. O
, O
the O
total O
lipid O
and O
phospholipid O
concentrations O
and O
the O
percentage O
of O
fatty B
acids I
of O
the O
total O
lipids O
) O
of O
adult O
specimens O
of O
daubed O
shanny O
( O
Leptoclinus O
maculatus O
) O
from O
Svalbard O
waters O
( O
Isfjord O
) O
and O
slender O
eel O
blenny O
( O
Lumpenus O
fabricii O
) O
from O
the O
White O
Sea O
( O
Onega O
Bay O
and O
Tersky O
shore O
) O
was O
performed O
to O
study O
the O
metabolism O
and O
functions O
of O
lipids O
of O
these O
fishes O
in O
ontogeny O
and O
under O
various O
ecological O
conditions O
. O

The O
model O
was O
extended O
to O
describe O
perchlorate B
, O
an O
environmental O
and O
food O
contaminant O
, O
that O
competes O
with O
the O
sodium B
iodide I
symporter O
protein O
for O
thyroidal O
uptake O
of O
iodide B
. O

The O
50 O
kDa O
fraction O
contains O
56 O
% O
of O
proteins O
, O
3 O
% O
of O
lipids O
and O
6 O
% O
of O
minerals O
on O
a O
dry O
weight O
basis O
and O
the O
lowest O
levels O
detected O
of O
taurine B
and O
methionine B
and O
highest O
levels O
of O
threonine B
, O
proline B
and O
glycine B
amino B
acids I
. O

Recent O
developments O
in O
design O
and O
synthesis O
of O
bicyclic B
azasugars I
, O
carbasugars B
and O
related O
molecules O
as O
glycosidase O
inhibitors O
. O

AP O
was O
induced O
with O
sodium B
taurocholate I
. O

Histopathologic O
scores O
in O
the O
AP O
+ O
Tau B
and O
Tau B
groups O
were O
significantly O
lower O
compared O
with O
the O
AP O
group O
( O
both O
p O
< O
0 O
. O
001 O
) O
. O
These O
results O
showed O
that O
Tau B
reduces O
lipid O
peroxidation O
, O
amylase O
and O
MPO O
activities O
and O
the O
concentrations O
of O
proinflammatory O
cytokines O
secondary O
to O
AP O
and O
also O
increases O
superoxide B
dismutase O
and O
glutathione B
peroxidase O
activities O
in O
rats O
with O
sodium B
taurocholate I
- O
induced O
AP O
. O

This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3 B
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
- I
( I
phenylseleno I
) I
oct I
- I
2 I
- I
en I
- I
1 I
- I
one I
( O
C21H2HOSe B
; O
organoselenium B
) O
and O
sodium B
selenate I
( O
inorganic O
Se B
) O
on O
adenosine B
deaminase O
( O
ADA O
) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric B
oxide I
( O
NO B
) O
and O
nonprotein O
thiols B
( O
NP O
- O
SH B
) O
content O
in O
the O
cerebral O
cortex O

This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3 B
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
- I
( I
phenylseleno I
) I
oct I
- I
2 I
- I
en I
- I
1 I
- I
one I
( O
C21H2HOSe B
; O
organoselenium B
) O
and O
sodium B
selenate I
( O
inorganic O
Se B
) O
on O
adenosine B
deaminase O
( O
ADA O
) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric B
oxide I
( O
NO B
) O
and O
nonprotein O
thiols B
( O
NP O
- O
SH B
) O
content O
in O
the O
cerebral O
cortex O

Inorganic O
Se B
was O
able O
to O
protect O
against O
sodium B
nitroprusside I
- O
induced O
oxidative O
damage O
and O
increased O
the O
NP O
- O
SH B
content O
. O

Comparison O
of O
the O
Relative O
Propensities O
of O
Isoamyl B
Nitrite I
and O
Sodium B
Nitrite I
to O
Ameliorate O
Acute O
Cyanide B
Poisoning O
in O
Mice O
and O
a O
Novel O
Antidotal O
Effect O
Arising O
from O
Anesthetics O
. O

Comparison O
of O
the O
Relative O
Propensities O
of O
Isoamyl B
Nitrite I
and O
Sodium B
Nitrite I
to O
Ameliorate O
Acute O
Cyanide B
Poisoning O
in O
Mice O
and O
a O
Novel O
Antidotal O
Effect O
Arising O
from O
Anesthetics O
. O

Isoamyl B
nitrite I
has O
previously O
been O
considered O
acceptable O
as O
an O
inhaled O
cyanide B
antidote O
; O
therefore O
, O
the O
antidotal O
utility O
of O
this O
organic O
nitrite B
compared O
with O
sodium B
nitrite I
was O
investigated O
. O

Isoamyl B
nitrite I
has O
previously O
been O
considered O
acceptable O
as O
an O
inhaled O
cyanide B
antidote O
; O
therefore O
, O
the O
antidotal O
utility O
of O
this O
organic O
nitrite B
compared O
with O
sodium B
nitrite I
was O
investigated O
. O

To O
facilitate O
a O
quantitative O
comparison O
, O
doses O
of O
both O
sodium B
nitrite I
and O
isoamyl B
nitrite I
were O
given O
intraperitoneally O
in O
equimolar O
amounts O
to O
sublethally O
cyanide B
- O
challenged O
mice O
. O

To O
facilitate O
a O
quantitative O
comparison O
, O
doses O
of O
both O
sodium B
nitrite I
and O
isoamyl B
nitrite I
were O
given O
intraperitoneally O
in O
equimolar O
amounts O
to O
sublethally O
cyanide B
- O
challenged O
mice O
. O

Righting O
recovery O
from O
the O
knockdown O
state O
was O
clearly O
compromised O
in O
the O
isoamyl B
nitrite I
- O
treated O
animals O
, O
the O
effect O
being O
attributable O
to O
the O
toxicity O
of O
the O
isoamyl B
alchol I
produced O
during O
hydrolysis O
of O
the O
isoamyl B
nitrite I
to O
release O
nitrite B
anion O
. O

Righting O
recovery O
from O
the O
knockdown O
state O
was O
clearly O
compromised O
in O
the O
isoamyl B
nitrite I
- O
treated O
animals O
, O
the O
effect O
being O
attributable O
to O
the O
toxicity O
of O
the O
isoamyl B
alchol I
produced O
during O
hydrolysis O
of O
the O
isoamyl B
nitrite I
to O
release O
nitrite B
anion O
. O

Righting O
recovery O
from O
the O
knockdown O
state O
was O
clearly O
compromised O
in O
the O
isoamyl B
nitrite I
- O
treated O
animals O
, O
the O
effect O
being O
attributable O
to O
the O
toxicity O
of O
the O
isoamyl B
alchol I
produced O
during O
hydrolysis O
of O
the O
isoamyl B
nitrite I
to O
release O
nitrite B
anion O
. O

Subsequently O
, O
inhaled O
aqueous O
sodium B
nitrite I
aerosol O
was O
demonstrated O
to O
ameliorate O
sublethal O
cyanide B
toxicity O
, O
when O
provided O
to O
mice O
after O
the O
toxic O
dose O
, O
by O
the O
more O
rapid O
recovery O
of O
righting O
ability O
compared O
to O
that O
of O
the O
control O
animals O
given O
only O
the O
toxicant O
. O

Aerosolized O
sodium B
nitrite I
has O
thus O
been O
shown O
by O
these O
experiments O
to O
have O
promise O
as O
a O
better O
alternative O
to O
organic O
nitrites B
for O
development O
as O
an O
inhaled O
cyanide B
antidote O
. O

The O
inhaled O
sodium B
nitrite I
led O
to O
the O
production O
of O
NO B
in O
the O
bloodstream O
as O
determined O
by O
the O
appearance O
of O
EPR O
signals O
attributable O
to O
nitrosylhemoglobin O
and O
methemoglobin O
. O

It O
is O
argued O
that O
administration O
of O
an O
effective O
inhaled O
aqueous O
sodium B
nitrite I
dose O
in O
humans O
is O
possible O
, O
though O
just O
beyond O
the O
capability O
of O
current O
individual O
metered O
- O
dose O
inhaler O
designs O
, O
such O
as O
those O
used O
for O
asthma O
. O

Furthermore O
, O
correct O
NMR O
data O
are O
being O
provided O
for O
gardenin B
C I
as O
the O
data O
reported O
in O
literature O
were O
found O
to O
be O
incorrect O
. O

New O
triterpene B
glycoside I
and O
other O
chemical O
constituents O
from O
the O
leaves O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
. O

A O
new O
triterpene B
saponin I
( O
1 O
) O
was O
isolated O
from O
a O
methanol B
extract O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
, O
together O
with O
the O
flavonoids B
mauritianin B
( O
2 O
) O
, O
kaempferol B
( O
3 O
) O
and O
the O
triterpene B
saponin I
beta B
- I
D I
- I
glucopyranosyl I
3 I
beta I
- I
hydroxy I
- I
olean I
- I
12 I
- I
en I
- I
28 I
- I
oate I
( O
4 O
) O
. O

A O
new O
triterpene B
saponin I
( O
1 O
) O
was O
isolated O
from O
a O
methanol B
extract O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
, O
together O
with O
the O
flavonoids B
mauritianin B
( O
2 O
) O
, O
kaempferol B
( O
3 O
) O
and O
the O
triterpene B
saponin I
beta B
- I
D I
- I
glucopyranosyl I
3 I
beta I
- I
hydroxy I
- I
olean I
- I
12 I
- I
en I
- I
28 I
- I
oate I
( O
4 O
) O
. O

The O
analysis O
by O
HR O
- O
ESI O
- O
MS O
showed O
a O
mass O
compatible O
with O
that O
of O
triterpene B
saponin I
1 O
. O

The O
effect O
of O
a O
Cimicifuga O
racemosa O
extracts O
Ze B
450 I
in O
the O
treatment O
of O
climacteric O
complaints O
- O
an O
observational O
study O
. O

METHOD O
: O
In O
this O
observational O
study O
, O
Cimicifuga O
racemosa O
( O
CR O
) O
extract O
Ze B
450 I
was O
studied O
in O
442 O
unselected O
ambulatory O
female O
outpatients O
with O
menopausal O
complaints O
under O
daily O
practice O
conditions O
. O

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Many O
cyanobacterial O
species O
can O
produce O
cyanotoxins O
, O
among O
which O
mycrocistins B
( O
MC O
) O
are O
a O
group O
of O
= O
~ O
100 O
congeners O
of O
hepatotoxic O
cyclic B
heptapeptides I
. O

Activating O
glucocorticoid O
receptor O
- O
ERK O
signaling O
pathway O
contributes O
to O
ginsenoside B
Rg1 I
protection O
against O
beta O
- O
amyloid O
peptide O
- O
induced O
human O
endothelial O
cells O
apoptosis O
. O

Ginsenoside B
Rg1 I
( O
Rg1 B
) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O

Carotenoid O
/ O
lipid O
hydro B
peroxide I
( O
LOOH O
) O
concentration O
was O
evaluated O
using O
two O
different O
methods O
: O
LOOH O
+ O
Fe B
( I
2 I
+ I
) I
reaction O
connected O
with O
a O
colored O
complex O
of O
ammonium B
thiocyanate I
determined O
with O
the O
help O
of O
a O
spectrophotometer O
, O
and O
LOOH O
determined O
with O
the O
help O
of O
a O
chemiluminometer O
. O

Carotenoid O
/ O
lipid O
hydro B
peroxide I
( O
LOOH O
) O
concentration O
was O
evaluated O
using O
two O
different O
methods O
: O
LOOH O
+ O
Fe B
( I
2 I
+ I
) I
reaction O
connected O
with O
a O
colored O
complex O
of O
ammonium B
thiocyanate I
determined O
with O
the O
help O
of O
a O
spectrophotometer O
, O
and O
LOOH O
determined O
with O
the O
help O
of O
a O
chemiluminometer O
. O

Using O
a O
combination O
of O
flow O
cytometry O
and O
microscopy O
, O
we O
found O
that O
zantrin B
Z1 I
, O
cinnamaldehyde B
, O
totarol B
, O
sanguinarine B
, O
and O
viriditoxin B
decreased O
the O
B O
. O
subtilis O
transmembrane O
potential O
or O
perturbed O
membrane O
permeability O
, O
and O
influenced O
the O
localization O
of O
the O
membrane O
- O
associated O
, O
division O
protein O
MinD O
. O

Antiallodynic O
and O
Analgesic O
Effects O
of O
Maslinic B
Acid I
, O
a O
Pentacyclic B
Triterpenoid I
from O
Olea O
europaea O
. O

Antiallodynic O
and O
Analgesic O
Effects O
of O
Maslinic B
Acid I
, O
a O
Pentacyclic B
Triterpenoid I
from O
Olea O
europaea O
. O

The O
effects O
of O
maslinic B
acid I
( O
1 O
) O
, O
a O
pentacyclic B
triterpenoid I
obtained O
from O
Olea O
europaea O
, O
were O
studied O
in O
several O
tests O
for O
nociception O
in O
mice O
. O

The O
effects O
of O
maslinic B
acid I
( O
1 O
) O
, O
a O
pentacyclic B
triterpenoid I
obtained O
from O
Olea O
europaea O
, O
were O
studied O
in O
several O
tests O
for O
nociception O
in O
mice O
. O

Systemic O
administration O
of O
1 O
reduced O
acetic B
acid I
- O
induced O
writhing O
, O
the O
inflammatory O
phase O
of O
formalin B
- O
induced O
pain O
, O
and O
capsaicin B
- O
induced O
mechanical O
allodynia O
. O

The O
present O
results O
demonstrate O
for O
the O
first O
time O
that O
maslinic B
acid I
induces O
antinociceptive O
and O
antiallodynic O
effects O
. O

The O
fine O
particulate O
( O
PM O
< O
2 O
. O
5 O
mu O
m O
) O
of O
wood O
smoke O
were O
the O
most O
potent O
TRPA1 O
agonists O
and O
several O
chemical O
constituents O
of O
wood O
smoke O
particulate O
, O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
, O
coniferaldehyde B
, O
formaldehyde B
, O
perinaphthenone B
, O
agathic B
acid I
, O
and O
isocupressic B
acid I
, O
were O
TRPA1 O
agonists O
. O

The O
fine O
particulate O
( O
PM O
< O
2 O
. O
5 O
mu O
m O
) O
of O
wood O
smoke O
were O
the O
most O
potent O
TRPA1 O
agonists O
and O
several O
chemical O
constituents O
of O
wood O
smoke O
particulate O
, O
3 B
, I
5 I
- I
ditert I
- I
butylphenol I
, O
coniferaldehyde B
, O
formaldehyde B
, O
perinaphthenone B
, O
agathic B
acid I
, O
and O
isocupressic B
acid I
, O
were O
TRPA1 O
agonists O
. O

Synthesis O
and O
biological O
evaluation O
of O
Foscan B
( O
( O
R O
) O
) O
bile B
acid I
conjugates O
to O
target O
esophageal O
cancer O
cells O
. O

Bile B
acids I
which O
are O
known O
to O
selectively O
bind O
to O
, O
or O
be O
readily O
taken O
up O
by O
cancer O
cells O
were O
chosen O
as O
targeting O
moieties O
. O

Synthesis O
of O
the O
conjugates O
was O
achieved O
via O
selective O
nucleophilic O
monofunctionalizatio O
of O
5 B
, I
10 I
, I
15 I
, I
20 I
- I
tetrahydroxyphenylpo I
with O
propargyl B
bromide I
followed O
by O
Cu B
( I
I I
) I
mediated O
cycloaddition O
with O
bile B
acid I
azides I
in O
good O
yields O
. O

A O
diazen B
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
analog O
of O
7 B
- I
azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
: O
Synthesis O
, O
nitric B
oxide I
and O
nitroxyl B
release O
, O
in O
vitro O
hemodynamic O
, O
and O
anti O
- O
hypertensive O
studies O
. O

1 B
- I
( I
7 I
- I
Azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
) I
diazen I
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
( O
16 O
) O
was O
designed O
with O
the O
expectation O
that O
it O
would O
act O
as O
a O
dual O
nitric B
oxide I
( O
NO B
) O
and O
nitroxyl B
( O
HNO B
) O
donor O
that O
is O
not O
carcinogenic O
or O
genotoxic O
. O

A O
new O
series O
of O
fluoro B
substituted I
pyrazoline I
derivatives O
5a O
- O
g O
and O
6a O
- O
g O
were O
synthesized O
in O
good O
to O
excellent O
yield O
from O
the O
corresponding O
pyrazole B
chalcones I
, O
4a O
- O
g O
, O
by O
using O
polyethylene B
glycol I
- I
400 I
( O
PEG B
- I
400 I
) O
as O
an O
alternative O
reaction O
medium O
. O

Identification O
of O
metal O
ion O
binding O
peptides O
containing O
unnatural O
amino B
acids I
by O
phage O
display O
. O

The O
bidentate O
metal O
binding O
amino B
acid I
bipyridylalanine B
( O
BpyAla B
) O
was O
incorporated O
into O
a O
disulfide B
linked O
cyclic O
peptide O
phage O
displayed O
library O
to O
identify O
metal O
ion O
binding O
peptides O
. O

Selection O
against O
Ni B
( I
2 I
+ I
) I
- O
nitrilotriacetic B
acid I
( O
NTA B
) O
enriched O
for O
sequences O
containing O
histidine B
and O
BpyAla B
. O

Incorporation O
of O
BpyAla B
and O
other O
metal O
binding O
amino B
acids I
into O
peptide O
and O
protein O
libraries O
should O
enable O
the O
evolution O
of O
novel O
binding O
and O
catalytic O
activities O
. O

Arsenic B
trioxide I
depletes O
cancer O
stem O
- O
like O
cells O
and O
inhibits O
repopulation O
of O
neurosphere O
derived O
from O
glioblastoma O
by O
downregulation O
of O
Notch O
pathway O
. O

We O
have O
recently O
demonstrated O
the O
inhibitory O
effect O
of O
arsenic B
trioxide I
( O
ATO B
) O
on O
CSLCs O
in O
glioblastoma O
cell O
lines O
. O

Sesquiterpene B
lactones I
( O
SLs B
) O
are O
natural O
products O
with O
a O
variety O
of O
biological O
activities O
. O

Oily O
nanosuspension O
for O
long O
- O
acting O
intramuscular O
delivery O
of O
curcumin B
didecanoate I
prodrug O
: O
Preparation O
, O
characterization O
and O
in O
vivo O
evaluation O
. O

The O
objective O
of O
this O
study O
was O
to O
prepare O
the O
nanocrystals O
of O
curcumin B
didecanoate I
( O
CurDD B
) O
by O
wet O
ball O
milling O
and O
to O
investigate O
the O
comparative O
pharmacokinetics O
of O
oily O
nano O
- O
and O
micro O
- O
suspensions O
after O
intramuscular O
( O
i O
. O
m O
. O
) O
administration O
to O
rats O
. O

Chloroaluminium B
phthalocyanine I
polymeric O
nanoparticles O
as O
photosensitisers O
: O
Photophysical O
and O
physicochemical O
characterisation O
, O
release O
and O
phototoxicity O
in O
vitro O
. O

Nanoparticles O
of O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
poly B
( I
d I
, I
l I
- I
lactide I
) I
and O
polyethylene B
glycol I
- I
block I
- I
poly I
( I
d I
, I
l I
- I
lactide I
) I
were O
developed O
to O
encapsulate O
chloroaluminium B
phthalocyanine I
( O
AlClPc B
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

Arsenic B
trioxide I
induces O
cardiac O
fibroblast O
apoptosis O
in O
vitro O
and O
in O
vivo O
by O
up O
- O
regulating O
TGF O
- O
beta O
1 O
expression O
. O

Arsenic B
trioxide I
( O
As2O3 B
; O
ATO B
) O
is O
clinically O
effective O
in O
treating O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
; O
however O
, O
it O
frequently O
causes O
cardiotoxic O
effects O
. O

Reproductive O
toxicity O
of O
phthalate B
esters I
( O
PEs B
) O
occurs O
in O
rat O
offspring O
exposed O
in O
utero O
, O
a O
phenomenon O
that O
is O
better O
studied O
in O
male O
offspring O
than O
females O
. O

The O
ameliorating O
effects O
of O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
, O
an O
oroxylin B
A I
derivative O
, O
against O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
in O
mice O
. O

We O
previously O
reported O
that O
oroxylin B
A I
, O
a O
gamma B
- I
aminobutyric I
acid I
A O
( O
GABAA O
) O
receptor O
antagonist O
, O
ameliorates O
drugs O
- O
induced O
memory O
impairments O
. O

We O
synthesized O
several O
oroxylin B
A I
derivatives O
in O
efforts O
to O
find O
a O
substance O
that O
has O
pro O
- O
cognitive O
effects O
as O
well O
as O
improves O
sensorimotor O
gating O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
effect O
of O
a O
novel O
oroxylin B
A I
derivative O
, O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
( O
DMPC B
) O
, O
on O
pharmacological O
models O
of O
schizophrenia O
, O
which O
exhibit O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
. O

Tryptanthrin B
, O
an O
indoloquinazoline B
alkaloid I
, O
was O
first O
obtained O
by O
sublimation O
of O
natural O
indigo O
and O
later O
isolated O
from O
the O
culture O
of O
fungus O
Candida O
lipolytica O
and O
a O
variety O
of O
other O
natural O
sources O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Transition B
metal I
- O
catalyzed O
efficient O
and O
green O
transformations O
of O
p O
( O
o O
) O
- O
h O
compounds O
to O
functional O
organophosphorus B
compounds O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition B
metal I
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P B
( I
O I
) I
- I
H I
bonds O
to O
various O
versatile O
organophosphorus B
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P B
( I
O I
) I
- I
H I
additions O
to O
carbon B
- O
carbon B
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P B
( I
O I
) I
- I
H I
compounds O
with O
carbon B
- O
H B
and O
heteroatom O
- O
H B
compounds O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

No O
oligoamides O
, O
but O
products O
1 O
and O
2 O
, O
were O
formed O
from O
the O
enzymatic O
reaction O
of O
dimethyl B
terephthalate I
and O
p B
- I
xylylenediamine I
. O

The O
method O
utilizes O
information O
- O
based O
virtual O
transformation O
of O
library O
carboxylates B
to O
hydroxamic B
acids I
prior O
to O
docking O
, O
followed O
by O
compound O
acquisition O
, O
one O
- O
pot O
( O
two O
steps O
) O
chemical O
synthesis O
and O
in O
vitro O
screening O
. O

After O
4 O
- O
h O
incubation O
in O
supplemented O
S9 O
fraction O
, O
the O
MTX B
content O
was O
35 O
% O
lower O
and O
5 O
metabolites O
were O
identified O
: O
an O
acetoxy O
ester O
derivative O
( O
never O
described O
before O
) O
, O
two O
glutathione B
conjugates O
, O
a O
monocarboxylic B
acid I
derivative O
, O
and O
the O
naphtoquinoxaline B
, O
the O
later O
commonly O
related O
to O
MTX B
pharmacological O
effects O
. O

The O
present O
investigations O
were O
carried O
out O
to O
study O
the O
protective O
potential O
of O
four O
extracts O
( O
namely O
petroleum B
ether I
extract O
( O
LCR O
) O
, O
chloroform B
extract O
( O
LCM O
) O
, O
ethyl B
acetate I
extract O
( O
LCE O
) O
, O
and O
alcoholic O
extract O
( O
LCL O
) O
) O
of O
Lavandula O
coronopifolia O
on O
oxidative O
stress O
- O
mediated O
cell O
death O
induced O
by O
ethanol B
, O
a O
known O
hepatotoxin O
in O
human O
hapatocellular O
carcinoma O
( O
HepG2 O
) O
cells O
. O

The O
present O
investigations O
were O
carried O
out O
to O
study O
the O
protective O
potential O
of O
four O
extracts O
( O
namely O
petroleum B
ether I
extract O
( O
LCR O
) O
, O
chloroform B
extract O
( O
LCM O
) O
, O
ethyl B
acetate I
extract O
( O
LCE O
) O
, O
and O
alcoholic O
extract O
( O
LCL O
) O
) O
of O
Lavandula O
coronopifolia O
on O
oxidative O
stress O
- O
mediated O
cell O
death O
induced O
by O
ethanol B
, O
a O
known O
hepatotoxin O
in O
human O
hapatocellular O
carcinoma O
( O
HepG2 O
) O
cells O
. O

After O
the O
exposure O
, O
cell O
viability O
using O
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
) O
and O
neutral B
red I
uptake O
assays O
and O
morphological O
changes O
in O
HepG2 O
cells O
were O
studied O
. O

Differential O
propensity O
of O
citrate B
- O
and O
polyethylene B
glycol I
- O
coated O
silver B
nanoparticles O
to O
bovine O
hemoglobin O
. O

However O
, O
our O
previous O
results O
show O
that O
polyethylene B
glycol I
- O
coated O
Ag B
- O
NPs O
strongly O
bind O
to O
Hb O
and O
effect O
on O
the O
secondary O
and O
tertiary O
structures O
of O
BHb O
. O

Biweekly O
maternal O
testosterone B
propionate I
( O
TP O
; O
100 O
mg O
) O
from O
day O
62 O
to O
day O
70 O
/ O
day O
90 O
of O
gestation O
altered O
male O
developmental O
trajectory O
. O

Controllable O
Hydrogen B
Sulfide I
Donors O
and O
Their O
Activity O
against O
Myocardial O
Ischemia O
- O
Reperfusion O
Injury O
. O

Hydrogen B
sulfide I
( O
H2S B
) O
, O
known O
as O
an O
important O
cellular O
signaling O
molecule O
, O
plays O
critical O
roles O
in O
many O
physiological O
and O
/ O
or O
pathological O
processes O
. O

Two O
new O
hybrid O
isoprenoids B
, O
named O
indotertine B
B I
( O
2 O
) O
and O
drimentine B
H I
( O
3 O
) O
, O
along O
with O
the O
known O
analogue O
drimentine B
C I
( O
4 O
) O
, O
were O
isolated O
from O
the O
reed O
rhizosphere O
soil O
derived O
actinomycete O
Streptomyces O
sp O
. O

Two O
new O
hybrid O
isoprenoids B
, O
named O
indotertine B
B I
( O
2 O
) O
and O
drimentine B
H I
( O
3 O
) O
, O
along O
with O
the O
known O
analogue O
drimentine B
C I
( O
4 O
) O
, O
were O
isolated O
from O
the O
reed O
rhizosphere O
soil O
derived O
actinomycete O
Streptomyces O
sp O
. O

Two O
new O
hybrid O
isoprenoids B
, O
named O
indotertine B
B I
( O
2 O
) O
and O
drimentine B
H I
( O
3 O
) O
, O
along O
with O
the O
known O
analogue O
drimentine B
C I
( O
4 O
) O
, O
were O
isolated O
from O
the O
reed O
rhizosphere O
soil O
derived O
actinomycete O
Streptomyces O
sp O
. O

Indotertine B
B I
( O
2 O
) O
exists O
as O
a O
pair O
of O
rotamers O
about O
the O
N B
- I
C I
( I
O I
) I
bond O
with O
a O
2 O
: O
1 O
ratio O
and O
displays O
activities O
against O
HCT O
- O
8 O
and O
A549 O
tumor O
cell O
lines O
with O
IC50 O
values O
of O
6 O
. O
96 O
and O
4 O
. O
88 O
mu O
M O
, O
respectively O
. O

The O
results O
demonstrated O
the O
evolutionary O
importance O
of O
the O
fatty B
acid I
syntheses O
and O
the O
photosynthetic O
system O
in O
algae O
. O

The O
reaction O
tolerates O
a O
broad O
range O
of O
benzhydroxamic B
acids I
and O
diazo B
compounds O
, O
including O
substituted O
2 B
, I
2 I
, I
2 I
- I
trifluorodiazoethane I
. O

First O
, O
the O
roles O
of O
the O
amino O
acids O
cysteine B
and O
methionine B
, O
are O
discussed O
, O
followed O
by O
an O
extensive O
discussion O
of O
the O
low O
- O
molecular O
- O
weight O
tripeptide B
, O
thiol B
glutathione I
, O
which O
plays O
a O
central O
part O
in O
plant O
stress O
response O
and O
oxidative O
signalling O
and O
of O
glutathione B
- O
related O
enzymes O
, O
including O
those O
involved O
in O
the O
biosynthesis O
of O
non O
- O
protein O
thiol B
compounds O
. O

Effects O
of O
exogenous O
thiocyanate B
on O
mineral O
nutrients O
, O
antioxidative O
responses O
and O
free O
amino B
acids I
in O
rice O
seedlings O
. O

The O
effects O
of O
exogenous O
thiocyanate B
( O
SCN B
( I
- I
) I
) O
on O
amino B
acids I
composition O
, O
content O
of O
mineral O
nutrients O
and O
antioxidative O
systems O
in O
plants O
were O
investigated O
. O

Young O
rice O
seedlings O
( O
Oryza O
sativa O
L O
. O
cv O
. O
XZX O
45 O
) O
were O
grown O
in O
nutrient O
solutions O
amended O
with O
potassium B
thiocyanate I
( O
KSCN B
) O
. O

Mineral O
nutrients O
and O
free O
amino B
acids I
in O
rice O
seedlings O
were O
also O
measured O
to O
determine O
metabolic O
responses O
to O
SCN B
( I
- I
) I
exposure O
. O

Although O
the O
change O
of O
total O
free O
amino B
acids I
in O
shoots O
of O
SCN B
- O
exposed O
seedlings O
was O
negligible O
( O
p O
> O
0 O
. O
05 O
) O
, O
responses O
of O
different O
amino B
acids I
to O
SCN B
( I
- I
) I
application O
were O
quite O
different O
. O

Although O
the O
change O
of O
total O
free O
amino B
acids I
in O
shoots O
of O
SCN B
- O
exposed O
seedlings O
was O
negligible O
( O
p O
> O
0 O
. O
05 O
) O
, O
responses O
of O
different O
amino B
acids I
to O
SCN B
( I
- I
) I
application O
were O
quite O
different O
. O

Among O
fifteen O
free O
amino B
acids I
detected O
, O
serine B
( O
Ser B
) O
, O
proline B
( O
Pro B
) O
, O
and O
methionine B
( O
Met B
) O
increased O
, O
while O
asparagine B
( O
Asp B
) O
decreased O
with O
an O
increase O
of O
the O
doses O
of O
SCN B
( I
- I
) I
supplied O
. O

Monocarbonyl B
Curcumin I
Analogues O
: O
Heterocyclic O
Pleiotropic O
Kinase O
Inhibitors O
That O
Mediate O
Anticancer O
Properties O
. O

Eight O
new O
cycloartane B
triterpenoids I
( O
1 O
- O
8 O
) O
, O
named O
carinatins B
A I
- I
H I
, O
and O
the O
known O
compounds O
secaubryolide B
( O
9 O
) O
and O
dikamaliartane B
D I
( O
10 O
) O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Gardenia O
carinata O
. O

Eight O
new O
cycloartane B
triterpenoids I
( O
1 O
- O
8 O
) O
, O
named O
carinatins B
A I
- I
H I
, O
and O
the O
known O
compounds O
secaubryolide B
( O
9 O
) O
and O
dikamaliartane B
D I
( O
10 O
) O
were O
isolated O
from O
the O
leaves O
and O
twigs O
of O
Gardenia O
carinata O
. O

UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC B
and O
UDP B
- O
glucuronic B
acid I
than O
the O
other O
UGTs O
. O

Immobilizing O
Individual O
Atoms O
beneath O
a O
Corrugated O
Single O
Layer O
of O
Boron B
Nitride I
. O

Single O
atoms O
, O
and O
in O
particular O
the O
least O
reactive O
noble B
gases I
, O
are O
difficult O
to O
immobilize O
at O
room O
temperature O
. O

Here O
we O
demonstrate O
that O
the O
boron B
nitride I
nanomesh O
, O
a O
corrugated O
single O
layer O
of O
hexagonal O
boron B
nitride I
( O
h B
- I
BN I
) O
with O
a O
3 O
. O
2 O
nm O
honeycomb O
superstructure O
formed O
on O
a O
Rh B
( I
111 I
) I
surface O
, O
can O
trap O
individual O
argon B
atoms O
at O
distinct O
subsurface O
sites O
at O
room O
temperature O
. O

Here O
we O
demonstrate O
that O
the O
boron B
nitride I
nanomesh O
, O
a O
corrugated O
single O
layer O
of O
hexagonal O
boron B
nitride I
( O
h B
- I
BN I
) O
with O
a O
3 O
. O
2 O
nm O
honeycomb O
superstructure O
formed O
on O
a O
Rh B
( I
111 I
) I
surface O
, O
can O
trap O
individual O
argon B
atoms O
at O
distinct O
subsurface O
sites O
at O
room O
temperature O
. O

Of O
the O
tested O
extracts O
, O
the O
ethyl B
acetate I
fraction O
was O
the O
most O
potent O
( O
half O
- O
maximal O
inhibitory O
concentration O
( O
IC50 O
) O
: O
97 O
micro O
g O
/ O
mL O
) O
followed O
by O
aqueous O
fraction O
IC50 O
: O
109 O
micro O
g O
/ O
mL O
) O
. O

S96 O
group O
) O
, O
or O
0 O
. O
9 O
% O
sodium B
chloride I
( O
control O
group O
) O
. O

Evaluating O
bone O
mineral O
density O
and O
vitamin B
D I
status O
in O
persons O
with O
HIV O
may O
be O
important O
steps O
in O
identifying O
those O
requiring O
pharmacotherapy O
; O
however O
, O
the O
appropriate O
timing O
for O
bone O
mineral O
density O
and O
vitamin B
D I
screening O
is O
uncertain O
, O
as O
is O
the O
appropriate O
method O
of O
replacing O
vitamin B
D I
in O
HIV O
- O
positive O
patients O
who O
are O
deficient O
. O

Evaluating O
bone O
mineral O
density O
and O
vitamin B
D I
status O
in O
persons O
with O
HIV O
may O
be O
important O
steps O
in O
identifying O
those O
requiring O
pharmacotherapy O
; O
however O
, O
the O
appropriate O
timing O
for O
bone O
mineral O
density O
and O
vitamin B
D I
screening O
is O
uncertain O
, O
as O
is O
the O
appropriate O
method O
of O
replacing O
vitamin B
D I
in O
HIV O
- O
positive O
patients O
who O
are O
deficient O
. O

Evaluating O
bone O
mineral O
density O
and O
vitamin B
D I
status O
in O
persons O
with O
HIV O
may O
be O
important O
steps O
in O
identifying O
those O
requiring O
pharmacotherapy O
; O
however O
, O
the O
appropriate O
timing O
for O
bone O
mineral O
density O
and O
vitamin B
D I
screening O
is O
uncertain O
, O
as O
is O
the O
appropriate O
method O
of O
replacing O
vitamin B
D I
in O
HIV O
- O
positive O
patients O
who O
are O
deficient O
. O

Further O
study O
is O
necessary O
to O
definitively O
determine O
the O
approach O
to O
evaluating O
bone O
health O
and O
managing O
low O
bone O
mineral O
density O
and O
vitamin B
D I
deficiency O
in O
patients O
with O
HIV O
infection O
. O

The O
widely O
used O
hypnosedative O
- O
anxiolytic O
agent O
R B
, I
S I
- I
lorazepam I
is O
cleared O
predominantly O
by O
conjugation O
with O
glucuronic B
acid I
in O
humans O
, O
but O
the O
enantioselective O
glucuronidation O
of O
lorazepam B
has O
received O
little O
attention O
. O

In O
order O
to O
identify O
potential O
drug O
- O
drug O
interactions O
, O
codeine B
, O
fluconazole B
, O
ketamine B
, O
ketoconazole B
, O
methadone B
, O
morphine B
, O
valproic B
acid I
, O
and O
zidovudine B
were O
screened O
as O
inhibitors O
of O
R B
- I
and I
S I
- I
lorazepam I
glucuronidation O
by O
HLM O
. O

Rapid O
chromatographic O
separation O
was O
achieved O
in O
the O
mobile O
phase O
composition O
of O
acetonitrile B
, O
water O
and O
formic B
acid I
( O
v O
/ O
v O
/ O
v O
, O
55 O
: O
45 O
: O
0 O
. O
1 O
) O
with O
a O
flow O
rate O
of O
0 O
. O
25 O
ml O
/ O
min O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo B
bromide I
( O
DTAB B
) O
, O
anionic O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium B
lauryl I
sulfate I
, O
nonionic O
tetraethylene B
glycol I
monooctyl I
ether I
( O
C8E4 B
) O
, O
and O
nonionic O
Pluronic B
( I
P I
- I
123 I
) I
surfactants O
at O
different O
concentrations O
. O

Global O
gene O
expression O
analysis O
reveals O
pathway O
differences O
between O
teratogenic O
and O
non O
- O
teratogenic O
exposure O
concentrations O
of O
bisphenol B
A I
and O
17 B
beta I
- I
estradiol I
in O
embryonic O
zebrafish O
. O

Transient O
developmental O
exposure O
to O
0 O
. O
1 O
mu O
M O
bisphenol B
A I
( O
BPA B
) O
results O
in O
larval O
zebrafish O
hyperactivity O
and O
learning O
impairments O
in O
the O
adult O
, O
while O
exposure O
to O
80 O
mu O
M O
BPA B
results O
in O
teratogenic O
responses O
, O
including O
craniofacial O
abnormalities O
and O
edema O
. O

Trichostatin B
A I
protects O
against O
cisplatin B
- O
induced O
ototoxicity O
by O
regulating O
expression O
of O
genes O
related O
to O
apoptosis O
and O
synaptic O
function O
. O

In O
the O
present O
study O
, O
we O
aim O
to O
investigate O
the O
protective O
effect O
of O
trichostatin B
A I
( O
TSA B
) O
, O
a O
specific O
inhibitor O
of O
HDACs O
, O
on O
cisplatin B
- O
induced O
ototoxicity O
and O
to O
determine O
the O
differentially O
expressed O
genes O
involved O
in O
this O
process O
. O

Rat O
liver O
epithelial O
cells O
( O
WB O
- O
F344 O
) O
were O
stained O
with O
the O
fluorescent O
dye O
Calcein B
AM I
( O
acetoxymethyl B
) O
and O
exposed O
to O
TPM O
from O
the O
Kentucky O
Reference O
Cigarette O
2R4F O
( O
a O
blend O
of O
Bright O
and O
Burley O
tobaccos O
) O
and O
from O
two O
single O
- O
tobacco O
cigarettes O
( O
Bright O
and O
Burley O
) O
for O
3h O
. O

Phorbol B
- I
12 I
- I
myristate I
- I
13 I
- I
acetate I
( O
TPA B
) O
was O
used O
as O
positive O
control O
and O
0 O
. O
5 O
% O
dimethyl B
sulfoxide I
( O
DMSO B
) O
as O
solvent O
control O
. O

Metabolites O
of O
norepinephrine B
[ O
3 B
- I
methoxy I
- I
4 I
- I
hydroxyphenylglycol I
( O
MHPG B
) O
and O
vanillylmandelic B
acid I
( O
VMA B
) O
] O
and O
dopamine B
[ O
homovanillic B
acid I
( O
HVA B
) O
] O
were O
measured O
by O
high O
- O
pressure O
liquid O
chromatography O
with O
electrochemical O
detection O
. O

Metabolites O
of O
norepinephrine B
[ O
3 B
- I
methoxy I
- I
4 I
- I
hydroxyphenylglycol I
( O
MHPG B
) O
and O
vanillylmandelic B
acid I
( O
VMA B
) O
] O
and O
dopamine B
[ O
homovanillic B
acid I
( O
HVA B
) O
] O
were O
measured O
by O
high O
- O
pressure O
liquid O
chromatography O
with O
electrochemical O
detection O
. O

Poly B
( I
vinyl I
alcohol I
) I
Physical O
Hydrogel O
Nanoparticles O
, O
Not O
Polymer O
Solutions O
, O
Exert O
Inhibition O
of O
Nitric B
Oxide I
Synthesis O
in O
Cultured O
Macrophages O
. O

Interaction O
of O
PVA B
HNP O
with O
mammalian O
cells O
was O
investigated O
using O
flow O
cytometry O
, O
viability O
screening O
, O
and O
measurements O
of O
nitric B
oxide I
production O
by O
cultured O
macrophages O
. O

The O
treatments O
chosen O
for O
combination O
were O
a O
fat O
removal O
process O
( O
FRP O
) O
( O
solvent O
extraction O
using O
an O
alcohol B
- O
benzene B
mixture O
) O
, O
a O
chemical O
treatment O
( O
CT O
) O
( O
hydrolysis O
using O
1 O
% O
hydrochloric B
acid I
) O
, O
and O
an O
enzymatic O
hydrolysis O
( O
EH O
) O
. O

The O
pectin O
yields O
and O
galacturonic B
acid I
contents O
were O
increased O
by O
FRP O
because O
72 O
. O
13 O
% O
of O
the O
total O
fat O
was O
removed O
; O
additionally O
, O
EH O
had O
a O
similar O
effect O
. O

However O
, O
CT O
decreased O
the O
yields O
because O
the O
treatment O
was O
too O
harsh O
and O
the O
galacturonic B
acid I
broke O
down O
. O

Pectin O
yields O
and O
galacturonic B
acid I
contents O
were O
highest O
in O
the O
combination O
process O
FRP O
/ O
EH O
( O
6 O
. O
23 O
% O
and O
64 O
. O
23 O
% O
, O
respectively O
) O
. O

Enrichment O
of O
two O
isoflavone B
aglycones I
in O
black O
soymilk O
by O
using O
spent O
coffee O
grounds O
as O
an O
immobiliser O
for O
beta O
- O
glucosidase O
. O

beta O
- O
Glucosidase O
was O
covalently O
immobilised O
onto O
spent O
coffee O
grounds O
for O
the O
conversion O
of O
isoflavone B
glycosides I
into O
their O
aglycones O
in O
black O
soymilk O
. O

The O
ethyl B
acetate I
and O
methanol B
bark O
extracts O
of O
Melicope O
glabra O
were O
evaluated O
for O
their O
antioxidant O
capacities O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
free O
radical O
scavenging O
activity O
and O
beta B
- I
carotene I
bleaching O
/ O
linoleic B
acid I
system O
. O

The O
ethyl B
acetate I
and O
methanol B
bark O
extracts O
of O
Melicope O
glabra O
were O
evaluated O
for O
their O
antioxidant O
capacities O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
free O
radical O
scavenging O
activity O
and O
beta B
- I
carotene I
bleaching O
/ O
linoleic B
acid I
system O
. O

Although O
a O
significant O
level O
of O
homology O
was O
observed O
in O
PPO O
nucleotide B
and O
conceptually O
translated O
protein O
sequence O
, O
two O
cultivars O
, O
which O
displayed O
highest O
PPO O
specific O
activity O
, O
differed O
in O
the O
38 O
amino B
acid I
stretch O
in O
the O
peptide O
region O
301 O
- O
338 O
. O

The O
seeds O
of O
the O
cultivars O
belonging O
to O
the O
species O
C O
. O
maxima O
are O
characterised O
by O
a O
higher O
content O
of O
fatty B
acids I
than O
are O
the O
cultivars O
of O
the O
species O
C O
. O
pepo O
. O

Owing O
to O
the O
considerable O
differences O
in O
composition O
among O
the O
fatty B
acids I
examined O
, O
it O
is O
possible O
to O
choose O
the O
desired O
pumpkin O
variety O
for O
the O
intended O
use O
. O

The O
extracts O
were O
digested O
with O
a O
mixture O
of O
pepsin O
- O
HCl B
for O
2h O
, O
followed O
by O
a O
2h O
incubation O
with O
pancreatin O
and O
bile B
salts I
including O
a O
cellulose O
dialysis O
tubing O
( O
molecular O
weight O
cut O
- O
off O
12kDa O
) O
at O
37 O
degrees O
C O
with O
shaking O
in O
the O
dark O
and O
under O
N2 O
. O

Synthesis O
of O
amino B
acid I
conjugates O
of O
tetrahydrocurcumin B
and O
evaluation O
of O
their O
antibacterial O
and O
anti O
- O
mutagenic O
properties O
. O

These O
results O
clearly O
demonstrated O
that O
the O
conjugation O
of O
THC B
at O
the O
phenolic B
position O
with O
amino B
acids I
led O
to O
significant O
improvement O
of O
its O
in O
vitro O
biological O
attributes O
. O

Furthermore O
, O
the O
effects O
of O
ursolic B
acid I
( O
UA O
) O
and O
oleanolic B
acid I
( O
OA O
) O
on O
the O
synthesis O
of O
certain O
pro O
- O
inflammatory O
proteins O
were O
examined O
. O

Furthermore O
, O
the O
effects O
of O
ursolic B
acid I
( O
UA O
) O
and O
oleanolic B
acid I
( O
OA O
) O
on O
the O
synthesis O
of O
certain O
pro O
- O
inflammatory O
proteins O
were O
examined O
. O

Two O
major O
polyphenolics B
, O
ferulic B
acid I
and O
quercetin B
, O
were O
identified O
from O
EEAP O
by O
HPLC O
- O
DAD O
. O

Effects O
of O
EEAP O
, O
ferulic B
acid I
and O
quercetin B
on O
high O
glucose O
( O
25mmol O
/ O
L O
) O
- O
induced O
pancreatic O
beta O
- O
cell O
apoptosis O
and O
dysfunction O
were O
further O
evaluated O
. O

Results O
showed O
that O
EEAP O
and O
quercetin B
but O
not O
ferulic B
acid I
protected O
beta O
- O
cells O
from O
glucotoxicity O
through O
several O
mechanisms O
, O
including O
: O
( O
1 O
) O
maintaining O
beta O
- O
cell O
viability O
; O
( O
2 O
) O
suppressing O
reactive O
oxygen B
species O
production O
; O
( O
3 O
) O
reducing O
characteristic O
features O
of O
apoptosis O
; O
( O
4 O
) O
inhibiting O
the O
activation O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
and O
the O
cleavage O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
( O
5 O
) O
upregulating O
pancreatic O
and O
duodenal O
homeobox O
1 O
gene O
expression O
and O
the O

Peach O
( O
Prunus O
persica O
) O
extract O
inhibits O
angiotensin B
II I
- O
induced O
signal O
transduction O
in O
vascular O
smooth O
muscle O
cells O
. O

Angiotensin B
II I
( O
Ang B
II I
) O
is O
a O
vasoactive O
hormone O
that O
has O
been O
implicated O
in O
cardiovascular O
diseases O
. O

Angiotensin B
II I
( O
Ang B
II I
) O
is O
a O
vasoactive O
hormone O
that O
has O
been O
implicated O
in O
cardiovascular O
diseases O
. O

Batsch O
, O
pulp O
extract O
on O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
mobilization O
, O
reactive O
oxygen B
species O
( O
ROS O
) O
production O
and O
signal O
transduction O
events O
in O
cultured O
vascular O
smooth O
muscle O
cells O
( O
VSMCs O
) O
was O
investigated O
. O

Pretreatment O
of O
peach O
ethyl B
acetate I
extract O
inhibited O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
in O
VSMCs O
. O

Pretreatment O
of O
peach O
ethyl B
acetate I
extract O
inhibited O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
in O
VSMCs O
. O

Furthermore O
, O
Ang B
II I
- O
induced O
ROS O
generation O
, O
essential O
for O
signal O
transduction O
events O
, O
was O
diminished O
by O
the O
peach O
ethyl B
acetate I
extract O
. O

Furthermore O
, O
Ang B
II I
- O
induced O
ROS O
generation O
, O
essential O
for O
signal O
transduction O
events O
, O
was O
diminished O
by O
the O
peach O
ethyl B
acetate I
extract O
. O

The O
peach O
ethyl B
acetate I
extract O
also O
attenuated O
the O
Ang B
II I
- O
induced O
phosphorylation O
of O
epidermal O
growth O
factor O
receptor O
and O
myosin O
phosphatase O
target O
subunit O
1 O
, O
both O
of O
which O
are O
associated O
with O
atherosclerosis O
and O
hypertension O
. O

The O
peach O
ethyl B
acetate I
extract O
also O
attenuated O
the O
Ang B
II I
- O
induced O
phosphorylation O
of O
epidermal O
growth O
factor O
receptor O
and O
myosin O
phosphatase O
target O
subunit O
1 O
, O
both O
of O
which O
are O
associated O
with O
atherosclerosis O
and O
hypertension O
. O

These O
results O
suggest O
that O
peach O
ethyl B
acetate I
extract O
may O
have O
clinical O
potential O
for O
preventing O
cardiovascular O
diseases O
by O
interfering O
with O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
, O
the O
generation O
of O
ROS O
, O
and O
then O
blocking O
signal O
transduction O
events O
. O

These O
results O
suggest O
that O
peach O
ethyl B
acetate I
extract O
may O
have O
clinical O
potential O
for O
preventing O
cardiovascular O
diseases O
by O
interfering O
with O
Ang B
II I
- O
induced O
intracellular O
Ca B
( I
2 I
+ I
) I
elevation O
, O
the O
generation O
of O
ROS O
, O
and O
then O
blocking O
signal O
transduction O
events O
. O

Free O
fatty B
acid I
profiles O
of O
emulsified O
lipids O
during O
in O
vitro O
digestion O
with O
pancreatic O
lipase O
. O

Individual O
free O
fatty B
acids I
released O
from O
milk O
protein O
- O
stabilized O
emulsions O
prepared O
with O
milk O
fat O
, O
soya O
bean O
oil O
or O
tuna O
fish O
oil O
during O
in O
vitro O
digestion O
with O
pancreatic O
lipase O
were O
monitored O
using O
gas O
chromatography O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
confirm O
that O
the O
release O
behaviour O
of O
fatty B
acids I
from O
emulsions O
during O
digestion O
is O
related O
not O
only O
to O
the O
position O
of O
the O
fatty B
acids I
in O
the O
triglycerides B
in O
the O
fat O
/ O
oil O
, O
but O
also O
to O
the O
length O
of O
the O
carbon B
chain O
of O
the O
fatty B
acid I
. O

The O
results O
confirm O
that O
the O
release O
behaviour O
of O
fatty B
acids I
from O
emulsions O
during O
digestion O
is O
related O
not O
only O
to O
the O
position O
of O
the O
fatty B
acids I
in O
the O
triglycerides B
in O
the O
fat O
/ O
oil O
, O
but O
also O
to O
the O
length O
of O
the O
carbon B
chain O
of O
the O
fatty B
acid I
. O

The O
results O
confirm O
that O
the O
release O
behaviour O
of O
fatty B
acids I
from O
emulsions O
during O
digestion O
is O
related O
not O
only O
to O
the O
position O
of O
the O
fatty B
acids I
in O
the O
triglycerides B
in O
the O
fat O
/ O
oil O
, O
but O
also O
to O
the O
length O
of O
the O
carbon B
chain O
of O
the O
fatty B
acid I
. O

The O
rates O
and O
the O
extents O
of O
the O
digestion O
of O
lipids O
consisting O
of O
short O
chain O
fatty B
acids I
are O
higher O
than O
those O
of O
lipids O
consisting O
of O
long O
chain O
fatty B
acids I
. O

The O
rates O
and O
the O
extents O
of O
the O
digestion O
of O
lipids O
consisting O
of O
short O
chain O
fatty B
acids I
are O
higher O
than O
those O
of O
lipids O
consisting O
of O
long O
chain O
fatty B
acids I
. O

Muscles O
from O
Frigate O
mackerel O
had O
greater O
content O
of O
sodium B
chloride I
than O
had O
catfish O
( O
p O
< O
0 O
. O
05 O
) O
. O

Most O
reported O
studies O
focused O
on O
specific O
oat O
extracts O
or O
particular O
oat O
components O
, O
such O
as O
beta O
- O
glucans O
, O
tocols B
( O
vitamin B
E I
) O
, O
or O
avenanthramides B
. O

Assay O
of O
phenolic B
compounds O
from O
four O
species O
of O
ber O
( O
Ziziphus O
mauritiana O
L O
. O
) O
fruits O
: O
Comparison O
of O
three O
base O
hydrolysis O
procedure O
for O
quantification O
of O
total O
phenolic B
acids I
. O

In O
addition O
, O
we O
also O
compared O
the O
impact O
of O
three O
different O
base O
hydrolysis O
techniques O
namely O
ultrasonic O
assisted O
base O
hydrolysis O
( O
UABH O
) O
, O
microwave O
assisted O
base O
hydrolysis O
( O
MWABH O
) O
, O
and O
pressurised O
liquid O
assisted O
base O
hydrolysis O
( O
PLABH O
) O
for O
the O
quantification O
of O
total O
phenolic B
acids I
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

Nine O
phenolic B
acids I
, O
protocatechuic B
acid I
, O
p B
- I
hydroxybenzoic I
acid I
, O
ferulic B
acid I
, O
chlorogenic B
acid I
, O
vanillic B
acid I
, O
caffeic B
acid I
, O
vanillin B
, O
ortho B
- I
and I
para I
- I
coumaric I
acids I
, O
were O
identified O
and O
quantified O
. O

The O
three O
major O
phenolic B
acids I
identified O
in O
all O
four O
ber O
species O
were O
p B
- I
coumaric I
acid I
, O
vanillin B
and O
ferulic B
acids I
. O

The O
three O
major O
phenolic B
acids I
identified O
in O
all O
four O
ber O
species O
were O
p B
- I
coumaric I
acid I
, O
vanillin B
and O
ferulic B
acids I
. O

Higher O
amounts O
( O
p O
< O
0 O
. O
05 O
) O
of O
total O
phenolic B
acids I
in O
all O
cultivars O
were O
obtained O
with O
the O
PLABH O
technique O
as O
compared O
to O
other O
two O
procedures O
( O
UABH O
and O
MWABH O
) O
. O

Seasonality O
had O
a O
more O
marked O
impact O
on O
the O
fatty B
acid I
composition O
of O
JG O
milk O
than O
had O
NS O
milk O
, O
while O
the O
opposite O
was O
found O
for O
protein O
composition O
. O

Ethyl B
acetate I
- O
n B
- I
butanol I
- O
water O
( O
1 O
: O
2 O
: O
3 O
, O
v O
/ O
v O
/ O
v O
) O
was O
selected O
as O
the O
optimum O
solvent O
system O
to O
purify O
geniposidic B
acid I
. O

Ethyl B
acetate I
- O
n B
- I
butanol I
- O
water O
( O
1 O
: O
2 O
: O
3 O
, O
v O
/ O
v O
/ O
v O
) O
was O
selected O
as O
the O
optimum O
solvent O
system O
to O
purify O
geniposidic B
acid I
. O

Ethyl B
acetate I
- O
ethanol B
- O
water O
( O
4 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
) O
was O
used O
to O
isolate O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
ferulic B
acid I
. O

Ethyl B
acetate I
- O
ethanol B
- O
water O
( O
4 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
) O
was O
used O
to O
isolate O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
ferulic B
acid I
. O

Ethyl B
acetate I
- O
ethanol B
- O
water O
( O
4 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
) O
was O
used O
to O
isolate O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
ferulic B
acid I
. O

Ethyl B
acetate I
- O
ethanol B
- O
water O
( O
4 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
) O
was O
used O
to O
isolate O
caffeic B
acid I
, O
chlorogenic B
acid I
and O
ferulic B
acid I
. O

While O
three O
flavonoids B
, O
quercetin B
- I
3 I
- I
O I
- I
sambubioside I
, O
rutin B
and O
isoquercitrin B
were O
purified O
by O
petroleum B
ether I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
1 O
: O
5 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
. O

While O
three O
flavonoids B
, O
quercetin B
- I
3 I
- I
O I
- I
sambubioside I
, O
rutin B
and O
isoquercitrin B
were O
purified O
by O
petroleum B
ether I
- O
ethyl B
acetate I
- O
methanol B
- O
water O
( O
1 O
: O
5 O
: O
1 O
: O
5 O
, O
v O
/ O
v O
/ O
v O
/ O
v O
) O
. O

Ellagic B
acid I
derivatives O
, O
ellagitannins O
, O
proanthocyanidins B
and O
other O
phenolics B
, O
vitamin B
C I
and O
antioxidant O
capacity O
of O
two O
powder O
products O
from O
camu O
- O
camu O
fruit O
( O
Myrciaria O
dubia O
) O
. O

Ellagic B
acid I
derivatives O
, O
ellagitannins O
, O
proanthocyanidins B
and O
other O
phenolics B
, O
vitamin B
C I
and O
antioxidant O
capacity O
of O
two O
powder O
products O
from O
camu O
- O
camu O
fruit O
( O
Myrciaria O
dubia O
) O
. O

The O
aims O
of O
this O
study O
were O
the O
evaluation O
of O
polyphenols B
and O
vitamin B
C I
content O
, O
and O
antioxidant O
capacity O
of O
dehydrated O
pulp O
powder O
and O
the O
dried O
flour O
obtained O
from O
the O
skin O
and O
seeds O
residue O
remaining O
after O
pulp O
preparation O
from O
camu O
- O
camu O
( O
Myrciaria O
dudia O
) O
. O

In O
both O
products O
the O
flavonol B
myricetin B
and O
conjugates O
, O
ellagic B
acid I
and O
conjugates O
and O
ellagitannins O
were O
detected O
. O

The O
vitamin B
C I
content O
was O
lower O
in O
pulp O
powder O
( O
3 O
. O
5 O
% O
) O
than O
in O
the O
flour O
( O
9 O
. O
1 O
% O
) O
. O

The O
radical O
- O
scavenging O
capacity O
of O
both O
powders O
was O
determined O
by O
the O
DPPH B
, O
ABTS B
and O
ORAC O
assays O
, O
and O
was O
higher O
for O
camu O
- O
camu O
flour O
as O
could O
be O
expected O
for O
its O
higher O
phenolics B
and O
vitamin B
C I
content O
. O

Analysis O
of O
fresh O
berries O
showed O
that O
ellagic B
acid I
derivatives O
and O
ellagitannins O
were O
mainly O
present O
in O
the O
seeds O
, O
while O
proanthocyanidins B
were O
present O
both O
in O
the O
seeds O
and O
skin O
. O

Five O
marinades O
were O
prepared O
with O
4 O
% O
( O
w O
/ O
v O
) O
sodium B
chloride I
and O
25 O
% O
( O
w O
/ O
v O
) O
soy O
sauce O
solutions O
( O
4 O
% O
salt O
concentration O
) O
and O
mixed O
with O
the O
ratios O
of O
100 O
: O
0 O
( O
S0 O
, O
pH O
6 O
. O
52 O
) O
, O
75 O
: O
25 O
( O
S25 O
, O
5 O
. O
40 O
) O
50 O
: O
50 O
( O
S50 O
, O
5 O
. O
24 O
) O
, O
25 O
: O
75 O
( O
S75 O
, O
5 O
. O
05 O
) O
, O
and O
0 O
: O
100 O
( O
S100 O
, O
4 O
. O
85 O
) O
, O
respectively O
. O

Amino B
acid I
analysis O
showed O
that O
the O
vicilin O
had O
high O
contents O
of O
acidic B
amino I
acids I
and O
a O
low O
lysine B
/ O
arginine B
ratio O
. O

Effect O
of O
temperature O
on O
the O
release O
of O
intentionally O
and O
non O
- O
intentionally O
added O
substances O
from O
polyethylene B
terephthalate I
( O
PET B
) O
bottles O
into O
water O
: O
Chemical O
analysis O
and O
potential O
toxicity O
. O

The O
Brazilian O
woods O
, O
similar O
to O
oak O
, O
were O
jequitib O
a O
rosa O
and O
cerejeira O
, O
which O
presented O
the O
highest O
contents O
of O
some O
maturation O
- O
related O
compounds O
, O
such O
as O
vanillin B
, O
vanilic B
acid I
, O
syringaldehyde B
and O
sinapaldehyde B
. O

The O
oxidation O
of O
chlorophyll B
a I
( O
chl B
a I
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 B
and O
2 B
, I
4 I
- I
dichlorophenol I
( O
2 B
, I
4 I
- I
DCP I
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

The O
oxidation O
of O
chlorophyll B
a I
( O
chl B
a I
) O
catalysed O
by O
peroxidase O
( O
POD O
) O
from O
mesocarp O
of O
the O
olive O
fruit O
( O
Olea O
europaea O
L O
. O
, O
cv O
Hojiblanca O
) O
in O
the O
presence O
of O
H2O2 B
and O
2 B
, I
4 I
- I
dichlorophenol I
( O
2 B
, I
4 I
- I
DCP I
) O
, O
is O
characterised O
via O
the O
individualised O
quantification O
of O
the O
products O
of O
the O
enzymatic O
reaction O
using O
a O
new O
methodology O
of O
HPLC O
- O
UV O
spectrometry O
. O

This O
innovation O
has O
allowed O
the O
discovery O
that O
, O
in O
addition O
to O
13 B
( I
2 I
) I
OH I
chl I
a I
and O
15 B
( I
1 I
) I
OH I
lactone I
chl I
a I
, O
which O
are O
the O
first O
products O
of O
POD O
on O
chl B
a I
, O
the O
reaction O
process O
sequentially O
creates O
another O
series O
of O
oxidised O
chlorophyll B
derivatives O
which O
have O
not O
been O
previously O
described O
. O

Seeds O
ground O
into O
a O
fine O
powder O
were O
first O
, O
subjected O
to O
oil O
extraction O
and O
fatty B
acids I
analysis O
. O

Gas O
chromatography O
analysis O
of O
the O
seed O
oil O
showed O
high O
percentages O
of O
linoleic B
acid I
in O
the O
four O
varieties O
ranging O
from O
58 O
% O
to O
63 O
% O
. O

The O
effectiveness O
of O
the O
extract O
from O
fermented O
soybeans O
was O
studied O
in O
3 O
model O
foods O
with O
different O
complexities O
, O
i O
. O
e O
. O
, O
linoleic B
acid I
emulsion O
, O
sunflower O
oil O
emulsions O
and O
bulk O
sunflower O
oil O
. O

A O
crude O
antioxidant O
extract O
( O
5mg O
/ O
g O
) O
showed O
a O
comparable O
antioxidant O
activity O
to O
0 O
. O
26mg O
/ O
g O
of O
butylated B
hydroxytoluene I
( O
BHT B
) O
in O
the O
linoleic B
acid I
emulsions O
. O

A O
crude O
antioxidant O
extract O
( O
5mg O
/ O
g O
) O
showed O
a O
comparable O
antioxidant O
activity O
to O
0 O
. O
26mg O
/ O
g O
of O
butylated B
hydroxytoluene I
( O
BHT B
) O
in O
the O
linoleic B
acid I
emulsions O
. O

The O
extract O
exhibited O
a O
better O
capability O
to O
retard O
primary O
products O
in O
the O
linoleic B
acid I
systems O
than O
the O
secondary O
products O
. O

A O
dipeptide B
and O
an O
amino B
acid I
present O
in O
whey O
protein O
hydrolysate O
increase O
translocation O
of O
GLUT O
- O
4 O
to O
the O
plasma O
membrane O
in O
Wistar O
rats O
. O

Additionally O
, O
glycogen O
, O
glycaemia O
, O
insulin O
and O
free O
amino B
acids I
were O
also O
determined O
by O
standard O
methods O
. O

In O
in O
vitro O
antioxidant O
study O
, O
the O
free O
radical O
scavenging O
effect O
of O
friedelin B
on O
2 B
, I
2 I
- I
diphenyl I
- I
picrylhydrazyl I
( O
DPPH B
) O
, O
hydroxyl B
, O
nitric B
oxide I
and O
superoxide B
radicals O
were O
evaluated O
. O

Friedelin B
showed O
very O
good O
scavenging O
effect O
on O
DPPH B
( O
IC50 O
21 O
. O
1mM O
) O
, O
hydroxyl B
( O
IC50 O
19 O
. O
8mM O
) O
, O
nitric B
oxide I
( O
IC50 O
22 O
. O
1mM O
) O
and O
superoxide B
( O
IC50 O
21 O
. O
9mM O
) O
radicals O
. O

In O
in O
vivo O
antioxidant O
study O
, O
CCl4 B
induced O
oxidative O
stress O
on O
rats O
produced O
significant O
increase O
in O
serum O
glutamate B
oxaloacetate B
transaminase O
( O
SGOT O
) O
, O
serum O
glutamate B
pyruvate B
transaminase O
( O
SGPT O
) O
and O
lactate B
dehydrogenase O
( O
LDH O
) O
levels O
along O
with O
reduction O
in O
liver O
superoxide B
dismutase O
( O
SOD O
) O
, O
catalase O
( O
CAT O
) O
, O
reduced B
glutathione I
( O
GSH B
) O
and O
glutathione B
peroxidase O
( O
GPx O
) O
levels O

Major O
Se B
species O
( O
selenium B
methionine I
and O
oxidized B
selenium I
methionine I
) O
from O
dialyzate O
were O
identified O
and O
characterized O
by O
HPLC O
coupled O
to O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
. O

Similar O
bioavailability O
percentages O
was O
achieved O
for O
total O
selenium B
as O
a O
sum O
of O
selenium B
species O
( O
selenocystine B
plus O
oxidized B
selenium I
methionine I
and O
selenium B
methionine I
, O
mainly O
) O
. O

High O
performance O
liquid O
chromatography O
analysis O
suggests O
that O
the O
major O
phenolic B
constituents O
in O
WFI O
are O
chlorogenic B
acid I
, O
rutin B
, O
quercetin B
, O
luteolin B
and O
kaempferol B
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl B
alcohols I
, O
benzaldehyde B
and O
guaiacol B
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl B
alcohols I
, O
ethyl B
vanillate I
and O
benzoic B
acid I
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl B
alcohols I
, O
benzaldehyde B
and O
guaiacol B
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl B
alcohols I
, O
ethyl B
vanillate I
and O
benzoic B
acid I
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl B
alcohols I
, O
benzaldehyde B
and O
guaiacol B
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl B
alcohols I
, O
ethyl B
vanillate I
and O
benzoic B
acid I
. O

Within O
the O
free O
volatile O
compounds O
, O
isoamyl B
alcohols I
, O
benzaldehyde B
and O
guaiacol B
registered O
the O
largest O
increase O
above O
the O
concentration O
effect O
due O
to O
water O
loss O
; O
while O
within O
the O
bound O
volatile O
compounds O
were O
isoamyl B
alcohols I
, O
ethyl B
vanillate I
and O
benzoic B
acid I
. O

The O
effect O
of O
sodium B
alginate O
and O
calcium B
chloride I
concentration O
on O
immobilization O
was O
studied O
and O
it O
was O
found O
that O
the O
optimal O
sodium B
alginate O
and O
calcium B
chloride I
concentration O
was O
3 O
. O
0 O
% O
and O
0 O
. O
2M O
, O
respectively O
. O

The O
effect O
of O
sodium B
alginate O
and O
calcium B
chloride I
concentration O
on O
immobilization O
was O
studied O
and O
it O
was O
found O
that O
the O
optimal O
sodium B
alginate O
and O
calcium B
chloride I
concentration O
was O
3 O
. O
0 O
% O
and O
0 O
. O
2M O
, O
respectively O
. O

X O
- O
ray O
diffraction O
pattern O
identification O
software O
and O
an O
inorganic O
X O
- O
ray O
diffraction O
database O
showed O
the O
origin O
of O
the O
sharp O
peaks O
to O
be O
due O
to O
sodium B
sulphate I
polymorphs O
. O

For O
this O
purpose O
, O
low O
esterified O
amidated O
( O
AM O
) O
, O
low O
( O
LM O
) O
and O
high O
( O
HM O
) O
methoxylated O
citrus O
and O
apple O
pectins O
and O
a O
sugar O
beet O
pectin O
were O
added O
to O
a O
purified O
anthocyanin B
extract O
( O
ACN B
- O
E O
) O
and O
to O
an O
extract O
containing O
anthocyanins B
and O
non O
- O
anthocyanin B
phenolics I
( O
PP O
- O
E O
) O
. O

This O
was O
primarily O
due O
to O
the O
strong O
interaction O
of O
delphinidin B
glycosides I
with O
the O
citrus O
pectins O
, O
whereas O
stabilisation O
of O
cyanidin B
derivatives O
was O
less O
important O
. O

In O
the O
presence O
of O
non O
- O
anthocyanin B
phenolics I
( O
PP O
- O
E O
) O
the O
impact O
of O
the O
pectin O
source O
was O
even O
more O
pronounced O
than O
the O
effect O
of O
the O
pectin O
type O
. O

An O
HTS O
campaign O
identified O
several O
weak O
M5 O
PAMs O
( O
M5 O
EC50 O
> O
10 O
mu O
M O
) O
with O
a O
structurally O
related O
isatin B
core O
that O
possessed O
a O
southern O
phenethyl B
ether I
linkage O
. O

While O
SAR O
within O
the O
HTS O
series O
was O
very O
shallow O
and O
unable O
to O
be O
optimized O
, O
grafting O
the O
phenethyl B
ether I
linkage O
onto O
the O
ML129 B
/ O
ML172 B
cores O
led O
to O
the O
first O
sub O
- O
micromolar O
M5 O
PAM O
, O
ML326 B
( O
VU0467903 B
) O
, O
( O
human O
and O
rat O
M5 O
EC50s O
of O
409nM O
and O
500nM O
, O
respectively O
) O
with O
excellent O
mAChR O
selectivity O
( O
M1 O
- O
M4 O
EC50s O
> O
30 O
mu O
M O
) O
and O
a O
robust O
20 O
- O
fold O
leftward O
shift O
of O
the O

Neohesperidin B
dihydrochalcone I
, O
4 B
- I
methoxychalcone I
, O
and O
hesperidin B
methylchalcone I
did O
not O
show O
the O
cytotoxicity O
on O
the O
MDA O
- O
MB O
- O
231cells O
. O

Neohesperidin B
dihydrochalcone I
, O
4 B
- I
methoxychalcone I
, O
and O
hesperidin B
methylchalcone I
did O
not O
show O
the O
cytotoxicity O
on O
the O
MDA O
- O
MB O
- O
231cells O
. O

Cyclosporin B
A I
and O
verapamil B
, O
both O
inhibitors O
of O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
, O
significantly O
decreased O
the O
efflux O
of O
AC O
. O

The O
alloy O
NPs O
strongly O
absorb O
light O
and O
efficiently O
enhance O
the O
conversion O
of O
several O
reactions O
, O
including O
Suzuki O
- O
Miyaura O
cross O
coupling O
, O
oxidative O
addition O
of O
benzylamine B
, O
selective O
oxidation O
of O
aromatic B
alcohols I
to O
corresponding O
aldehydes B
and O
ketones B
, O
and O
phenol B
oxidation O
. O

These O
findings O
provide O
useful O
guidelines O
for O
designing O
efficient O
catalysts O
composed O
of O
alloys O
of O
a O
plasmonic O
metal O
and O
a O
catalytically O
active O
transition B
metal I
for O
various O
organic O
syntheses O
driven O
by O
sunlight O
. O

Effects O
of O
Curcumin B
on O
Apoptosis O
and O
Oxidoinflammatory O
Regulation O
in O
a O
Rat O
Model O
of O
Acetic B
Acid I
- O
Induced O
Colitis O
: O
The O
Roles O
of O
c O
- O
Jun O
N B
- O
Terminal O
Kinase O
and O
p38 O
Mitogen O
- O
Activated O
Protein O
Kinase O
. O

Abstract O
The O
present O
study O
evaluated O
the O
effects O
of O
curcumin B
on O
epithelial O
cell O
apoptosis O
, O
the O
immunoreactivity O
of O
the O
phospho O
- O
c O
- O
Jun O
N B
- O
terminal O
kinase O
( O
JNK O
) O
and O
phospho O
- O
p38 O
mitogen O
- O
activated O
protein O
kinases O
( O
MAPKs O
) O
in O
inflamed O
colon O
mucosa O
, O
and O
oxidative O
stress O
in O
a O
rat O
model O
of O
ulcerative O
colitis O
induced O
by O
acetic B
acid I
. O

Rats O
were O
randomly O
divided O
into O
three O
groups O
: O
control O
, O
acetic B
acid I
, O
and O
acetic B
acid I
+ O
curcumin B
. O

Rats O
were O
randomly O
divided O
into O
three O
groups O
: O
control O
, O
acetic B
acid I
, O
and O
acetic B
acid I
+ O
curcumin B
. O

Acetic B
acid I
- O
induced O
colitis O
caused O
a O
significant O
increase O
in O
the O
macroscopic O
and O
microscopic O
tissue O
ranking O
scores O
as O
well O
as O
an O
elevation O
in O
colonic O
myeloperoxidase O
( O
MPO O
) O
activity O
, O
malondialdehyde B
( O
MDA B
) O
levels O
, O
and O
the O
number O
of O
apoptotic O
epithelial O
cells O
in O
colon O
tissue O
compared O
to O
controls O
. O

Curcumin B
treatment O
was O
associated O
with O
amelioration O
of O
macroscopic O
and O
microscopic O
colitis O
sores O
, O
decreased O
MPO O
activity O
, O
and O
decreased O
MDA B
levels O
in O
acetic B
acid I
- O
induced O
colitis O
. O

Oligonol O
supplementation O
attenuates O
body O
temperature O
and O
the O
circulating O
levels O
of O
prostaglandin B
e2 I
and O
cyclooxygenase O
- O
2 O
after O
heat O
stress O
in O
humans O
. O

This O
study O
investigated O
the O
effect O
of O
Oligonol O
supplementation O
on O
circulating O
levels O
of O
prostaglandin B
E2 I
( O
PGE2 B
) O
and O
cyclooxygenase O
( O
COX O
) O
- O
2 O
, O
as O
well O
as O
body O
temperature O
, O
after O
heat O
stress O
in O
17 O
healthy O
human O
male O
volunteers O
( O
age O
, O
21 O
. O
6 O
+ O
/ O
- O
2 O
. O
1 O
years O
) O
. O

Furthermore O
, O
the O
treatment O
of O
inhibitors O
specific O
for O
PI3K O
/ O
Akt O
( O
LY294002 B
) O
, O
ERK O
( O
U0126 B
) O
, O
or O
NF O
- O
kappa O
B O
( O
pyrrolidine B
dithiocarbamate I
) O
to O
A549 O
cells O
reduced O
cell O
invasion O
and O
MMP O
- O
2 O
/ O
9 O
expression O
. O

Microcystins B
are O
cyclic B
heptapeptides I
from O
cyanobacteria O
which O
are O
responsible O
for O
poisonings O
of O
livestock O
and O
humans O
. O

The O
salts O
of O
TEF B
and O
LOX B
with O
organic B
amines I
diethylamine B
( O
DEtA B
) O
, O
triethylamine B
( O
TEtA B
) O
, O
diethanolamine B
( O
DEA B
) O
, O
triethanolamine B
( O
TEA B
) O
and O
N B
- I
( I
2 I
' I
- I
hydroxy I
- I
ethanol I
) I
- I
piperdine I
( O
NP O
) O
were O
prepared O
to O
improve O
the O
skin O
permeation O
of O
the O
parent O
drug O
. O

Anti O
- O
inflammatory O
and O
analgesic O
effects O
of O
the O
optimized O
compound O
patch O
were O
evaluated O
using O
the O
adjuvant O
arthritis O
model O
and O
the O
pain O
model O
induced O
by O
acetic B
acid I
, O
respectively O
. O

The O
in O
vitro O
experiment O
results O
showed O
that O
the O
amine B
salts I
of O
TEF B
and O
LOX B
, O
especially O
TEF B
- I
TEtA I
and O
LOX B
- I
TEtA I
, O
enhanced O
the O
skin O
permeation O
of O
TEF B
and O
LOX B
from O
the O
transdermal O
patch O
system O
. O

BM O
remarkably O
inhibited O
UVB O
- O
induced O
activation O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
therefore O
generation O
of O
nitric B
oxide I
( O
NO B
) O
and O
nitrotyrosine B
, O
in O
a O
UVB O
single O
dose O
regimen O
. O

BM O
remarkably O
inhibited O
UVB O
- O
induced O
activation O
of O
inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
and O
therefore O
generation O
of O
nitric B
oxide I
( O
NO B
) O
and O
nitrotyrosine B
, O
in O
a O
UVB O
single O
dose O
regimen O
. O

The O
apoptosis O
was O
carried O
out O
with O
Hoechst B
33258 I
staining O
method O
and O
flow O
cytometry O
. O

These O
results O
in O
combination O
to O
their O
known O
AChE O
/ O
BuChE O
inhibitory O
activities O
led O
us O
to O
propose O
these O
indolyl B
carbohydrazides I
as O
new O
multifunctional O
compounds O
against O
AD O
. O

None O
of O
the O
compounds O
showed O
significant O
cytotoxicity O
on O
human O
C3A O
hepatocytes O
in O
a O
neutral B
red I
dye O
uptake O
assay O
and O
no O
genotoxicity O
or O
mutagenicity O
was O
observed O
as O
demonstrated O
by O
a O
VITOTOX O
( O
TM O
) O
test O
and O
confirmed O
with O
a O
comet O
assay O
. O

Cyclic B
AMP I
responsive O
element O
binding O
protein O
- O
a O
vital O
link O
in O
embryonic O
hormonal O
adaptation O
. O

The O
transcription O
factor O
cyclic B
AMP I
responsive O
element O
binding O
protein O
( O
CREB O
) O
and O
activating O
transcription O
factors O
( O
ATFs O
) O
are O
downstream O
components O
of O
the O
insulin O
/ O
IGF O
cascade O
, O
playing O
crucial O
roles O
in O
maintaining O
cell O
viability O
and O
embryo O
survival O
. O

Effect O
of O
Topical O
Application O
of O
Chlorogenic B
Acid I
on O
Excision O
Wound O
Healing O
in O
Rats O
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
therapeutic O
effects O
of O
topical O
chlorogenic B
acid I
on O
excision O
wounds O
in O
Wistar O
rats O
. O

A O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
or O
silver B
sulfadiazine I
ointment O
was O
applied O
topically O
once O
a O
day O
for O
15 O
days O
on O
full O
- O
thickness O
excision O
wounds O
created O
on O
rats O
. O

A O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
or O
silver B
sulfadiazine I
ointment O
was O
applied O
topically O
once O
a O
day O
for O
15 O
days O
on O
full O
- O
thickness O
excision O
wounds O
created O
on O
rats O
. O

The O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
ointment O
had O
potent O
wound O
healing O
capacity O
as O
evident O
from O
the O
wound O
contraction O
on O
the O
15th O
post O
- O
surgery O
day O
, O
which O
was O
similar O
to O
that O
produced O
by O
1 O
% O
( O
w O
/ O
w O
) O
silver B
sulfadiazine I
ointment O
. O

The O
1 O
% O
( O
w O
/ O
w O
) O
chlorogenic B
acid I
ointment O
had O
potent O
wound O
healing O
capacity O
as O
evident O
from O
the O
wound O
contraction O
on O
the O
15th O
post O
- O
surgery O
day O
, O
which O
was O
similar O
to O
that O
produced O
by O
1 O
% O
( O
w O
/ O
w O
) O
silver B
sulfadiazine I
ointment O
. O

It O
also O
improved O
cellular O
proliferation O
, O
increased O
tumor O
necrosis O
factor O
- O
alpha O
levels O
during O
the O
inflammatory O
phase O
( O
12 O
h O
, O
24 O
h O
, O
48 O
h O
, O
and O
72 O
h O
post O
- O
wounding O
) O
of O
wound O
healing O
, O
upregulated O
transforming O
growth O
factor O
- O
beta O
1 O
and O
elevated O
collagen O
IV O
synthesis O
in O
the O
chlorogenic B
acid I
- O
treated O
group O
. O

The O
results O
also O
indicated O
that O
chlorogenic B
acid I
possesses O
potent O
antioxidant O
activity O
by O
increasing O
superoxide B
dismutase O
, O
catalase O
, O
and O
glutathione B
, O
and O
decreasing O
lipid O
peroxidation O
. O

In O
conclusion O
, O
these O
results O
demonstrate O
that O
topical O
application O
of O
chlorogenic B
acid I
can O
accelerate O
the O
process O
of O
excision O
wound O
healing O
by O
its O
ability O
to O
increase O
collagen O
synthesis O
through O
upregulation O
of O
key O
players O
such O
as O
tumor O
necrosis O
factor O
- O
alpha O
and O
transforming O
growth O
factor O
- O
beta O
1 O
in O
different O
phases O
of O
wound O
healing O
as O
well O
as O
by O
its O
antioxidant O
potential O
. O

Here O
we O
compared O
, O
in O
the O
same O
sequence O
context O
, O
the O
relative O
NER O
dual O
incision O
efficiencies O
elicited O
by O
two O
stereochemically O
distinct O
pairs O
of O
guanine B
( O
N O
( O
2 O
) O
- O
dG O
) O
and O
adenine B
( O
N O
( O
6 O
) O
- O
dA O
) O
DNA O
lesions O
, O
derived O
from O
enantiomeric O
genotoxic O
diol B
epoxides I
of O
the O
highly O
tumorigenic O
fjord O
region O
polycyclic O
aromatic O
hydrocarbon O
dibenzo B
[ I
a I
, I
l I
] I
pyrene I
( O
DB B
[ I
a I
, I
l I
] I
P I
) O
. O

A O
facile O
strategy O
to O
design O
zeolite B
L I
crystals O
with O
tunable O
morphology O
and O
surface O
architecture O
. O

We O
examined O
over O
30 O
molecules O
as O
potential O
zeolite B
growth O
modifiers O
( O
ZGMs O
) O
of O
zeolite B
L I
( O
LTL O
type O
) O
crystallization O
. O

We O
present O
a O
combined O
experimental O
and O
theoretical O
quantification O
of O
the O
adsorption O
enthalpies O
of O
seven O
organic O
molecules O
( O
acetone B
, O
acetonitrile B
, O
dichloromethane B
, O
ethanol B
, O
ethyl B
acetate I
, O
hexane B
, O
and O
toluene B
) O
on O
graphene B
. O

A O
series O
of O
overlapped O
peptide O
fragments O
of O
Ixosin O
- O
B O
, O
an O
antimicrobial O
peptide O
with O
amino B
acid I
sequence O
of O
QLKVDLWGTRSGIQPEQHSS O
, O
was O
designed O
, O
synthesized O
and O
examined O
for O
their O
antimicrobial O
activities O
against O
Escherichia O
coli O
, O
Staphylococcus O
aureus O
, O
and O
Pseudomonas O
aeruginosa O
. O

Pyranocycloartobilox B
A I
, O
a O
novel O
gastroprotective O
compound O
from O
Artocarpus O
obtusus O
Jarret O
, O
against O
ethanol B
- O
induced O
acute O
gastric O
ulcer O
in O
vivo O
. O

Pyranocycloartobilox B
A I
( O
PA O
) O
, O
a O
xanthone B
derived O
from O
the O
Artocarpus O
obtusus O
Jarret O
, O
belongs O
to O
the O
Moraceae O
family O
which O
is O
native O
to O
the O
tropical O
forest O
of O
Malaysia O
. O

The O
ulcer O
index O
, O
gastric O
juice O
acidity O
, O
mucus O
content O
, O
histological O
analysis O
, O
glutathione B
( O
GSH B
) O
levels O
, O
malondialdehyde B
level O
( O
MDA B
) O
, O
nitric B
oxide I
( O
NO B
) O
and O
non O
- O
protein O
sulfhydryl B
group O
( O
NP O
- O
SH B
) O
contents O
were O
evaluated O
in O
vivo O
. O

Some O
members O
of O
the O
HKT O
protein O
family O
have O
been O
shown O
to O
be O
critical O
for O
salinity O
tolerance O
in O
commercially O
important O
crop O
species O
, O
particularly O
in O
grains O
, O
through O
exclusion O
of O
Na B
+ I
ions O
from O
sensitive O
shoot O
tissues O
in O
plants O
. O

The O
nacre O
- O
mimicking O
fibers O
are O
highly O
electrically O
conductive O
( O
~ O
350 O
S O
m O
( O
- O
1 O
) O
) O
after O
immersing O
in O
hydroiodic B
acid I
, O
enabling O
them O
to O
connect O
a O
circuit O
to O
illuminate O
an O
LED O
lamp O
. O

Walter O
on O
antioxidant O
enzyme O
activities O
such O
as O
peroxidases O
( O
PODs O
) O
, O
super B
oxide I
dismutases O
( O
SODs O
) O
and O
catalase O
( O
CAT O
) O
and O
on O
total O
protein O
contents O
( O
TPC O
) O
, O
cellular O
injury O
( O
CI O
) O
, O
and O
malondialdehyde B
( O
MDA B
) O
in O
the O
germinating O
seeds O
of O
Brassica O
napus O
L O
. O

Direct O
- O
type O
catalytic O
Mannich O
reaction O
for O
the O
synthesis O
of O
beta B
- I
aminoketones I
from O
cyclohexanone B
, O
substituted O
aromatic B
amines I
and I
aromatic I
or I
hetero I
- I
aromatic I
aldehydes I
has O
been O
applied O
in O
water O
with O
bismuth B
triflate I
under O
ultrasound O
. O

Hydrogen B
peroxide I
( O
H2O2 B
) O
production O
, O
lipid O
peroxidation O
( O
LPO O
) O
, O
protein O
carbonyl B
content O
and O
activities O
of O
uridine B
5 I
' I
- I
diphospho I
- O
glucuronyltransferas O
( O
UDPGT O
) O
and O
P450 O
were O
significantly O
increased O
. O

Organic O
Solvent O
- O
Based O
Graphene B
Oxide I
Liquid O
Crystals O
: O
A O
Facile O
Route O
toward O
the O
Next O
Generation O
of O
Self O
- O
Assembled O
Layer O
- O
by O
- O
Layer O
Multifunctional O
3D O
Architectures O
. O

We O
introduce O
soft O
self O
- O
assembly O
of O
ultralarge O
liquid O
crystalline O
( O
LC O
) O
graphene B
oxide I
( O
GO O
) O
sheets O
in O
a O
wide O
range O
of O
organic O
solvents O
overcoming O
the O
practical O
limitations O
imposed O
on O
LC O
GO O
processing O
in O
water O
. O

In O
this O
paper O
, O
we O
obtained O
various O
water O
- O
soluble O
polymer O
functionalized O
graphene B
in O
dimethyl B
sulfoxide I
under O
ultrasonication O
. O

As O
a O
result O
, O
a O
catalyst O
based O
on O
polyvinyl B
pyrrolidone I
( O
PVP B
) O
/ O
graphene B
shows O
better O
methanol B
oxidation O
performance O
than O
that O
based O
on O
PVP B
/ O
reduced O
graphene B
oxide I
. O

As O
a O
result O
, O
a O
catalyst O
based O
on O
polyvinyl B
pyrrolidone I
( O
PVP B
) O
/ O
graphene B
shows O
better O
methanol B
oxidation O
performance O
than O
that O
based O
on O
PVP B
/ O
reduced O
graphene B
oxide I
. O

If O
only O
one O
of O
( O
1 O
) O
and O
( O
2 O
) O
are O
met O
, O
we O
recommend O
that O
other O
clinical O
features O
are O
considered O
in O
the O
diagnosis O
of O
SCS O
, O
including O
serum O
dehydroepiandrostero B
sulfate I
levels O
, O
urine O
free O
cortisol B
levels O
, O
adrenal O
scintigraphy O
, O
and O
clinical O
manifestation O
. O

TCE B
exposure O
resulted O
in O
a O
decrease O
in O
urine O
of O
metabolites O
involved O
in O
fatty B
acid I
metabolism O
, O
resulting O
from O
altered O
expression O
of O
PPAR O
alpha O
target O
genes O
. O

Attenuation O
of O
Gouty O
Arthritis O
by O
Emodinol B
in O
Monosodium B
Urate I
Crystal O
- O
Treated O
Mice O
. O

A O
series O
of O
studies O
have O
recently O
demonstrated O
that O
the O
release O
of O
interleukin O
1 O
beta O
induced O
by O
monosodium B
urate I
crystals O
is O
central O
to O
the O
experimental O
gouty O
arthritis O
. O

Results O
showed O
that O
it O
significantly O
ameliorated O
the O
hyperalgesia O
, O
inflammation O
, O
and O
levels O
of O
multiple O
proinflammatory O
cytokines O
in O
monosodium B
urate I
crystals O
- O
treated O
mice O
. O

These O
findings O
elucidate O
that O
emodinol B
exhibits O
a O
prominent O
effect O
on O
improving O
symptoms O
of O
acute O
gouty O
arthritis O
induced O
by O
monosodium B
urate I
crystals O
through O
inhibiting O
the O
generation O
of O
proinflammatory O
cytokines O
. O

Profile O
hidden O
Markov O
models O
( O
HMMs O
) O
were O
used O
to O
predict O
the O
configuration O
of O
secondary B
alcohols I
and O
alpha B
- I
methyl I
branches O
of O
modular O
polyketides O
. O

The O
MM O
and O
NMR O
experiments O
indicate O
that O
the O
WHWTYYW O
peptide O
exhibits O
a O
bent O
structure O
when O
bound O
, O
allowing O
the O
Y5 O
amino B
acid I
to O
form O
a O
CH B
/ O
pi O
stacking O
interaction O
and O
H B
- O
bond O
with O
the O
glucose B
ring O
of O
cellulose O
. O

The O
mechanism O
of O
the O
recently O
discovered O
, O
unusual O
tetrabutylammonium B
fluoride I
( O
TBAF B
) O
deacylation O
of O
cellulose O
esters O
has O
been O
investigated O
by O
methods O
including O
kinetic O
isotope O
effect O
( O
KIE O
) O
studies O
. O

The O
biological O
activities O
of O
6 B
- I
DHSG I
were O
attenuated O
by O
sulfhydryl B
antioxidants O
such O
as O
glutathione B
( O
GSH B
) O
or O
N B
- I
acetyl I
cysteine I
( O
NAC B
) O
, O
but O
not O
ascorbic B
acid I
( O
ASC B
) O
. O

Polyphenols B
in O
noni O
juice O
( O
NJ O
) O
are O
mainly O
composed O
of O
phenolic B
acids I
, O
mainly O
gentisic B
, I
p I
- I
hydroxybenoic I
, I
and I
chlorogenic I
acids I
. O

NJ O
also O
decreased O
( O
p O
< O
0 O
. O
05 O
) O
serum O
/ O
liver O
lipids O
but O
enhanced O
( O
p O
< O
0 O
. O
05 O
) O
daily O
faecal O
lipid O
/ O
bile B
acid I
outputs O
in O
the O
high O
- O
fat O
dietary O
hamsters O
. O

The O
addition O
of O
sodium B
sulphite I
or O
sodium B
dodecyl I
sulphate I
also O
inhibited O
precipitate O
formation O
after O
freeze O
- O
thawing O
, O
resulting O
in O
no O
fractionation O
. O

In O
this O
work O
, O
UV O
- O
activated O
visual O
oxygen B
indicator O
films O
were O
fabricated O
using O
thionine B
, O
glycerol B
, O
P25 B
TiO2 I
, O
and O
zein O
as O
a O
redox O
dye O
, O
a O
sacrificial O
electron O
donor O
, O
UV O
- O
absorbing O
semiconducting O
photocatalyst O
, O
and O
an O
encapsulation O
polymer O
, O
respectively O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Impact O
of O
( B
+ I
) I
- I
catechin I
and O
gallic B
acid I
on O
sensory O
perception O
and O
volatility O
of O
isoamyl B
acetate I
, O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
was O
investigated O
in O
model O
solutions O
, O
by O
means O
of O
triangle O
tests O
, O
detection O
threshold O
determination O
and O
HS O
- O
GC O
- O
MS O
analyses O
. O

Catechin B
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters B
( O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
) O
while O
gallic B
acid I
displayed O
no O
impact O
. O

Catechin B
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters B
( O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
) O
while O
gallic B
acid I
displayed O
no O
impact O
. O

Catechin B
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters B
( O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
) O
while O
gallic B
acid I
displayed O
no O
impact O
. O

Catechin B
significantly O
altered O
the O
sensory O
perception O
of O
most O
esters B
( O
ethyl B
isobutyrate I
, O
ethyl B
butyrate I
and O
ethyl B
octanoate I
) O
while O
gallic B
acid I
displayed O
no O
impact O
. O

Ethyl B
butyrate I
and O
ethyl B
octanoate I
odour O
thresholds O
doubled O
or O
tripled O
in O
the O
presence O
of O
catechin B
, O
underlining O
a O
retention O
impact O
of O
phenolic B
compounds O
in O
liquid O
matrix O
. O

Ethyl B
butyrate I
and O
ethyl B
octanoate I
odour O
thresholds O
doubled O
or O
tripled O
in O
the O
presence O
of O
catechin B
, O
underlining O
a O
retention O
impact O
of O
phenolic B
compounds O
in O
liquid O
matrix O
. O

The O
headspace O
analyses O
displayed O
a O
decrease O
only O
in O
ethyl B
octanoate I
volatility O
in O
presence O
of O
catechin B
, O
whereas O
no O
significant O
difference O
in O
other O
esters B
concentrations O
was O
observed O
. O

Grain O
tocopherol B
as O
well O
as O
flag O
leaf O
vitamin B
E I
levels O
were O
also O
investigated O
for O
comparison O
. O

T3 O
precursors O
such O
as O
homogentisate O
and O
geranylgeranyl B
pyrophosphate I
decreased O
during O
maturation O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

Amino B
acid I
profiles O
and O
quantitative O
structure O
- O
property O
relationship O
models O
as O
markers O
for O
Merlot O
and O
Torront O
e O
s O
wines O
. O

Dragon O
theoretical O
descriptors O
were O
derived O
for O
a O
set O
of O
optimized O
amino B
acid I
structures O
with O
the O
purpose O
of O
establishing O
QSPR O
models O
. O

Predicted O
QSPR O
results O
were O
in O
good O
agreement O
with O
experimental O
amino B
acid I
profiles O
. O

The O
developed O
QSPR O
approach O
showed O
to O
be O
of O
practical O
value O
for O
distinguishing O
each O
wine O
varietal O
, O
and O
for O
calculating O
experimentally O
non O
- O
available O
amino B
acid I
concentrations O
of O
Torront O
e O
s O
and O
Merlot O
wines O
. O

Conjugated O
linoleic B
acid I
and O
calcium B
co O
- O
supplementation O
improves O
bone O
health O
in O
ovariectomised O
mice O
. O

Osteoporosis O
is O
a O
significant O
health O
concern O
for O
the O
elderly O
; O
conjugated O
linoleic B
acid I
( O
CLA O
) O
has O
been O
shown O
to O
improve O
overall O
bone O
mass O
when O
calcium B
is O
included O
as O
a O
co O
- O
supplement O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
how O
dietary O
calcium B
modulates O
the O
effects O
of O
conjugated O
linoleic B
acid I
( O
CLA O
) O
in O
preventing O
bone O
loss O
, O
using O
an O
ovariectomised O
mouse O
model O
. O

The O
study O
investigated O
the O
role O
of O
Spirulina O
platensis O
in O
reversing O
sodium B
fluoride I
- O
induced O
thyroid O
, O
neurodevelopment O
and O
oxidative O
alterations O
in O
offspring O
of O
pregnant O
rats O
. O

The O
total O
antioxidant O
activity O
, O
phycocyanins O
, O
and O
beta B
carotene I
content O
were O
quantified O
in O
Spirulina O
. O

Treatment O
groups O
included O
control O
, O
Spirulina O
alone O
, O
sodium B
fluoride I
( O
20mg O
/ O
kg O
) O
alone O
, O
and O
sodium B
fluoride I
along O
with O
Spirulina O
( O
250 O
and O
500mg O
/ O
kg O
) O
. O

Treatment O
groups O
included O
control O
, O
Spirulina O
alone O
, O
sodium B
fluoride I
( O
20mg O
/ O
kg O
) O
alone O
, O
and O
sodium B
fluoride I
along O
with O
Spirulina O
( O
250 O
and O
500mg O
/ O
kg O
) O
. O

Among O
the O
11 O
phenolics B
characterised O
in O
leaves O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
mass O
spectrometric O
detection O
, O
several O
caffeic B
acid I
derivatives O
, O
5 B
- I
feruloylquinic I
and I
5 I
- I
p I
- I
coumaroylquinic I
acids I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

In O
fruits O
, O
10 O
phenolics B
were O
detected O
, O
whereas O
rutin B
, O
a O
dicaffeic B
acid I
derivative O
and O
two O
feruloylquinic B
and I
caffeoylquinic I
acid I
isomers O
were O
newly O
detected O
. O

Though O
the O
phosphoryloxymethyle B
carbamates I
( O
3 O
, O
4 O
, O
and O
5 O
) O
and O
alpha B
- I
aminoacyloxymethylen I
carbamates I
( O
22 O
, O
23 O
, O
and O
26 O
) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric B
acid I
derived O
acyloxymethylene B
carbamates I
( O
2 O
, O
28 O
, O
and O
31 O
) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions O
. O

Though O
the O
phosphoryloxymethyle B
carbamates I
( O
3 O
, O
4 O
, O
and O
5 O
) O
and O
alpha B
- I
aminoacyloxymethylen I
carbamates I
( O
22 O
, O
23 O
, O
and O
26 O
) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric B
acid I
derived O
acyloxymethylene B
carbamates I
( O
2 O
, O
28 O
, O
and O
31 O
) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions O
. O

Though O
the O
phosphoryloxymethyle B
carbamates I
( O
3 O
, O
4 O
, O
and O
5 O
) O
and O
alpha B
- I
aminoacyloxymethylen I
carbamates I
( O
22 O
, O
23 O
, O
and O
26 O
) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric B
acid I
derived O
acyloxymethylene B
carbamates I
( O
2 O
, O
28 O
, O
and O
31 O
) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions O
. O

To O
our O
knowledge O
, O
the O
unique O
type O
of O
prodrugs O
like O
2 O
, O
28 O
, O
and O
31 O
was O
not O
reported O
in O
the O
past O
and O
could O
represent O
a O
novel O
prodrug O
approach O
for O
secondary B
amides I
, O
a O
class O
of O
molecules O
frequently O
identified O
as O
drug O
candidates O
. O

Aim O
of O
present O
study O
was O
to O
investigate O
the O
effect O
of O
NAC B
on O
experimental O
chronic O
hepatotoxicity O
models O
induced O
by O
carbon B
tetrachloride I
( O
CCl4 B
) O
and O
thioacetamide B
( O
TAA B
) O
. O

Incretin O
hormone O
action O
on O
beta O
- O
cells O
stimulates O
in O
parallel O
two O
different O
intracellular O
cyclic B
AMP I
- O
dependent O
signaling O
branches O
mediated O
by O
PKA O
and O
EPAC2A O
. O

However O
, O
when O
mice O
are O
exposed O
to O
diet O
- O
induced O
insulin O
resistance O
, O
pharmacologic O
secretagogue O
stimulation O
of O
beta O
- O
cells O
with O
an O
incretin O
hormone O
glucagon O
- O
like O
peptide O
- O
1 O
analogue O
or O
with O
a O
Fatty B
Acid I
Receptor O
1 O
/ O
GPR40 O
selective O
activator O
, O
EPAC2A O
is O
required O
for O
the O
increased O
beta O
- O
cell O
response O
to O
secretory O
demand O
. O

Salicylic B
acid I
alleviates O
copper B
toxicity O
in O
rice O
( O
Oryza O
sativa O
L O
. O
) O
seedlings O
by O
up O
- O
regulating O
antioxidative O
and O
glyoxalase O
systems O
. O

The O
present O
study O
investigated O
the O
effect O
of O
salicylic B
acid I
( O
SA O
) O
on O
toxic O
symptoms O
, O
lipid O
peroxidation O
, O
reactive O
oxygen B
species O
generation O
and O
responses O
of O
antioxidative O
and O
glyoxalase O
systems O
in O
rice O
seedlings O
grown O
hydroponically O
under O
copper B
( O
Cu B
) O
stress O
for O
48 O
h O
. O

Exposures O
of O
75 O
and O
150 O
mu O
M O
Cu B
( I
2 I
+ I
) I
caused O
toxicity O
symptoms O
( O
chlorosis O
, O
necrosis O
and O
rolling O
in O
leaves O
) O
, O
sharp O
increases O
in O
malondialdehyde B
( O
MDA B
) O
, O
hydrogen B
peroxide I
( O
H2O2 B
) O
contents O
and O
lipoxygenase O
( O
LOX O
) O
activity O
with O
concomitant O
reductions O
of O
chlorophyll O
( O
Chl O
) O
and O
relative O
water O
content O
( O
RWC O
) O
. O

Both O
levels O
of O
Cu B
decreased O
ascorbic B
acid I
( O
AsA B
) O
, O
glutathione B
( O
GSH B
) O
, O
non O
- O
protein O
thiol B
( O
NPT O
) O
and O
proline B
contents O
in O
roots O
but O
rather O
increased O
in O
leaves O
except O
that O
AsA B
decreased O
in O
leaves O
too O
. O

Multi O
- O
walled O
CNTs O
have O
been O
decorated O
with O
iron B
oxide I
superparamagnetic O
NPs O
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

The O
results O
indicated O
that O
a O
mixture O
of O
OP O
pesticides O
induced O
DNA O
damage O
, O
oxidative O
stress O
, O
disturbed O
the O
metabolism O
of O
lipids O
as O
well O
as O
interfered O
with O
the O
tricarboxylic B
acid I
cycle O
. O

Patchy O
surfaces O
stabilize O
dextran O
- O
polyethylene B
glycol I
aqueous O
two O
- O
phase O
system O
liquid O
patterns O
. O

Polyethylene B
glycol I
( O
PEG B
) O
and O
dextran O
( O
DEX O
) O
are O
used O
as O
phase O
- O
forming O
polymers O
for O
the O
ATPS O
. O

PDMS B
surface O
modifications O
studied O
include O
primary B
amine I
groups O
, O
carboxylic B
acid I
groups O
, O
and O
neutral O
polymer O
surfaces O
. O

PDMS B
surface O
modifications O
studied O
include O
primary B
amine I
groups O
, O
carboxylic B
acid I
groups O
, O
and O
neutral O
polymer O
surfaces O
. O

Types O
of O
damaged O
lesions O
frequently O
found O
inside O
clustered O
DNA O
damage O
sites O
include O
oxidized O
bases O
, O
abasic O
sites O
, O
nucleotide B
dimers I
, O
strand O
breaks O
or O
their O
complex O
combinations O
. O

Naturally O
occuring O
quercetin B
protects O
hepatocytes O
from O
ethanol B
- O
induced O
oxidative O
stress O
, O
and O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
induction O
and O
carbon B
monoxide I
( O
CO B
) O
metabolite O
may O
be O
implicated O
in O
the O
beneficial O
effect O
. O

Oxysterol B
- O
dependent O
NOX1 O
activation O
, O
as O
well O
as O
interleukin O
synthesis O
, O
were O
completely O
prevented O
by O
Cannonau O
red O
wine O
extract O
that O
contains O
an O
abundant O
phenolic O
fraction O
, O
in O
particular O
phenolic B
acids I
and O
flavonoids B
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

Molecular O
mechanisms O
for O
the O
anti O
- O
cancer O
effects O
of O
diallyl B
disulfide I
. O

Oil O
- O
soluble O
compounds O
such O
as O
diallyl B
sulfide I
( O
DAS B
) O
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
( O
DATS B
) O
and O
ajoene B
are O
more O
effective O
than O
water O
- O
soluble O
compounds O
in O
protection O
against O
cancer O
. O

Oil O
- O
soluble O
compounds O
such O
as O
diallyl B
sulfide I
( O
DAS B
) O
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
( O
DATS B
) O
and O
ajoene B
are O
more O
effective O
than O
water O
- O
soluble O
compounds O
in O
protection O
against O
cancer O
. O

Oil O
- O
soluble O
compounds O
such O
as O
diallyl B
sulfide I
( O
DAS B
) O
, O
diallyl B
disulfide I
( O
DADS B
) O
, O
diallyl B
trisulfide I
( O
DATS B
) O
and O
ajoene B
are O
more O
effective O
than O
water O
- O
soluble O
compounds O
in O
protection O
against O
cancer O
. O

Moreover O
, O
as O
plants O
are O
frequently O
contaminated O
with O
toxic O
environmental O
substances O
, O
the O
mutual O
influence O
on O
the O
transdermal O
behavior O
between O
spilanthol B
and O
six O
model O
mycotoxins O
( O
aflatoxin B
B1 I
, O
ochratoxin B
A I
, O
fumonisin B
B1 I
, O
citrinin B
, O
zearalenone B
, O
T B
- I
2 I
toxin I
) O
was O
investigated O
. O

Moreover O
, O
as O
plants O
are O
frequently O
contaminated O
with O
toxic O
environmental O
substances O
, O
the O
mutual O
influence O
on O
the O
transdermal O
behavior O
between O
spilanthol B
and O
six O
model O
mycotoxins O
( O
aflatoxin B
B1 I
, O
ochratoxin B
A I
, O
fumonisin B
B1 I
, O
citrinin B
, O
zearalenone B
, O
T B
- I
2 I
toxin I
) O
was O
investigated O
. O

Moreover O
, O
as O
plants O
are O
frequently O
contaminated O
with O
toxic O
environmental O
substances O
, O
the O
mutual O
influence O
on O
the O
transdermal O
behavior O
between O
spilanthol B
and O
six O
model O
mycotoxins O
( O
aflatoxin B
B1 I
, O
ochratoxin B
A I
, O
fumonisin B
B1 I
, O
citrinin B
, O
zearalenone B
, O
T B
- I
2 I
toxin I
) O
was O
investigated O
. O

Anti O
- O
inflammatory O
activity O
of O
Cymbopogon O
citratus O
leaves O
infusion O
via O
proteasome O
and O
nuclear O
factor O
- O
kappa O
B O
pathway O
inhibition O
: O
Contribution O
of O
chlorogenic B
acid I
. O

Chlorogenic B
acid I
was O
identified O
, O
by O
HPLC O
/ O
PDA O
/ O
ESI O
- O
MS O
( O
n O
) O
. O

Chlorogenic B
acid I
was O
identified O
, O
by O
HPLC O
/ O
PDA O
/ O
ESI O
- O
MS O
( O
n O
) O
, O
as O
the O
main O
phenolic B
acid I
of O
the O
Cy O
infusion O
, O
and O
it O
demonstrated O
to O
be O
, O
at O
least O
in O
part O
, O
responsible O
by O
that O
effect O
. O

Chlorogenic B
acid I
was O
identified O
, O
by O
HPLC O
/ O
PDA O
/ O
ESI O
- O
MS O
( O
n O
) O
, O
as O
the O
main O
phenolic B
acid I
of O
the O
Cy O
infusion O
, O
and O
it O
demonstrated O
to O
be O
, O
at O
least O
in O
part O
, O
responsible O
by O
that O
effect O
. O

Additionally O
, O
Cy O
polyphenols B
, O
in O
particular O
chlorogenic B
acid I
, O
were O
highlighted O
as O
bio O
- O
active O
compounds O
. O

Moreover O
by O
the O
mean O
of O
an O
endothelial O
cell O
tube O
formation O
in O
vitro O
model O
2f O
tartaric B
acid I
salt O
proved O
to O
block O
angiogenesis O
of O
HUVEC O
at O
mu O
M O
level O
. O

Meclofenamic B
acid I
blocks O
the O
gap O
junction O
communication O
between O
the O
retinal O
pigment O
epithelial O
cells O
. O

Therefore O
, O
we O
aimed O
to O
investigate O
the O
effect O
of O
meclofenamic B
acid I
( O
MFA B
) O
on O
retinal O
pigment O
epithelium O
( O
RPE O
) O
. O

Results O
: O
Analysis O
of O
Lucifer B
yellow I
( O
LY O
) O
transfer O
revealed O
that O
the O
gap O
junction O
communication O
existed O
between O
RPE O
cells O
. O

Importantly O
, O
MFA B
largely O
inhibited O
the O
gap O
junction O
conductance O
and O
induced O
the O
uncoupling O
of O
RPE O
cells O
. O
Other O
NSAIDs O
, O
like O
aspirin B
and O
flufenamic B
acid I
( O
FFA B
) O
, O
had O
the O
same O
effect O
. O

Tandem O
assays O
of O
protein O
and O
glucose B
in O
combination O
with O
mannose B
- O
functionalized O
Fe3 B
O4 I
@ O
SiO2 B
and O
Ag B
@ O
SiO2 B
tag O
particles O
have O
promising O
potential O
in O
effective O
magnetic O
separation O
and O
highly O
sensitive O
and O
selective O
SERS O
assays O
of O
biomaterials O
. O

We O
have O
employed O
in O
situ O
X O
- O
ray O
reflectivity O
( O
IXRR O
) O
to O
study O
the O
adsorption O
of O
a O
variety O
of O
proteins O
( O
lysozyme O
, O
cytochrome O
c O
, O
myoglobin O
, O
hemoglobin O
, O
serum O
albumin O
, O
and O
immunoglobulin O
G O
) O
on O
model O
hydrophilic O
( O
silicon B
oxide I
) O
and O
hydrophobic O
surfaces O
( O
octadecyltrichlorosi B
self O
- O
assembled O
monolayers O
) O
, O
evaluating O
this O
recently O
developed O
technique O
for O
its O
applicability O
in O
the O
area O
of O
biomolecular O
studies O
. O

The O
functional O
heterostructures O
are O
fabricated O
by O
layer O
- O
by O
- O
layer O
, O
template O
- O
directed O
, O
electrochemical O
synthesis O
in O
porous O
anodic O
aluminum B
oxide I
membranes O
to O
produce O
high O
density O
arrays O
of O
electronically O
autonomous O
, O
nanostructured O
, O
corrosion O
resistant O
, O
photoactive O
units O
( O
~ O
10 O
( O
9 O
) O
- O
10 O
( O
10 O
) O
PAHs O
per O
cm O
( O
2 O
) O
) O
. O

When O
illuminated O
with O
visible O
light O
, O
the O
free O
floating O
devices O
have O
been O
demonstrated O
to O
produce O
hydrogen B
at O
a O
stable O
rate O
for O
over O
24 O
h O
in O
corrosive O
hydroiodic B
acid I
electrolyte O
with O
light O
as O
the O
only O
input O
. O

Here O
we O
explore O
the O
hidden O
sensing O
modalities O
responsible O
for O
tailoring O
the O
gas O
detection O
ability O
of O
pristine B
graphene I
sensors O
by O
exposing O
graphene B
chemFETs O
to O
electron O
donor O
and O
acceptor O
trace O
gas O
vapors O
. O

We O
uncover O
that O
the O
sensitivity O
( O
in O
terms O
of O
modulation O
in O
electrical O
conductivity O
) O
of O
pristine B
graphene I
chemFETs O
is O
not O
necessarily O
intrinsic O
to O
graphene B
, O
but O
rather O
it O
is O
facilitated O
by O
external O
defects O
in O
the O
insulating O
substrate O
, O
which O
can O
modulate O
the O
electronic O
properties O
of O
graphene B
. O

Structure O
and O
Absolute O
Configuration O
of O
Fumiquinazoline B
L I
, O
an O
Alkaloid O
from O
a O
Gorgonian O
- O
Derived O
Scopulariopsis O
sp O
. O

Fumiquinazoline B
L I
( O
1 O
) O
, O
an O
alkaloid O
with O
a O
heptacyclic O
skeleton O
formed O
via O
a O
bridging O
hemiaminal O
linkage O
, O
was O
isolated O
from O
a O
gorgonian O
- O
derived O
Scopulariopsis O
sp O
. O
fungus O
. O

Fumiquinazoline B
L I
( O
1 O
) O
showed O
no O
cytotoxic O
or O
antibacterial O
activities O
. O

As O
a O
result O
, O
we O
determined O
that O
a O
fosK O
- O
encoded O
cytochrome O
P450 O
monooxygenase O
is O
responsible O
for O
C O
- O
18 O
hydroxylation O
, O
formation O
of O
an O
unsaturated B
lactone I
is O
dependent O
upon O
FosM O
, O
and O
the O
fosG O
gene O
product O
is O
involved O
in O
hydroxylation O
at O
C O
- O
4 O
after O
the O
action O
of O
FosM O
to O
yield O
PD B
113 I
, I
271 I
from O
FST B
. O

The O
accumulated O
analogues O
from O
the O
Delta O
fosK O
and O
Delta O
fosM O
mutant O
strains O
possessed O
a O
malonyl B
ester I
moiety O
that O
suggested O
that O
all O
the O
post O
- O
PKS O
modification O
steps O
in O
FST O
biosynthesis O
occur O
with O
the O
polyketide O
chain O
bearing O
a O
malonyl B
ester I
at O
the O
C O
- O
3 O
position O
, O
with O
formation O
of O
the O
unsaturated O
six O
- O
membered O
lactone B
as O
the O
last O
step O
in O
FST B
biosynthesis O
. O

The O
accumulated O
analogues O
from O
the O
Delta O
fosK O
and O
Delta O
fosM O
mutant O
strains O
possessed O
a O
malonyl B
ester I
moiety O
that O
suggested O
that O
all O
the O
post O
- O
PKS O
modification O
steps O
in O
FST O
biosynthesis O
occur O
with O
the O
polyketide O
chain O
bearing O
a O
malonyl B
ester I
at O
the O
C O
- O
3 O
position O
, O
with O
formation O
of O
the O
unsaturated O
six O
- O
membered O
lactone B
as O
the O
last O
step O
in O
FST B
biosynthesis O
. O

The O
nonspherical O
shapes O
were O
created O
by O
stretching O
spherical O
microspheres O
on O
a O
film O
of O
polyvinyl B
alcohol I
( O
PVA B
) O
. O

The O
structural O
hierarchy O
of O
these O
collagen O
- O
based O
biomaterials O
is O
replicated O
by O
the O
infiltration O
and O
condensation O
of O
fluidic O
polymer O
- O
stabilized O
silicic B
acid I
precursors O
within O
the O
intrafibrillar O
milieu O
of O
type O
I O
collagen O
fibrils O
. O

Two O
new O
cyclic B
hexapeptides I
, O
nocardiamides B
A O
( O
1 O
) O
and O
B O
( O
2 O
) O
, O
were O
isolated O
from O
the O
culture O
broth O
of O
marine O
- O
derived O
actinomycete O
CNX037 O
strain O
that O
was O
identified O
as O
a O
Nocardiopsis O
species O
. O

The O
use O
of O
pre O
- O
treated O
material O
( O
10 O
: O
1 O
glibenclamide B
/ O
docusate B
sodium I
salt O
ratio O
spray O
- O
dried O
as O
ethanolic O
solution O
) O
resulted O
in O
a O
mean O
particle O
size O
of O
236nm O
and O
volume O
- O
based O
size O
distribution O
values O
of O
0 O
. O
131 O
mu O
m O
( O
d50 O
% O
) O
and O
0 O
. O
285 O
mu O
m O
( O
d90 O
% O
) O
. O

Our O
study O
shows O
that O
only O
the O
B O
chain O
in O
the O
presence O
of O
TCEP B
is O
converted O
into O
aggregates O
with O
morphology O
( O
according O
to O
atomic O
force O
microscopy O
) O
and O
optical O
activity O
( O
manifested O
as O
an O
extrinsic O
Cotton O
effect O
induced O
in O
bound O
thioflavin B
T I
) O
characteristic O
of O
amyloid O
superstructures O
that O
are O
normally O
formed O
by O
insulin O
in O
the O
absence O
of O
TCEP B
. O

Good O
separation O
of O
the O
mentioned O
compounds O
was O
achieved O
on O
a O
C18 O
stationary O
phase O
with O
a O
sodium B
azide I
and O
sodium B
heptane I
sulfonate I
solution O
, O
acetonitrile B
and O
water O
at O
ratio O
of O
50 O
: O
1 O
: O
49 O
( O
v O
/ O
v O
/ O
v O
) O
. O

Micellar O
nanoparticles O
were O
assembled O
from O
amphiphilic O
diblock O
copolymers O
composed O
of O
an O
ampholytic O
core O
- O
forming O
block O
and O
a O
redesigned O
polycationic O
corona O
block O
doped O
with O
thiol B
- O
reactive O
pyridyl B
disulfide I
groups O
to O
enable O
dual O
- O
delivery O
of O
antigens O
and O
immunostimulatory O
CpG B
oligodeoxynucleotide O
( O
CpG B
ODN O
) O
adjuvants O
. O

Sodium B
salts O
of O
maleamic B
acid I
derivatives O
of O
lauryl B
ester I
of O
tyrosine B
( O
MTNa O
) O
and O
phenyl B
alanine I
( O
MPNa O
) O
in O
water O
exhibited O
strong O
pH O
- O
responsive O
behaviors O
of O
viscosity O
and O
specific O
conductivity O
that O
originate O
from O
the O
concentration O
and O
pH O
dependence O
of O
their O
aggregation O
states O
. O

Sodium B
salts O
of O
maleamic B
acid I
derivatives O
of O
lauryl B
ester I
of O
tyrosine B
( O
MTNa O
) O
and O
phenyl B
alanine I
( O
MPNa O
) O
in O
water O
exhibited O
strong O
pH O
- O
responsive O
behaviors O
of O
viscosity O
and O
specific O
conductivity O
that O
originate O
from O
the O
concentration O
and O
pH O
dependence O
of O
their O
aggregation O
states O
. O

Sodium B
salts O
of O
maleamic B
acid I
derivatives O
of O
lauryl B
ester I
of O
tyrosine B
( O
MTNa O
) O
and O
phenyl B
alanine I
( O
MPNa O
) O
in O
water O
exhibited O
strong O
pH O
- O
responsive O
behaviors O
of O
viscosity O
and O
specific O
conductivity O
that O
originate O
from O
the O
concentration O
and O
pH O
dependence O
of O
their O
aggregation O
states O
. O

Discovery O
of O
aryl B
ureas I
and O
aryl B
amides I
as O
potent O
and O
selective O
histamine B
H3 O
receptor O
antagonists O
for O
the O
treatment O
of O
obesity O
( O
Part O
I O
) O
. O

Discovery O
of O
aryl B
ureas I
and O
aryl B
amides I
as O
potent O
and O
selective O
histamine B
H3 O
receptor O
antagonists O
for O
the O
treatment O
of O
obesity O
( O
Part O
I O
) O
. O

A O
series O
of O
structurally O
novel O
aryl B
ureas I
was O
derived O
from O
optimization O
of O
the O
HTS O
lead O
as O
selective O
histamine B
H3 O
receptor O
( O
H3R O
) O
antagonists O
. O

A O
new O
potential O
nano O
- O
oncological O
therapy O
based O
on O
polyamino B
acid I
nanocapsules O
. O

Herein O
, O
we O
disclose O
a O
new O
biodegradable O
nanocarrier O
, O
polyglutamic B
acid I
( O
PGA B
) O
nanocapsules O
, O
and O
present O
the O
in O
vivo O
pharmacokinetics O
/ O
toxicity O
proof O
- O
of O
- O
concept O
for O
the O
anticancer O
drug O
plitidepsin B
. O

These O
novel O
nanocapsules O
were O
prepared O
using O
a O
modified O
solvent O
displacement O
technique O
where O
the O
polyamino B
acid I
was O
electrostatically O
deposited O
onto O
the O
lipid O
core O
. O

Overall O
, O
beyond O
the O
value O
of O
this O
specific O
formulation O
, O
the O
work O
reported O
here O
represents O
the O
evidence O
of O
the O
potential O
of O
polyamino B
acid I
nanocapsules O
in O
nano O
- O
oncological O
therapy O
. O

Experimental O
animals O
were O
divided O
into O
a O
control O
group O
, O
a O
sodium B
fluoride I
- O
treated O
group O
( O
NaF B
, O
50 O
mg O
/ O
L O
) O
, O
three O
sodium B
selenite I
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
) O
, O
and O
three O
selenium B
+ O
NaF B
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
; O
NaF B
, O
50 O
mg O
/ O
L O
) O
. O

Experimental O
animals O
were O
divided O
into O
a O
control O
group O
, O
a O
sodium B
fluoride I
- O
treated O
group O
( O
NaF B
, O
50 O
mg O
/ O
L O
) O
, O
three O
sodium B
selenite I
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
) O
, O
and O
three O
selenium B
+ O
NaF B
- O
treated O
groups O
( O
Na2SeO3 B
, O
0 O
. O
375 O
, O
0 O
. O
75 O
, O
and O
1 O
. O
5 O
mg O
/ O
L O
; O
NaF B
, O
50 O
mg O
/ O
L O
) O
. O

The O
defects O
arising O
from O
SMAD4 O
depletion O
could O
not O
be O
rescued O
by O
intra O
- O
ovarian O
mediators O
of O
LH O
actions O
, O
such O
as O
EGF O
- O
like O
factors O
and O
prostaglandin B
E2 I
. O

Formation O
Mechanism O
of O
TiO B
2 I
Nanotubes O
and O
Their O
Applications O
in O
Photoelectrochemical O
Water O
Splitting O
and O
Supercapacitors O
. O

Structural O
observations O
of O
the O
transition O
of O
TiO B
2 I
nanopores O
into O
nanotubes O
by O
increasing O
the O
OH B
( I
- I
) I
concentration O
in O
the O
electrolyte O
challenge O
the O
validity O
of O
existing O
formation O
mechanisms O
of O
anodic O
TiO B
2 I
nanotubes O
. O

Structural O
observations O
of O
the O
transition O
of O
TiO B
2 I
nanopores O
into O
nanotubes O
by O
increasing O
the O
OH B
( I
- I
) I
concentration O
in O
the O
electrolyte O
challenge O
the O
validity O
of O
existing O
formation O
mechanisms O
of O
anodic O
TiO B
2 I
nanotubes O
. O

In O
this O
study O
, O
dehydration O
of O
titanium B
hydroxide I
in O
the O
cell O
wall O
is O
proposed O
as O
the O
mechanism O
that O
leads O
to O
the O
separation O
of O
neighboring O
nanotubes O
. O

Based O
on O
this O
understanding O
, O
bamboo O
- O
type O
TiO B
2 I
nanotubes O
with O
large O
surface O
area O
and O
excellent O
interconnectivity O
are O
achieved O
by O
cycling O
high O
and O
low O
applied O
potentials O
. O

After O
thermal O
treatment O
in O
a O
H B
2 I
atmosphere O
, O
the O
bamboo O
- O
type O
TiO B
2 I
nanotubes O
show O
large O
photoelectrochemical O
water O
splitting O
efficiency O
and O
supercapacitors O
performace O
. O

After O
thermal O
treatment O
in O
a O
H B
2 I
atmosphere O
, O
the O
bamboo O
- O
type O
TiO B
2 I
nanotubes O
show O
large O
photoelectrochemical O
water O
splitting O
efficiency O
and O
supercapacitors O
performace O
. O

Three O
kinds O
of O
phyllanthin B
crystals O
, O
recrystallized O
by O
petroleum B
ether I
, O
absolute O
ethanol B
and O
25 O
% O
ethanol B
solution O
, O
showed O
only O
one O
polymorph O
and O
no O
polymorphic O
impurity O
. O

Thus O
, O
the O
selective O
H2 B
gas O
permeability O
for O
TOCN O
- O
COOH B
was O
probably O
due O
to O
a O
larger O
average O
size O
in O
free O
volume O
holes O
present O
between O
nanofibrils O
in O
the O
layer O
and O
film O
than O
those O
of O
other O
TOCNs O
with O
metal B
carboxylate I
groups O
. O

The O
metabolism O
of O
nitrooxybutyl B
- I
esters I
of O
flurbiprofen B
and O
ferulic B
- I
acid I
, O
a O
class O
of O
organic O
nitrates B
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO B
donor O
( O
NOC B
- I
5 I
) O
as O
a O
reference O
tool O
. O

Comparative O
study O
on O
effects O
of O
two O
different O
types O
of O
titanium B
dioxide I
nanoparticles O
on O
human O
neuronal O
cells O
. O

Titanium B
dioxide I
( O
TiO2 B
) O
are O
among O
most O
frequently O
used O
nanoparticles O
( O
NPs O
) O
. O

In O
terms O
of O
the O
mechanisms O
, O
we O
found O
that O
fatty B
acid I
amide B
hydrolase O
( O
FAAH O
) O
which O
degrades O
anandamide B
, O
was O
upregulated O
after O
nerve O
injury O
at O
both O
ages O
, O
so O
that O
this O
upregulation O
likely O
did O
not O
account O
for O
the O
age O
- O
dependent O
differences O
. O

Recently O
, O
the O
c O
- O
Abl O
kinase O
inhibitor O
imatinib B
mesylate I
( O
imatinib B
) O
has O
become O
the O
focus O
of O
research O
as O
a O
fertoprotective O
drug O
against O
cisplatin B
. O

Use O
of O
' O
split O
waves O
' O
for O
the O
measurement O
of O
electrocatalytic O
kinetics O
: O
methyl B
viologen I
mediated O
oxygen B
reduction O
on O
a O
boron B
- O
doped O
diamond B
electrode O
. O

The O
mediated O
reduction O
of O
oxygen B
via O
the O
reduced O
form O
of O
methyl B
viologen I
is O
studied O
voltammetrically O
. O

The O
recombinant O
C B
- O
terminal O
fragment O
of O
AFP O
( O
AFP O
- O
3BC O
, O
which O
consists O
of O
amino B
acid I
residues O
473 O
- O
596 O
) O
was O
obtained O
by O
the O
expression O
in O
Escherichia O
coli O
. O

Sixty O
two O
composite O
samples O
, O
made O
up O
of O
between O
5 O
and O
12 O
sub O
- O
samples O
, O
were O
collected O
in O
2010 O
and O
were O
analysed O
for O
fatty B
acids I
, O
and O
a O
range O
of O
nutrients O
. O

The O
top O
five O
ethnic O
foods O
containing O
highest O
levels O
of O
selected O
nutrients O
were O
lamb O
balti O
( O
3mg O
/ O
100g O
iron B
) O
, O
lamb O
kebab O
( O
3 O
. O
2mg O
/ O
100g O
zinc B
) O
, O
mixed O
dhal O
( O
62 O
mu O
g O
/ O
100g O
folate B
) O
, O
fish O
curry O
( O
1 O
. O
4 O
mu O
g O
/ O
100g O
vitamin B
D I
) O
, O
ghee O
( O
968 O
mu O
g O
/ O
100g O
retinol B
) O
and O
toor O
dhal O
( O
9 O
. O
1g O
/ O
100g O
dietary O
fibre O
) O
. O

When O
compared O
to O
other O
meat O
products O
( O
beef O
, O
mutton O
and O
chicken O
) O
it O
is O
clear O
that O
pork O
is O
a O
good O
source O
of O
B B
vitamins I
, O
especially O
vitamin B
B3 I
. O

When O
compared O
to O
other O
meat O
products O
( O
beef O
, O
mutton O
and O
chicken O
) O
it O
is O
clear O
that O
pork O
is O
a O
good O
source O
of O
B B
vitamins I
, O
especially O
vitamin B
B3 I
. O

The O
cooked O
loin O
cut O
contained O
the O
least O
vitamin B
B1 I
( O
0 O
. O
22mg O
/ O
100g O
) O
, O
B2 O
( O
0 O
. O
02mg O
/ O
100g O
) O
but O
the O
most O
vitamin B
B3 I
( O
7 O
. O
09mg O
/ O
100g O
) O
, O
of O
the O
three O
cooked O
cuts O
. O

The O
cooked O
loin O
cut O
contained O
the O
least O
vitamin B
B1 I
( O
0 O
. O
22mg O
/ O
100g O
) O
, O
B2 O
( O
0 O
. O
02mg O
/ O
100g O
) O
but O
the O
most O
vitamin B
B3 I
( O
7 O
. O
09mg O
/ O
100g O
) O
, O
of O
the O
three O
cooked O
cuts O
. O

The O
100g O
cooked O
shoulder O
, O
loin O
and O
leg O
cuts O
provide O
on O
average O
40 O
. O
11 O
% O
protein O
, O
5 O
. O
19 O
% O
magnesium B
, O
3 O
. O
37 O
% O
calcium B
, O
24 O
. O
29 O
% O
phosphorus B
, O
18 O
. O
22 O
% O
zinc B
, O
22 O
. O
33 O
% O
iron B
and O
22 O
. O
50 O
% O
vitamin B
B1 I
, O
2 O
. O
57 O
% O
vitamin B
B2 I
and O
42 O
. O
6 O
% O
vitamin B
B3 I
of O
Recommended O
Daily O
Allowances O
for O
males O
, O
age O
25 O
- O
50 O
. O

The O
100g O
cooked O
shoulder O
, O
loin O
and O
leg O
cuts O
provide O
on O
average O
40 O
. O
11 O
% O
protein O
, O
5 O
. O
19 O
% O
magnesium B
, O
3 O
. O
37 O
% O
calcium B
, O
24 O
. O
29 O
% O
phosphorus B
, O
18 O
. O
22 O
% O
zinc B
, O
22 O
. O
33 O
% O
iron B
and O
22 O
. O
50 O
% O
vitamin B
B1 I
, O
2 O
. O
57 O
% O
vitamin B
B2 I
and O
42 O
. O
6 O
% O
vitamin B
B3 I
of O
Recommended O
Daily O
Allowances O
for O
males O
, O
age O
25 O
- O
50 O
. O

The O
100g O
cooked O
shoulder O
, O
loin O
and O
leg O
cuts O
provide O
on O
average O
40 O
. O
11 O
% O
protein O
, O
5 O
. O
19 O
% O
magnesium B
, O
3 O
. O
37 O
% O
calcium B
, O
24 O
. O
29 O
% O
phosphorus B
, O
18 O
. O
22 O
% O
zinc B
, O
22 O
. O
33 O
% O
iron B
and O
22 O
. O
50 O
% O
vitamin B
B1 I
, O
2 O
. O
57 O
% O
vitamin B
B2 I
and O
42 O
. O
6 O
% O
vitamin B
B3 I
of O
Recommended O
Daily O
Allowances O
for O
males O
, O
age O
25 O
- O
50 O
. O

Also O
the O
composition O
in O
fatty B
acids I
of O
triacylglycerols B
is O
very O
sensitive O
to O
the O
contents O
of O
cereals O
in O
the O
feed O
; O
for O
instance O
, O
polyunsaturated B
fatty I
acids I
may O
range O
from O
10 O
% O
to O
22 O
% O
in O
pork O
meat O
. O

Some O
bioactive O
substances O
like O
coenzyme B
Q10 I
, O
taurine B
, O
glutamine B
, O
creatine B
, O
creatinine B
, O
carnosine B
and O
anserine B
show O
a O
large O
dependence O
on O
the O
type O
of O
muscle O
. O

We O
screened O
a O
small O
collection O
of O
compounds O
and O
identified O
an O
oxygenated B
flavonoid I
derivative O
that O
inhibits O
sumoylation O
in O
vitro O
. O

Synthesis O
and O
biological O
evaluation O
of O
phosphorylated B
flavonoids I
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol B
esterase O
. O

A O
series O
of O
phosphorylated B
flavonoids I
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol B
esterase O
( O
CEase O
) O
and O
acetylcholinesterase O
( O
AChE O
) O
. O

Furthermore O
, O
these O
phosphorylated B
flavonoids I
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O

The O
structure O
- O
activity O
relationships O
revealed O
that O
the O
free O
hydroxyl B
group O
at O
position O
5 O
and O
phosphate B
group O
at O
position O
7 O
of O
the O
phosphorylated B
flavonoids I
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O

The O
nonplanar O
base O
thymine B
glycol I
in O
a O
3 O
' O
overhang O
severely O
inhibited O
cleavage O
by O
Metnase O
in O
the O
vicinity O
of O
the O
modified O
base O
, O
while O
Artemis O
was O
less O
affected O
. O

Nevertheless O
, O
thymine B
glycol I
moieties O
could O
be O
removed O
by O
Metnase O
- O
or O
Artemis O
- O
mediated O
cleavage O
at O
sites O
farther O
from O
the O
terminus O
than O
the O
lesion O
itself O
. O

Superparamagnetic O
iron B
oxide I
nanoparticles O
( O
SPIONs O
) O
show O
a O
great O
promise O
for O
a O
wide O
specter O
of O
bioapplications O
, O
due O
to O
their O
characteristic O
magnetic O
properties O
exhibited O
only O
in O
the O
presence O
of O
magnetic O
field O
. O

Their O
advantages O
in O
the O
fields O
of O
magnetic O
drug O
targeting O
and O
imaging O
are O
well O
established O
and O
their O
safety O
is O
assumed O
, O
since O
iron B
oxide I
nanoparticles O
have O
already O
been O
approved O
for O
in O
vivo O
application O
, O
however O
, O
according O
to O
many O
literature O
reports O
the O
bare O
metal O
oxide O
nanoparticles O
may O
cause O
toxic O
effects O
on O
treated O
cells O
. O

In O
the O
current O
research O
ricinoleic B
acid I
coated O
maghemite B
nanoparticles O
were O
successfully O
synthesized O
, O
characterized O
and O
incorporated O
in O
the O
polymeric O
matrix O
, O
resulting O
in O
nanosized O
magnetic O
polymeric O
particles O
. O

The O
aim O
of O
this O
work O
was O
to O
study O
the O
environment O
- O
reflecting O
short O
- O
term O
responses O
at O
different O
levels O
of O
organization O
of O
epipsammic O
diatoms O
from O
the O
R O
i O
o O
de O
la O
Plata O
estuary O
, O
Argentina O
that O
had O
been O
exposed O
to O
hexavalent B
chromium I
within O
experimental O
microcosms O
. O

MATERIALS O
AND O
METHODS O
: O
The O
effects O
of O
HEGG O
were O
assessed O
in O
melanin O
content O
assays O
in O
B16F10 O
melanoma O
cells O
compared O
with O
the O
reference O
drug O
kojic B
acid I
( O
500mM O
) O
. O

Murine O
N2A O
and O
human O
SK O
- O
N O
- O
AS O
neuroblastoma O
cells O
and O
murine O
preadipocyte O
fibroblasts O
( O
3T3 O
- O
L1 O
) O
were O
exposed O
to O
tributyltin B
( O
TBT B
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
bisphenol B
A I
( O
BPA B
) O
, O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
[ I
p I
] I
- I
dioxin I
( O
TCDD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I

Prostagrandin O
( B
PG I
) I
E2 I
production O
stimulated O
by O
arachidonic B
acid I
was O
suppressed O
by O
SAL B
- I
2 I
. O

To O
identify O
the O
bioactive O
components O
of O
X O
. O
strumarium O
, O
7 O
caffeoylquinic B
acids I
and O
3 O
phenolic B
compounds O
were O
isolated O
and O
their O
chemical O
structures O
were O
elucidated O
on O
the O
basis O
of O
spectroscopic O
evidence O
and O
comparison O
with O
published O
data O
. O

FBP B
suppressed O
the O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
but O
did O
not O
affect O
cyclooxygenase O
- O
2 O
expression O
and O
prostaglandin B
E2 I
production O
in O
endothelial O
cells O
stimulated O
with O
LPS O
. O

In O
this O
study O
, O
30 O
Wistar O
rats O
were O
randomly O
divided O
into O
three O
groups O
: O
a O
control O
group O
, O
a O
sodium B
fluoride I
( O
NaF B
) O
+ O
EGb O
group O
, O
and O
a O
NaF B
group O
. O

Facile O
Preparation O
of O
Ordered O
Porous O
Graphene B
- O
Metal B
Oxide I
@ O
C O
Binder O
- O
Free O
Electrodes O
with O
High O
Li B
Storage O
Performance O
. O

Such O
ordered O
porous O
electrodes O
demonstrate O
superior O
Li B
storage O
properties O
; O
for O
example O
, O
graphene B
- O
Fe3 B
O4 I
@ O
C O
depicts O
high O
capacities O
of O
1123 O
. O
8 O
and O
505 O
mAh O
g O
( O
- O
1 O
) O
at O
current O
densities O
of O
0 O
. O
5 O
and O
10 O
A O
g O
( O
- O
1 O
) O
, O
respectively O
. O

Total O
Synthesis O
of O
the O
Marine O
Cyclic O
Depsipeptide O
Viequeamide B
A I
. O

The O
first O
total O
synthesis O
of O
viequeamide B
A I
, O
a O
natural O
cyclic O
depsipeptide O
isolated O
from O
a O
marine O
button O
cyanobacterium O
, O
was O
achieved O
with O
the O
N B
- I
Me I
- I
Val I
- I
Thr I
peptide O
bond O
as O
the O
final O
macrocyclization O
site O
. O

Protective O
effect O
of O
ethyl B
acetate I
fraction O
of O
Acacia O
ferruginea O
DC O
. O
against O
ethanol B
- O
induced O
gastric O
ulcer O
in O
rats O
. O

RESULTS O
: O
Ethyl B
acetate I
fraction O
( O
AFE O
) O
of O
Acacia O
ferruginea O
stem O
bark O
registered O
higher O
antioxidant O
and O
free O
radical O
scavenging O
activities O
than O
the O
crude O
acetone B
extract O
and O
other O
fractions O
. O

CONCLUSION O
: O
It O
is O
concluded O
that O
the O
ethyl B
acetate I
fraction O
of O
Acacia O
ferruginea O
stem O
bark O
possessed O
higher O
antioxidant O
and O
anti O
- O
ulcerogenic O
activities O
. O

The O
phytochemical O
investigations O
showed O
the O
presence O
of O
cyclopeptid B
alkaloids I
, O
flavonoids B
( O
e O
. O
g O
. O
, O
( B
- I
) I
- I
epicatechin I
, O
quercetin B
, O
kaempferol B
, O
kaempferol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
' I
' I
- I
E I
- I
p I
- I
coumaryl I
) I
- I
glucopyranoside I
) I
, O
tannins B
, O
sterols B
, O
terpenes B
, O
saponins B
, O
anthraquinones B
. O

beta B
- I
estradiol I
17 I
- I
valerate I
( O
EV O
) O
is O
a O
synthetic O
estrogen B
widely O
used O
in O
combination O
with O
other O
steroid B
hormones I
in O
hormone O
replacement O
therapy O
drugs O
and O
is O
detected O
in O
natural O
waters O
. O

In O
this O
study O
, O
a O
novel O
series O
of O
cycloartane B
triterpenoids I
isolated O
from O
Schisandra O
glaucescens O
Diels O
was O
found O
to O
have O
ER O
antagonistic O
effect O
, O
the O
most O
potent O
antagonist O
of O
which O
exhibited O
activity O
with O
EC50 O
value O
of O
2 O
. O
55 O
and O
4 O
. O
68 O
mu O
M O
for O
ER O
alpha O
and O
ER O
beta O
, O
respectively O
. O

All O
subjects O
were O
put O
on O
continuous O
1mg O
/ O
day O
estradiol B
valerate I
orally O
and O
followed O
up O
monthly O
. O

Amphiphilic O
Polypeptides O
as O
a O
Bifunctional O
Template O
in O
the O
Mineralization O
of O
Calcium B
Carbonate I
at O
the O
Air O
/ O
Water O
Interface O
. O

Deprotection O
of O
the O
resultant O
polymers O
afforded O
poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
with O
a O
functionalizable O
pendant O
primary B
hydroxyl I
group O
. O

Physicochemical O
characterization O
of O
nimodipine B
- O
polyethylene B
glycol I
solid O
dispersion O
systems O
. O

Abstract O
This O
study O
investigates O
the O
solid O
- O
solid O
interactions O
between O
nimodipine B
( O
NIM B
) O
and O
polyethylene B
glycol I
( O
PEG B
) O
of O
different O
mean O
molecular O
weights O
( O
PEG B
2000 I
, I
4000 I
and I
6000 I
) O
, O
in O
solid O
dispersion O
systems O
, O
applying O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
Fourier O
- O
Transform O
infrared O
spectroscopy O
, O
powder O
X O
- O
ray O
diffraction O
( O
PXRD O
) O
, O
hot O
stage O
microscopy O
( O
HSM O
) O
and O
theoretical O
modeling O
by O
the O
Flory O
- O
Huggins O
( O
FH O
) O
solution O
theory O
. O

Moreover O
, O
activation O
of O
Th1 O
type O
and O
suppression O
of O
Th2 O
type O
immune O
responses O
and O
induction O
in O
nitric B
oxide I
generation O
proved O
that O
8a O
and O
8g O
induce O
murine O
macrophages O
to O
prevent O
survival O
of O
parasites O
. O

New O
trifluoromethyl B
quinolone I
derivatives O
: O
Synthesis O
and O
investigation O
of O
antimicrobial O
properties O
. O

A O
series O
of O
quinolone B
derivatives O
, O
containing O
different O
heterocyclic B
amines I
were O
prepared O
. O

Changes O
in O
the O
capacity O
of O
different O
depots O
to O
store O
and O
release O
fatty B
acids I
and O
to O
produce O
adipocytokines O
are O
important O
determinants O
of O
fat O
distribution O
and O
its O
metabolic O
consequences O
. O

Cyclic B
GMP I
- O
elevating O
agents O
are O
beneficial O
in O
PAH O
, O
but O
their O
mechanism O
( O
s O
) O
of O
action O
are O
incompletely O
understood O
. O

TRPV6 O
channels O
function O
as O
epithelial O
Ca2 B
+ I
entry O
pathways O
in O
the O
epididymis O
, O
prostate O
and O
placenta O
. O

The O
increased O
translation O
of O
the O
shorter O
TRPV6 O
cDNA O
version O
may O
overestimate O
the O
in O
vivo O
situation O
where O
translation O
efficiency O
may O
represent O
an O
additional O
mechanism O
to O
tightly O
control O
the O
TRPV6 O
- O
mediated O
Ca2 B
+ I
entry O
in O
order O
to O
prevent O
deleterious O
Ca2 B
+ I
overload O
. O

The O
increased O
translation O
of O
the O
shorter O
TRPV6 O
cDNA O
version O
may O
overestimate O
the O
in O
vivo O
situation O
where O
translation O
efficiency O
may O
represent O
an O
additional O
mechanism O
to O
tightly O
control O
the O
TRPV6 O
- O
mediated O
Ca2 B
+ I
entry O
in O
order O
to O
prevent O
deleterious O
Ca2 B
+ I
overload O
. O

One O
- O
Pot O
in O
Situ O
Mixed O
Film O
Formation O
by O
Azo B
Coupling O
and O
Diazonium B
Salt I
Electrografting O
. O

So O
simple O
: O
The O
in O
situ O
synthesis O
of O
an O
aryldiazonium B
salt I
and O
an O
azo B
- I
aryldiazonium I
salt I
by O
azo B
coupling O
from O
sulfanilic B
acid I
and O
aniline B
is O
reported O
. O

So O
simple O
: O
The O
in O
situ O
synthesis O
of O
an O
aryldiazonium B
salt I
and O
an O
azo B
- I
aryldiazonium I
salt I
by O
azo B
coupling O
from O
sulfanilic B
acid I
and O
aniline B
is O
reported O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
from O
Isodon O
japonica O
var O
. O
glaucocalyx O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Total O
blood O
count O
, O
blood O
indices O
of O
creatine B
kinase O
( O
CK O
) O
, O
gamma O
- O
glutamyltranspeptida O
( O
gamma O
- O
GT O
) O
, O
superoxide B
dismutase O
( O
SOD O
) O
, O
nitric B
oxide I
( O
NO B
) O
, O
malondialdehyde B
( O
MDA B
) O
, O
interleukin O
( O
IL O
) O
- O
2 O
, O
tumor O
necrosis O
factors O
( O
TNF O
) O
alpha O
, O
alpha O
- O
fetoprotein O
( O
AFP O
) O
, O
carbohydrate B
antigen O
( O
CA O
) O
19 O
. O
9 O
and O
carcinoembrionic O
antigen O
( O
CEA O
) O
were O
assayed O

Vitamin B
C I
forestalls O
cigarette O
smoke O
induced O
NF O
- O
kappa O
B O
activation O
in O
alveolar O
epithelial O
cells O
. O

It O
is O
possible O
that O
vitamin B
C I
, O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
( O
CS O
) O
- O
induced O
NF O
- O
kappa O
B O
activation O
that O
involves O
degradation O
of O
I O
- O
kappa O
B O
epsilon O
and O
nuclear O
translocation O
of O
c O
- O
Rel O
/ O
p50 O
in O
alveolar O
epithelial O
cells O
. O

Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin B
C I
on O
CS O
- O
induced O
expression O
of O
NF O
- O
kappa O
B O
driven O
luciferase O
reporter O
and O
NF O
- O
kappa O
B O
binding O
at O
its O
target O
DNA O
by O
EMSA O
in O
alveolar O
epithelial O
A549 O
cells O
. O

We O
also O
examined O
the O
level O
of O
I O
- O
kappa O
B O
epsilon O
and O
sub O
- O
cellular O
distribution O
of O
c O
- O
Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE O
- O
treated O
A549 O
cells O
with O
or O
without O
vitamin B
C I
pretreatment O
. O

We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF O
- O
kappa O
B O
DNA O
binding O
, O
I O
- O
kappa O
B O
epsilon O
degradation O
and O
c O
- O
Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin B
C I
. O

To O
further O
validate O
the O
result O
, O
we O
examined O
sub O
- O
cellular O
distribution O
of O
c O
- O
Rel O
in O
lungs O
of O
CS O
- O
exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin B
C I
. O

Result O
showed O
that O
vitamin B
C I
treatment O
resulted O
in O
markedly O
reduced O
c O
- O
Rel O
nuclear O
translocation O
. O

All O
these O
results O
demonstrate O
that O
vitamin B
C I
prevents O
CS O
( O
E O
) O
- O
induced O
NF O
- O
kappa O
B O
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS O
- O
induced O
inflammatory O
diseases O
. O

Furthermore O
, O
HPLC O
analysis O
was O
performed O
for O
the O
estimation O
of O
gallic B
acid I
, O
ellagic B
acid I
, O
tannins B
and O
flavonols B
as O
marker O
compounds O
. O

Furthermore O
, O
HPLC O
analysis O
was O
performed O
for O
the O
estimation O
of O
gallic B
acid I
, O
ellagic B
acid I
, O
tannins B
and O
flavonols B
as O
marker O
compounds O
. O

Whereas O
Helianthemum O
alypoides O
, O
Helianthemum O
cinereum O
subsp O
. O
rotundifolium O
, O
Helianthemum O
hirtum O
, O
Helianthemum O
asperum O
, O
and O
Helianthemum O
marifolium O
subsp O
. O
marifolium O
were O
characterized O
by O
the O
presence O
of O
gallic B
acid I
, O
egallic B
derivatives O
and O
ellagitannins O
; O
the O
polyphenolic O
profile O
of O
Helianthemum O
apenninum O
subsp O
. O
cavanillesianum O
, O
Helianthemum O
syriacum O
and O
Helianthemum O
polygonoides O
was O
mostly O
based O
on O

Locked O
nucleic O
acid O
( O
LNA O
) O
is O
a O
chemical O
modification O
which O
introduces O
a O
- O
O B
- I
CH2 I
- O
linkage O
in O
the O
furanose B
sugar I
of O
nucleic O
acids O
and O
blocks O
its O
conformation O
in O
a O
particular O
state O
. O

Boronated B
carbohydrate I
derivatives O
as O
potential O
boron B
neutron O
capture O
therapy O
reagents O
. O

Among O
the O
types O
of O
boron B
- O
containing O
molecules O
used O
as O
boron B
neutron O
capture O
therapy O
agents O
, O
boronated B
carbohydrate I
derivatives O
have O
received O
significant O
attention O
because O
of O
their O
preferential O
uptake O
by O
growing O
tumor O
cells O
. O

We O
recently O
reported O
that O
dispersing O
citrate B
- O
capped O
gold O
nanoparticles O
( O
AuNPs B
) O
in O
polymers O
such O
as O
polyethylene B
glycol I
( O
PEG B
) O
can O
achieve O
such O
a O
goal O
due O
to O
contributions O
from O
depletion O
stabilization O
. O

The O
LPS O
molecule O
consists O
of O
lipid B
A I
, O
which O
anchors O
the O
LPS O
within O
the O
OM O
, O
a O
core O
polysaccharide O
region O
and O
a O
variable O
O O
- O
antigen O
polysaccharide O
chain O
. O

In O
this O
work O
we O
used O
RcLPS O
( O
consisting O
of O
lipid B
A I
plus O
the O
first O
seven O
sugars B
of O
the O
core O
polysaccharide O
) O
from O
a O
rough O
strain O
of O
E O
. O
coli O
to O
form O
stable O
monolayers O
of O
LPS O
at O
the O
air O
- O
liquid O
interface O
. O

This O
is O
in O
contrast O
to O
lipid B
A I
which O
displays O
hexagonal O
or O
, O
above O
20 O
mN O
m O
( O
- O
1 O
) O
, O
distorted O
hexagonal O
packing O
. O

Probing O
the O
Role O
of O
the O
Vancomycin B
E O
- O
Ring O
Aryl B
Chloride I
: O
Selective O
Divergent O
Synthesis O
and O
Evaluation O
of O
Alternatively O
Substituted O
E O
- O
Ring O
Analogues O
. O

The O
selective O
functionalization O
of O
a O
vancomycin B
aglycon O
derivative O
through O
direct O
conversion O
of O
the O
E O
- O
ring O
aryl B
chloride I
to O
a O
reactive O
boronic B
acid I
, O
and O
its O
use O
in O
the O
synthesis O
of O
a O
systematic O
series O
of O
vancomycin B
E O
- O
ring O
analogues O
are O
described O
. O

The O
selective O
functionalization O
of O
a O
vancomycin B
aglycon O
derivative O
through O
direct O
conversion O
of O
the O
E O
- O
ring O
aryl B
chloride I
to O
a O
reactive O
boronic B
acid I
, O
and O
its O
use O
in O
the O
synthesis O
of O
a O
systematic O
series O
of O
vancomycin B
E O
- O
ring O
analogues O
are O
described O
. O

Interestingly O
the O
application O
of O
lithium B
chloride I
, O
a O
GSK O
- O
3 O
beta O
inhibitor O
, O
reversed O
the O
suppressive O
effect O
of O
TCDD B
on O
beta O
- O
catenin O
in O
PC12 O
cells O
and O
primary O
cortical O
neurons O
restoring O
cell O
viability O
and O
protecting O
cells O
from O
apoptosis O
as O
compared O
to O
untreated O
controls O
. O

Tandutinib B
reversed O
ABCG2 O
- O
mediated O
drug O
resistance O
in O
ABCG2 O
- O
482 O
- O
R2 O
, O
ABCG2 O
- O
482 O
- O
G2 O
, O
ABCG2 O
- O
482 O
- O
T7 O
and O
S1 O
- O
M1 O
- O
80 O
cells O
and O
increased O
the O
accumulation O
of O
doxorubicin B
, O
rhodamine B
123 I
and O
[ B
H I
( I
3 I
) I
] I
mitoxantrone I
in O
ABCG2 O
- O
overexpressing O
cells O
. O

To O
extend O
light O
transmission O
beyond O
lambda O
= O
3 O
. O
7 O
mu O
m O
, O
a O
spectral O
region O
where O
a O
typical O
silicon B
dioxide I
under O
- O
clad O
is O
absorbing O
, O
we O
fabricate O
a O
unique O
air O
- O
clad O
silicon B
pedestal O
waveguide O
. O

For O
instance O
, O
we O
show O
that O
when O
testing O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
can O
distinguish O
hexane B
from O
the O
rest O
of O
the O
tested O
analytes O
( O
methanol B
, O
toluene B
, O
carbon B
tetrachloride I
, O
ethanol B
and O
acetone B
) O
, O
since O
hexane B
has O
a O
strong O
absorption O
from O
the O
aliphatic O
C B
- I
H I
stretch O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
. O

Analogously O
, O
applying O
the O
same O
technique O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
is O
able O
to O
determine O
the O
concentration O
of O
toluene B
dissolved O
in O
carbon B
tetrachloride I
, O
because O
toluene B
has O
a O
strong O
absorption O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
from O
the O
aromatic O
C B
- I
H I
stretch O
. O

We O
apply O
highly O
porous O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
microparticles O
and O
functionalize O
them O
introducing O
both O
sugar B
ligands O
for O
specific O
bacteria O
targeting O
and O
cationic O
moieties O
for O
electrostatic O
loading O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
. O

Insertion O
of O
CO2 B
and O
COS B
into O
Bi B
- I
C I
Bonds O
: O
Reactivity O
of O
a O
Bismuth B
NCN I
Pincer O
Complex O
of O
an O
Oxyaryl B
Dianionic O
Ligand O
, O
[ B
2 I
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] I
Bi I
( I
C6H2tBu2O I
) I
. O

Silyl B
halides I
and O
pseudohalides B
, O
R3SiX B
( O
X O
= O
Cl B
, O
CN B
, O
N3 B
; O
R O
= O
Me B
, O
Ph B
) O
, O
react O
with O
1 O
by O
attaching O
X O
to O
bismuth B
and O
R3Si B
to O
the O
oxyaryl B
oxygen B
to O
form O
Ar B
' I
Bi I
( I
X I
) I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
OSiR3 I
- I
4 I
) I
complexes O
, O
a O
formal O
addition O
across O
five O
bonds O
. O

Evaluation O
of O
Chlorpheniramine B
Maleate I
microparticles O
in O
orally O
disintegrating O
film O
and O
orally O
disintegrating O
tablet O
for O
pediatrics O
. O

Abstract O
Objective O
: O
To O
mask O
the O
bitterness O
of O
Chlorpheniramine B
Maleate I
via O
encapsulating O
drug O
into O
Eudragit B
EPO I
microparticles O
, O
and O
then O
incorporate O
these O
microparticles O
into O
orally O
disintegrating O
films O
( O
ODF O
) O
and O
orally O
disintegrating O
tablets O
( O
ODT O
) O
for O
pediatric O
uses O
. O

Abstract O
Objective O
: O
To O
mask O
the O
bitterness O
of O
Chlorpheniramine B
Maleate I
via O
encapsulating O
drug O
into O
Eudragit B
EPO I
microparticles O
, O
and O
then O
incorporate O
these O
microparticles O
into O
orally O
disintegrating O
films O
( O
ODF O
) O
and O
orally O
disintegrating O
tablets O
( O
ODT O
) O
for O
pediatric O
uses O
. O

Methods O
: O
Spray O
drying O
of O
water O
- O
in O
- O
oil O
emulsion O
was O
utilized O
to O
encapsulate O
Chlorpheniramine B
Maleate I
into O
Eudragit B
EPO I
microparticles O
. O

Methods O
: O
Spray O
drying O
of O
water O
- O
in O
- O
oil O
emulsion O
was O
utilized O
to O
encapsulate O
Chlorpheniramine B
Maleate I
into O
Eudragit B
EPO I
microparticles O
. O

Conclusion O
: O
Both O
ODF O
and O
ODT O
are O
shown O
to O
be O
suitable O
vehicles O
for O
taste O
masked O
Chlorpheniramine B
Maleate I
microparticles O
with O
potential O
for O
pediatric O
uses O
. O

Abstract O
The O
conservative O
single O
- O
layered O
wound O
dressing O
system O
is O
decomposed O
when O
mixed O
in O
polyvinyl B
alcohol I
( O
PVA B
) O
solution O
, O
which O
means O
it O
cannot O
be O
used O
with O
a O
temperature O
- O
sensitive O
drug O
. O

The O
double O
- O
layered O
wound O
dressing O
was O
developed O
with O
PVA B
/ O
sodium B
alginate I
using O
a O
freeze O
- O
melting O
technique O
; O
one O
layer O
was O
PVA B
layer O
and O
the O
other O
was O
the O
drug O
- O
loaded O
sodium B
alginate I
layer O
. O

The O
double O
- O
layered O
wound O
dressing O
was O
developed O
with O
PVA B
/ O
sodium B
alginate I
using O
a O
freeze O
- O
melting O
technique O
; O
one O
layer O
was O
PVA B
layer O
and O
the O
other O
was O
the O
drug O
- O
loaded O
sodium B
alginate I
layer O
. O

The O
double O
- O
layered O
wound O
dressing O
gave O
a O
similar O
gel O
fraction O
and O
Young O
' O
s O
module O
as O
single O
- O
layered O
wound O
bandages O
developed O
with O
only O
PVA B
, O
and O
a O
similar O
inflammation O
ability O
and O
WVTR O
as O
single O
- O
layered O
wound O
dressings O
developed O
with O
PVA B
and O
sodium B
alginate I
. O

Compared O
to O
the O
commercial O
product O
, O
the O
double O
- O
layered O
wound O
dressing O
comprising O
6 O
. O
7 O
% O
PVA B
, O
0 O
. O
5 O
% O
sodium B
alginate I
and O
0 O
. O
01 O
% O
AME O
significantly O
enhanced O
the O
wound O
- O
healing O
effect O
in O
the O
wound O
- O
healing O
test O
. O

Nine O
new O
triterpene B
derivatives O
, O
yunnanterpenes B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
15 B
, I
16 I
- I
seco I
- I
cimiterpenes I
A I
and I
B I
( O
7 O
, O
8 O
) O
, O
and O
cimilactone B
C I
( O
9 O
) O
, O
and O
15 O
known O
analogues O
( O
10 O
- O
24 O
) O
were O
isolated O
from O
the O
aerial O
parts O
of O
Cimicifuga O
yunnanensis O
. O

Cytotoxic O
Bisbenzylisoquinolin B
Alkaloids I
from O
Stephania O
epigaea O
. O

Six O
new O
bisbenzylisoquinolin B
alkaloids I
( O
1 O
- O
6 O
) O
and O
seven O
known O
compounds O
( O
8 O
- O
14 O
) O
were O
isolated O
from O
the O
tubers O
of O
Stephania O
epigaea O
, O
in O
addition O
to O
the O
major O
alkaloid O
, O
cepharanthine B
( O
7 O
) O
. O

Compounds O
1 O
- O
6 O
belong O
to O
the O
oxyacanthine B
type O
of O
bisbenzylisoquinolin B
alkaloids I
and O
have O
a O
rare O
methylenedioxy B
substituent O
. O

Compound O
1 O
, O
a O
dimer O
composed O
of O
benzylisoquinoline B
and O
seco B
- I
aristolactam I
units O
, O
represents O
a O
new O
type O
of O
bisbenzylisoquinolin B
alkaloid I
, O
while O
compounds O
3 O
- O
6 O
are O
bisbenzylisoquinolin B
N I
- I
oxides I
. O

Melanogenesis O
inhibitory O
daphnane B
diterpenoids I
from O
the O
flower O
buds O
of O
Daphne O
genkwa O
. O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes B
, O
yuanhuacine B
( O
3 O
) O
, O
yuanhuadine B
( O
4 O
) O
, O
yuanhuahine B
( O
5 O
) O
, O
genkwadaphnin B
( O
6 O
) O
, O
genkwanine B
A I
( O
7 O
) O
, O
genkwanine B
F I
( O
8 O
) O
, O
and O
genkwanine B
H I
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes B
, O
yuanhuacine B
( O
3 O
) O
, O
yuanhuadine B
( O
4 O
) O
, O
yuanhuahine B
( O
5 O
) O
, O
genkwadaphnin B
( O
6 O
) O
, O
genkwanine B
A I
( O
7 O
) O
, O
genkwanine B
F I
( O
8 O
) O
, O
and O
genkwanine B
H I
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Two O
new O
daphnane O
- O
type O
diterpene O
esters O
, O
daphneresiniferins B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
along O
with O
seven O
known O
diterpenes B
, O
yuanhuacine B
( O
3 O
) O
, O
yuanhuadine B
( O
4 O
) O
, O
yuanhuahine B
( O
5 O
) O
, O
genkwadaphnin B
( O
6 O
) O
, O
genkwanine B
A I
( O
7 O
) O
, O
genkwanine B
F I
( O
8 O
) O
, O
and O
genkwanine B
H I
( O
9 O
) O
, O
were O
isolated O
from O
the O
methanol B
extract O
of O
the O
flower O
buds O
of O
Daphne O
genkwa O

Amino B
acid I
sequences O
of O
cynomolgus O
FMO1 O
- O
5 O
, O
respectively O
, O
shared O
high O
sequence O
identities O
( O
94 O
- O
98 O
% O
) O
and O
were O
closely O
clustered O
in O
a O
phylogenetic O
tree O
, O
with O
human O
FMO1 O
- O
5 O
. O

Structural O
requirements O
within O
protoporphyrin B
IX I
in O
the O
inhibition O
of O
heat O
shock O
protein O
90 O
. O

This O
study O
investigated O
the O
structural O
requirements O
within O
protoporphyrin B
IX I
( O
PPIX B
) O
for O
the O
inhibition O
of O
HSP90 O
activity O
. O

In O
silico O
analysis O
, O
molecular O
docking O
model O
indicated O
that O
a O
tetrapyrrole B
macrocycle I
and O
two O
propionate B
chains O
within O
PPIX B
are O
necessary O
for O
the O
binding O
to O
the O
adenosine B
triphosphate I
( O
ATP B
) O
- O
binding O
pocket O
of O
HSP90 O
. O

In O
silico O
analysis O
, O
molecular O
docking O
model O
indicated O
that O
a O
tetrapyrrole B
macrocycle I
and O
two O
propionate B
chains O
within O
PPIX B
are O
necessary O
for O
the O
binding O
to O
the O
adenosine B
triphosphate I
( O
ATP B
) O
- O
binding O
pocket O
of O
HSP90 O
. O

The O
predicted O
structural O
requirement O
was O
verified O
by O
the O
differential O
inhibitory O
effects O
of O
PPIX B
analogs O
, O
or O
the O
precursor O
of O
PPIX B
, O
on O
HIF O
- O
1 O
alpha O
; O
compounds O
lacking O
either O
the O
tetrapyrrole B
macrocycle I
or O
the O
propionate B
chains O
were O
inactive O
. O

Our O
results O
show O
that O
a O
tetrapyrrole B
macrocycle I
and O
two O
attached O
propionate B
chains O
in O
PPIX B
coordinately O
interact O
with O
the O
ATP B
- O
binding O
pocket O
of O
HSP90 O
, O
offering O
structural O
information O
on O
the O
inhibitory O
effect O
of O
porphyrins O
on O
angiogenesis O
. O

Oxidative O
damage O
induced O
by O
chlorpyrifos B
in O
the O
hepatic O
and O
renal O
tissue O
of O
Kunming O
mice O
and O
the O
antioxidant O
role O
of O
vitamin B
E I
. O

Chlorpyrifos B
is O
a O
broad O
- O
spectrum O
, O
chlorinated B
organophosphate I
pesticide O
employed O
for O
pest O
control O
in O
various O
agricultural O
and O
animal O
husbandries O
. O

We O
investigated O
neurotoxicity O
of O
CPF B
- O
treated O
mice O
, O
and O
evaluated O
the O
antioxidant O
effect O
of O
vitamin B
E I
against O
oxidative O
stress O
and O
histological O
changes O
in O
the O
livers O
and O
kidneys O
of O
CPF B
- O
treated O
mice O
. O

Kunming O
mice O
were O
divided O
randomly O
into O
five O
exposure O
groups O
of O
six O
: O
( O
A O
) O
peanut O
oil O
; O
( O
B O
) O
3mg O
/ O
kg O
CPF B
; O
( O
C O
) O
6mg O
/ O
kg O
CPF B
; O
( O
D O
) O
12mg O
/ O
kg O
CPF B
; O
( O
E O
) O
vitamin B
E I
( O
100mg O
/ O
kg O
) O
, O
3h O
after O
administration O
of O
CPF B
( O
12mg O
/ O
kg O
) O
and O
used O
as O
a O
post O
- O
treatment O
group O
. O

Except O
for O
AChE O
activity O
levels O
, O
administration O
of O
vitamin B
E I
to O
CPF B
- O
treated O
mice O
restored O
these O
biochemical O
parameters O
to O
within O
normal O
levels O
, O
and O
resulted O
in O
overall O
improvement O
in O
damage O
to O
livers O
and O
kidneys O
. O

These O
data O
suggest O
that O
oxidative O
stress O
is O
involved O
in O
CPF B
- O
induced O
toxicity O
and O
that O
vitamin B
E I
can O
protect O
against O
the O
tissue O
damage O
induced O
by O
CPF B
. O

At O
present O
, O
there O
are O
three O
types O
of O
non O
- O
calcium B
- O
based O
phosphate O
binders O
available O
: O
sevelamer B
, O
lanthanum B
carbonate I
and O
magnesium B
salts O
. O

In O
contrast O
, O
lanthanum B
carbonate I
and O
magnesium B
salts O
are O
absorbed O
in O
the O
gut O
and O
their O
route O
of O
excretion O
is O
biliary O
for O
lanthanum B
and O
urinary O
for O
magnesium B
. O

Store O
- O
operated O
Ca2 B
+ I
Entry O
( O
SOCE O
) O
Induced O
by O
Protease O
- O
activated O
Receptor O
- O
1 O
mediates O
STIM1 O
Phosphorylation O
to O
inhibit O
SOCE O
in O
Endothelial O
Cells O
through O
AMP B
- O
activated O
Protein O
Kinase O
and O
p38beta O
Mitogen O
- O
activated O
Protein O
Kinase O
. O

The O
Ca2 B
+ I
sensor O
STIM1 O
is O
crucial O
for O
activation O
of O
store O
- O
operated O
Ca2 B
+ I
entry O
( O
SOCE O
) O
through O
TRPC O
and O
Orai O
channels O
. O

The O
Ca2 B
+ I
sensor O
STIM1 O
is O
crucial O
for O
activation O
of O
store O
- O
operated O
Ca2 B
+ I
entry O
( O
SOCE O
) O
through O
TRPC O
and O
Orai O
channels O
. O

Activation O
of O
AMPK O
using O
AICAR B
resulted O
in O
STIM1 O
phosphorylation O
on O
serine B
residues O
and O
prevented O
PAR O
- O
1 O
- O
induced O
Ca2 B
+ I
entry O
. O

Interestingly O
, O
SB203580 B
, O
a O
selective O
inhibitor O
of O
p38 O
MAPK O
, O
blocked O
STIM1 O
phosphorylation O
and O
led O
to O
sustained O
STIM1 O
- O
puncta O
formation O
and O
Ca2 B
+ I
entry O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
design O
novel O
pentablock O
copolymers O
( O
polylatide B
- O
polycaprolactone B
- O
polyethylene B
glycol I
- O
polycaprolactone B
- O
polylatide B
) O
( O
PLA B
- O
PCL B
- O
PEG B
- O
PCL B
- O
PLA B
) O
to O
prepare O
nanoparticle O
formulations O
which O
provide O
continuous O
delivery O
of O
steroids B
over O
a O
longer O
duration O
with O
minimal O
burst O
effect O
. O

Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly B
( I
L I
- I
lactide I
) I
( O
PLLA B
) O
or O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA B
) O
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone B
acetonide I
( O
selected O
as O
model O
drug O
) O
from O
nanoparticles O
. O

Release O
of O
triamcinolone B
acetonide I
from O
nanoparticles O
was O
significantly O
affected O
by O
crystallinity O
of O
the O
copolymers O
. O

Burst O
release O
of O
triamcinolone B
acetonide I
from O
nanoparticles O
was O
significantly O
minimized O
with O
incorporation O
of O
proper O
ratio O
of O
PDLLA B
in O
the O
existing O
triblock O
( O
PCL B
- O
PEG B
- O
PCL B
) O
copolymer O
. O

Moreover O
, O
pentablock O
copolymer O
based O
nanoparticles O
exhibited O
continuous O
release O
of O
triamcinolone B
acetonide I
. O

Bischler O
- O
Napieralski O
conditions O
were O
employed O
in O
the O
key O
step O
for O
the O
conversion O
of O
acyclic B
amides I
to O
the O
corresponding O
tetrahydroisoquinoli B
containing O
analogs O
. O

The O
synthetic O
APF O
provided O
a O
platform O
to O
study O
amino B
acid I
modifications O
and O
their O
effect O
on O
APF O
activity O
, O
based O
on O
which O
a O
structure O
- O
activity O
relationship O
( O
SAR O
) O
for O
APF O
activity O
was O
previously O
proposed O
. O

APF O
activity O
correlates O
with O
hydrophobic O
clustering O
associated O
with O
amino B
acids I
4A O
, O
6V O
and O
8V O
. O

Results O
showed O
that O
PPF B
supported O
similar O
cell O
metabolic O
activities O
of O
hMSC O
, O
L929 O
, O
MC3T3 O
, O
and O
cMSC O
compared O
to O
the O
noncytotoxic O
control O
, O
high O
- O
density O
polyethylene B
( O
HDPE O
) O
and O
were O
statistically O
different O
than O
those O
cultured O
with O
the O
cytotoxic O
control O
, O
a O
polyurethane B
film O
containing O
0 O
. O
1 O
% O
zinc B
diethyldithiocarbama I
( O
ZCF B
) O
. O

Inducible O
nitric B
oxide I
synthase O
( O
iNOS O
) O
mRNA O
and O
protein O
levels O
at O
6h O
were O
significantly O
lower O
in O
lpr O
mice O
, O
which O
correlated O
with O
reduced O
nitrotyrosine B
staining O
. O

Earlier O
, O
we O
reported O
that O
quinoa O
( O
Chenopodium O
quinoa O
Willd O
. O
) O
, O
a O
facultative O
C3 O
halophyte O
species O
, O
can O
efficiently O
control O
the O
activity O
of O
slow O
( O
SV O
) O
and O
fast O
( O
FV O
) O
tonoplast O
channels O
to O
match O
specific O
growth O
conditions O
by O
ensuring O
that O
most O
of O
accumulated O
Na B
+ I
is O
safely O
locked O
in O
the O
vacuole O
( O
Bonales O
- O
Alatorre O
et O
al O
. O
( O
2013 O
) O
Plant O
Physiology O
) O
. O

These O
include O
: O
( O
i O
) O
a O
higher O
rate O
of O
Na B
+ I
exclusion O
from O
leaf O
mesophyll O
; O
( O
ii O
) O
maintenance O
of O
low O
cytosolic O
Na B
+ I
levels O
; O
( O
iii O
) O
better O
K B
+ I
retention O
in O
the O
leaf O
mesophyll O
; O
( O
iv O
) O
a O
high O
rate O
of O
H B
+ I
pumping O
, O
which O
increases O
the O
ability O
of O
mesophyll O
cells O
to O
restore O
their O
membrane O
potential O
; O
and O
( O
v O
) O
the O
ability O
to O
reduce O
the O
activity O
of O
SV O
and O
FV O
channels O
under O
saline O
conditions O
. O

These O
include O
: O
( O
i O
) O
a O
higher O
rate O
of O
Na B
+ I
exclusion O
from O
leaf O
mesophyll O
; O
( O
ii O
) O
maintenance O
of O
low O
cytosolic O
Na B
+ I
levels O
; O
( O
iii O
) O
better O
K B
+ I
retention O
in O
the O
leaf O
mesophyll O
; O
( O
iv O
) O
a O
high O
rate O
of O
H B
+ I
pumping O
, O
which O
increases O
the O
ability O
of O
mesophyll O
cells O
to O
restore O
their O
membrane O
potential O
; O
and O
( O
v O
) O
the O
ability O
to O
reduce O
the O
activity O
of O
SV O
and O
FV O
channels O
under O
saline O
conditions O
. O

These O
include O
: O
( O
i O
) O
a O
higher O
rate O
of O
Na B
+ I
exclusion O
from O
leaf O
mesophyll O
; O
( O
ii O
) O
maintenance O
of O
low O
cytosolic O
Na B
+ I
levels O
; O
( O
iii O
) O
better O
K B
+ I
retention O
in O
the O
leaf O
mesophyll O
; O
( O
iv O
) O
a O
high O
rate O
of O
H B
+ I
pumping O
, O
which O
increases O
the O
ability O
of O
mesophyll O
cells O
to O
restore O
their O
membrane O
potential O
; O
and O
( O
v O
) O
the O
ability O
to O
reduce O
the O
activity O
of O
SV O
and O
FV O
channels O
under O
saline O
conditions O
. O

These O
include O
: O
( O
i O
) O
a O
higher O
rate O
of O
Na B
+ I
exclusion O
from O
leaf O
mesophyll O
; O
( O
ii O
) O
maintenance O
of O
low O
cytosolic O
Na B
+ I
levels O
; O
( O
iii O
) O
better O
K B
+ I
retention O
in O
the O
leaf O
mesophyll O
; O
( O
iv O
) O
a O
high O
rate O
of O
H B
+ I
pumping O
, O
which O
increases O
the O
ability O
of O
mesophyll O
cells O
to O
restore O
their O
membrane O
potential O
; O
and O
( O
v O
) O
the O
ability O
to O
reduce O
the O
activity O
of O
SV O
and O
FV O
channels O
under O
saline O
conditions O
. O

In O
vivo O
FT O
- O
Raman O
spectroscopy O
reveals O
the O
presence O
of O
H2O2 B
, O
methionine B
sulfoxide I
, O
and O
tryptophan B
metabolites O
; O
i O
. O
e O
. O
, O
N B
- I
formylkynurenine I
and O
kynurenine B
, O
implying O
Fenton O
chemistry O
in O
the O
cascade O
( O
n O
= O
10 O
) O
. O

Taken O
together O
, O
our O
contribution O
strongly O
supports O
H2O2 B
/ O
ONOO B
- I
mediated O
stress O
in O
the O
pathogenesis O
of O
SSV O
. O

New O
series O
of O
pyrrolidine B
mercaptosulfide I
, O
2 B
- I
mercaptocyclopentane I
arylsulfonamide I
, O
and O
3 B
- I
mercapto I
- I
4 I
- I
arylsulfonamido I
pyrrolidine I
matrix O
metalloproteinase O
inhibitors O
( O
MMPIs O
) O
were O
designed O
, O
synthesized O
, O
and O
evaluated O
. O

Three O
peptides O
, O
in O
which O
the O
catalytic O
triad O
residues O
were O
arranged O
in O
different O
orders O
along O
the O
strand O
, O
were O
generated O
to O
reveal O
potential O
differences O
in O
interactions O
with O
paraoxon B
as O
a O
function O
of O
the O
order O
of O
these O
amino B
acids I
. O

One O
additional O
peptide O
with O
amino B
acids I
introduced O
in O
random O
order O
was O
studied O
to O
highlight O
the O
contribution O
of O
the O
beta O
- O
sheet O
secondary O
structure O
to O
any O
interactions O
with O
paraoxon B
. O

Langmuir O
isotherms O
, O
Brewster O
angle O
microscope O
at O
interfaces O
and O
circular O
dichroism O
measurements O
in O
bulk O
showed O
that O
both O
the O
beta O
- O
sheet O
conformation O
and O
the O
order O
of O
the O
amino B
acids I
along O
the O
strand O
influenced O
the O
interactions O
of O
paraoxon B
with O
the O
peptides O
. O

Secondary B
aminopentene I
cyclizations O
require O
a O
primary B
amine I
( O
1 O
- O
2 O
equiv O
vs O
catalyst O
) O
. O

Secondary B
aminopentene I
cyclizations O
require O
a O
primary B
amine I
( O
1 O
- O
2 O
equiv O
vs O
catalyst O
) O
. O

Aminoalkenes B
are O
unchanged O
in O
the O
presence O
of O
a O
zirconium B
monoamido I
complex O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
2 I
} I
Zr I
( I
NMe2 I
) I
Cl I
or O
a O
cyclopentadienylmono B
( I
oxazolinyl I
) I
borato I
zirconium I
diamide I
{ B
Ph2B I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
} I
Zr I
( I
NMe2 I
) I
2 I
. O

Herein O
, O
we O
investigate O
the O
effect O
of O
CP B
- I
778 I
875 I
on O
the O
pharmacokinetics O
of O
atorvastatin B
acid I
and O
its O
metabolites O
in O
humans O
. O

Chromatographic O
separation O
was O
performed O
on O
an O
Acquity O
UPLC O
with O
Agela O
C18 O
column O
, O
and O
the O
solvents O
of O
5 O
mM O
ammonium B
acetate I
( O
pH O
7 O
. O
8 O
) O
- O
acetonitrile B
( O
65 O
: O
35 O
, O
v O
/ O
v O
) O
were O
used O
as O
mobile O
phase O
for O
elution O
. O

An O
investigation O
of O
the O
effect O
of O
thiamine B
pyrophosphate I
on O
cisplatin B
- O
induced O
oxidative O
stress O
and O
DNA O
damage O
in O
rat O
brain O
tissue O
compared O
with O
thiamine B
: O
Thiamine B
and O
thiamine B
pyrophosphate I
effects O
on O
cisplatin B
neurotoxicity O
. O

An O
investigation O
of O
the O
effect O
of O
thiamine B
pyrophosphate I
on O
cisplatin B
- O
induced O
oxidative O
stress O
and O
DNA O
damage O
in O
rat O
brain O
tissue O
compared O
with O
thiamine B
: O
Thiamine B
and O
thiamine B
pyrophosphate I
effects O
on O
cisplatin B
neurotoxicity O
. O

This O
study O
investigated O
the O
effects O
of O
thiamine B
pyrophosphate I
( O
TPP B
) O
at O
dosages O
of O
10 O
and O
20 O
mg O
/ O
kg O
on O
oxidative O
stress O
induced O
in O
rat O
brain O
tissue O
with O
cisplatin B
and O
compared O
this O
with O
thiamine B
. O

In O
addition O
, O
the O
level O
of O
8 B
- I
Gua I
( O
guanine B
) O
, O
a O
product O
of O
DNA O
damage O
, O
was O
1 O
. O
7 O
+ O
/ O
- O
0 O
. O
12 O
8 B
- I
hydroxyl I
guanine I
( O
8 B
- I
OH I
Gua I
) O
/ O
105 O
Gua B
in O
brain O
tissue O
in O
the O
control O
group O
receiving O
cisplatin B
, O
compared O
with O
0 O
. O
97 O
+ O
/ O
- O
0 O
. O
03 O
8 O
- O
OH O
Gua B
/ O
105 O
Gua B
in O
the O
thiamine B
pyrophosphate I
( O
20 O
mg O
/ O
kg O
) O
group O
and O
1 O
. O
55 O
+ O
/ O
- O
0 O
. O
11 O
8 B
- I
OH I
Gua I
/ O
105 O
Gua B
in O
the O

These O
results O
show O
that O
thiamine B
pyrophosphate I
significantly O
prevents O
oxidative O
damage O
induced O
by O
cisplatin B
in O
brain O
tissue O
, O
while O
the O
protective O
effect O
of O
thiamine B
is O
insignificant O
. O

Immunoregulatory O
effects O
of O
Glycyrrhizic B
acid I
exerts O
anti O
- O
asthmatic O
effects O
via O
modulation O
of O
Th1 O
/ O
Th2 O
cytokines O
and O
enhancement O
of O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
Foxp3 O
( O
+ O
) O
regulatory O
T O
cells O
in O
ovalbumin O
- O
sensitized O
mice O
. O

ETHNOPHARMACOLOGICAL O
RELEVANCE O
: O
Glycyrrhizic B
acid I
( O
GA O
) O
is O
the O
main O
bioactive O
ingredient O
of O
licorice O
( O
Glycyrrhiza O
glabra O
) O
, O
and O
has O
been O
found O
to O
be O
associated O
with O
multiple O
therapeutic O
properties O
. O

AIM O
OF O
THE O
STUDY O
: O
In O
this O
study O
, O
we O
investigated O
immunoregulatory O
effects O
of O
glycyrrhizic B
acid I
on O
anti O
- O
asthmatic O
effects O
and O
underlying O
mechanisms O
. O

In O
this O
work O
we O
excite O
or O
ionize O
doped O
He B
droplets O
using O
synchrotron O
radiation O
and O
study O
the O
effect O
onto O
the O
dopant O
atoms O
depending O
on O
their O
location O
inside O
the O
droplets O
( O
rare O
gases O
) O
or O
outside O
at O
the O
droplet O
surface O
( O
alkali B
metals I
) O
. O

The O
surprising O
finding O
is O
that O
alkali B
metals I
, O
in O
contrast O
to O
the O
rare O
gases O
, O
are O
efficiently O
Penning O
ionized O
upon O
excitation O
of O
the O
( O
n O
= O
2 O
) O
- O
bands O
of O
the O
host O
droplets O
. O

In O
addition O
, O
lobophytone B
K I
( O
1b O
) O
, O
recently O
isolated O
from O
Hainan O
soft O
coral O
Lobophytum O
pauciflorum O
by O
Lin O
et O
al O
. O
, O
was O
proved O
to O
be O
the O
same O
compound O
as O
1 O
and O
1a O
. O

The O
absolute O
configuration O
of O
1 O
was O
determined O
by O
comparing O
its O
electronic O
circular O
dichroism O
curve O
with O
that O
of O
co O
- O
occurring O
ximaolide B
A I
( O
2 O
) O
. O

Monitoring O
Conformational O
Changes O
in O
Peroxisome O
Proliferator O
- O
Activated O
Receptor O
alpha O
by O
a O
Genetically O
Encoded O
Photo O
- O
Amino B
Acid I
, O
Cross O
- O
Linking O
, O
and O
Mass O
Spectrometry O
. O

Using O
E O
. O
coli O
cells O
with O
a O
special O
tRNA O
/ O
aminoacyl O
- O
tRNA O
synthetase O
pair O
, O
two O
PPAR O
alpha O
variants O
were O
prepared O
, O
in O
which O
Leu B
- O
258 O
or O
Phe B
- O
273 O
were O
site O
- O
specifically O
replaced O
by O
the O
genetically O
encoded O
photo O
- O
reactive O
amino B
acid I
para B
- I
benzoylphenylalanine I
( O
Bpa B
) O
. O

Liver O
and O
kidney O
were O
susceptible O
to O
cyfluthrin B
- O
dependent O
induction O
of O
12 O
- O
and O
11 O
- O
hydroxylation O
of O
lauric B
acid I
, O
suggesting O
CYP4A O
subfamily O
induction O
. O

Finally O
, O
we O
found O
that O
I3S B
worsened O
experimental O
autoimmune O
encephalomyelitis O
( O
EAE O
) O
, O
which O
is O
primarily O
mediated O
by O
Th17 O
cells O
, O
enhancing O
the O
frequency O
of O
IL O
- O
17 O
- O
producing O
cells O
in O
draining O
lymph O
nodes O
. O

MATERIALS O
AND O
METHODS O
: O
The O
present O
study O
aimed O
to O
investigate O
the O
effect O
of O
CI O
ethanolic O
extract O
( O
CIE O
) O
on O
productions O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
RAW264 O
. O
7 O
macrophages O
. O

MATERIALS O
AND O
METHODS O
: O
The O
present O
study O
aimed O
to O
investigate O
the O
effect O
of O
CI O
ethanolic O
extract O
( O
CIE O
) O
on O
productions O
of O
nitric B
oxide I
( O
NO B
) O
, O
prostaglandin B
E2 I
( O
PGE2 B
) O
, O
and O
interleukin O
- O
1 O
beta O
( O
IL O
- O
1 O
beta O
) O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
RAW264 O
. O
7 O
macrophages O
. O

Of O
seven O
different O
GluN2D O
C B
- O
terminal O
fragments O
used O
as O
bait O
, O
only O
the O
construct O
containing O
amino B
acids I
983 O
- O
1097 O
associated O
with O
an O
E3 O
ligase O
, O
Nedd4 O
. O

A O
dihydrochalcone B
and O
several O
homoisoflavonoids B
from O
Polygonatum O
odoratum O
are O
activators O
of O
adenosine B
monophosphate I
- O
activated O
protein O
kinase O
. O

Adenosine B
monophosphate I
( O
AMP B
) O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
is O
a O
major O
cellular O
energy O
sensor O
and O
master O
regulator O
of O
metabolic O
homeostasis O
; O
thus O
, O
AMPK O
plays O
a O
central O
role O
in O
studies O
on O
diabetes O
and O
related O
metabolic O
diseases O
. O

S B
- O
nitrosylation O
of O
protein O
cysteine B
residues O
is O
known O
to O
be O
an O
important O
mechanism O
for O
nitric B
oxide I
signaling O
. O

Additionally O
, O
reduced B
glutathione I
and O
superoxide B
dismutase O
in O
plasma O
indicated O
that O
oxidative O
damage O
might O
partly O
contribute O
to O
BDE209 B
- O
induced O
hyperglycemia O
. O

This O
results O
from O
the O
relative O
balance O
between O
the O
electrostatic O
attraction O
between O
the O
SDS B
and O
amine B
nitrogen I
group O
which O
decreases O
as O
the O
charge O
density O
decreases O
with O
increasing O
pH O
, O
the O
ion O
- O
dipole O
interaction O
between O
the O
amine B
nitrogen I
and O
SDS B
sulfate I
group O
which O
is O
dominant O
at O
higher O
pH O
, O
and O
the O
hydrophobic O
interalkyl O
chain O
interaction O
between O
bound O
SDS B
molecules O
which O
changes O
with O
oligoamine O
molecular O
weight O
. O

This O
results O
from O
the O
relative O
balance O
between O
the O
electrostatic O
attraction O
between O
the O
SDS B
and O
amine B
nitrogen I
group O
which O
decreases O
as O
the O
charge O
density O
decreases O
with O
increasing O
pH O
, O
the O
ion O
- O
dipole O
interaction O
between O
the O
amine B
nitrogen I
and O
SDS B
sulfate I
group O
which O
is O
dominant O
at O
higher O
pH O
, O
and O
the O
hydrophobic O
interalkyl O
chain O
interaction O
between O
bound O
SDS B
molecules O
which O
changes O
with O
oligoamine O
molecular O
weight O
. O

This O
results O
from O
the O
relative O
balance O
between O
the O
electrostatic O
attraction O
between O
the O
SDS B
and O
amine B
nitrogen I
group O
which O
decreases O
as O
the O
charge O
density O
decreases O
with O
increasing O
pH O
, O
the O
ion O
- O
dipole O
interaction O
between O
the O
amine B
nitrogen I
and O
SDS B
sulfate I
group O
which O
is O
dominant O
at O
higher O
pH O
, O
and O
the O
hydrophobic O
interalkyl O
chain O
interaction O
between O
bound O
SDS B
molecules O
which O
changes O
with O
oligoamine O
molecular O
weight O
. O

Ethylene B
sulfide I
( O
ES O
) O
, O
propargyl B
carbonylimidazole I
( O
PPC B
) O
and O
azidoethyl B
carbonylimidazole I
( O
AEC B
) O
reacted O
with O
amine B
and O
/ O
or O
hydroxyl B
groups O
in O
BC O
to O
introduce O
the O
corresponding O
thiol B
, O
alkyne B
and O
azide B
groups O
on O
SS O
surfaces O
( O
SS O
- O
thiol B
, O
SS O
- O
alkyne B
and O
SS O
- O
azide B
, O
respectively O
) O
. O

Ethylene B
sulfide I
( O
ES O
) O
, O
propargyl B
carbonylimidazole I
( O
PPC B
) O
and O
azidoethyl B
carbonylimidazole I
( O
AEC B
) O
reacted O
with O
amine B
and O
/ O
or O
hydroxyl B
groups O
in O
BC O
to O
introduce O
the O
corresponding O
thiol B
, O
alkyne B
and O
azide B
groups O
on O
SS O
surfaces O
( O
SS O
- O
thiol B
, O
SS O
- O
alkyne B
and O
SS O
- O
azide B
, O
respectively O
) O
. O

Ethylene B
sulfide I
( O
ES O
) O
, O
propargyl B
carbonylimidazole I
( O
PPC B
) O
and O
azidoethyl B
carbonylimidazole I
( O
AEC B
) O
reacted O
with O
amine B
and O
/ O
or O
hydroxyl B
groups O
in O
BC O
to O
introduce O
the O
corresponding O
thiol B
, O
alkyne B
and O
azide B
groups O
on O
SS O
surfaces O
( O
SS O
- O
thiol B
, O
SS O
- O
alkyne B
and O
SS O
- O
azide B
, O
respectively O
) O
. O

The O
approach O
used O
in O
this O
paper O
allows O
the O
calculation O
of O
the O
free O
energy O
profile O
and O
enable O
us O
to O
explain O
the O
mechanism O
and O
kinetics O
of O
the O
neutral O
hydrolysis O
of O
normal O
( O
methyl B
acetate I
) O
and O
activated O
( O
methyl B
trifluoroacetate I
) O
esters B
. O

The O
approach O
used O
in O
this O
paper O
allows O
the O
calculation O
of O
the O
free O
energy O
profile O
and O
enable O
us O
to O
explain O
the O
mechanism O
and O
kinetics O
of O
the O
neutral O
hydrolysis O
of O
normal O
( O
methyl B
acetate I
) O
and O
activated O
( O
methyl B
trifluoroacetate I
) O
esters B
. O

Vibrational O
dynamics O
of O
the O
T1u O
CO B
stretching O
mode O
of O
tungsten B
hexacarbonyl I
is O
explored O
when O
the O
molecule O
is O
embedded O
in O
a O
nitrogen B
matrix O
at O
low O
temperature O
. O

In O
addition O
, O
melamine B
significantly O
increased O
COX O
- O
2 O
expression O
and O
prostaglandin B
E2 I
( O
PGE2 B
) O
production O
. O

In O
line O
with O
this O
observation O
, O
incubation O
of O
striatal O
slices O
with O
okadaic B
acid I
and O
calyculin B
A I
, O
two O
inhibitors O
of O
PP O
- O
1 O
, O
increased O
Ser240 B
/ O
244 O
phosphorylation O
. O

In O
line O
with O
this O
observation O
, O
incubation O
of O
striatal O
slices O
with O
okadaic B
acid I
and O
calyculin B
A I
, O
two O
inhibitors O
of O
PP O
- O
1 O
, O
increased O
Ser240 B
/ O
244 O
phosphorylation O
. O

The O
inhibition O
of O
autophagy O
using O
LC3 O
beta O
gene O
silencing O
or O
pharmacological O
autophagy O
blockers O
3 B
- I
methyladenine I
or O
bafilomycin B
A1 I
, O
mimicked O
the O
cytoprotective O
effect O
of O
6b O
. O

A O
potential O
drawback O
with O
the O
use O
of O
mannitol B
as O
a O
bulking O
agent O
is O
its O
existence O
as O
mannitol B
hemihydrate I
( O
MHH B
; O
C6H14O6 B
( I
. I
) I
0 I
. I
5H2O I
) O
in O
the O
lyophile O
. O

Investigation O
on O
the O
interaction O
of O
the O
toxicant O
, O
gentian B
violet I
, O
with O
bovine O
hemoglobin O
. O

Gentian B
violet I
( O
GV O
) O
is O
a O
well O
- O
known O
triarylmethane B
dye O
that O
is O
used O
in O
aquacultural O
, O
industrial O
and O
medicinal O
fields O
. O

Heterologously O
expressed O
formyl B
peptide O
receptor O
2 O
( O
FPR2 O
/ O
ALX O
) O
does O
not O
respond O
to O
lipoxin B
A4 I
. O

Lipoxin B
A4 I
( O
LXA4 B
) O
has O
been O
described O
as O
an O
anti O
- O
inflammatory O
mediator O
, O
which O
exerts O
its O
effects O
through O
the O
formyl O
peptide O
receptor O
FPR2 O
, O
also O
known O
as O
ALX O
. O

Elucidation O
of O
the O
pharmacophore O
of O
echinocystic B
acid I
, O
a O
new O
lead O
for O
blocking O
HCV O
entry O
. O

To O
elucidate O
the O
pharmacophore O
of O
echinocystic B
acid I
( O
EA O
) O
, O
an O
oleanane B
- O
type O
triterpene B
displaying O
substantial O
inhibitory O
activity O
on O
HCV O
entry O
, O
two O
microbial O
strains O
, O
Rhizopus O
chinensis O
CICC O
3043 O
and O
Alternaria O
alternata O
AS O
3 O
. O
4578 O
, O
were O
utilized O
to O
modify O
the O
chemical O
structure O
of O
EA O
. O

Bioassays O
were O
set O
up O
to O
compare O
the O
efficacy O
of O
our O
range O
of O
N B
- O
alkylated O
compounds O
against O
classic O
antifungal O
agents O
; O
Amphotericin B
B I
and O
Thiabendazole B
. O

In O
previous O
studies O
we O
described O
the O
development O
of O
novel O
spirocyclic O
HDAC O
inhibitors O
based O
on O
the O
combination O
of O
privileged O
structures O
with O
hydroxamic B
acid I
moieties O
as O
zinc B
binding O
group O
. O

Steroidal B
glycosides I
from O
the O
bulbs O
of O
Easter O
lily O
( O
Lilium O
longiflorum O
Thunb O
. O
) O
promote O
dermal O
fibroblast O
migration O
in O
vitro O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
evaluate O
fractionated O
Easter O
lily O
bulb O
extracts O
and O
their O
steroidal B
glycosides I
( O
1 O
- O
5 O
) O
for O
the O
promotion O
of O
dermal O
fibroblast O
migration O
in O
vitro O
, O
as O
a O
model O
for O
the O
early O
events O
in O
wound O
healing O
. O

To O
gain O
insight O
into O
the O
mode O
of O
action O
of O
the O
steroidal B
glycosides I
, O
nitric B
oxide I
( O
NO B
) O
production O
, O
and O
expression O
of O
genes O
for O
transforming O
growth O
factor O
beta O
- O
1 O
( O
TGF O
- O
beta O
) O
and O
its O
receptors O
were O
evaluated O
. O

To O
gain O
insight O
into O
the O
mode O
of O
action O
of O
the O
steroidal B
glycosides I
, O
nitric B
oxide I
( O
NO B
) O
production O
, O
and O
expression O
of O
genes O
for O
transforming O
growth O
factor O
beta O
- O
1 O
( O
TGF O
- O
beta O
) O
and O
its O
receptors O
were O
evaluated O
. O

RESULTS O
: O
Fractionated O
bulb O
extracts O
and O
the O
two O
isolated O
steroidal B
glycoalkaloids I
( O
1 O
) O
and O
( O
2 O
) O
induced O
NO B
production O
and O
TGF O
- O
beta O
receptor O
I O
mRNA O
expression O
in O
fibroblast O
cell O
culture O
. O

In O
a O
cytotoxicity O
assay O
, O
steroidal B
glycosides I
( O
1 O
) O
and O
( O
3 O
) O
had O
IC50 O
values O
of O
8 O
. O
2 O
and O
8 O
. O
7 O
micro O
M O
, O
but O
the O
natural O
acetylation O
of O
the O
C O
- O
6 O
' O
' O
' O
hydroxy B
of O
the O
terminal O
glucose B
unit O
in O
( O
2 O
) O
resulted O
in O
a O
3 O
- O
fold O
decrease O
in O
cell O
cytotoxicity O
when O
compared O
with O
( O
1 O
) O
. O

Results O
from O
the O
dermal O
fibroblast O
migration O
assay O
revealed O
that O
the O
steroidal B
glycoalkaloids I
( O
1 O
) O
and O
( O
2 O
) O
, O
and O
the O
furostanol B
saponin I
( O
3 O
) O
promoted O
fibroblast O
migration O
from O
the O
range O
of O
23 O
. O
7 O
+ O
/ O
- O
5 O
. O
7 O
to O
37 O
. O
7 O
+ O
/ O
- O
5 O
. O
1 O
% O
, O
as O
compared O
with O
the O
control O
. O

Results O
from O
the O
dermal O
fibroblast O
migration O
assay O
revealed O
that O
the O
steroidal B
glycoalkaloids I
( O
1 O
) O
and O
( O
2 O
) O
, O
and O
the O
furostanol B
saponin I
( O
3 O
) O
promoted O
fibroblast O
migration O
from O
the O
range O
of O
23 O
. O
7 O
+ O
/ O
- O
5 O
. O
7 O
to O
37 O
. O
7 O
+ O
/ O
- O
5 O
. O
1 O
% O
, O
as O
compared O
with O
the O
control O
. O

CONCLUSION O
: O
Collectively O
, O
our O
data O
demonstrate O
that O
the O
steroidal B
glycosides I
present O
in O
Easter O
lily O
bulbs O
induce O
, O
at O
least O
in O
part O
, O
the O
observed O
dermal O
fibroblast O
migration O
activity O
of O
the O
bulb O
extracts O
. O

This O
is O
the O
first O
evidence O
that O
steroidal B
glycosides I
from O
L O
. O
longiflorum O
may O
potentially O
play O
a O
role O
in O
the O
wound O
healing O
process O
and O
may O
provide O
a O
scientific O
basis O
for O
the O
historical O
use O
of O
lily O
bulbs O
for O
this O
purpose O
. O

